<SEC-DOCUMENT>0001628280-23-007727.txt : 20230313
<SEC-HEADER>0001628280-23-007727.hdr.sgml : 20230313
<ACCEPTANCE-DATETIME>20230313170215
ACCESSION NUMBER:		0001628280-23-007727
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230313
DATE AS OF CHANGE:		20230313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		23728059

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cpix-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:f3294900-4a6d-4934-9914-8de8a2261475,g:98ef8ed7-f771-4377-a070-411ae3070b66,d:3e36cfc56e1a4275a52b7d560014d176--><html xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:cpix="http://www.cumberlandpharma.com/20221231" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8yLTEtMS0xLTM0Mzg0_693fc9b6-7876-4a40-b6c6-d210990eb130">TRUE</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8zLTEtMS0xLTM0Mzg0_b9da7085-6105-4076-a145-2460138feb0e">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl80LTEtMS0xLTM0Mzg0_9d4fabe8-be1d-43ef-917f-fa67f9745f55">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl82LTEtMS0xLTM0Mzg0_94180230-d072-4397-a979-dc511b518443">Non-accelerated Filer</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-month-day-year" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl84LTEtMS0xLTM0Mzg0_b769ffa9-cd89-49b6-ba78-598080123546">12/31/2022</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl85LTEtMS0xLTM0Mzg0_255d4800-37c3-4be8-a701-06d072702afd">2022</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xMC0xLTEtMS0zNDM4NA_6c16f37b-9d81-4b98-83ff-0cddced75087">FY</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xMS0xLTEtMS0zNDM4NA_dcf1ffd5-c952-4522-b7ac-d028817fa5ff">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xMi0xLTEtMS0zNDM4NA_f5cabfc5-7df9-4654-9fcf-cb97b32ff100">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xMy0xLTEtMS0zNDM4NA_258c0537-c1d5-431d-94b2-5b33b2f868c3">TRUE</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xNC0xLTEtMS0zNDM4NA_72b59c6f-b790-4d32-acb3-3fe12ccd3321">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xNS0xLTEtMS00MzY2Mw_5a2332bf-1fdd-4397-a324-65091dafdb8d">No</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xNi0xLTEtMS00MzY2Ng_5b534e76-0ec0-43a3-945a-86f4a2fd2f64">No</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xNy0xLTEtMS00MzY2OA_a7cc24e6-aa76-4cc4-8fd1-008db894a3a6">Yes</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xOC0xLTEtMS00MzY3MA_f554a7d9-d065-4039-b9e7-9e25320efcf0">Yes</ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGV4dHJlZ2lvbjo4YzEzYzFiODYzOGU0ZWExYjIzNjA3YmE4YjE1NTIzZl80NA_72237d44-0471-412a-be0c-7af7a5cb15e8">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cf98cdc48c644138ca1c6dedc85be6e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i40f46dea598c4f3cba52391f5ebaf18b_I20230307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0531c6598004c5d9158b8763683f643_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idf6dac19d6f34192bbf220dba001eef3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82deea75887548fe9dd05c788a9a95d9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78d55d038f4f4a95b6d5aa9d8870f9f3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492284a80be94550bc059ef2e65088e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b1f58f544414d679bba8a83be98bb54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963f0ace48ae4299a000f7fd5b7c18c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia40cff38220f4a42a215676712cd7975_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f553aa99c0e4216aa251a6245b1cab1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia770bc31d52a493aa78146feba302866_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4d8da0743ab4c0488940b1685dbba30_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f8ac4bf33e4693be58ae3e7731aca1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id569c4eed8f24390a0083034cd6006fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie04970d0133c449fb025dee41a90d071_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb757a4c3914eb9b95796ad9e20eacc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1705f3f062cc44839738fe486e114ad6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb948d137eb4bae9cb3425ba6c840db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdae3b5e1dd2405b904488b32eb4db3b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d4b30bb244846a8ba4078cdae06919f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9062e0d132343aaa03943a47c77e779_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HarbinGloriaPharmaceuticalsCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbd696f587e24eb997ec609f8ce82517_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7002a7773f304b60a1fb957d9bf22167_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id417cd67920147a1928abf32d83fb11f_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ed29773e4754bd1a441c809e5231f15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6c780a0c3e87440c8eb1928bb0ce5f86_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i920d5ee9a6184682bc7bf8c05423756f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i478ad941e6444190835fbd70e6a0fda2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cpix:segment</xbrli:measure></xbrli:unit><xbrli:context id="ia21564bd7ce142dcadc0c24df7ea1958_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie03b356b24224df284680048170d1d18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba80f17d75f466d9b1472a3319fada7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i516902d591354e20a3baac1f1747a355_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cfbfa92c9f74d5d8ecb902cacdb2307_D20180101-20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8074777558e4350be02e8d826a67f22_D20211227-20211227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-27</xbrli:startDate><xbrli:endDate>2021-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc21cd41019b4937823097e3a64ff8a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3025fb68648c4df5b3dc39a998179c33_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c75d11680284d93969ed668e797eebc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa1891de07e463882de10e63f32527d_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i021bbc1b476b4fbe8c8498630b3444b9_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9301d1c169904a1d9355a5854c6f29e3_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ea797c011744d19c463a47c6cbbd46_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b29c34edaba455b8ebdd48b45de02d6_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d899e86c97433d9a3fa65fce7361e2_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7fa09f75a3b48cea5b2fb00b556fbe9_I20220712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec5e58bac724452b876b92a905e3ca14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i133c71a4398845698d7d7701abc49b01_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e22ba92c2194833a0319101083d1275_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f2090fcc89c46fc8c515cd09cc5ffae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib36b29930b41472aaa5de35a1e59cb95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i924046424f4a4ad5a7dce8e0bfe36d8b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb014f15e52c4aa7b4a00972e8c2037e_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44944cd121824f49afdb95c8a1b230c0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e74c81ece854dfcb8d7c8c3bc0a2f03_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i155bdf692bf44e60a73258a7452baa96_I20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8f59b1cd25d434eb648fc77c3dea5b1_D20220103-20220103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81f3f0b045ff491da276024b81457433_D20220103-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if92534bff0f1467fbb22f084f101995f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i469400cc5d084372975262bfe96ab0fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4696b3ec55c74a54b9b5653d2452aca1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if32dce83e48c4a7b91a0d4e335b66480_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98dc7a56a6ee4bc5ace7b118374a0de5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaddae84fd5b4b89a3139c9ac38b23c6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f3d9b8292154fa0b504704f80f2e116_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf29047eb0424eef806c96c842debe22_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e3b77ebc51845fd880355bb1563cc5f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18b3e901750344aba9b2ac8dc3d8398e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37ab018ed1464e58a2e6f54a577ad077_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8fd80adb04d4f22a287d4e54e9550dc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa10efc46e9e461386aa80220fb7a4ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe04d4939aef4eb2ae85d6d4c47c642d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9859c4aed134140b347fcfab3e9f9f9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e9d7a75c774347844d3abe0e6a3d75_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82ef6903bdd04aa7be5bf21326a39725_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6aca6f1f4640128e84638b21a73ac8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d9484ddbcb49fda1792dcd0ca0e89c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b9bb498b204e8a9f03c0c2fdc55984_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if13d0a3b9ba3470186981ffcd4cd386c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:WorkInProcessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf903ddd161947ba816eea446f55a857_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90d887a51969486c9881a5eac45b76a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b7caf11e1a24164b014dcb9cc1efa95_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib30352d285114277aebd23aebdefc31a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebc3383fa2574ae1802474eb1d124ef3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic80dac19a3234cf59481be62a47b00c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15d3092260845f9b57d3c442a6f6c72_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f1325d766c543488d6cdd933169b69f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16957755b21643ba9ebe843a90bb7625_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7d4d8a23fe54b748a284173ad96a122_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7da33aa95f3a43abb0a94e5e28dc81d1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66cf95bb11704c8fa28b1cc8873b54c6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i440984280e14489e94de83929fda92ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f49ad0b1cb54a7283fcda38b5eb92cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie029fb915f8742fabfa273ab1ade8a96_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1323af37504488a64c07cf8beb4baf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a40ef618bc943579e158b9494ffce7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57964ce83e4b45c18274c46575c33640_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69aeb359c79e41b78bca28b92da3cc0b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i463edf77a5cf4cd68d974b7c5d2166e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d06b1820bd54620a60f0c01d91fbf4d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3983a09554e4ca699dbcaf2db560e0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i574bc1e7d0d2481ea5ad466e8f534855_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic223906cd81348c4bac59dcace59f34e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb47557bdc1b4a7091a589c3dd4e833b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e9d77deb33f4194ba7a35755cec59a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FifthAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac3baa3852034481ab2a2c089e20758c_I20220929"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:NinthAmemdmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f310f91304f4cc89cb705d8722a8d08_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28084a381e4f4f1491853ea7f60c1025_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4808a45eee974fbfbe990af48bc945ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i061a02db1e2b4e1792f9dfd792d617e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic015a17daf5344f9a4de26b8e32f3873_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:InterestRateFloorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i755231ed00d14acf800c9c3404c31e20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8724ef42665454e9a5d3f598e52ab38_D20170731-20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-31</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5e93a72679646699ff0eec55311987d_D20200420-20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:PaymentProtectionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-20</xbrli:startDate><xbrli:endDate>2020-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf6a2ed9c9c1455893589f101ba5b4cc_I20200420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:PaymentProtectionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib78383e8396e49768661e5b1015fc86b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:PaymentProtectionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-08-09</xbrli:startDate><xbrli:endDate>2009-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1061cd07c59c4fc190c499065ffea5e3_I20100531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cpix:ShareRepurchaseProgramAuthorizedIn2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c8e554b334e4bf692425f706564fc4d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia90dbbcb1d5e494382b065f737613908_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0027eb6bc44b4567a5351c10399f22e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifea0d070c6124183897a66bb2df920d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30e86908009643eebb68ac0e3a1ae95e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99d9d087686e4acaa131dcf7f56b02b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66d5038d3ea5413287c0c60e6f8d6e13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8ffa57a973c45d89dc9e53e23854361_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if08c5ee420b248ac902a128ef7d90e7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4ecd0e4253e46d69b1840d128d714e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81a18b4c882d437cb25a611496aa56a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54dfc16f99534c19b2867a069f58d483_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i795293f449e54a6eb5e7aa63c13b396d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>cpix:plan</xbrli:measure></xbrli:unit><xbrli:context id="ibe55a7e9ab974665911b58f2cf2ab1d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:LongTermIncentiveCompensationPlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8296dfa01cf5426fa8af917b505e162d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:DirectorsIncentivePlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13b23c2311f046879e4fd6dafe94a991_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d9c25b92eff4d35973caf424807a5d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i070ea86904974ad18860cbc73c3202cc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i955de8aa181944039f7145e41a74c991_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09447f6af13b4f27a9f24d32a75cda9b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7684a832b0134542abe7faecbea0573e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c58bd8eaaf40cd8f6a0c93cdb60c2a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d9566f966de4bd4968bb2d10e0af05b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e34c07ebd764d17a96ec1d0f497c811_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89c60f8924f748d98ade2ba26f585e11_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i214555a81d9942d3a95516724918bd8d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91bab75ee1804a1097fbe90085dc4f12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:RestrictedIncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:RestrictedIncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b943054825b4193b3cf6fbcea5877d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:RestrictedIncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:RestrictedIncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfea5a17cdad49b5b643bd1bf2db9833_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:RestrictedIncentiveStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b65c4b8b6aa447481044537155a6d9a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if838a7aa53664232926aca1c69b23238_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2a4df839364457ca572567fd0e125dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i430e1a4cd7514fe59de28ed3a49bbab5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i872072012a784d598051e80fd8fb06ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i554be9ce2c1b41b4a99da09551040eaf_I20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ic57bcfd058014d5d98c77360f419b471_I20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cpix:BroadwestLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewalterm"><xbrli:measure>cpix:renewalTerm</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerSqft"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib2fa7c2f4e86401a88e3022cb2d1309b_I20211115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a4d2edd7a324a55a81eb502f58e0069_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48b2fbaeed6a477c8536c9109ab9bde5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:A1600WestEndAvenuePartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffad826a3e6c41bd89cf0a3c062b03ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:CETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8047e420d87647ca865218062adc1b3c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb1ed446076641e2b06e8f65764e9641_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie513e297486b4dc29fca145454075e01_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0510690b6b854b9d8843a2b97df3ce27_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40f47c6c3c2345c982dcd1e267fd6145_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaff5c56f78a34c10b47d66d78992346f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42772db945f14e0d885bd05151e93291_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:Customer12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3990e4402eb64fb980a6bad3eb7430b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:Customer12And3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40eb7705a474e4fa7d98cfa3a5cb554_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="supplier"><xbrli:measure>cpix:supplier</xbrli:measure></xbrli:unit><xbrli:context id="ie088610f3d64485c98806a39268009ee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>cpix:installment</xbrli:measure></xbrli:unit><xbrli:context id="i03b6a63983b64d8bbf3a1a5e92a62c3b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e7165d6a14540d69539b738e13cdf8d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i284259e69f3e4e4e84c466d1e02a1e56_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia952b89d554e4c89bf3b5882567c2d5f_I20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:CollaborativeArrangementMilestonePaymentThresholdAxis">cpix:Within30DaysOfFirstSNDAFilingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49eca3268edc4ad8b4e63d2e71cfa018_I20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cpix:CollaborativeArrangementMilestonePaymentThresholdAxis">cpix:FollowingApprovalOfFirstSNDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f878acd95a045fd934d5052dde987c6_I20221107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5de2643b16c42518868295369efe808_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a1250f3410e437492a31418c8974e8c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ed7d5354534fbd81b84cc0aa0d8e79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id183facaeebd467fa69fbb2fec9d0b3e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9019082259e456fb9c5846dc8fa2c23_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief70e45bdb5146d0818d09d8a9fc3591_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13f27dbe43754f2393a096db946b5293_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c9db8d427e4e07a83726736dbc62f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idce9bb4f17eb40309dbdc88fdb74adc9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1857a0d9d671486aa8f09353d5b63f37_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3e36cfc56e1a4275a52b7d560014d176_1"></div><div style="min-height:22.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8xODc_2c55060e-6d1f-4dfb-b0d1-6ff7408dd9e2">10-K</ix:nonNumeric></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM2_bffd3e7c-47f5-43ca-a114-523ef7399430">December 31, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">of</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:26pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8zMjU_99aa2bfa-d010-4486-ac59-9cd3fe73e5e3">CUMBERLAND PHARMACEUTICALS INC</ix:nonNumeric>.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzMy_a48c74b7-b8ad-435d-a250-2fa5530ade51">Tennessee</ix:nonNumeric> Corporation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IRS Employer Identification No.  <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzMz_449894e6-3107-45bb-ac0d-83a8fde7cf15">62-1765329</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commission file number&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM0_ce8ce56e-4bd3-4917-aa0a-106657e96d92">001-33637</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl81NDk3NTU4MTY3OTE_a1a17fe8-42f0-409b-a47c-00a8e0eb4208">1600 West End Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM3_ff92e11a-32ea-4a4d-8f3a-cf0899f01e1f">Suite 1300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM1_fa127974-4a39-4cec-903b-659b42662080">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM4_438a23b5-5f18-49a4-b81c-6f983aee3247">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM5_02cec2d4-2157-4996-9f5b-2f7b9213e737">37203</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzQw_86079046-6990-4511-a732-03f0bda7cf3b">615</ix:nonNumeric>) <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzQx_a32a54e4-9c93-45a6-a910-3c9225c79953">255-0068</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.548%"><tr><td style="width:1.0%"></td><td style="width:37.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.003%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.540%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trading Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGFibGU6Mjk0ODVhOWUwM2UwNDQwMzljNjVjMWEwNmU0NDJiZTgvdGFibGVyYW5nZToyOTQ4NWE5ZTAzZTA0NDAzOWM2NWMxYTA2ZTQ0MmJlOF8xLTAtMS0xLTM0Mzg0_65d7444a-f077-49c6-9be5-bafcb5aae907">Common Stock, $0.00 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGFibGU6Mjk0ODVhOWUwM2UwNDQwMzljNjVjMWEwNmU0NDJiZTgvdGFibGVyYW5nZToyOTQ4NWE5ZTAzZTA0NDAzOWM2NWMxYTA2ZTQ0MmJlOF8xLTItMS0xLTM0Mzg0_ba286f93-0f00-45cb-932d-4d410188ae4b">CPIX</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGFibGU6Mjk0ODVhOWUwM2UwNDQwMzljNjVjMWEwNmU0NDJiZTgvdGFibGVyYW5nZToyOTQ4NWE5ZTAzZTA0NDAzOWM2NWMxYTA2ZTQ0MmJlOF8xLTQtMS0xLTM0Mzg0_e588fa23-4cb8-4812-bd87-0907b1679a04">Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">None</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. is not a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.  &#160;&#160;&#160;&#160;</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. is required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.  Cumberland Pharmaceuticals Inc. (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months, and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months. </span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. is a non-accelerated filer and a smaller reporting company as defined in Rule&#160;12b-2 of the Exchange Act and is not a shell company.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. has not filed a report on and attestation to its management's assessment of  the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared and issued its audit report.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates as of June&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i0cf98cdc48c644138ca1c6dedc85be6e_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8xOTI1_0ae9fca7-4104-41ce-b1a2-2b3d3f2f2bce">17,300,356</ix:nonFraction>. The number of shares of the registrant&#8217;s Common Stock, no par value, outstanding as of March&#160;7, 2023 was <ix:nonFraction unitRef="shares" contextRef="i40f46dea598c4f3cba52391f5ebaf18b_I20230307" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMDIz_d1b90d8d-3709-43aa-871e-88968e678fb6">14,395,401</ix:nonFraction>.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzQy_ea3043c3-4791-4189-ad15-e8d83a52cc57" escape="true">Certain information required in Part III of Form 10-K is incorporated by reference from the registrant&#8217;s Proxy Statement for its 2023 annual meeting of shareholders.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________________________</span></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Index</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:77.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.387%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page Number</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_10">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_10">1</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_13">Item&#160;1: Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_13">1</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_76">Item&#160;1A: Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_76">37</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_94">Item&#160;1B: Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_94">58</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_97">Item&#160;2: Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_97">58</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_100">Item&#160;3: Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_100">58</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_103">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_103">58</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_106">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_106">58</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_109">Item 5: Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_109">58</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_112">Item&#160;6: Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_112">60</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_115">Item&#160;7: Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_115">60</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_136">Item&#160;7A: Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_136">72</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_139">Item&#160;8: Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_139">72</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_142">Item&#160;9: Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_142">72</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_145">Item&#160;9A: Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_145">72</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_148">Item&#160;9B: Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_148">73</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_151">Item 9C: Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_151">73</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_154">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_154">73</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_157">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_157">74</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_160">Item&#160;15: Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_157">74</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_163">Item 16: Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_163">80</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_166">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_166">81</a></span></div></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_13"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1. Business.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_16"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE COMPANY</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;our&#8221;), is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. We are dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital, field and oncology sales divisions in the United States while we continue to build a network of international partners to register and provide our medicines to patients in their countries. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of brands approved for marketing by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) includes:</span></div><div style="margin-top:4pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of acetaminophen poisoning; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of pain and fever;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for oral solution, a prescription laxative, for the treatment of constipation;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Omeclamox-Pak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">omeprazole, clarithromycin, amoxicillin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) oral, for the treatment of Helicobacter pylori (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">H. pylori</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) infection and related duodenal ulcer disease;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">methotrexate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">granisetron)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidate for patients with cardiomyopathy associated with 1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duchenne Muscular Dystrophy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;DMD&#8221;), a fatal, genetic neuromuscular disease, 2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Systemic Sclerosis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;SSc&#8221;) or scleroderma, a debilitating autoimmune disorder characterized by fibrosis of the skin and internal organs and 3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aspirin-Exacerbated Respiratory Disease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;AERD&#8221;), a severe form of asthma.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has built core competencies for the acquisition, development and commercialization of pharmaceutical products in the U.S. &#8211; and we believe we can leverage this existing infrastructure to support our continued growth. Our management team consists of pharmaceutical industry veterans with experience in business development, product development, regulatory, manufacturing, sales, marketing and finance.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co- promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability and delivery of our products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2020, the U.S. declared a health care emergency following the outbreak of SARS-CoV-2, a novel strain of coronavirus that causes COVID-19. The Company managed through the resulting pandemic, continuing to operate our business &#8211; keeping facilities open and our organization intact. We moved quickly to ensure the health and safety of our team. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded pharmaceutical company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our clinical studies were also impacted, as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. We carefully monitored our supply chain, including the flow of raw materials and the batches of finished products emerging from the facilities that manufacture our products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We welcomed a return to a more typical operating environment as 2022 progressed, following the economic and societal effects of the pandemic. We were encouraged to see enrollment in our clinical trials resume, patient procedures return to more customary levels and access for our sales representatives improve as they gained more face-to-face meetings with medical professionals.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we continued to expand our product portfolio, starting the year with the announcement of our Sancuso acquisition from the U.S. affiliate of Japan-based Kyowa Kirin. With significant contributions from Sancuso, we experienced strong year-over-year revenue growth.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the year we continued our mission, delivering our products to improve patient care, while also addressing the interests of our shareholders, employees, partners and community.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Headquarters</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late October 2022, we opened our new headquarter offices at the Broadwest campus in the Vanderbilt/West End corridor of Nashville. Our move into the new state-of-the-art facilities will enable the Company to accommodate our growth, support our team, and better serve our international base of customers and partners. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sustainability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we released our second annual Sustainability Report (the &#8220;2021 Sustainability Report&#8221;), which detailed Cumberland&#8217;s activities pertaining to our environmental, social and governance matters. We issued our inaugural Sustainability Report in 2019 and remain committed to sustainability and to maintaining transparency of our corporate operations. As the largest biopharmaceutical company founded and headquartered in the Mid-South, we hold ourselves to the highest standards of ethical practices and understand the importance of recognizing and addressing our impact on our constituents, the community and the environment.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Sustainability Report noted that during that year we provided nearly 2.5 million patient doses of our products, safely disposed of over 6,000 pounds of expired and damaged products and had no product recalls. We also had no Company brands listed on the FDA&#8217;s MedWatch Safety Alerts for Human Medical Products, no Company product issues identified by the FDA&#8217;s Adverse Event Reporting System and no clinical trials terminated due to failure to practice good clinical standards.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Sustainability Report also highlighted our investment in our employees through our continuing education programs, employee development initiatives and employee recognition awards. We reported that women represented 44% of Cumberland&#8217;s workforce and 15% of our employees were minorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our sustainability initiatives, we will continue to identify and address critical industry issues, monitor relevant guidelines and utilize best practices.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has taken appropriate steps to monitor an adequate level of cybersecurity.  The Company is insured against cyber attacks and has appropriate detection and mitigation controls in place.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in 1999 and have been headquartered in Nashville, Tennessee since inception. During 2009, we completed an initial public offering of our common shares and listing on the Nasdaq stock exchange. Our website address is </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.cumberlandpharma.com</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Reports (on Form 10-K), Quarterly Reports (on Form 10-Q), Current Reports (on Form 8-K) and all material press releases are available on our website as soon as reasonably practicable after their filing with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). These filings are also available to the public at </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.794%"><tr><td style="width:1.0%"></td><td style="width:30.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.975%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetaminophen Poisoning</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pain and Fever</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chronic and Acute Constipation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Pak</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H. pylori Infection and Related Duodenal Ulcer Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arthritis and Psoriasis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nausea and Vomiting Associated with Chemotherapy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euvolemic and Hypervolemic Hyponatremia</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serious Bacterial Infections</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote is an intravenous formulation of N-acetylcysteine, indicated for the treatment of liver toxicity associated with acetaminophen poisoning. Cumberland developed and obtained U.S. FDA approval for Acetadote, and then introduced the product through our hospital sales force. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote is typically used in hospital emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter and prescription pain relieving and fever-reducing products. Acetaminophen overdose continues to be a leading cause of poisonings reported by hospital emergency departments in the U.S., and Acetadote has become a standard of care for treating this potentially life-threatening condition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote received U.S. FDA approval as an orphan drug, which provided seven years of marketing exclusivity from the date of approval. That exclusivity has since expired.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA&#8217;s approval of Acetadote, we committed to certain post-marketing activities for the product. Completion of our first Phase IV commitment resulted in the FDA&#8217;s approval of expanded labeling for the product for use in pediatric patients. Completion of our second Phase IV commitment resulted in further revised labeling for the product with FDA approval of additional safety data.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completion of our third and final Phase IV commitment culminated in the FDA&#8217;s approval of a new formulation for the product. The next generation formulation contains no ethylene diamine tetracetic acid (&#8220;EDTA&#8221;) or other stabilization agent, chelating agent or preservative. Cumberland introduced this new Acetadote formulation replacing the original form of the product which we no longer manufacture.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA subsequently approved updated labeling for Acetadote revising the product&#8217;s indication and providing new dosing guidance for specific patient populations. As a result, dosing guidance is now included for patients weighing over 100 kg, and new language was added to alert health care providers that, in certain clinical situations, therapy should be extended for some patients.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Patent and Trademark Office (the &#8220;USPTO&#8221;) issued us a series of patents associated with our Acetadote product. These patents are discussed in Part I, Item I &#8211; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business - Trademarks and Patents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; &#8211; of this Form 10-K. The FDA has approved several abbreviated new drug applications (&#8220;ANDA&#8221;) filed by various generics companies referencing Acetadote. Those products all possess the old formulation containing EDTA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an agreement with Perrigo Company resulting in the distribution of our Authorized Generic acetylcysteine injection (our &#8220;Authorized Generic&#8221;) product. Both Acetadote and our Authorized Generic utilize the new, EDTA-free formulation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An Illinois judge issued a final ruling in favor of Cumberland Pharmaceuticals Inc. in a patent case associated with Acetadote. By ruling in Cumberland&#8217;s favor, the court upheld the validity of the patent that encompasses our EDTA-free formulation. The court also granted a permanent injunction preventing challengers from marketing a generic version of our proprietary Acetadote product formulation before the expiration of Cumberland&#8217;s patent in August 2025. An Appeals Court affirmed the District Court ruling in the Company's favor upholding Cumberland's Acetadote patent and expressly rejected the validity challenge.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we continued to distribute our Acetadote brand, however our Authorized Generic product is now distributed through Padagis US LLC (formerly a division of Perrigo Company).</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor, our intravenous formulation of ibuprofen, was the first injectable product approved in the U.S. for the treatment of both pain and fever. We conducted a series of clinical studies in over 900 adult patients to develop the data to support our FDA submission for the product's registration. Following a priority review, the FDA approved Caldolor for marketing in the U.S.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-steroidal anti-inflammatory drug (&#8220;NSAID&#8221;), the product was indicated for use in adults as a sole treatment for the management of mild to moderate pain and for the management of moderate to severe pain as an adjunct to opioid analgesics. It was also the first FDA approved intravenous therapy for treating fever.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then launched Caldolor and continue to promote the product in the U.S. through our hospital sales force.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed a series of Phase IV studies to gather additional data to support our Caldolor product. Those clinical trials involved another 1,000 adult and pediatric patients. These studies included data on a shortened infusion time and pre-surgical administration of the product. To address our Phase IV commitment to the FDA, these studies also included evaluation of the product for the reduction of fever in hospitalized children and the treatment of pain in children undergoing tonsillectomy surgeries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then received FDA approval for the use of Caldolor in pediatric patients 6 months of age and older. Caldolor is the first and only injectable non-steroidal anti-inflammatory drug approved for use in children. We subsequently initiated a study to collect data on the use of Caldolor in children ranging in age from birth up to 6 months of age. Enrollment in that study was completed in 2019.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2018, we completed and filed the application for FDA approval of a next generation Caldolor product featuring an improved presentation and formulation which was approved in January 2019. The new, premixed presentation provides healthcare professionals a formulation that is easy to administer, helping manage the treatment of patient pain and fever, while reducing opioid consumption. It is provided in a pre-mixed bag containing 800 mg of ibuprofen in a 200 mL patented low sodium formulation for injection that is ready to use. It is the first and only </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA-approved pre-mixed bag of ibuprofen. Caldolor is still available as an 800 mg/8mL single&#8211;dose vial for dilution in addition to the ready-to-use bag. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we initiated a full-scale launch of this ready-to-use product. Unfortunately, the launch was impacted by the COVID-19 pandemic and the resulting postponement of elective surgeries. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FDA approved our submission to expand the labeling for Caldolor to include administration of the product prior to surgery. During our clinical studies we found that the product delivered its best results when dosed prior to surgery, reducing both patient pain as well as their need for opiates.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we distributed both the vial and the ready-to-use premixed bag presentations of Caldolor. We also announced an agreement with PiSA Pharmaceutical for the registration and commercialization of Caldolor in Mexico. Under the terms of the agreement, Cumberland will be responsible for providing the product dossier and supplies. PiSA will be responsible for obtaining regulatory approval for the product in Mexico and introducing it to the new market. PiSA expects to provide the product in both 400- and 800-milligram vials.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose is a prescription laxative administered orally for the treatment of acute and chronic constipation. An innovative, dry powder crystalline formulation of lactulose, Kristalose is designed to enhance patient acceptance and compliance. It is the only prescription laxative available in pre-measured powder packets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose dissolves easily in 4 ounces of water, offering patients a virtually taste-free, grit-free and essentially calorie-free alternative to lactulose syrups. We conducted a preference study which indicated that 77% of patients surveyed prefer the taste, consistency and portability of Kristalose over similar products in syrup forms.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the assets and exclusive rights to Kristalose through a series of transactions, then assembled a dedicated field sales force which re-launched the product as a Cumberland brand. We directed our sales efforts to physicians who are the most prolific writers of prescription laxatives, including gastroenterologists and internists. We supplemented this personal promotion with telemarketing campaigns to expand our reach and support of the product. Using preference data as a cornerstone of our marketing efforts, we repositioned the brand, enhancing patient affordability through a coupon program and expanded managed care coverage for the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We added a co-promotion partner, Poly Pharmaceuticals, who is promoting Kristalose to physician targets not covered by our field sales forces. We then added another partner, Foxland Pharmaceuticals, Inc., who is repackaging Kristalose and featuring it with additional new physician targets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we continued to support Kristalose through our field sales force as well as our partnerships with Poly Pharmaceuticals and Foxland Pharmaceuticals, Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Kristalose award-winning marketing campaign was refreshed for 2022 to support increased engagement with our customers. We also expanded patient support for the brand and it was added to the GoodRx platform during the year.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Omeclamox-Pak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many ulcers of the gastrointestinal tract are caused by an infection from the Helicobacter pylori (&#8220;H. pylori&#8221;) bacterium. Omeclamox-Pak is a branded prescription product used for the treatment of these infections and the related duodenal ulcer disease. This innovative product combines three well-known and widely prescribed medications: omeprazole, clarithromycin, and amoxicillin.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak was the first FDA-approved triple therapy combination medication to contain omeprazole as the proton pump inhibitor, which works to decrease the amount of acid the stomach produces. Clarithromycin and amoxicillin are both antibiotic agents that hinder the growth of the H. pylori bacteria. Interaction of these agents allows the stomach lining to heal effectively. The medications are packaged together on convenient daily dosing cards, making it simple to follow the twice a day dosing before meals.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the assets and exclusive rights to Omeclamox-Pak through a series of transactions and re-launched the product as a Cumberland brand supported by our field sales force.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The packager for Omeclamox-Pak encountered financial difficulties due to the impact of COVID-19.  They are under new management and are in the process of a reorganization. Discussions with the packager are ongoing.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into an exclusive license and supply agreement to register and commercialize a methotrexate product line in the United States. RediTrex is a line of pre-filled syringes specifically designed for ease of handling and dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RediTrex treats patients with severe, active rheumatoid arthritis, and polyarticular juvenile idiopathic arthritis who have difficulty tolerating or responding to orally delivered methotrexate. It is also approved for symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With more than 54 million Americans living with some form of arthritis, the disease is among the most common causes of work disability in the U.S., according to the CDC. The oral form of methotrexate is typically the first line of treatment for rheumatoid arthritis. As the disease progresses, the dose must be increased to stay effective, often causing intolerable gastrointestinal side effects.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Injectable methotrexate has been proven to be more effective than oral delivery, with fewer gastrointestinal reactions. Because of the increased efficacy and tolerability, injectable methotrexate can delay the need to move to costly biologics, lowering overall patient treatment costs. Once disease progression requires the use of biologics, continuing the treatment of injectable methotrexate along with the biologic has been shown to increase overall efficacy.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other injectable methotrexate options available may not optimally meet the needs of arthritis patients who are offered either a vial and syringe for self-injection, or the use of an expensive autoinjector. The vial and syringe method can be difficult for a patient to handle due to limited dexterity in their hands. Additionally, obtaining the exact dose needed while preventing skin exposure to the caustic methotrexate can be quite challenging for many patients. The autoinjectors provide a better alternative to the vial and syringe, but they remove injection control from the patient and can be painful to administer. They are also the most expensive methotrexate delivery.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we received FDA approval for RediTrex and began planning for a launch of the product line. In late 2020, we received initial product supplies and then provided shipments of RediTrex to select accounts. Due to the pandemic, we delayed the national launch of the product, which was then implemented during the fourth quarter of 2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we entered into two amendments to our agreement with Nordic Pharma, who had provided us with a license for the U.S. rights associated with our RediTrex line.  Pursuant to these amendments, in exchange for financial consideration, Nordic may assume responsibility for distributing the methotrexate products in the U.S. after June 30, 2023.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2021, we entered into an agreement with Kyowa Kirin to acquire the U.S. assets and rights to Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (granisetron transdermal system), an FDA-approved oncology supportive care medicine. This transaction closed in January 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment for their cancer. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, we assumed full commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing, and medical support activities. Kyowa Kirin retained international rights, continuing to deliver the product to address oncology patients&#8217; needs throughout the rest of the world. In January 2022, we began shipments of the product and formed a new sales force, Cumberland Oncology, to support the brand. During this past year, we completed the transition of Sancuso from Kyowa Kirin to Cumberland. We have already seen Sancuso quickly become one of our most important brands and a significant contributor to our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the assets and rights to Vaprisol, a prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. It is one of two branded prescription products indicated for the treatment of hyponatremia, and the only intravenously administered branded treatment.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients. These electrolyte disturbances occur when the sodium ion concentration in the plasma is lower than normal and are often associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. Vaprisol raises serum sodium to appropriate levels and promotes free water secretion. Our Vaprisol product is one of two branded prescription products indicated for the treatment of hyponatremia, and the only intravenously administered branded treatment. It has a proven day-one response rate to normalize serum sodium levels in hyponatremic patients and move them out of the Intensive Care Unit as efficiently as possible.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol is supported by our hospital sales division. Demand for the product increased in 2020 during the pandemic, and we worked to support the expanded use of the product in hospitals and clinics during the health care crisis. During 2021, we shipped all remaining inventory of the product and have notified the FDA that supplies of the product are not currently available. We have since transferred manufacturing of the product to a new manufacturing facility. Our new manufacturing partner is working with the FDA to address several Form 483 and warning letter issues in a timely manner. Meanwhile, we are working with them to support a special, interim supply of compounded product for critically ill patients, while awaiting the needed facility approval to relaunch Vaprisol.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the Company announced an agreement to acquire the Vibativ assets and assume global responsibility for the brand including the related marketing, distribution, manufacturing and regulatory activities. In early 2021, we introduced the Cumberland-packaged product, which is supported by our hospital sales force.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ is a patented, FDA-approved injectable anti-infective. It is designed to treat serious infections due to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Staphylococcus aureus (&#8220;S. Aureus") </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other Gram-positive bacteria, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Methicillin-sensitive Staphylococcus aureus (&#8220;MSSA&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Vibativ addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ can serve as a potentially life-saving treatment in patients with hospital-acquired and ventilator-associated pneumonia resulting from infections including the flu, RSV and COVID-19.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pneumonia caused by secondary bacterial infections is common among patients with viral respiratory infections. The risk of such infections grows as hospitals see more patients with respiratory symptoms due to COVID-19. Research shows that hospital-acquired pneumonia (&#8220;HAP&#8221;) and ventilator-associated pneumonia (&#8220;VAP&#8221;) have historically accounted for 22% of common hospital-acquired infections. Methicillin-sensitive and methicillin-resistant </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">S. aureus </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;MSSA&#8221; and &#8220;MRSA&#8221;) are important disease-causing pathogens in these cases.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While many recently introduced antibiotics are quickly losing the battle to fight the bacteria they were designed to kill because those bacteria have become drug-resistant, Vibativ was specifically designed to kill drug-resistant bacteria. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The molecule of an existing antibiotic to which bacteria had developed a resistance, vancomycin, was altered by adding a lipophilic (fat-loving) component and a hydrophilic (water-loving) component. The lipophilic addition </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increases Vibativ&#8217;s ability to penetrate the cell wall and inhibits the formation of new cell walls (the development of new and/or additional cell walls is the most common way that bacteria become resistant to drugs). The hydrophilic addition increases Vibativ&#8217;s penetration into tissue &#8211; so it is able to attack infections that are not reachable by other antibiotics. In comparison to vancomycin, Vibativ is 32 times more potent against MRSA strains when tested under in vitro conditions. Further, in clinical trials, Vibativ demonstrated superior cure rates of patients with hospital-acquired bacterial pneumonia.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we remain focused on promoting Vibativ in the U.S. market, we are building a network of other established companies to bring Vibativ to patients in their countries and territories. In March 2022, we announced the launch of Vibativ in Puerto Rico through a partnership with Verity Pharmaceuticals, who has a particular strength and experience in that market. Also in March 2022, we announced a new partnership with Saudi Arabia-based Tabuk Pharmaceutical to introduce Vibativ into the Middle East. The arrangement provides Tabuk exclusive rights to distribute Vibativ in Saudi Arabia and Jordan, with the option to expand into other countries in the region.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Meanwhile, our Vibativ partner for the Chinese market, SciClone Pharmaceuticals, had their approval application in China accepted for review in September 2021. We have since been supporting SciClone and their requests associated with review of that submission. They are working toward the approval and SciClone believes that there is significant potential for Vibativ in their country.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PIPELINE</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ifetroban Clinical Studies</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ifetroban is a selective thromboxane-prostanoid receptor (&#8220;TPr&#8221;) antagonist dosed in nearly 1,400 subjects and found to be safe and well tolerated in healthy volunteers and various patient populations. We are currently sponsoring a series of Phase II clinical programs to evaluate our ifetroban product candidates in 1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aspirin-Exacerbated Respiratory Disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a severe form of asthma, 2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Systemic Sclerosis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 3) patients with cardiomyopathy associated with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Duchenne Muscular Dystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a genetic neuromuscular disease that results in deterioration of the skeletal, heart and lung muscles.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:26.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment in our clinical studies was interrupted due to the COVID-19 pandemic. However, many of our clinical study sites have reopened and resumed screening of patients for potential participation into our studies during 2022. We also closed unproductive sites and opened qualified replacements during the year. We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, our first new chemical entity.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is more information about the clinical programs in which we are evaluating ifetroban:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.05pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Aspirin-Exacerbated Respiratory Disease (&#8220;AERD&#8221;)</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed the manufacturing and initiated clinical development of an oral formulation of ifetroban under the brand name Boxaban</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are evaluating this candidate for patients suffering from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aspirin-Exacerbated Respiratory Disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;AERD&#8221;), also known as Samter&#8217;s Triad, a chronic medical condition that consists of three clinical features: asthma, sinus disease with nasal polyposis and sensitivity to aspirin. AERD is characterized by sharp increases in inflammatory mediators and platelet activity within the respiratory system. Approximately one in 20 asthmatic adults in the U.S. suffer from AERD and awareness of the disease is growing within the medical community. There is no U.S. approved pharmaceutical treatment for AERD.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Researchers at Brigham and Women&#8217;s Hospital have completed an investigator-initiated study evaluating the impact of ifetroban on the aspirin desensitization process in patients with AERD. This single center study closed early due to poor patient accrual and exhausted funding. The researchers found no statistical difference in the dose of aspirin needed to provide an increase in an extended version of the patient&#8217;s total nasal symptom score. The researchers are pursuing a publication of the full study results. It should be noted that the results from this investigator study were inconsistent with the previously published preclinical findings that demonstrated ifetroban blockade inhibited all features of aspirin reactions in a model of AERD. It also differs in design from our corporate-sponsored AERD studies.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed an initial Phase II clinical study at several U.S. medical centers led by the Scripps Research Institute entitled, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Determine the Safety of Oral Ifetroban in Patients with a History of AERD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. That study randomized 16 subjects 3:1 (ifetroban: placebo), demonstrated no safety concerns and provided several signals of efficacy. A follow-on phase II study designed to evaluate the safety and efficacy of eight weeks of oral ifetroban entitled, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A Phase 2 Multicenter, Double-blind, Randomized, Placebo- Controlled Trial to Evaluate Oral Ifetroban in Subjects with Symptomatic Aspirin Exacerbated Respiratory Disease (&#8220;AERD&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was then initiated. The patient enrollment in that study is now closed, and we are awaiting the completion of the data analysis and availability of top line study results.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Systemic Sclerosis (&#8220;SSc&#8221;)</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also initiated the clinical development of ifetroban oral capsules under the brand name Vasculan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Systemic sclerosis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also called scleroderma. It&#8217;s a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs, including the heart, as well as vascular dysfunction. SSc has a high morbidity and the highest case-specific mortality of any rheumatic disorder, with 50% of patients dying or developing major internal organ complications within three years of diagnosis. Although several medications are used to treat the skin disease associated with SSc, there is no universally effective treatment to improve the function of affected internal organs including the cardiovascular system.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiac involvement associated with SSc is often underestimated due to its subtle and atypical presentation. Despite the cardiovascular events associated with its elevated mortality at later stages of the disease, overt signs are suggestive of advance disease including myocardial or pericardial inflammation, heart failure and pulmonary arterial hypertension (&#8220;PAH&#8221;). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vanderbilt collaborators completed preclinical studies demonstrating TPr blockade with ifetroban prevents cardiac fibrosis and can restore cardiac function in animal models of PAH.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA cleared our Investigational New Drug (IND) application to evaluate 12 months of oral ifetroban (Vasculan) in a 34-subject phase II trial entitled, A </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase II Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients with Diffuse Cutaneous Systemic Sclerosis or Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment in this study is well underway and includes patients with diffuse cutaneous SSc, as well as those with pulmonary arterial hypertension associated with their SSc.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duchenne Muscular Dystrophy (&#8220;DMD&#8221;)</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also initiated the clinical development of oral ifetroban under the brand name Dyscorban</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of cardiomyopathy associated with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duchenne Muscular Dystrophy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;DMD&#8221;), a rare and fatal disease caused by a genetic defect which leads to inexorable muscle damage. Cardiomyopathy is the leading cause of death in DMD patients. TPr and its ligand, isoprostanes, are found to have increased in DMD patients.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies by our Vanderbilt collaborators demonstrated TPr blockade by ifetroban prevented cardiac dysfunction and improved mortality in several animal models of muscular dystrophy. These results, published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of the American Heart Association, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suggest TPr activation contributes to DMD cardiomyopathy and blockade with ifetroban may serve as a novel therapeutic for DMD patients.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA cleared Cumberland&#8217;s IND application to evaluate 12 months of oral ifetroban (Dyscorban) in a Phase II study entitled, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study with an Open-Label Extension to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects with Duchenne Muscular Dystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. With medical centers across the U.S. screening patients, our clinical study is enrolling those with 48 ambulatory and non-ambulatory DMD, 7 years of age and older with stable cardiac function.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland was awarded just over $1 million in federal funding to support this clinical trial, which is the first DMD clinical study awarded FDA Orphan Product Development funding. As a result of the COVID-19 pandemic and its global impact on clinical research in 2020, the FDA awarded a supplemental grant in support of our Phase II DMD study.  During 2022, patient enrollment in this DMD study continued.</span></div><div style="margin-top:8pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Progressive Fibrosing Interstitial Lung Diseases</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, our Board of Directors approved a new clinical program for the use of ifetroban to treat </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Progressive Fibrosing Interstitial Lung Diseases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;PF-ILDs&#8221;). Nonclinical studies are complete, and the resulting manuscript was prepared and submitted for publication in 2021. A Phase II clinical study is planned and an application to the FDA is in preparation to support this new clinical program.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Ifetroban Programs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also completed Phase II clinical programs with ifetroban in patients with Hepatorenal Syndrome (&#8220;HRS&#8221;) and patients with Portal Hypertension (&#8220;PH&#8221;). Additional preclinical and pilot clinical studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan going forward is to complete each of our Company-sponsored studies, analyze their final data, announce top-line results and decide on the best development path for the registration of ifetroban, which we continue to believe has the potential to benefit many patients with orphan diseases that represent unmet medical needs.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Hospital Product Candidate</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed the preclinical studies for a cholesterol-reducing agent for use in the hospital setting. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA. A Phase II study has been initiated and patient enrollment is complete. We have also completed the clinical study report, filed it with the FDA and continue to consider any next steps for this program. </span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_22"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GROWTH STRATEGY</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s growth strategy involves maximizing the potential of our existing brands while continuing to build a portfolio of differentiated products. We currently feature eight products approved by the FDA in the United States. We are also continuing to explore international partnerships to bring our medicines to patients in other countries. Additionally, we look for opportunities to expand our products into additional patient populations through clinical trials, new presentations and our support of select, investigator-initiated studies. We actively pursue opportunities to acquire additional marketed products as well as late-stage development product candidates in our target medical specialties. Our clinical team is developing a pipeline of new product candidates largely to address poorly met medical needs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supplementing these activities with the earlier-stage drug development at Cumberland Emerging Technologies (&#8220;CET&#8221;), our majority-owned subsidiary. CET partners with academic research institutions to identify and support the progress of promising new product candidates, which Cumberland has the opportunity to further develop and commercialize. Specifically, we are seeking long-term, sustainable growth by:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Supporting and expanding the use of our marketed products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our products following their FDA approval to determine if additional clinical data could expand their market and use. For example, we have secured pediatric approval of Acetadote and Caldolor and are expanding the labeling for both brands accordingly. We also recently further expanded the labeling for Caldolor to allow its use prior to surgery. We will continue to explore such opportunities to bring our products to new patient populations.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Selectively adding complementary brands. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our product development activities, we are also seeking to acquire products or late-stage development product candidates to continue to build a portfolio of complementary brands. We focus on under-promoted, FDA-approved drugs as well as late-stage development products that address poorly met medical needs. We will continue to target product acquisition candidates that are competitively differentiated, have valuable intellectual property or other protective features, and allow us to leverage our existing infrastructure. Our acquisition of Sancuso is an example of this strategy.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Progressing our clinical pipeline and incubating future product opportunities at CET.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe it is important to build a pipeline of innovative new product opportunities, as we are doing through our ifetroban Phase II development programs. We are also supplementing our acquisitions and late-stage development activities with early-stage drug development activities with CET.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Leveraging our infrastructure through co-promotion partnerships. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our commercial infrastructure can help drive prescription volume and product sales. We look for strategic partners that can complement our capabilities and enhance opportunities for our brands. For example, our co-promotion partnerships have allowed us to expand the support for Kristalose across the U.S.     </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Building an international contribution to our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have established our own commercial capabilities, including three sales divisions, to cover the U.S. market for our products. We are also building a network of select international partners to register our products and make them available to patients in their countries. We will continue to develop our network of international partners while supporting our partners&#8217; registration and commercialization efforts in their respective territories. The acquisition of Vibativ resulted in several new international partners and market opportunities. For example, we have new partnerships Tabuk Pharmaceutical for Vibativ in Saudi Arabia and PiSA Pharmaceutical for Caldolor in Mexico.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Managing our operations with financial discipline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continually work to manage our expenses in line with our revenues in order to deliver positive cash flow from operations. We remain in a strong financial position, with favorable gross margins and positive cash flow from operations. </span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_25"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SALES AND MARKETING</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland's sales and marketing team has broad industry experience in selling branded pharmaceuticals. Our sales and marketing executives direct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">national</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing campaigns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">key</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">national</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">account</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relationships. They also manage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dedicated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hospital,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">field</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oncology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forces, which are comprised of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">professionals. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hospital market:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We promote Caldolor, Vaprisol, Acetadote and Vibativ through our dedicated hospital sales division. This organization targets key hospitals across the U.S. and is comprised of sales professionals with substantial experience in the hospital market. Independent market data continues to indicate that the majority of pharmaceutical promotional spending is directed toward large, outpatient markets on drugs intended for chronic use rather than short-term, hospital use. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the hospital market is under-served and highly concentrated, and that it can be penetrated effectively by a small, dedicated sales force without large-scale promotional activity. Our established position in the hospital market provided the rationale for adding Vibativ as our first infectious disease product that complements our hospital product line. Our strategy has been to focus our hospital sales team on select, high-priority accounts. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gastroenterology market:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We promote Kristalose and Omeclamox-Pak through a dedicated field sales team addressing a targeted group of physicians who are large prescribers of the products. Because the market for gastrointestinal diseases is broad in-patient scope, yet relatively narrow in physician base, we believe it provides opportunities that can be penetrated with a modest-sized sales force. We also believe that we can increase market share for these products through our sales and marketing activities.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology market: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2022, we formed a new oncology sales force to promote our Sancuso brand. This organization targets key oncologists and clinics across the U.S. and is comprised of both inside and field-based sales professionals. The division is initially comprised of seven individuals who formerly supported Sancuso for Kyowa Kirin. This initial group can be expanded through additional personnel or augmented through co-promotion arrangements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial executives conduct ongoing analyses to evaluate marketing campaigns and promotional programs in support of our brands. The evaluations include development of product profiles, testing of the profiles against the needs of the market, determining what additional product information or development work is needed to effectively market the products and preparing financial forecasts. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize professional branding and packaging as well as promotional items to support our products, including direct mail, sales brochures, journal advertising, educational and reminder leave-behinds, patient educational pieces, coupons and product sampling. We also regularly attend select medical meetings and trade shows to expand the awareness of our products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our national accounts team is responsible for key large buyers and related marketing programs. This team maintains relationships with our wholesaler customers as well as with third-party payors such as group purchasing organizations, pharmacy benefit managers, hospital buying groups, outpatient centers, state and federal government purchasers, and health insurance companies. </span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_28"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL CUSTOMERS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary customers are wholesale pharmaceutical distributors in the United States. Total revenue by customer for each customer representing 10% or more of consolidated gross revenues are summarized below for the year ended December&#160;31, 2022:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.237%"><tr><td style="width:1.0%"></td><td style="width:64.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.463%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTERNATIONAL PARTNERSHIPS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established our own capabilities to support the commercialization of our products in the U.S.  Our international strategy is to identify and partner with other companies that have the appropriate capabilities to support our products in their respective countries. We have entered into a series of agreements to establish an international network, which is summarized in the table below and includes information on our primary partners:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:29.334%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International Partner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Phebra Pty Ltd</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote &amp; Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DB Pharm Korea Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandor Medicaids Pvt. Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GerminMED</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qatar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R-Pharm JSC</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tabuk Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Saudi Arabia and Jordan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PiSA Pharmaceutical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SciClone Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China and Hong Kong</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DB Pharm Korea Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ &amp; Vaprisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">WinHealth Pharma Group Co.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor &amp; Acetadote</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China and Hong Kong</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international commercialization agreements include a license to one or more Cumberland products for a specific territory as noted in the table above. We seek partners who have the local infrastructure to support the registration and commercialization of our products in their territory. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our agreements our partners are responsible for:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Seeking regulatory approvals for the products;</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Launching the brand;</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Managing the ongoing marketing, sales and product distribution; </span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Addressing the ongoing regulatory requirements in the international territories;</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Remitting any upfront, regulatory and sales milestone payments; </span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Providing the transfer price for supplies of the product; and</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Calculating and paying any royalties, as applicable. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our responsibilities include:</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Providing a dossier of relevant information to support product registration;</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Maintaining our intellectual property associated with the product;</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Sharing our marketing strategy, experience and materials for the brand; and</span></div><div style="margin-top:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Manufacturing and providing the finished product for sale.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we worked to support our existing international partners, conclude unproductive arrangements and  identify new companies to represent our products in select additional territories. </span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_34"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BUSINESS DEVELOPMENT</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have had an active business development initiative focused on acquiring rights to marketed products and product candidates that fit our strategy and target markets. We source business development opportunities through our international network of advisory firms and individual pharmaceutical industry and medical advisors. A multi-disciplinary internal management team reviews these opportunities on a regular basis using a group of selection criteria. We have historically focused on product opportunities that are a strategic fit with our commercial organization, development expertise and medical focus, employing a variety of transaction structures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have continued to build our product portfolio of complementary, niche brands largely through product acquisitions and late-stage development of product candidates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary targets are under-promoted, FDA - approved drugs with existing brand recognition and late-stage development product candidates that address unmet or poorly met medical needs in the hospital acute care, gastroenterology and oncology markets. We believe that by focusing mainly on approved or late-stage products, we can minimize the significant risk, cost and time associated with drug development.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to strategically review our brands, pipeline and capabilities, as well as our international partners. We believe that it is prudent to continually evaluate our product portfolio, partners, and organization in order to ensure a proper focus and the needed supporting capabilities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Partners</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.B. Pharm Korea Co., Ltd. (&#8220;D.B. Pharm&#8221;) has licensed our Caldolor product for the South Korean market, and they obtained regulatory approval for Caldolor in their country. During 2022, D.B. Pharm continued to purchase supplies of Caldolor and distributed the brand in South Korea. We have also entered into agreements with D.B. Pharm to register and commercialize our Vaprisol and Vibativ brands in their country. During 2022, we worked with them to prepare the submissions for the approval of each brand there.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have executed a license and distribution agreement with HongKong WinHealth Pharma Group Co. Limited (&#8220;WinHealth&#8221;) for our Caldolor and Acetadote brands in China and Hong Kong. Under the terms of the agreement, WinHealth will provide development milestone payments and purchase supplies of the products following their registration in China.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also entered into a strategic alliance agreement with WinHealth to explore future business opportunities that will further the mission and goals of each organization. Founded in Hangzhou, China and currently headquartered in Hong Kong, WinHealth has developed a wide breadth of capabilities, including drug licensing, product development and registration, and has established a strong network of distribution and sales promotional capabilities for the Chinese market. WinHealth has established partnerships with international companies that include Boehringer-Ingelheim, Janssen, Novartis, Pfizer and Roche, generating several hundred million dollars in sales annually.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an agreement with WinHealth Investment (Singapore) Ltd. creating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">WHC Biopharmaceuticals, Pte. Ltd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The joint venture will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R-Pharma JSC (&#8220;R Pharma&#8221;) has licensed our Vibativ product for a territory that includes Russia and a number of adjacent countries in Eastern Europe. R-Pharma is one of the leading multinational pharmaceutical organizations based in Russia. Headquartered in Moscow and focusing on a wide breadth of therapeutic areas in the specialty and hospital care markets, R-Pharma generates $1 billion in annual revenue. R-Pharma has registered Vibativ in Russia and during 2022, continued to purchase supplies of the product for that market. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SciClone Pharmaceuticals (Holdings) Limited (&#8220;SciClone&#8221;) has licensed our Vibativ product for sale and distribution in China and several adjacent countries. In February 2021, SciClone completed an initial public offering and listing of their shares on the Hong Kong stock exchange. In June 2021, SciClone submitted an application to the Chinese regulatory authority for the approval of Vibativ in that country. In October 2021, SciClone informed us that the filing was accepted by the regulatory agency for review. SciClone is in the review period of their application and believes that the potential for Vibativ in China may be significant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we signed an agreement with Verity Pharmaceuticals International Limited (&#8220;Verity&#8221;) to license and commercialize our Vibativ product in Puerto Rico. Verity is a specialty pharmaceutical company with commercial operations in the U.S. and Canada. They have a particular strength and experience in the Puerto Rican market.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we established distribution for our Vibativ product in the Middle East through a partnership with Tabuk Pharmaceutical Manufacturing Company. Through our partnership, Tabuk will introduce the product in Saudi Arabia, Jordan and potentially other countries in the Middle East.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced an agreement with PiSA Pharmaceutical for the registration and commercialization of Caldolor in Mexico. Under the terms of the agreement, Cumberland will be responsible for providing the product dossier and supplies. PiSA will be responsible for obtaining regulatory approval for the product in Mexico and introducing it to the new market. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Verity Co-Promotion Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into an agreement with Verity Pharmaceuticals International Limited (&#8220;Verity&#8221;) for the national co-promotion of Sancuso&#174;. Verity is a specialty pharmaceutical company that agreed to utilize its established oncology commercial organization to co-promote Sancuso throughout the United States. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verity was to provide sales representation in the U.S. market for an initial three-year term, with an option to extend for an additional two years. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we sent a 30-day notice of default to Verity due to failure of the parties to reach agreement regarding fundamental elements of the agreement, including targets and detailing obligations, among other items. As a result, the agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">erminated effective February 25, 2023. We hope to work with Verity to seek a new arrangement for their continued co-promotion of Sancuso.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Poly Co-Promotion Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a co-promotion arrangement with Poly Pharmaceuticals, Inc. (&#8220;Poly&#8221;) for our Kristalose product in 2017. Poly is a privately held U.S. specialty pharmaceutical company that is featuring Kristalose to an expanded number of physicians. Poly&#8217;s sales organization is more than doubling the number of nationwide physicians that are reached with the Kristalose brand message. In 2019, we extended our co-promotion arrangement with Poly.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2R and Foxland Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we entered into another co-promotion arrangement related to our Kristalose product. We have agreements with 2R Investments, LLC and with Foxland Pharmaceuticals, Inc. ("Foxland") to package, distribute and promote an authorized generic form of our Kristalose product to physician targets that we do not cover.  We renewed our agreement with Foxland in 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nordic License Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into an amendment to our agreement with Nordic Pharma (&#8220;Nordic&#8221;) that addresses the responsibilities and financial arrangements regarding our license to Nordic&#8217;s methotrexate line of products for the U.S. Our line of prefilled methotrexate syringes, marketed under the brand name RediTrex in the U.S., is covered by the license.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the amendment, Nordic may assume responsibility for commercializing the methotrexate products in the U.S. after June 30, 2023. We will continue to distribute and support the RediTrex product line during a transition period until then. Following the return of the license, Nordic will provide us with a royalty on their future sales of the products through April 2035. The companies will continue to collaborate on any transition and the ongoing commercialization of the product line.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland transferred the marketing authorization associated with the RediTrex product line to Nordic. Nordic returned the 180,000 shares we issued to them that were associated with the license and refunded the $1 million we paid them following the brand&#8217;s approval in the U.S. Nordic has also issued a credit note in favor of Cumberland in the amount of $1 million for the unpaid milestone payment due from us which was associated with our launch of the product line.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinigen Strategic Dissolution Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously entered into an agreement with the Clinigen Group plc ("Clinigen"), an international specialty pharmaceutical and services company, to commercialize select Clinigen products in the U.S. In May 2016, we announced an agreement with Clinigen to acquire an exclusive license and commercialize Ethyol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. We then announced in January 2017, our second agreement with Clinigen to acquire an exclusive license and launch Totect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, following a strategic review of our partners, products and organization, we entered into a dissolution agreement with Clinigen in which Cumberland returned the exclusive rights to commercialize Ethyol and Totect in the United States to Clinigen. Under the final terms of the amended dissolution agreement we transitioned from our current arrangement with Clinigen effective December 31, 2019. Under the terms of the agreement, Cumberland was no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products. In exchange for the return of these product license rights and not competing with either product, we received $5 million in financial consideration paid over the two-years ending December 31, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CET University Collaboration Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through CET, we collaborate with a select group of academic research institutions located in the Mid-South region of the U.S. to identify, co-develop and seek grant funding for promising biomedical technologies emerging from those research institutions. CET is collaborating with Vanderbilt University and other regional academic research institutions and has entered into a series of agreements to access and collaborate on the development of innovative product candidates. These arrangements enable CET to team with university-based researchers to advance their scientific discoveries and breakthroughs by designing new product candidates to improve patient care and address unmet medical needs. CET has been able to help secure federal small business grant funding to support these various projects.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, CET operates a Life Sciences Center in downtown Nashville to house its own research and development activities while  providing laboratory space for other biomedical ventures.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_37"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLINICAL AND REGULATORY AFFAIRS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in-house capabilities for the management of our clinical, professional and regulatory affairs. Our team develops and manages our clinical trials, prepares regulatory submissions, manages ongoing product-related regulatory responsibilities and manages our medical information call center. Team members have been responsible for devising the regulatory and clinical strategies for all our products as well as obtaining FDA approvals for Acetadote, Caldolor and RediTrex brands.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical development personnel are responsible for: </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">creating clinical development strategies; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">designing, implementing and monitoring our clinical trials:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">creating case report forms and other study-related documents; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">analyzing efficacy and safety data obtained from clinical trials for subsequent submissions and approval of new drugs.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory and Quality Affairs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal regulatory and quality affairs team is responsible for: </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing and submitting INDs for clearance to begin patient studies;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparing and submitting NDAs and fulfilling post-approval marketing commitments; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining investigational and marketing applications through the submission of appropriate reports; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submitting supplemental applications for additional label indications, product line extensions and manufacturing improvements;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating regulatory risk profiles for product acquisition candidates, including compliance with manufacturing, labeling, distribution and marketing regulations;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitoring applicable third-party service providers for quality and compliance with current Good Manufacturing Practices ("GMPs"), Good Laboratory Practices ("GLPs"), and Good Clinical Practices ("GCPs"), and performing periodic audits of such vendors; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining systems for document control, product and process change control and customer complaints. </span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_40"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROFESSIONAL AND MEDICAL AFFAIRS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical team provides in-house, medical information support for our marketed products. This includes interacting directly with healthcare professionals to address any product or medical inquiries through our medical information call center and medical science liaisons. In addition to coordinating the call center, our clinical/regulatory group generates medical information letters, provides informational memos to our sales forces and assists with ongoing training for the sales forces.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_43"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CLINICAL DEVELOPMENT AND STUDY RESULTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ Clinical Manuscripts</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2019, we announced a publication in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Infectious Diseases and Therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with study results showing numerically superior cure rates of telavancin compared to vancomycin within a subset of patients who were enrolled in Phase 3 ATTAIN trials and had hospital-acquired pneumonia caused by bacteria with low susceptibility to vancomycin. Additionally, an online publication in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drugs - Real World Outcomes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, detailed the positive clinical outcomes that resulted from treating multiple infection types with Vibativ, including complicated skin infections, bone and joint infections, bacteremia and endocarditis, and lower respiratory tract infections.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Cumberland announced a new study published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drugs - Real World Outcomes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, detailing the positive clinical outcomes that resulted from treating patients with bacteremia or endocarditis with Vibativ. This publication is a sub analysis of The Telavancin Observational Use Registry (TOUR&#8482;), a study conducted to record population characteristics, prescription information, and real-world clinical outcomes of patients with Gram-positive infections treated with Vibativ. The analysis suggests Vibativ is a promising and viable option for patients with bacteremia or endocarditis, including those with MRSA or another S. aureus pathogen.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in May 2020, we announced the publication of two studies confirming the continued in vitro potency of telavancin. Both publications were part of continued surveillance of telavancin activity since 2011. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first publication tested a global collection of 24,408 Gram-positive clinical isolates, and the second publication tested a U.S. collection of 15,882 S. aureus isolates. Both studies documented the sustained in vitro antimicrobial activity and spectrum of telavancin&#8212;many years after its clinical approval&#8212;against Gram-positive clinical isolates collected worldwide over seven years, from 2011 through 2017.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caldolor Clinical Manuscripts</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we announced a study published in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Orthopedic Trauma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, evaluating the efficacy of Caldolor administration in the management of acute pain in orthopedic trauma patients. The study also measured Caldolor&#8217;s ability in minimizing opioid use. This single-center, randomized, double-blind, placebo-controlled study found that Caldolor (ibuprofen) Injection reduced the quantity of opioids required to manage pain after a traumatic injury with fracture. In addition, the time to first narcotic medication was longer in the Caldolor group than with hospital standard of care. Pain was also managed better in the Caldolor group compared to standard of care narcotics. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in August 2020, we announced the results of a review of nine clinical studies evaluating Caldolor. The comprehensive review was published in the journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Therapeutics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and involved 1,062 adult patients, with 757 receiving Caldolor and 305 receiving placebo or a comparator medication. The data noted that the use of Caldolor improved post-surgery recovery, decreased surgical stress, and reduced the use of opioids and over-the-counter medication. The study determined that patients given Caldolor experienced less postoperative pain and decreased opioid use. Study authors also concluded that the rapid administration and preemptive use of Caldolor should be considered in Enhanced Recovery After Surgery protocols for the management of postoperative pain including that of traumatic origin. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caldolor Newborn Study</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously received FDA approval for the use of Caldolor in pediatric patients six months of age and older. Caldolor is the first and only injectable NSAID approved for use in children.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then initiated a study to collect data on the use of Caldolor in children ranging in age from birth up to six months of age. Enrollment in that multi-center study was completed in 2019, and topline results were announced in 2020, indicating that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor was well tolerated in this patient population, with no safety concerns noted. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Colic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Study</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we report results from a clinical trial studying the comparison of intravenous ibuprofen with injectable ketorolac in renal colic pain management demonstrated that ibuprofen is the more rapid-acting drug in controlling pain caused by kidney stones. The study also indicated that the complete relief from pain with ibuprofen was twice as much as that of ketorolac. The findings build upon a body of medical evidence supporting the use of our Caldolor product for the treatment of patient pain.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hyponatremia Publication</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 we also reported on The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Outcome Predictive Evaluation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;HOPE&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 Registry Analysis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It was an international study of over 4,000 patients published in November 2020, found that patients hospitalized with COVID-19 had a high risk of developing hyponatremia. These COVID-19 patients also had a higher incidence of mortality due to their hyponatremia. The study results support the use of an intravenous vaptan to treat hyponatremia in critically ill patients afflicted with COVID-19.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hyponatremia, an imbalance of serum sodium to body water, is the most common electrolyte disorder among hospitalized patients. Our Vaprisol product is one of two branded prescription products indicated for the treatment of hyponatremia, and the only intravenously administered branded treatment. Vaprisol has a proven day-1 response rate to normalize serum sodium levels in hyponatremic patients and move them out of the Intensive Care Unit as efficiently as possible.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ifetroban Phase II Studies</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating our ifetroban product candidate in a series of clinical studies. We have three Phase II clinical programs underway evaluating our ifetroban product candidate in 1)  Aspirin-Exacerbated Respiratory Disease, a severe form of asthma, 2) Systemic Sclerosis or scleroderma, a debilitating autoimmune disorder characterized by diffuse fibrosis of the skin and internal organs and 3) patients with cardiomyopathy associated with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duchenne Muscular Dystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a rare, fatal, genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles. Investigational new study applications have been cleared by the FDA enabling us to launch clinical studies in each of these areas.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also completed two pilot Phase II studies involving 1) patients suffering from Hepatorenal Syndrome, a life-threatening condition involving liver and kidney failure and 2) patients with Portal Hypertension associated with chronic liver disease. There</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identified</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ifetroban</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional pilot studies of ifetroban are underway, including several investigator-initiated trials. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enrollment in our clinical studies was interrupted during 2021 and 2020 due to the COVID-19 pandemic. In 2022, many of our clinical study sites have reopened and resumed screening of patients for potential enrollment into our studies. We are awaiting results from the studies underway before deciding on the best development path for the registration of ifetroban, our first new chemical entity.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Hospital Product Candidate Study</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland was responsible for the formulation, development and FDA approval of both Acetadote and Caldolor. Our Medical Advisory Board has helped us identify additional opportunities that address unmet or poorly met medical needs. As a result, Cumberland has successfully designed, formulated and completed preclinical studies for a cholesterol reducing agent for use in the hospital setting. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously completed a Phase I study which defined the pharmacokinetic properties and provided a favorable safety profile for this new product candidate. The study results and a proposed clinical development plan were discussed with the FDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase II study has been initiated and patient enrollment completed. We have completed the study report, filed it with the FDA and continue to consider next steps for this product development program.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Additional Testing Program</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland entered into a non-clinical evaluation agreement, to test one of our products against bacterial strains utilizing the preclinical services program funded by the Division of Microbiology and Infectious Diseases (&#8220;DMID&#8221;), part of the National Institute of Allergy and Infectious Diseases (&#8220;NIAID&#8221;),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an institute of the National Institutes of Health (&#8220;NIH&#8221;), which is part of the Department of Health and Human Services (&#8220;HHS&#8221;), an agency of the U.S. government.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_46"></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE DEVELOPMENT</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumberland</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foundation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have formed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumberland Pharma Foundation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Foundation&#8221;) to provide the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as an independent, nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities including charitable contributions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initially provided a grant of 50,000 shares of our common stock to the Foundation. The shares will address the ongoing financial needs of the Foundation, with most of the shares expected to be held for the opportunity to realize long term appreciation to support the Foundation&#8217;s future.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation maintains independent financial statements and its contributions will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumberland Health and Wellness Political Action Committee</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also formed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumberland Health and Wellness Political Action Committee </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;PAC&#8221;). The objective of the PAC is to support candidates and policies that are consistent with Cumberland&#8217;s mission of advancing patient care.  The PAC&#8217;s activities will be at the local, state and federal level and conducted in a bi-partisan manner. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial committee membership is comprised of Cumberland Pharmaceuticals employees. The PAC received initial funding from us, and future funding will include voluntary individual contributions from Cumberland Pharmaceuticals directors and employees.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_49"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING AND DISTRIBUTION</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We partner with third parties for certain non-core, capital-intensive capabilities, including the manufacturing and distribution of our products. We manage these third-party relationships and are responsible for the quality review and release of each lot of our products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an agreement with one manufacturer, who provided commercial supplies of Acetadote in 2022. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with multiple manufacturers for the supply of Caldolor and during 2022 we obtained commercial supplies from three of these manufacturers for our international and domestic Caldolor requirements. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an agreement for the purchase of Kristalose API with an international supplier.  We also had manufacturing arrangements with a packager who provided finished supplies of the product for commercial and sampling purposes during 2022.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omeclamox-Pak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The packager for Omeclamox-Pak encountered financial difficulties in 2020 due to the economic impact of COVID-19, and their operations are currently suspended. As a result, we depleted our inventory of the product and notified the FDA that the product is currently unavailable. We are awaiting resumption of those operations, while also exploring other alternatives to restart the product&#8217;s packaging.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we entered into an agreement to acquire the exclusive U.S. rights to an injectable methotrexate product line of pre-filled syringes. In 2019, we received FDA approval for the product line. Our licensor is responsible for providing us the packaged and labeled commercial supply of the product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we entered into two amendments to our agreement with Nordic Pharma. Pursuant to the amendments, in exchange for financial consideration, Nordic may assume responsibility for distributing the methotrexate products in the U.S. after June 30, 2023.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Sancuso, we obtained an initial supply of finished goods inventory. The agreement with the manufacturer of Sancuso was assigned to us and there were additional goods supplied to us during 2022. The production is in the process of being moved to one of the manufacturer&#8217;s other facilities. In late 2022, that new facility was approved by the FDA to manufacture and supply Sancuso. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the acquisition of Vaprisol, we obtained a significant existing supply of raw material inventory. We reached an agreement during 2020 with a new manufacturer to provide us with long-term supplies of the product. We subsequently completed the transfer of the product&#8217;s manufacturing to the new facility in 2021. We informed the FDA that supplies of the product are not currently available and are awaiting approval for that new facility. Our new manufacturing partner is working with the FDA to address several Form 483 and warning letter issues in a timely manner. Meanwhile, we are working with them to support a special, interim supply of compounded product for critically ill patients, while awaiting the needed facility approval to relaunch Vaprisol.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our acquisition of Vibativ, we obtained a multi-year supply of raw material, work in process and finished goods inventory. As a result of the agreement, we are now responsible for the future manufacturing of the product.  We completed the transfer of the product&#8217;s manufacturing activities to a new supplier and received FDA approval for that facility.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like many pharmaceutical companies, we engage a third-party with appropriate facilities and logistical expertise to support the U.S. distribution of our products.  In 2022, Cardinal Health Specialty Solutions exclusively handled our U.S. product logistics activities, including warehousing, shipping, and various other customer activities.  Our primary customers are the wholesalers of pharmaceuticals who provide our products to hospitals, clinics and retail pharmacies in the U.S.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_52"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PATENTS, TRADEMARKS AND OTHER INTELLECTUAL PROPRIETARY RIGHTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own the trademarks for each of our branded pharmaceutical products as well as for our corporate name and logo. We have applied for trademark registration for other various names and logos.  Over time, we intend to maintain registrations on trademarks that remain valuable to our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect our products from competition through a combination of patents, trademarks, trade secrets, FDA exclusivity and contractual restrictions on disclosure. Proprietary rights, including patents, are an important element of our business. We seek to protect our proprietary information by requiring our employees, consultants, contractors and other advisors to execute agreements providing for protection of our confidential information upon commencement of their employment or engagement. We also require confidentiality agreements from entities to which we provide our confidential information or materials.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed a new formulation of Acetadote (acetylcysteine) Injection as part of a Phase IV commitment in response to a request by the FDA to evaluate the reduction of ethylene diamine tetraacetic acid ("EDTA") from the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product's formulation.  In April 2012, the USPTO issued U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to us. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the issuance of the 356 Acetadote Patent, we received separate Paragraph IV certification notices from InnoPharma, Inc. ("InnoPharma"), Paddock Laboratories, LLC (&#8220;Paddock&#8221;), Mylan Institutional LLC (&#8220;Mylan&#8221;), Sagent Agila LLC ("Sagent") and Perrigo Company ("Perrigo") challenging the 356 Acetadote Patent on the basis of non-infringement and/or invalidity. We responded by filing five separate infringement lawsuits, in the appropriate United States District Courts, to contest each of the challenges. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2012, we entered into a Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Paddock and Perrigo to resolve the challenges and the pending litigation with those two companies.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2013, the United States District Courts filed opinions granting Sagent&#8217;s and InnoPharma&#8217;s motions to dismiss our suits and we agreed not to file an appeal or motion to reconsider, thereby resolving the challenges and the pending litigation with those two companies. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Settlement Agreement, Paddock and Perrigo admit that the 356 Acetadote Patent is valid and enforceable and that any Paddock or Perrigo generic version of Acetadote (with or without EDTA) would infringe upon the 356 Acetadote Patent. In addition, Paddock and Perrigo will not challenge the validity, enforceability, ownership or patentability of the 356 Acetadote Patent through its expiration currently scheduled for May 2026. On November 12, 2012, in connection with the execution of the Settlement Agreement, we entered into a License and Supply Agreement with Paddock and Perrigo (the &#8220;License and Supply Agreement&#8221;).  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the License and Supply Agreement, if a third party  receives final approval from the FDA for an ANDA to sell a generic Acetadote product and such third party made such generic version available for purchase in commercial quantities in the United States, we are to supply Perrigo with an Authorized Generic version of our Acetadote product.   </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;18, 2012, we also submitted a Citizen Petition to the FDA requesting that the FDA refrain from approving any applications for acetylcysteine injection that contain EDTA, based in part on the FDA's request that we evaluate the reduction or removal of EDTA from our original Acetadote formulation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2012, the FDA responded to the Citizen Petition denying our request and on November 8, 2012, we learned that the FDA approved the ANDA referencing Acetadote filed by InnoPharma, Inc. We brought suit against the FDA contesting the FDA's decision to approve the InnoPharma generic on November 13, 2012. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2013, the United States District Court filed an opinion granting a summary judgment in favor of the FDA regarding this suit.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, during 2012 the FDA approved the ANDA referencing Acetadote filed by InnoPharma, Inc. Upon this condition, in accordance with the License and Supply agreement with Perrigo, we began to supply Perrigo with our Authorized Generic.  On January 7, 2013, Perrigo announced initial distribution of our Authorized Generic acetylcysteine injection product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2013, the USPTO issued U.S. Patent number 8,399,445 (the &#8220;445 Acetadote Patent&#8221;) which is assigned to us. The claims of the 445 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose. On April 8, 2013, the 445 Acetadote Patent was listed in the FDA Orange Book. The 445 Acetadote Patent is scheduled to expire in August 2025. Following the issuance of the 445 Acetadote Patent we received separate Paragraph IV certification notices from Perrigo, Sagent Pharmaceuticals, Inc., and Mylan challenging the 445 Acetadote Patent on the basis of non-infringement, unenforceability and/or invalidity.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 10, 2013, we became aware of a Paragraph IV certification notice from Akorn, Inc. challenging the 445 Acetadote Patent and the 356 Acetadote Patent on the basis of non-infringement. On July 12, 2013, we filed a lawsuit for infringement of the 356 Acetadote Patent against Akorn, Inc. in United States District Court.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2014, the USPTO issued U.S. Patent number 8,653,061 (the &#8220;061 Acetadote Patent&#8221;) which is assigned to us. The claims of the 061 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acetaminophen overdose.  Following its issuance, the 061 Acetadote Patent was listed in the FDA Orange Book. The 061 Acetadote Patent is scheduled to expire in August 2025.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 13, 2014, the USPTO issued U.S. Patent number 8,722,738 (the &#8220;738 Acetadote Patent&#8221;) which is assigned to us.  The claims of the 738 Acetadote Patent encompass administration methods of acetylcysteine injection, without specification of the presence or lack of EDTA in the injection. Following its issuance, the 738 Acetadote Patent was listed in the FDA Orange Book and it is scheduled to expire in April 2032.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2014, and March 3, 2015, we became aware of Paragraph IV certification notices from Aurobindo Pharma Limited and Zydus Pharmaceuticals (USA) Inc., respectively, challenging the 356, 445, 061, and 738 Acetadote Patents on the basis of non-infringement.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2015, the USPTO issued U.S. Patent number 8,952,065 (the &#8220;065 Acetadote Patent&#8221;) which is assigned to us.  The claims of the 065 Acetadote Patent encompass the use of the 200 mg/ml Acetadote formulation to treat patients with acute liver failure.  The 065 Acetadote Patent is scheduled to expire in August 2025.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2015, the United States District Court for the Northern District of Illinois, Eastern Division ("District Court") ruled in our favor in our lawsuit against Mylan for infringement of the 445 Acetadote Patent. &#160;The opinion upheld&#160;our 445 Acetadote Patent and expressly rejected Mylan's validity challenge. &#160; The District Court ruled&#160;that Mylan is liable to us for infringement of the 445 Acetadote patent in light of Mylan's&#160;Abbreviated New Drug Application in which Mylan sought to market a generic version of Acetadote.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2015, the District Court entered an order enjoining Mylan and its affiliates from selling or using its generic version of Acetadote until August 2025, the date of expiration of the 445 Acetadote Patent. On October 30, 2015, Mylan filed a notice of appeal to the U.S. Court of Appeals for the Federal Circuit (the "Appeals Court").</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2016, the USPTO issued U.S. Patent number 9,327,028 (the &#8220;028 Acetadote Patent&#8221;) which is assigned to us. The claims of the 028 Acetadote Patent encompass administration methods of acetylcysteine injection, without specification of the presence or lack of EDTA in the injection. Following its issuance, the 028 Acetadote Patent was listed in the FDA Orange Book and it is scheduled to expire in July 2031.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 26, 2017, the Appeals Court affirmed the District Court ruling in our favor in our lawsuit against Mylan for infringement of the 445 Acetadote Patent. The Appeals Court opinion affirmed the District Court&#8217;s ruling upholding our 445 Acetadote Patent and expressly rejected Mylan's validity challenge.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2017, we became aware of a Paragraph IV certification notice from Exela Pharma Sciences, LLC challenging the 356, 445, 061, 738, and 028 Acetadote Patents on the basis of non-infringement.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive, worldwide license to clinical data for intravenous ibuprofen from Vanderbilt University, in consideration for royalty obligations related to Caldolor.  During 2014, we obtained additional patents for the brand. On May 27, 2014, the USPTO issued U.S. Patent number 8,735,452 (the &#8220;452 Caldolor Patent&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is assigned to us.  The claims of the 452 Caldolor Patent encompass methods of treating pain using intravenous ibuprofen.  Following its issuance, the 452 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2014, the USPTO issued U.S. Patent number 8,871,810 (the &#8220;810 Caldolor Patent&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which is assigned to us.  The claims of the 810 Caldolor Patent encompass methods of treating pain using intravenous ibuprofen.   Following its issuance, the 810 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2015, we obtained four additional patents for Caldolor.  On July 7, 2015, the USPTO issued U.S. Patent number&#8217;s 9,072,710 (the &#8220;710 Caldolor Patent&#8221;) and 9,072,661 (the &#8220;661 Caldolor Patent&#8221;) which are assigned to us.  The claims of the 710 Caldolor Patent and the 661 Caldolor Patent include composition and methods of treating pain, inflammation and fever using intravenous ibuprofen.  These Caldolor Patents are listed in the FDA Orange Book and are scheduled to expire in March 2032. On April 21, 2015, the USPTO issued U.S. Patent No. 9,012,508 (the &#8220;508 Caldolor Patent&#8221;) which is assigned to us.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims of the 508 Caldolor Patent include methods of treating pain using intravenous ibuprofen.  Following its issuance, the 508 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2030.  On August 25, 2015, the USPTO issued U.S. Patent number 9,114,068 (the &#8220;068 Caldolor Patent&#8221;) which is assigned to us.  The claims of the 068 Caldolor Patent include methods of treating pain using intravenous ibuprofen.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following its issuance, the 068 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029.  On September 22, 2015, the USPTO issued U.S. Patent number 9,138,404 (the &#8220;404 Caldolor Patent&#8221;) which is assigned to us.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims of the 404 Caldolor Patent include methods of treating pain in critically ill patients with intravenous ibuprofen.  Following its issuance, the 404 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2016, the USPTO issued U.S. Patent number 9,295,639 (the "639 Caldolor Patent") which is assigned to us.  The claims of the 639 Caldolor Patent include methods of treating pain in critically ill patients with intravenous ibuprofen.  Following its issuance, the 639 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2017, the USPTO issued U.S. Patent number 9,649,284 (the "284 Caldolor Patent") which is assigned to us.  The claims of the 284 Caldolor Patent include methods of treating pain in critically ill patients with intravenous ibuprofen.  Following its issuance, the 284 Caldolor Patent was listed in the FDA Orange Book and is scheduled to expire in September 2029. We also have additional patent applications related to Caldolor pending with the USPTO.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own numerous U.S. patents and related international patents for Vibativ. These patents were acquired in our November 2018 acquisition of certain product rights, intellectual property and related assets of Vibativ from Theravance.  Two Vibativ patents are listed in the FDA Orange Book.  U.S. Patent number 7,531,623 (the &#8220;623 Vibativ Patent&#8221;) is scheduled to expire in January 2027 and includes composition of matter claims that encompass the Vibativ drug substance as well as methods for preparing the Vibativ drug substance. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the owner of U.S. Patent number 7,608,282 (the &#8220;282 Sancuso Patent&#8221;) for Sancuso. This patent was acquired in our December 2021 acquisition, that closed in January 2022, of certain product rights, intellectual property and related assets of Sancuso from Kyowa Kirin, Inc. The 282 Sancuso Patent is listed in the FDA Orange Book and is scheduled to expire in January 2025. The 282 Sancuso Patent includes composition of matter claims that encompass the Sancuso drug product as well as methods of using Sancuso for treatment and/or prophylaxis.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Products</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no issued patents for our Vaprisol, RediTrex, Omeclamox-Pak or Kristalose products. We have multiple granted patents relating to our ifetroban products and patent applications pending with the USPTO.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITION</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by intense competition and rapid innovation. Our continued success in developing and commercializing pharmaceutical products will depend, in part, upon our ability to compete against existing and future products in our target markets. Competitive factors directly affecting our markets include but are not limited to: </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product attributes such as efficacy, safety, ease-of-use and cost-effectiveness; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">brand awareness and recognition driven by sales, marketing and distribution capabilities; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property and other exclusivity rights; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of resources to build and maintain developmental and commercial capabilities; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful business development activities; </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extent of third-party reimbursements, insurance coverage; and </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of advantageous collaborations to conduct development, manufacturing or commercialization efforts.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our competitors possess research and development and sales and marketing capabilities as well as financial resources greater than ours. These competitors, in addition to emerging companies and academic research institutions, may be developing, or in the future could develop, new technologies that could compete with our current and future products or render our products obsolete.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products face competition from other branded products, generics, and alternate medical treatments. Our task is to position each brand to feature its competitive advantages, implement a well thought out marketing plan and provide focused sales and other tactical support. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acetadote</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote is our injectable formulation of N-acetylcysteine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NAC") for the treatment of acetaminophen overdose. NAC is accepted worldwide as the standard of care for acetaminophen overdose. Our competitors in the acetaminophen overdose market are those companies selling orally administered NAC including, but not limited to, Geneva Pharmaceuticals, Inc., Bedford Laboratories division of Hikma Pharmaceuticals, Roxane Laboratories, Inc., InnoPharma Inc. and Hospira Inc.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2012, InnoPharma Inc. was granted approval by the FDA to distribute their generic form of the old formulation of Acetadote containing EDTA.  In late 2012, we entered into the Settlement Agreement with Paddock and Perrigo that included the right to distribute our Authorized Generic Acetadote injection product.  Our branded Acetadote now competes with both the EDTA free Authorized Generic Acetadote distributed by Paddock and Perrigo along with generic Acetadote products that contain EDTA. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of the old Acetadote formulation include: Akorn, AuroMedics Pharma, Fresenius Kabi and Sagent Pharmaceuticals. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor is marketed for the treatment of pain and fever, primarily in a hospital or surgery center setting. A variety of other products address the acute pain market:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Morphine, the most commonly used product for the treatment of acute, post-operative pain, is manufactured and distributed by several generic pharmaceutical companies;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other generic injectable opioids, including fentanyl, meperidine and hydromorphone, address this market;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ketorolac tromethamine (brand name Toradol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an injectable NSAID, is also manufactured and distributed by several generic pharmaceutical companies;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IV acetaminophen (brand name Ofirmev</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an injectable analgesic product is sold by Mallinckrodt plc, and there are also generic versions from different manufacturers available; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Bupivacaine injectable suspension (brand name Exparel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold by Pacira Pharmaceuticals, Inc., two additional bupivacaine products, Xaracoll and Posimir, were more recently approved.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of other product candidates in development to treat acute pain including injectable NSAIDs, novel opioids, new formulations of existing therapies and extended release anesthetics. We believe non-narcotic analgesics for the treatment of post-surgical pain are the primary potential competitors to Caldolor.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the injectable analgesic products above, many companies are developing analgesics for specific indications such as migraine and neuropathic pain, oral extended-release forms of existing narcotic and non-narcotic products, as well as those with new methods of delivery such as transdermal. We are not aware of any approved injectable products indicated for the treatment of fever in the U.S. other than Caldolor and Ofirmev. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are, however, numerous drugs available to physicians to reduce fevers in hospital settings via oral administration to the patient, including ibuprofen, acetaminophen, and aspirin. These drugs are manufactured by numerous pharmaceutical companies.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kristalose</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose is a dry powder crystalline prescription formulation of lactulose indicated for the treatment of constipation. The U.S. constipation therapy market includes various prescription and over the counter, or OTC, products. The branded prescription products which we believe are our primary competitors are:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Lubiproston (brand name Amitiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of chronic  idiopathic constipation, irritable bowel syndrome with constipation in adults, is manufactured and sold by Mallinckrodt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceuticals.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Naloxegol (brand name Movantik</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of opioid-induced constipation in adults with chronic non-cancer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pain and recently acquired by RedHill Biopharma in the first quarter of 2020. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Linaclotide (brand name Linzess</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. It is sold by Allergan, Inc. and Ironwood Pharmaceuticals, Inc.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Plecanatide (brand name Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an oral product indicated for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is sold by Synergy Pharmaceuticals.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Generic and branded liquid lactulose products are marketed by a number of pharmaceutical companies.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Lactitol for oral solution (brand name Pizensy), an oral, osmotic laxative indicated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of chronic idiopathic constipation and distributed by Braintree Laboratories, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was recently approved by the FDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several hundred OTC products used to treat constipation marketed by numerous pharmaceutical and consumer health companies. MiraLax (polyethylene glycol 3350), previously a prescription product, was indicated for the treatment of constipation and manufactured and marketed by Bayer.  MiraLax was converted to an OTC product in February 2007 and recently, the FDA rescinded the approval of the generic prescription polyethylene glycol 3350 products.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Omeclamox-Pak</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak is a branded prescription product used for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease.  It combines three well-known and widely prescribed medications packaged in a daily dose pack for patient convenience: omeprazole, clarithromycin, and amoxicillin. The three individual components of Omeclamox-Pak are also available from other suppliers through three separate prescriptions. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are several competitor products, Omeclamox-Pak is one of the two actively marketed products for this condition.  In addition, compared to the competing products, Omeclamox-Pak has the lowest pill burden, fewest days of therapy and convenient twice daily dosing. The prescription combination products, indicated for treatment of H. pylori, which we believe are our primary competitors are:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PrevPac</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral product sold by Takeda Pharmaceutical Company.  There are also approved generic versions of PrevPac;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pylera</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral product manufactured and sold by Allergan plc; and</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Talicia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an oral product manufactured by RedHill Biopharma which was recently approved by the FDA.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RediTrex is methotrexate for subcutaneous administration in a unique syringe designed for ease of use, improved accuracy, and enhanced safety. It is indicated for treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and severe, recalcitrant, or disabling psoriasis unresponsive to alternative treatments.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This market is highly competitive with drugs from several different therapeutic classes available for treatment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Methotrexate is considered a standard of care especially when patients fail to respond adequately to low dose steroids or non-steroidal anti-inflammatory drugs (NSAIDs). Methotrexate is available in multiple dose forms including oral, subcutaneous, and intra-venous.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Methotrexate may be used alone or in combination with drugs from other therapeutic classes to adequately control patient symptoms.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RediTrex competes with other dose forms and delivery systems for methotrexate including, oral tablets, conventional vial and syringe administration, and auto-injector pens.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral tablets and conventional vials are generic and available from many suppliers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two auto-injector pen products available, Rasuvo and Otrexup. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RediTrex also competes with or may be used in combination with drugs from other therapeutic classes including, injectable biologics like Humira and Enbrel and oral JAK inhibitors like Xaljanz. These newer agents are more expensive than the methotrexate products but benefit from significant promotion to patients and doctors. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the only transdermal patch FDA approved for the management of chemotherapy induced nausea and vomiting (CINV). Each patch delivers up to 5 days of treatment with granisetron, a standard of care for CINV, through the skin. Recommended treatment suggests the patch be applied 24 to 48 hours prior to chemotherapy treatment and remain in place for five days.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:26.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are no other transdermal products available to treat CINV, there are a large number of generic and branded oral products as well as a limited number of injectables. Cumberland considers the oral branded products to be the most important competition including Akynzeo, Emend Oral, Varubi, Zuplenz, and Kytril.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaprisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. The product was developed and registered by Astellas and then launched in 2006. It is one of two branded prescription products indicated for the treatment of hyponatremia, and the first and only intravenously administered branded treatment.  The other competing product is Samsca, an oral product sold by Otsuka Pharmaceutical Company.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ is a potent, once-daily, injectable antibiotic for the treatment of certain gram-positive infections. Vibativ is approved for the treatment of complicated skin and skin structure infections and hospital-acquired or ventilator-associated bacterial pneumonia caused by susceptible isolates of Staphylococcus aureus when alternative treatments are not suitable. There are several generic and branded antibiotics that compete for these indications. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major generic competitors are vancomycin, linezolid, and daptomycin. Vancomycin is by far the most widely used agent. Newer branded agents are also available including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Ceftaroline fosamil (brand name Teflaro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ) an injectable antibiotic manufactured and sold by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allergan</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Dalbavancin (brand name Dalvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ), an injectable antibiotic manufactured and sold by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allergan</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Oritavancin (brand name Orbactiv</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ), an injectable antibiotic manufactured and sold by</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Melinta</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of a number of other novel antibiotics which are currently in development. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antibiotic drug selection is based both on an empiric and susceptibility proven basis. In the hospital setting, cost is an important factor which favors the use of generic agents as long as they are effective. Newer agents are often reserved for two reasons: they are valuable in the treatment of patients that fail to respond to generics and it is considered good practice to conserve the use of these agents to reduce the risk of resistance. </span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_58"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new pharmaceutical products can be a long, expensive and risky process. There is no assurance we will obtain successful study results or secure the needed market approvals for our pipeline product candidates. Governmental authorities in the U.S. and other countries extensively regulate the research, development, testing, manufacturing, distribution, marketing and sale of pharmaceutical products.  For more information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Risks Relating to Government Regulation"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1A of this Form 10K. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA under the Federal Food, Drug, and Cosmetic Act, ("FDCA"), the Public Health Service Act, and other federal statutes and regulations, subjects pharmaceutical products to rigorous review.  Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending New Drug Application ("NDAs") or biologics license applications, ("BLAs"), warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our manufacturers and contract research organizations may also be subject to regulations under other federal, state and local laws, including the Occupational Safety and Health Act, (OSHA), the Resource Conservation and Recovery Act, the Clean Air Act and import, export and customs regulations as well as the laws and regulations of other countries.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FDA Approval Process</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is a regulatory agency within the Department of Health and Human Services. A key responsibility is to regulate the safety and effectiveness of drugs sold in the United States. The FDA manages this responsibility into two phases: pre-approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(premarket) and post approval</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(post market). The FDA reviews manufacturers' applications to market drugs in the United States; a drug may not be sold unless it has FDA approval. The FDA continues its oversight of drug safety and effectiveness as long as the drug is on the market.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To market a prescription drug in the United States, a manufacturer needs FDA approval. To get that approval, the manufacturer must demonstrate the drug's safety and effectiveness according to criteria specified in law and agency regulations, ensure that its manufacturing plant passes FDA inspection, and obtain FDA approval for the drug's labeling, a term that includes all written material about the drug, including, for example, packaging, prescribing information for physicians and patient brochures.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The progression to drug approval begins before FDA involvement. First, scientists work in the laboratory to discover and develop a new compound. Next, basic questions on safety are answered by nonclinical testing with animals and then, a drug or biotechnology company develops a prototype drug. That company must seek clearance from the FDA by way of an Investigational New Drug ("IND") application to test the product with human subjects. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those tests, called clinical trials, are carried out sequentially in Phase I, II, and III studies, which involve increasing numbers of subjects. The manufacturer then compiles the resulting data and analyses in an NDA. The FDA reviews the NDA with three major concerns: (1) safety and effectiveness in the drug's proposed use; (2) appropriateness of the proposed labeling; and (3) adequacy of manufacturing methods to assure the drug's identity, strength, quality, and purity.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and associated regulations detail the requirements at each step. The FDA uses a few special mechanisms to expedite drug development and the review process when a drug might address an unmet need or a serious disease or condition. Those mechanisms include accelerated approval, fast track and priority reviews and the newer designation, breakthrough therapy.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sponsor of the drug typically conducts human clinical trials in three sequential phases, but the phases may overlap. Phase I clinical trials are generally conducted in a small number of healthy volunteers, primarily to collect and assess pharmacokinetics and safety data at one or more dosages prior to proceeding into patients. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Phase II clinical trials, the sponsor evaluates the early efficacy of the product in short term trials on the targeted indication and identifies possible adverse effects and safety risks in a patient population. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase III clinical trials typically involve testing for patients in long term trials examining safety and clinical efficacy in an expanded population at geographically-dispersed test sites.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA requires that clinical trials be conducted in accordance with the FDA's Good Clinical Practice GCP requirements. The FDA may order the partial, temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The institutional review board ("IRB"), or ethics committee (outside of the U.S.), of each clinical site generally must approve the clinical trial design and patient informed consent and may also require the clinical trial at that site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements or may impose other conditions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the nonclinical and clinical trials, together with detailed information on the manufacturing and composition of the product and proposed labeling, are submitted to the FDA in the form of an NDA for marketing approval. The NDA undergoes a 60-day validation review period before it is accepted for filing. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the NDA is found to be incomplete, it will not be accepted.  Once the NDA is validated and accepted for filing, the FDA begins an in-depth review of the NDA. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA (currently PDUFA VI - effective October 1, 2017), the FDA has a target timeline of 10 months in which to complete its initial review of a standard NDA and respond to the applicant. The review process and the PDUFA goal date may be extended by two months to address deficiencies, or by three months if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding information already provided in the submission at any time during the review clock period. If the FDA's evaluations of the NDA and the clinical and manufacturing procedures and facilities are favorable and meet all regulations, the FDA will issue an approval letter. Priority review is reserved for drugs that represent a &#8220;significant improvement in safety or efficacy&#8221; over existing treatments and FDA endeavors to complete these reviews in six months.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the NDA meets with FDA approval, a letter will be sent out indicating approval and final labeling recommendations. If not, a complete response letter will be sent to applicants indicating that the review cycle for an application is complete and that the application is not ready for approval. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complete response letter will describe the specific deficiencies that the agency has identified in an application and what changes must be made before the application can be approved, with no implication regarding </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether the application will ultimately be approved.  An approval letter authorizes commercial marketing of the drug for the proposed indication(s) under study. While the FDA's PDUFA 2021 Performance Report showed a continued increase in the percentage of first-cycle approval letters for new molecular entities rising from 56% for FY 2009 to preliminary reports of 100% for FY 2021, we cannot be certain that timely first-cycle approvals will be maintained by the FDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the time and cost of completing these steps and obtaining FDA approval can vary dramatically depending on the drug, it can take many years and cost millions of dollars for a novel drug.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 505(b) New Drug Applications</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An NDA may be submitted under different methods, a 505(b)(1), 505(b)(2) or 505(j). Section 505(b) provides for the submission of an NDA to support the approval of a drug. Upon approval, a drug may be marketed only for the FDA-approved indication(s) in the approved dosage form. Further clinical trials may be necessary to gain approval for the use of the product for any additional indications or dosage forms. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also requires post market safety surveillance reporting to monitor the side effects of the drug, which may result in withdrawal of approval after marketing begins if significant adverse safety findings are found.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 505(b)(1) or the 'full' NDA is used for new chemical entities ("NCEs") and requires full clinical and nonclinical development of a compound. Marketing exclusivity assigned to a 505(b)(1) approval is five years. A 505(b)(2) NDA permits the submission of an NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant using previously reported safety and efficacy data, and for which the applicant has not obtained a right of reference. Generally new studies are required to provide data on the proposed change. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some examples of products that may be allowed to follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication or combination drugs. Marketing exclusivity for a 505(b)(2) submission is three years. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both 505 (b)(1) and (b)(2) are eligible for seven years of exclusivity for orphan drugs and/or six months for pediatric exclusivity. Any marketing exclusivity is independent of patent exclusivity.  We successfully secured FDA approvals for Acetadote in January 2004, for Caldolor in June 2009 and for RediTrex in 2019 pursuant to the 505(b)(2) pathway. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan drug designation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Orphan Drug Act of 1983 (the "Orphan Drug Act") encourages manufacturers to seek approval of products intended to treat &#8220;rare diseases and conditions&#8221; with a prevalence of fewer than 200,000 patients in the U.S. or for which there is no reasonable expectation of recovering the development costs for the product. For products that receive orphan drug designation by the FDA, the Orphan Drug Act provides tax credits for clinical research, FDA assistance with protocol design, eligibility for FDA grants to fund clinical studies, waiver of the FDA application fee, and a period of seven years of marketing exclusivity for the product following FDA marketing approval. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote received Orphan Drug designation in October 2001 and in 2004 the FDA approved the product to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. Acetadote was entitled to marketing exclusivity until January 2011 for the treatment of this approved indication.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 505(j) abbreviated new drug applications</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An abbreviated new drug application ("ANDA") is a type of NDA where approval of a generic drug is based on demonstrating comparability to an innovator drug product (the RLD or Reference Listed Drug). Applications are "abbreviated" because they generally don't include preclinical and clinical data to establish safety and effectiveness. Generics must demonstrate that the product is bioequivalent (i.e., performs in the same manner and is comparable to the 'innovator' product in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics and intended use). </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Abbreviated applications may be submitted for drug products that are the same as a listed drug and must be identical in active ingredient(s), form, strength, route of administration, and identical in conditions of use (non-exclusive uses).  Products are declared suitable based on a suitability petition to the FDA. If the petition is approved, the sponsor may then submit the ANDA.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hatch-Waxman Act</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Price Competition and Patent Term Restoration Act, informally known as the "Hatch-Waxman Act", is a 1984 United States federal law which established the modern system of generic drugs. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hatch-Waxman amended the Federal Food, Drug, and Cosmetic Act. Section 505(j) 21 U.S.C. 355(j) sets forth the process by which would-be marketers of generic drugs can file ANDAs to seek FDA approval of the generic. Section 505(j)(2)(A)(vii)(IV), the so-called Paragraph IV, allows 180-day exclusivity to companies that are the "first-to-file" an ANDA against holders of patents for branded counterparts.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These Hatch-Waxman amendments grant generic manufacturers the ability to mount a validity challenge without incurring the cost of entry or risking enormous damages flowing from any possible infringement. Hatch-Waxman essentially redistributes the relative risk assessments and explains the flow of settlement funds and their magnitude. Hatch-Waxman gives generics considerable leverage in patent litigation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health care legislation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act, or PPACA. On March 30, 2010, the Health Care and Education Reconciliation Act of 2010, or HCERA, was enacted into law, which modified the revenue provisions of the PPACA. The PPACA as amended by the HCERA constitutes the healthcare reform legislation. The following highlights certain provisions of the legislation that may affect us.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Industry Fee: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in calendar-year 2011, an annual fee was imposed on pharmaceutical manufacturers and importers that sell branded prescription drugs to specified government programs (e.g., Medicare Part D, Medicare Part B, Medicaid, Department of Veterans Affairs programs, Department of Defense programs and TRICARE). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual fee is allocated to companies based on their previous calendar-year market share using sales data that the government agencies that purchase the pharmaceuticals will provide to the Treasury Department. Although we participate in governmental programs that subject us to this fee, our sales volume in such programs is less than $10 million, with the first $5 million of sales being exempt from the fee. This fee has not had a material impact and is not expected to have a material impact on our results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, PDUFA imposes annual program fees. An applicant will be assessed annual prescription drug program fees for prescription drug products, incurring a fee for each strength of a drug product. An applicant may not be assessed more than five prescription drug program fees for a fiscal year for prescription drug products identified in a single approved application.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Payments Sunshine Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPACA also includes provisions known as the Physician Payments Sunshine Act, or Sunshine Act, which requires manufacturers of pharmaceuticals and medical devices covered under Medicare and Medicaid to record any transfers of value to physicians and teaching hospitals and to report this data to the Centers for Medicare and Medicaid Services, or CMS, for aggregation and subsequent public disclosure. Under the Sunshine Act, beginning August 1, 2013, we have collected data regarding reportable transfers of value and have reported such data to CMS. Failure to report appropriate data may result in civil or criminal fines and/or penalties.  In addition to the Federal Sunshine Act, similar reporting requirements have also been enacted on the state level requiring transparency of interactions with health care professionals.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid Rebate Rate:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the Medicaid Drug Rebate program we currently are required to provide rebates for covered outpatient drugs that are dispensed to Medicaid beneficiaries.  In addition, we also are required to participate in the Public Health Service's 340B drug pricing program, which requires us to agree to charge no more than a designated ceiling price for covered outpatient drugs that are dispensed to community health clinics and other </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Serialization:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In November of 2013, the FDA passed the Drug Supply Chain Security Act (DSCSA). The DSCSA was created to strengthen the security of the drug distribution supply chain by adding controls such as a national pharmaceutical track and trace system and establishing national standards for licensing of prescription drug wholesale distributors and third-party logistics providers. DSCSA requires trading partners, including manufacturers, repackagers, wholesale distributors and dispensers to provide transaction information to subsequent purchasers for certain prescription drugs. We have taken necessary steps to implement this program and are in compliance with all requirements by the November 2018 deadline.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">21</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Century Cures Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The 21st Century Cures Act (Cures Act), signed into law on December 13, 2016, is designed to help accelerate medical product development and bring new innovations and advances to patients who need them faster and more efficiently. The law builds on the FDA's ongoing work to incorporate the perspectives of patients into the development of drugs, biological products, and devices in the FDA's decision-making process. The Cures Act enhances the FDA's ability to modernize clinical trial designs and clinical outcome assessments, which will speed the development and review of novel medical products, including medical countermeasures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the Cures Act enables us to work with the FDA in the development of new biomarkers, clinical outcome assessments, surrogate endpoints, and patient reported outcomes. It allows for the use of data summaries (rather than full clinical trials for approval) as well as the use of real-world evidence to support approval of new indications of approved medical products, or to help satisfy post-approval study requirements for marketed products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Build Back Better Act and Other Proposed Legislation:  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Build Back Better Act ("BBBA") was introduced in the 117</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress and included provisions that were intended to lower the price of prescription drugs, including granting the Medicare program the authority to negotiate prescription drug prices and imposing tax penalties on drug manufacturers if the price of drugs increase too rapidly.  Ultimately the BBBA was not enacted, however, future legislative initiatives are likely to include provisions targeted at containing costs in the prescription drug market.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post Approval Activities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a drug is on the U.S. market (following FDA approval of the NDA), the FDA continues to address drug production, distribution, and use. FDA activities are based on ensuring drug safety and effectiveness.  They address product integrity, labeling, reporting of research and adverse events, surveillance, drug studies, risk management, information dissemination, off-label use, physician advertising and direct-to-consumer advertising.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we amend the NDA for an FDA approved product, such as adding safety or efficacy labeling claims, promoting those new claims, making certain manufacturing changes or product enhancements, we will need FDA review and approval before the change can be implemented. While physicians may use products for indications that have not been approved by the FDA, we may not label or promote the product for an indication that has not been approved. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing FDA approval for new indications, product enhancements, and manufacturing and labeling changes may require us to conduct additional clinical trials under the FDA's IND regulations. Even if such studies are conducted, they are still subject to the same requirements and timelines as an original NDA.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA continuously gathers information about possible adverse reactions to the products it has approved for use. The FDA requires all manufacturers to report adverse events. It also provides a procedure for consumers and physicians to voluntarily report their concerns about drugs. The agency collects those reports through MedWatch and uses its FDA Adverse Event Reporting System (FAERS) to store and analyze them. Because some events may occur after the use of a drug for reasons unrelated to the product, the FDA reviews the events to assess which ones may indicate a problem with that particular drug. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They then use information gleaned from the surveillance data to determine a course of action. They might recommend a change in drug labeling to alert users to a potential problem, or perhaps, require the manufacturer to study the observed association between the drug and the adverse event.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry in recent years. These laws include anti-kickback statutes and false claims statutes. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal health care program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any health care item or service reimbursable under Medicare, Medicaid or other federally financed health care programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Violations of the anti-kickback statute are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal health care programs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these U.S. laws, we are subject to similar laws that govern our marketing practices and financial arrangements with health care providers and otherwise are intended to prohibit illicit kickbacks and bribery, including the Foreign Corrupt Practices Act.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal False Claims Act</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of pharmaceutical and other health care companies have been prosecuted under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HIPAA and Other Data Protection Laws</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we and our collaborators are subject to numerous federal and state privacy and security laws and regulations, including the Health Insurance Portability and Accountability Act of 1996.  These laws include obligations related to protecting the privacy and security of health-related personal information, including information that we may obtain through the clinical trial process.  In addition, similar laws and regulations exist in Europe and other jurisdictions, including the European Union's General Data Protection Regulation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ICH - International Committee on Harmonization</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the U.S., our ability to market our products will depend on receiving marketing authorizations from the appropriate regulatory authorities. The International Committee on Harmonization (ICH) provides a set of standards that most regulatory authorities adhere to (e.g. U.S., Europe, and Japan) allowing greater harmonization in the interpretation and application of technical guidelines and requirements for pharmaceutical product registration, thereby reducing or obviating duplication of testing carried out during the research and development of new human medicines. Regulatory harmonization offers many direct benefits to both regulatory authorities and the pharmaceutical industry with beneficial impact for the protection of public health.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENVIRONMENTAL MATTERS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal, state and local environmental laws and regulations and we believe that our operations comply with such regulations. We anticipate that the effects of compliance with federal, state and local laws and regulations relating to the discharge of materials into the environment will not have any material effect on our capital expenditures, earnings or competitive position.   </span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_64"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEASONALITY</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no significant seasonal aspects to our business.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_67"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BACKLOG</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the relatively short lead-time required to fill orders for our products, backlog of orders is not considered material to our business.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_70"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EMPLOYEES</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 85 employees.  We believe that our future will depend in part on our continued ability to attract, hire, and retain qualified personnel, including hospital oncology and field sales personnel in particular.  To that end, we work with qualified search firms to identify talent, we measure and adjust compensation levels to remain competitive and we work closely with team members to support their success.</span></div><div><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_73"></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make statements in this Annual Report on Form&#160;10-K that are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statement of historical facts may be forward-looking statements.  In particular, forward-looking statements include, among other things, statements regarding our intent, belief or expectations, and can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;anticipate&#8221; and other comparable terms or the negative thereof. In addition, we, through our senior management, from time to time make forward-looking oral and written public statements concerning our expected future operations and other developments. While forward-looking statements reflect our good-faith beliefs and best judgment based upon current information, they are not guarantees of future performance and are subject to known and unknown risks and uncertainties, including those mentioned in Item&#160;1A, &#8220;Risk Factors,&#8221; Item&#160;7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Form&#160;10-K. Accordingly, investors are cautioned not to place undue reliance on any forward-looking statements. Actual results may differ materially from the expectations contained in the forward-looking statements as a result of various factors. Such factors include, but are not limited to:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The possible or assumed future results of operations, including the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in national or regional economic conditions, including changes in interest rates and the availability and the cost of capital to us;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of a pandemic, epidemic or outbreak of a contagious disease, such as the novel coronavirus (COVID-19) pandemic, including any recurrence of the COVID-19 pandemic, the impact on our employees, the extent of the impact on overall demand for our key products and the impact on our suppliers, including any disruptions and inefficiencies in the supply chain for our products; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our competitive position and competitors, including the size and growth potential of the markets for our products and product candidates;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The success, cost and timing of our product acquisition and development activities and clinical trials; and our ability to successfully commercialize our product candidates;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product efficacy or safety concerns, whether or not based on scientific evidence, resulting in product withdrawals, recalls, regulatory action on the part of the FDA (or international counterparts) or declining sales;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The performance of our third-party suppliers and manufacturers which impacts our supply chain and could create business shutdowns or product shortages; and the retention of key scientific and management personnel;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Challenges to our patents and the introduction of generic versions of our products and product candidates, which could negatively impact our ability to commercialize and sell our products and product candidates and decrease sales a result of market exclusivity;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in reimbursement available to us, including changes in Medicare and Medicaid payment levels and availability of third-party insurance coverage and the effects of future legislation or regulations, including changes to regulatory approval of new products, licensing and patent rights, environmental protection and possible drug re-importation legislation;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interruptions and breaches of our computer and communications systems, and those of our vendors, including computer viruses, hacking and cyber-attacks, that could impair our ability to conduct business and communicate internally and with our customers, or result in the theft of trade secrets or other misappropriation of assets, or otherwise compromise privacy of sensitive information belonging to us, our customers or other business partners; and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issuance of new or revised accounting standards by the Financial Accounting Standards Board and the Securities and Exchange Commission. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The list above contains many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties. For more information about the risks, uncertainties, and other factors that could affect our future results, please refer to Item 1A, Risk Factors, included herein.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_79"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1A. Risk Factors.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factor Summary</span></div><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider all information in this Annual Report on Form 10-K prior to investing in our common stock. These risks are discussed more fully in the section titled &#8220;Risk Factors.&#8221; These risks and uncertainties include, but are not limited to, the following:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General economic conditions can have a material adverse effect on our business, financial conditions and result of operations.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Global and national events, including, but not limited to the COVID-19 pandemic, increased inflation, rising interest rates, supply chain disruptions, labor conditions, and international conflict, may adversely affect our revenues, results of operations and financial condition.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to implement strategies to enhance our performance could have a material adverse effect on our business, results of operations and financial conditions.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to perform depends on keeping and hiring exceptionally talented management and employees, and our failure to do so could have a material adverse effect on our business, revenues, results of operations and financial condition.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends, in part, on our ability to successfully obtain or retain high-performing third-party performers on commercially acceptable terms, and the failure to do so can have a material adverse effect on our business, financial conditions and results of operations.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to stringent government regulations, it must adhere to numerous complex pieces of legislation, and all of our products face regulatory challenges.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business depends on the successful protection of our intellectual property rights and our product candidates becoming approved by regulatory agencies, commercially viable, and accepted by the market.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business faces a serious financial risk if generic products that compete with any of our branded pharmaceutical products are approved and sold because sales of our products will be adversely-affected and our business may not recover the capital costs of bringing that product to market.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business faces an inherent risk of product liability lawsuits related to the testing of our product candidates and the commercial sale of our products, and if we cannot successfully defend ourselves against the product liability claim, we may incur substantial liabilities.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may attempt to develop internationally and license our products globally, as well as invest in other businesses or joint ventures, all of which may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors described below and throughout this report should be carefully considered and could materially affect our business. There are also risks that are not presently known or not presently material, as well as the other information set forth in this report that could materially affect our business. In addition, in our periodic filings with the SEC, press releases and other statements, we discuss estimates and projections regarding our future performance and business outlook. By their nature, such &#8220;forward-looking statements&#8221; involve known and unknown risks, uncertainties and other factors that in some cases are out of our control. For a further discussion of forward-looking statements, please refer to the section entitled &#8220;Special Note Regarding Forward-Looking Statements.&#8221; These factors could cause our actual results to differ materially from our historical results or our present expectations and projections. These risk factors and uncertainties include, but are not limited to the following:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR BUSINESS</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks related to the COVID-19 pandemic, natural disasters, public health epidemics, and other events beyond our control may adversely affect our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has been adversely impacted by the COVID-19 pandemic which has affected more than 200 countries and has significantly disrupted the day-to-day activities of both individuals and companies. We rely on individuals and third-party organizations around the world to supply components, manufacture and distribute our products, and execute our clinical trials. We have and may continue to experience revenue loss, supply interruptions, time delays and incur unplanned expenses as a result of the impact of the COVID-19 pandemic.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global and national economic and other events, including, but not limited to increased inflation, rising interest rates, supply chain disruptions, labor conditions and international conflicts, could affect our future access to liquidity and materially adversely affect our results of operations and financial condition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Ongoing global and national events including, but not limited to increased inflation, rising interest rates, supply chain disruptions, labor conditions and the war between Russia and Ukraine, have had a significant adverse impact on economic and market conditions around the world, including the United States. While the economic impact brought by, and the duration of, such global events is difficult to assess or predict, such events could result in additional disruption of global financial markets, reducing our ability to access capital in the future, which could negatively affect our liquidity in the future and in ways that cannot be predicted potentially including a prolonged recessionary environment in the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, there could be significant new regulatory actions and other events that could limit our activities and investment opportunities or change the functioning of the capital markets, and there is the possibility of a severe worldwide economic downturn. Consequently, we may not be capable of, or successful at, generating positive investment returns or effectively managing risks. Accordingly, we cannot predict the extent to which our results of operations, financial condition and cash flows will be affected.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An adverse development regarding our products could have a material and adverse impact on our future revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product portfolio currently includes eight brands: Acetadote, Caldolor, Kristalose, Vaprisol, Omeclamox-Pak, Vibativ, RediTrex and Sancuso. A product contamination or other safety or regulatory issues, such as a failure to meet certain FDA reporting requirements involving our products, could negatively impact us and possibly lead to a product recall. In addition, changes impacting any of our products in areas such as competition, lack of market acceptance or demand, government regulation, intellectual property, reimbursement and manufacturing could have an adverse impact on our future revenues and profitability including:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in intellectual property protection available for our products or competing treatments; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any unfavorable publicity concerning us, our products, or the markets for these products such as information concerning product contamination or other safety issues in any of our product markets, whether or not directly involving our products;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Perception by physicians and other members of the healthcare community of the safety or efficacy of our products or competing products;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory developments related to our marketing and promotional practices or the manufacture or continued use of our products;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The prices of our products relative to other drugs or competing treatments;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The impact of current or additional generic competitors;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The availability and level of third-party reimbursement for sales of our products;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The continued availability of adequate supplies of our products to meet demand:</span></div><div style="margin-top:8pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Weakened demand for our products; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Unforeseen or serious adverse effects outside of those specified in current product labeling being attributed to any of our approved products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote may be used to treat acetaminophen overdoses. The FDA has previously requested prescribers and manufacturers of prescription combination products that contain acetaminophen to limit the amount of acetaminophen to no more than 325 milligrams (mg) in each tablet or capsule. The FDA requested this action to protect consumers from the risk of severe liver damage which can result from excess acetaminophen which may reduce the number of acetaminophen overdoses which could result in a lower demand for Acetadote. If the demand for Acetadote decreases, it could have an adverse impact on our future revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of Caldolor is dependent on many third-parties, including physicians, pharmacists, hospital pharmacy and therapeutics committees, or P&amp;T committees, suppliers and distributors, all of whom we have little or no control over. We expect Caldolor to continue to be administered primarily to hospital and surgery center patients who are unable to receive oral therapies for the treatment of pain or fever. Before we can distribute Caldolor to any new hospital customers, Caldolor must be approved for addition to the hospitals&#8217; formulary lists by their P&amp;T committees. A hospital&#8217;s P&amp;T committee generally governs all matters pertaining to the use of medications within the institution, including review of medication formulary data and recommendations of drugs to the medical staff. We cannot guarantee that we will be successful in getting the approvals we need from enough P&amp;T committees to be able to optimize hospital sales of Caldolor. Even if we obtain hospital approval for Caldolor, we must still convince individual hospital physicians to prescribe Caldolor repeatedly. The commercial success of Caldolor also depends on our ability to coordinate supply, distribution, marketing, sales and education efforts. As with our other products, if Caldolor is not accepted in the marketplace, it could have an adverse impact on our future revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to review and approve new products and otherwise affect the FDA&#8217;s ability to perform routine functions. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs or modifications to approved drugs to be reviewed and/or approved by necessary government agencies. Such disruptions could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any manufacturer or partner we rely upon fails to supply our products in the amounts we require on a timely basis, or fails to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may be unable to meet demand for our products and may lose potential revenues.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not manufacture any of our products, and we do not currently plan to develop any capacity to do so. Our dependence upon third parties for the manufacture of our products could adversely affect our profit margins or our ability to develop and deliver products on a timely and competitive basis. If for any reason we are unable to obtain or retain third-party manufacturers on commercially acceptable terms, we may not be able to sell our products as planned. Furthermore, if we encounter delays or difficulties with contract manufacturers in producing our products, the distribution, marketing and subsequent sales of these products could be adversely affected. A long-term inability to meet demand for our products could result in impairment of our brands overall future and the carrying value of the assets associated with our brands. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acetadote:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have an agreement with one manufacturer to provide commercial supply of Acetadote. If this manufacturer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is unable to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for Acetadote.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Caldolor:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  We have agreements with multiple manufacturers for the supply of Caldolor. If the manufacturers of Caldolor are unable to produce marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for Caldolor.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kristalose:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The active pharmaceutical ingredient for Kristalose is manufactured at a single facility through a complex process. It would be particularly difficult to find a new manufacturer of the Kristalose active pharmaceutical ingredient on an expedited basis. We have manufacturing relationship with one packager who provided finished supplies of Kristalose  for commercial and sampling purposes during 2022. If the manufacturing </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or packaging facilities are unable to produce useable or marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for Kristalose.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omeclamox-Pak:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our packager for  Omeclamox-Pak  encountered financial difficulties due to the impact of COVID-19, and their operations are currently suspended. Cumberland is awaiting resumption of those operations while also exploring other alternatives to restart the product&#8217;s packaging. In October 2020, we informed the FDA of a shortage of Omeclamox-Pak which continues. If we are unable to obtain marketable inventory in the future, we could suffer an inability to meet demand for Omeclamox-Pak.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaprisol:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2018, the manufacturer of Vaprisol informed us that they would no longer be able to provide the product following the manufacturing of one final batch which is providing us with a multi-year supply. We are currently working with a new manufacturer to provide us with long term supplies of the product. In February 2022, we notified the FDA of a shortage of Vaprisol.  If we are unable to produce additional marketable inventory in sufficient quantities, in the required  time frame, we could suffer an inability to meet demand for Vaprisol.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Through our acquisition of Vibativ, we acquired a multi-year supply of raw material, work in process and finished goods inventory. In 2020, we completed the transfer of Vibativ manufacturing activities to a new supplier. If we are unable to continue to obtain marketable inventory in sufficient quantities, in the agreed upon time period, we could suffer an inability to meet demand for Vibativ.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: : As part of the acquisition of Sancuso in January 2022, we obtained an initial supply of finished goods inventory and work in progress.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2022, we received notification from Kyowa Kirin, Inc. that the FDA approved a supplemental new drug application associated with a new site at Kindeva Drug Delivery L.P., for the manufacturing and primary packaging of the Sancuso brand.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products and product candidates must comply with current good manufacturing practices, ("GMPs"), enforced by the FDA through its facilities inspection program. These requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our products must be unable to comply with GMP requirements and with other FDA, state, and foreign regulatory requirements.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no control over our manufacturers&#8217; compliance with these regulations and standards. If our third-party manufacturers do not comply with these requirements, we could be subject to fines and civil penalties; suspension of production or distribution; suspension or delay in product approval; product seizure or recall; and withdrawal of product approval.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on a variety of other third parties. If these third parties fail to perform as we expect, our operations could be disrupted and our financial results could suffer.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a relatively small internal infrastructure. We rely on a variety of third parties, in addition to our manufacturers, to help us operate our business. If these third parties do not continue to provide services to us, or collaborate with us, we might not be able to obtain others who can serve these functions. This could disrupt our business operations, increase our operating expenses or otherwise adversely affect our operating results. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competitive pressures could reduce our revenues and profits.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is intensely competitive. Our strategy is to target differentiated products in specialized markets. However, this strategy does not relieve us from competitive pressures and can entail distinct competitive risks. Certain of our competitors do not aggressively promote their products in our markets. An increase in promotional activity in our markets could result in large shifts in market share, adversely impacting us.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may sell or develop drugs that are more effective and useful or less costly than ours, and they may be more successful in manufacturing and marketing their products. Many of our competitors have significantly greater financial and marketing resources than we do. Additional competitors may enter our markets.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by constant and significant investment in new product development, which can result in rapid technological change. The introduction of new products could substantially reduce our market share or render our products obsolete. The selling prices of pharmaceutical products tend to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decline as competition increases, through new product introduction or otherwise, which could reduce our revenues and profitability.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If generic products that compete with any of our branded pharmaceutical products are approved and sold, sales of our products will be adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic equivalents for branded pharmaceutical products are typically sold at lower costs than the branded products. The regulatory approval process in the United States exempts generic products from costly and time-consuming clinical trials to demonstrate their safety and efficacy and rely instead on the safety and efficacy of prior products, manufacturers of generic products can invest far less in research and development. After the introduction of a competing generic product, a significant percentage of the prescriptions previously written for the branded product are often written for the generic version. In addition, legislation enacted in most U.S. states allows or, in some instances mandates, that a pharmacist dispense an available generic equivalent when filling a prescription for a branded product, in the absence of specific instructions from the prescribing physician. Governmental and private healthcare payors also emphasize substitution of branded pharmaceuticals with less expensive generic equivalents. Pursuant to the provisions of the Hatch-Waxman Act, manufacturers of branded products often bring lawsuits to enforce their patent rights against generic products released prior to the expiration of branded products&#8217; patents, but it is possible for generic manufacturers to offer generic products while such litigation is pending. As a result, branded products typically experience a significant loss in revenues following the introduction of a competing generic product, even if subject to an existing patent. Our branded pharmaceutical products are or may become subject to competition from generic equivalents because there is no proprietary protection for some of the branded pharmaceutical products we sell, because our patent protection expires or because our patent protection is not sufficiently broad or enforceable. In addition, we may not be successful in our efforts to extend the proprietary protection afforded our branded products through the development and commercialization of proprietary product improvements. Competition from generic equivalents could result in a decrease in revenues of our branded pharmaceuticals or result in a material impairment of our intangible assets or the acceleration of amortization on our non-impaired intangible assets and may have a material adverse impact on our revenues, financial condition, results of operations and cash flows.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any attempt by us to expand the potential market for any of our products is subject to limitations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expansion of the market for our products may be subject to certain limitations. In the past, these limitations have included FDA required Phase IV commitments. We may also experience delays associated with future required Phase IV clinical studies potentially resulting from, among other factors, difficulty enrolling patients. Such delays could impact our ability to explore opportunities for label expansion and limit our ability to bring our products to new patient populations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have largely obtained regulatory approval to market our products in the United States. Not all foreign jurisdictions may represent attractive opportunities for our products due to pricing, competitive, regulatory or other factors. In certain foreign jurisdictions, we have licensed the right to market some of our products to third parties. These third parties are responsible for seeking and maintaining regulatory approval for the products in their respective jurisdictions. We have no control over these third parties and cannot be sure that marketing approval for our products will be obtained outside the United States.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth depends on our ability to identify, acquire rights and successfully integrate new brands into our operations. If we do not successfully identify and acquire rights to products or if we do not successfully integrate acquired product brands into our operations, our growth opportunities may be limited.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have added six products to our portfolio of brands through acquisitions. Our business strategy is to continue to acquire rights to FDA-approved products as well as pharmaceutical product candidates in the late stages of development. We do not plan to conduct basic research or preclinical product development, except to the extent of our investment in CET. As compared to large multi-national pharmaceutical companies, we have limited resources to acquire third-party products, businesses and technologies and integrate them into our current infrastructure. Many acquisition opportunities involve competition among several potential purchasers including large multi-national pharmaceutical companies and other competitors that have access to greater financial resources than we do. With </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future acquisitions, we may face financial and operational risks and uncertainties. We may not be able to engage in future product acquisitions, and those we do complete may not be beneficial to us in the long term.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, other products in development may encounter unforeseen issues during their clinical trials. Any unforeseen issues or lack of FDA approval will negatively affect marketing and development plans for those products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully integrate the marketing, sale and distribution of any other potential products into our current infrastructure or if they require significantly greater resources than originally anticipated, we may face financial and operational risks and uncertainties. If we are unable to successfully integrate any acquired brands, both current and future, these product acquisitions may not be beneficial to us in the long term.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ifetoban product candidates have not been approved for sale and may never be successfully commercialized.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that a portion of our future revenue growth may come from sales of our ifetroban product candidates. However, none of these products have been approved by the FDA for marketing, and these product candidates are still subject to risks associated with their development. Drug development is a long, expensive and inherently uncertain process with a high risk of failure at every stage of development, and results of earlier studies and trials may not be predictive of future trial results</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has cleared our IND's for the ifetroban product candidates as we evaluate them as treatments for these conditions. Delays in the enrollment and completion of the clinical studies could significantly delay commercial launch and affect our product development costs. Moreover, results from the clinical studies may not be favorable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if they are eventually developed and approved by the FDA, they may never gain significant acceptance in the marketplace and therefore never generate substantial revenue or profits for us. Physicians may determine that existing drugs are adequate to address patients' needs. The extent to which these product candidates will be reimbursed by the U.S. government or third-party payors is also currently unknown.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the foregoing and other factors, we do not know the extent to which our product candidates will contribute to our future growth.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain, train and build an effective sales and marketing infrastructure, we will not be able to commercialize and grow our products and product candidates successfully.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we grow, we may not be able to secure sales personnel or organizations that are adequate in number or expertise to successfully market and sell our products. This risk would be accentuated if we acquire products in areas outside of our current focus areas since our sales forces specialize in our existing areas. If we are unable to expand our sales and marketing capability, train our sales force effectively or provide any other capabilities necessary to commercialize our products and product candidates, we will need to contract with third parties to market and sell our products. We must train our employees on proper regulatory compliance, including, but not limited to, &#8220;fair balance&#8221; promotion of our products and anti-kickback laws. If we are unable to establish and maintain compliant and adequate sales and marketing capabilities, we may not be able to increase our product revenue, may generate increased expenses and may experience regulatory compliance issues.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If governmental or third-party payors do not provide adequate reimbursement for our products, our revenue and prospects for profitability may be limited.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial success depends, in part, on the availability of adequate reimbursement from third-party healthcare payors. Such third-party payors include governmental health programs such as Medicare and Medicaid, managed care providers and private health insurers. Third-party payors are increasingly challenging the pricing of medical products and services, while governments continue to propose and pass legislation designed to reduce the cost of healthcare. Adoption of such legislation could further limit reimbursement for pharmaceuticals. In addition, as part of the Inflation Reduction Act legislation, provisions intended to lower the price of prescription drugs, including permitting Medicare to negotiate the price of prescription drugs once they have been on the market for a fixed number of years, and imposing a tax penalty on drug manufacturers if the price of their drugs increase faster than the rate of inflation.  At this time no assurances can be given that these measures, or subsequent legislative </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proposals, will not have an adverse effect on our revenues in the future. Future cost control initiatives, legislation, and regulations could decrease the price that we receive for our products, which would limit our revenue and profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, reimbursement practices of third-party payors might preclude us from achieving market acceptance for our products or maintaining price levels sufficient to realize an appropriate return on our investment in product acquisition and development. If we cannot obtain adequate reimbursement levels, our business, financial condition and results of operations would be materially and adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees have been trained to submit accurate and correct pricing information to payors. If, despite the training, our employees provide incorrect or fraudulent information, then we will be subject to various administrative and judicial investigations and litigation.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Formulary&#8221; practices of third-party payors could adversely affect our competitive position.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many managed healthcare organizations control the pharmaceutical products included on their formulary lists. Having products listed on these formulary lists creates competition among pharmaceutical companies which, in turn, has created a trend of downward pricing pressure in our industry. In addition, many managed care organizations are pursuing various ways to reduce pharmaceutical costs and are considering formulary contracts primarily with those pharmaceutical companies that can offer a full line of products for a given therapy sector or disease state. Our products might not be included on the formulary lists of managed care organizations, and downward pricing pressure in our industry generally could negatively impact our operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continued consolidation of distributor networks in the pharmaceutical industry as well as increases in retailer concentration may limit our ability to profitably sell our products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell most of our products to large pharmaceutical wholesalers, who in turn sell to hospitals, surgery centers and retail pharmacies. The distribution network for pharmaceutical products has become increasingly consolidated in recent years. Further consolidation or financial difficulties could also cause our customers to reduce the amounts of our products that they purchase, adversely impacting our business, financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our CET joint initiative may not result in our gaining access to commercially viable products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CET joint initiative with Vanderbilt University, WinHealth and Tennessee Technology Development Corporation is designed to help us investigate, in a cost-effective manner, early-stage products and technologies. However, we may never gain access to commercially viable products from CET for a variety of reasons, including:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CET investigates early-stage products, which have risk of failure prior to FDA approval and commercialization;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In some programs, we do not have pre-set rights to product candidates developed by CET. We would need to agree with CET and its collaborators on the terms of any product licensed or acquired by us;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely principally on government grants to fund CET&#8217;s research and development programs. If these grants were no longer available, we or our co-owners might be unable or unwilling to fund CET operations at current levels or at all;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become involved in disputes with our co-owners regarding CET policy or operations, such as how best to deploy CET assets or which product opportunities to pursue. Disagreement could disrupt or halt product development; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CET may disagree with one of the various universities with which CET is collaborating on research. A disagreement could disrupt or halt product development.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on our key personnel, the loss of whom would adversely affect our operations. If we fail to attract and retain the talent required for our business, our business will be materially harmed.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a relatively small company, and we depend to a great extent on principal members of our management, scientific staff, and sales representatives and managers. If we lose the services of any key personnel, in particular, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.J. Kazimi, our Chief Executive Officer, or other members of senior management it could have a material adverse effect on our business prospects. Mr. Kazimi, plays a key role in several operational and strategic decisions such that any loss of his services due to death or disability would adversely impact our day-to-day operations. We have a life insurance policy covering the life of Mr. Kazimi. We have entered into agreements with each of our employees that contain restrictive covenants relating to non-competition and non-solicitation of our customers and suppliers for one year after termination of employment. Nevertheless, each of our officers and key employees may terminate his or her employment at any time without notice and without cause or good reason, and so as a practical matter these agreements do not guarantee the continued service of these employees. Our success depends on our ability to attract and retain highly qualified scientific, technical, sales and managerial personnel and research partners. Competition among pharmaceutical companies for qualified employees is intense, and we may not be able to retain existing personnel or attract and retain qualified staff in the future. If we experience difficulties in hiring and retaining personnel in key positions, we could suffer from delays in product development, loss of customers and sales and diversion of management resources, which could adversely affect operating results.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have recently observed an overall tightening and increasingly competitive labor market. Our business could be adversely affected by an inability to retain personnel or upward pressure on wages as a result of the competitive labor market.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The size of our organization and our potential growth may lead to difficulties in managing operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had 85 employees. We may need to continue to expand our managerial, operational, financial and other resources in order to increase our marketing efforts with regard to our currently marketed products, continue our business development and product development activities and commercialize our product candidates. We have experienced, and may continue to experience, growth and increased expenses in the scope of our operations in connection with the continued marketing and development of our products. Our financial performance will depend, in part, on our ability to manage any such growth and expenses of the current organization effectively.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product or product candidate and may have to limit its commercialization.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability lawsuits related to the testing of our product candidates and the commercial sale of our products. An individual may bring a liability claim against us if one of our product candidates or products causes, or appears to have caused, an injury. If we cannot successfully defend ourselves against the product liability claim, we may incur substantial liabilities. Liability claims may result in decreased demand for our products; injury to our reputation; withdrawal of clinical trial participants; significant litigation costs; substantial monetary awards to or costly settlement with patients; product recalls; loss of revenue; and the inability to commercialize our product candidates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have product liability insurance that covers our clinical trials, the marketing and sale of our products up to a $10 million annual aggregate limit, subject to specified deductibles. Our current or future insurance coverage may prove insufficient to cover any liability claims brought against us.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the increasing costs of insurance coverage, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory approval for any approved product is limited by the FDA to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approval is limited to those specific diseases and indications for which a product is deemed to be safe and effective by the FDA. In addition to the FDA approval required for new formulations, any new indication for an approved product also requires FDA approval. If we are not able to obtain FDA approval for any desired future indications for our products, our ability to effectively market and sell our products may be reduced and our business may be adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to follow FDA rules and guidelines relating to promotion and advertising  may cause the FDA to suspend or withdraw an approved product from the market, require a recall or payment of fines, or could result in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disgorgement of money, operating restrictions, injunctions or criminal prosecution, any of which could harm our business.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures, security breaches, including any cybersecurity incidents, adverse events or other disruptions within our information technology infrastructure at our corporate headquarters; or in the event of intellectual property infringement.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends on effective, secure and operational information systems which include systems provided by external contractors and other service providers. Despite the implementation of security measures, our computer systems and information technology infrastructure, including those resources at our corporate headquarters, are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Our business is at risk from and may be impacted by information security incidents, including ransomware, malware, phishing, social engineering, and other security events. Such incidents can range from individual attempts to gain unauthorized access to information technology systems to more sophisticated security threats. These events can also result from internal compromises, such as human error or malicious acts. These events can occur on our systems or on the systems of our partners and subcontractors. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we store sensitive data, including intellectual property, our proprietary business information and that of our customers. We also maintain personally identifiable information of our employees in our data centers and on our networks. The secure processing and maintenance of this information is critical to our operations. Problems with, or the failure of, our technology and systems or any system upgrades or programming changes associated with such technology and systems would have a substantial and material negative effect on our operations. Furthermore, any system failure, accident or security breach that causes interruptions in our operations could result in a material disruption of our drug development programs. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to invest in data protection and information technology, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. If we are subject to cyber-attacks or security breaches, this could result in business interruptions and delays; the loss, misappropriation, corruption or unauthorized access of data; litigation and potential liability under privacy, security and consumer protection laws or other applicable laws; reputational damage and federal and state governmental inquiries. Any such problems or failures and the costs incurred in correcting any such problems or failures, could have a material adverse effect on our business and financial condition, results of operations and cash flows. To the extent that any disruption or security breach results in a loss or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we may incur liability and the further development of our products or product candidates may be delayed. A failure to restore our information systems after the occurrence of any of these events could have a material adverse effect on our business and financial condition, results of operations and cash flows. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information systems and applications also require maintenance, upgrading and enhancement to meet our operational needs. We regularly upgrade and expand our information systems&#8217; capabilities. If we experience difficulties with the transition and integration of information systems or are unable to implement, maintain, or expand our systems properly, we could suffer from, among other things, operational disruptions, regulatory problems and increases in administrative expenses. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As cyber threats continue to evolve, we may be required to expend significant capital and other resources to protect against the threat of security breaches or to mitigate and alleviate problems caused by breaches, including unauthorized access to proprietary information and personally identifiable information stored in our information systems, and the introduction of computer viruses or other malicious software programs to our systems. Our security measures may be inadequate to prevent security breaches and our business operations could be materially adversely affected by federal and state fines and penalties, legal claims or proceedings, cancellation of contracts and loss of customers if security breaches are not prevented.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our subcontractors and vendors take precautionary measures to prevent problems that could affect our business operations as a result of failure or disruption to their information systems. However, there is no guarantee such efforts will be successful in preventing a disruption, and it is possible that we may be impacted by </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">information system failures. The occurrence of any information system failures could result in interruptions, delays, loss or corruption of data and cessations or interruptions in the availability of these systems. All of these events or circumstances, among others, could have an adverse effect on our business, results of operations, financial position and cash flows, and they could harm our business reputation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have all the necessary licenses from third parties to use technology and software that we do not own. A third party could, however, allege that we are infringing its rights, which may deter our ability to obtain licenses on commercially reasonable terms from the third party, if at all, or cause the third party to commence litigation against us. In addition, we may find it necessary to initiate litigation to protect our trade secrets, to enforce our intellectual property rights and to determine the scope and validity of any proprietary rights of others. Any such litigation, or the failure to obtain any necessary licenses or other rights, could materially and adversely affect our business.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license our products globally; therefore, we may have exposure to foreign regulatory requirements and fluctuations in foreign currency exchange rates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued foreign licensure inherently subjects us to a number of risks and uncertainties, including:</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political and economic instability or sanctions in areas in which we operate;</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers;</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulations related to customs and import/export matters (including sanctions);</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tax issues, such as tax law changes and variations in tax laws;</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges in collecting accounts receivable from customers in the jurisdictions in which we operate;</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complying with laws, rules and regulations relating to the manufacturing, marketing, distribution and sale of pharmaceutical products in the jurisdictions in which we do or will operate;</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating under regulations in jurisdictions related to obtaining eligibility for government or private payor reimbursement for our products at the wholesale/retail level;</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from local, regional and international competitors;</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties and costs of staffing and managing foreign operations, including cultural and language differences and additional employment regulations, union workforce negotiations and potential disputes in the jurisdictions in which we operate;</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties associated with compliance with a variety of laws and regulations governing international trade, including the Foreign Corrupt Practices Act;</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties protecting or procuring intellectual property rights; and</span></div><div style="margin-top:8pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. These or other similar risks could adversely affect our revenue and profitability. As we continue to develop internationally, our exposure to these factors will increase.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may decide not to commercialize one of our drug candidates once it obtains regulatory approval if we determine that commercialization of that product would require more capital and time than we are willing to invest.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our drug candidates receives regulatory approval, it could be subject to matters such as post-regulatory surveillance, additional clinical trials or testing, reformulation,  changes in labeling, warnings to the public, recall, competition from similar or superior products, and lack of sufficient payor reimbursement by insurance companies or Medicare. As a result, we may not commercialize or continue to commercialize a product that has obtained regulatory approval. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any approved drug product that we bring to the market may not gain market acceptance by physicians, patients, healthcare payors and others in the medical community.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are successful in gaining regulatory approval of any of our drug candidates or acquire rights to approved drug products, we may not generate significant product revenues and we may not become profitable if these drug products do not achieve an adequate level of acceptance. Physicians may not recommend our drug products until longer-term clinical data or other factors demonstrate the safety and efficacy of our drug products as compared to other alternative treatments. Even if the clinical safety and efficacy of our drug products is established, physicians may elect not to prescribe these drug products for a variety of reasons, including the reimbursement policies of government and other third-party payors and the effectiveness of our competitors in marketing their products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance of our drug products, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness and ability of patients and the healthcare community to use our drug products;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to manufacture our drug products in sufficient quantities with acceptable quality and to offer our drug products for sale at competitive prices;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception of patients and the healthcare community, including third-party payors, regarding the safety, efficacy and benefits of our drug products compared to those of competing products or therapies;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the label and promotional claims allowed by the FDA; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our drug products relative to existing treatments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire businesses or assets, form joint ventures or make investments in other companies that may be unsuccessful, divert our management&#8217;s attention and harm our operating results and prospects.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may pursue additional acquisitions of what we believe to be complementary businesses or assets or seek to enter into joint ventures. We also may pursue strategic alliances in an effort to leverage our existing infrastructure and industry experience to expand our product offerings or distribution, or make investments in other companies. The success of our acquisitions, joint ventures, strategic alliances and investments will depend on our ability to identify, negotiate, complete and, in the case of acquisitions, integrate those transactions and, if necessary, obtain satisfactory debt or equity financing to fund those transactions. We may not realize the anticipated benefits of any acquisition, joint venture, strategic alliance or investment. We may not be able to integrate acquisitions successfully into our existing business, maintain the key business relationships of businesses we acquire, or retain key personnel of an acquired business, and we could assume unknown or contingent liabilities or incur unanticipated expenses. Integration of acquired companies or businesses also may require management resources that otherwise would be available for ongoing development of our existing business. Any acquisitions or investments made by us also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could harm our operating results. In addition, if we choose to issue shares of our stock as consideration for any acquisition, dilution to our shareholders could result.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to modify our business practices, pay fines and significant expenses or experience other losses due to governmental investigations or other enforcement activities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become subject to litigation or governmental investigations in the United States and foreign jurisdictions that may arise from the conduct of our business. Like many companies in our industry, we have from time to time received inquiries and other types of information requests from government authorities.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the ultimate outcomes of investigations and legal proceedings are difficult to predict, adverse resolutions or settlements of those matters could result in, among other things:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant damage awards, fines, penalties or other payments, and administrative remedies, such as exclusion and/or debarment from government programs, or other rulings that preclude us from operating our business in a certain manner;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes and additional costs to our business operations to avoid risks associated with such litigation or investigations;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reputational damage and decreased demand for our products; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditure of significant time and resources that would otherwise be available for operating our business.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_82"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATING TO GOVERNMENT REGULATION</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virtually all aspects of our business activities are regulated by government agencies. The manufacturing, processing, formulation, packaging, labeling, distribution, promotion and sampling, advertising of our products, and disposal of waste products arising from such activities are subject to governmental regulation. These activities are regulated by one or more of the FDA, the Federal Trade Commission, ("FTC"), the Consumer Product Safety Commission, the U.S. Department of Agriculture and the U.S. Environmental Protection Agency, ("EPA"), as well as by comparable agencies in foreign countries. These activities are also regulated by various agencies of the states and localities in which our products are sold. For more information, see &#8220; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business&#8212;Government Regulation"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1 of this Form 10-K.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like all pharmaceutical manufacturers, we are subject to regulation by the FDA under the Federal Food, Drug and Cosmetic Act ("FDCA"). All new drugs must be the subject of an FDA-approved new drug application, ("NDA"), before they may be marketed in the United States. The FDA has the authority to withdraw existing NDA approvals and to review the regulatory status of products marketed under the enforcement policy. The FDA may require an approved NDA for any drug product marketed under the enforcement policy if new information reveals questions about the drug&#8217;s safety and effectiveness. All drugs must be manufactured in conformity with GMP, and drug products subject to an approved NDA must be manufactured, processed, packaged, held and labeled in accordance with information contained in the NDA. Since we rely on third parties to manufacture our products, GMP requirements directly affect our third party manufacturers and indirectly affect us. The manufacturing facilities of our third-party manufacturers are continually subject to inspection by such governmental agencies, and manufacturing operations could be interrupted or halted in any such facilities if such inspections prove unsatisfactory. Our third-party manufacturers are subject to periodic inspection by the FDA to assure such compliance.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after regulatory approval, certain developments may decrease demand for our products, including the following:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">the re-review of products that are already marketed;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">new scientific information and evolution of scientific theories;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">the recall or loss of marketing approval of products that are already marketed;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">changing government standards or public expectations regarding safety, efficacy or labeling changes; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">greater scrutiny in advertising and promotion.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain regulatory changes or decisions could make it more difficult for us to sell our products and could have a material adverse effect on our business, results of operations, financial condition and cash flows. Manufacturers of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with GMP and other applicable regulations. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with a facility where the product is manufactured, a regulatory agency may impose restrictions on that product or the manufacturer, including withdrawal of the product from the market or suspension of manufacturing. If we, our partners or the manufacturing facilities for our products fail to comply with applicable regulatory requirements or violate healthcare laws, a regulatory agency may take the following actions, among others:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">issue warning letters or untitled letters;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">impose civil or criminal penalties</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">refuse to approve pending applications or supplements to applications submitted by us;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">seize or detain products or require us to initiate a product recall.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in the FDA&#8217;s enforcement policy could have a material adverse effect on our business, financial condition and results of operations. We cannot determine what effect changes in regulations or statutes or legal interpretation, when and if promulgated or enacted, may have on our business in the future. Such changes, or new legislation, could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed legislation may permit re-importation of drugs from other countries into the U.S., including foreign countries where the drugs are sold at lower prices than in the U.S., which could materially and adversely affect our operating results and our overall financial condition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In previous years, legislation has been introduced in Congress that, if enacted, would permit more widespread re-importation of drugs from foreign countries into the U.S., which may include re-importation from foreign countries where the drugs are sold at lower prices than in the U.S. Such legislation, or similar regulatory changes, if enacted, could decrease the price we receive for any approved products which, in turn, could materially and adversely affect our operating results and our overall financial condition.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must comply with the CREATES Act.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been a number of recent regulatory and legislative initiatives designed to encourage generic competition for pharmaceutical products, including expedited review procedures for generic manufacturers and incentives designed to spur generic competition of branded drugs. In particular, FDA and FTC have been focused on brand companies&#8217; denial of drug supply to potential generic competitors for testing. In December 2019, the Creating and Restoring Equal Access to Equivalent Samples Act, or the CREATES Act, was enacted, which provides a legislatively defined private right of action under which eligible product developers can bring suit against companies who refuse to sell sufficient quantities of their branded products on commercially reasonable, market-based terms to support such eligible product developers&#8217; marketing applications. We cannot currently predict the specific outcome or impact on our business of such regulatory and legislative initiatives. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must comply with the Foreign Corrupt Practices Act.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with the United States Foreign Corrupt Practices Act, which prohibits U.S. companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. Foreign companies, including some of our competitors, are not subject to these prohibitions. If our competitors engage in these practices, they may receive preferential treatment from officials or agencies in some countries, giving our competitors an advantage in securing business from government officials who might give them priority in obtaining new licenses, which would put us at a disadvantage. We have established formal policies or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures for prohibiting or monitoring this conduct, but we cannot assure you that our employees or other agents will not engage in such conduct for which we might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must comply with the Physician Payment Sunshine Act.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with the United States Physician Payment Sunshine Act, which requires manufacturers of drugs, medical devices and biologicals that participate in U.S. federal healthcare programs to report certain payments and items of value given to physicians and teaching hospitals. Manufacturers are required to report this information annually to The Centers for Medicare &amp; Medicaid Services ("CMS").  In addition, some states require reporting information concerning payments to health care providers or other transfers of value by drug manufacturers beyond the requirements of the Federal Sunshine Act.  Cumberland has implemented a series of policies and procedures for every employee involved in the data collection process, and has systems in place to capture the data, which is verified by an outside firm that specializes in reporting the payments. Cumberland has also established a system to ensure that data was reported completely, in the correct format, and on time. Despite these policies, procedures and systems, we cannot assure you that we will collect and report all data accurately. If we fail to accurately report this information, we could suffer severe penalties.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If  we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We participate in the Medicaid Drug Rebate program, the 340B program, and other governmental pricing programs and have obligations to report the average sales price for certain of our drugs to CMS.  These programs and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies and the courts, which can change over time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate program and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. CMS, could also decide to terminate our Medicaid drug rebate agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. We cannot assure you that our submissions will not be found by CMS to be incomplete or incorrect. Our failure to comply with our reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively impact our financial results.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to foreign, federal, and state data privacy and security laws, and failure to protect our information systems against security breaches, service interruptions, or misappropriation of data could disrupt operations, compromise sensitive data, and expose us to liability, possibly causing our business and reputation to suffer.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, numerous federal and state laws and regulations govern the collection, use, disclosure and protection of health-related and other personal information and could apply to our operations or the operations of our collaborators and third-party providers. Certain of these laws grant individual rights with respect to their information, and we may be required to expend significant resources to comply with these laws. For example, the California Consumer Privacy Act, or CCPA, was enacted in 2020. These laws and regulations are evolving and subject to interpretation and may impose limitations on our activities or otherwise adversely affect our business. Similarly, there are a number of legislative proposals in the European Union, the United States, at both the federal </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and state level, as well as other jurisdictions that could impose new obligations or limitations in areas affecting our business. These changes may lead to additional costs and increase our overall risk exposure.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_85"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATING TO INTELLECTUAL PROPERTY</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategy to secure and extend marketing exclusivity or patent rights may provide only limited or no protection from competition.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to secure and extend marketing exclusivity for our products through a variety of means, including FDA exclusivity and patent rights. Additional barriers for competitors seeking to enter the market include the time and cost associated with the development, regulatory approval and manufacturing of a similar product formulation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Part I, Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business - Patents, Trademarks, and Other Intellectual Proprietary Rights,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this report on Form 10-K, we have several patents for formulations of Acetadote, and have previously engaged in litigation to enforce our patent rights. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to vigorously defend and protect our Acetadote product and related intellectual property rights. If we are unsuccessful in protecting our Acetadote intellectual property rights, our competitors may be able to introduce products into the marketplace that reduce the sales and market share of our Acetadote product which may require us to take measures such as reducing prices or increasing our marketing expense, any of which may result in a material adverse effect to our financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we consider patent protection when evaluating product acquisition opportunities, any products we acquire in the future may not have significant patent protection. Neither the USPTO nor the courts have a consistent policy regarding the breadth of claims allowed or the degree of protection afforded under many pharmaceutical patents. Patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months following the filing date of the first related application, and in some cases not at all. In addition, publication of discoveries in scientific literature often lags significantly behind actual discoveries. Therefore, neither we nor our licensors can be certain that we or they were the first to make the inventions claimed in our issued patents or pending patent applications, or that we or they were the first to file for protection of the inventions set forth in these patent applications. In addition, changes in either patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. Furthermore, our competitors may independently develop similar technologies or duplicate technology developed by us in a manner that does not infringe our patents or other intellectual property. As a result of these factors, our patent rights may not provide any commercially valuable protection from competing products.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we rely upon trade secrets, unpatented proprietary know-how and continuing technological innovation where we do not believe patent protection is appropriate or attainable. For example, the manufacturing process for Kristalose involves substantial trade secrets and proprietary know-how. We have entered into confidentiality agreements with certain key employees and consultants pursuant to which such employees and consultants must assign to us any inventions relating to our business if made by them while they are our employees, as well as certain confidentiality agreements relating to the acquisition of rights to products. Confidentiality agreements can be breached, though, and we might not have adequate remedies for any breach. Also, others could acquire or independently develop similar technology.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may depend on certain licensors for the maintenance and enforcement of intellectual property rights and have limited, if any, control over the amount or timing of resources that our licensors devote on our behalf.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we license products, we often depend on our licensors to protect the proprietary rights covering those products. We have limited, if any, control over the amount or timing of resources that our licensors devote on our behalf or the priority they place on maintaining patent or other rights and prosecuting patent applications to our advantage. While any such licensor is expected to be contractually obligated to diligently pursue its patent applications and allow us the opportunity to consult, review and comment on patent office communications, we cannot be sure that it will perform as required. If a licensor does not perform and if we do not assume the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">maintenance of the licensed patents in sufficient time to make required payments or filings with the appropriate governmental agencies, we risk losing the benefit of all or some of those patent rights.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the use of our technology conflicts with the intellectual property rights of third parties, we may incur substantial liabilities, and we may be unable to commercialize products based on this technology in a profitable manner or at all.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our products conflict with the intellectual property rights of others, they could bring legal action against us or our licensors, licensees, manufacturers, customers or collaborators. If we were found to be infringing a patent or other intellectual property rights held by a third party, we could be forced to seek a license to use the patented or otherwise protected technology. We might not be able to obtain such a license on terms acceptable to us or at all. If legal action involving an alleged infringement or misappropriation were to be brought against us or our licensors, we would incur substantial costs in defending the action. If such a dispute were to be resolved against us, we could be subject to significant damages, and the manufacturing or sale of one or more of our products could be enjoined.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, which could be costly and time consuming.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been involved in lawsuits for infringement of the Acetadote Patents as previously described. Because of their nature, these lawsuits can be costly and time-consuming, and we only experience limited benefits and patent protection. A significant adverse ruling in any such lawsuit could put our patents at risk of being invalidated or interpreted narrowly and could compromise the issuance of our existing patent applications.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe on our patents or the patents of our collaborators or licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings brought by the USPTO may be necessary to determine the priority of inventions with respect to our patent applications or those of our collaborators or licensors. Litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distraction of our management. We may not be able, alone or with our collaborators and licensors, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, some of our confidential information could be disclosed during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our trademarks or for allegedly infringing the trademark rights of others, which could be costly and time consuming.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own certain trademark registrations for each of our branded pharmaceutical products as well as for our corporate name and logo. We have applied for trademark registration for other various names and logos. We also may have common law trademark rights in unregistered names, phrases, and logos under which we market or offer certain products and services. Over time, we intend to obtain and maintain registrations on trademarks that remain valuable to our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may oppose registration of our federal trademark applications. Further, we could be involved in lawsuits for allegedly infringing the rights of others with respect to their prior-existing trademarks. These lawsuits or opposition proceedings can be costly and time-consuming. A significant adverse ruling in any such lawsuit could put our trademarks at risk of being invalidated and could compromise the issuance of our existing trademark applications.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe on our trademarks or the trademarks of our collaborators or licensors. To counter infringement or unauthorized use, we may be required to file trademark infringement claims, which can be expensive and time-consuming. In addition, in a trademark infringement proceeding, a court may decide that a trademark registration of ours is not valid or is unenforceable, or may refuse to stop the other party from using the mark or a mark that is similar to our registered mark at issue on the grounds that the competitor&#8217;s use of the mark is not confusingly similar to our registered trademark. An adverse result in any litigation or defense proceeding could put one or more of our trademark registrations at risk of being invalidated or interpreted narrowly and could put our trademark applications at risk of not registering.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, some of our confidential information could be disclosed during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we breach any of the agreements under which we license rights to our products and product candidates from others, we could lose the ability to continue commercialization of our products and development and commercialization of our product candidates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive licenses for the marketing and sale of certain products and may acquire additional licenses. Such licenses may terminate prior to expiration if we breach our obligations under the license agreement related to these pharmaceutical products. For example, the licenses may terminate if we fail to meet specified quality control standards, including GMP with respect to the products, or commit a material breach of other terms and conditions of the licenses. Such early termination could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we or these employees have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. We are subject to stringent government regulation. All of our products face regulatory challenges.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_88"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are likely to fluctuate from period to period.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a company actively seeking to deliver significant growth. As we execute our business strategy of adding new products, increasing market share in our existing growth products and striving to maintain market share in our other products, we anticipate that there may be fluctuations in our future operating results. We may not be able to maintain or improve our current levels of revenue or income. Potential causes of future fluctuations in our operating results may include:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New product launches, which could increase revenues but also increase sales and marketing expenses;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquisition activity and other charges;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increases in research and development expenses resulting from the acquisition of a product candidate that requires significant additional studies and development;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ability to utilize unrecognized federal and state net operating loss carryforwards as a result of the exercise of nonqualified options</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the competitive, regulatory or reimbursement environment, which could drive down revenues or drive up sales and marketing or compliance costs; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unexpected product liability or intellectual property claims and lawsuits.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8212;Liquidity and capital resources.&#8221; Fluctuation in operating results, particularly if not anticipated by investors and other members of the financial community, could add to volatility in our stock price. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our focus on acquisitions as a growth strategy has created intangible assets whose amortization could negatively affect our results of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total assets include intangible assets related to our acquisitions. As of December&#160;31, 2022, intangible assets relating to products, which are being amortized, represented approximately 33% of our total assets. We may never realize the value of these assets. U.S. Generally Accepted Accounting Principles ("GAAP") require that we evaluate on a regular basis whether events and circumstances have occurred that indicate that all or a portion of the carrying amount of the asset may no longer be recoverable, in which case we would write down the value of the asset and take a corresponding charge to earnings. Any determination requiring the write-off of a significant portion of unamortized intangible assets would adversely affect our results of operations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional funding and may be unable to raise capital when needed, which could force us to delay, reduce or eliminate our product development or commercialization and marketing efforts.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to raise additional funds in order to meet the capital requirements of running our business and acquiring and developing new pharmaceutical products. If we require additional funding, we may seek to sell common stock or other equity or equity-linked securities, which could result in dilution to our shareholders. We may also seek to raise capital through a debt financing, which would result in ongoing debt-service payments and increased interest expense. Furthermore, the terms of any additional debt securities we may issue in the future may impose restrictions on our operations, which may include limiting our ability to incur additional indebtedness, pay dividends on or repurchase our common shares, or make certain acquisitions or investments. In addition, we may be subject to covenants requiring us to satisfy certain financial tests and ratios, and our ability to satisfy such covenants may be affected by events outside of our control. Any financings would also likely involve operational and financial restrictions being imposed on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain any needed additional funding, we may be required to reduce the scope of, delay, or eliminate some or all of, our planned research, development and commercialization activities or to license to third parties the rights to develop and/or commercialize products or technologies that we would otherwise seek to develop and/or commercialize ourselves or on terms that are less attractive than they might otherwise be, any of which could materially harm our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We might also seek to sell assets or rights in one or more commercial products or product development programs. Additional capital might not be available to us when we need it. We are unable to predict the impact of global credit market trends, and if economic conditions deteriorate, our business, results of operations and ability to raise needed capital could be materially and adversely affected. If we are unable to raise additional capital when needed due to the reasons listed above and lack of creditworthiness, bank failures, or price decline in market investments, we could be forced to scale back our operations to conserve cash.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur losses in the future and we may not achieve or maintain profitability.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to continue to spend significant amounts on our efforts to discover and develop drugs. As a result, we may incur losses in future periods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our drug discovery and development efforts and related expenditures will increase as we focus on the studies, including clinical trials prior to seeking regulatory approval, that are required before we can sell a drug product.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of drug products will require us to spend significant funds on research, development, testing, obtaining regulatory approvals, manufacturing and marketing.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain whether or when we will achieve profitability because of the significant uncertainties relating to our ability to generate commercially successful drug products. Even if we are successful in obtaining regulatory approvals for manufacturing and commercializing additional drug products, we may incur losses if our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug products do not generate significant revenues. If we achieve profitability, we may not be able to sustain or increase profitability.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our officers, directors, and principal shareholders, acting as a group, could significantly influence corporate actions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our officers and directors control approximately 41.81 percent of our common stock. Acting together, these shareholders could significantly influence any matter requiring approval by our shareholders, including the election of directors and the approval of mergers or other business combinations. The interests of this group may not always coincide with our interests or the interests of other shareholders and may prevent or delay a change in control. This significant concentration of share ownership may adversely affect the trading price of our common stock because many investors perceive disadvantages to owning stock in companies with controlling shareholders.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research analysts may not continue to provide or initiate coverage of our common stock or may issue negative reports.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our common stock may be affected by the reports financial analysts publish about us. If one of the analysts covering us downgrades our stock, its price could decline rapidly and significantly. Securities analysts covering our common stock may discontinue coverage. A lack of research coverage may adversely affect our stock&#8217;s market price.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_91"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OWNING OUR STOCK</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may fluctuate substantially.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price for the shares of our common stock sold in our initial public offering was determined by negotiation between the representatives of the underwriters and us. This price may not have reflected the market price of our common stock following our initial public offering. Moreover, the market price of our common stock might decline below current levels. In addition, the market price of our common stock is likely to be highly volatile and may fluctuate substantially. Sales of a substantial number of shares of our common stock in the public market or the perception that these sales may occur could cause the market price of our common stock to decline.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of any of the risks described in these &#8220;Risk Factors&#8221; could have a dramatic and material adverse impact on the market price of our common stock. In addition, securities class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Any such securities litigation brought against us could result in substantial costs and a diversion of management&#8217;s attention and resources, which could negatively impact our business, operating results and financial condition. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market conditions may have serious adverse consequences on our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general business strategy may be adversely affected by unpredictable and unstable market conditions. While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, a radical economic downturn or increase in our expenses could require additional financing on less than attractive rates or on terms that are dilutive to existing shareholders. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical developments plans. There is a risk that one or more of our current service providers, manufacturers and other partners may encounter difficult economic circumstances, which would directly affect our ability to attain our operating goals on schedule and on budget. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The equity and lending markets have been and will most likely continue to be negatively impacted for an unknown period of time due to global events such as the COVID-19 pandemic, increased inflation and the U.S. government&#8217;s response thereto.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to maintain our listing on the NASDAQ Global Select Market (&#8220;NASDAQ&#8221;), which could have a material adverse effect on us and our stockholders.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The standards for continued listing on NASDAQ include, among other things, that the minimum bid price for the listed securities not fall below $1.00 for a period in excess of thirty consecutive business days. If the closing bid </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price of our common stock were to fail to meet NASDAQ&#8217;s minimum closing bid price requirement, or if we otherwise fail to meet any other applicable requirements of NASDAQ and we are unable to regain compliance, NASDAQ may make a determination to delist our common stock. The delisting of our common stock from NASDAQ could negatively impact us by (i) reducing the liquidity and market price of our common stock; (ii) reducing the number of investors willing to hold or acquire our common stock, which could negatively impact our ability to raise equity financing; (iii) impacting our ability to use a registration statement to offer and sell freely tradable securities, thereby preventing or limiting us from accessing the public capital markets; and (iv) impairing our ability to provide equity incentives to our employees.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some provisions of our third amended and restated charter, bylaws and Tennessee law may inhibit potential acquisition bids that you may consider favorable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate documents contain provisions that may enable our board of directors to resist a change in control of our company even if a change in control were to be considered favorable by you and other shareholders. These provisions include:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The authorization of undesignated preferred stock, the terms of which may be established and shares of which may be issued without shareholder approval;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advance notice procedures required for shareholders to nominate candidates for election as directors or to bring matters before an annual meeting of shareholders;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limitations on persons authorized to call a special meeting of shareholders;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A staggered board of directors;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restriction prohibiting shareholders from removing directors without cause;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A requirement that vacancies in directorships are to be filled by a majority of the directors then in office and the number of directors is to be fixed by the board of directors; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">No cumulative voting.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions contained in our third amended and restated charter and bylaws could delay or discourage transactions involving an actual or potential change in control of us or our management, including transactions in which our shareholders might otherwise receive a premium for their shares over then current prices, and may limit the ability of shareholders to remove our current management or approve transactions that our shareholders may deem to be in their best interests and, therefore, could adversely affect the price of our common stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to control share acquisitions provisions and affiliated transaction provisions of the Tennessee Business Corporation Act, the applications of which may have the effect of delaying or preventing a merger, takeover or other change in control of us and therefore could discourage attempts to acquire our company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our capital stock.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our capital stock. The availability of funds for distributions to shareholders will depend on our financial performance and assets. Any future decision to declare or pay dividends will be at the sole discretion of our Board of Directors.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">DEBT-RELATED RISKS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Revolving Credit Agreement impose restrictive and financial covenants on us. Our failure to comply with these covenants could trigger events that would have a material adverse effect on our business.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Revolving Credit Agreement contains covenants that restrict the way we conduct business and require us to satisfy certain financial tests in order to incur debt or take other actions. Additionally, our Revolving Credit Agreement contains financial covenants that, for example, require us to maintain certain financial ratios which are measured at the end of each fiscal quarter.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Revolving Credit Agreement contains specified quarterly financial maintenance covenants. As of December&#160;31, 2022, we were in compliance with the Maximum Funded Debt Ratio financial covenant of the Revolving Credit Agreement. However, we can make no assurance that we will be able to comply with the restrictive and financial covenants contained in the Revolving Credit Agreement in the future.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to comply with the covenants in our debt instruments could lead to a default or an event of default under the terms thereof, for which we may need to seek relief from our lender in order to waive the associated default or event of default and avoid a potential acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lender under our Revolving Credit Agreement may impose additional operating and financial restrictions on us as a condition to granting any such waiver. If an event of default is not cured or is not otherwise waived, the lender under our Revolving Credit Agreement may accelerate the maturity of the related debt, foreclose upon any collateral securing the debt and terminate any commitments to lend, any of which would have a material adverse effect on our business, financial condition, cash flows and results of operations and would cause the market value of our securities to decline.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have risks related to interest rates.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit facility bears interest based on variable interest. Thus, a change in the short-term interest rate environment (especially a material change) could have a material adverse effect on our business, financial condition, cash flows and results of operations. As of December&#160;31, 2022, we did not have any outstanding interest rate swap contracts.</span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1B. Unresolved Staff Comments.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_97"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;2. Properties.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we leased approximately 16,903 rentable square feet of space at the new Broadwest development in Nashville, Tennessee for our corporate headquarters.  The lease commencement date occurred in October 2022 with a term of 157 months leased through November 2035.  We believe these facilities are adequate to meet our current needs for office space. Manufacturing, packaging or warehousing services are provided to us through contracts with third-party organizations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laboratory space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. CET leases approximately 14,200 square feet of office and wet laboratory space in Nashville, Tennessee to operate the CET Life Sciences Center.  Cumberland's product formulation and testing laboratories are located at this facility, along with CET's offices. The CET Life Sciences Center also provides laboratory and office space, equipment and infrastructure to early-stage life sciences companies and university spin-outs.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_100"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;3. Legal Proceedings.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see discussion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Melinta Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Note 20 Commitments and Contingencies contained in the Notes to Consolidated Financial Statements, which is incorporated herein by reference.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_103"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;4. Mine Safety Disclosures.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_106"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_109"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock, no par value, has been traded on the Nasdaq Global Select Market since August&#160;11, 2009 under the symbol &#8220;CPIX.&#8221; As of March&#160;7, 2023, we had 89 shareholders of record of our common stock.  This excludes shareholders whose shares are held by brokers and other institutions on behalf of shareholders. The closing price of our common stock on the Nasdaq Global Select Market on March&#160;7, 2023 was $2.31 per share.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash dividends on our common stock.  Any future decision to declare or pay dividends will be at the sole discretion of our Board of Directors.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock performance graph below illustrates a comparison of the total cumulative stockholder return on our common stock since December 31, 2017 to the Nasdaq Composite and a composite of eleven Nasdaq Pharmaceutical and Specialty Pharmaceutical Stocks which most closely compare to our Company - Avadel Pharmaceuticals plc, Harrow Health, Inc., Eagle Pharmaceuticals, Inc., Assertio Holdings, Inc., HLS Therapeutics, EyePoint Pharmaceuticals, Inc., Eton Pharmaceuticals, Inc., Theratechnologies Inc., Impel Pharmaceuticals Inc., Acorda Therapeutics Inc. and AcelRX Pharmaceuticals, Inc. The graph assumes an initial investment of $100 on December 31, 2017, and that all dividends were reinvested.</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><img src="cpix-20221231_g1.jpg" alt="cpix-20221231_g1.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:650px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has a share repurchase program to repurchase up to $10.0 million of our common stock pursuant to Rule 10b-18 of the Securities Exchange Act of 1934, as amended. In January 2019, the Company's Board of Directors established the current $10.0 million repurchase program to replace the prior authorizations.  We repurchased  367,793 shares and 438,359 shares of common stock for approximately $1.0 million and  $1.4 million, and during the years ended December&#160;31, 2022 and 2021, respectively.  The following table summarizes the activity, by month, during the fourth quarter of 2022:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:23.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares (or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price&#160;Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">per Share</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(or Unit)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares (or Units)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased as</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Part of Publicly</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Announced Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Programs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum&#160;Number&#160;(or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value) of Shares (or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units)&#160;that&#160;May&#160;Yet&#160;Be</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased Under the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plans or Programs</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.52</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,887</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3,882,881</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.05</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,240</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3,808,415</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,094&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,094</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3,753,797</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,221&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Of this amount, 4,925 shares were repurchased directly in private purchases at the then-current fair market value of common stock.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_112"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;6. Reserved.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_115"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial position and results of operations should be read together with our audited consolidated financial statements and related notes appearing elsewhere in this Form 10-K. This discussion and analysis may contain forward-looking statements that involve risks and uncertainties &#8211; please refer to the section entitled, &#8220;Special Note Regarding Forward-Looking Statements,&#8221; contained in Part I, Item&#160;1A, &#8220;Risk Factors,&#8221; of this Form 10-K. You should review the &#8220;Risk Factors&#8221; section of this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements described in the following discussion and analysis.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE SUMMARY </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. We are dedicated to providing innovative products that improve the quality of care for patients and address poorly met medical needs.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:25.93pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial portfolio includes eight branded products approved for marketing by the U.S. Food and Drug Administration (&#8220;FDA&#8221;). In addition to these commercial brands, we have Phase II clinical programs underway evaluating our ifetroban product candidate for patients with 1) cardiomyopathy associated with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duchenne Muscular Dystrophy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a fatal, genetic neuromuscular disease, 2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Systemic Sclerosis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or scleroderma, a debilitating autoimmune disorder characterized by fibrosis of the skin and internal organs and 3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aspirin-Exacerbated Respiratory Disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,  a severe form of asthma.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:25.93pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that we believe can be served effectively by small, targeted sales forces. We promote our approved products through our hospital, field, and oncology sales divisions in the United States and are building a network of international partners to register and provide our medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:25.93pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established the capabilities needed to acquire, develop, and commercialize branded pharmaceuticals  in the U.S. We believe we can leverage this existing infrastructure to support new products and our expected growth. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:25.93pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management  team consists of pharmaceutical industry veterans with significant experience in their areas of responsibility. Our business development team identifies, evaluates, and negotiates product acquisition, licensing and co-promotion agreements. Our product development team creates proprietary formulations, manages our clinical studies, prepares our FDA submissions and staffs our medical call center. Our quality and manufacturing professionals oversee the manufacturing, release and shipment of our products. Our marketing and sales organization is responsible for our commercial activities, and we work closely with our distribution partners to ensure the availability of our brands.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Highlights</span></div><div style="margin-top:8pt;text-align:justify;text-indent:8.95pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Below is a list of our company&#8217;s highlights from 2022. For more information, please see Part I, Item I, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Form 10-K.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Formed a specialty sales division, Cumberland Oncology, to support Sancuso. To augment those efforts, we also entered into a co-promotion agreement to feature Sancuso through another national oncology sales organization.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Launched Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Puerto Rico, through a partnership with Verity Pharmaceuticals, who has a particular strength and experience in that market.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced a new partnership with Saudi Arabia-based Tabuk Pharmaceutical Manufacturing Co., a fully owned subsidiary of the Astra Industrial Group, to introduce Vibativ in the Middle East.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Signed a new agreement with Laboratorios Pisa, S.A. de C.V. for the exclusive supply and distribution of Caldolor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cumberland&#8217;s ibuprofen injection product, in Mexico.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Entered into two amendments to our agreement with Nordic Group B.V. who had provided us with a license for the U.S. rights associated with our RediTrex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line.  Pursuant to the amendment, in exchange for financial consideration, Nordic may assume responsibility for distributing the methotrexate products in the U.S. after June 30, 2023. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced the relocation of our headquarters into new offices located on the Broadwest campus in the Vanderbilt/West End corridor of Nashville, which will allow us to accommodate our expected growth and better serve our international base of customers and partners.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">Named Martin S. Brown Jr. to our Board of Directors. Mr. Brown is an attorney with over 30 years of corporate law experience who brings significant legal, public company, health care and civic experience to our board.  The Company relies on several law firms for legal advice, including the firm in which Martin is affiliated.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Released our third annual Sustainability Report, which details the company&#8217;s activities pertaining to our environmental, social and governance matters.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Modified our line of credit with Pinnacle Bank, which provides for a remaining three-year facility for up to $20 million which ends in October 2024.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continued our corporate share repurchase initiative, with a group of our board members also purchasing shares through Rule 10b5-1 trading plans in order to add to their holdings in the company.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_121"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Judgments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on past experience and on other factors we deem reasonable given the circumstances. Past results help form the basis of our judgments about the carrying value of assets and liabilities that are not determined from other sources. Actual results could differ from these estimates. These estimates, judgments and assumptions are most critical with respect to our accounting for revenue recognition, inventory, intangible assets and goodwill, research and development accounting, contingent consideration liability, provision for income taxes and share-based payments.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with the Accounting Standards Codification (ASC) Topic 606. Effective January 1, 2018, we adopted the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) amended guidance in the form of Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, "Revenue from Contracts with Customers," (ASC 606). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is derived primarily from the product sales of our FDA approved pharmaceutical brands. Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which occurs upon either shipment of the product or arrival at its destination, depending upon the shipping terms of the transaction. Payment terms typically range from 30 to 60 days from date of shipment. Our net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, and discounts and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. Other revenue, which is a component of net revenues, includes non-refundable upfront payments and milestone payments under licensing agreements along with grant and rental income. Other revenue was approximately 3.2% percent of net revenues in 2022 and 2.6% in 2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements reflect accounts receivable allowances of $0.6 million and $0.3 million at December&#160;31, 2022 and 2021, respectively, for chargebacks and early pay discounts for products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects our sales-related accrual activity for the periods indicated below:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:64.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.160%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.162%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,063,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,426,431&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,127,410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual product returns and credits issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,759,894)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,510,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,347,214&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680,677&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allowances for chargebacks and discounts and sales related accruals for rebates, fee for service and product returns are determined on a product-by-product basis. We establish them using our best estimate at the time of sale based on: </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The contractual terms with direct and indirect customers;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analyses of historical levels of chargebacks, discounts and returns of product; </span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Communications with customers;</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchased information about the rate of prescriptions being written and the level of inventory remaining in the distribution channel, if known; and</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expectations about the market for each product, including any anticipated introduction of competitive products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from us based on either negotiated contracts to carry our products or reimbursements for filled prescriptions. These entities are considered our indirect customers. When recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by our estimate of the rebate that may be claimed. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances for chargebacks and accruals for rebates and product returns are the most significant estimates used in the recognition of our revenue from product sales. Of the accounts receivable allowances and our sales related accruals, our accrual for product returns and rebates represents the majority of the balance. Sales related accrued liabilities for rebates, product returns, service fees, and administrative fees totaled $8.3 million and $3.7 million as of December&#160;31, 2022 and 2021 , respectively. Of these amounts, our estimated liability for fee for services represented $1.5 million and $1.0 million, respectively, while our accrual for product returns totaled $2.7 million and $1.9 million, respectively. If the actual amount of cash discounts, chargebacks, rebates, and product returns differs from the amounts estimated by management, material differences may result from the amount of our revenue recognized from product sales. A change in our rebate estimate of one percentage point would have impacted net sales by approximately $0.6 million and $0.4 million for the year ended December&#160;31, 2022 and 2021, respectively.  A change in our product return estimate of one percentage point would have impacted net sales by $0.4 million for the years ended December&#160;31, 2022 and 2021. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record amounts for estimated obsolescence or unmarketable inventory in an amount equal to the difference between the cost of inventory and the net realizable value based upon assumptions about remaining shelf life, future demand and market conditions. The estimated inventory obsolescence amounts are calculated based upon specific review of the inventory expiration dates and the quantity on-hand at December&#160;31, 2022, in comparison to our expected inventory usage. The amount of actual inventory obsolescence and unmarketable inventory could differ </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(either higher or lower) in the near term from the estimated amounts. Changes in our estimates would be recorded in our statement of operations in the period of the change.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current inventories consist of API which typically has an extended life and selected finished good products with extended life longer than one year.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to operating loss and tax credit carry-forwards and differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Our principal differences are related to the timing of deductibility of certain items such as depreciation, amortization and expense for options issued to nonemployees. Deferred tax assets and liabilities are measured using management&#8217;s estimate of tax rates expected to apply to taxable income in the years in which management believes those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in our results of operations in the period that includes the enactment date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense for all share-based payments based on the fair value of the award on the date of grant. In addition, incremental compensation expense is recognized upon the modification of equity awards. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We issue restricted stock and incentive stock option awards to employees, directors and consultants. Compensation expense for restricted equity awards granted to employees and directors is generally equal to the fair market value of the underlying common stock on the date of grant. If a sufficient disincentive for nonperformance does not exist at the date of grant, the compensation cost is remeasured at each reporting date at the then-current fair market value of the underlying common stock until the award vests.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for and expense research and development costs based on estimates of work performed, patient enrollment or fixed-fee-for-services. As work is performed and/or invoices are received, we adjust our estimates and accruals. To date, our accruals have not differed materially from our estimates. Total research and development costs are a function of studies being conducted and will increase or decrease based on the level of activity in any particular year.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets include product rights, license agreements, other identifiable intangible assets and goodwill associated with the Vibativ acquisition. We assess the impairment of goodwill at least annually. We assess the impairment of identifiable intangible assets subject to amortization whenever events or changes in circumstances indicate the carrying value may not be recoverable. In determining the recoverability of our intangible assets, we make assumptions regarding estimated future cash flows and other factors. If the estimated undiscounted future cash flows do not exceed the carrying value of the intangible assets, we must determine the fair value of the intangible assets. If the fair value of the intangible assets is less than the carrying value, an impairment loss will be recognized in an amount equal to the difference. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models, as considered necessary.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_124"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year ended December&#160;31, 2022 compared to year ended December&#160;31, 2021</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the statements of operations for the years ended December&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:39.061%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.932%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,010,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,985,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,025,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,118,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,811,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,660,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,015,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,688,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,684,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,180,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,780,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,715,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,662,463&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,053,415&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,704,929)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,677,420)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,972,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - gain on insurance proceeds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,187,140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(585,995)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,031)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,581,189)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,562,230)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,959)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,959)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,597,121)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,918)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes net revenues for the years presented:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.397%"><tr><td style="width:1.0%"></td><td style="width:40.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.955%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,205,155&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,993,658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(788,503)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,205,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,205,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,704,062&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,216,600)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,827,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850,993&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349,953)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,697)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859,581&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,307,278)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,047)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329,767&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">939,784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,983&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,010,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,985,043&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,025,906&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Net revenues for the year ended December&#160;31, 2022, were approximately $42.0 million compared to $36.0 million for the year ended December&#160;31, 2021, representing an increase of $6.0 million or 16.7%.  Net revenue increased during the 2022 period as a result of our newest product Sancuso which contributed net revenue of $13.2 million.  This increase was offset by decreased net sales of Vibativ and Vaprisol.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristalose revenue declined by $0.8 million, or (4.9)%, compared to December&#160;31, 2021, primarily as a result of timing of sales of our shipments to one of our co-promotion partners.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ revenue was $7.5 million compared to $11.7 million in the prior year.  This $4.2 million decline in net revenue was a result higher sales volume for the product in 2021 associated in part with wholesale stocking of our new packaged product. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caldolor revenue experienced a 2.9% decrease to $4.8 million during the year ended December 31, 2022, compared to $5.0 million in the same period last year. This decrease in Caldolor revenue for the year ended December 31, 2022, w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as the result of the timing of international shipments. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaprisol revenue decreased $2.3 million during the year ended December 31, 2022, compared to the prior year period due primarily to a temporary out of stock situation associated with a change in manufacturers. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acetadote revenue included net sales of our branded product and our share of net sales from our Authorized Generic. For the year ended December 31, 2022, the Acetadote net revenue decreased $0.3 million compared to the prior year due to an increase in expired product returns in 2022.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omeclamox-Pak revenue increased $0.4 million during the year ended December 31, 2022, compared to the prior year. The increase was due to favorable sales adjustments and ownership changes at our packager which resulted in a temporary out of stock situation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reditrex revenue decreased $0.2 million in 2022 compared to 2021. Our 2022 gross wholesale revenue increased by $0.4 million, but the revenue growth was offset by expired product returns.</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Cost of products sold for the year ended December&#160;31, 2022, were $9.1 million compared to $8.8 million in the prior year.  As a percentage of net revenues, cost of products sold were 21.7% compared to 24.5% during the prior year.  This change in costs of products sold as a percentage of revenue was attributable to a change in the product sales mix, particularly the addition of our Sancuso sales.  </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Selling and marketing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Selling and marketing expense for the year ended December&#160;31, 2022, were $16.7&#160;million compared to $15.0 million in the prior year, which was an increase of $1.6 million.  This increase was primarily a result of an increase in marketing expenses associated with the Sancuso acquisition including royalty costs, promotional spending and the cost associated with our new Oncology division. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Research and development costs for the year ended December&#160;31, 2022, were $6.7&#160;million, compared to $5.7 million last year, representing an increase of $1.0 million. A portion of our research and development costs is variable based on the number of trials, study sites, number of patients and the cost per patient in each of our clinical programs. We continue to fund our ongoing clinical initiatives associated with our pipeline products.  During 2022, we also experienced an increase in our annual FDA user fees.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  General and administrative expenses for the year ended December&#160;31, 2022, were $10.2 million compared to $9.8 million in the prior year. The change resulted from an increase in insurance expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Vibativ:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Vibativ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,637,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,704,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,535,851&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814,464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,011,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,018,466&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878,140&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2022 net revenue includes a $150,000 payment to Cumberland required under the terms of a new licensee agreement. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Vibativ inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2018.</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the statements of operations discussed above reflect the following impacts from Sancuso:</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Impact of Sancuso</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,555,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543,600&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty and operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,202,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,809,977&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 2022 net revenue  includes a $250,000 payment to Cumberland required under the terms of a new licensee agreement and a $100,000 payment to Cumberland required under a sales representation agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Sancuso inventory included in the costs of product sold during the period was acquired and paid for by Cumberland as part of the acquisition of the brand during 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Amortization expenses represent the ratable use of our capitalized intangible assets including product and license rights, patents, trademarks and patent defense costs.  Amortization for 2022 totaled approximately $5.1&#160;million which is an increase of $0.7 million due to the addition of Sancuso.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Income taxes totaled $68,850 for the year ended December&#160;31, 2022, and $34,891 for the year ended December&#160;31, 2021. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_127"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash flows provided by our operations, the amounts borrowed and available under our line of credit and the cash proceeds from our initial public offering of common stock that was completed in August 2009. We believe that our internally generated cash flows, existing working capital and our line of credit will be adequate to finance internal growth, finance business development initiatives, and fund capital expenditures for the foreseeable future.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and December&#160;31, 2021, all our investments had original maturities of less than ninety days and as a result were classified as cash equivalents.  </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our liquidity and working capital as of the years ended December 31:</span></div><div style="margin-top:7pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.314%"><tr><td style="width:1.0%"></td><td style="width:65.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.631%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.876%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:7pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757,970&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,040,816&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,757,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,040,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital (current assets less current liabilities)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,290,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,409,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current ratio (multiple of current assets to current liabilities)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit availability</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800,000&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net changes in cash and cash equivalents for the years ended December&#160;31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:65.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,453,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,342,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,674,456)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(501,893)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,061,786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,553,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash equivalents </span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,282,846)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287,020&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $7.3 million decrease in cash and cash equivalents for the year ended December&#160;31, 2022, was attributable to cash provided by operating activities offset by cash used in investing and financing activities.  Cash provided by operating activities of $8.5 million includes a decrease of inventory of $0.9 million, most of which was Vibativ and Sancuso related, an increase in accounts payable and other accrued liabilities of $14.5 million, partially offset by a $6.1 million increase in accounts receivable and a decrease in non-cash contingent consideration of $2.1 million.  Cash used in investing activities of $13.7 million was the result of the acquisition of Sancuso of $13.5 million, additions to intangibles of $2.0 million, additions to property and equipment of $0.1 million and the proceeds of officer life insurance proceeds of $0.9 million.  Our financing activities included payments of $2.2 million of contingent consideration for Vibativ and Sancuso and $1.1 million in cash used to repurchase shares of our common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we continue to repurchase shares of our common stock, as discussed in Part II, Item&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities",</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of this Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net $2.3 million increase in cash and cash equivalents for the year ended December 31, 2021, was attributable to cash provided by operating activities partially offset by cash used in investing and financing activities.  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities of $6.3 million includes a reduction of inventory of $4.8 million, most of which was Vibativ related, and cash payments received of $2.0 million provided by discontinued operations.  Cash used in investing activities of $0.5 million was the result of additions to intangibles of $0.3 million, additions to property and equipment of $0.1 million and the payment of $0.2 million to the WHC joint venture.  Our financing activities included payments of $2.2 million of contingent consideration for Vibativ and $1.4 million in cash used to repurchase shares of our common stock.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100 million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19 million.  The Company amended the At the Market Sales Agreement on December 27, 2021, in order to allow the Company to continue using its ATM feature to sell shares at market prices. </span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to continue an ATM feature through B. Riley FBR, Inc. which allows the Company to issue shares of its common stock. The Company did not issue any shares under this ATM during the year ended December&#160;31, 2022.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Agreement</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $8,500,000, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.  For the year ended December&#160;31, 2022, we were in compliance with the Funded Debt Ratio financial covenant. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022, the Company entered into the Eighth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank permitting the Maximum Funded Debt Ratio to be calculated on a rolling four-quarter basis to be no more than 3.00 to 1.00 for the second and third quarters of 2022 and 2.50 to 1.00 for each quarter thereafter.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2022, the Company and Pinnacle Bank entered into a Seventh Amendment to the Revolving Credit Loan Agreement to revise and update the Maximum Funded Debt Ratio financial covenant and to delete from the Pinnacle Agreement the Funded Debt to Tangible Capital Ratio financial covenant. These changes were made to more appropriately reflect the impact from the Sancuso acquisition. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company and Pinnacle Bank entered into the Fifth Amendment to the Revolving Credit Note and the Sixth Amendment to the Revolving Credit Loan Agreement in order to increase the principal amount of the Note from $15 million to $20 million.  On October 28, 2021, the Company entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement with Pinnacle Bank. Among other terms, the Fourth Amendment extended the maturity date to October 1, 2024.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.  From the date of funding, we have used the loan amount for such qualifying expenses.  Due to the assistance from our PPP loan, the Company did not lay off or furlough any employees as a result of the Covid-19 pandemic.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Cumberland submitted a request for the loan&#8217;s forgiveness. On June 11, 2021, the Company received a formal notice from the SBA that the full amount of the loan was forgiven. The Company accounted for the forgiveness of the PPP loan under IAS 20 and recorded the $2,187,140 as other income.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Minimum Product Purchase Requirements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing and supply agreements do not require minimum annual purchase obligations. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual cash obligations</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual cash obligations as of December&#160;31, 2022:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:22.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.854%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments Due by Year</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026 and thereafter</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Line of credit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated interest on debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,949,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ contingent consideration liability payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso contingent consideration liability payments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,757,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,608,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,427,446&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,061&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,347&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,101,575&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,488,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,337,324&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,476,814&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,023,658&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The sum of the individual amounts may not agree due to rounding.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The line of credit payments represent the estimated unused line of credit payments and the amount due at maturity. The estimated interest on debt represents the interest on the principal outstanding on the line of credit.  These amounts are based on the $16.2 million line of credit assuming the current $16.2 million balance outstanding on December&#160;31, 2022 is consistently outstanding through maturity of October 2024.  Interest and unused line of credit payments are due and payable quarterly in arrears. </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The contingent consideration liability represents the fair value of the royalty payments of up to 20% of future net sales as part of the Vibativ acquisition.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The contingent consideration liability represents the fair value of the royalty payments of up to 10% of future net sales as part of the Sancuso acquisition.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.25pt">The Broadwest contractual cash obligation began upon commencement in October 2022.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021 we did not engage in any off-balance sheet arrangements.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_133"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENT ACCOUNTING PRONOUNCEMENTS</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements - Not Yet Adopted</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_136"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates on our cash on deposit in highly-liquid money market accounts and revolving credit facility. We do not utilize derivative financial instruments or other market risk-sensitive instruments to manage exposure to interest rate changes. The main objective of our cash investment activities is to preserve principal while maximizing interest income through low-risk investments. Our investment policy focuses on principal preservation and liquidity.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our interest rate risk related to our cash and cash equivalents is not material. The risk related to interest rates for these accounts would produce less income than expected if market interest rates fall. Based on current interest rates, we do not believe we are exposed to significant downside risk related to a change in interest on our money market accounts. The Company did not have any investments in marketable securities at December&#160;31, 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate risk related to borrowings under our line of credit is based on LIBOR plus an interest rate spread.  There is no LIBOR minimum and the LIBOR pricing provides for an interest rate spread of 1.75% to 2.75% (representing an interest rate of 6.875% at December&#160;31, 2022).   When the LIBOR rate is discontinued, the Pinnacle Agreement allows for the LIBOR rate to be replaced by a Benchmark Rate, which may be the Daily Simple SOFR (Secured Overnight Financing Rate).  The Benchmark Rate will be determined in consultation with Pinnacle Bank.  As of December&#160;31, 2022, we had $16.2 million in borrowings outstanding under our revolving line of credit. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exchange Rate Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we operate primarily in the U.S., we are exposed to foreign currency risk. A portion of our research and development is performed abroad. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we do not utilize financial instruments to hedge exposure to foreign currency fluctuations. We believe our exposure to foreign currency fluctuation is minimal as our purchases in foreign currency have a maximum exposure of 90 days based on invoice terms with a portion of the exposure being limited to 30 days based on the due date of the invoice. Foreign currency exchange losses were immaterial for 2022, 2021 and 2020. Neither a five percent increase nor decrease from current exchange rates would have had a material effect on our operating results or financial condition.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_139"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See consolidated financial statements, including the reports of the independent registered public accounting firm, starting on page F-1, which is incorporated herein by reference.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_142"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_145"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;9A. Controls and Procedures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and Chief Financial Officer, with the participation of other members of management, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") as of  December&#160;31, 2022.  Based on such evaluations, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective (at the reasonable assurance level) to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC&#8217;s rules and forms and to ensure that such information is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s report on internal control over financial reporting is included on page F-1 of this annual report on Form 10-K, and incorporated herein by reference.  During our fourth quarter of 2022, there were no changes in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our internal control over financial reporting (as defined in Rule&#160;13a-15(f) or 15d-15(f)) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_148"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;9B. Other Information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_151"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 9C:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_154"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by Part III of Form 10-K (Item 10 &#8211; Directors, Executive Officers and Corporate Governance, Item&#160;11 &#8211; Executive Compensation, Item&#160;12 &#8211; Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters, Item&#160;13 &#8211; Certain Relationships and Related Transactions, and Director Independence, Item&#160;14 &#8211; Principal Accountant Fees and Services), is incorporated by reference from our proxy statement related to our 2023 annual meeting of shareholders, which is expected to be filed with the SEC on or around March&#160;13, 2023.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_157"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_160"></div><div style="-sec-extract:summary;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;15. Exhibits, Financial Statement Schedules.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Documents filed as part of this report:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Financial Statements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.378%"><tr><td style="width:1.0%"></td><td style="width:79.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page&#160;Number</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_169">Management&#8217;s Report on Internal Control over Financial Reporting</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-1</span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_172">Reports of Independent Registered Public Accounting Firm &#8211; Consolidated Financial Statements</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_172"> - </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_172">FORVIS</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_172">, LLP</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_172"> (form</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_172">er</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_172">ly BKD, LLP)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_172">; Nashville, TN  PCAOB ID:</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNjAvZnJhZzpkZmJiOWUxNmNiOTI0MDVhYjc0NzUyZmNjZjljYWJlMS90YWJsZTpmMTQyNWI1ZDJmOWE0MjgxOWNlYzA5NzcwZGQ3NWMzMC90YWJsZXJhbmdlOmYxNDI1YjVkMmY5YTQyODE5Y2VjMDk3NzBkZDc1YzMwXzQtMC0xLTEtMzQzODQvdGV4dHJlZ2lvbjpmYWUxZGIxNzQwMDY0MjI3YTk1NTE0YTliNjBjYWUzN18xMzU_2dd22a9e-f662-4a1a-be1d-bd7d44dff3a1">686</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-2</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_175">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_175">5</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_178">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_178">6</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_181">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_181">7</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_184">Consolidated Statements of Equity</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_184">9</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_187">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_187">10</a></span></div></td></tr></table></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Financial Statement Schedule</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.378%"><tr><td style="width:1.0%"></td><td style="width:79.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.454%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_253">Valuation and Qualifying Accounts</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3e36cfc56e1a4275a52b7d560014d176_253">42</a></span></div></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">b. Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex11.htm">At Market Issuance Sales Agreement, dated November 7, 2017, by and between Cumberland Pharmaceuticals Inc. and B. Riley FBR, Inc., incorporated herein by reference to the corresponding Exhibit 1.1 of our Registration Statement on Form S-3 (File No. 333-221402) as filed with the SEC on November 7, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828021025612/ex12amendmentno1toatmsales.htm">Amendment No. 1 to At Market Issuance Sales Agreement, dated December 27, 2021, by and between Cumberland Pharmaceuticals Inc. and B. Riley Securities, Inc., incorporated herein by reference to the corresponding exhibit 1.2 of the Registrant&#8217;s Form 8-K  (File No. 001-33637) as filed with the SEC on December 27, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022000440/finalforexecutionkkuscipde.htm">Asset Purchase Agreement, dated December 31, 2021, by and between Cumberland Pharmaceuticals Inc. and Kyowa Kirin, Inc., incorporated herein by reference to the corresponding exhibit 2.1 of the Registrant&#8217;s Form 8-K  (File No. 001- 001-33637) as filed with the SEC on January 6, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095012309023228/c0628619exv3w1.htm">Third Amended and Restated Charter of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 19 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on July 17, 2009</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095012309023228/c0628619exv3w2.htm">Second Amended and Restated Bylaws of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 19 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on July 17, 2009</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407007248/g06286a5exv4w1.htm">Specimen Common Stock Certificate of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 5 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on August 6, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517372414/d489256dex42.htm">Preferred Stock Terms, Rights, and Provisions, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-221402) as filed with the SEC on December 19, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex42.htm">Form of Senior Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-221402) as filed with the SEC on November 7, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex43.htm">Form of Subordinated Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-221402) as filed with the SEC on November 7, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv4w5.htm">Form of Option Agreement under 1999 Stock Option Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6.1#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit461.htm">Form of Incentive Stock Option Agreement under the Amended and Restated 2007 Long-Term Incentive Compensation Plan of Cumberland Pharmaceuticals Inc. incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6.2#</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit462.htm">Form of Non-Statutory Stock Option Agreement under the Amended and Restated 2007 Long-Term Incentive Compensation Plan of Cumberland Pharmaceuticals Inc. incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7#</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit47.htm">Form of Non-Statutory Stock Option Agreement under the Amended and Restated 2007 Directors&#8217; Compensation Plan of Cumberland Pharmaceuticals Inc. incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095012310026333/g22569exv4w8.htm">Warrant to Purchase Common Stock of Cumberland Pharmaceuticals Inc., issued to Bank of America, N.A. on July 22, 2009, incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 19, 2010</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex42.htm">Form of Senior Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-184091) as filed with the SEC on September 25, 2012.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex43.htm">Form of Subordinated Indenture, incorporated herein by reference to the corresponding exhibit to Registrant's Registration Statement Form S-3 (File No. 333-184091) as filed with the SEC on September 25, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022q4exhibit411.htm">Description of Cumberland Pharmaceutical's Common Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000129993310003084/exhibit1.htm">Exclusive Distribution Agreement, effective as of July 1, 2010, by and between Cardinal Health 105, Inc. and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on August 13, 2010</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000108729413000004/exhibit1071amendmenttoexcl.htm">First Amendment to Exclusive Distribution Agreement, dated March 31, 2013, by and between Cardinal Health 105, Inc. and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit of the Registrant's Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on June 3, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407006504/g06286a3exv10w10.htm">License Agreement, dated May 28, 1999, by and between Vanderbilt University and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 3 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on July 11, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registrant's Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on May13, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">Employment Agreement dated March </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">, effective as of January 1, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm"> inco</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">rporated herein by reference </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">to</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm"> Exhibit 10.1 of the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1011ajkazimi.htm">Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on May 13, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1014johnhamm.htm">Employment Agreement dated March 7, 2022, effective as of January 1, 2022, by and between John M. Hamm and Cumberland Pharmaceuticals Inc., incorporated herein by reference to Exhibit 10.3 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on May 13, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1015jimherman.htm">Employment Agreement dated March </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1015jimherman.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1015jimherman.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1015jimherman.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1015jimherman.htm">, effective as of January 1, 2021, by and between James L. Herman and Cumberland Pharmaceuticals Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1015jimherman.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1015jimherman.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxex1015jimherman.htm">incorporated herein by reference to Exhibit 10.4 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on May 13, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w17.htm">1999 Stock Option Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512107956/d293470ddef14a.htm">Amended and Restated 2007 Long-Term Incentive Compensation Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to Appendix A of the Registrant&#8217;s Schedule 14A as filed with the SEC on March 12, 2012 and approved by the Registrant's shareholders on April 17, 2012 </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512107956/d293470ddef14a.htm">Amended and Restated 2007 Directors&#8217; Incentive Plan of Cumberland Pharmaceuticals Inc., incorporated herein by reference to Appendix B of the Registrant's Schedule 14A as filed with the SEC on March 12, 2012 and approved by the Registrant's shareholders on April 17, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w20.htm">Form of Indemnification Agreement between Cumberland Pharmaceuticals Inc. and all members of its Board of Directors, incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w23.htm">Amended and Restated Lease Agreement, dated November 11, 2004, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv10w24.htm">First Amendment to Amended and Restated Lease Agreement, dated August 23, 2005, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 1, 2007</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014408004306/g06286b1exv10w24w1.htm">Second Amendment to Amended and Restated Lease Agreement, dated January 9, 2006, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to Amendment No. 10 of the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May 21, 2008</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512347942/d334181dex10241.htm">Third Amendment to Amended and Restated Lease Agreement, dated July 3, 2012, by and between The Gateway to Nashville LLC and Cumberland Emerging Technologies, Inc., incorporated herein by reference to the corresponding exhibit to the Registrant's Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 9, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828016012682/a2015-10kxexhibit1025gelli.htm">License and Supply Agreement, dated November 16, 2015, by and between Cumberland Pharmaceuticals Inc. and Gastro-Entero Logic, LLC incorporated herein by reference to the corresponding exhibit of the Registrant's Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 14, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000129993311003397/exhibit1.htm">Asset Purchase and Royalty Agreement for Kristalose dated November 15, 2011 by and between Mylan Inc. and Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit of the Registrant&#8217;s Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on November 22, 2011</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312512247355/d358671dex1030.htm">Supplemental Executive Retirement and Savings Plan, incorporated herein by reference to the corresponding exhibit to the Registrant's Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on May 24, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit1031-perrigoxpa.htm">Settlement Agreement, dated November 9, 2012, by and between Cumberland Pharmaceuticals Inc., Paddock Laboratories, LLC and Perrigo Company incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000144530513000573/cpixexhibit1032-perrigoxpa.htm">License and Supply Agreement, dated November 9, 2012, by and between Cumberland Pharmaceuticals Inc., Paddock Laboratories, LLC and Perrigo Company incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 12, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828017011224/loanagreementexhibit1034.htm">Revolving Credit Loan Agreement, dated July 31, 2017, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank incorporated herein by reference to the corresponding exhibit to the Registrant's Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on November 8, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex43.htm">Amendment to Revolving Credit Loan Agreement, by and between Pinnacle Bank and Cumberland Pharmaceuticals Inc., dated August 14, 2018, incorporated herein by reference to Exhibit 10.1 to the Registrant's Quarterly Report Form 10-Q (File No. 001-33637) as filed with the SEC on August 14, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000119312517335943/d489256dex43.htm">First Amendment to Revolving Credit Note and Second Amendment to Revolving Credit Loan Agreement, dated as of October 17, 2018, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-33637) as filed with the SEC on October 19, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000162828017011224/loanagreementexhibit1034.htm">Second Amendment to Revolving Credit Note and Third Amendment to Revolving Credit Loan Agreement, dated as of May 10, 2019, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-336371) as filed with the SEC on May 15, 2019.  </a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828020012738/exhibit101-amendment2l.htm">Amendment Number 2 to the Amended and Restated 2007 Long-Term Incentive Plan, incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 14, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828020012738/exhibit102-amendment2d.htm">Amendment Number 2 to the Amended and Restated 2007 Directors&#8217; Incentive Compensation Plan, incorporated herein by reference to Exhibit 10.2 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 14, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828020016446/a2020q3-exhibit101.htm">Third Amendment to Revolving Credit Note and Fourth Amendment to Revolving Credit Loan Agreement, dated as of October 7, 2020, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on November 13, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828021023213/pinnaclelocrenewal4thloa.htm">Fourth Amendment to Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement, dated as of October 28, 2021, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on November 12, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/pinnaclebank-cpiamend5to.htm">Fifth Amendment to the Revolving Credit Note and Sixth Amendment to Revolving Credit Loan Agreement, dated as of December 31, 2021, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to the corresponding exhibit of the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 11, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.808%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.634%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:70.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022005942/a1600westendavepartnersl.htm">Lease Agreement, dated November 15, 2021, by and between Cumberland Pharmaceuticals Inc. and  1600 West End Avenue Partners, LLC., incorporated herein by reference to the corresponding exhibit of the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-33637) as filed with the SEC on March 11, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022014372/pinnaclebank-cpiamend7tolo.htm">Seventh Amendment to Revolving Credit Loan Agreement, dated as of March 31, 2022, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank, incorporated herein by reference to Exhibit 10.5 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on May 13, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022022735/pinnaclebank-cpiamend8tolo.htm">Eighth Amendment to Revolving Credit Loan Agreement, dated as of June 30, 2022, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank., incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on August 12, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1087294/000162828022029906/pinnaclebank-cpiamend9tolo.htm">Ninth Amendment to Revolving Credit Loan Agreement, dated as of September 29, 2022, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank., incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-33637) as filed with the SEC on November 14, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.776%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1087294/000095014407004069/g06286exv21.htm">Subsidiaries of Cumberland Pharmaceuticals Inc., incorporated herein by reference to the corresponding exhibit to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-142535) as filed with the SEC on May&#160;1, 2007</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-xex232consentofforvi.htm">Consent of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-xex232consentofforvi.htm"> FORVIS</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-xex232consentofforvi.htm">, LLP</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxexhibit311.htm">Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxexhibit312.htm">Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2022-10kxexhibit321.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:15.055%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan.</span></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted for portions of this exhibit. These portions have been omitted from the Registration Statement and submitted separately to the Securities and Exchange Commission.</span></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted from the Registration Statement and submitted separately to the Securities and Exchange Commission.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the U.S. Securities and Exchange Commission upon request, provided, however, that the parties may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended for any document so furnished.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith. </span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_163"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item 16. Form 10-K Summary</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_166"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March&#160;13, 2023.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:49.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumberland Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ A. J. Kazimi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:8pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:42.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.287%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ A. J. Kazimi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and CEO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer and Director)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John M. Hamm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Director and CFO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accounting Officer</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Gordon R. Bernard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gordon R. Bernard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ James R. Jones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James R. Jones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Caroline R. Young</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caroline R. Young </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Kenneth J. Krogulski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth J. Krogulski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Joseph C. Galante</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Galante</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Martin S. Brown, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Martin S. Brown, Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_169"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of Cumberland Pharmaceuticals Inc. and its subsidiaries (the&#160;"Company") is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;The Company's internal control system was designed to provide reasonable assurance to the Company&#8217;s management and board of directors regarding the preparation and fair presentation of published financial statements.&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022.&#160;In making this assessment, it used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its assessment, management has concluded that, as of December&#160;31, 2022, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ A. J. Kazimi</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. J. Kazimi</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.628%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John M. Hamm</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</span></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_172"></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders, Board of Directors and Audit Committee</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Cumberland Pharmaceuticals Inc. (the "Company") as of December&#160;31, 2022 and 2021, the related consolidated statements of operations, equity, and cash flows for each of the years in the two-year period ended December&#160;31, 2022, and the related notes and schedule  (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two-year period ended December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management.  Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.  Accordingly, we express no such opinion.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.  Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.  We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.  The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Customer Allowances for Chargebacks, Discounts and Damaged Goods, and Accruals for Rebates, Coupons, Product Returns, and Certain Fees </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, the allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis and established by management as the Company&#8217;s best estimate at the time of sale based on each </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, allowances in accounts receivable for chargebacks, cash discounts, and damaged goods were $0.6 million and the estimated liability for rebates, coupons, product returns, and certain fees were $8.3 million.  These provisions are recognized concurrently with the sales of products.  Provisions for chargebacks involve estimates of usage by retailers and other indirect buyers with varying contract prices for multiple wholesalers.  The provision for chargebacks varies in relation to changes in sales volume, product mix, pricing, and the level of inventory at the wholesalers.  Provisions are calculated using historical chargeback experience, and/or expected chargeback levels for new products and anticipated pricing changes.  Provisions for rebates are recognized based on contractual obligations in place at the time of sales with consideration given to relevant factors that may affect the payment, as well as historical experience for estimated market activity.  Provisions for product returns are calculated based on the expiration dates of products sold, the window where customers are permitted to return products, and the history of returns for individual products in relation to the sales volume for each product.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the customer allowances for chargebacks, discounts, and damaged goods and accruals for rebates, coupons, product returns, and certain fees as a critical audit matter.  The principal consideration for our determination was the significant measurement uncertainty involved in developing the reserves.   Management exercises judgment in computing the amount of sales subject to the allowances and tracks the amount of allowances taken over time.  All of this in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions, which includes the assumption that historical activity is a good predictor of future allowance activity and modifications made to calculations based on more recent history.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary procedures we performed to address this critical audit matter included: </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tested management&#8217;s process for calculating the allowances, including a look back analysis of prior year reserves compared to actual experience in the current year.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tested the completeness and accuracy of underlying data used to estimate the accrual by agreeing sales data used in the calculations to reports that were reconciled to the consolidated financial statements, reconciling various allowance percentages to signed customer contracts, and tracing allowance amounts used by various customers during the year to supporting documentation.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluated the reasonableness of significant assumptions used by management in the computation of selected allowances, including comparison to historical results and considering recent changes in factors that could influence the future allowances to be claimed, such as changes in the shelf life of the products.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tested the clerical accuracy of individual customer allowances computed by management and agreeing the total of all estimated allowances to the respective accounts on the consolidated financial statements.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developed an independent expectation of the reserve balance for certain allowances and comparing that to the balance recorded on the December 31, 2022, consolidated balance sheet.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compared actual activity for chargebacks, discounts, and damaged goods and rebates, coupons, product returns, and certain fees reported after December 31, 2022, to estimated reserves and accruals on the December 31, 2022, consolidated balance sheet.  </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Valuation of Contingent Consideration, Acquired Intangible Assets and Inventory Associated with Business Combinations</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 3 to the consolidated financial statements, the Company acquired the U.S. rights to the FDA approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc., the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. during the year ended December 31, 2022, resulting in the expansion of the Company&#8217;s product offerings.  This acquisition resulted in additional goodwill of $0.03 million, additional intangible assets of $14.1 million, and contingent liabilities of $5.1 million being recognized on the Company&#8217;s consolidated balance </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sheet.  As part of this acquisition, management assessed that the acquisition qualified as a business combination and all identifiable assets and liabilities acquired were recorded at fair value as part of the purchase price allocation as of the asset date.  The identification and valuation of such acquired assets and assumed liabilities requires management to exercise significant judgment and consider the use of outside vendors to estimate the fair value allocations.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the consummated acquisition and the valuation of acquired assets and assumed liabilities as a critical audit matter. Our principal consideration for this determination included high degree of audit effort, including utilizing individuals with specialized skills, in evaluating management's significant assumptions including its forecasts of future performance of the component, discount rates and other inputs into the model used in computing the fair value of the intangible asset, acquired inventory and contingent consideration liability.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary procedures we performed to address this critical audit matter included:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We obtained an understanding of management&#8217;s process for determining the fair value measurements of the contingent consideration, acquired intangible assets and inventory, including reviewing the executed Asset Purchase Agreement documents to gain an understanding of the underlying terms of the consummated acquisition.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Evaluated forward-looking assumptions, such as forecasted revenue and earnings used by management by performing procedures that included, but not limited to, comparisons to industry and historical performance data, and sensitivity analysis to assess their reasonableness.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Utilizing a valuation specialist, we evaluated the significant assumptions and methods utilized in developing the fair value of the contingent consideration, acquired intangible assets, and inventory including:</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Evaluated the reasonableness of the Company&#8217;s third-party valuation models and methodologies, expected cash flow calculations, and reviewed significant assumptions.</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Developed an independent calculation of the discount rates used and compared our rates to those used by management.</span></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.46pt">Prepared an independent calculation of the fair value of the contingent consideration and the intangible assets to test the accuracy of management&#8217;s valuation models.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reviewing and evaluating the adequacy of the disclosures made in the Company&#8217;s SEC filings.</span></div><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzIvZnJhZzoxMzhmNTAxOTExN2Y0MjExYjkxYWYwNmEyZmM4N2VkYi90ZXh0cmVnaW9uOjEzOGY1MDE5MTE3ZjQyMTFiOTFhZjA2YTJmYzg3ZWRiXzEwODkz_355805b7-b957-468d-8a72-0c263c288022" continuedAt="i7ef6c0c6dcfd4f28880a2ddbd3da7ccb">FORVIS, LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7ef6c0c6dcfd4f28880a2ddbd3da7ccb">(Formerly, BKD, LLP)</ix:continuation></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzIvZnJhZzoxMzhmNTAxOTExN2Y0MjExYjkxYWYwNmEyZmM4N2VkYi90ZXh0cmVnaW9uOjEzOGY1MDE5MTE3ZjQyMTFiOTFhZjA2YTJmYzg3ZWRiXzEwODk0_fef29421-5135-4db7-b738-1b0dddc7f584">Nashville, Tennessee</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;13, 2023</span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_175"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022 and 2021 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:64.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMtMi0xLTEtMzQzODQ_8e357b67-2226-45fe-b3ba-623142dcd2de">19,757,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMtNC0xLTEtMzQzODQ_ee257a49-08bb-4961-899b-1e0dcf464ade">27,040,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzUtMi0xLTEtMzQzODQ_b5a26a4f-13c1-4112-af32-7361eb785af9">13,163,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzUtNC0xLTEtMzQzODQ_80b35395-3279-4f89-935c-28c897949c68">6,877,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzYtMi0xLTEtMzQzODQ_761d778b-7ac6-4411-9251-f899a72a217b">9,863,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzYtNC0xLTEtMzQzODQ_a91b6957-c70d-48c0-b9ab-14af4fc7ed69">8,429,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzctMi0xLTEtMzQzODQ_a57781b9-5195-4a43-909f-2a8e4d552db0">3,084,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzctNC0xLTEtMzQzODQ_99a2455c-0838-46ef-a15f-7be38189ac83">3,339,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzgtMi0xLTEtMzQzODQ_e4781204-94d7-4da2-b776-ff04023da4d0">45,870,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzgtNC0xLTEtMzQzODQ_45ddaa41-6f33-49cf-b411-accf77bf757f">45,688,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzktMi0xLTEtMzQzODQ_e1fc1e2b-ced5-44d4-8cb9-21fc4e8f5477">7,527,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzktNC0xLTEtMzQzODQ_5764d81e-0ab7-494d-8352-72d089690ffa">9,048,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEwLTItMS0xLTM0Mzg0_84db3688-3095-4398-9ac8-cba927846cda">284,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEwLTQtMS0xLTM0Mzg0_eec1eeeb-f03f-4ce3-a9ff-5e0e38ab01d2">442,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzExLTItMS0xLTM0Mzg0_f0ce02ea-add8-4fe8-b959-eb5c9ff8367c">30,590,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzExLTQtMS0xLTM0Mzg0_ea4cc267-c650-4b3c-b0c7-88c4b13fd2bb">23,954,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEyLTItMS0xLTM0Mzg0_78b5da45-50fe-48e7-a004-fb4c05368aa4">914,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEyLTQtMS0xLTM0Mzg0_0face6d7-076c-4b76-b6ab-3a560ad7a33d">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEzLTItMS0xLTM0Mzg0_3901c6a2-f4db-4ce4-8258-8dfa30c5c735">5,218,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEzLTQtMS0xLTM0Mzg0_401c446f-2c3c-431c-95a3-2e3d099fb8c1">1,024,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE0LTItMS0xLTM0Mzg0_58d8f739-d6cf-476f-bc76-37134f3dda5c">2,520,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE0LTQtMS0xLTM0Mzg0_b62bc93b-be59-4d89-ae41-86f69c33a1af">3,419,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE1LTItMS0xLTM0Mzg0_71ad6410-fd91-4ca2-9a80-f32346da4f94">92,925,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE1LTQtMS0xLTM0Mzg0_4676c965-ba71-4b75-a60a-1497734aefa7">84,459,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE5LTItMS0xLTM0Mzg0_90537ccc-234d-465d-8e54-59f7a5f3ae9c">10,819,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE5LTQtMS0xLTM0Mzg0_5be8ea5e-9f3b-4e0e-9aa4-4b86bde0ff5c">9,640,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIwLTItMS0xLTM0Mzg0_a2467877-60a1-4855-ab9c-f2eaeeaab8ea">172,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIwLTQtMS0xLTM0Mzg0_aa359a79-2780-44d7-a494-e1adb278ff2d">969,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIxLTItMS0xLTM0Mzg0_5eb36ea6-a379-43b3-82f2-1989ac49fd77">17,587,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIxLTQtMS0xLTM0Mzg0_d49f665e-276c-4740-8e6e-bff414fc1a2b">8,668,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIyLTItMS0xLTM0Mzg0_58bfdf9a-093d-4c4f-82fe-b7ef0389d867">28,579,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIyLTQtMS0xLTM0Mzg0_ac4bc582-5dbc-4617-845f-4c4580eca05e">19,278,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving line of credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIzLTItMS0xLTM0Mzg0_27cb8e24-2aa5-452c-be26-036b53d2df42">16,200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIzLTQtMS0xLTM0Mzg0_640e3f6e-3ad3-47e6-aa91-1edfebfc8b64">15,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI0LTItMS0xLTM0Mzg0_c303e501-2f8d-4d46-91fe-4b21199aa06d">4,586,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI0LTQtMS0xLTM0Mzg0_7ebe5c98-c9ee-48e4-be4a-27077ecfe8f6">90,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI1LTItMS0xLTM0Mzg0_eaec4cdb-f744-4ead-b122-da3da96da907">7,585,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI1LTQtMS0xLTM0Mzg0_26c7423e-da97-4a55-a917-c313d2336d19">7,488,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI2LTItMS0xLTM0Mzg0_7c0184cf-dc5b-46f6-b7e6-d1483483cdd6">56,951,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI2LTQtMS0xLTM0Mzg0_4e007662-c46f-4148-97ca-4da8352f26d2">41,857,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI3LTItMS0xLTM0Mzg0_df625dbf-1f40-4c4a-8ba9-bdbef6b8b4e5"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI3LTQtMS0xLTM0Mzg0_0ea1bde9-966b-47d8-9f12-9cb54b42f31d"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8211; <ix:nonFraction unitRef="usdPerShare" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfMTk_2a61f772-8dc5-472c-9127-dd744b3eab65"><ix:nonFraction unitRef="usdPerShare" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:CommonStockNoParValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfMTk_ace6eb65-cf35-4560-a811-cc4d5aa9d618">no</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfMzM_894f9261-4c18-4493-8554-12147ff863bb"><ix:nonFraction unitRef="shares" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfMzM_f67f824a-bc1e-4a45-9230-3264ffc09721">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfNTU_626e21f2-f772-4e4b-8703-9c65973469eb"><ix:nonFraction unitRef="shares" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfNTU_d1b25bd3-11a6-44c8-be11-8cc0afe4e643">14,366,316</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfNjI_8399b24e-c5b1-4506-8246-34d253bf75e5"><ix:nonFraction unitRef="shares" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfNjI_c28f7a6a-01b8-4b24-9c1f-5feff49e5988">14,742,754</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTItMS0xLTM0Mzg0_93930bee-b7e2-42e9-99cd-3bb102ba731e">47,474,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:CommonStockValueOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTQtMS0xLTM0Mzg0_0482ecb4-dd1e-4e5f-9ca1-ac389be90ec6">48,452,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMxLTItMS0xLTM0Mzg0_e15b995a-70de-439d-9cac-839bbae1c21c">11,208,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMxLTQtMS0xLTM0Mzg0_ce994bdb-c18b-4890-907d-87a6fb6a56d5">5,638,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMyLTItMS0xLTM0Mzg0_a5f0c8ed-f70a-4d8b-9035-c79e59d38f12">36,266,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMyLTQtMS0xLTM0Mzg0_97194f39-6e2f-43b1-98cd-5dd2eb402ba6">42,814,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMzLTItMS0xLTM0Mzg0_413cb8ac-24db-4524-95b0-2f3fad2f53ba">292,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" sign="-" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMzLTQtMS0xLTM0Mzg0_0325baf2-fe38-48da-a5cf-507c57d9d99a">212,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzM0LTItMS0xLTM0Mzg0_27fd546a-adad-43df-aa68-c3c3e5521366">35,974,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzM0LTQtMS0xLTM0Mzg0_750b9710-8c97-4f6a-9408-a7a9e048d261">42,601,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzM1LTItMS0xLTM0Mzg0_53c3fb80-c3b7-44b2-ac75-4a05a433cb91">92,925,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzM1LTQtMS0xLTM0Mzg0_31e77d40-3456-446b-9893-ba5b140c9316">84,459,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_178"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2022 and 2021 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.467%"><tr><td style="width:1.0%"></td><td style="width:66.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.981%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf6dac19d6f34192bbf220dba001eef3_D20220101-20221231" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzItMi0xLTEtMzQzODQ_8cc4e979-86c8-40d3-a16e-deeb4180bde0">40,681,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82deea75887548fe9dd05c788a9a95d9_D20210101-20211231" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzItNC0xLTEtMzQzODQ_5efeff65-f9a6-409e-baf7-31ba557bd41c">35,045,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78d55d038f4f4a95b6d5aa9d8870f9f3_D20220101-20221231" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMtMi0xLTEtMzQzODQ_9ced2568-122f-4284-8db6-00da62375981">1,329,767</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492284a80be94550bc059ef2e65088e9_D20210101-20211231" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMtNC0xLTEtMzQzODQ_213742f3-de81-4ad7-9e63-5a3d11f7db01">939,784</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzQtMi0xLTEtMzQzODQ_545fdfb8-ad07-4105-974b-5d623cbfcb8a">42,010,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzQtNC0xLTEtMzQzODQ_cac86d8d-786b-47a2-9785-81a13dcff175">35,985,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzYtMi0xLTEtMzQzODQ_44cb5588-75b4-47e0-af96-d8ca965abbd4">9,118,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzYtNC0xLTEtMzQzODQ_d70b80c1-93be-4394-a7b9-b2583650e62f">8,811,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling and marketing</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzctMi0xLTEtMzQzODQ_4502b818-656c-4434-af72-ce671606cb03">16,660,945</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzctNC0xLTEtMzQzODQ_82a663af-9f1e-4b6e-9660-2328969c9063">15,015,424</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzgtMi0xLTEtMzQzODQ_f555c75b-63d9-4a71-a76b-15e83035efbf">6,688,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzgtNC0xLTEtMzQzODQ_68376946-5900-407f-9ac2-6cacc5e97e0e">5,684,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzktMi0xLTEtMzQzODQ_882fe21b-e631-45d7-a3cf-7f223ea24a53">10,180,120</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzktNC0xLTEtMzQzODQ_e8683580-c6b5-463d-8446-20117142cc6a">9,780,026</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEwLTItMS0xLTM0Mzg0_8a75d7f5-3759-4b9b-8362-dc969071f851">5,067,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEwLTQtMS0xLTM0Mzg0_7d0e1723-89cd-48fa-84c4-425a24d385a5">4,371,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzExLTItMS0xLTM0Mzg0_9e9543af-83ee-4908-a7fc-c8e911480f26">47,715,878</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzExLTQtMS0xLTM0Mzg0_6d72a092-f0c5-4076-8c74-445cb5d7e70d">43,662,463</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEyLTItMS0xLTM0Mzg0_462e5e9c-f7bc-49db-911d-dd00dbf1da08">5,704,929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEyLTQtMS0xLTM0Mzg0_9f324b0e-1c16-4ebb-b39b-351a6d11b1c4">7,677,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEzLTItMS0xLTM0Mzg0_928c8bd0-0b31-4f63-8b9c-3099f17a6f31">98,405</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEzLTQtMS0xLTM0Mzg0_77ffff6d-e2ac-4993-a799-eeda6efddb55">26,081</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:OtherIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE0LTItMS0xLTM0Mzg0_2b42df4a-977a-45c4-9a09-855cc40c0df1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:OtherIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE0LTQtMS0xLTM0Mzg0_6d61a0dc-fb79-412e-86b2-30c4bb7499cc">2,187,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income - gain on insurance proceeds</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE1LTItMS0xLTM4Mzgx_c3295a38-6d16-4e5c-8399-f498655e6d93">611,330</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:InsuredEventGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE1LTQtMS0xLTM4Mzgx_1807ae5c-c948-4ca0-a41c-d20789855bce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE1LTItMS0xLTM0Mzg0_94527528-79e9-46c2-882e-eb8ec6f805a1">585,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE1LTQtMS0xLTM0Mzg0_bea9a146-b927-4a81-8065-51f41cfb3f94">98,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE2LTItMS0xLTM0Mzg0_ce06dcc0-f7b3-4cd2-9916-a523cfef01f2">5,581,189</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE2LTQtMS0xLTM0Mzg0_edce455a-7c41-44ef-9c9d-0a94ccc88883">5,562,230</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE3LTItMS0xLTM0Mzg0_f8001bb8-47c0-4756-ab50-2198621ef6d3">68,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE3LTQtMS0xLTM0Mzg0_9a126991-5456-4b6a-abdc-861f795c9d3a">34,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE4LTItMS0xLTM0Mzg0_db4d81a0-02eb-4ec4-9f83-43571fc908ec">5,650,039</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE4LTQtMS0xLTM0Mzg0_d4ccc55b-061d-4671-b20f-3aa2e5f7aab6">5,597,121</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE5LTItMS0xLTM0Mzg0_f67cb05b-98cd-4076-b7f8-abd264f3c575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE5LTQtMS0xLTM0Mzg0_4207b02a-8aee-429a-a0ab-c761f4d74561">1,994,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIwLTItMS0xLTM0Mzg0_1b737811-2bb4-4d41-bd6d-cc4c47c638fe">5,650,039</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIwLTQtMS0xLTM0Mzg0_0fd71f32-dedb-474f-b807-cbb1f18941c3">3,602,799</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIxLTItMS0xLTM0Mzg0_b61ce7e9-df0d-44fb-98d4-26d6b618e9fc">79,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIxLTQtMS0xLTM0Mzg0_9d29cd60-538e-4a3c-a017-88646f4ab240">95,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIyLTItMS0xLTM0Mzg0_349e369d-2ed7-4299-94cf-fcc1d4a72964">5,570,241</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIyLTQtMS0xLTM0Mzg0_c11896fa-9e95-43fe-b104-9b27eb2e768c">3,507,587</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Continuing operations-basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI1LTItMS0xLTM0Mzg0_d11fc394-1d50-46fa-ae71-c2cc576614ca">0.38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI1LTQtMS0xLTM0Mzg0_ae816b14-8fbf-41d5-aac8-f75c1a1c408c">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Discontinued operations-basic</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI2LTItMS0xLTM0Mzg0_8101d92c-7b24-4608-9d91-9c28e4e6bb56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI2LTQtMS0xLTM0Mzg0_38d883b1-0059-4084-9b96-4da2fb1b08b5">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI3LTItMS0xLTM0Mzg0_0384c07b-5fb9-40c8-9dfd-870db3ad64c7">0.38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI3LTQtMS0xLTM0Mzg0_ecee08eb-ca74-4cb4-8d7a-b970f7fb6e7f">0.24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Continuing operations-diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI5LTItMS0xLTM0Mzg0_4c8e2cd3-6467-4ee5-8e53-2d29154bee16">0.38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI5LTQtMS0xLTM0Mzg0_1d85b8d2-213d-414c-afa9-42eee6486514">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-Discontinued operations-diluted</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMwLTItMS0xLTM0Mzg0_1117dfb6-8d22-42d0-a280-7492920528c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMwLTQtMS0xLTM0Mzg0_edfe25bb-dfba-4062-ae4d-cf1adeff97f1">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMxLTItMS0xLTM0Mzg0_d68ccf0d-6b8f-4e1e-8ea4-765ef06bfc35">0.38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMxLTQtMS0xLTM0Mzg0_06b2af62-7dae-4c33-ad88-77e28c0eb2c1">0.24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMzLTItMS0xLTM0Mzg0_77d73480-200e-48f8-9ba0-2fc417f838ea">14,563,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMzLTQtMS0xLTM0Mzg0_3d3efbef-7a12-4391-9370-ef2cdd85ac62">14,904,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzM0LTItMS0xLTM0Mzg0_158e62d8-1a26-4891-8ed0-1713e4220dce">14,563,592</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzM0LTQtMS0xLTM0Mzg0_00dc128d-89c3-48fe-bc42-89108b16b078">14,904,834</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_181"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2022 and 2021 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.456%"><tr><td style="width:1.0%"></td><td style="width:70.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzItMi0xLTEtMzQzODQ_350ebc79-8574-4ce5-901f-5ce28b6708e3">5,650,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzItNC0xLTEtMzQzODQ_a8c24ae2-8503-40b9-a804-1cdd532e1fcb">3,602,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMtMi0xLTEtMzQzODQ_5e4a460a-7007-4d3c-bc60-bfb2b5941dfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMtNC0xLTEtMzQzODQ_08d8af61-7652-4a8a-b3b4-f2de2d715265">1,994,322</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzQtMi0xLTEtMzQzODQ_e0e37b7f-cfc2-48e2-bf03-6e8de9415997">5,650,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzQtNC0xLTEtMzQzODQ_95d02f18-6400-4838-b26a-9276f2633e26">5,597,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash flows provided by operating activities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzYtMi0xLTEtMzQzODQ_d0c49473-1ec9-468e-948d-55a21b2ac409">5,328,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzYtNC0xLTEtMzQzODQ_bb57def1-a423-40b2-b3ad-9d763717a7c1">4,606,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzctMi0xLTEtMzQzODQ_9e9da306-9d4d-47b2-a70e-6ab46ecb30e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzctNC0xLTEtMzQzODQ_ea37bfcc-ccdf-418a-854c-e0e85acbd8dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzgtMi0xLTEtMzQzODQ_073467d8-e8c7-494d-a2ce-9d8b7716eacd">447,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzgtNC0xLTEtMzQzODQ_ba7ed6af-4314-4776-9fc1-bf70b0b0bdac">741,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in non-cash contingent consideration</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEwLTItMS0xLTM0Mzg0_1f9ddd31-5923-422d-8cf1-22f2ac266eea">2,088,296</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEwLTQtMS0xLTM0Mzg0_7e55cd4e-bfd6-41a1-8b6e-c95617cd5189">1,147,750</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (Increase) in cash surrender value of life insurance policies over premiums paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEyLTItMS0xLTM0Mzg0_d598b9e3-c274-4a17-8496-adfc32584f2c">613,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEyLTQtMS0xLTM0Mzg0_9bea4e70-bcec-4817-8eeb-a7fed7e83845">282,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash interest expense</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEzLTItMS0xLTM0Mzg0_310a7939-4136-4769-a798-920118f57cec">11,237</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEzLTQtMS0xLTM0Mzg0_78da5d84-3f77-411a-b959-8cfa2f834b4a">34,053</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash gain on RediTrex transaction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="cpix:NoncashOrPartNoncashGainOnTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE0LTItMS0xLTM4ODg0_eb20a801-9fdc-4cf0-b6ed-ca51d2e5ab40">37,882</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="cpix:NoncashOrPartNoncashGainOnTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE0LTQtMS0xLTM4ODg0_11df188d-adf6-40b6-af95-5f5215f93d47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on receipt of life insurance policies</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:OtherNonoperatingGainsLosses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE0LTItMS0xLTM0Mzg0_05ab363f-47c7-4d76-99c8-03497e391740">611,330</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:OtherNonoperatingGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE0LTQtMS0xLTM0Mzg0_8079d155-723b-4d28-b6c2-81b687b6f2e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on forgiveness of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE1LTItMS0xLTM0Mzg0_0583a41d-3e12-47ab-8df9-e6889a37ef6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE1LTQtMS0xLTM0Mzg0_a7437192-834a-4cff-a1de-2537f67e1b0c">2,187,140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities affecting operating activities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE3LTItMS0xLTM0Mzg0_219ffc6a-7d8d-42f7-9467-b4b4e8240d45">6,115,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE3LTQtMS0xLTM0Mzg0_cbffe78b-28ae-4b8b-b139-8433afd2c0c5">5,500,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE4LTItMS0xLTM0Mzg0_9336c5d5-4878-43fb-8882-43c64effd555">911,078</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE4LTQtMS0xLTM0Mzg0_bb4888b2-29b2-45ce-b984-2fca95febd6b">4,816,450</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE5LTItMS0xLTM0Mzg0_77f11e2e-c511-40dc-8903-3db88f1c3e04">689,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE5LTQtMS0xLTM0Mzg0_bcadfe6f-1cc8-4a12-94b7-5cba9e40d246">35,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other current liabilities</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIwLTItMS0xLTM0Mzg0_71cccd90-f701-4349-80bf-e8d8a3965bff">14,536,076</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIwLTQtMS0xLTM0Mzg0_b9a7704a-8481-4cde-8ddd-379cebc77b78">757,591</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIxLTItMS0xLTM0Mzg0_910ee84a-14b2-4f4a-ad96-8c65b468cddf">419,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIxLTQtMS0xLTM0Mzg0_0951ebb9-b187-4b12-bc42-7c387a45d080">1,343,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities from continuing operations</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIyLTItMS0xLTM0Mzg0_eede9e2d-23ea-4605-a740-405219b78737">8,453,396</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIyLTQtMS0xLTM0Mzg0_1eb182b5-e817-4052-adf7-5b936c05ad33">4,348,121</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIzLTItMS0xLTM0Mzg0_d5134832-c38d-450b-8d4a-21836df1ee08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIzLTQtMS0xLTM0Mzg0_7a1b72df-b16a-4b66-bba6-3ce2a03eb578">1,994,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI0LTItMS0xLTM0Mzg0_50c924cc-5a65-4be6-8361-2770fb48e44b">8,453,396</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI0LTQtMS0xLTM0Mzg0_eddcc8d3-63a0-47b1-809b-c11b872ec2c1">6,342,443</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI2LTItMS0xLTM0Mzg0_e6ee662e-c291-4b4c-93bf-4ff7f02c0f14">102,148</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI2LTQtMS0xLTM0Mzg0_55ef4d4e-808b-4db6-9589-c9942f4c12b0">103,532</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI3LTItMS0xLTM0Mzg0_d5d2f2bd-7b12-4e78-9a29-8ed6c3b6ca31">1,971,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI3LTQtMS0xLTM0Mzg0_6782fa9f-d3d5-4d4c-ac74-4f4b547d96e0">250,930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of RediTrex</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="cpix:ProceedsFromCollaborationArrangement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI4LTItMS0xLTM4MDU5_57fe2f6b-b29a-486f-9ced-cf80da2f70e5">1,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="cpix:ProceedsFromCollaborationArrangement" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI4LTQtMS0xLTM4MDU5_1a174d16-d87f-4833-bd56-2811d972e153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from surrender of life insurance policies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="cpix:ProceedsFromSurrenderOfLifeInsurancePolicy" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI4LTItMS0xLTM0Mzg0_4b93e108-ab34-4d1b-8d79-ebd7f145447b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="cpix:ProceedsFromSurrenderOfLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI4LTQtMS0xLTM0Mzg0_77a7af0c-abaf-4efe-a2ed-4a2942e9d462">85,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums paid for life insurance policies</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI5LTItMS0xLTM0Mzg0_91dac0c7-ec2b-4beb-9539-05c5df8815bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI5LTQtMS0xLTM0Mzg0_98f79024-8672-4804-a425-96f2c017de89">33,375</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life insurance policy proceeds received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromLifeInsurancePolicies" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMxLTItMS0xLTM4Mzk4_4388d8ee-18bf-441b-9a3c-904a2b9f8970">877,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromLifeInsurancePolicies" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMxLTQtMS0xLTM4Mzk4_9a0c152e-20bf-462c-b29b-19dd4f02d317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement of patent litigation</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="cpix:ProceedsFromSettlementOfPatentLitigation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMyLTItMS0xLTM4NDA2_7e3714f9-3dd5-4ff1-818f-90ecc82f4255">21,757</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="cpix:ProceedsFromSettlementOfPatentLitigation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMyLTQtMS0xLTM4NDA2_e083a5f5-bcc1-4029-b234-4e2eb5be6e8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMwLTItMS0xLTM0Mzg0_45d682b0-4e6a-48cb-95f2-8f742f8e53f0">13,500,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMwLTQtMS0xLTM0Mzg0_ed57d964-7d56-4b9b-8a86-45a62294104c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note receivable investment funding</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMxLTItMS0xLTM0Mzg0_209f3969-9782-49f5-ab16-e744fc4ff7ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMxLTQtMS0xLTM0Mzg0_77835488-ac3d-4751-9bb9-b41a197d0e63">200,000</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzM0LTItMS0xLTM0Mzg0_bbc50b19-9d3b-4280-8f7e-da3299bcb78a">13,674,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzM0LTQtMS0xLTM0Mzg0_c9f02282-ffde-4ff1-9673-08ebad0df766">501,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2022 and 2021 </span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.456%"><tr><td style="width:1.0%"></td><td style="width:70.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzItMi0xLTEtMzQzODQ_7a5f50b2-e023-4cdb-9c06-6eb89535f79f">52,900,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromRepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzItNC0xLTEtMzQzODQ_6a6f45e2-0791-43f8-a3f5-95e2b9f71014">59,000,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on line of credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzMtMi0xLTEtMzQzODQ_c0b2bf7c-90fb-44b7-8283-68669ebf5d22">51,700,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzMtNC0xLTEtMzQzODQ_686690ed-09ea-46ec-b0a9-62a2eaf95eb4">59,000,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments made in connection with repurchase of common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzQtMi0xLTEtMzQzODQ_78c1e78a-bd9c-4fb9-9e1d-03d1a74b0886">1,053,042</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzQtNC0xLTEtMzQzODQ_84855dd2-d555-4714-a985-dbf988a608ef">1,386,849</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash settlement of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzUtMi0xLTEtMzQzODQ_18556817-0723-4af5-bd4d-cd911353abb7">2,208,744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzUtNC0xLTEtMzQzODQ_02c2169a-0043-439e-8739-db6336b397e1">2,166,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEwLTItMS0xLTM0Mzg0_6baa7206-0594-4c98-8502-a8b754ced7aa">2,061,786</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEwLTQtMS0xLTM0Mzg0_825bd200-2e5f-413e-a5e9-da52b6b495f0">3,553,530</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzExLTItMS0xLTM0Mzg0_3e56a357-592b-43db-989c-c71c697b8720">7,282,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzExLTQtMS0xLTM0Mzg0_70093414-098f-4cab-ae29-7e56723e1298">2,287,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEyLTItMS0xLTM0Mzg0_785d6f60-3287-4b69-b706-99ca9d22a1c0">27,040,816</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1f58f544414d679bba8a83be98bb54_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEyLTQtMS0xLTM0Mzg0_019c0412-25e5-4b92-994d-f2bc085a3367">24,753,796</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEzLTItMS0xLTM0Mzg0_779c6b7c-72e7-4edc-80c6-6b1f7420016a">19,757,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEzLTQtMS0xLTM0Mzg0_c0fa4ae6-224b-4d5d-a96b-d4828cf2ae23">27,040,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.596%"><tr><td style="width:1.0%"></td><td style="width:69.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid during the year for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzItMi0xLTEtMzQzODQ_0c179874-2226-4e1e-9554-0e6b244685c8">523,161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzItNC0xLTEtMzQzODQ_524e8f21-a4ba-4344-8b11-c2fba33289be">63,978</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzMtMi0xLTEtMzQzODQ_8c46aebd-7fc4-423d-97fc-2722604cd560">3,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzMtNC0xLTEtMzQzODQ_faabf9eb-3a41-4287-9bf0-3bb4768febee">327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash investing and financing activities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unpaid invoices for intangible asset additions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzUtMi0xLTEtMzQzODQ_02197945-af3e-4b45-8fb5-84bf43f02a48">1,803,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzUtNC0xLTEtMzQzODQ_8adab520-bee7-4875-b0ed-286bc4dcdaa9">43,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unpaid invoices for offering costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzYtMi0xLTEtMzQzODQ_de59117a-c2d3-41f0-8e46-dd640e49edf0">94,689</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzYtNC0xLTEtMzQzODQ_73e1e041-5af7-4c1a-a8cd-997e8caf0208">90,512</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of operating lease assets and liabilities through adoption of ASC 842</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzctMi0xLTEtMzQzODQ_2bf79584-3611-40c4-876d-a5b5a0085934">4,590,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzctNC0xLTEtMzQzODQ_47196222-a12f-43c4-bc37-d6dacd46e369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex forgiveness of milestone payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="cpix:CreditIssuedForMilestonePayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzgtMi0xLTEtNDIxMjM_63485aa9-b253-4897-8253-6a7e23833dd5">1,000,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="cpix:CreditIssuedForMilestonePayable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzgtNC0xLTEtNDIyMDY_3b797934-cbf4-471f-868a-0cb1403d407e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of shares related to RediTrex</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzktMi0xLTEtNDIxMjM_52f813e1-6c28-4165-937a-c4fb5d3a7153">399,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzktNC0xLTEtNDIyMDY_9c681ef7-67f5-4f26-a781-808a1eaf8c4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_184"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Equity</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2022 and 2021 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:29.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.774%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.888%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumberland Pharmaceuticals Inc. Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained earnings (deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i963f0ace48ae4299a000f7fd5b7c18c5_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI2LTItMS0xLTM0Mzg0_e21d682b-cf85-46c2-8536-95f168da3825">14,988,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i963f0ace48ae4299a000f7fd5b7c18c5_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI2LTQtMS0xLTM0Mzg0_6b4c9d31-6442-4408-b761-42ebd53677b8">49,121,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia40cff38220f4a42a215676712cd7975_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI2LTYtMS0xLTM0Mzg0_fed9facc-5511-4ec9-b956-92b3bda35325">2,131,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f553aa99c0e4216aa251a6245b1cab1_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI2LTgtMS0xLTM0Mzg0_4cbc2eb9-882d-46c5-bb20-a36dad4cb7e7">117,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1f58f544414d679bba8a83be98bb54_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI2LTEwLTEtMS0zNDM4NA_06ed5fe5-18b5-4f9a-9c22-d19d9680b3c1">46,873,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia770bc31d52a493aa78146feba302866_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI3LTYtMS0xLTM0Mzg0_9727cfe5-84ba-47b9-84ea-2d7b074a50e7">3,507,587</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4d8da0743ab4c0488940b1685dbba30_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI3LTgtMS0xLTM0Mzg0_4b9419a0-3c36-452d-ab55-36a4552a2b84">95,212</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI3LTEwLTEtMS0zNDM4NA_5e1764f6-3a57-4658-ad70-fef8e613a27a">3,602,799</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI4LTItMS0xLTM0Mzg0_056e4d57-6913-493f-9a03-1e95790256af">192,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI4LTQtMS0xLTM0Mzg0_bd8086be-0747-4202-9bbe-57df9a853f51">741,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI4LTEwLTEtMS0zNDM4NA_a8e0ca43-8267-4908-92fe-6b4d852f3c6a">741,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI5LTItMS0xLTM0Mzg0_ece52727-a001-4d35-a5e2-48d66139e4c4">438,359</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI5LTQtMS0xLTM0Mzg0_830d8892-f399-4a5a-8d4b-7584a5caa41e">1,410,484</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI5LTEwLTEtMS0zNDM4NA_28391fd4-eb6d-47fb-b4fd-3d0a80f83032">1,410,484</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34f8ac4bf33e4693be58ae3e7731aca1_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMwLTItMS0xLTM0Mzg0_a69af357-e98e-4d35-b54e-3bdf378df58d">14,742,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34f8ac4bf33e4693be58ae3e7731aca1_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMwLTQtMS0xLTM0Mzg0_8684f711-5ed4-475a-88cc-78df33ac7a15">48,452,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id569c4eed8f24390a0083034cd6006fd_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMwLTYtMS0xLTM0Mzg0_6631f39c-dcdd-4d8c-be44-595676fbb3af">5,638,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie04970d0133c449fb025dee41a90d071_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMwLTgtMS0xLTM0Mzg0_3d2a5ec6-4034-4f53-a874-c602a3ce6716">212,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMwLTEwLTEtMS0zNDM4NA_ba1f9625-8e3e-4ceb-9d65-fb62aef3a5b5">42,601,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffb757a4c3914eb9b95796ad9e20eacc_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMxLTYtMS0xLTM2MjY2_82b52deb-3c4b-4ffe-b478-8a808e4156c5">5,570,241</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1705f3f062cc44839738fe486e114ad6_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMxLTgtMS0xLTM2MjY2_04972fe0-b9de-4d53-9cc6-b0899e35a446">79,798</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMxLTEwLTEtMS0zNjI2Ng_309391ea-8dba-4b6e-a571-a1e7c25ef994">5,650,039</ix:nonFraction>)</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of common stock - Methotrexate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231" decimals="INF" name="us-gaap:StockRedeemedOrCalledDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMyLTItMS0xLTM2MjY2_8611fe5a-5f2d-43d7-9433-a80951acc8f5">180,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMyLTQtMS0xLTM2MjY2_39a8dc72-2f43-469c-b76c-4486d9ca4ace">399,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMyLTEwLTEtMS0zNjI2Ng_75aa48b9-9510-4cd2-bf8c-1fd513c3e6b7">399,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMzLTItMS0xLTM2MjY2_9e77c040-6e8f-4b56-bcba-aa02d4e39417">171,655</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMzLTQtMS0xLTM2MjY2_733af5bc-33ee-4c9d-a0f4-1d344da07c9f">447,503</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMzLTEwLTEtMS0zNjI2Ng_9f952b50-a526-471b-9a4b-0d33409755f9">447,503</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM0LTItMS0xLTM2MjY2_98476a2c-879c-40e9-97bb-bc5feeaeeef9">367,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM0LTQtMS0xLTM2MjY2_446c3e01-b254-4a36-b341-e055c704c9bf">1,025,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM0LTEwLTEtMS0zNjI2Ng_3be0a2d3-28c4-4058-a21f-c8911366bac5">1,025,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cb948d137eb4bae9cb3425ba6c840db_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM1LTItMS0xLTM2MjY2_43a03f0d-9d63-4426-8ad3-6f1662ec731a">14,366,616</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb948d137eb4bae9cb3425ba6c840db_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM1LTQtMS0xLTM2MjY2_9392c0e8-5214-4af1-9f90-0bc9fff6504f">47,474,973</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibdae3b5e1dd2405b904488b32eb4db3b_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM1LTYtMS0xLTM2MjY2_48bb0f5e-585c-4d2c-b726-f071ada83581">11,208,841</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d4b30bb244846a8ba4078cdae06919f_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM1LTgtMS0xLTM2MjY2_daf019e7-6f96-4ffa-8d96-f5d732f74f83">292,126</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM1LTEwLTEtMS0zNjI2Ng_01dd64f2-9db3-4d45-b73e-3fc9ab819c5c">35,974,006</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_187"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_190"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)   <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzMyNzA_9443dbca-27f7-452f-b5d3-fdc8e4f2252d" continuedAt="i9a95f44800dc4967b560ce6ef6619528" escape="true">Organization</ix:nonNumeric></span></div><ix:continuation id="i9a95f44800dc4967b560ce6ef6619528" continuedAt="icdac3eb710fa45fe8c23affdc9c3da95"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology  and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, field and oncology sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace.  In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET including an investment of approximately $<ix:nonFraction unitRef="usd" contextRef="ib9062e0d132343aaa03943a47c77e779_D20220101-20221231" decimals="-5" name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzE4MjU_99ba9d41-77af-4e6b-b939-6a0e0458d64a">1.0</ix:nonFraction> million from Gloria Pharmaceuticals Co., Ltd. (&#8220;Gloria&#8221;).  As a result, Gloria received shares in CET and joined the CET ownership group. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited ("WinHealth") </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whereby WinHealth made a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="ifbd696f587e24eb997ec609f8ce82517_I20190430" decimals="-5" name="cpix:SubsidiaryInvestmentPurchaseOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzIwOTE_14c8bd48-b5c0-4d50-88c4-2aab2b0b5f71">1.0</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $<ix:nonFraction unitRef="usd" contextRef="ifbd696f587e24eb997ec609f8ce82517_I20190430" decimals="-5" name="cpix:SubsidiaryInvestmentPurchaseOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzIzNzg_0aca40ab-4dd3-4a66-aeff-80a102da0179">1.0</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in CET.  Cumberland purchased additional CET shares through contribution of $<ix:nonFraction unitRef="usd" contextRef="i7002a7773f304b60a1fb957d9bf22167_D20190401-20190430" decimals="-5" name="cpix:ContributionOfCashAdditionalSharesPurchased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzI0Njg_92fb6f13-c13a-4730-8d42-5a7cc02069e0">0.3</ix:nonFraction>&#160;million in cash and a conversion of $<ix:nonFraction unitRef="usd" contextRef="ifbd696f587e24eb997ec609f8ce82517_I20190430" decimals="-5" name="cpix:IntercompanyLoansPayableConvertedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzI0OTk_eb7eb769-fd03-40a7-baf2-07bef1de8b19">0.7</ix:nonFraction>&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="id417cd67920147a1928abf32d83fb11f_D20190401-20190430" decimals="-5" name="cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzI2NzU_2fcbf77b-3a7c-4433-a4e2-6ae4a9512970">0.8</ix:nonFraction> million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that was funded during 2020.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's ownership in CET is now <ix:nonFraction unitRef="number" contextRef="i6ed29773e4754bd1a441c809e5231f15_I20221231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzI3NDc_02dd2402-fa9e-41c2-8daa-a41b31871fbe">85</ix:nonFraction>% while the remaining interest is owned by WinHealth, Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzI5OTk_e5fa013d-74a1-4eba-9af8-274c51e6d2f6">79,798</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzMwMDQ_00287421-6934-476d-a4d3-2cb216b37593">95,212</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC").  CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities including charitable contributions. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:15pt;text-align:justify;text-indent:18pt"><ix:continuation id="icdac3eb710fa45fe8c23affdc9c3da95"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Cumberland provided a grant of <ix:nonFraction unitRef="shares" contextRef="i6c780a0c3e87440c8eb1928bb0ce5f86_D20180101-20181231" decimals="INF" name="cpix:SharebasedCompensationCharitableContributionofSharesShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzQ4NDA_e13e060e-6e04-4173-a00f-2871a1b5acc6">50,000</ix:nonFraction> shares of the Company's common stock to the Foundation. The shares will address the ongoing financial needs of the Foundation.  The organization also plans to hold a portion of the shares for long-term appreciation. The Foundation maintains separate financial statements and its ongoing operations will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.  During 2019, Cumberland Pharmaceuticals committed approximately $<ix:nonFraction unitRef="usd" contextRef="i920d5ee9a6184682bc7bf8c05423756f_D20190101-20191231" decimals="-3" name="cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzQ4NDQ_da967638-58ef-4064-bb08-4394b47f6602">50,000</ix:nonFraction> in cash contributions that were paid to the Foundation during 2020.  Likewise, during 2020, the Company committed approximately $<ix:nonFraction unitRef="usd" contextRef="i478ad941e6444190835fbd70e6a0fda2_D20200101-20201231" decimals="-3" name="cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzQ4NDg_26c2346d-7f27-4c93-a0f4-b5d02b7c10e2">25,000</ix:nonFraction> in cash contributions paid to the Foundation during 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company made a $<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="-3" name="cpix:ShareBasedCompensationCharitableContributionOfSharesCashContributions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzU0OTc1NTgxODc0Nw_1a2964f1-37a3-407c-8962-260e1fcd2112">25,000</ix:nonFraction> cash contribution to the Foundation.</span></ix:continuation></div><div id="i3e36cfc56e1a4275a52b7d560014d176_193"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)   <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE4_3ac6b3bf-994f-4e0b-9ab4-2846e1049086" continuedAt="ie9fef4e7dac9458996de387bcb9b638d" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ie9fef4e7dac9458996de387bcb9b638d" continuedAt="ic6a1f844c5af4c2c90f4aedc5734f064"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODI5_fc1f4b1a-4b2a-4248-93ea-cfa2df14975d" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2020, the U.S. declared a health care emergency following the outbreak of SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness. The Company has managed through the resulting COVID-19 pandemic, continuing to operate our business &#8211; keeping facilities open and our organization intact. We moved quickly to ensure the health and safety of our team. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded pharmaceutical company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our business and our clinical studies were impacted, as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carefully monitored our supply chain, including the flow of raw materials and the batches of finished products emerging from the facilities that manufacture our products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio that includes other brands that have delivered a strong performance during the pandemic.  Overall, we have been able to continue the delivery of our products while addressing the interests of our shareholders, employees, partners and community.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE0_38f6d9c1-8cac-4d40-adf1-3ccb3e725326" continuedAt="ic35b712c36f64919b64cabf041ca310b" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic35b712c36f64919b64cabf041ca310b">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.</ix:continuation>  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liability associated with business combinations.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ic6a1f844c5af4c2c90f4aedc5734f064" continuedAt="i2742cc0a3c10496995acf3a01a58649a"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODMy_15ca949c-074c-40d6-a961-8abb866def83" continuedAt="i40283f046f224a27adad7f95bf049cf0" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i40283f046f224a27adad7f95bf049cf0">The Company has <ix:nonFraction unitRef="segment" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzM0Mjg_5bed2b35-0c4f-4ad4-92b2-fa02e9aa295f">one</ix:nonFraction> operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.</ix:continuation>  Net revenues from customers outside the United States were approximately $<ix:nonFraction unitRef="usd" contextRef="ia21564bd7ce142dcadc0c24df7ea1958_D20220101-20221231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzQzMDA_416fa45e-16e0-499f-9dc2-885397a2841c">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie03b356b24224df284680048170d1d18_D20210101-20211231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzQzMDU_6ce59c5d-b88b-453a-8e54-bdabee115258">2.2</ix:nonFraction> million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODEw_dbba7cf6-62b5-4661-8594-0001366e4964" continuedAt="id3aff43044c64d358259a389d0be1089" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id3aff43044c64d358259a389d0be1089">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.</ix:continuation> </span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODIy_f2c6a704-68a6-4304-be23-7c15fdbdd1fc" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2022 and 2021, cash equivalents consist primarily of money market funds.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i2742cc0a3c10496995acf3a01a58649a" continuedAt="ie3e6514574634083b27934c2728b68f8"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODIz_262bb82a-fff2-480d-aac9-d2d7e8c12e3a" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, as well as amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $<ix:nonFraction unitRef="usd" contextRef="i0ba80f17d75f466d9b1472a3319fada7_I20221231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2Xzc5MDk_3e471dee-be7a-419b-8e91-fac3b8ebbfaa">0.6</ix:nonFraction> million at December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i516902d591354e20a3baac1f1747a355_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2Xzc5MjI_42e46e5a-33e6-45d6-abc0-ef60e5db300f">0.3</ix:nonFraction> million at December 31, 2021. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE1_64d51fb0-8002-45f1-8e00-0e96cef18596" continuedAt="iec92096576de44c390c5a1088a679a47" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale at third party facilities located in the U.S. and international locations.  Periodic inventory counts are made by the warehouse teams and by the Company on a regular basis.  In addition, the Company re-tests API inventory prior to use to confirm product expiration.  Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iec92096576de44c390c5a1088a679a47">The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.  The Company classifies the Vibativ inventories and ifetroban inventories that it does not expect to sell within one year as non-current inventories.</ix:continuation> </span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODA0_3014e112-8251-4dec-90e0-f38eb4ae4ca8" escape="true"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $<ix:nonFraction unitRef="usd" contextRef="i7cfbfa92c9f74d5d8ecb902cacdb2307_D20180101-20180131" decimals="-6" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzEwMzQw_ca0a6021-6d9f-4e53-98b3-400322efc24b">100</ix:nonFraction>&#160;million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $<ix:nonFraction unitRef="usd" contextRef="if8074777558e4350be02e8d826a67f22_D20211227-20211227" decimals="-6" name="cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzEwOTE3_a37d79f2-46d2-4319-83e3-d947554f934f">19</ix:nonFraction>&#160;million.  The Company amended the At the Market Sales Agreement on December 27, 2021, in order to allow the Company to continue using its ATM feature to sell shares at market prices.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ie3e6514574634083b27934c2728b68f8" continuedAt="ic81d38ff0bba43e1abf838a12aab67f5"><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded deferred offering costs for payments directly related to the current Shelf Registration on Form S-3 that was completed during December 2021. These costs consist of legal and accounting fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2022. </span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE5_2f9d4d9a-2327-4d22-920f-886d5a98c9d2" escape="true"><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#8217;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODA1_7cda8ede-fe6e-4353-8763-34c22a7f3a9a" continuedAt="i5f4b6df5c25d4d3d8df3df077d32030c" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ and Sancuso acquisitions. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5f4b6df5c25d4d3d8df3df077d32030c">Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.</ix:continuation>  </span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODI1_40c25816-0952-45a2-883c-58f59a1a4217" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"><tr><td style="width:1.0%"></td><td style="width:46.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icc21cd41019b4937823097e3a64ff8a3_D20220101-20221231" name="cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTphOTg3YzBkZWZmZjk0OGY5YjY5NTYzMDU3NjcxYTkzYy90YWJsZXJhbmdlOmE5ODdjMGRlZmZmOTQ4ZjliNjk1NjMwNTc2NzFhOTNjXzAtMi0xLTEtMzQzODQ_725b0238-e56a-4d6e-93b6-36fadbdcdca2">Estimated economic life</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3025fb68648c4df5b3dc39a998179c33_D20220101-20221231" name="cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTphOTg3YzBkZWZmZjk0OGY5YjY5NTYzMDU3NjcxYTkzYy90YWJsZXJhbmdlOmE5ODdjMGRlZmZmOTQ4ZjliNjk1NjMwNTc2NzFhOTNjXzEtMi0xLTEtMzQzODQ_841cc257-a6ad-421c-b54f-92770b575e46">Term of license agreement</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c75d11680284d93969ed668e797eebc_D20220101-20221231" name="cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTphOTg3YzBkZWZmZjk0OGY5YjY5NTYzMDU3NjcxYTkzYy90YWJsZXJhbmdlOmE5ODdjMGRlZmZmOTQ4ZjliNjk1NjMwNTc2NzFhOTNjXzItMi0xLTEtMzQzODQ_62ffe953-a25f-45a4-9747-9807af43e3d9">Life of patent</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ic81d38ff0bba43e1abf838a12aab67f5" continuedAt="i22dfa5997f23481c82c2f6861d144dc6"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODMw_f50bb195-0da7-4afc-8921-7db95ab819ce" continuedAt="if34e6410434b48b98d918c3f124c2801" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if34e6410434b48b98d918c3f124c2801">Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.</ix:continuation>  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment.  The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit.  The Company's goodwill was acquired in November 2018 with the Vibativ acquisition and in January 2022 with the Sancuso acquisition. As a result, the Vibativ and Sancuso components of the Company are the reporting units evaluated for goodwill impairment.  Cumberland determined the fair value of the reporting units through current and future estimated revenue and profitability of the product.  The Company recorded <ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzE1OTE3_392ce18e-4393-4a7d-b5c5-1ab28046bc66"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzE1OTE3_a1d81838-6bbb-45a0-aa6a-1a1cfb144039">no</ix:nonFraction></ix:nonFraction> impairment charges during 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $<ix:nonFraction unitRef="usd" contextRef="i3aa1891de07e463882de10e63f32527d_I20200831" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzE2NDI3_74525836-ebe9-4f2a-b871-0fe183d15de7">0.2</ix:nonFraction>&#160;million equity contribution and an initial investment from Cumberland in the form of $<ix:nonFraction unitRef="usd" contextRef="i3aa1891de07e463882de10e63f32527d_I20200831" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzE2NTA3_855e00c8-8a22-40da-9ec1-ccb532d350dc">0.2</ix:nonFraction>&#160;million convertible note. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.   </span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODA2_806f563b-64a8-4a66-9764-473e88c9567c" continuedAt="i6a89201507534283bd0ff51e00b5581a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i22dfa5997f23481c82c2f6861d144dc6" continuedAt="id85090712c5f426aaa3a20c2bc123ddb"><ix:continuation id="i6a89201507534283bd0ff51e00b5581a"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.</span></div></ix:continuation><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE2_3e2d23f0-f56f-4f1b-8a52-c7da2c840ab0" continuedAt="i6c64b8bbb5ef4b839cad97f63ab143c4" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6c64b8bbb5ef4b839cad97f63ab143c4">Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</ix:continuation> <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:ScheduleOfDistributionCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODEy_35718620-f413-401c-8573-1f46483fcb55" continuedAt="icf58f0f6625343fbbafc86c7515dec1a" escape="true">Distribution costs were as follows for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><ix:continuation id="icf58f0f6625343fbbafc86c7515dec1a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:65.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.110%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:ProductionAndDistributionCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTo1ZGMzYWViMDc5OTM0NzBjOTMzNWJmZjA5ODkyNTkxZC90YWJsZXJhbmdlOjVkYzNhZWIwNzk5MzQ3MGM5MzM1YmZmMDk4OTI1OTFkXzItMi0xLTEtMzQzODQ_dc6a10ea-72c6-46e0-a172-1b247e7080b5">857,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:ProductionAndDistributionCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTo1ZGMzYWViMDc5OTM0NzBjOTMzNWJmZjA5ODkyNTkxZC90YWJsZXJhbmdlOjVkYzNhZWIwNzk5MzQ3MGM5MzM1YmZmMDk4OTI1OTFkXzItNC0xLTEtMzQzODQ_cb06a171-6462-4484-9fa6-bdc0395a0d03">806,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODA4_95316f6b-1ec0-42e3-abff-88e40134a1b2" continuedAt="ibc1d8c2346724c42b42de18788531482" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibc1d8c2346724c42b42de18788531482">Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</ix:continuation> <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:ScheduleOfAdvertisingCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODEz_dcb32322-35c3-4a56-bf8f-43dddb848c04" continuedAt="i7189da871254445ebe9b47fe291cdd46" escape="true">Advertising costs were as follows for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><ix:continuation id="i7189da871254445ebe9b47fe291cdd46"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:65.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.110%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTpiZmMzOTVlNzE1ZWQ0YWRmOTVkZTc5ZDA2ZjA2MzUxYy90YWJsZXJhbmdlOmJmYzM5NWU3MTVlZDRhZGY5NWRlNzlkMDZmMDYzNTFjXzItMi0xLTEtMzQzODQ_0f7273a2-b96f-494b-9dd5-b4e34ac58a1e">2,927,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTpiZmMzOTVlNzE1ZWQ0YWRmOTVkZTc5ZDA2ZjA2MzUxYy90YWJsZXJhbmdlOmJmYzM5NWU3MTVlZDRhZGY5NWRlNzlkMDZmMDYzNTFjXzItNC0xLTEtMzQzODQ_f7f43824-a9ad-41e3-ae91-ed889407c736">1,927,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="id85090712c5f426aaa3a20c2bc123ddb" continuedAt="i765067e856644e46b2fa09e4978005ba"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE3_94ac3285-4277-4fed-b164-f5f85e1a43d7" escape="true"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODI2_9a344509-dd54-42a1-8246-fb2aaa90377b" escape="true"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODI3_89097ba2-f3fd-4870-b41f-87691c8eba2a" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODMx_fd013424-46f8-471a-b947-4d48094e059e" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODI4_2c0fe5ca-f70f-48df-8418-730c8b8992bf" continuedAt="i9785145481834f90914842fce6ed5e76" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3 do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i765067e856644e46b2fa09e4978005ba"><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9785145481834f90914842fce6ed5e76">incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the consolidated statements of operations.</ix:continuation></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Cumberland named Martin S. Brown Jr. to our Board of Directors. Mr. Brown is an attorney with over 30 years of corporate law experience who brings significant legal, public company, health care and civic experience to our board.  The Company relies on several law firms for legal advice, including the firm Martin is affiliated.  In 2022, the Company paid Martin's law firm $<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="-4" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzU0OTc1NTg0NDI0Nw_37c9e544-8a59-42c2-9467-6e057eebec55">0.04</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzU0OTc1NTg0NDI0NQ_89bcbe8e-c34a-4aaa-8d39-6ab1a9537fd6" escape="true"><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 19, for additional information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODA5_fb9161d0-2fd2-4fa0-97bb-e24aa46fd681" escape="true"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i3e36cfc56e1a4275a52b7d560014d176_196"></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQ1NDU_ac926586-b60c-448f-9713-8542934e94c7" continuedAt="ie8fd4346a7c544cc8df4ba1b6ce78f70" escape="true">RediTrex</ix:nonNumeric></span><ix:continuation id="ie8fd4346a7c544cc8df4ba1b6ce78f70" continuedAt="i2e6bd7b813df4ee787b15bcfc8df0371"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> and Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation></div><ix:continuation id="i2e6bd7b813df4ee787b15bcfc8df0371" continuedAt="i29b00bb7d70840f28838501bfe22b069"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $<ix:nonFraction unitRef="usd" contextRef="i021bbc1b476b4fbe8c8498630b3444b9_D20161101-20161130" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQzMg_73945a27-438b-4439-9e3a-613a94cf6476">0.1</ix:nonFraction> million at closing.  The Company provided $<ix:nonFraction unitRef="usd" contextRef="i021bbc1b476b4fbe8c8498630b3444b9_D20161101-20161130" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQ2OQ_6f523173-544f-4665-86dc-d93970394f33">0.9</ix:nonFraction> million in consideration through a grant of <ix:nonFraction unitRef="shares" contextRef="i9301d1c169904a1d9355a5854c6f29e3_D20161101-20161130" decimals="-4" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzUwOA_a1cfee3e-6440-4794-92e9-a57f033d788a">180,000</ix:nonFraction> restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i29b00bb7d70840f28838501bfe22b069" continuedAt="i9a90510f36a241118d07855404487576"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name. The <ix:nonFraction unitRef="shares" contextRef="i9301d1c169904a1d9355a5854c6f29e3_D20161101-20161130" decimals="-4" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzExMTg_a1cfee3e-6440-4794-92e9-a57f033d788a">180,000</ix:nonFraction> shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $<ix:nonFraction unitRef="usd" contextRef="i49ea797c011744d19c463a47c6cbbd46_D20220101-20221231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzEyMzY_4f642d35-a2e3-40ee-8d4c-e2b5a27efecf">0.9</ix:nonFraction> million on the vesting date. The FDA approval also resulted in a $<ix:nonFraction unitRef="usd" contextRef="i9b29c34edaba455b8ebdd48b45de02d6_I20211031" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzEyOTY_223bb06a-5ebd-4697-818d-1c42ed96978f">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020.  During December 2020, Cumberland began distributing RediTrex which also resulted in a $<ix:nonFraction unitRef="usd" contextRef="i9b29c34edaba455b8ebdd48b45de02d6_I20211031" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzE1MzQ_223bb06a-5ebd-4697-818d-1c42ed96978f">1.0</ix:nonFraction>&#160;million milestone payment due to Nordic.  The full launch of RediTrex occurred in October 2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after June 30, 2023. Cumberland will continue to distribute and support the product until then.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of the amendment, Nordic has agreed to return the <ix:nonFraction unitRef="shares" contextRef="id9d899e86c97433d9a3fa65fce7361e2_I20220712" decimals="0" name="cpix:CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTE3Mw_9c5d6724-88fa-499c-905b-a4dd41d01fd6">180,000</ix:nonFraction> restricted Cumberland shares we previously issued to Nordic which will be cancelled, refund to Cumberland the milestone payment of $<ix:nonFraction unitRef="usd" contextRef="if7fa09f75a3b48cea5b2fb00b556fbe9_I20220712" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTE0NQ_a40283d2-fdee-4a0c-a310-434774ed0689">1.0</ix:nonFraction>&#160;million we made associated with the brand's U.S. approval and issue a credit note in favor of the Company in the amount of $<ix:nonFraction unitRef="usd" contextRef="if7fa09f75a3b48cea5b2fb00b556fbe9_I20220712" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTE1OQ_2de67d93-cccf-4434-b71c-cd76abb836ac">1.0</ix:nonFraction>&#160;million for the unpaid milestone payment due from us for launch of the product line. The companies will cooperate on any transition and Cumberland will receive a long-term royalty on any Nordic sales of the product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland had approximately $<ix:nonFraction unitRef="usd" contextRef="iec5e58bac724452b876b92a905e3ca14_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzE3Njc_b2ff4080-86f7-4831-80e1-9449e4b65b0e">2.6</ix:nonFraction>&#160;million in net intangible assets related to RediTrex at December&#160;31, 2021.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i133c71a4398845698d7d7701abc49b01_D20181101-20181130" decimals="2" name="cpix:TieredRoyaltyPaymentsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzMwODk_bbe0466a-e0f7-400c-8c31-3f3e906eb1b8">20</ix:nonFraction>% on future net sales of the product after a $<ix:nonFraction unitRef="usd" contextRef="i133c71a4398845698d7d7701abc49b01_D20181101-20181130" decimals="-5" name="cpix:TieredRoyaltyPaymentsThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzI3NDg3NzkwNzk3MDI_8ed970ae-05a1-48e3-bc8f-c09b250e383e">2.5</ix:nonFraction> million threshold is met.  The future royalty payments were required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQ1NDg_16029336-6a95-403b-8e41-1bbca0c8c497" continuedAt="i65e1a3af76134c478217f9be1b4f270e" escape="true">The following table presents the changes in the Company's Level 3 contingent consideration liability.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i9a90510f36a241118d07855404487576" continuedAt="i7d03b170d5914561bd4d226d2f1a89ac"><div style="margin-top:8pt;text-align:center"><ix:continuation id="i65e1a3af76134c478217f9be1b4f270e" continuedAt="ic3364392a20141fdb2ef9d131537f9cf"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e22ba92c2194833a0319101083d1275_I20201231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzEzLTEtMS0xLTM0Mzg0_daf23246-d314-4a5e-88ba-54eb38420876">8,200,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f2090fcc89c46fc8c515cd09cc5ffae_D20210101-20211231" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE0LTEtMS0xLTM0Mzg0_6516dfaa-ea89-4cef-95ff-e37433b0733e">2,166,682</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f2090fcc89c46fc8c515cd09cc5ffae_D20210101-20211231" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE1LTEtMS0xLTM0Mzg0_e8eaf588-5ec7-4312-ae2f-483315a5f91a">1,147,750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f2090fcc89c46fc8c515cd09cc5ffae_D20210101-20211231" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE2LTEtMS0xLTM0Mzg0_42f4d485-240b-4fa4-926d-7f4554af0c0e">1,629,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib36b29930b41472aaa5de35a1e59cb95_I20211231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE3LTEtMS0xLTM0Mzg0_70ddd47a-c6d0-495a-a607-acea9b80c84d">6,515,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i924046424f4a4ad5a7dce8e0bfe36d8b_D20220101-20221231" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE4LTEtMS0xLTQxNzAw_54ac0175-6d7b-4244-9f3c-00eb6b2d3d2f">1,133,113</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i924046424f4a4ad5a7dce8e0bfe36d8b_D20220101-20221231" decimals="0" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE5LTEtMS0xLTQxNzAw_e995975c-6487-46a2-ad34-4cf9bcc60dfe">2,104,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924046424f4a4ad5a7dce8e0bfe36d8b_D20220101-20221231" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzIwLTEtMS0xLTQxNzAw_cab586cf-dc2a-47c6-9062-2dee63fe2471">876,999</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzIxLTEtMS0xLTQxNjk4_1dcb699a-67cf-471f-b2b3-338873b5a234">4,154,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of the contingent consideration liability is $<ix:nonFraction unitRef="usd" contextRef="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQ0OTg_cc850bdc-7173-412b-96b9-5d4cbac61b08">1.3</ix:nonFraction>&#160;million and the non-current portion is $<ix:nonFraction unitRef="usd" contextRef="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQ1MzI_cc39afcf-616a-46f2-89c6-462ad1e855ad">2.8</ix:nonFraction>&#160;million, as of December&#160;31, 2022. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ieb014f15e52c4aa7b4a00972e8c2037e_I20220103" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTE4NA_058b003f-223c-46e6-becf-67365fd46338">13.5</ix:nonFraction>&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="ieb014f15e52c4aa7b4a00972e8c2037e_I20220103" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTE5OQ_789e9895-73c6-4b56-8165-3cb500790bc5">3.5</ix:nonFraction>&#160;million based on the attainment of various approvals and sales performance. The Company believes that $<ix:nonFraction unitRef="usd" contextRef="i44944cd121824f49afdb95c8a1b230c0_D20220101-20221231" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTIxMw_559ec805-9121-4a90-bc22-37797b8bddc1">1.5</ix:nonFraction>&#160;million of the milestone payments will be earned and paid.  The remaining milestone of $<ix:nonFraction unitRef="usd" contextRef="i44944cd121824f49afdb95c8a1b230c0_D20220101-20221231" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTIyNw_323ba0b8-1148-40ae-8b27-a4fa49d1bd47">2.0</ix:nonFraction>&#160;million will be paid if and when annual net revenue exceeds $<ix:nonFraction unitRef="usd" contextRef="i44944cd121824f49afdb95c8a1b230c0_D20220101-20221231" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTI0MQ_892a772a-80c6-49e8-9e4c-475b1c7f04e6">20</ix:nonFraction>&#160;million.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to <ix:nonFraction unitRef="number" contextRef="i4e74c81ece854dfcb8d7c8c3bc0a2f03_I20220103" decimals="2" name="cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTI1NA_68672903-f067-4f83-8566-ae65202e3063">10</ix:nonFraction>% of on-going net sales of the product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a valuation of the contingent consideration liability utilizing significant unobservable inputs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the valuation is classified as Level 3 fair value measurement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company worked with an outside consultant firm to finalize the Sancuso valuation of the transaction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value for the assets and liabilities assumed were as follows: prepaid expenses $<ix:nonFraction unitRef="usd" contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTI1OQ_608985b0-3640-45ae-9d17-ab6d8fb06f45">1.8</ix:nonFraction>&#160;million, inventory $<ix:nonFraction unitRef="usd" contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTMwMg_3662f66b-e2bf-4e2a-be88-0b2487cc4680">2.6</ix:nonFraction>&#160;million, goodwill $<ix:nonFraction unitRef="usd" contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTMxNg_8c75a671-1e23-4bef-8c4c-70d76e5ccc3f">0.03</ix:nonFraction>&#160;million, intangible assets $<ix:nonFraction unitRef="usd" contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103" decimals="0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTI3Mw_e4915840-0ee5-45cf-ac3c-20db31c522df">14.1</ix:nonFraction>&#160;million, milestone payable $<ix:nonFraction unitRef="usd" contextRef="if8f59b1cd25d434eb648fc77c3dea5b1_D20220103-20220103" decimals="-5" name="us-gaap:OtherPaymentsToAcquireBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTI4OA_f9cf97cc-e8a7-455a-838d-e80603c1dfc4">1.7</ix:nonFraction>&#160;million and contingent liability $<ix:nonFraction unitRef="usd" contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTMzMQ_8b69071b-3a6f-4c36-8384-dd813077e136">3.4</ix:nonFraction>&#160;million.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic3364392a20141fdb2ef9d131537f9cf" continuedAt="i2e967339767b427ba8ebc26956dbf771">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</ix:continuation></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i7d03b170d5914561bd4d226d2f1a89ac" continuedAt="i48b9c52f7b7245da9821cfbaab19e134"><div style="text-align:justify"><ix:continuation id="i2e967339767b427ba8ebc26956dbf771"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:74.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.578%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at January 3, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTplYjg3OTk3NGU5ZDA0ODAwOTE5ZjRkM2UyZTI1ZDQwZi90YWJsZXJhbmdlOmViODc5OTc0ZTlkMDQ4MDA5MTlmNGQzZTJlMjVkNDBmXzEtMS0xLTEtNDE2OTY_e52b0499-e366-4b8b-8085-982b9daccf28">3,384,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash payment of royalty during the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(<ix:nonFraction unitRef="usd" contextRef="i81f3f0b045ff491da276024b81457433_D20220103-20221231" decimals="0" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTplYjg3OTk3NGU5ZDA0ODAwOTE5ZjRkM2UyZTI1ZDQwZi90YWJsZXJhbmdlOmViODc5OTc0ZTlkMDQ4MDA5MTlmNGQzZTJlMjVkNDBmXzItMS0xLTEtNDE3MTQ_349a6236-d19c-40b3-ab04-1e5739f9a9ae">1,075,631</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in fair value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="i81f3f0b045ff491da276024b81457433_D20220103-20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTplYjg3OTk3NGU5ZDA0ODAwOTE5ZjRkM2UyZTI1ZDQwZi90YWJsZXJhbmdlOmViODc5OTc0ZTlkMDQ4MDA5MTlmNGQzZTJlMjVkNDBmXzMtMS0xLTEtNDE2OTY_f137ee35-cdb4-488e-a683-4014d69fab78">16,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent consideration earned and accrued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="i81f3f0b045ff491da276024b81457433_D20220103-20221231" decimals="0" name="cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTplYjg3OTk3NGU5ZDA0ODAwOTE5ZjRkM2UyZTI1ZDQwZi90YWJsZXJhbmdlOmViODc5OTc0ZTlkMDQ4MDA5MTlmNGQzZTJlMjVkNDBmXzQtMS0xLTEtNDE2OTY_b4cfe5db-453d-48a9-a60a-86f1cde4f484">675,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="if92534bff0f1467fbb22f084f101995f_I20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTplYjg3OTk3NGU5ZDA0ODAwOTE5ZjRkM2UyZTI1ZDQwZi90YWJsZXJhbmdlOmViODc5OTc0ZTlkMDQ4MDA5MTlmNGQzZTJlMjVkNDBmXzUtMS0xLTEtNDE2OTY_89d3e5ab-b610-499e-bbb6-931a23852c27">3,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of the contingent consideration liability is $<ix:nonFraction unitRef="usd" contextRef="if92534bff0f1467fbb22f084f101995f_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzI3NDg3NzkwNzk2NDY_c940433c-060c-4e5d-9771-445f285521cb">1.7</ix:nonFraction> million and the non-current portion is $<ix:nonFraction unitRef="usd" contextRef="if92534bff0f1467fbb22f084f101995f_I20221231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzI3NDg3NzkwNzk2Nzg_32d1a419-161d-443a-b64d-2e4338023c46">1.3</ix:nonFraction> million, as of December&#160;31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso Intangible Assets, Goodwill, Revenue and Earnings</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An outside consultant prepared the Sancuso valuation and the valuation is complete.  The goodwill of $<ix:nonFraction unitRef="usd" contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103" decimals="-4" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgxNTU3ODE_c6feca57-5cf0-456c-8075-dd9b3765fa09">0.03</ix:nonFraction>&#160;million arising from this acquisition consists largely of the synergies and economies of scale expected from combining the operations of the Company and the acquired company. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on discussions with Management, the identified intangible assets were valued as a composite asset referred to as the Sancuso product rights. It is comprised of:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">   Technology &#8211; patented and unpatented IP and know-how;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">   Marketing intangible assets including product trademarks/names/dress; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">   Customer base to which the product is sold.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is a common practice in the life sciences industry to value intangible assets under a portfolio approach given the nature of the intangible assets and facts and circumstances that are common to the industry. The Goodwill amount to be deducted for tax purposes is expected to be $<ix:nonFraction unitRef="usd" contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103" decimals="-4" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgxNTU4MTA_8878acff-35c3-4453-9762-74c851736852">0.03</ix:nonFraction>&#160;million and will be amortized over 15 years. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso was acquired on January 3, 2022. For the year ended December 31, 2022, the amounts included in the income statement for revenue and operating profit were $<ix:nonFraction unitRef="usd" contextRef="i469400cc5d084372975262bfe96ab0fc_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgzMDczMQ_fd6a0e02-8437-4085-896c-bf8a883b0f77">13.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i469400cc5d084372975262bfe96ab0fc_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgzMDcxNw_ad779922-06c5-4d91-9c29-6902c8a5b3cb">6.6</ix:nonFraction>&#160;million, respectively.  </span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgzMDcwMQ_46c3f877-e25d-4285-960c-4cbe15ba047e" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a pro-forma basis, the revenue and earnings of the combined entity as though the business combination had occurred in 2021 appears below:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:57.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumberland 2022 Results</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pro-forma 2021 Results</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTpmMWYxNDJhZmFhMTc0MTQzYTcyNmJjMGY1MTBiOTMyZi90YWJsZXJhbmdlOmYxZjE0MmFmYWExNzQxNDNhNzI2YmMwZjUxMGI5MzJmXzEtMS0xLTEtNDM1MDg_c85a7225-4ae3-4383-8ce4-c3827a8a4bd7">42,010,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTpmMWYxNDJhZmFhMTc0MTQzYTcyNmJjMGY1MTBiOTMyZi90YWJsZXJhbmdlOmYxZjE0MmFmYWExNzQxNDNhNzI2YmMwZjUxMGI5MzJmXzEtMy0xLTEtNDM1MDg_6f570f51-46c7-43e0-a615-bc68401cbcc9">50,085,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTpmMWYxNDJhZmFhMTc0MTQzYTcyNmJjMGY1MTBiOTMyZi90YWJsZXJhbmdlOmYxZjE0MmFmYWExNzQxNDNhNzI2YmMwZjUxMGI5MzJmXzMtMS0xLTEtNDM1MDg_082099de-1df5-4c11-8381-d340ec8030d7">5,704,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTpmMWYxNDJhZmFhMTc0MTQzYTcyNmJjMGY1MTBiOTMyZi90YWJsZXJhbmdlOmYxZjE0MmFmYWExNzQxNDNhNzI2YmMwZjUxMGI5MzJmXzMtMy0xLTEtNDM1MDg_592ee01c-c25d-4ff4-84a0-0bfc1b6ba02d">5,447,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 pro-forma results include results for Sancuso as provided by the management of Kyowa Kirin. The Seller is a pharmaceutical company similar to Cumberland. The 2021 results for Sancuso as reported by Kyowa Kirin reflect accounting methodology and reporting which were similar to those employed by the Company.   </span></div></ix:continuation><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i48b9c52f7b7245da9821cfbaab19e134">The Company&#8217;s 2022 balance sheet reflects the full year impact of the Sancuso acquisition, as the acquisition occurred on January 3, 2022.</ix:continuation>  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_199"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzMyMDE_8a0e588c-6c4b-442a-a08c-92003fe375b7" continuedAt="i0d08bc335da34abcb8a6ad0ff68f2ab8" escape="true">Revenues</ix:nonNumeric></span></div><ix:continuation id="i0d08bc335da34abcb8a6ad0ff68f2ab8"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzMyMDM_6acae24e-e085-4e3f-8160-c1f851a0947a" escape="true"><div style="margin-top:7pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-top:7pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:65.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4696b3ec55c74a54b9b5653d2452aca1_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzItMi0xLTEtMzQzODQ_eb9a93b1-550c-493c-97f7-1032056bd6d1">15,205,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if32dce83e48c4a7b91a0d4e335b66480_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzItNC0xLTEtMzQzODQ_74c17705-a313-4874-ae98-9036e7a6d9e9">15,993,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98dc7a56a6ee4bc5ace7b118374a0de5_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzMtMi0xLTEtMzY2Nzc_80e6f48f-c88b-42cd-b8a3-1f697cbb8f42">13,205,603</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaddae84fd5b4b89a3139c9ac38b23c6_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzMtNC0xLTEtMzY2Nzc_9e37825f-6dd2-4c33-b3f5-824f216e78c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f3d9b8292154fa0b504704f80f2e116_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzMtMi0xLTEtMzQzODQ_1e9c80af-9464-4113-81b7-6f4db0729cb7">7,487,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf29047eb0424eef806c96c842debe22_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzMtNC0xLTEtMzQzODQ_2972dd2d-0ce2-4477-b58c-eac4128b6615">11,704,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3b77ebc51845fd880355bb1563cc5f_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzQtMi0xLTEtMzQzODQ_b730d73c-2780-4dd9-9a50-b33132ea491b">4,827,200</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b3e901750344aba9b2ac8dc3d8398e_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzQtNC0xLTEtMzQzODQ_e2b58ac3-5cdf-46e7-b371-0d89c227ab5d">4,970,301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37ab018ed1464e58a2e6f54a577ad077_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzUtMi0xLTEtMzQzODQ_5fdb7170-7c10-430d-ac97-381ec20b47c9">501,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8fd80adb04d4f22a287d4e54e9550dc_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzUtNC0xLTEtMzQzODQ_4fc50890-1751-4c85-abce-28ed9ed4c5c4">850,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa10efc46e9e461386aa80220fb7a4ce_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzYtMi0xLTEtMzQzODQ_f4a0bf31-e0b2-49e1-b900-a137fedc40f1">29,145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe04d4939aef4eb2ae85d6d4c47c642d_D20210101-20211231" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzYtNC0xLTEtMzQzODQ_673407a2-c2d0-44ae-81e0-563ae8960015">388,657</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9859c4aed134140b347fcfab3e9f9f9_D20220101-20221231" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzctMi0xLTEtMzQzODQ_a5cec3fe-bad3-4e7e-93c9-8ee56a7b4fb6">447,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e9d7a75c774347844d3abe0e6a3d75_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzctNC0xLTEtMzQzODQ_52249283-931f-4ae0-a19c-90b3e80939ff">1,859,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82ef6903bdd04aa7be5bf21326a39725_D20220101-20221231" decimals="0" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzgtMi0xLTEtMzQzODQ_8aede2ee-b194-4258-83ab-10db95bec6d2">126,726</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6aca6f1f4640128e84638b21a73ac8_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzgtNC0xLTEtMzQzODQ_25b06301-279b-465f-926c-c3f31bfbb85b">55,321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzktMi0xLTEtMzQzODQ_d9ee1cd2-476f-446d-afe3-bbfd3f72eb1e">40,681,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzktNC0xLTEtMzQzODQ_e9206437-4974-46be-ba21-d4f8bc83adc3">35,045,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.  The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The international agreements provide for $<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="-5" name="cpix:RevenueRecognitionUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzIzMjg_4b4ff2f3-6a9a-4f86-a0e7-842d31ae6900">1.5</ix:nonFraction> million in non-refundable up-front payments, milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="-5" name="cpix:RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzIzOTY_5a56f374-a0f5-4cd1-acaf-a952f747013b">2.4</ix:nonFraction> million related to regulatory approvals and up to $<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="-5" name="cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzI0NDE_2f508c2e-f670-40e5-bdc1-d659e0736d5a">5.6</ix:nonFraction> million in payments related to product sales.  From 2012 through December&#160;31, 2022, the Company has recognized a cumulative $<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="-5" name="cpix:RevenueRecognitionCumulativeUpfrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzI1NDU_33f3b14e-969f-4aa6-bdbd-078e7b642764">1.9</ix:nonFraction> million in upfront payments as other revenue and has recognized $<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="-5" name="cpix:RevenueRecognitionMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzI2MDQ_4dd5b10c-9427-4aa7-9d44-8e06ba73629c">0.5</ix:nonFraction>&#160;million during the year 2022.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues during 2022 and 2021 also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $<ix:nonFraction unitRef="usd" contextRef="if6d9484ddbcb49fda1792dcd0ca0e89c_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzMxMzc_66a1dea7-e5cb-4760-a09c-3ddcf917a212">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i16b9bb498b204e8a9f03c0c2fdc55984_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzMxNDI_f4d02420-0c09-4927-b9dc-6d6a47dc33a1">0.4</ix:nonFraction> million for the years ending December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_202"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzIxODQ_c574e980-dd55-4ecd-8505-a2c520f1907c" continuedAt="i6483c324032f413b80340cf26387e218" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i6483c324032f413b80340cf26387e218"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzIxODU_85541f90-8382-45f5-b387-a086aa8a0772" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.339%"><tr><td style="width:1.0%"></td><td style="width:60.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.248%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzItMi0xLTEtMzQzODQ_aeb7050a-f8e8-4828-81ee-d2e3e9a74fd2">12,899,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzItNC0xLTEtMzQzODQ_24ad947d-de61-497b-bbe4-b4c863453960">12,374,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzMtMi0xLTEtMzQzODQ_ef499dad-7f1f-44d0-b53b-f10daf54954f">168,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzMtNC0xLTEtMzQzODQ_9c16c44d-ef39-4f56-9923-3f32bac1a0b4">164,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzQtMi0xLTEtMzQzODQ_ef9c1f47-5fac-48e9-8f4d-df00e245ee82">4,322,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzQtNC0xLTEtMzQzODQ_21d95ed3-a9a7-45a6-a2a7-991128699fc2">4,939,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzUtMi0xLTEtMzQzODQ_71fb9144-1490-459c-a8ac-2a5ed501b587">17,390,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzUtNC0xLTEtMzQzODQ_0fe121be-c06b-4691-bd80-c3b3efa55257">17,478,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzYtMi0xLTEtMzQzODQ_8fca7dea-7aff-4678-b423-a79a76043036">7,527,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzYtNC0xLTEtMzQzODQ_53f0c8b7-68df-4f37-9d67-7e45992b19bb">9,048,567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzctMi0xLTEtMzQzODQ_0020fa23-0977-493f-ab58-9f78b2573f89">9,863,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzctNC0xLTEtMzQzODQ_767737b5-899f-43b4-b761-ac7e954392d7">8,429,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzExMTY_ad2a5c2e-eea2-4c7f-8ebe-3035b6b5c9dc">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="-5" name="us-gaap:InventoryValuationReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzExMjM_a6270ed4-07a9-4e12-b85c-1849b5b8d66f">1.4</ix:nonFraction>&#160;million, respectively.  </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers.  As the API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory total at December&#160;31, 2022 and 2021. Consigned inventory represents Authorized Generic inventory stored with Padagis until shipment.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $<ix:nonFraction unitRef="usd" contextRef="if13d0a3b9ba3470186981ffcd4cd386c_I20221231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzE4MTQ_5bf1d94b-5129-446e-a3e1-4bd93fa5f578">15.6</ix:nonFraction> million  that were classified as non-current inventories.  The Vibativ non-current API inventory was $<ix:nonFraction unitRef="usd" contextRef="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzE5MTc_b49bbd5d-eb3f-418b-ae3b-5920d6ea5136">7.1</ix:nonFraction> million at December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ib36b29930b41472aaa5de35a1e59cb95_I20211231" decimals="0" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzE5MjQ_f85ed280-01b8-4ab6-bc58-0e0feba8537e">8.1</ix:nonFraction> million at December&#160;31, 2021.  The Company had <ix:nonFraction unitRef="usd" contextRef="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzU0OTc1NTgxNzIxNQ_7513d223-b587-4f4f-88ba-408189d047d3">no</ix:nonFraction> Vibativ finished goods included in the non-current inventories at December&#160;31, 2022, and $<ix:nonFraction unitRef="usd" contextRef="ib36b29930b41472aaa5de35a1e59cb95_I20211231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzEwOTk1MTE2MzA5OTI_6d1bf7b0-4428-4aa2-a98d-0384a99ddee0">0.5</ix:nonFraction> million at December&#160;31, 2021.  At  December&#160;31, 2022 and 2021, Cumberland had $<ix:nonFraction unitRef="usd" contextRef="icf903ddd161947ba816eea446f55a857_I20221231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzIxMDM_c6eda3fe-ed3b-4274-84fb-a42708f4fef3"><ix:nonFraction unitRef="usd" contextRef="i90d887a51969486c9881a5eac45b76a6_I20211231" decimals="-5" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzIxMDM_d2d1b0e9-4e7a-40e5-9586-3c2228c2abd3">0.3</ix:nonFraction></ix:nonFraction> million in non-current inventory for API related to its ifetroban clinical initiatives and $<ix:nonFraction unitRef="usd" contextRef="icf903ddd161947ba816eea446f55a857_I20221231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzEwOTk1MTE2MzEwNzk_22ff11d2-0b9a-4eeb-b081-86779e43143b"><ix:nonFraction unitRef="usd" contextRef="i90d887a51969486c9881a5eac45b76a6_I20211231" decimals="0" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzEwOTk1MTE2MzEwNzk_ab0da3a9-285c-4371-9ca0-dc218fdee75f">0.1</ix:nonFraction></ix:nonFraction> million of finished goods</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_205"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90ZXh0cmVnaW9uOjczOGNkNTBjMWIwMzRiMzM5NzdiYWYzNzI5ZGE0MTkwXzM1Ng_f2abd26c-53d3-46e4-8c6b-d0b3567d3926" continuedAt="i8d214c3a8e7648a191f2a725ec7f5e9f" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="i8d214c3a8e7648a191f2a725ec7f5e9f"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90ZXh0cmVnaW9uOjczOGNkNTBjMWIwMzRiMzM5NzdiYWYzNzI5ZGE0MTkwXzM1OA_f7e40b8c-7204-44f1-bf02-7731b58aa90e" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"></td><td style="width:34.965%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.892%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0b7caf11e1a24164b014dcb9cc1efa95_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzItMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjowMjY1ZmRlY2RiMjE0OTRiYjc4YjRjZTkwZThlYzk4Nl80_1f7cd11a-5f17-478b-987f-59796ecf7b09">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="ib30352d285114277aebd23aebdefc31a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzItMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjowMjY1ZmRlY2RiMjE0OTRiYjc4YjRjZTkwZThlYzk4Nl85_3bce3ebc-73dc-48ae-a500-a664f3f10656">5</ix:nonNumeric>&#160;years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebc3383fa2574ae1802474eb1d124ef3_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzItNC0xLTEtMzQzODQ_9ed34f02-1d15-4ec8-bd34-a1f41686f520">465,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic80dac19a3234cf59481be62a47b00c2_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzItNi0xLTEtMzQzODQ_42199d93-644a-47c6-b562-897664c87f94">1,352,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib15d3092260845f9b57d3c442a6f6c72_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzMtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjo1YzhjM2I5YmJkNTk0NmFlYWMzMjViYzMzZDUxMGQ2Yl80_e883d573-36b8-4216-a80a-b695647b538e">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="i8f1325d766c543488d6cdd933169b69f_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzMtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjo1YzhjM2I5YmJkNTk0NmFlYWMzMjViYzMzZDUxMGQ2Yl85_99384b92-58e3-4c74-9d96-916b57622e62">15</ix:nonNumeric>&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16957755b21643ba9ebe843a90bb7625_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzMtNC0xLTEtMzQzODQ_cbc2a271-898d-4f9d-8918-191469f34280">746,602</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d4d8a23fe54b748a284173ad96a122_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzMtNi0xLTEtMzQzODQ_45f7f078-660b-4af2-b649-ec1ac11f9793">820,712</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7da33aa95f3a43abb0a94e5e28dc81d1_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzQtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjoyZWIwYzJhOGY1MGQ0ZWM2YWFhZGM4NDAzZjI0MzUzMF80_5736e966-5bca-472c-9e84-5eae6dc90c8f">5</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="i66cf95bb11704c8fa28b1cc8873b54c6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzQtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjoyZWIwYzJhOGY1MGQ0ZWM2YWFhZGM4NDAzZjI0MzUzMF85_770d5d48-d9eb-4e10-a0d1-8160b7d7d3a5">15</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440984280e14489e94de83929fda92ea_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzQtNC0xLTEtMzQzODQ_d427da64-1d9e-4322-b0b6-da38406b5f2f">369,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f49ad0b1cb54a7283fcda38b5eb92cd_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzQtNi0xLTEtMzQzODQ_19597ee6-8c04-4346-8322-66ca5144985d">638,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie029fb915f8742fabfa273ab1ade8a96_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzUtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjo1MjFiYjQ1YWNlYzM0MDQ0OGRkZDEzZmJhODBmZjcwYl80_ad36b072-a772-42b0-a70e-37a28dccb673">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="iec1323af37504488a64c07cf8beb4baf_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzUtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjo1MjFiYjQ1YWNlYzM0MDQ0OGRkZDEzZmJhODBmZjcwYl85_94221337-7e60-41bb-afb2-5bd2097644fa">15</ix:nonNumeric>&#160;years,&#160;or remaining&#160;lease&#160;term</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a40ef618bc943579e158b9494ffce7d_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzUtNC0xLTEtMzQzODQ_fa605282-9abd-4dfd-b332-dd7d145cb486">787,749</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57964ce83e4b45c18274c46575c33640_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzUtNi0xLTEtMzQzODQ_601a8df4-7a5c-4056-8783-f36112be264f">1,422,439</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzYtNC0xLTEtMzQzODQ_57d37ea6-74e3-453b-b208-68725e289410">2,369,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzYtNi0xLTEtMzQzODQ_0def6d0b-5c39-497d-bedd-043144fb56c6">4,234,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzctNC0xLTEtMzQzODQ_5b9a27bc-2a7c-433c-85d2-d4e3ff216ae7">2,085,185</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzctNi0xLTEtMzQzODQ_b269f8a2-f182-4a38-acbc-68da6da8bfd4">3,792,153</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzgtNC0xLTEtMzQzODQ_10b0c384-6a92-407c-bdf3-8360b45ff9f5">284,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzgtNi0xLTEtMzQzODQ_36fe9a6a-4a74-45e1-ac28-2bef9d19e028">442,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations.  <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:ScheduleofDepreciationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90ZXh0cmVnaW9uOjczOGNkNTBjMWIwMzRiMzM5NzdiYWYzNzI5ZGE0MTkwXzM2MA_ef8ad0d0-52a8-43ad-b231-78b40b7833a4" continuedAt="i262bab05be324887a7f0f997e4f85d61" escape="true">Depreciation expense was as follows for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><ix:continuation id="i262bab05be324887a7f0f997e4f85d61"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:65.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.269%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZTpkZTAzODJhZGQ5YzI0MTYwYTliNDY2OWEwODJhNjM0Yy90YWJsZXJhbmdlOmRlMDM4MmFkZDljMjQxNjBhOWI0NjY5YTA4MmE2MzRjXzItMi0xLTEtMzQzODQ_e5c2282e-d333-4bcf-af0b-dd8ccb70d1b5">260,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZTpkZTAzODJhZGQ5YzI0MTYwYTliNDY2OWEwODJhNjM0Yy90YWJsZXJhbmdlOmRlMDM4MmFkZDljMjQxNjBhOWI0NjY5YTA4MmE2MzRjXzItNC0xLTEtMzQzODQ_fdf594d3-e0e1-407f-8d2e-835b1a54e4d5">235,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_208"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzIwMDg_46fe1ebe-4499-468c-9a60-e07effb6cd7b" continuedAt="icbbb530b9a914b38b3ecf3c601e6318e" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="icbbb530b9a914b38b3ecf3c601e6318e"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzIwMDk_0c07489d-317e-45b4-b8ab-f259ab74e8a8" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31, 2022 and 2021. </span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.217%"><tr><td style="width:1.0%"></td><td style="width:59.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69aeb359c79e41b78bca28b92da3cc0b_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzItMi0xLTEtMzQzODQ_ed910ed3-e1ad-487b-8f52-054f61bf0f86">49,668,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463edf77a5cf4cd68d974b7c5d2166e3_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzItNC0xLTEtMzQzODQ_61848a0b-3739-45ad-a09c-daa2845b197b">38,543,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69aeb359c79e41b78bca28b92da3cc0b_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzMtMi0xLTEtMzQzODQ_f9abb6ed-b558-4306-b95d-b7c2725988da">21,891,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i463edf77a5cf4cd68d974b7c5d2166e3_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzMtNC0xLTEtMzQzODQ_37fbaf55-3c90-4678-8672-1718935b77a4">18,015,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69aeb359c79e41b78bca28b92da3cc0b_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzQtMi0xLTEtMzQzODQ_249705f6-6a53-4525-9f58-ee31a3fb1dbf">27,776,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463edf77a5cf4cd68d974b7c5d2166e3_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzQtNC0xLTEtMzQzODQ_082b81c9-2ad6-4020-a533-c72d3f80eeed">20,528,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d06b1820bd54620a60f0c01d91fbf4d_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzUtMi0xLTEtMzQzODQ_4bf1f048-ac98-4362-9dd6-79d2e2c19e6c">10,610,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3983a09554e4ca699dbcaf2db560e0f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzUtNC0xLTEtMzQzODQ_323c33dc-f93b-407e-817e-4ee80d8410f3">10,478,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d06b1820bd54620a60f0c01d91fbf4d_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzYtMi0xLTEtMzQzODQ_9f234780-0e6d-415d-acd3-e891d8dd32af">8,051,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3983a09554e4ca699dbcaf2db560e0f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzYtNC0xLTEtMzQzODQ_da5b2549-a066-4bee-94a0-142272a28d73">7,333,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d06b1820bd54620a60f0c01d91fbf4d_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzctMi0xLTEtMzQzODQ_3887e98a-94a1-425c-9cc2-fe8efac3c7e1">2,559,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3983a09554e4ca699dbcaf2db560e0f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzctNC0xLTEtMzQzODQ_a8a44f47-600b-4fdc-ae3c-ec2a5024054d">3,145,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574bc1e7d0d2481ea5ad466e8f534855_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzgtMi0xLTEtMzQzODQ_3e944ea0-e85c-4daf-9c32-2109763d24e3">397,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic223906cd81348c4bac59dcace59f34e_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzgtNC0xLTEtMzQzODQ_99b69894-930b-404f-9a1d-5cbe09888ea2">373,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i574bc1e7d0d2481ea5ad466e8f534855_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzktMi0xLTEtMzQzODQ_5cd25e3f-f169-4ef4-8533-9e6b3b7302d4">142,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic223906cd81348c4bac59dcace59f34e_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzktNC0xLTEtMzQzODQ_7fe20f19-6224-4316-9d71-3fb35d8e5d6b">93,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574bc1e7d0d2481ea5ad466e8f534855_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzEwLTItMS0xLTM0Mzg0_ff5d0812-54e1-4d43-867b-a545fac5fec7">255,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic223906cd81348c4bac59dcace59f34e_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzEwLTQtMS0xLTM0Mzg0_fd74b421-adcf-4e3d-bd3b-1c02618e551f">280,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzExLTItMS0xLTM0Mzg0_35220684-d427-462a-8a79-3d663949022c">30,590,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzExLTQtMS0xLTM0Mzg0_6498e9d5-e707-4bb0-8e7b-eb3a0844f548">23,954,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzEzLTItMS0xLTM0Mzg0_78b5da45-50fe-48e7-a004-fb4c05368aa4">914,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzEzLTQtMS0xLTM0Mzg0_0face6d7-076c-4b76-b6ab-3a560ad7a33d">882,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product and license rights include assets associated with the Company's acquired products, including those discussed in Note 3, RediTrex, Vibativ and Sancuso.  RediTrex is only represented in 2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Company recorded an additional $<ix:nonFraction unitRef="usd" contextRef="idb47557bdc1b4a7091a589c3dd4e833b_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzE0ODE_9ad1d029-2c2a-433b-b1a1-fce0dd484db3"><ix:nonFraction unitRef="usd" contextRef="i4c75d11680284d93969ed668e797eebc_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzE0ODE_d72cb995-1bbc-459a-9fdf-8bf9579824a9">0.2</ix:nonFraction></ix:nonFraction> million in each year in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property.  The Company also recorded an additional $<ix:nonFraction unitRef="usd" contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzEwOTk1MTE2MzEzNjA_b8bb3838-82be-40b8-b159-dbfdb87803c5">14.1</ix:nonFraction> million in product rights and $<ix:nonFraction unitRef="usd" contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103" decimals="-4" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzEwOTk1MTE2MzEzODk_1b773546-3e7a-4e2d-b329-be6b984d6432">0.03</ix:nonFraction> million in goodwill related to the Sancuso acquisition.  These costs will be amortized over the remaining expected useful life of the associated patents.</span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzIwMDU_4afdf478-5d81-41c4-a77f-2680aa0c18cc" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.756%"><tr><td style="width:1.0%"></td><td style="width:65.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.296%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTpmMWRhZDk1ZGY1ODc0OTVmYTg1MWFlMTI0ZjY0YThjYS90YWJsZXJhbmdlOmYxZGFkOTVkZjU4NzQ5NWZhODUxYWUxMjRmNjRhOGNhXzItMi0xLTEtMzQzODQ_39f6c8a0-0fd0-473c-8ce0-106beedc1f67">5,067,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTpmMWRhZDk1ZGY1ODc0OTVmYTg1MWFlMTI0ZjY0YThjYS90YWJsZXJhbmdlOmYxZGFkOTVkZjU4NzQ5NWZhODUxYWUxMjRmNjRhOGNhXzItNC0xLTEtMzQzODQ_81934119-91dd-439e-8553-87961f187957">4,371,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.769%"><tr><td style="width:1.0%"></td><td style="width:72.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzEtMi0xLTEtMzQzODQ_0e53515b-190f-425b-bb72-32e90541994c">4,736,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzItMi0xLTEtMzQzODQ_04b1bdf3-6ebc-4947-8a3f-3621f15718b2">4,687,365</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzMtMi0xLTEtMzQzODQ_70055b73-cdce-4de0-babb-92ee5b45171b">4,652,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzQtMi0xLTEtMzQzODQ_fa8b3617-bd5a-41b7-bcfa-2fe4709b08ef">4,092,961</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzUtMi0xLTEtMzQzODQ_9cfba557-9afa-4672-b7e2-c59d4e5190a4">12,421,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzYtMi0xLTEtMzQzODQ_912db1ac-2dac-4597-ba27-12999d586816">30,590,678</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_211"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90ZXh0cmVnaW9uOjc3NjU0NjYwZmRhNDRmYTJhYzMwNGZkMjRkMmI4MWRjXzEyOA_eb041acb-dadc-4dbb-8e98-7bd625a08842" continuedAt="i155121b117274b97b7ea70e00f309622" escape="true">Other Current and Other Long-term Liabilities</ix:nonNumeric></span></div><ix:continuation id="i155121b117274b97b7ea70e00f309622"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90ZXh0cmVnaW9uOjc3NjU0NjYwZmRhNDRmYTJhYzMwNGZkMjRkMmI4MWRjXzEyOQ_b6d2f2b2-325a-42f3-9d80-6effbd58542c" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.378%"><tr><td style="width:1.0%"></td><td style="width:59.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:ProductSalesRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzItMi0xLTEtMzQzODQ_27dd1a06-25ec-4ba8-9c73-afe27a90bd7d">8,347,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:ProductSalesRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzItNC0xLTEtMzQzODQ_47c7dd26-ee07-4c2a-a340-43668ff97853">3,680,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzMtMi0xLTEtMzQzODQ_463dab6b-fe0a-41a7-b104-deff04e281a3">1,440,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzMtNC0xLTEtMzQzODQ_6abcd81e-7315-4576-97ed-89ff1092325e">1,340,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:AccruedLiabilitiesStockPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzQtMi0xLTEtMzQzODQ_c6f08ceb-d882-4179-a607-75091623dc39">2,226,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:AccruedLiabilitiesStockPayable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzQtNC0xLTEtMzQzODQ_0ada5b9d-4525-4e3b-b26a-5c83632e8767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzUtMi0xLTEtMzQzODQ_cccfb567-13ca-4481-a55b-9d2c3fdc15ba">3,006,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzUtNC0xLTEtMzQzODQ_e2768154-589f-409f-940e-0e04f634583b">2,685,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzctMi0xLTEtMzc5NDk_b727890f-237c-4de8-97df-93e5dffabcf2">614,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzctNC0xLTEtMzc5NDk_8adccee8-28f1-414d-a5f0-c433f1d7b437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:AccruedLiabilitiesInventoryPurchases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzctMi0xLTEtMzQzODQ_7e694194-ba93-448d-a28b-455668d78fe1">609,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:AccruedLiabilitiesInventoryPurchases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzctNC0xLTEtMzQzODQ_8e1bd4c1-0b04-43db-a761-d537049ad6c7">18,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzktMi0xLTEtMzQzODQ_3e9ad4ec-4e60-4daa-a4d8-08140f90cb1e">1,342,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzktNC0xLTEtMzQzODQ_ba78b7f7-4edd-41ac-9cbc-70a68ba6be87">943,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzEwLTItMS0xLTM0Mzg0_d12a9f08-d6bf-48d6-9de6-918214fef2c9">17,587,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzEwLTQtMS0xLTM0Mzg0_e299adf3-9f9f-4057-954e-e41d56b1376e">8,668,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90ZXh0cmVnaW9uOjc3NjU0NjYwZmRhNDRmYTJhYzMwNGZkMjRkMmI4MWRjXzEzMg_988f86e7-c424-48b7-8a6b-af4305bfed6a" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.897%"><tr><td style="width:1.0%"></td><td style="width:59.907%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.559%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzItMi0xLTEtMzQzODQ_aebe7246-f35d-4b89-9ee4-12bed522c15c">4,931,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzItNC0xLTEtMzQzODQ_8fffdead-baa7-4e19-9363-4a121c978161">3,830,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzMtMi0xLTEtMzQzODQ_f44a0d8e-1fe4-483a-898f-bed53eab315f">2,522,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzMtNC0xLTEtMzQzODQ_d2d315d8-d80c-4a4b-bbe7-a7749f4df014">3,433,962</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzQtMi0xLTEtMzQzODQ_6bb3bbe1-6850-42af-86d0-6e6f5abd7ed3">131,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzQtNC0xLTEtMzQzODQ_7f6868a5-8a6c-4e25-801f-a0333442036f">224,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzUtMi0xLTEtMzQzODQ_95297be3-c08e-4958-a482-da8846379568">7,585,019</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzUtNC0xLTEtMzQzODQ_38cda877-efbe-46ad-907f-83a76cf05a22">7,488,844</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_214"></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzM5ODE_d5ac46eb-ece6-4bc7-83e4-218ab615915c" continuedAt="i7ee3d60506984239aae086cedfaa78fe" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i7ee3d60506984239aae086cedfaa78fe" continuedAt="i642d0e29e05a420987d5c03e3d919624"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company entered into a Fifth Amendment to the Revolving Credit Note and Sixth Amendment (the "Sixth Amendment") to Revolving Credit Loan Agreement with Pinnacle Bank (the "Pinnacle Agreement"). The Sixth Amendment increased the principal amount by $<ix:nonFraction unitRef="usd" contextRef="i6e9d77deb33f4194ba7a35755cec59a1_I20221231" decimals="-6" name="cpix:LineOfCreditFacilityAdditionalBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzI4OQ_2a46dde0-e70e-44ea-8571-014f44db5ee3">5</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i6e9d77deb33f4194ba7a35755cec59a1_I20221231" decimals="-6" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzI5NQ_24424c00-3d64-4d1d-8c48-d74a202fae45">20</ix:nonFraction> million. On October 28, 2021, the Company entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement with Pinnacle Bank. Among other terms, the Fourth Amendment extended the maturity date to October 1, 2024.  The Pinnacle Agreement includes specific financial covenants including Debt Ratio and Tangible Capital Ratio.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company and Pinnacle Bank agreed to modify the financial covenants to align with the current use of the line of credit.  On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $<ix:nonFraction unitRef="usd" contextRef="iac3baa3852034481ab2a2c089e20758c_I20220929" decimals="0" name="cpix:DebtInstrumentCovenantUnrestrictedCashThreshold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzI3NDg3NzkwNzQwMTk_6a6f3bde-b8d1-47bd-8628-bf428ba3c767">8,500,000</ix:nonFraction>, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.  For the year ended December&#160;31, 2022, we were in compliance with the Funded Debt Ratio financial covenant. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company had $<ix:nonFraction unitRef="usd" contextRef="i7f310f91304f4cc89cb705d8722a8d08_I20221231" decimals="-5" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzY4Mw_d2fab109-498c-4ba8-ac2e-ffd53ca8238c">16.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i28084a381e4f4f1491853ea7f60c1025_I20211231" decimals="-5" name="us-gaap:LongTermLineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzEwOTk1MTE2MzE3NzU_f018d467-a9e7-4c4e-9921-2503a526a3da">15.0</ix:nonFraction> million in borrowings outstanding under the Pinnacle Agreement at December&#160;31, 2022 and  2021, respectively.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of <ix:nonFraction unitRef="number" contextRef="i4808a45eee974fbfbe990af48bc945ad_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzkxNw_4984ff15-0620-4427-a019-4951dcd1c5be">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i061a02db1e2b4e1792f9dfd792d617e4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzkyMw_e0593284-a0a1-4f7a-b609-20df3fa11cd0">2.75</ix:nonFraction>% above LIBOR with a minimum LIBOR of <ix:nonFraction unitRef="number" contextRef="ic015a17daf5344f9a4de26b8e32f3873_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzk2Mg_48f9a57c-95e1-405e-9e7d-b8fd87cacbc4">0.90</ix:nonFraction>% (representing an interest rate of <ix:nonFraction unitRef="number" contextRef="i755231ed00d14acf800c9c3404c31e20_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzk5OQ_75566fc8-be15-4168-ab40-c974aa942016">6.875</ix:nonFraction>% at December&#160;31, 2022).  In addition, a fee of <ix:nonFraction unitRef="number" contextRef="ib8724ef42665454e9a5d3f598e52ab38_D20170731-20170731" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzEwMzM_bb30fdf0-bcb2-4eac-a0d2-1d0c801932ad">0.25</ix:nonFraction>% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  In 2022, the LIBOR benchmark rate is expected to be discontinued. When the LIBOR rate is no longer available, the Pinnacle Agreement calls for a new Benchmark rate to be used to determine the interest rate for the Agreement.  It is expected that SOFR will become the replacement benchmark.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Borrowings under the line of credit are collateralized by substantially all of our assets. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ic5e93a72679646699ff0eec55311987d_D20200420-20200420" decimals="0" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzE2MDM_a5230a0d-ebc1-4dd7-af4e-5060257d7dc9">2,187,140</ix:nonFraction> pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP is administered by the U.S. Small Business Administration ("SBA").  The loan was scheduled to  mature April 14, 2022, and bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="icf6a2ed9c9c1455893589f101ba5b4cc_I20200420" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzE5Mzk_b4700785-9ae8-4b11-a7f2-98f5893f5733">1.0</ix:nonFraction>% per year, payable monthly. The loan could be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.  From the date of funding the Company has used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company has recorded the $<ix:nonFraction unitRef="usd" contextRef="ib78383e8396e49768661e5b1015fc86b_D20210101-20211231" decimals="0" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzI4ODU_701f2b74-ce93-45b7-a307-7b0c377eef89">2,187,140</ix:nonFraction> as a deferred income liability, which is included as a component of other current liabilities on the consolidated balance sheet as of December&#160;31, 2021. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i642d0e29e05a420987d5c03e3d919624" continuedAt="ie920e98f5c564e1cb444816e1eb0b5b9">Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. In October 2020, the Company submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to SBA for the SBA's review and approval. </ix:continuation></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie920e98f5c564e1cb444816e1eb0b5b9">On June 11, 2021, the Company received a notice from the SBA that the full amount of the loan was forgiven. The Company accounted for the forgiveness of the loan under IAS 20 and recorded the $<ix:nonFraction unitRef="usd" contextRef="ib78383e8396e49768661e5b1015fc86b_D20210101-20211231" decimals="0" name="cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzM5Mzc_14122d62-fd71-4948-9dfe-d4ba856c3a37">2,187,140</ix:nonFraction> as other income during the year ended December 31, 2021.</ix:continuation> </span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_217"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzU0MTU_50e8e697-7ec0-400e-b99f-e985cf4a74cf" continuedAt="i14ccfa20b1f1443d988711a8aa5ba717" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i14ccfa20b1f1443d988711a8aa5ba717"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Initial Public Offering</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810" name="us-gaap:SaleOfStockTransactionDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzYy_531ba6c5-60a6-4e74-bd36-16e4516163af">August&#160;10, 2009</ix:nonNumeric>, the Company completed its initial public offering of <ix:nonFraction unitRef="shares" contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzExOQ_df8e27cc-0fb7-4d1f-aa86-6069846ad242">5,000,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810" decimals="INF" name="cpix:StockIssuedDuringPeriodPricePerShareNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzE2MA_d31a83f8-0d30-412e-8949-3e8a66b045ec">17.00</ix:nonFraction> per share, raising gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810" decimals="-5" name="cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIwMQ_165e8d7f-a912-4017-8dfd-ad817730f8a7">85.0</ix:nonFraction> million. After deducting underwriting discounts of approximately $<ix:nonFraction unitRef="usd" contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810" decimals="-5" name="cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzI2Mg_55502961-0223-4808-8b0a-66f07c1bd99d">6.0</ix:nonFraction> million and offering costs incurred of approximately $<ix:nonFraction unitRef="usd" contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzMxMQ_d3c5ab0b-3b26-430f-a8ae-795447ad63b1">4.2</ix:nonFraction> million, the net proceeds to the Company were approximately $<ix:nonFraction unitRef="usd" contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810" decimals="-5" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzM2Nw_373bdd4c-72b1-40c6-924b-6820d1e46480">74.8</ix:nonFraction> million. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Preferred Stock</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzQyNw_479041e2-92c1-4894-ba5c-6508f3924f1f">20,000,000</ix:nonFraction>&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2022 and 2021, there was <ix:nonFraction unitRef="shares" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzcwOA_29855f1c-0369-499f-8ba4-a859bf204111"><ix:nonFraction unitRef="shares" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzcwOA_f6f57106-ae82-4362-8daa-60a229b18d30">no</ix:nonFraction></ix:nonFraction> preferred stock outstanding.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Common Stock</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1Xzc5OA_9e77c040-6e8f-4b56-bcba-aa02d4e39417">171,655</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzEwOTk1MTE2MzY5Nzc_056e4d57-6913-493f-9a03-1e95790256af">192,684</ix:nonFraction>  shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances.  There were no option exercise transactions during 2022 and  2021.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Share Repurchases</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has a share repurchase program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="i1061cd07c59c4fc190c499065ffea5e3_I20100531" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIwNDE_5d4e89d1-1fe5-4c0d-a906-c72ded2350e8">10</ix:nonFraction> million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act, as amended. In January 2019, the Company's Board of Directors established the current $<ix:nonFraction unitRef="usd" contextRef="i1061cd07c59c4fc190c499065ffea5e3_I20100531" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIyMDc_9bdde191-5ac8-40db-be3b-bc1e6831586d">10</ix:nonFraction> million repurchase program to replace the prior authorizations. The Company repurchased <ix:nonFraction unitRef="shares" contextRef="i3c8e554b334e4bf692425f706564fc4d_D20220101-20221231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIyOTA_1a7eed0e-a442-491f-aa29-0d7e5c6f81a4">367,793</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="ia90dbbcb1d5e494382b065f737613908_D20210101-20211231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIzMDE_63282362-f6d9-4cbe-ad1a-a826de339f60">438,359</ix:nonFraction> shares of common stock for approximately $<ix:nonFraction unitRef="usd" contextRef="i3c8e554b334e4bf692425f706564fc4d_D20220101-20221231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIzNTk_98ed8ac9-67d2-4601-8c95-730580dd1e93">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia90dbbcb1d5e494382b065f737613908_D20210101-20211231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIzNjM_2cc381fa-05e8-4d64-be69-22154c60519a">1.4</ix:nonFraction> million during the years ended December&#160;31, 2022 and 2021, respectively. There remains $<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzI0NDA_55dc105a-f5af-486b-93d0-f9d0ae5b3efe">3.8</ix:nonFraction> million available under the current repurchase program available for share repurchases at December&#160;31, 2022.</span></div></ix:continuation><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_220"></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90ZXh0cmVnaW9uOjRkYTI0ODdjYTQwNjRhYmI4ZDhiMzE2NzY5Yjg0ZTZhXzMzMg_b6453cfe-be3e-4000-9fe6-e392bf88547f" continuedAt="i2d059e7177d84c6f8ff8e351e932196d" escape="true">Earnings (Loss) Per Share </ix:nonNumeric></span></div><ix:continuation id="i2d059e7177d84c6f8ff8e351e932196d"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90ZXh0cmVnaW9uOjRkYTI0ODdjYTQwNjRhYmI4ZDhiMzE2NzY5Yjg0ZTZhXzMyOQ_3820e561-4752-4d3e-aa39-3187eb00fbbe" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"></td><td style="width:67.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.633%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzMtMi0xLTEtMzQzODQ_8e704678-0623-47f7-976a-9e504b124692">5,650,039</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzMtNC0xLTEtMzQzODQ_ff64fb6b-db67-4784-9fb6-67df26533f59">5,597,121</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzQtMi0xLTEtMzQzODQ_f67cb05b-98cd-4076-b7f8-abd264f3c575">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzQtNC0xLTEtMzQzODQ_4207b02a-8aee-429a-a0ab-c761f4d74561">1,994,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzUtMi0xLTEtMzQzODQ_20c34513-8d42-4ce0-a686-e966c84de141">5,650,039</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzUtNC0xLTEtMzQzODQ_4d7bfefe-9479-4f1e-9c6c-c287085bca14">3,602,799</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzYtMi0xLTEtMzQzODQ_b61ce7e9-df0d-44fb-98d4-26d6b618e9fc">79,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzYtNC0xLTEtMzQzODQ_9d29cd60-538e-4a3c-a017-88646f4ab240">95,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzctMi0xLTEtMzQzODQ_5049b4b1-e863-4a9a-b9af-fa0fb899c1a2">5,570,241</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzctNC0xLTEtMzQzODQ_0873b96f-570b-496f-97a2-b6620ba0e23c">3,507,587</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzktMi0xLTEtMzQzODQ_6a06b5c8-cbe1-48f9-b206-a2f0aa931ff9">14,563,592</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzktNC0xLTEtMzQzODQ_3d3efbef-7a12-4391-9370-ef2cdd85ac62">14,904,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzExLTItMS0xLTM0Mzg0_158e62d8-1a26-4891-8ed0-1713e4220dce">14,563,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzExLTQtMS0xLTM0Mzg0_f5df5ed5-bf9a-4c6b-b87e-1d9474280c28">14,904,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90ZXh0cmVnaW9uOjRkYTI0ODdjYTQwNjRhYmI4ZDhiMzE2NzY5Yjg0ZTZhXzMzMA_7a677ec6-f58f-43cc-96b2-97a05ec8069c" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:66.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpiYzU0NDhhZDI1MzQ0MWMyODlkNGJjYTg4NjZmYjQ0Ny90YWJsZXJhbmdlOmJjNTQ0OGFkMjUzNDQxYzI4OWQ0YmNhODg2NmZiNDQ3XzItMi0xLTEtMzQzODQ_62c0ee97-00cb-46e5-9282-a6e7b0c010c3">227,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpiYzU0NDhhZDI1MzQ0MWMyODlkNGJjYTg4NjZmYjQ0Ny90YWJsZXJhbmdlOmJjNTQ0OGFkMjUzNDQxYzI4OWQ0YmNhODg2NmZiNDQ3XzItNC0xLTEtMzQzODQ_66aa6a58-2025-477e-aaa4-efe34cb399bf">183,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_223"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2Mjc_5bb32a41-24ca-4551-a86c-d9c42bee2f2b" continuedAt="ic51d225dde9843fcbb29fd74d6586d9a" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="ic51d225dde9843fcbb29fd74d6586d9a" continuedAt="ic74c56a184c846e997c9b1a4bcb6ff6b"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2MjM_e8dde4a0-23fd-4ccc-871c-ead761f5bdc8" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"></td><td style="width:61.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzMtMi0xLTEtMzQzODQ_915f05e9-5bda-4fbf-9615-2c4bb434156e">16,164,754</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzMtNC0xLTEtMzQzODQ_d90af3d9-7dc1-42e7-99d1-718b0222cb51">16,817,070</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzQtMi0xLTEtMzQzODQ_7166ec7f-73df-45ca-a646-00b4c6d5b1c0">264,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzQtNC0xLTEtMzQzODQ_84a5f344-7567-470b-b174-826c3ffed0bb">222,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:DeferredTaxAssetOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzUtMi0xLTEtMzg2MDc_dce67d3a-c3b9-4828-aeff-ce983823789f">1,121,800</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:DeferredTaxAssetOperatingLeaseLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzUtNC0xLTEtMzg2MDc_e5f1fc46-d2b0-4212-bd95-e23707101781">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzYtMi0xLTEtMzg2MDc_2ef2ba7c-0f43-49d9-9d53-6baa2ece9f6a">866,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzYtNC0xLTEtMzg2MDc_8be81636-edb3-4e0d-885c-080d59d88949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzctMi0xLTEtMzg2MDc_43580677-a5da-4712-aaaa-7ae663b09912">1,481,455</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzctNC0xLTEtMzg2MDc_1d4bc2a3-02eb-4b3e-8e60-fcc5bd3cc352">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzUtMi0xLTEtMzQzODQ_0182e6ef-f91c-4c82-9010-3202de2f82be">145,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzUtNC0xLTEtMzQzODQ_ae863a18-b443-4c7a-b64a-ec7630efee5c">83,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzYtMi0xLTEtMzQzODQ_1d450590-dd1a-4002-8440-6b8960106796">654,148</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzYtNC0xLTEtMzQzODQ_c83e18e3-99b4-47b2-8e0c-798770e45f0d">457,723</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzctMi0xLTEtMzQzODQ_28cfa6c9-b28c-48ca-a820-bf3f660dab6a">217,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzctNC0xLTEtMzQzODQ_883bcdb8-25e6-43c1-a8d0-bb0219301b27">104,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:DeferredTaxAssetsDeferredCharges" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzgtMi0xLTEtMzQzODQ_ace9da83-fb03-4ec8-a74d-fc882cee35e9">1,156,150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:DeferredTaxAssetsDeferredCharges" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzgtNC0xLTEtMzQzODQ_e92f0fd9-fe6d-4f71-a037-5a8f62376fcc">1,303,664</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzktMi0xLTEtMzQzODQ_7168d7e9-53fb-405f-8719-7335ca4cd3de">635,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzktNC0xLTEtMzQzODQ_e9e6343e-61e9-484b-aa58-5835c0336e0f">834,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzEwLTItMS0xLTM0Mzg0_9d07038b-4be1-4afa-9d1e-74e65f53994a">22,708,719</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzEwLTQtMS0xLTM0Mzg0_a62466ec-a2b0-40f6-a71d-e7cf75cd0f0a">19,824,175</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE2LTItMS0xLTM4NjY1_7ebe5cdc-b36c-40e3-9077-df480cb39835">1,150,935</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE2LTQtMS0xLTM4NjY1_fa212276-7b07-42ad-a8be-ec43beacb26e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzEzLTItMS0xLTM0Mzg0_84a54e01-5faf-4ae5-889e-3fced0979441">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzEzLTQtMS0xLTM0Mzg0_de906b01-c3ab-45b9-834c-8f643c2b51c1">62,253</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:NetDeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE0LTItMS0xLTM0Mzg0_6cfd394e-fc6e-4e66-b643-a5b26ba917d6">21,557,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:NetDeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE0LTQtMS0xLTM0Mzg0_6e456ccb-0948-4f59-8f18-04a579a0970a">19,761,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE1LTItMS0xLTM0Mzg0_2fc804d5-200f-456c-a4b1-b262979402e2">21,557,784</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE1LTQtMS0xLTM0Mzg0_9a29dbd7-bb03-47dc-9b66-29cd6d5e18fd">19,761,922</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE2LTItMS0xLTM0Mzg0_8d26a4a3-73f9-468b-8738-090cade54c8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE2LTQtMS0xLTM0Mzg0_be022081-810c-452c-8971-0789bc189344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2Mjg_5c2c5b37-3857-4eb9-a0c2-135564926a27" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2022:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"></td><td style="width:61.377%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0027eb6bc44b4567a5351c10399f22e7_I20221231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzItMi0xLTEtMzQzODQ_fe4585ae-5096-43bf-b41f-f578d7abd673">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea0d070c6124183897a66bb2df920d4_I20211231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzItNC0xLTEtMzQzODQ_1458ccdd-be91-427e-91ae-e0ecd5710ab9">251,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024-2042</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e86908009643eebb68ac0e3a1ae95e_I20221231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzMtMi0xLTEtMzQzODQ_15413f0d-d491-441c-8118-10ca4a6efc6f">46,656,666</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d9d087686e4acaa131dcf7f56b02b5_I20211231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzMtNC0xLTEtMzQzODQ_c60a75dd-8fe5-43c5-bef1-1139115770d9">55,790,944</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66d5038d3ea5413287c0c60e6f8d6e13_I20221231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzYtMi0xLTEtMzQzODQ_2c97a8d0-c254-4321-84c0-93c927f655f8">6,405,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ffa57a973c45d89dc9e53e23854361_I20211231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzYtNC0xLTEtMzQzODQ_a359d6f6-0e6d-4fe3-85dd-bc749d197656">433,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08c5ee420b248ac902a128ef7d90e7a_I20221231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzgtMi0xLTEtMzQzODQ_079f3551-b67b-48a2-8b09-cc74bf057fd7">53,062,501</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4ecd0e4253e46d69b1840d128d714e3_I20211231" decimals="0" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzgtNC0xLTEtMzQzODQ_68f0e995-0137-45c4-925f-9f50344a7445">56,475,958</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ic74c56a184c846e997c9b1a4bcb6ff6b" continuedAt="id95212c1730c4468b899a9e9dfb421e9"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2MjU_39ccc5a6-13b8-47ee-b041-1a6c5e54972b" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) benefit includes the following components for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:64.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzMtMi0xLTEtMzQzODQ_f9b6f768-53ba-43da-a367-288fdab10c39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzMtNC0xLTEtMzQzODQ_540f6b6e-b08e-4784-a4fa-c3f7d300af6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzQtMi0xLTEtMzQzODQ_2f747be7-cf75-4fd6-bd61-39394ad6d4e1">68,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzQtNC0xLTEtMzQzODQ_fe4cc092-13f1-4fdd-8e37-6136836bdb49">34,891</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzUtMi0xLTEtMzQzODQ_d35bf5bb-494a-48c6-878e-0384ab61cf90">68,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzUtNC0xLTEtMzQzODQ_8b413d50-1f7d-483f-9bec-2a3688dc7fbf">34,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzgtMi0xLTEtMzQzODQ_578b6a4f-707a-43e1-81c2-8fe7a9a1e51a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzgtNC0xLTEtMzQzODQ_beb8fe17-86bd-4492-aa18-31992d0ca85c">61,678</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzktMi0xLTEtMzQzODQ_aaac097c-b498-41ea-875e-cb35764cd309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzktNC0xLTEtMzQzODQ_2f5b707f-c596-4624-a032-504eaad5f893">61,678</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax (expense) benefit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:DeferredOtherTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzEwLTItMS0xLTM0Mzg0_ecab8cb7-4fea-4070-84f3-fc7781314bc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:DeferredOtherTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzEwLTQtMS0xLTM0Mzg0_15a706d9-2ff8-4cf3-a75c-bea68cd27c47">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzExLTItMS0xLTM0Mzg0_625d78de-7e0c-4523-a58a-bee8f2f458fe">68,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzExLTQtMS0xLTM0Mzg0_9d9d1c12-f5c1-4191-ac69-912ff3bfb83a">34,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2MzA_5ddd9891-14fa-4280-a559-e551c83c66a5" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2022 and 2021 reconciles with the federal statutory tax rate as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:64.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzItMi0xLTEtMzQzODQ_e87aaacd-c52c-44e8-95bb-575391bf4822">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzItNC0xLTEtMzQzODQ_7e050f9c-b546-4453-b5e6-07a4d267dbd1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzMtMi0xLTEtMzQzODQ_fbb62d4a-df31-478e-a666-221b514e52e6">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzMtNC0xLTEtMzQzODQ_779026eb-1ec4-4f52-a720-700cd57f73fe">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzQtMi0xLTEtMzQzODQ_62327273-a20a-4d11-8014-bbbb3e1cb75c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzQtNC0xLTEtMzQzODQ_0f453276-f510-402e-be2c-eaab95ed9611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzUtMi0xLTEtMzQzODQ_17a5915e-1002-462a-8b73-e65824029baf">22</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzUtNC0xLTEtMzQzODQ_2d11d1c0-a649-4c34-96c8-4ef99848994f">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzYtMi0xLTEtMzQzODQ_55b6223b-dba6-4a39-b91b-f225d9341db4">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzYtNC0xLTEtMzQzODQ_548d2dd2-633a-4541-ae54-36ca71e7b80e">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzctMi0xLTEtMzQzODQ_98d1c9b3-e887-4ba8-8a30-b16affb7a514">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzctNC0xLTEtMzQzODQ_6a6ce6c3-8ccd-43e9-b4b9-97e07ee82cfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzgtMi0xLTEtMzQzODQ_1dd1b20e-5c71-4766-aba7-94ccd29b3388">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzgtNC0xLTEtMzQzODQ_d6ffa7ba-3605-49da-ae96-e16693b33560">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is not more likely than not that its net deferred tax assets will be realized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, the net deferred tax assets are fully offset with a valuation allowance as of the periods ended December&#160;31, 2022 and  2021.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:45pt;padding-right:45pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:45pt;padding-right:45pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:45pt;padding-right:45pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:45pt;padding-right:45pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:45pt;padding-right:45pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="id95212c1730c4468b899a9e9dfb421e9"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2MjA_d419bf69-a52a-44cf-a38a-7a8df8bd340f" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company has general business credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i81a18b4c882d437cb25a611496aa56a5_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzc3NQ_bed46fdd-b2b5-409b-ae32-b47e9897a7c9">1.5</ix:nonFraction>&#160;million.  These credit carryforwards will expire in years 2023 through 2042.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.596%"><tr><td style="width:1.0%"></td><td style="width:78.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54dfc16f99534c19b2867a069f58d483_I20221231" decimals="0" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTpiNmY3NGE3Zjk1NzU0MDRmYmRlOGJhZmIzYTVkYzhhMS90YWJsZXJhbmdlOmI2Zjc0YTdmOTU3NTQwNGZiZGU4YmFmYjNhNWRjOGExXzEtMi0xLTEtMzQzODQ_7c9080ec-a921-4ca1-8300-929e8c747488">200,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024-2042</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795293f449e54a6eb5e7aa63c13b396d_I20221231" decimals="0" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTpiNmY3NGE3Zjk1NzU0MDRmYmRlOGJhZmIzYTVkYzhhMS90YWJsZXJhbmdlOmI2Zjc0YTdmOTU3NTQwNGZiZGU4YmFmYjNhNWRjOGExXzItMi0xLTEtMzQzODQ_ba520d0e-213e-4813-829c-b1cae7127b92">1,319,161</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81a18b4c882d437cb25a611496aa56a5_I20221231" decimals="0" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTpiNmY3NGE3Zjk1NzU0MDRmYmRlOGJhZmIzYTVkYzhhMS90YWJsZXJhbmdlOmI2Zjc0YTdmOTU3NTQwNGZiZGU4YmFmYjNhNWRjOGExXzUtMi0xLTEtMzQzODQ_a36adbba-67d4-4914-91b8-b2f6ff6e178b">1,519,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is no longer subject to U.S. federal tax examinations for tax years before 2019, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2019.  Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2019 remain subject to examination and adjustment.  During 2012, the 2009 federal tax return was examined by the Internal Revenue Service with no significant findings or adjustments.  The Company has no unrecognized tax benefits at December 31, 2022 and 2021.</span></div></ix:continuation><div id="i3e36cfc56e1a4275a52b7d560014d176_226"></div><div style="margin-top:8pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzUwMDc_5f3d14dd-908c-4a5a-bfca-18e5267b42c9" continuedAt="i3c41cea886264ddfaab68232595deed3" escape="true">Stock-Based Compensation Plans</ix:nonNumeric></span></div><ix:continuation id="i3c41cea886264ddfaab68232595deed3" continuedAt="ibd0c6adcc47b4f27873c13923425c59b"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under <ix:nonFraction unitRef="plan" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="INF" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzI3NDg3NzkwNzQ1MDU_19b49766-cfd5-42ae-86a2-49fede6aff34">two</ix:nonFraction> equity compensation plans. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#8217; Incentive Plan (the "Directors&#8217; Plan"), which were approved by shareholders, superseded the 1999 Stock Option Plan.  Both plans are available for future grants of equity compensation awards to employees, consultants and directors.  The 2007 Plan and the Directors&#8217; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved <ix:nonFraction unitRef="shares" contextRef="ibe55a7e9ab974665911b58f2cf2ab1d1_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzczMg_ccc7ef22-aa9e-4e09-b75e-19970b00c42c">2.4</ix:nonFraction> million shares of common stock for issuance under the 2007 Plan and <ix:nonFraction unitRef="shares" contextRef="i8296dfa01cf5426fa8af917b505e162d_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3Xzc5NQ_c9ac0f7f-785b-4926-a9d0-9cd49a7d4769">250,000</ix:nonFraction> shares for issuance under the Directors&#8217; Plan.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is generally <ix:nonFraction unitRef="number" contextRef="i13b23c2311f046879e4fd6dafe94a991_D20220101-20221231" decimals="INF" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3Xzg5NA_7e109521-c430-4ea3-80c8-d7bd98c3c94b">100</ix:nonFraction>% of the fair market value of the underlying common stock on the grant date. The maximum contractual term of stock options is <ix:nonNumeric contextRef="i2d9c25b92eff4d35973caf424807a5d5_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEwMjE_538b3f65-9919-426a-b322-4e9b22a1987d">ten years</ix:nonNumeric> from the date of grant, except for incentive stock options granted to <ix:nonFraction unitRef="number" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" name="cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEwOTQ_0285d10c-7f69-431b-a443-ca02f22c0c03">10</ix:nonFraction>% shareholders, which is <ix:nonNumeric contextRef="i070ea86904974ad18860cbc73c3202cc_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzExMjA_d056c866-e660-4ccf-be83-9fb881783c0e">five years</ix:nonNumeric>.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant. Restricted stock issued to directors vests on the <ix:nonNumeric contextRef="i955de8aa181944039f7145e41a74c991_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEzOTQ_22088b4b-19ef-48ed-9d04-ecf0b11b63a8">one year</ix:nonNumeric> anniversary of the date of grant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzUwMDQ_5402c37a-ecab-4b0a-99bd-2c95d503f18d" continuedAt="i45de4990546b48c3ac2ad500b56ef148" escape="true">Stock compensation expense consisted of the following for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><ix:continuation id="i45de4990546b48c3ac2ad500b56ef148"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:64.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09447f6af13b4f27a9f24d32a75cda9b_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzItMi0xLTEtMzQzODQ_3807f16d-8f8e-4b4c-a086-2463aae85d2a">449,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7684a832b0134542abe7faecbea0573e_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzItNC0xLTEtMzQzODQ_6656ee5b-669a-4709-b9d3-2044fc4cddde">730,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - nonemployees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66c58bd8eaaf40cd8f6a0c93cdb60c2a_D20220101-20221231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzMtMi0xLTEtMzQzODQ_d5e14e21-c2c8-4a21-bd1e-f12e7ec8afdd">1,964</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d9566f966de4bd4968bb2d10e0af05b_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzMtNC0xLTEtMzQzODQ_37513f21-2edb-4741-a513-f1e303ad8630">11,455</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e34c07ebd764d17a96ec1d0f497c811_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzQtMi0xLTEtMzQzODQ_02f5ae8e-4050-4261-ae38-677a0745976a">447,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c60f8924f748d98ade2ba26f585e11_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzQtNC0xLTEtMzQzODQ_cf849878-73d6-4328-b819-e939a2192528">741,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i214555a81d9942d3a95516724918bd8d_I20181231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzE2OTc_b61b69a1-4ffd-46fd-a86e-5d56914455bf">0.8</ix:nonFraction> million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i6c780a0c3e87440c8eb1928bb0ce5f86_D20180101-20181231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzE4MzY_d8ebcf59-38e3-41ba-9c36-16e454ac10ab">1.81</ix:nonNumeric> years. This amount relates primarily to unrecognized compensation cost for employee restricted stock and stock options awards.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="ibd0c6adcc47b4f27873c13923425c59b" continuedAt="i369b282514854e2aa2572f637a434790"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzIwMDA_b55a804b-bfdf-4e9b-8cdd-5173abb96bc2">178,950</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEwOTk1MTE2MzI3OTM_81fd14ad-0e4a-4d74-9b25-eaae20a9beb1">186,900</ix:nonFraction> incentive stock options during 2022 and 2021, respectively, which vest in <ix:nonNumeric contextRef="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzIwNTI_901d1e37-f15f-4e06-9c9e-6a6621c4eb47">four years</ix:nonNumeric>.  There were no options exercised during 2022 and 2021.  As such, there was no intrinsic value of options or weighted-average fair value of options exercised for the periods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Stock Options</span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzU0OTc1NTgyMjAwMw_3cd25138-9dc1-451f-a190-b2a5968c8040" continuedAt="i91a7a13e0a0f4cebbc75fe2471197720" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incentive stock options activity was as follows:</span></div><div style="margin-bottom:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.858%"><tr><td style="width:1.0%"></td><td style="width:40.597%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.907%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.351%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of option shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average remaining contractual term</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91bab75ee1804a1097fbe90085dc4f12_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzItMi0xLTEtNDI0Njk_32bde3d9-6bfa-41a1-9f62-972dd4ccd935">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i91bab75ee1804a1097fbe90085dc4f12_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzItNC0xLTEtNDI0Njk_7c62a89f-2742-49f2-a599-01b8f014794d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzMtMi0xLTEtNDI0Njk_7694572e-b761-4cb6-a683-b6fbd6792807">186,900</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzMtNC0xLTEtNDI0Njk_fef05afc-9953-4cd3-9f55-b622dc01d10e">3.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzQtMi0xLTEtNDI0Njk_b0ea1569-a3ee-4e3d-be92-9054a3764172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzQtNC0xLTEtNDI0Njk_21b50c7b-343d-4e0a-9e81-172f57d78900">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option shares forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzUtMi0xLTEtNDI0Njk_9108beed-d466-4c63-8b42-4285bccd1e1b">16,300</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzUtNC0xLTEtNDI0Njk_20562ba6-9069-4993-87d4-ee025cdb217f">3.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b943054825b4193b3cf6fbcea5877d1_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzYtMi0xLTEtNDI0Njk_c262062c-45a5-4fb5-80d0-112cf5d55b8b">170,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b943054825b4193b3cf6fbcea5877d1_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzYtNC0xLTEtNDI0Njk_56ea6b53-264d-4d1f-b035-f5c453eed2e9">3.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzctMi0xLTEtNDI0Njk_72e218a4-ef5c-41ac-8e11-7cbcdae9f6af">178,950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzctNC0xLTEtNDI0Njk_62202713-f0c1-45df-bc78-333df381657a">2.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzgtMi0xLTEtNDI0Njk_c7bc2b65-e596-4894-ac34-c578f93a5903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzgtNC0xLTEtNDI0Njk_019f3616-f5a1-4d8f-b344-a7b879f1e2b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option shares forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzktMi0xLTEtNDI0Njk_185f6aba-7d71-4d09-bddc-96cb397e1de6">29,900</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzktNC0xLTEtNDI0Njk_2bfc046f-ff6f-4b7b-a764-9e9222d57c8b">2.98</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idfea5a17cdad49b5b643bd1bf2db9833_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzEwLTItMS0xLTQyNDY5_6a8f4954-69f5-47c5-ab5d-2e5ee3ad0999">319,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idfea5a17cdad49b5b643bd1bf2db9833_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzEwLTQtMS0xLTQyNDY5_512d66bf-5ee6-458b-a616-0a9ecaa4007f">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzEwLTYtMS0xLTQyNjQ4_519fc1e8-7b3b-46ff-abf2-220468c855c5">6.15</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The weighted-average grant-date fair value of options granted during  the years 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEwOTk1MTE2MzU1OTk_6d57bfe7-46e2-4f05-959d-34b205ce47d3">1.29</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEwOTk1MTE2MzU2MDc_2dc9ac7c-4da6-4e15-bc16-27f73c95d5a8">1.10</ix:nonFraction>, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is calculated using the Black-Scholes (&#8220;Black-Scholes-Merton&#8221;, or &#8220;BSM&#8221;) option-pricing model on the date of grant. Since 2012, the Company had been issuing RSA&#8217;s (Restricted Share Awards) where the grant date Fair Value (&#8220;FV&#8221;) equaled the closing share price.  The ISO&#8217;s required a BSM valuation to approximate FV.  The following inputs were used in the creation of the valuation.   </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We estimate volatility in accordance with SAB No. 107, as amended by SAB No. 110. We have been publicly traded since August 2009, so we have sufficient years of trading history and volatility to appropriately evaluate this component of the BSM model.  As such, we are using our own historical volatility to value stock options.  We have noted no conditions that would indicate the historical volatility would not be an indicator of future volatility, as such we are using historical volatility over the same period as the expected term of the awards (<ix:nonNumeric contextRef="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzMzNzQ_1bded0db-7b6f-4843-83f8-2b60195a2c61">7</ix:nonNumeric> years) back to 2015 and believe it to be sufficient. Calculated volatility for the grants issued in 2022 ranges from <ix:nonFraction unitRef="number" contextRef="i1b65c4b8b6aa447481044537155a6d9a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzM0ODg_e96dac89-5190-4e79-bfe6-101788bba8c5">44</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if838a7aa53664232926aca1c69b23238_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzM0OTQ_cf0d0e1b-c821-4ace-8213-25fe16722ec9">45</ix:nonFraction>%.  Our average volatility over the life of stock being public is <ix:nonFraction unitRef="number" contextRef="i1b65c4b8b6aa447481044537155a6d9a_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzM1NjE_43c0059b-fe7b-4496-9012-2c76342bb917">42</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if838a7aa53664232926aca1c69b23238_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzM1Njg_cdcee96a-8b90-4676-82b4-f492ec5411b8">45</ix:nonFraction>% over the last 6 months.  Based on the similar amounts, we believe our volatility estimate for the ISO&#8217;s are appropriate.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We estimate the expected life of employee share options based on the simplified method allowed by SAB No. 107, as amended by SAB No. 110. Under this approach, the expected term is presumed to be the average between the weighted-average vesting period and the contractual term.  The ISO&#8217;s have a <ix:nonNumeric contextRef="i2d9c25b92eff4d35973caf424807a5d5_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzUwMTA_bc2e7751-59c6-4327-9acf-c31909ddb11f">10-year</ix:nonNumeric> contractual term and the vesting period is <ix:nonNumeric contextRef="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzQwNTQ_a0658c65-0c0e-45e4-960e-8a2ce4bc1aa9">4</ix:nonNumeric> years.  This results in a calculated expected term of <ix:nonNumeric contextRef="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzQxMDU_efd4878d-3235-4fa7-8364-d9db23f10916">7</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i369b282514854e2aa2572f637a434790"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Risk Free rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The risk-free interest rate is based on the U.S. Treasury Note, on the date of grant with a term equal to the corresponding option&#8217;s expected term. So, in this case, we are using the 7 year treasury note as of the date of grant, which ranges from <ix:nonFraction unitRef="number" contextRef="i1b65c4b8b6aa447481044537155a6d9a_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzQzNzM_2d5a7afd-c79d-4a4b-9910-6252fdde0424">2.22</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if838a7aa53664232926aca1c69b23238_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzQzODA_69981b9c-5226-48f2-9df2-44a461130f29">3.92</ix:nonFraction>% at the date of the grants.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We have never declared or paid any cash dividends and there is currently no expected cash dividend payments as of the date of this grant. As such, dividend yield is <ix:nonFraction unitRef="usd" contextRef="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzQ1OTI_16fa1d38-ddeb-4655-88e8-80559f63709f">zero</ix:nonFraction>. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><ix:continuation id="i91a7a13e0a0f4cebbc75fe2471197720"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.192%"><tr><td style="width:1.0%"></td><td style="width:50.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.733%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2a4df839364457ca572567fd0e125dc_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzItMi0xLTEtMzQzODQ_16c79e75-ff71-4c59-958d-1ff54dff452e">779,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2a4df839364457ca572567fd0e125dc_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzItNC0xLTEtMzQzODQ_fa0ea2d4-0117-4abf-a227-d7d1f3ca5992">5.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzMtMi0xLTEtMzQzODQ_3a50ed90-36e9-4e73-8d8f-57a0a0c5dd0d">36,850</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzMtNC0xLTEtMzQzODQ_2d0f863e-07fe-4171-9640-e8f09788247a">3.21</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzQtMi0xLTEtMzQzODQ_e71fd994-fd7a-4f3d-9028-e20d7a07407c">192,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzQtNC0xLTEtMzQzODQ_248c533a-f5df-4356-95e7-8fbf766c56d7">6.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzUtMi0xLTEtMzQzODQ_847c841c-12c5-414a-83bc-5c54fd325fb6">55,400</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzUtNC0xLTEtMzQzODQ_9fc52311-ef4f-4aea-8a05-1b9ca904584d">5.39</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i430e1a4cd7514fe59de28ed3a49bbab5_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzYtMi0xLTEtMzQzODQ_89d54dbc-3c63-4366-9531-6c35722ea49c">568,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i430e1a4cd7514fe59de28ed3a49bbab5_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzYtNC0xLTEtMzQzODQ_c3f2125a-f3f4-462a-85ff-8436a1c64459">5.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzctMi0xLTEtMzQzODQ_656a3f46-4773-4fea-8a36-12d0d95ecd03">65,225</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzctNC0xLTEtMzQzODQ_6a9d4e2f-c72f-4a77-9e8b-b74df99e13c1">2.59</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzgtMi0xLTEtMzQzODQ_0e47d727-1d0f-4d14-af21-f507e6e21d4f">171,655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzgtNC0xLTEtMzQzODQ_24f3c9b7-2b98-4eb9-8355-929dfdc9bcb6">6.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzktMi0xLTEtMzQzODQ_0b7d7e9d-3708-4812-b382-f604fd3ac06d">66,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzktNC0xLTEtMzQzODQ_eb82cc9f-05fe-468e-bf25-58002fe01cd3">4.67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i872072012a784d598051e80fd8fb06ed_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzEwLTItMS0xLTM0Mzg0_dd9bcfdf-65f1-4e61-948b-860b20d0a7e1">395,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i872072012a784d598051e80fd8fb06ed_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzEwLTQtMS0xLTM0Mzg0_6c36ac0c-b96f-4a2a-a5fb-7db619115f81">4.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:16pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock granted was based on the closing market price of the Company&#8217;s common stock on the date of grant.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest.  Once vested they are included in the basic weighted shares outstanding computation.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_229"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEzMzA_056c4c8e-cbe4-41e9-aa5d-0ec901fead27" continuedAt="ia5d8a93ba2474224894d5e3dd3094196" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="ia5d8a93ba2474224894d5e3dd3094196"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzI5OA_cd0d861c-f0c8-46af-8a95-78a1e9de7b16">21</ix:nonNumeric>, having been employed by the Company for at least <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzM1MQ_00f1fe9e-0744-4d09-aa3e-a7b9d922a3e7">six months</ix:nonNumeric>. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2022 and 2021, the Company contributed approximately $<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzY3OA_81bc1796-3e1f-45e5-a084-fc818da45ff8">60,000</ix:nonFraction> and <ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="-3" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEwOTk1MTE2MjkxMzU_f30f0e84-d02f-4287-b5b4-422d2f5df564">50,000</ix:nonFraction>, respectively, in each year to the Plan as an employer match of participant contributions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheets, was $<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="-5" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEwMzg_6debcf29-56e7-4612-b6da-f5b6f9941d64">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="-5" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEwNDU_aa37b187-38c8-46eb-a351-e4c9641d784e">3.4</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.  The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEyOTE_41f0ab71-cf80-4a47-ba5f-327bb44e834c">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="-5" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEyOTg_6b676918-072d-4ec3-86a7-ad4d48efbe8a">3.2</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_232"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzQxODE_4c545014-df85-4a2d-baea-d585741a500e" continuedAt="i477311d09e604a7f84ff0ccda2e63583" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i477311d09e604a7f84ff0ccda2e63583" continuedAt="i501395ec9e414b34868b5cd473e2314b"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i554be9ce2c1b41b4a99da09551040eaf_I20211115" decimals="0" name="cpix:LesseeOperatingLeaseLeasedArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzM4OA_a9cf372e-5a79-4330-a7b0-db366286d8a9">16,903</ix:nonFraction> rentable square feet of space at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise serves as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (<ix:nonNumeric contextRef="i554be9ce2c1b41b4a99da09551040eaf_I20211115" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzY2MA_fab39dee-eb1f-47b8-ad84-647961b51e78">157</ix:nonNumeric>) months, with <ix:nonFraction unitRef="renewalterm" contextRef="ic57bcfd058014d5d98c77360f419b471_I20211115" decimals="INF" name="cpix:LesseeOperatingLeaseNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzY3Nw_46c9e87d-b813-46cf-9a72-7a7a3f087c7d">two</ix:nonFraction> consecutive options to renew for a period of <ix:nonNumeric contextRef="ic57bcfd058014d5d98c77360f419b471_I20211115" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzcyNQ_fda85d93-3645-4cf7-bf1e-f10ebba06f04">five years</ix:nonNumeric> each, with the commencement date of October 25, 2022.  This lease currently expires in November 2035.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for paying rent to the Landlord under the Lease beginning three months after the Commencement Date. The Company pays a base rent of $<ix:nonFraction unitRef="usdPerSqft" contextRef="i554be9ce2c1b41b4a99da09551040eaf_I20211115" decimals="2" name="cpix:LesseeOperatingLeaseBaseRent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzExMjY_c96b088c-be17-4feb-a414-6dd34e05f869">33.06</ix:nonFraction> per square foot of rentable space with a gradual rental rate increase of <ix:nonFraction unitRef="number" contextRef="ib2fa7c2f4e86401a88e3022cb2d1309b_I20211115" decimals="3" name="cpix:LesseeOperatingLeaseRentIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzEyMDI_71f24c20-92e2-4e6d-8f2d-b60c70586017">2.5</ix:nonFraction>% for each year period thereafter of the prior year's base rental. In addition to the monthly base rent, the Company is responsible for its percentage share of the operating expenses of the Building. The Lease also provides for a tenant improvement allowance for the space.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the operating leases also include the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="i5a4d2edd7a324a55a81eb502f58e0069_I20221231" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzU0OTc1NTgxOTc1OA_67ff1778-c604-4dde-882a-1a9bd72fa5ea">14,200</ix:nonFraction> square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  The research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzQxNzg_81d34608-3a7d-4bc3-a73e-f52847dce121" continuedAt="i383a6a6e9f8640c49499587fdde02ca7" escape="true">Rent expense and sublease income  as follows for the years ended December 31:</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><ix:continuation id="i383a6a6e9f8640c49499587fdde02ca7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"></td><td style="width:64.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.567%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTpmODAzMTJjNDhkZWM0OTY3YWQzNjliZDkwZmM0MjNiNC90YWJsZXJhbmdlOmY4MDMxMmM0OGRlYzQ5NjdhZDM2OWJkOTBmYzQyM2I0XzItMi0xLTEtMzQzODQ_cccca164-537a-4310-9f49-84ff127fd1c1">1,159,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTpmODAzMTJjNDhkZWM0OTY3YWQzNjliZDkwZmM0MjNiNC90YWJsZXJhbmdlOmY4MDMxMmM0OGRlYzQ5NjdhZDM2OWJkOTBmYzQyM2I0XzItNC0xLTEtMzQzODQ_58aae358-d391-4e73-bdb5-92b980442c23">1,209,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTpmODAzMTJjNDhkZWM0OTY3YWQzNjliZDkwZmM0MjNiNC90YWJsZXJhbmdlOmY4MDMxMmM0OGRlYzQ5NjdhZDM2OWJkOTBmYzQyM2I0XzQtMi0xLTEtMzQzODQ_2e1bf8d3-092d-49cf-aa73-b7330fce4cb1">529,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTpmODAzMTJjNDhkZWM0OTY3YWQzNjliZDkwZmM0MjNiNC90YWJsZXJhbmdlOmY4MDMxMmM0OGRlYzQ5NjdhZDM2OWJkOTBmYzQyM2I0XzQtNC0xLTEtMzQzODQ_2dbb5645-8658-49f9-a6dd-ab22fdd7e45f">699,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019 and October 25, 2022. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term for the Broadwest lease is <ix:nonNumeric contextRef="i48b2fbaeed6a477c8536c9109ab9bde5_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzM1NzQ_4cc4d1f3-82d3-4832-8c6e-93901092508c">12.7</ix:nonNumeric> years and for the CET lease is <ix:nonNumeric contextRef="iffad826a3e6c41bd89cf0a3c062b03ad_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzEwOTk1MTE2MzI4MDQ_c724cf49-ab6a-4a9c-8391-0606e5eab0fe">0.1</ix:nonNumeric> years. The weighted-average incremental borrowing rate used to discount the present value of the remaining CPI lease payments is <ix:nonFraction unitRef="number" contextRef="i48b2fbaeed6a477c8536c9109ab9bde5_I20221231" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzEwOTk1MTE2MzI3MzU_2c937a42-7eda-4a67-93da-9f7d990fdbda">9.28</ix:nonFraction>% and remaining CET lease payments is <ix:nonFraction unitRef="number" contextRef="iffad826a3e6c41bd89cf0a3c062b03ad_I20221231" decimals="INF" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzM3MDU_84d96882-eef0-4146-93fb-6a880baa4840">7.42</ix:nonFraction>%.</span></div></ix:continuation><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i501395ec9e414b34868b5cd473e2314b"><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzQxNzk_2a905982-0d8a-4913-bfa9-c03143f26de1" escape="true"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company recorded the following on the Consolidated Balance Sheet:</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo1NWI3M2NiZjc1MTQ0YzZiYTQ4OWRjMzM4MmNiNmQxZS90YWJsZXJhbmdlOjU1YjczY2JmNzUxNDRjNmJhNDg5ZGMzMzgyY2I2ZDFlXzEtMi0xLTEtMzQzODQ_b419299c-6b3b-4f73-9ccb-8e7ee43bc2ac">5,218,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo1NWI3M2NiZjc1MTQ0YzZiYTQ4OWRjMzM4MmNiNmQxZS90YWJsZXJhbmdlOjU1YjczY2JmNzUxNDRjNmJhNDg5ZGMzMzgyY2I2ZDFlXzEtNC0xLTEtMzQzODQ_3f1fa727-82d8-4bd9-aefd-3a0bc71aa765">1,024,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzEtMi0xLTEtMzQzODQ_f25a2a7a-70df-430e-bb9a-f447d062162e">172,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzEtNC0xLTEtMzQzODQ_41d82ab1-f3f3-4cf8-83f1-af6c07b14ace">969,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzItMi0xLTEtMzQzODQ_438cf634-b7ab-438e-a5e4-493ee1daa023">4,586,301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzItNC0xLTEtMzQzODQ_98ecc334-2da2-4b8c-8c97-30858d19bc85">90,016</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="cpix:LeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzMtMi0xLTEtMzQzODQ_6980412e-a3e7-4625-a006-e9a1d4c2fa08">4,759,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0531c6598004c5d9158b8763683f643_I20211231" decimals="0" name="cpix:LeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzMtNC0xLTEtMzQzODQ_125aa044-3921-463d-bfd6-ee02577388f9">1,059,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzM5NTA_84324d9c-2ea5-4105-9d08-df0ea793e3c8">0.1</ix:nonFraction> million and will be paid through the leases ending in April 2023. <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzQxODM_aa133497-dbe7-4611-9ea9-57cadb40f843" continuedAt="i878971487ec74aaa93ad84c344257e42" escape="true">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><ix:continuation id="i878971487ec74aaa93ad84c344257e42"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.132%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at December&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzEtMi0xLTEtMzc3OTg_0d2df6c6-4008-4291-bc10-8d233949ee01">607,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzItMi0xLTEtMzc3OTg_1accef55-c7e2-4a0f-aaad-dff71a68ae81">575,209</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzMtMi0xLTEtMzc3OTg_781ddb4a-5213-4f29-abf4-12a92d6c7ebf">539,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzEtMi0xLTEtMzQzODQ_93b0b8c8-1e46-4e36-b348-5065fb31b339">604,254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzItMi0xLTEtMzQzODQ_0370f165-c13c-4943-b9fe-e17cc494d584">619,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzMtMi0xLTEtMzQzODQ_12975783-56e6-47c8-a276-c741ba43f95d">5,482,220</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzctMi0xLTEtMzc3OTg_224cb619-67dd-4170-9451-d18eabe2ebcf">8,427,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzQtMi0xLTEtMzQzODQ_b770c709-6d99-44d9-b1bf-6d682b6ad15f">3,668,234</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzUtMi0xLTEtMzQzODQ_d11c21e4-b2dc-4d0e-a75e-cf94db42b7a8">4,759,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_235"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(16)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90ZXh0cmVnaW9uOmNlNGU1YTc5MWFhMDQyMmQ5NDExOTlmZTI5ODM3NWQ4XzkwMw_1b6a8ba4-076a-4b21-8c64-b6c9ce41c2c3" continuedAt="i13c6a3f6d9264ef5be917adfa17e5033" escape="true">Market Concentrations</ix:nonNumeric></span></div><ix:continuation id="i13c6a3f6d9264ef5be917adfa17e5033"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#8217;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90ZXh0cmVnaW9uOmNlNGU1YTc5MWFhMDQyMmQ5NDExOTlmZTI5ODM3NWQ4XzkwNQ_1a0d4329-8bf6-4993-80a2-6437feb22a60" continuedAt="i9eb35ae790a34ff0a6b4ee81d96e1fbb" escape="true">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31: </ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="i9eb35ae790a34ff0a6b4ee81d96e1fbb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.538%"><tr><td style="width:1.0%"></td><td style="width:49.941%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.819%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8047e420d87647ca865218062adc1b3c_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzItMi0xLTEtMzQzODQ_56799a9a-f6ea-47e2-8dbb-de5b372f6e36">29</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb1ed446076641e2b06e8f65764e9641_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzItNC0xLTEtMzQzODQ_fcdbae52-8d55-42da-94ea-416dd3c6fdc9">27</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie513e297486b4dc29fca145454075e01_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzMtMi0xLTEtMzQzODQ_f9ab68d6-b706-49fa-a047-e1e0fd745d10">24</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0510690b6b854b9d8843a2b97df3ce27_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzMtNC0xLTEtMzQzODQ_e5a7bbdc-966a-4449-9e0f-e67fc3216134">24</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i40f47c6c3c2345c982dcd1e267fd6145_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzQtMi0xLTEtMzQzODQ_fdf9df26-d7e1-44e0-901c-43a674b47326">22</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaff5c56f78a34c10b47d66d78992346f_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzQtNC0xLTEtMzQzODQ_dca2fe03-2d42-466a-8a75-1266008c9008">20</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was <ix:nonFraction unitRef="number" contextRef="i42772db945f14e0d885bd05151e93291_D20220101-20221231" decimals="4" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90ZXh0cmVnaW9uOmNlNGU1YTc5MWFhMDQyMmQ5NDExOTlmZTI5ODM3NWQ4Xzg2Nw_e9e71fc8-a87d-4a77-8fb8-e9575dbfc8b4">51.77</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i3990e4402eb64fb980a6bad3eb7430b8_D20210101-20211231" decimals="4" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90ZXh0cmVnaW9uOmNlNGU1YTc5MWFhMDQyMmQ5NDExOTlmZTI5ODM3NWQ4Xzg3NA_fed94039-1c32-4d8e-b57c-c0a45fc2d537">51.1</ix:nonFraction>% at December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div id="i3e36cfc56e1a4275a52b7d560014d176_238"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:ManufacturingAndSupplyAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzgvZnJhZzo2ZTc0NWVmNDBmNjg0MGIzYWZjM2Y4MzVkMWViODI3YS90ZXh0cmVnaW9uOjZlNzQ1ZWY0MGY2ODQwYjNhZmMzZjgzNWQxZWI4MjdhXzYzOQ_6a938ac8-27d5-4526-a487-cd260b140731" continuedAt="i164d6210952a4d889f2bd2370212b523" escape="true">Manufacturing and Supply Agreements</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i164d6210952a4d889f2bd2370212b523">The Company utilizes <ix:nonFraction unitRef="supplier" contextRef="ic40eb7705a474e4fa7d98cfa3a5cb554_I20221231" decimals="INF" name="cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzgvZnJhZzo2ZTc0NWVmNDBmNjg0MGIzYWZjM2Y4MzVkMWViODI3YS90ZXh0cmVnaW9uOjZlNzQ1ZWY0MGY2ODQwYjNhZmMzZjgzNWQxZWI4MjdhXzY3_6e9543d6-0c91-4bcb-9c54-75ab58e21d66">one</ix:nonFraction> or <ix:nonFraction unitRef="supplier" contextRef="ie088610f3d64485c98806a39268009ee_I20221231" decimals="INF" name="cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzgvZnJhZzo2ZTc0NWVmNDBmNjg0MGIzYWZjM2Y4MzVkMWViODI3YS90ZXh0cmVnaW9uOjZlNzQ1ZWY0MGY2ODQwYjNhZmMzZjgzNWQxZWI4MjdhXzcz_40fbbfbb-d4ef-49ab-826f-d5fce106328e">two</ix:nonFraction> primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms.  A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.</ix:continuation></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_241"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:EmploymentAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDEvZnJhZzpjZjY2ZGYxMTAzMmE0ZjRjOGU3ZTE2MjNmZTEzMDkxZC90ZXh0cmVnaW9uOmNmNjZkZjExMDMyYTRmNGM4ZTdlMTYyM2ZlMTMwOTFkXzMzOA_9ad5acc0-6a12-4d89-8826-eb06ca897783" continuedAt="i77e948cc331c4dd992492412a3dc4175" escape="true">Employment Agreements</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i77e948cc331c4dd992492412a3dc4175">The Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock and incentive stock option agreement.</ix:continuation></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_244"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(19)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDQvZnJhZzo0Y2E1ODA3YWFkMGM0NDFjYTg5ZDNkNzQ1MDk4NTkzNi90ZXh0cmVnaW9uOjRjYTU4MDdhYWQwYzQ0MWNhODlkM2Q3NDUwOTg1OTM2XzMwNjg_9c1fe4f2-ccf9-48aa-ac84-48d617ef892b" continuedAt="i2f0a16ddc2fc4c159b13973e29c5d46b" escape="true">Discontinued Operations</ix:nonNumeric></span></div><ix:continuation id="i2f0a16ddc2fc4c159b13973e29c5d46b"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2016, Cumberland entered into an agreement with Clinigen Group Plc ("Clinigen") for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  Ethyol and Totect are collectively referred to herein as the "Products."</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, Cumberland felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#8220;the Products&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $<ix:nonFraction unitRef="usd" contextRef="i478ad941e6444190835fbd70e6a0fda2_D20200101-20201231" decimals="-6" name="us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDQvZnJhZzo0Y2E1ODA3YWFkMGM0NDFjYTg5ZDNkNzQ1MDk4NTkzNi90ZXh0cmVnaW9uOjRjYTU4MDdhYWQwYzQ0MWNhODlkM2Q3NDUwOTg1OTM2XzE2NTU_770a83a3-5840-42f1-b712-afe1514f6b1d">5</ix:nonFraction>&#160;million in financial consideration paid in quarterly installments over the <ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="cpix:FinancialConsiderationPaymentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDQvZnJhZzo0Y2E1ODA3YWFkMGM0NDFjYTg5ZDNkNzQ1MDk4NTkzNi90ZXh0cmVnaW9uOjRjYTU4MDdhYWQwYzQ0MWNhODlkM2Q3NDUwOTg1OTM2XzMwNjk_2507053a-3619-419f-ab52-567c0ef141d9">two-years</ix:nonNumeric> following the transition date.  Cumberland recorded the last <ix:nonFraction unitRef="installment" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="INF" name="cpix:FinancialConsiderationNumberOfInstallments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDQvZnJhZzo0Y2E1ODA3YWFkMGM0NDFjYTg5ZDNkNzQ1MDk4NTkzNi90ZXh0cmVnaW9uOjRjYTU4MDdhYWQwYzQ0MWNhODlkM2Q3NDUwOTg1OTM2XzE3OTU_21dd2166-c52d-4cb6-83dc-7d652f1fbb78">four</ix:nonFraction> quarterly installments totaling $<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="-5" name="us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDQvZnJhZzo0Y2E1ODA3YWFkMGM0NDFjYTg5ZDNkNzQ1MDk4NTkzNi90ZXh0cmVnaW9uOjRjYTU4MDdhYWQwYzQ0MWNhODlkM2Q3NDUwOTg1OTM2XzE4MzA_6b92f55d-bc78-46de-9746-c2b29eccb538">2.0</ix:nonFraction> million during the year ended December 31, 2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from the Ethyol and Totect products meets the accounting criteria to be reported as discontinued operations.  As a result, January 1, 2020, was the first day of discontinued operations for the Products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subsequent to the transaction date, th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i3e36cfc56e1a4275a52b7d560014d176_247"></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(20)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzQxNzE_6b7ce4e0-1a7b-4d3d-8370-f7ee59d0bdc9" continuedAt="i4f606ea7162f4544ae093702e76bfa71" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i4f606ea7162f4544ae093702e76bfa71" continuedAt="i5f1734a8fafb49729d5ee279abdbbf25"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product.  At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Sancuso, the Company is required to pay up to $<ix:nonFraction unitRef="usd" contextRef="i03b6a63983b64d8bbf3a1a5e92a62c3b_I20221231" decimals="-5" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzExODY_fdcd9580-3421-48a5-aef2-0f308030a8c9">3.5</ix:nonFraction>&#160;million in milestones and tiered royalties ranging from <ix:nonFraction unitRef="number" contextRef="i1e7165d6a14540d69539b738e13cdf8d_I20221231" decimals="2" name="cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzEyMzc_123d4cfa-23c4-42f5-b9fa-53fbb4f04755">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i284259e69f3e4e4e84c466d1e02a1e56_I20221231" decimals="2" name="cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzEyNDM_71d28cd6-487d-4901-ba8c-f626a551ca4f">5</ix:nonFraction>% on U.S. net product sales for <ix:nonNumeric contextRef="i03b6a63983b64d8bbf3a1a5e92a62c3b_I20221231" name="cpix:CollaborativeArrangementRightsAndObligationsTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzEyNzY_676ee604-107d-45d4-aa49-9a00fda47c66">ten years</ix:nonNumeric>.    </span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><ix:continuation id="i5f1734a8fafb49729d5ee279abdbbf25" continuedAt="ic922ba3ece774fc7a703136a5d323a90"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has a number of patents issued through the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) including U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2012, Cumberland has continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Melinta Litigation</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company filed an action for breach of contract against Melinta Therapeutics, LLC and Targanta Therapeutics Corporation (collectively, the &#8220;Defendants&#8221;) in the United States District Court for the Southern District of New York (Case No. 1:22-cv-00915-VM).  The Company and the Defendants are parties to an agreement (the &#8220;Agreement&#8221;), pursuant to which the Defendants have a license to develop and commercialize products under certain Company patents, in exchange for the Defendants paying the Company certain milestone payments and royalties on net sales of the licensed products.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the Agreement requires the Defendants to, among other things, make a $<ix:nonFraction unitRef="usd" contextRef="ia952b89d554e4c89bf3b5882567c2d5f_I20220202" decimals="-3" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzU0OTc1NTgyNTQ5Ng_6fa76533-8b7a-4620-aaf8-0f6b10ce1030">500,000</ix:nonFraction> payment to the Company within 30 days following the first filing of an sNDA in relation to the Product (as defined the Agreement) and a $<ix:nonFraction unitRef="usd" contextRef="i49eca3268edc4ad8b4e63d2e71cfa018_I20220202" decimals="-3" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzU0OTc1NTgyNTUwNg_3e68ec46-7c71-4be6-a00e-062a1b1a83fe">500,000</ix:nonFraction> payment to the Company following the approval of the first sNDA in relation to the Product.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After Defendants disclosed the domiciles of its limited partners to the Company, as required by the Court, on October 24, 2022, the action for breach of contract was refiled in the Supreme Court of the State of New York, County of New York (Index No. 654234/2022) on November 7, 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaint alleges that, despite the Defendants filing an NDA and sNDA for the Product and receiving FDA approval for both applications, the Defendants failed to make the required total of $<ix:nonFraction unitRef="usd" contextRef="i1f878acd95a045fd934d5052dde987c6_I20221107" decimals="-6" name="cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzU0OTc1NTgyNTUxNg_2e95ce16-03fa-4a46-bacf-50f0d4ff5e57">1</ix:nonFraction>&#160;million in milestone payments to the Company.  The Company is seeking damages in the amount of no less than $<ix:nonFraction unitRef="usd" contextRef="i1f878acd95a045fd934d5052dde987c6_I20221107" decimals="-6" name="us-gaap:GainContingencyUnrecordedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzU0OTc1NTgyNTUyOA_0a15fc9e-ae05-4dfa-a31a-a61db3ced3a3">1</ix:nonFraction>&#160;million, pre- and post-judgment interest under N.Y. C.P.L.R. &#167; 5001, costs, and such further relief as the court deems just and proper.</span></div></ix:continuation><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic922ba3ece774fc7a703136a5d323a90">The Company is a party to various other legal proceedings in the ordinary course of its business. In the opinion of management, the liability associated with these matters, will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</ix:continuation>  </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_250"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements  (Continued)</span></div></div><div style="margin-top:8pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(21)&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90ZXh0cmVnaW9uOjY5N2YxZTM0MTU4MDRhMGI4M2RjOWNlNzE3OWUwZDk1XzM1Mg_ea9eb396-06b9-40ee-9aee-27cac8a1bb14" continuedAt="ib3ddb4bcfa9a42d6bf9968f0fb5123c0" escape="true">Quarterly Financial Information (Unaudited)</ix:nonNumeric></span></div><ix:continuation id="ib3ddb4bcfa9a42d6bf9968f0fb5123c0"><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90ZXh0cmVnaW9uOjY5N2YxZTM0MTU4MDRhMGI4M2RjOWNlNzE3OWUwZDk1XzM1Mw_0e9c8ad5-a80b-4a83-b1a5-4bbe44840dee" escape="true"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMtMi0xLTEtMzQzODQ_f10820e2-9fc8-4aa8-b32f-5abacd8566ae">11,175,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMtNC0xLTEtMzQzODQ_48f5f969-850f-43e7-9964-7233dad4e84a">10,299,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMtNi0xLTEtMzQzODQ_0e373468-1153-4375-803c-4b075ce60281">11,413,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMtOC0xLTEtMzQzODQ_5bf55f90-e999-4c38-a93a-a675323b0646">9,123,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMtMTAtMS0xLTM0Mzg0_083b2ec7-92dd-43d1-9814-402b50f9b147">42,010,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzQtMi0xLTEtMzQzODQ_b5a5797b-9c6e-429a-a226-01d7152cc966">1,291,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzQtNC0xLTEtMzQzODQ_5bc820b6-7504-4c05-9a08-3450d16dde40">1,846,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzQtNi0xLTEtMzQzODQ_ee62f3ae-dfea-47fe-8bf5-eb079cb53a5f">288,588</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzQtOC0xLTEtMzQzODQ_70e616cb-3cf6-4964-a3b9-d50a13d13fbe">2,277,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzQtMTAtMS0xLTM0Mzg0_e41cea7a-a760-42e4-9bd5-8004ec49635c">5,704,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzUtMi0xLTEtMzQzODQ_b116281f-b493-4a19-a62a-126ee72c5279">1,402,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzUtNC0xLTEtMzQzODQ_7fa9b083-1d78-442a-b3c0-a8a3e8eb056c">1,364,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzUtNi0xLTEtMzQzODQ_f71458f3-188a-45c4-a7aa-2c9f166576a8">423,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzUtOC0xLTEtMzQzODQ_1ad765cc-1a5f-453c-bd79-4424086e4d9c">2,459,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzUtMTAtMS0xLTM0Mzg0_20dc1b98-e13b-4956-910a-8cac75847869">5,650,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzctMi0xLTEtMzQzODQ_f6233868-e602-4a91-86c0-eeac0970470a">1,385,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzctNC0xLTEtMzQzODQ_33f787f4-4757-4c14-b191-74d0f146bf26">1,335,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzctNi0xLTEtMzQzODQ_be462f91-af07-425a-a78b-e9cf46b2df20">408,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzctOC0xLTEtMzQzODQ_a9aa53d2-aa9d-4940-845e-c06f8827f84d">2,440,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzctMTAtMS0xLTM0Mzg0_b71b95d0-fc57-46cc-96ed-9dc5a90f1e94">5,570,241</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzktMi0xLTEtMzQzODQ_e4067b22-c74a-4da6-9bbd-b225015fa549">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzktNC0xLTEtMzQzODQ_a9cc1609-5d14-4c3a-ba0c-e8cd9bcb573d">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzktNi0xLTEtMzQzODQ_432de364-39de-4efe-8aba-814b10c034e2">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzktOC0xLTEtMzQzODQ_5dcd3ad6-728f-4a01-b454-2b5084a862bd">0.17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzktMTAtMS0xLTM0Mzg0_5dfd8dc3-bb54-42cd-9751-95a51828e7ec">0.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEwLTItMS0xLTM0Mzg0_b0d6fba1-2ff6-4722-ba82-7313c1f1f7b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEwLTQtMS0xLTM0Mzg0_03819879-7c72-461d-abc7-0ca781b95161">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEwLTYtMS0xLTM0Mzg0_fa56d630-94cb-4998-bb53-611517f22617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEwLTgtMS0xLTM0Mzg0_22cda5b4-7bfd-4ce4-9537-316b9ece3aef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEwLTEwLTEtMS0zNDM4NA_c9675e1c-13c0-4255-9e49-8d9372c2fb47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzExLTItMS0xLTM0Mzg0_506cdbbb-f774-49e0-acff-61c7f22044d8">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzExLTQtMS0xLTM0Mzg0_e4dda22e-6419-4d85-9f0a-5d3a56f45db0">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzExLTYtMS0xLTM0Mzg0_f526160c-32a4-4c3e-9e80-1b876bf33c96">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzExLTgtMS0xLTM0Mzg0_a7035de0-c160-408d-bce6-a5b9e3b7fb35">0.17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzExLTEwLTEtMS0zNDM4NA_b21f773c-e5c4-4d5c-a6b1-4cfbf0571d3e">0.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEzLTItMS0xLTM0Mzg0_48f65c86-5ab6-4b69-a643-7f9a7d07f998">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEzLTQtMS0xLTM0Mzg0_e7096625-c098-4637-92f6-2e8d093e3eef">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEzLTYtMS0xLTM0Mzg0_5889da6c-753d-4027-8950-983d36fd74d7">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEzLTgtMS0xLTM0Mzg0_0a92ab88-cbeb-4db6-a505-5b0ce9fcda1d">0.17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEzLTEwLTEtMS0zNDM4NA_f98f24ef-68a9-41db-8734-b16427bb6272">0.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE0LTItMS0xLTM0Mzg0_7316830b-4f5e-459d-920a-a423d7c7e4f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE0LTQtMS0xLTM0Mzg0_6043ff49-5817-461b-8b8b-1212189476ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE0LTYtMS0xLTM0Mzg0_c8741812-7226-4919-8ad8-acd4a547bba4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE0LTgtMS0xLTM0Mzg0_94361242-036c-420a-a9e7-f94f03db8b94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE0LTEwLTEtMS0zNDM4NA_29770a5b-b254-4fe9-898b-b44b8398c306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE1LTItMS0xLTM0Mzg0_7efd16fa-f737-4879-99e3-56ed363c7b9a">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE1LTQtMS0xLTM0Mzg0_c05afa12-ba25-41b7-a9e1-e5697cd2d685">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE1LTYtMS0xLTM0Mzg0_2dbe362d-aaa9-4127-af58-7216c86f6fac">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE1LTgtMS0xLTM0Mzg0_933b3a07-1134-4a6f-9886-8e869dfc7a12">0.17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE1LTEwLTEtMS0zNDM4NA_f116d8e6-315f-4667-b0d4-a0a6308b5710">0.38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE4LTItMS0xLTM0Mzg0_ef041951-ca12-4002-ba50-931cd6a8bff1">10,537,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE4LTQtMS0xLTM0Mzg0_96000932-0374-4546-9549-dc9cc593b299">9,055,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE4LTYtMS0xLTM0Mzg0_2a78de12-a49f-4b14-8662-259feb4a9ad1">8,072,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE4LTgtMS0xLTM0Mzg0_cb276c4b-c0b3-4d04-af90-e587bd63ea67">8,319,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE4LTEwLTEtMS0zNDM4NA_df5f82c3-b080-439b-946e-1bb7024fe9a1">35,985,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE5LTItMS0xLTM0Mzg0_fee854b5-9c2f-4b1c-b681-1c3a202f9d70">324,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE5LTQtMS0xLTM0Mzg0_c08a8225-232a-4fcd-87c3-3084770edf04">1,435,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE5LTYtMS0xLTM0Mzg0_acdb2854-fc06-45d6-82ab-85c2012cea12">1,563,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE5LTgtMS0xLTM0Mzg0_737ff08b-cba5-4819-8648-386479e3df1e">4,353,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE5LTEwLTEtMS0zNDM4NA_19cb8c05-8e85-4338-a787-7dd54be09730">7,677,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIwLTItMS0xLTM0Mzg0_66127bc2-b539-4d74-9390-056a563a7eb2">350,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="0" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIwLTQtMS0xLTM0Mzg0_72752da9-76c4-44a9-b299-ea014a4de724">724,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIwLTYtMS0xLTM0Mzg0_83d16a29-7627-4ce6-b0e2-d17ca38809bf">1,583,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIwLTgtMS0xLTM0Mzg0_a6267f36-45fb-404a-9313-15fd40361916">4,387,576</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIwLTEwLTEtMS0zNDM4NA_d1ad7396-3385-4387-8896-2a9c50aef556">5,597,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIxLTItMS0xLTM0Mzg0_269a04e1-772e-4528-96a1-4260a4c641ff">495,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIxLTQtMS0xLTM0Mzg0_4174497e-1732-4f40-97c6-b3be909443e3">498,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIxLTYtMS0xLTM0Mzg0_2f3e8c88-dcc5-4211-8f07-0b3447ec4a27">496,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIxLTgtMS0xLTM0Mzg0_a9fb0ef2-ac01-47fc-843f-3b2d27086ab9">503,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIxLTEwLTEtMS0zNDM4NA_4ee2f49a-4763-48b8-9c02-6ee1a7a0f0be">1,994,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIyLTItMS0xLTM0Mzg0_f4cccda9-08e5-4603-be57-606cba65057d">166,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="0" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIyLTQtMS0xLTM0Mzg0_fd8e2473-5863-4a9d-b688-0dbe10eea184">1,228,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIyLTYtMS0xLTM0Mzg0_8fde1823-1547-4d74-b93f-30e767f1c684">1,055,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIyLTgtMS0xLTM0Mzg0_63b7601a-06eb-4631-996c-edf111a4cb65">3,847,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIyLTEwLTEtMS0zNDM4NA_6677bf5c-5aff-4625-9f21-8628b660d8b7">3,507,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI0LTItMS0xLTM0Mzg0_fa48d15d-ef36-4614-91a8-ec96ff8da22f">0.02</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI0LTQtMS0xLTM0Mzg0_2eaae03a-9377-40f1-ad02-8f0f4d952476">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI0LTYtMS0xLTM0Mzg0_deabef38-79c1-4d29-89ea-bc71e8ae0471">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI0LTgtMS0xLTM0Mzg0_aca43702-48bd-43b6-a171-42a4645280b5">0.29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI0LTEwLTEtMS0zNDM4NA_56d79589-7900-4f34-9991-3f1567c7745e">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI1LTItMS0xLTM0Mzg0_df1c704d-a720-4774-81ae-2fee3bc2a370">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI1LTQtMS0xLTM0Mzg0_592988dc-7fe0-405b-8729-532b1809f3d7">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI1LTYtMS0xLTM0Mzg0_997c5c6a-5701-4ca1-a2ff-20294d41270a">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI1LTgtMS0xLTM0Mzg0_5fc6248a-d392-40c3-a214-e26bb3a866b5">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI1LTEwLTEtMS0zNDM4NA_ef38ecf9-8129-4bbd-bdfc-7aa2a6defb96">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI2LTItMS0xLTM0Mzg0_61db8188-7054-4c70-8dde-5a1f43f4900a">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI2LTQtMS0xLTM0Mzg0_970eee0e-406c-4eb6-805b-a2dfe48db11f">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI2LTYtMS0xLTM0Mzg0_80ca3f37-bfc6-48cc-bf35-a141eda8b8b0">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI2LTgtMS0xLTM0Mzg0_f2f0ee4c-686d-4b24-b729-d3a27bc3f9fb">0.26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI2LTEwLTEtMS0zNDM4NA_ca138677-f4d6-4a85-b1cb-e9fb7c5b699d">0.24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI4LTItMS0xLTM0Mzg0_1cce7548-20d7-42e7-9e3b-60ab7c734bdf">0.02</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI4LTQtMS0xLTM0Mzg0_f86c691b-c248-4b39-8499-852cb99f7d8d">0.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI4LTYtMS0xLTM0Mzg0_4df581f8-589e-4aff-84da-ed1c659247d1">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI4LTgtMS0xLTM0Mzg0_3fa2c47d-08b8-4c72-b3f3-c7cda026f16b">0.29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI4LTEwLTEtMS0zNDM4NA_207d2429-21f5-47f9-88bf-6a3cb4e87548">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI5LTItMS0xLTM0Mzg0_54bcc6e4-9463-4230-a4d3-daa1618fe67c">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI5LTQtMS0xLTM0Mzg0_01f6d502-e5b3-46ac-8e19-b771bf305f7e">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI5LTYtMS0xLTM0Mzg0_5c9c3ba5-361e-4894-83d1-bffaadd7d4ad">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI5LTgtMS0xLTM0Mzg0_d832061e-3dde-4f52-9a23-a49c5b7fcb8d">0.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI5LTEwLTEtMS0zNDM4NA_8418700f-6016-4980-8361-0b702c0d1d56">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMwLTItMS0xLTM0Mzg0_dcf435e4-88e9-4c52-a486-f1f131b1cf09">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMwLTQtMS0xLTM0Mzg0_543bdb15-7469-4071-8d67-a2790733e3a0">0.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMwLTYtMS0xLTM0Mzg0_4dc8019e-1ce7-44a6-a80f-394c9e93f379">0.07</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMwLTgtMS0xLTM0Mzg0_6ea292bf-08be-4457-8326-f43489ab5699">0.26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMwLTEwLTEtMS0zNDM4NA_5dba6695-53eb-4f40-a575-7f4c6e9120ee">0.24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><div id="i3e36cfc56e1a4275a52b7d560014d176_253"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:right"><span><br/></span></div><ix:nonNumeric contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90ZXh0cmVnaW9uOjM0MGEyNzRlZDE4MTQyYmM4NjVhYzI3M2Y5MGI5MGMyXzIxMg_eebc72d0-73e2-4c0f-867a-2c721aedba84" escape="true"><div style="margin-top:8pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2022, 2021 and 2020</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">beginning&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">period</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">costs and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">expenses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">accounts</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">end&#160;of&#160;period</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5de2643b16c42518868295369efe808_I20201231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzUtMi0xLTEtMzQzODQ_c4bb0b63-4f03-4462-893c-31cd20b21b50">984,677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1250f3410e437492a31418c8974e8c_D20210101-20211231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzUtNC0xLTEtMzQzODQ_c5e9e937-0870-4796-9eda-237ab787d18f">2,963,279</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a1250f3410e437492a31418c8974e8c_D20210101-20211231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzUtNi0xLTEtMzQzODQ_be24a9ce-af22-451a-9f95-fdef1b26ea1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a1250f3410e437492a31418c8974e8c_D20210101-20211231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzUtOC0xLTEtMzQzODQ_25479654-2fa1-4d77-8158-5e2d3888d851">3,606,992</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ed7d5354534fbd81b84cc0aa0d8e79_I20211231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzUtMTAtMS0xLTM0Mzg0_62b3968d-2b51-4ce0-b452-a94223e0140d">340,964</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ed7d5354534fbd81b84cc0aa0d8e79_I20211231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzYtMi0xLTEtMzQzODQ_8e5f7ff0-4c2b-4c76-b006-1d0009e06a9f">340,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id183facaeebd467fa69fbb2fec9d0b3e_D20220101-20221231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzYtNC0xLTEtMzQzODQ_806db7f6-7c50-45fb-b5ae-638e5455eef0">6,673,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id183facaeebd467fa69fbb2fec9d0b3e_D20220101-20221231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzYtNi0xLTEtMzQzODQ_c25011be-45b9-47de-a406-daaf9617a76d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id183facaeebd467fa69fbb2fec9d0b3e_D20220101-20221231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzYtOC0xLTEtMzQzODQ_43d642a4-8c71-4805-ba9b-bd2d02a27f70">6,417,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9019082259e456fb9c5846dc8fa2c23_I20221231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzYtMTAtMS0xLTM0Mzg0_3dec28da-86ab-403d-830b-71dba4612df6">596,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief70e45bdb5146d0818d09d8a9fc3591_I20201231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzExLTItMS0xLTM0Mzg0_350e1d22-161f-410b-b01c-bd358e67a109">19,196,121</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f27dbe43754f2393a096db946b5293_D20210101-20211231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzExLTQtMS0xLTM0Mzg0_3d139dc2-ee73-4768-9284-5cfdd6447245">565,801</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f27dbe43754f2393a096db946b5293_D20210101-20211231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzExLTYtMS0xLTM0Mzg0_dd71b828-d578-402d-964e-a09ebeda0468">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f27dbe43754f2393a096db946b5293_D20210101-20211231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzExLTgtMS0xLTM0Mzg0_4563f5b0-6a8a-4177-9cb5-d59ff949b3b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c9db8d427e4e07a83726736dbc62f8_I20211231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzExLTEwLTEtMS0zNDM4NA_5f35502a-68a7-4c78-87a2-31db9c3c128b">19,761,922</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c9db8d427e4e07a83726736dbc62f8_I20211231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzEyLTItMS0xLTM0Mzg0_1c776c7b-4a4c-4a57-a228-d2d6d96b271f">19,761,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce9bb4f17eb40309dbdc88fdb74adc9_D20220101-20221231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzEyLTQtMS0xLTM0Mzg0_3659327f-d347-412b-b9a9-67067ac0b83c">1,795,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce9bb4f17eb40309dbdc88fdb74adc9_D20220101-20221231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzEyLTYtMS0xLTM0Mzg0_33d23c93-056e-4b54-b676-6e6ab08a357f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce9bb4f17eb40309dbdc88fdb74adc9_D20220101-20221231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzEyLTgtMS0xLTM0Mzg0_0dd3cae7-881f-46fd-ac6d-0d9f6524baa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1857a0d9d671486aa8f09353d5b63f37_I20221231" decimals="0" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzEyLTEwLTEtMS0zNDM4NA_f1e3fb31-af04-45d3-b1c7-041d204ae47b">21,557,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Composed of actual returns and credits for chargebacks and cash discounts.</span></div></ix:nonNumeric><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.11
<SEQUENCE>2
<FILENAME>a2022q4exhibit411.htm
<DESCRIPTION>EX-4.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i82f3cf858fe84fc5be6fdc5ba5e9d6a1_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Exhibit 4.11</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">DESCRIPTION OF THE REGISTRANT&#8217;S COMMON STOCK </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The common stock of Cumberland Pharmaceuticals, Inc. ( &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or the &#8220;Company&#8221;) is registered under Section 12 of the Securities Exchange Act of 1934, as amended.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The following description of our common stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the actual terms and provisions contained in our Third Amended and Restated Charter, as amended (the &#8220;Charter&#8221;), and our Second Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), copies of are filed as an exhibit to this Annual Report on Form 10-K and are incorporated herein, and to the applicable provisions of Tennessee law. We encourage you to read our Charter and Bylaws and the applicable provisions of Tennessee law for additional information.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Authorized Capital </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">We are authorized to issue up to 120,000,000 shares of capital stock, of which 100,000,000 may be shares of common stock, par value $0.00 per share, and 20,000,000 may be shares of preferred stock, par value $0.00 per share. The Company currently has no preferred stock issued and outstanding. All of the Company&#8217;s outstanding shares of common stock are fully paid and nonassessable. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Voting Rights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of common stock are entitled to one vote for each share registered in his or her name on our books on all matters voted on by our shareholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of our common stock do not have cumulative voting rights. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Dividends </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to any preferences or other rights of any of our preferred stock that may be issued from time to time, each share of our common stock is entitled to share equally with each other share of common stock in dividends from sources legally available therefore, when, as, and if declared by the Board of Directors of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Absence of Other Rights </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Holders of our common stock do not have any preemptive rights to subscribe for or purchase any of our securities of any class or kind. Holders of our common stock do not have any subscription, redemption or conversion privileges. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Liquidation Rights</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Upon our liquidation or dissolution, whether voluntary or involuntary, each share of our common stock is entitled to share equally in the assets that are available for distribution to our shareholders, after payment of all debts and liabilities and subject to the prior rights of nay holders of preferred stock then outstanding. </font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Listing </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;CPIX.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Transfer Agent and Registrar </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Continental Stock Transfer &#38; Trust Company is the transfer agent and registrar of our common stock.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Anti-Takeover Effects of our Charter and Bylaws</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter and Bylaws contain certain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of the Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These provisions, which are summarized below, could discourage takeovers, coercive or otherwise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These provisions are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Staggered Board</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter divides our Board of Directors into three separate classes, and directors are assigned to each class in accordance by resolution of the Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Each class of directors serves for a full term of three years, and the terms of the respective classes expire in succession so that only one class of directors is required to stand for re-election at each annual meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This provision prevents our shareholders or a potential acquirer from replacing all of our incumbent directors at a single annual meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Removal of Directors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Under Tennessee law, a director can be removed by the shareholders with or without cause, unless a corporation&#8217;s charter provides that the director can only be removed for cause.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter includes this restriction, which could make it more difficult for shareholders to remove incumbent directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Advance Notice Provisions</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Bylaws contain advance notice provisions applicable to shareholder proposals and the nomination of candidates for election as directors by shareholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These advance notice provisions may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed and may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempt to obtain control of the Company. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Vacancies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter provides that the Board of Directors, by a majority vote of the remaining directors in office, shall fill any vacant directorships caused by the death, resignation, disqualification, removal of a director.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter also gives the Board of Directors the power to fill any vacancies resulting from the increase in the number of directors serving on the Board.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">These provisions could make it more difficult for an acquiror to gain control of our Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Calling of Special Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. Under Tennessee law, a special meeting of a Tennessee corporation&#8217;s shareholders can be called by its board of directors or, unless the charter provides otherwise, the holders of at least 10% of the outstanding voting stock of the corporation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter provides that a special meeting can be called by our Chairman of the Board or the Chief Executive Officer only when shareholders owning at least two-thirds of the votes entitled to be cast on any issue proposed to be considered at the meeting deliver to the Company a written demand stating the purposes of the special meeting and a certified check in the amount of $50,000.00.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">This provision may make it harder for our shareholders to call special meetings without the consent of the Board of Directors of the Company. </font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Undesignated Preferred Stock</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Board of Directors has the ability to designate and issue preferred stock without shareholder approval, and such preferred stock could have voting or other rights or preferences that could deter hostile takeovers or delay changes in control.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">No Cumulative Voting</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Our Charter and Bylaws do not allow shareholders to cumulate votes for the election of directors, which may have the effect of deterring our shareholder&#8217;s ability to replace incumbent directors serving on the Board of Directors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Tennessee Anti-Takeover Statutes</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">In addition to the Charter and Bylaws provisions discussed above, Tennessee has adopted a series of statutes which can have an anti-takeover effect and may delay or prevent a tender offer or takeover attempt that a shareholder might consider in its best interest, including those attempts that might result in a premium over the market price for our capital stock.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Business Combination Act </font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tennessee Business Combination Act (the &#8220;TBCA&#8221;) governs all Tennessee corporations. It imposes a five-year standstill on transactions such as mergers, share exchanges, sales of assets, liquidations and other interested party transactions between Tennessee corporations and &#8220;interested shareholders&#8221; and their associates or affiliates, unless the business combination is approved by the board of directors before the interested shareholder goes above the 10% ownership threshold. Thereafter, the transaction either requires a two-thirds vote of the shareholders other than the interested shareholder or satisfaction of certain fair price standards.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The TBCA also provides for additional exculpatory protection for the board of directors in resisting mergers, exchanges and tender offers if a Tennessee corporation&#8217;s charter specifically opts-in to such provisions. In particular, a Tennessee corporation&#8217;s charter may specifically authorize the members of a board of directors, in the exercise of their judgment, to give due consideration to factors other than price and to consider whether a merger, exchange, tender offer or significant disposition of assets would adversely affect the corporation&#8217;s employees, customers, suppliers, the communities in which the corporation operates, or any other relevant factor in the exercise of their fiduciary duty to the shareholders.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Charter currently does not opt-in to the additional exculpation provisions available under the TBCA. In the future, if we amend our Charter to opt-in to such provisions, it could have the effect of protecting our management and Board of Directors from hostile takeover bids.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Control Share Acquisition Act</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Tennessee Control Share Acquisition Act (the &#8220;TCSA&#8221;) limits the voting rights of shares owned by a person above certain percentage thresholds, unless the non-interested shareholders of the corporation approve the acquisition above the designated threshold. However, the TCSA only applies to corporations whose charter or bylaws contain an express declaration that control share acquisitions are to be governed by the TCSA. In addition, the charter or bylaws must specifically provide for the redemption of control shares or appraisal rights for dissenting shareholders in a control share transaction. Neither our Charter nor our Bylaws make the express declarations necessary to opt into the TCSA. In the future, if we amend our Bylaws or our Charter to opt into the TCSA, it will have the general effect of discouraging, or rendering more difficult, acquisition attempts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Investor Protection Act</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Tennessee Investor Protection Act (&#8220;TIPA&#8221;) generally requires the registration, or an exemption from registration, before a person can make a tender offer for shares of a Tennessee corporation which, if successful, will result in the offeror beneficially owning more than 10% of any class of shares. Registration requires the filing with the Tennessee Commissioner of Commerce and Insurance of a registration statement, a copy of which must be sent to the target company, and the public disclosure of the material terms of the proposed offer. Additional requirements are imposed under that act if the offeror beneficially owns 5% or more of any class of equity securities of the target company, any of which was purchased within one year prior to the proposed takeover offer. TIPA also prohibits fraudulent and deceptive practices in connection with takeover offers, and provides remedies for violations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">TIPA does not apply to an offer involving a vote by holders of equity securities of the offeree company, pursuant to its charter, on a share exchange, consolidation or sale of corporate assets in consideration of the issuance of securities of another corporation, or on a sale of its securities in exchange for cash or securities of another corporation. Also exempt from TIPA are tender offers which are open on substantially equal terms to all shareholders, are recommended by the board of directors of the target company, and include full disclosure of all terms.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Tennessee Greenmail Act</font></div><div><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">The Tennessee Greenmail Act (&#8220;TGA&#8221;) prohibits us from purchasing or agreeing to purchase any of our securities, at a price higher than fair market value, from a holder of 3% or more of any class of its securities who has beneficially owned the securities for less than two years. We can, however, make this purchase if the majority of the outstanding shares of each class of voting stock issued by us approves the purchase or if we make an offer of at least equal value per share to all holders of shares of the same class of securities as those held by the prospective seller.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>a2022-10kxex1011ajkazimi.htm
<DESCRIPTION>EX-10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib80e7b3b07684fcb9f08ceb85fc53916_1"></div><div style="min-height:100.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.11</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 7, 2022</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mr. AJ Kazimi </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN  37203</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of AJ Kazimi as Chief Executive Officer by Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear AJ, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2022, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Chief Executive Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of six hundred thirty-five thousand dollars ($635,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2022.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.&#160; The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="ib80e7b3b07684fcb9f08ceb85fc53916_4"></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Standards of Business Conduct and Ethics.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:252pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.455%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely yours,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUMBERLAND PHARMACEUTICALS INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:69pt"><td colspan="6" style="border-bottom:1pt solid #000000;padding:0 1pt"><div><img alt="ssmithsign.jpg" src="ssmithsign.jpg" style="height:87px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"></div></td></tr><tr><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;   Stephanie Smith HRM, MBA</font></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Human Resource Manager</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.858%"><tr><td style="width:1.0%"></td><td style="width:66.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 7th of March, 2022&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#47;s&#47; A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.J. Kazimi</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>4
<FILENAME>a2022-10kxex1014johnhamm.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i515c866b17cc45088ba93b0ec5cac789_1"></div><div style="min-height:100.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.14</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 7, 2022</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mr. John Hamm </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN  37203</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of John Hamm as Senior Director of Finance &#38; Accounting &#38; Chief Financial Officer Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear John, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Senior Director of Finance &#38; Accounting &#38; Chief Financial Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of one hundred and ninety-two thousand dollars ($192,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2022.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.&#160; The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="i515c866b17cc45088ba93b0ec5cac789_4"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14. Standards of Business Conduct and Ethics. Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.455%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely yours,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUMBERLAND PHARMACEUTICALS INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:252pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.858%"><tr><td style="width:1.0%"></td><td style="width:66.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 7th of March, 2022&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Hamm</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:36pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">John Hamm</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>5
<FILENAME>a2022-10kxex1015jimherman.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i323027936041431db85f79890f119574_1"></div><div style="min-height:100.08pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.15</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 7, 2022</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Mr. James Herman </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2525 West End Avenue, Suite 950</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nashville, TN  37203</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Employment of James Herman as Executive Vice President, National Accounts and Chief Compliance Officer Cumberland Pharmaceuticals Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Jim, </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective January 1, 2023, this letter agreement (the &#8220;Agreement&#8221;) will evidence the terms and conditions under which you will be employed by Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) In consideration of your appointment as Executive Vice President, National Accounts and Chief Compliance Officer of the Company, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company agrees to compensate you as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company agrees to pay you on a salary basis for services performed based on an annual rate of two hundred and ninety-two thousand dollars ($292,000.00), payable in arrears in equal monthly installments on the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of each calendar month of 2022.  For each year, thereafter, you will be paid on a salary basis for services performed based on an annual rate determined by the Company in its sole discretion&#59; provided, however, that any obligation to make payments under this Section 1(a) will cease upon termination of your employment for any reason.  Notwithstanding the foregoing, nothing in this Section 1(a) alters or is intended to alter the at-will nature of your employment as described in Section 3 of this Agreement.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You will be eligible to participate in any Company-wide employee benefits as approved by the Board of Directors.  The terms of your eligibility and participation will be governed by the provisions of the employee benefit plans, as such plans may be amended from time to time in the discretion of the Company's Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;You may be eligible for any Company bonus program, based upon performance in meeting your individual objectives and the Company&#8217;s overall performance, both as determined and approved by the Board of Directors of the Company.  Any such bonus will be discretionary and will be subject to the terms of the applicable bonus program, the terms of which program may be modified from year to year in the sole discretion of the Company&#8217;s Board of Directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;You will receive a grant of Cumberland Pharmaceuticals common stock, pursuant to a stock options agreement (SOA).  Such shares will be subject to the SOA and the terms set forth in the incentive compensation plan under which they are awarded.  You may, at the Company&#8217;s sole discretion, receive additional awards of Company equity, which will be subject to their designated agreements and the incentive compensation plans under which they are awarded.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;Except as set forth in Section 2, the Company shall not be liable to you for any expense incurred by you unless you receive the Company's prior written consent to reimburse you for such expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Additional Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. During the term hereof, you shall be entitled to receive prompt reimbursement for all reasonable and documented expenses incurred in the performance of services in accordance with the expense reimbursement policy of the Company.  Such reimbursement policy shall require adequate documentation by you of the expenses and payment by the Company of such amounts shall be made within a reasonable period after the close of the year in which the expenses were incurred.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment at Will</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   This Agreement is not intended to and shall not be understood in any manner as affecting or modifying the at-will status of your employment with the Company.  As an at-will employee either you or the Company may terminate the employment relationship at any time with or without cause or notice.  The obligations of Sections 4, 5, 6, 7, 8, 10, 11 and 12 herein shall survive the termination of the employment relationship or of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All knowledge and information, not already available to the public, which you acquire, have acquired, or will acquire in the course of your employment with the Company with respect to the Company&#8217;s business, work methods, or pending regulatory matters, or other Company matters that are treated by the Company as confidential, shall be regarded by you as trade secrets, whether or not they are classifiable legally as trade secrets, and shall be treated by you as strictly confidential.  Such knowledge and information shall not either directly or indirectly be used, disclosed, or made accessible to anyone by you for any purpose, except in the ordinary course of the Company&#8217;s business under circumstances in which you are authorized to use or disclose such information.  No disclosures of such confidential information shall be made outside of those you are authorized to make in the regular and ordinary course of your duties unless and until you receive prior written permission of the Board of Directors of the Company to make such disclosure.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Discoveries and Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the time that you are employed by the Company, all confidential information, trade secrets, or proprietary information and all other discoveries, inventions, software programs, processes, methods and improvements that are conceived, developed, or otherwise made by you , alone or with others, that relate in any way to the Company&#8217;s present or planned business or products (collectively the &#8220;Developments&#8221;), whether or not patentable or subject to copyright protection and whether or not reduced to tangible form or reduced to practice, shall be the sole property of the Company.  You agree to disclose all Developments promptly, fully and in writing to the Company.  You agree to keep and maintain adequate and current dated and witnessed written records of all such Developments, in the form of notes, sketches, drawings, or reports, which records shall  be promptly submitted to the Company and shall be and remain the property of the Company at all times.  You agree to assign, and hereby do assign, to, the Company all your right, title and interest throughout the world in and to all Developments.  You agree that all Developments shall constitute &#8220;Works for Hire&#8221; (as such are defined under the U.S. Copyright Laws) and hereby assign to the Company all copyrights, patents and other proprietary rights you may have in any Developments without any obligation on the part of the Company to pay royalties or any other consideration to you for such Developments.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All documents and other writings produced by you during the period of your employment, which relate to work you are doing or have done for the Company or to the business of the Company or its affiliates, shall belong to the Company.  You will not publish outside of the Company any such writing without the prior written consent of the Board of Directors of the Company.  You will, without further compensation, execute at any time (whether or not you are still employed by the Company) all documents requested of you relating to the protection of such rights, including the assignment of such rights to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Litigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You shall notify the Company within three business days if no longer employed and immediately if still employed by the Company if you are contacted by any person relating to any claim or litigation against the Company.  You shall not communicate in any manner with any person related to any claim or litigation against the Company without the prior consent of the Board of Directors of the Company unless compelled to do so by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.   For so long as you are employed by the Company or any Affiliate (as defined below) and for a period of one year after you cease to be employed by the Company or any Affiliate, you shall not, directly or indirectly, engage in any work or other activity--whether as owner, stockholder, partner, officer, consultant, or otherwise--involving a trademark, product, or process that, in the opinion of the Company&#8217;s Chief Executive Officer, is  similar to a trademark, product or process on which you worked for the Company (or any Affiliate) or obtained knowledge about while working for the Company at any time during the period of employment, if such work or other activity is then, or reasonably expected to become, competitive with that of the Company (or any Affiliate).  The restriction in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such work or activity and have received a release in writing from the Board of Directors of the Company allowing you to engage in such work or activity. The Company&#8217;s Chief Executive Officer shall have sole discretion to determine whether your work or activity for another employer involves trademarks, products, or processes that are similar to trademarks, products, or processes that you worked on for the Company. Ownership by you of five percent (5%) or less of the outstanding shares of stock of any company either (i) listed on a national securities exchange, or (ii) having at least one hundred (100) stockholders shall not make you a &#8220;stockholder&#8221; within the meaning of that term as used in this paragraph.  For one year after you cease to work for the Company, you will not engage in any work or activity that will cause you to inevitably disclose to anyone not employed by the Company (or an Affiliate) any trade secret or confidential information that belongs to the Company or one of its Affiliates.   Nothing in this paragraph shall limit the rights or remedies of the Company arising, directly or indirectly, from such competitive employment, including, without limitation, claims based upon breach of fiduciary duty, misappropriation, or theft of confidential information.  The term &#8220;Affiliate&#8221; shall mean the Company and any entity controlling, controlled by, or under common control with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Conflicting Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You represent and warrant that you are not now under any obligation resulting from any contract or arrangement, to any person, firm, or corporation, which is inconsistent or in conflict with this Agreement.  Likewise you represent and warrant that you are not now under any obligation resulting from any contract or arrangement to any person, firm, or corporation which would prevent, limit, or impair in any way the performance by you of your obligations to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  After you cease to be employed by the Company (or a Company affiliate)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;You agree not to solicit, directly or indirectly, business related to the development or sales of pharmaceutical products from any entity, organization, or person which is contracted with the Company, which has been doing business with the Company or from which the Company was soliciting at the time of your termination, or a firm which you knew or had reason to know that the Company was going to solicit business at the time you ceased to be employed by the Company.&#160; The restriction set forth in the preceding sentence shall not apply if you have disclosed to the Company in writing all the known facts relating to such solicitation and have received a release in writing from the Board of Directors of the Company to engage in such solicitation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;You agree not to solicit, recruit, hire, or assist in the hiring of any employee of the Company to work for you or another person, firm, corporation, or business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of your employment for any reason, you shall immediately return to the Company all documents and things belonging to the Company.  This includes, but is not limited to, trade secrets, confidential information, knowledge, data or know-how, and software containing such information, whether or not the documents are marked &#8220;Confidential.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that in the event of breach of this Agreement by you, actual damages to the Company will be impossible to calculate, the Company&#8217;s remedies at law will be inadequate, and the Company will suffer irreparable harm.  Therefore, you agree that any of the covenants contained in this Agreement may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude the Company from other remedies which may be available to it.  You further agree that should you fail to keep any of the promises made by you in this Agreement, or any way violate this Agreement, the Company shall be entitled to recover all monies the Company is required to spend, including attorneys&#8217; fees, to enforce the provisions of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Best Efforts and Conflicts of Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;  You are hired with the understanding that Cumberland is your sole employer and you will provide a full-time work effort. You agree to devote your entire professional and business-related time and best efforts t&#92;o the services required of you by the express and implicit terms of this Agreement, to the reasonable satisfaction of Cumberland in its sole and complete discretion.  Engaging in activities outside of work that create a conflict of interest, or detract from your ability to perform your assigned responsibilities or meet your defined goals and objectives with Cumberland, is a problem and may lead to disciplinary action up to and including termination of employment.  If you believe that you are potentially involved in a situation that could create a conflict of interest and affect your ability to adequately perform your job with&#160;Cumberland, you should inform your direct supervisor and Cumberland&#8217;s Human Resources Department immediately.</font></div><div id="i323027936041431db85f79890f119574_4"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14. Standards of Business Conduct and Ethics. Cumberland&#8217;s commitment to a culture of integrity, ethics and compliance with the law is comprised in this policy, which will be provided to you as part of the conditions of your employment. You will have the opportunity to read, discuss and understand this policy prior to accepting and signing its Letter of Agreement.</font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Debarment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  You represent and warrant that you have not been debarred and will notify the Company immediately if you are debarred, pursuant to subsection 306(a) or 306(b) of the Federal Food, Drug, and Cosmetic Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given under this Agreement shall be sufficient if in writing and if sent by registered or certified mail to your residence or to the Company&#8217;s principal office in the case of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement contains the entire agreement of the parties and may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension, or discharge is sought.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by the laws of the State of Tennessee.  Any dispute arising out of this Agreement shall be resolved, at the Company&#8217;s sole option, by courts sitting in Nashville, Tennessee, and you waive any objection to such venue.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that any provision of this Agreement shall be held by a court to be unenforceable, such provision will be enforced to the maximum extent permissible, and the remaining portions of this Agreement shall remain in full force and effect.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding any termination of your employment, this Agreement shall survive and remain in effect in accordance with its terms.</font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:3pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">#   #   #   #</font></div><div style="padding-left:1.5pt;padding-right:1.5pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.08pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter agreement may be signed in one or more counterparts, each of which shall be an original and all of which will constitute one and the same instrument.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.455%"><tr><td style="width:1.0%"></td><td style="width:49.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sincerely yours,</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CUMBERLAND PHARMACEUTICALS INC.</font></td></tr><tr style="height:12pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">A.J. Kazimi</font></div></td></tr><tr style="height:15pt"><td colspan="6" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  &#160;&#160;&#160;&#160;A.J. Kazimi</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.858%"><tr><td style="width:1.0%"></td><td style="width:66.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted as to all terms and conditions</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">as of the 7th of March, 2022&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; James L. Herman</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">James L. Herman</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:100.08pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>6
<FILENAME>a2022-xex232consentofforvi.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i122493d72a10460293ddf9903a271176_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 23.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in the registration statement of Cumberland Pharmaceuticals Inc. (Company) on Form S-3 (No. 333-251308) and Form S-8 (No. 333-164376) of our report dated March&#160;13, 2023, on our audits of the consolidated financial statements of the Company as of December&#160;31, 2022 and 2021, and for each of the two years in the period ended December&#160;31, 2022, which report is included in this Annual Report on Form 10-K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; FORVIS, LLP (formally BKD, LLP)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nashville, Tennessee</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;13, 2023</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>a2022-10kxexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i78e91ab419e04ae48ba75ed84bd79952_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, A.J. Kazimi, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Form 10-K of Cumberland Pharmaceuticals Inc.&#59;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; </font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:40.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.226%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>a2022-10kxexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2de06c2e99514157bcdf7b134c3fc53d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John M. Hamm, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:8pt;padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Form 10-K of Cumberland Pharmaceuticals Inc.&#59;&#160;</font></div><div style="margin-top:8pt;padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:8pt;padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.59pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.02pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.59pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.02pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:30.48pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.59pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;padding-left:30.48pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:34.02pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:41.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.289%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John M. Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Director and Chief Financial Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>a2022-10kxexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i43def2457a20453eae340015e912da21_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AND CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION&#160;906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Cumberland Pharmaceuticals Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the fiscal year ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, A.J. Kazimi, Chief Executive Officer, and John M. Hamm, Senior Director and Chief Financial Officer, of the Company, certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. section 1350), that, based on my knowledge&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.804%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A.J. Kazimi</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.804%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; John M. Hamm</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John M. Hamm</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Director and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 13, 2023</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>cpix-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f3294900-4a6d-4934-9914-8de8a2261475,g:98ef8ed7-f771-4377-a070-411ae3070b66-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://www.cumberlandpharma.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt-types="http://fasb.org/srt-types/2022" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cumberlandpharma.com/20221231">
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cumberlandpharma.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.cumberlandpharma.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationandQualifyingAccounts" roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts">
        <link:definition>0000008 - Statement - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.cumberlandpharma.com/role/Organization">
        <link:definition>0000009 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RediTrexVibativandSancuso" roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancuso">
        <link:definition>0000011 - Disclosure - RediTrex&#174;, Vibativ&#174; and Sancuso&#174;</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.cumberlandpharma.com/role/Revenues">
        <link:definition>0000012 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.cumberlandpharma.com/role/Inventories">
        <link:definition>0000013 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment">
        <link:definition>0000014 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill">
        <link:definition>0000015 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilities" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities">
        <link:definition>0000016 - Disclosure - Other Current and Other Long-term Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.cumberlandpharma.com/role/Debt">
        <link:definition>0000017 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity">
        <link:definition>0000018 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShare" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare">
        <link:definition>0000019 - Disclosure - Earnings (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlans" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans">
        <link:definition>0000021 - Disclosure - Stock-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans">
        <link:definition>0000022 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cumberlandpharma.com/role/Leases">
        <link:definition>0000023 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrations" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations">
        <link:definition>0000024 - Disclosure - Market Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ManufacturingandSupplyAgreements" roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements">
        <link:definition>0000025 - Disclosure - Manufacturing and Supply Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmploymentAgreements" roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements">
        <link:definition>0000026 - Disclosure - Employment Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations">
        <link:definition>0000027 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies">
        <link:definition>0000028 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnaudited" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited">
        <link:definition>0000029 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>0000030 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables">
        <link:definition>0000031 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RediTrexVibativandSancusoTables" roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoTables">
        <link:definition>0000032 - Disclosure - RediTrex&#174;, Vibativ&#174; and Sancuso&#174; (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.cumberlandpharma.com/role/RevenuesTables">
        <link:definition>0000033 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.cumberlandpharma.com/role/InventoriesTables">
        <link:definition>0000034 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables">
        <link:definition>0000035 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>0000036 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilitiesTables" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables">
        <link:definition>0000037 - Disclosure - Other Current and Other Long-term Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareTables" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables">
        <link:definition>0000038 - Disclosure - Earnings (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables">
        <link:definition>0000039 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansTables" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables">
        <link:definition>0000040 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cumberlandpharma.com/role/LeasesTables">
        <link:definition>0000041 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrationsTables" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables">
        <link:definition>0000042 - Disclosure - Market Concentrations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedTables" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables">
        <link:definition>0000043 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails">
        <link:definition>0000044 - Disclosure - Organization (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000045 - Disclosure - Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails">
        <link:definition>0000046 - Disclosure - Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesScheduleofDistributionCostsDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails">
        <link:definition>0000047 - Disclosure - Significant Accounting Policies (Schedule of Distribution Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails" roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails">
        <link:definition>0000048 - Disclosure - Significant Accounting Policies (Schedule of Advertising Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RediTrexVibativandSancusoNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails">
        <link:definition>0000049 - Disclosure - RediTrex&#174;, Vibativ&#174; and Sancuso&#174; - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails" roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails">
        <link:definition>0000050 - Disclosure - RediTrex&#174;, Vibativ&#174; and Sancuso&#174; - Schedule of Contingent Consideration and Preliminary Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RediTrexVibativandSancusoProFormaResultsDetails" roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoProFormaResultsDetails">
        <link:definition>0000051 - Disclosure - RediTrex&#174;, Vibativ&#174; and Sancuso&#174; - Pro Forma Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesScheduleofNetProductRevenuesbyProductDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails">
        <link:definition>0000052 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails">
        <link:definition>0000053 - Disclosure - Revenues (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>0000054 - Disclosure - Inventories (Schedule of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails">
        <link:definition>0000055 - Disclosure - Inventories (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentScheduleofPropertyandEquipmentDetails" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
        <link:definition>0000056 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDepreciationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails">
        <link:definition>0000057 - Disclosure - Property and Equipment (Depreciation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails">
        <link:definition>0000058 - Disclosure - Intangible Assets and Goodwill (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>0000059 - Disclosure - Intangible Assets and Goodwill (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails">
        <link:definition>0000060 - Disclosure - Intangible Assets and Goodwill - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails">
        <link:definition>0000061 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails" roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails">
        <link:definition>0000062 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtLineofCreditDetails" roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails">
        <link:definition>0000063 - Disclosure - Debt (Line of Credit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails">
        <link:definition>0000064 - Disclosure - Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails">
        <link:definition>0000065 - Disclosure - Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails">
        <link:definition>0000066 - Disclosure - Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails">
        <link:definition>0000067 - Disclosure - Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails">
        <link:definition>0000068 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails">
        <link:definition>0000069 - Disclosure - Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails">
        <link:definition>0000070 - Disclosure - Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>0000071 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails">
        <link:definition>0000072 - Disclosure - Income Taxes (Schedule of tax credit carryforwards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails">
        <link:definition>0000073 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails">
        <link:definition>0000074 - Disclosure - Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails">
        <link:definition>0000075 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Incentive Stock Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails">
        <link:definition>0000076 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails">
        <link:definition>0000077 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails">
        <link:definition>0000078 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofRentExpenseandSubleaseIncomeDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails">
        <link:definition>0000079 - Disclosure - Leases (Schedule of Rent Expense and Sublease Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeasePositionDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails">
        <link:definition>0000080 - Disclosure - Leases (Lease Position) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails">
        <link:definition>0000081 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1">
        <link:definition>0000081 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails">
        <link:definition>0000082 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails">
        <link:definition>0000083 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAdditionalInformationDetails" roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails">
        <link:definition>0000084 - Disclosure - Discontinued Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000085 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails">
        <link:definition>0000086 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ValuationandQualifyingAccountsDetails" roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails">
        <link:definition>0000087 - Disclosure - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cpix_NoncashOrPartNoncashGainOnTransaction" abstract="false" name="NoncashOrPartNoncashGainOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SharebasedCompensationCharitableContributionofSharesShares" abstract="false" name="SharebasedCompensationCharitableContributionofSharesShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_AcetadoteMember" abstract="true" name="AcetadoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" abstract="false" name="DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" abstract="false" name="DefinedContributionPlanEligibilityMinimumEmployeeAge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_SancusoMember" abstract="true" name="SancusoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CumberlandEmergingTechnologiesIncMember" abstract="true" name="CumberlandEmergingTechnologiesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" abstract="false" name="StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductRightsMember" abstract="true" name="ProductRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ScheduleOfDistributionCostsTableTextBlock" abstract="false" name="ScheduleOfDistributionCostsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_ContributionOfCashAdditionalSharesPurchased" abstract="false" name="ContributionOfCashAdditionalSharesPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsDeferredCharges" abstract="false" name="DeferredTaxAssetsDeferredCharges" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_OtherRevenuesAbstract" abstract="true" name="OtherRevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" abstract="false" name="ShareBasedCompensationCharitableContributionOfSharesCashContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_IfetrobanClinicalMember" abstract="true" name="IfetrobanClinicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsThreshold" abstract="false" name="TieredRoyaltyPaymentsThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SecondAmendmentMember" abstract="true" name="SecondAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ScheduleOfAdvertisingCostsTableTextBlock" abstract="false" name="ScheduleOfAdvertisingCostsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" abstract="false" name="FiniteLivedIntangibleAssetsUsefulLivesTextual" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" abstract="true" name="CollaborativeArrangementMilestonePaymentThresholdAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VaprisolMember" abstract="true" name="VaprisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CreditIssuedForMilestonePayable" abstract="false" name="CreditIssuedForMilestonePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CaldolorMember" abstract="true" name="CaldolorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_Within30DaysOfFirstSNDAFilingMember" abstract="true" name="Within30DaysOfFirstSNDAFilingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseLeasedArea" abstract="false" name="LesseeOperatingLeaseLeasedArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseNumberOfRenewalTerms" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalTerms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPurchaseOfShares" abstract="false" name="SubsidiaryInvestmentPurchaseOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" abstract="false" name="PurchasesOfIntangibleAssetsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NordicGroupBVMember" abstract="true" name="NordicGroupBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" abstract="false" name="StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_HongKongWinHealthPharmaGroupCoLimitedMember" abstract="true" name="HongKongWinHealthPharmaGroupCoLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_DenominatorAbstract" abstract="true" name="DenominatorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_RevenueRecognitionMilestonePayments" abstract="false" name="RevenueRecognitionMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_TieredRoyaltyPaymentsPercentage" abstract="false" name="TieredRoyaltyPaymentsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" abstract="false" name="ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsTerm" abstract="false" name="CollaborativeArrangementRightsAndObligationsTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_DeferredTaxAssetOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" abstract="true" name="CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FinancialConsiderationNumberOfInstallments" abstract="false" name="FinancialConsiderationNumberOfInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_ExpirationTimePeriodDomain" abstract="true" name="ExpirationTimePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_ExpirationTermOneMember" abstract="true" name="ExpirationTermOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ProductAndLicenseRightsMember" abstract="true" name="ProductAndLicenseRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" abstract="false" name="BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" abstract="false" name="DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" abstract="false" name="DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cpix_CETMember" abstract="true" name="CETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_NonemployeeMember" abstract="true" name="NonemployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ExpirationTimePeriodAxis" abstract="true" name="ExpirationTimePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IntercompanyLoansPayableConvertedAmount" abstract="false" name="IntercompanyLoansPayableConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseBaseRent" abstract="false" name="LesseeOperatingLeaseBaseRent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="srt-types:perUnitItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_KristaloseMember" abstract="true" name="KristaloseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_FollowingApprovalOfFirstSNDAMember" abstract="true" name="FollowingApprovalOfFirstSNDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" abstract="false" name="ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_KyowaKirinMember" abstract="true" name="KyowaKirinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_RevenueRecognitionCumulativeUpfrontPayment" abstract="false" name="RevenueRecognitionCumulativeUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AccountsReceivableAllowancesByComponentAxis" abstract="true" name="AccountsReceivableAllowancesByComponentAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_AccruedLiabilitiesStockPayable" abstract="false" name="AccruedLiabilitiesStockPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" abstract="false" name="CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_EmploymentAgreementsAbstract" abstract="true" name="EmploymentAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_HarbinGloriaPharmaceuticalsCoMember" abstract="true" name="HarbinGloriaPharmaceuticalsCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_FederalAndStateMember" abstract="true" name="FederalAndStateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ScheduleofDepreciationExpenseTableTextBlock" abstract="false" name="ScheduleofDepreciationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" abstract="false" name="DebtInstrumentCovenantUnrestrictedCashThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" abstract="false" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_WinHealthInvestmentSingaporeLtdMember" abstract="true" name="WinHealthInvestmentSingaporeLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_InitialPublicOfferingAbstract" abstract="true" name="InitialPublicOfferingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ExpirationTermTwoMember" abstract="true" name="ExpirationTermTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CashPaidDuringYearForAbstract" abstract="true" name="CashPaidDuringYearForAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_IndefiniteMember" abstract="true" name="IndefiniteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ManufacturingandSupplyAgreementLineItems" abstract="true" name="ManufacturingandSupplyAgreementLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" abstract="false" name="CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cpix_NumeratorAbstract" abstract="true" name="NumeratorAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" abstract="false" name="ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_NonprincipalOwnerMember" abstract="true" name="NonprincipalOwnerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" abstract="true" name="CollaborativeArrangementMilestonePaymentThresholdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ProceedsFromCollaborationArrangement" abstract="false" name="ProceedsFromCollaborationArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" abstract="false" name="StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_SharesRepurchaseActivityTypeDomain" abstract="true" name="SharesRepurchaseActivityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_FinancialConsiderationPaymentPeriod" abstract="false" name="FinancialConsiderationPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cpix_ProductSalesRelatedLiabilitiesCurrent" abstract="false" name="ProductSalesRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LongTermIncentiveCompensationPlan2007Member" abstract="true" name="LongTermIncentiveCompensationPlan2007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LesseeOperatingLeaseRentIncrease" abstract="false" name="LesseeOperatingLeaseRentIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" abstract="false" name="DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PreferredStockAbstract" abstract="true" name="PreferredStockAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_NetDeferredTaxAssetsGross" abstract="false" name="NetDeferredTaxAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_NinthAmemdmentMember" abstract="true" name="NinthAmemdmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" abstract="false" name="RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_VIBATIVMember" abstract="true" name="VIBATIVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" abstract="true" name="ChargebacksCashDiscountsAndDamagedGoodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" abstract="true" name="MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_SalesRevenueGoodsGrossMember" abstract="true" name="SalesRevenueGoodsGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ProductRevenuesAbstract" abstract="true" name="ProductRevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" abstract="false" name="PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_PinnacleBankMember" abstract="true" name="PinnacleBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_RediTrexMember" abstract="true" name="RediTrexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ManufacturingAndSupplyAgreementsTextBlock" abstract="false" name="ManufacturingAndSupplyAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" abstract="false" name="CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ProductVibativMember" abstract="true" name="ProductVibativMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ProceedsFromSurrenderOfLifeInsurancePolicy" abstract="false" name="ProceedsFromSurrenderOfLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_CommonStockAbstract" abstract="true" name="CommonStockAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" abstract="false" name="DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" abstract="false" name="RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ShareRepurchaseProgramAuthorizedIn2010Member" abstract="true" name="ShareRepurchaseProgramAuthorizedIn2010Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_SharesRepurchaseActivityTypeAxis" abstract="true" name="SharesRepurchaseActivityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_ManufacturingAndSupplyAgreementsAbstract" abstract="true" name="ManufacturingAndSupplyAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cpix_MethotrexateMember" abstract="true" name="MethotrexateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" abstract="false" name="SubsidiaryInvestmentPaymentsForReturnOfCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_RevenueRecognitionUpfrontPayment" abstract="false" name="RevenueRecognitionUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_ManufacturingandSupplyAgreementTable" abstract="true" name="ManufacturingandSupplyAgreementTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cpix_EmploymentAgreementsTextBlock" abstract="false" name="EmploymentAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_StockIssuedDuringPeriodPricePerShareNewIssues" abstract="false" name="StockIssuedDuringPeriodPricePerShareNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" abstract="false" name="TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_DirectorsIncentivePlan2007Member" abstract="true" name="DirectorsIncentivePlan2007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_FifthAmendmentMember" abstract="true" name="FifthAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_AccountsReceivableAllowancesByComponentDomain" abstract="true" name="AccountsReceivableAllowancesByComponentDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_RestrictedIncentiveStockOptionsMember" abstract="true" name="RestrictedIncentiveStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_OmeclamoxPakMember" abstract="true" name="OmeclamoxPakMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" abstract="false" name="ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cpix_GloriaPharmaceuticalsMember" abstract="true" name="GloriaPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" abstract="false" name="LineOfCreditFacilityAdditionalBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_PaymentProtectionProgramMember" abstract="true" name="PaymentProtectionProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_ProceedsFromSettlementOfPatentLitigation" abstract="false" name="ProceedsFromSettlementOfPatentLitigation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_EmployeeNonemployeeandFoundationContributionMember" abstract="true" name="EmployeeNonemployeeandFoundationContributionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_WorkInProcessMember" abstract="true" name="WorkInProcessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" abstract="false" name="IncreaseDecreaseInProceedsFromLifeInsurancePolicy" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cpix_BroadwestLeaseFiveYearRenewalOptionMember" abstract="true" name="BroadwestLeaseFiveYearRenewalOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_A1600WestEndAvenuePartnersLLCMember" abstract="true" name="A1600WestEndAvenuePartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" abstract="true" name="SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_Customer12And3Member" abstract="true" name="Customer12And3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cpix_AccruedLiabilitiesInventoryPurchases" abstract="false" name="AccruedLiabilitiesInventoryPurchases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>cpix-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f3294900-4a6d-4934-9914-8de8a2261475,g:98ef8ed7-f771-4377-a070-411ae3070b66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8efa4eed-d3fe-4ceb-a949-c3a7d34077d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_693e58bb-afe7-4379-aeca-af46aae17f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8efa4eed-d3fe-4ceb-a949-c3a7d34077d6" xlink:to="loc_us-gaap_Liabilities_693e58bb-afe7-4379-aeca-af46aae17f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ea0a5fb9-ea0c-4a7f-b117-607415220fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8efa4eed-d3fe-4ceb-a949-c3a7d34077d6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ea0a5fb9-ea0c-4a7f-b117-607415220fa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8fcc07c7-9775-4909-9570-3802f2d8b23b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8efa4eed-d3fe-4ceb-a949-c3a7d34077d6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8fcc07c7-9775-4909-9570-3802f2d8b23b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_db740415-391d-470d-aefb-9cf9387b7132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_21a1b318-5758-4d8e-b007-0fef5b580a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db740415-391d-470d-aefb-9cf9387b7132" xlink:to="loc_us-gaap_AssetsCurrent_21a1b318-5758-4d8e-b007-0fef5b580a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_35d7b974-497a-4816-8dd3-9f6a82dbcd3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db740415-391d-470d-aefb-9cf9387b7132" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_35d7b974-497a-4816-8dd3-9f6a82dbcd3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7e04eb65-7a35-418c-ac19-ebff2c91d731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db740415-391d-470d-aefb-9cf9387b7132" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7e04eb65-7a35-418c-ac19-ebff2c91d731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0cfdcb2c-8d5e-4db5-8561-1ecdad6f057c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db740415-391d-470d-aefb-9cf9387b7132" xlink:to="loc_us-gaap_Goodwill_0cfdcb2c-8d5e-4db5-8561-1ecdad6f057c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fcaa93e0-31a2-4894-81c7-dd6f2b370dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db740415-391d-470d-aefb-9cf9387b7132" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fcaa93e0-31a2-4894-81c7-dd6f2b370dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_fa8bcb56-77af-40c9-9833-fd56583a18c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db740415-391d-470d-aefb-9cf9387b7132" xlink:to="loc_us-gaap_InventoryNoncurrent_fa8bcb56-77af-40c9-9833-fd56583a18c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1537f872-9dcb-410c-b88a-448007c639ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_db740415-391d-470d-aefb-9cf9387b7132" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1537f872-9dcb-410c-b88a-448007c639ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_22154bf4-c9c5-4156-8233-20e40ed77f51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_500925b5-890a-4764-8d61-fa7145cc871f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_22154bf4-c9c5-4156-8233-20e40ed77f51" xlink:to="loc_us-gaap_StockholdersEquity_500925b5-890a-4764-8d61-fa7145cc871f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_6097a326-20db-4c89-870d-c3cf602eba67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_22154bf4-c9c5-4156-8233-20e40ed77f51" xlink:to="loc_us-gaap_MinorityInterest_6097a326-20db-4c89-870d-c3cf602eba67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9662f0fd-90c2-4505-8111-81c2d7258754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_6eba98f3-a55b-421b-bedb-227f448f1b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9662f0fd-90c2-4505-8111-81c2d7258754" xlink:to="loc_us-gaap_AccountsPayableCurrent_6eba98f3-a55b-421b-bedb-227f448f1b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5259926c-96df-4374-bd30-a4b43b4ad4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9662f0fd-90c2-4505-8111-81c2d7258754" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5259926c-96df-4374-bd30-a4b43b4ad4e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2183a1af-fc1a-4e0d-b882-7888fcb9b6d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9662f0fd-90c2-4505-8111-81c2d7258754" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2183a1af-fc1a-4e0d-b882-7888fcb9b6d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_abdf239d-8f84-464d-8a44-ec97436b60a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_633b204a-b5e1-48b3-baad-b3063fe57d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_abdf239d-8f84-464d-8a44-ec97436b60a4" xlink:to="loc_us-gaap_CommonStockValueOutstanding_633b204a-b5e1-48b3-baad-b3063fe57d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8d0249b3-7ecb-4cfe-95a2-714275ecb8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_abdf239d-8f84-464d-8a44-ec97436b60a4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8d0249b3-7ecb-4cfe-95a2-714275ecb8aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_371c5567-f750-4179-9118-b69d645add3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_865d21c2-351a-4fa9-9e29-afe9a6c2d942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_371c5567-f750-4179-9118-b69d645add3a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_865d21c2-351a-4fa9-9e29-afe9a6c2d942" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8cf4218c-d745-478b-8e8c-6196a65a5b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_371c5567-f750-4179-9118-b69d645add3a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8cf4218c-d745-478b-8e8c-6196a65a5b95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d7d9f9ed-9baf-497e-927f-da434401e918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_371c5567-f750-4179-9118-b69d645add3a" xlink:to="loc_us-gaap_InventoryNet_d7d9f9ed-9baf-497e-927f-da434401e918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cec7f9b8-e56a-4d31-923c-af3ae78cc440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_371c5567-f750-4179-9118-b69d645add3a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cec7f9b8-e56a-4d31-923c-af3ae78cc440" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5001fd90-806e-4b00-af21-fe09378ff622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2e4b00f2-6545-4bd1-bcdd-8517266518cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5001fd90-806e-4b00-af21-fe09378ff622" xlink:to="loc_us-gaap_LiabilitiesCurrent_2e4b00f2-6545-4bd1-bcdd-8517266518cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_8cb95980-9987-4ed8-b5f1-c76d98ea3100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5001fd90-806e-4b00-af21-fe09378ff622" xlink:to="loc_us-gaap_LongTermLineOfCredit_8cb95980-9987-4ed8-b5f1-c76d98ea3100" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ea98c4a9-6331-493d-b317-4192d376e3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5001fd90-806e-4b00-af21-fe09378ff622" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ea98c4a9-6331-493d-b317-4192d376e3fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1fae1118-9aaa-43fe-8349-0e7102d4ff86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5001fd90-806e-4b00-af21-fe09378ff622" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1fae1118-9aaa-43fe-8349-0e7102d4ff86" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1aebffc9-d544-4b9c-a785-58fcab1e39ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c1ccb651-ba20-4039-a77a-c0501f12f56f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1aebffc9-d544-4b9c-a785-58fcab1e39ac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c1ccb651-ba20-4039-a77a-c0501f12f56f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_93c60055-9afa-45fb-be49-6810e423b71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1aebffc9-d544-4b9c-a785-58fcab1e39ac" xlink:to="loc_us-gaap_SellingAndMarketingExpense_93c60055-9afa-45fb-be49-6810e423b71b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_24fc1083-e736-4495-8ff0-2cbebc69f140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1aebffc9-d544-4b9c-a785-58fcab1e39ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_24fc1083-e736-4495-8ff0-2cbebc69f140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_301ee96f-9a99-441a-a3ef-0c3e3ffc6761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1aebffc9-d544-4b9c-a785-58fcab1e39ac" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_301ee96f-9a99-441a-a3ef-0c3e3ffc6761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_e17cb292-6b10-40f5-b44f-129376194b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1aebffc9-d544-4b9c-a785-58fcab1e39ac" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_e17cb292-6b10-40f5-b44f-129376194b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b62f2933-dfbc-4e6b-9f88-e42a23645184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_03681a60-bdac-4ab5-b1ae-f2b59f253aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b62f2933-dfbc-4e6b-9f88-e42a23645184" xlink:to="loc_us-gaap_CostsAndExpenses_03681a60-bdac-4ab5-b1ae-f2b59f253aa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9dd1cee3-73e1-4892-a2eb-f8506c320e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b62f2933-dfbc-4e6b-9f88-e42a23645184" xlink:to="loc_us-gaap_Revenues_9dd1cee3-73e1-4892-a2eb-f8506c320e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_02251a8b-5801-4072-b710-e8084c46d6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a6cab8c9-8833-4840-83c9-5fd1c32aa74a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_02251a8b-5801-4072-b710-e8084c46d6f8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_a6cab8c9-8833-4840-83c9-5fd1c32aa74a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0dc0645f-0bfb-4c1e-b56a-90c75c78b917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_02251a8b-5801-4072-b710-e8084c46d6f8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0dc0645f-0bfb-4c1e-b56a-90c75c78b917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2c66dce1-ff2b-4ced-842f-3196f6339315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd4214e0-6c5a-4785-9443-b3666c112045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2c66dce1-ff2b-4ced-842f-3196f6339315" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cd4214e0-6c5a-4785-9443-b3666c112045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e54e6bbb-4b4d-499d-8061-bd67d259403b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2c66dce1-ff2b-4ced-842f-3196f6339315" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e54e6bbb-4b4d-499d-8061-bd67d259403b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1fe86cd0-410a-4e6c-926a-6b49f19041f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9915f78d-8d1f-4191-ac8d-785f53b173f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1fe86cd0-410a-4e6c-926a-6b49f19041f9" xlink:to="loc_us-gaap_OperatingIncomeLoss_9915f78d-8d1f-4191-ac8d-785f53b173f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_90a3da41-1aa6-4e0f-b9e4-1d2f36482d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1fe86cd0-410a-4e6c-926a-6b49f19041f9" xlink:to="loc_us-gaap_InterestExpense_90a3da41-1aa6-4e0f-b9e4-1d2f36482d00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_9fcd49ae-d0b0-447e-9e82-56d526c45132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1fe86cd0-410a-4e6c-926a-6b49f19041f9" xlink:to="loc_us-gaap_OtherIncome_9fcd49ae-d0b0-447e-9e82-56d526c45132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2bfd71e7-0af8-413a-b193-6ca9441991be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1fe86cd0-410a-4e6c-926a-6b49f19041f9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2bfd71e7-0af8-413a-b193-6ca9441991be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_0247354f-4a4d-42bd-b4ba-1ea4c4a0566a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1fe86cd0-410a-4e6c-926a-6b49f19041f9" xlink:to="loc_us-gaap_InsuredEventGainLoss_0247354f-4a4d-42bd-b4ba-1ea4c4a0566a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_107c6d59-7418-4eac-9cd3-1399725b4367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2eb988f0-2a14-4862-9407-37629ec722dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_107c6d59-7418-4eac-9cd3-1399725b4367" xlink:to="loc_us-gaap_ProfitLoss_2eb988f0-2a14-4862-9407-37629ec722dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2e1d9537-bd8b-4ce0-9a7c-499f0623947f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_107c6d59-7418-4eac-9cd3-1399725b4367" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2e1d9537-bd8b-4ce0-9a7c-499f0623947f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_5de6f390-6e0b-4993-bc34-23350ce4819f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_5de6f390-6e0b-4993-bc34-23350ce4819f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9f5ff766-fcbd-4c8a-95e1-2eddb870501f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_9f5ff766-fcbd-4c8a-95e1-2eddb870501f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_462e604d-1b9b-4656-a8ff-7ad3cbcfb9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_462e604d-1b9b-4656-a8ff-7ad3cbcfb9c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_08d7dd57-6b18-4998-b209-47f55bfc87a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_08d7dd57-6b18-4998-b209-47f55bfc87a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_626f2c14-dbdd-4506-bce7-35ad0ce2d9e0" xlink:href="cpix-20221231.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_626f2c14-dbdd-4506-bce7-35ad0ce2d9e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8fae2d7b-b3f2-42fd-a57f-136cbf2d447b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8fae2d7b-b3f2-42fd-a57f-136cbf2d447b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_42f29924-5afe-4533-ba14-4a3e0358ff20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_42f29924-5afe-4533-ba14-4a3e0358ff20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_eb06a09e-45a9-4e01-a6d3-c458189ea8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_eb06a09e-45a9-4e01-a6d3-c458189ea8fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c7e0173c-1a0e-4095-a535-269359ac9f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_ShareBasedCompensation_c7e0173c-1a0e-4095-a535-269359ac9f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_54b86155-cff4-4fec-b5b8-2630740a1981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_54b86155-cff4-4fec-b5b8-2630740a1981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NoncashOrPartNoncashGainOnTransaction_0b7944dd-8f5f-4c8b-93ac-e111796048e0" xlink:href="cpix-20221231.xsd#cpix_NoncashOrPartNoncashGainOnTransaction"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_cpix_NoncashOrPartNoncashGainOnTransaction_0b7944dd-8f5f-4c8b-93ac-e111796048e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_c23579d9-edce-4f09-9eb5-1c4e7af82114" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_c23579d9-edce-4f09-9eb5-1c4e7af82114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_a760d613-b844-492c-bd56-e61690cc0337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_a760d613-b844-492c-bd56-e61690cc0337" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7c9d28c3-d4cc-4901-afe4-4e5881be4dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7c9d28c3-d4cc-4901-afe4-4e5881be4dbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0dc3376b-ca8d-4ec3-9282-6c222407b280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0a3c58-bab1-436b-86af-6e4b22809871" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_0dc3376b-ca8d-4ec3-9282-6c222407b280" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6344f7e0-310f-4a6c-b7f0-4525d6687361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_20dcca18-1f37-4903-b060-46312ddb08d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6344f7e0-310f-4a6c-b7f0-4525d6687361" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_20dcca18-1f37-4903-b060-46312ddb08d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_f7bae8e0-b5aa-468d-aadd-81eac02d4c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6344f7e0-310f-4a6c-b7f0-4525d6687361" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_f7bae8e0-b5aa-468d-aadd-81eac02d4c9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19d940ea-2630-400f-8140-fbf15df56a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ef53ee96-7810-441c-8b17-d692cb10e138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19d940ea-2630-400f-8140-fbf15df56a01" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ef53ee96-7810-441c-8b17-d692cb10e138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3d8724ca-6a63-442c-9d16-2641a3ff9ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19d940ea-2630-400f-8140-fbf15df56a01" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3d8724ca-6a63-442c-9d16-2641a3ff9ef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_cc83d86c-8356-4b54-a54c-9af8ea62814e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19d940ea-2630-400f-8140-fbf15df56a01" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_cc83d86c-8356-4b54-a54c-9af8ea62814e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_33dddfbe-8148-4531-a678-5b6fa26b5ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_19d940ea-2630-400f-8140-fbf15df56a01" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_33dddfbe-8148-4531-a678-5b6fa26b5ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_458bc346-7a3b-4d60-b6b8-adbdb8dd4ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0faad43-064b-438f-a579-fbbc8e445e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_458bc346-7a3b-4d60-b6b8-adbdb8dd4ec8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0faad43-064b-438f-a579-fbbc8e445e34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c721645-faf3-4311-bcff-f7a3aabf0ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_458bc346-7a3b-4d60-b6b8-adbdb8dd4ec8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3c721645-faf3-4311-bcff-f7a3aabf0ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3338166d-4d8a-44ce-8525-8b6200ef9b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_458bc346-7a3b-4d60-b6b8-adbdb8dd4ec8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3338166d-4d8a-44ce-8525-8b6200ef9b12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8740ab8f-6b9e-4b55-a6c6-ee2712e9a9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_dbd3fcb4-74c8-4188-b153-79194c920246" xlink:href="cpix-20221231.xsd#cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8740ab8f-6b9e-4b55-a6c6-ee2712e9a9c0" xlink:to="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_dbd3fcb4-74c8-4188-b153-79194c920246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_88674e26-7748-4cb2-b4f8-d3bdab17229c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8740ab8f-6b9e-4b55-a6c6-ee2712e9a9c0" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_88674e26-7748-4cb2-b4f8-d3bdab17229c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_336c309f-d18e-4b5d-aac6-204d8a3120c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8740ab8f-6b9e-4b55-a6c6-ee2712e9a9c0" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_336c309f-d18e-4b5d-aac6-204d8a3120c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSettlementOfPatentLitigation_e05e85cb-10f8-4e32-920e-a8a22c282f3f" xlink:href="cpix-20221231.xsd#cpix_ProceedsFromSettlementOfPatentLitigation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8740ab8f-6b9e-4b55-a6c6-ee2712e9a9c0" xlink:to="loc_cpix_ProceedsFromSettlementOfPatentLitigation_e05e85cb-10f8-4e32-920e-a8a22c282f3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1c1d12b1-15f2-43a9-96d0-36ce59820718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8740ab8f-6b9e-4b55-a6c6-ee2712e9a9c0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1c1d12b1-15f2-43a9-96d0-36ce59820718" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d4a5201c-c356-41fd-8453-4b241d5b946a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8740ab8f-6b9e-4b55-a6c6-ee2712e9a9c0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_d4a5201c-c356-41fd-8453-4b241d5b946a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromCollaborationArrangement_d0510b87-cebe-40ce-8501-ba7713c9113b" xlink:href="cpix-20221231.xsd#cpix_ProceedsFromCollaborationArrangement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8740ab8f-6b9e-4b55-a6c6-ee2712e9a9c0" xlink:to="loc_cpix_ProceedsFromCollaborationArrangement_d0510b87-cebe-40ce-8501-ba7713c9113b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c5fbdf98-b2d5-4da8-bebc-81cae182abca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8740ab8f-6b9e-4b55-a6c6-ee2712e9a9c0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c5fbdf98-b2d5-4da8-bebc-81cae182abca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy_5e015011-e636-4914-aa81-8a14cf394f30" xlink:href="cpix-20221231.xsd#cpix_ProceedsFromSurrenderOfLifeInsurancePolicy"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8740ab8f-6b9e-4b55-a6c6-ee2712e9a9c0" xlink:to="loc_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy_5e015011-e636-4914-aa81-8a14cf394f30" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_9de847e9-cad5-46bc-a8e9-a39f2d84ef02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_0d3bdda3-2a3f-48b7-84eb-b37e45bd269c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_9de847e9-cad5-46bc-a8e9-a39f2d84ef02" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_0d3bdda3-2a3f-48b7-84eb-b37e45bd269c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e19fd055-09fd-480a-98fb-6b02425c48ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_9de847e9-cad5-46bc-a8e9-a39f2d84ef02" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e19fd055-09fd-480a-98fb-6b02425c48ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_dd5a072a-6138-4bba-81bb-b392a1b99a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_9de847e9-cad5-46bc-a8e9-a39f2d84ef02" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_dd5a072a-6138-4bba-81bb-b392a1b99a90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_84884a37-b044-467b-ac63-27ae2562309a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b9c072a9-6988-4c12-b026-962f25e21d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_84884a37-b044-467b-ac63-27ae2562309a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b9c072a9-6988-4c12-b026-962f25e21d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4ba72ff3-d042-4382-b713-bf7d0a030902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_84884a37-b044-467b-ac63-27ae2562309a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4ba72ff3-d042-4382-b713-bf7d0a030902" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f36e46a-75a7-48c7-aec9-b82ef1067ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_def3807f-a0bf-43ca-a631-7d0370179a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f36e46a-75a7-48c7-aec9-b82ef1067ca9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_def3807f-a0bf-43ca-a631-7d0370179a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ec688969-5c0e-4720-ac09-15f32cedc2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f36e46a-75a7-48c7-aec9-b82ef1067ca9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ec688969-5c0e-4720-ac09-15f32cedc2bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2063c181-aa3f-48d7-9cd2-b6e7473b58c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0a515e00-7508-4810-923e-a72854c4650d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2063c181-aa3f-48d7-9cd2-b6e7473b58c9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0a515e00-7508-4810-923e-a72854c4650d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_aeca0a57-021e-48d6-bb1f-d6a149e75a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2063c181-aa3f-48d7-9cd2-b6e7473b58c9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_aeca0a57-021e-48d6-bb1f-d6a149e75a95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4692c2b7-1373-420b-bc6c-a6b4aff9a99a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2063c181-aa3f-48d7-9cd2-b6e7473b58c9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4692c2b7-1373-420b-bc6c-a6b4aff9a99a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_08db7801-e7e2-454a-9b11-7a2ee0b9f26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2063c181-aa3f-48d7-9cd2-b6e7473b58c9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_08db7801-e7e2-454a-9b11-7a2ee0b9f26f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_c291afe0-add1-4b64-88d1-7e225d0fddc9" xlink:href="cpix-20221231.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2063c181-aa3f-48d7-9cd2-b6e7473b58c9" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_c291afe0-add1-4b64-88d1-7e225d0fddc9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b241895d-416c-4a15-83a6-a5de5ac9a75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_33ad6869-f5ac-453e-9c05-f9da78f9a9c0" xlink:href="cpix-20221231.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b241895d-416c-4a15-83a6-a5de5ac9a75c" xlink:to="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_33ad6869-f5ac-453e-9c05-f9da78f9a9c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6331ba2b-29d5-4a47-a3f3-c5192c0d2c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b241895d-416c-4a15-83a6-a5de5ac9a75c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6331ba2b-29d5-4a47-a3f3-c5192c0d2c9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ae911d4c-8b99-4ca9-93af-5fb1a5603dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b241895d-416c-4a15-83a6-a5de5ac9a75c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ae911d4c-8b99-4ca9-93af-5fb1a5603dcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStockPayable_c21bfc7b-fca3-41e2-b403-dcb0c6047516" xlink:href="cpix-20221231.xsd#cpix_AccruedLiabilitiesStockPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b241895d-416c-4a15-83a6-a5de5ac9a75c" xlink:to="loc_cpix_AccruedLiabilitiesStockPayable_c21bfc7b-fca3-41e2-b403-dcb0c6047516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases_48a7419c-a3fa-490d-aac1-d1d7d0c1a0eb" xlink:href="cpix-20221231.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b241895d-416c-4a15-83a6-a5de5ac9a75c" xlink:to="loc_cpix_AccruedLiabilitiesInventoryPurchases_48a7419c-a3fa-490d-aac1-d1d7d0c1a0eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_a15f1cdf-ebef-4ee5-bd1c-d08bce45459d" xlink:href="cpix-20221231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b241895d-416c-4a15-83a6-a5de5ac9a75c" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_a15f1cdf-ebef-4ee5-bd1c-d08bce45459d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8705bcde-b90a-43d1-82a4-16bc6194518e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b241895d-416c-4a15-83a6-a5de5ac9a75c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_8705bcde-b90a-43d1-82a4-16bc6194518e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0488b077-4dc3-406d-9042-4b83464cc3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_1669a123-7a4b-43d6-b73d-d808b9fc0497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_0488b077-4dc3-406d-9042-4b83464cc3c0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_1669a123-7a4b-43d6-b73d-d808b9fc0497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3a9876dc-424b-4d0c-9693-a24f49c6b75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_0488b077-4dc3-406d-9042-4b83464cc3c0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_3a9876dc-424b-4d0c-9693-a24f49c6b75d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_00bfb7f4-3526-4083-9050-f637074d8811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_0488b077-4dc3-406d-9042-4b83464cc3c0" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_00bfb7f4-3526-4083-9050-f637074d8811" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_7c76c3b9-a214-4c88-9c38-c78da9a70fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_7c76c3b9-a214-4c88-9c38-c78da9a70fb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_21204671-f911-4dc0-b1f2-81a3a281a18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_21204671-f911-4dc0-b1f2-81a3a281a18c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_590fb0ba-17c9-4251-a501-c1d609c406dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_590fb0ba-17c9-4251-a501-c1d609c406dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fc874426-76ca-436f-be75-223078ca02e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fc874426-76ca-436f-be75-223078ca02e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_095d6e4c-ea26-48d9-aff6-3528f61eabae" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:to="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_095d6e4c-ea26-48d9-aff6-3528f61eabae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges_7d675a79-3a91-4e4c-ac86-9097c21a7980" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:to="loc_cpix_DeferredTaxAssetsDeferredCharges_7d675a79-3a91-4e4c-ac86-9097c21a7980" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities_a98c46a5-12d7-4663-9f1f-4e8194f84913" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetOperatingLeaseLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:to="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities_a98c46a5-12d7-4663-9f1f-4e8194f84913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5596c01a-2d54-47bb-b18a-e7018f2ed74c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5596c01a-2d54-47bb-b18a-e7018f2ed74c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_fe7c4a77-0b34-4f30-b765-eea32626e6ff" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:to="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_fe7c4a77-0b34-4f30-b765-eea32626e6ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_36cce670-df11-497d-aff2-80f31ae558a5" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6ca70900-f996-4c41-801e-26ee76451aef" xlink:to="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_36cce670-df11-497d-aff2-80f31ae558a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_1f80aeb0-de16-428d-8a34-bb5683f8ba8d" xlink:href="cpix-20221231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_96053e5d-20fb-418e-96dc-64ec8c329dd8" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_1f80aeb0-de16-428d-8a34-bb5683f8ba8d" xlink:to="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_96053e5d-20fb-418e-96dc-64ec8c329dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_dd063d4a-1381-457a-a610-41000aac92e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_NetDeferredTaxAssetsGross_1f80aeb0-de16-428d-8a34-bb5683f8ba8d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_dd063d4a-1381-457a-a610-41000aac92e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_355170e6-a480-4719-9f60-cc01c751e947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_deb4fa6f-e238-40be-bcce-2b6408dd4a5b" xlink:href="cpix-20221231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_355170e6-a480-4719-9f60-cc01c751e947" xlink:to="loc_cpix_NetDeferredTaxAssetsGross_deb4fa6f-e238-40be-bcce-2b6408dd4a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c0db510f-2d02-42f0-931d-d4b0911342d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_355170e6-a480-4719-9f60-cc01c751e947" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c0db510f-2d02-42f0-931d-d4b0911342d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a1701cdd-9f96-4e73-b2e0-2bf674e8e4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_025c70ea-4699-419b-92d4-3ba159a956e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a1701cdd-9f96-4e73-b2e0-2bf674e8e4e5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_025c70ea-4699-419b-92d4-3ba159a956e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_60b027e4-aa41-4561-b8c9-ad49e8243f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a1701cdd-9f96-4e73-b2e0-2bf674e8e4e5" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_60b027e4-aa41-4561-b8c9-ad49e8243f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_77e3781e-46f7-4d87-a964-162f99ff9a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_083ee327-8807-4ccd-8a16-d15f272fc230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_77e3781e-46f7-4d87-a964-162f99ff9a3b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_083ee327-8807-4ccd-8a16-d15f272fc230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1fc624e4-1d17-4ae6-a40c-0e0f2dea1ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit_77e3781e-46f7-4d87-a964-162f99ff9a3b" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1fc624e4-1d17-4ae6-a40c-0e0f2dea1ce0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c68cdb62-d496-4e67-a8ce-fb35fa7275fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2e74cc94-f651-40e4-84bc-475403e2f604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c68cdb62-d496-4e67-a8ce-fb35fa7275fc" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2e74cc94-f651-40e4-84bc-475403e2f604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_dd363dda-3b8f-4c2c-8279-4ecb5928c8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c68cdb62-d496-4e67-a8ce-fb35fa7275fc" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_dd363dda-3b8f-4c2c-8279-4ecb5928c8cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e00f1ccf-d71a-4271-85b0-88488dbbf3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7e38ac69-25ff-43ef-91a3-31873a8b03b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e00f1ccf-d71a-4271-85b0-88488dbbf3c9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7e38ac69-25ff-43ef-91a3-31873a8b03b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bd0a6f3a-6c7c-429c-8300-052b2d799b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e00f1ccf-d71a-4271-85b0-88488dbbf3c9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bd0a6f3a-6c7c-429c-8300-052b2d799b92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_84384d04-f7f2-4d29-8319-79a20f353a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e00f1ccf-d71a-4271-85b0-88488dbbf3c9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_84384d04-f7f2-4d29-8319-79a20f353a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_848988e5-7486-4789-8235-475e6db8ddd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e00f1ccf-d71a-4271-85b0-88488dbbf3c9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_848988e5-7486-4789-8235-475e6db8ddd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_cbd4cd0d-63de-4309-a466-cc04295479f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e00f1ccf-d71a-4271-85b0-88488dbbf3c9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_cbd4cd0d-63de-4309-a466-cc04295479f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e9d16859-d068-4e08-8f21-efa7c0ef1901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e00f1ccf-d71a-4271-85b0-88488dbbf3c9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e9d16859-d068-4e08-8f21-efa7c0ef1901" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#LeasesLeasePositionDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_42a952cd-3a01-4cd0-912c-5dc911a2768e" xlink:href="cpix-20221231.xsd#cpix_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_797b44f6-45b4-409f-982b-fe8c657f251d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_LeaseLiability_42a952cd-3a01-4cd0-912c-5dc911a2768e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_797b44f6-45b4-409f-982b-fe8c657f251d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e2af2e4a-80f1-437c-b800-bc2a1f15c913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cpix_LeaseLiability_42a952cd-3a01-4cd0-912c-5dc911a2768e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e2af2e4a-80f1-437c-b800-bc2a1f15c913" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a4c1f6dd-ee15-4a9a-a832-a3567065d824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3412ca33-ad29-4fe0-9b86-f216e032627a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a4c1f6dd-ee15-4a9a-a832-a3567065d824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3412ca33-ad29-4fe0-9b86-f216e032627a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a4e6eb8a-56be-4e1d-b2b3-9f9698c2f8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a4c1f6dd-ee15-4a9a-a832-a3567065d824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a4e6eb8a-56be-4e1d-b2b3-9f9698c2f8c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e5dc31b4-138e-413e-9a40-bcdfa2226396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a4c1f6dd-ee15-4a9a-a832-a3567065d824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e5dc31b4-138e-413e-9a40-bcdfa2226396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f0b7b612-b389-4ae4-ae30-33fb39127eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a4c1f6dd-ee15-4a9a-a832-a3567065d824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f0b7b612-b389-4ae4-ae30-33fb39127eb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ad81a2a6-57db-4b94-b1a2-0b9cf0cea31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a4c1f6dd-ee15-4a9a-a832-a3567065d824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ad81a2a6-57db-4b94-b1a2-0b9cf0cea31a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_beec931e-e90e-4d43-9459-a7f4a552f1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a4c1f6dd-ee15-4a9a-a832-a3567065d824" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_beec931e-e90e-4d43-9459-a7f4a552f1e6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="simple" xlink:href="cpix-20221231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c16e2090-58e3-4261-a423-10d71e4b4493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_12373d45-b809-430d-b643-20be5840a5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c16e2090-58e3-4261-a423-10d71e4b4493" xlink:to="loc_us-gaap_OperatingLeaseLiability_12373d45-b809-430d-b643-20be5840a5b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ee3ab1f4-5c96-4bcc-bd2d-42cc26eef4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c16e2090-58e3-4261-a423-10d71e4b4493" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ee3ab1f4-5c96-4bcc-bd2d-42cc26eef4aa" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>cpix-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f3294900-4a6d-4934-9914-8de8a2261475,g:98ef8ed7-f771-4377-a070-411ae3070b66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="ia9e99b0e827b4899bf89e3597c32b91d_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a560a093-25be-4638-8d0b-e26a1db91f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_RevenuesAbstract_a560a093-25be-4638-8d0b-e26a1db91f2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9151ee6b-0d75-4b54-90b4-13449e158f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a560a093-25be-4638-8d0b-e26a1db91f2e" xlink:to="loc_us-gaap_Revenues_9151ee6b-0d75-4b54-90b4-13449e158f70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_356d4bf9-a10e-40f9-a585-159147cfff18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_356d4bf9-a10e-40f9-a585-159147cfff18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d611f36c-a654-41e7-a71e-40d9d973e3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d611f36c-a654-41e7-a71e-40d9d973e3b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f2e35393-e0e5-450b-89ea-326b972f3b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f2e35393-e0e5-450b-89ea-326b972f3b34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_08430f5a-5543-4e34-8575-0279b433b7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_08430f5a-5543-4e34-8575-0279b433b7ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ad03585c-0138-408a-95ec-0e8bd0857acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ad03585c-0138-408a-95ec-0e8bd0857acc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fce0f67c-bf01-4e81-be91-76fc9fb3035e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_CostsAndExpenses_fce0f67c-bf01-4e81-be91-76fc9fb3035e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ea328df7-8a4f-45dc-98d5-8fb8b37e1fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_OperatingIncomeLoss_ea328df7-8a4f-45dc-98d5-8fb8b37e1fca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e7932b01-f1eb-43c3-be21-aefb4c20c41a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e7932b01-f1eb-43c3-be21-aefb4c20c41a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_a9a11545-5602-48af-8b5a-ba2458cd331f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_OtherIncome_a9a11545-5602-48af-8b5a-ba2458cd331f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_bb1214c3-57cf-44a5-8710-08eef18a2155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_InsuredEventGainLoss_bb1214c3-57cf-44a5-8710-08eef18a2155" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bbe51062-8cda-41cf-a433-f201aa64ac7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_InterestExpense_bbe51062-8cda-41cf-a433-f201aa64ac7e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d046fb62-732e-4ef7-aa43-78e61eb1e361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d046fb62-732e-4ef7-aa43-78e61eb1e361" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ccdc04ce-8ae1-49aa-9b98-d13a0a614f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ccdc04ce-8ae1-49aa-9b98-d13a0a614f0e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f721959a-98bc-45f4-a40a-5812070ee31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f721959a-98bc-45f4-a40a-5812070ee31b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9280d99d-8daa-4cb8-ae81-6b32771cc2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9280d99d-8daa-4cb8-ae81-6b32771cc2ef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_356aad5f-5112-473b-b704-f1f7d8d73ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_ProfitLoss_356aad5f-5112-473b-b704-f1f7d8d73ad0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6bae5eaf-133c-4008-a80b-f271c9247bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6bae5eaf-133c-4008-a80b-f271c9247bd4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_725d4db8-0ee8-4a83-8573-0ebd691b4ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_NetIncomeLoss_725d4db8-0ee8-4a83-8573-0ebd691b4ee8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e12f7eba-9927-4b5e-a1c4-790fd6df7001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e12f7eba-9927-4b5e-a1c4-790fd6df7001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_a89fc7c8-7c3c-43a3-8f90-ecb023d39634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_a89fc7c8-7c3c-43a3-8f90-ecb023d39634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3b9dd7e5-928b-4887-8f50-27c52d3a6917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_EarningsPerShareBasic_3b9dd7e5-928b-4887-8f50-27c52d3a6917" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_64673057-acc2-4fec-9ca9-fb89733bb8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_64673057-acc2-4fec-9ca9-fb89733bb8e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_024fc8cb-7bd8-4644-894f-34d38d7edcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_024fc8cb-7bd8-4644-894f-34d38d7edcc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1b00fbac-4333-4105-b20c-fd2cf28464ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1b00fbac-4333-4105-b20c-fd2cf28464ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_655eb915-1dd5-4155-926b-9f840df65713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_655eb915-1dd5-4155-926b-9f840df65713" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fd4b2f9f-312a-4bef-9ffb-e12af42c8fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_655eb915-1dd5-4155-926b-9f840df65713" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fd4b2f9f-312a-4bef-9ffb-e12af42c8fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5493f149-727a-415c-a52d-fc230a7bae9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_655eb915-1dd5-4155-926b-9f840df65713" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5493f149-727a-415c-a52d-fc230a7bae9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9304a0e2-a0c2-4977-b784-1e6ffa05caba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_StatementTable_9304a0e2-a0c2-4977-b784-1e6ffa05caba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_24c982f4-ee9a-4011-baca-308c6a3a217f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9304a0e2-a0c2-4977-b784-1e6ffa05caba" xlink:to="loc_srt_ProductOrServiceAxis_24c982f4-ee9a-4011-baca-308c6a3a217f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_24c982f4-ee9a-4011-baca-308c6a3a217f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_24c982f4-ee9a-4011-baca-308c6a3a217f" xlink:to="loc_srt_ProductsAndServicesDomain_24c982f4-ee9a-4011-baca-308c6a3a217f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5099d65c-7543-40c7-96e4-bf3faf8572a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_24c982f4-ee9a-4011-baca-308c6a3a217f" xlink:to="loc_srt_ProductsAndServicesDomain_5099d65c-7543-40c7-96e4-bf3faf8572a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_75bbebba-1dab-48b9-8de1-2a76478c22df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5099d65c-7543-40c7-96e4-bf3faf8572a2" xlink:to="loc_us-gaap_ProductMember_75bbebba-1dab-48b9-8de1-2a76478c22df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_60115f0b-993d-4a2a-ba31-43f0fc07a68c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5099d65c-7543-40c7-96e4-bf3faf8572a2" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_60115f0b-993d-4a2a-ba31-43f0fc07a68c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20221231.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="id939a19f35ee4430bdb2c9913a7bd70e_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_55fed691-fa85-4d7a-8243-3592475270a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55fed691-fa85-4d7a-8243-3592475270a1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_29a950f4-ecf6-4f58-9f2e-5160fd7e5d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_29a950f4-ecf6-4f58-9f2e-5160fd7e5d24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7cb3bc0-18e0-4513-94f2-02f0758198e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7cb3bc0-18e0-4513-94f2-02f0758198e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3f7a243f-cb40-4f68-87ae-8921cf2a97da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_NetIncomeLoss_3f7a243f-cb40-4f68-87ae-8921cf2a97da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_15b00173-d7af-4e84-86ee-9a06009c5dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_15b00173-d7af-4e84-86ee-9a06009c5dcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_52246a98-41c9-4ea4-8be8-f0531be476d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_ProfitLoss_52246a98-41c9-4ea4-8be8-f0531be476d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_cbab720b-b704-4c40-94d4-68f69f979b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_cbab720b-b704-4c40-94d4-68f69f979b18" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_38428cf0-70d5-4792-994d-092a787bc456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_38428cf0-70d5-4792-994d-092a787bc456" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_71ad5ba4-7225-4288-b800-15f451f33409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_71ad5ba4-7225-4288-b800-15f451f33409" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_919348d2-3247-4c2e-b289-b76a7f504a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_919348d2-3247-4c2e-b289-b76a7f504a26" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_d8404652-eb7f-4d6a-b7e5-45adb4e1f18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_d8404652-eb7f-4d6a-b7e5-45adb4e1f18a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_b05f5a73-6937-4943-b63b-d26b4fbbf7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_b05f5a73-6937-4943-b63b-d26b4fbbf7cb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0c7c41bb-6ff9-44c5-92fb-c6c388b28870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_210bb1f5-ca2a-44e5-9f46-7ece3a6d24c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ee2a8d2-e3c7-4925-a6e8-9fc6735beb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_55fed691-fa85-4d7a-8243-3592475270a1" xlink:to="loc_us-gaap_StatementTable_2ee2a8d2-e3c7-4925-a6e8-9fc6735beb4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fde97187-8844-4077-8a47-f0d18f7bb54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2ee2a8d2-e3c7-4925-a6e8-9fc6735beb4c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fde97187-8844-4077-8a47-f0d18f7bb54f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fde97187-8844-4077-8a47-f0d18f7bb54f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fde97187-8844-4077-8a47-f0d18f7bb54f" xlink:to="loc_us-gaap_EquityComponentDomain_fde97187-8844-4077-8a47-f0d18f7bb54f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c19329a0-4cfb-4d19-817c-304bb598a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fde97187-8844-4077-8a47-f0d18f7bb54f" xlink:to="loc_us-gaap_EquityComponentDomain_c19329a0-4cfb-4d19-817c-304bb598a84a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e4fe6a16-abed-486c-bb3c-b1aceba101a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c19329a0-4cfb-4d19-817c-304bb598a84a" xlink:to="loc_us-gaap_CommonStockMember_e4fe6a16-abed-486c-bb3c-b1aceba101a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_45a168d8-7291-43ca-bf42-da0baedce858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c19329a0-4cfb-4d19-817c-304bb598a84a" xlink:to="loc_us-gaap_RetainedEarningsMember_45a168d8-7291-43ca-bf42-da0baedce858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2eb9de6e-5cba-487d-87cb-253c093955ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c19329a0-4cfb-4d19-817c-304bb598a84a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2eb9de6e-5cba-487d-87cb-253c093955ab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#OrganizationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended" id="i7f33d63e4a8844a8a11622d0f5c4e4c2_OrganizationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_285ffdd9-f89b-4eac-b348-2101ec07dd44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_285ffdd9-f89b-4eac-b348-2101ec07dd44" xlink:to="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_2ac2b9bf-07b9-4831-829f-43e26ad508e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_2ac2b9bf-07b9-4831-829f-43e26ad508e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d6253f9f-2c13-4751-9370-e93267edb112" xlink:href="cpix-20221231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d6253f9f-2c13-4751-9370-e93267edb112" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ContributionOfCashAdditionalSharesPurchased_5c1ba1d3-38b0-4477-a493-4876e8de44e8" xlink:href="cpix-20221231.xsd#cpix_ContributionOfCashAdditionalSharesPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_ContributionOfCashAdditionalSharesPurchased_5c1ba1d3-38b0-4477-a493-4876e8de44e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IntercompanyLoansPayableConvertedAmount_92cf3db8-a9f5-4925-a623-1a670f0a6868" xlink:href="cpix-20221231.xsd#cpix_IntercompanyLoansPayableConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_IntercompanyLoansPayableConvertedAmount_92cf3db8-a9f5-4925-a623-1a670f0a6868" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_48e52e1b-93ae-48d9-981b-52bbba36efe4" xlink:href="cpix-20221231.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_48e52e1b-93ae-48d9-981b-52bbba36efe4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ab9efc7f-780c-4b8f-9030-a0459de9373a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ab9efc7f-780c-4b8f-9030-a0459de9373a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9fa8574f-3e07-4ccf-8bd2-d584d761ff73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9fa8574f-3e07-4ccf-8bd2-d584d761ff73" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_8f1d4e3f-b79a-4c81-abc2-35edcad17002" xlink:href="cpix-20221231.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_8f1d4e3f-b79a-4c81-abc2-35edcad17002" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_99fa45e2-1b51-4949-a340-8350d46e8e2c" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_99fa45e2-1b51-4949-a340-8350d46e8e2c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_08198cf8-173e-485e-88b6-963bd77a9eba" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_08198cf8-173e-485e-88b6-963bd77a9eba" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_285ffdd9-f89b-4eac-b348-2101ec07dd44" xlink:to="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_415b9f0e-36f5-43a4-b351-07984bd82ea7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:to="loc_dei_LegalEntityAxis_415b9f0e-36f5-43a4-b351-07984bd82ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_415b9f0e-36f5-43a4-b351-07984bd82ea7_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_415b9f0e-36f5-43a4-b351-07984bd82ea7" xlink:to="loc_dei_EntityDomain_415b9f0e-36f5-43a4-b351-07984bd82ea7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5e28d212-51af-4840-aefb-4db6ffa964d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_415b9f0e-36f5-43a4-b351-07984bd82ea7" xlink:to="loc_dei_EntityDomain_5e28d212-51af-4840-aefb-4db6ffa964d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_8c6cbbfc-6451-4eaa-a332-f2eb10dc7653" xlink:href="cpix-20221231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5e28d212-51af-4840-aefb-4db6ffa964d0" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_8c6cbbfc-6451-4eaa-a332-f2eb10dc7653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_560d39e0-8551-454e-a8c0-0e498cd86971" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:to="loc_srt_CounterpartyNameAxis_560d39e0-8551-454e-a8c0-0e498cd86971" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_560d39e0-8551-454e-a8c0-0e498cd86971_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_560d39e0-8551-454e-a8c0-0e498cd86971" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_560d39e0-8551-454e-a8c0-0e498cd86971_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_078e820e-d5fe-43ce-8525-b2f3c458e01a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_560d39e0-8551-454e-a8c0-0e498cd86971" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_078e820e-d5fe-43ce-8525-b2f3c458e01a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_c49ac435-5569-49e9-be4e-b093c8f7065b" xlink:href="cpix-20221231.xsd#cpix_HarbinGloriaPharmaceuticalsCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_078e820e-d5fe-43ce-8525-b2f3c458e01a" xlink:to="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_c49ac435-5569-49e9-be4e-b093c8f7065b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_f241153e-d73d-40a2-b26f-9d3142bf523d" xlink:href="cpix-20221231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_078e820e-d5fe-43ce-8525-b2f3c458e01a" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_f241153e-d73d-40a2-b26f-9d3142bf523d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_295c8b28-78ff-445f-8a31-3e0fd9f985d3" xlink:href="cpix-20221231.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_078e820e-d5fe-43ce-8525-b2f3c458e01a" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_295c8b28-78ff-445f-8a31-3e0fd9f985d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_2811e01e-cb15-4c18-ba3f-3e0260cb5d63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:to="loc_srt_OwnershipAxis_2811e01e-cb15-4c18-ba3f-3e0260cb5d63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_2811e01e-cb15-4c18-ba3f-3e0260cb5d63_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_2811e01e-cb15-4c18-ba3f-3e0260cb5d63" xlink:to="loc_srt_OwnershipDomain_2811e01e-cb15-4c18-ba3f-3e0260cb5d63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_663e3ddf-5fff-40a6-b98d-78a30bfb735a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_2811e01e-cb15-4c18-ba3f-3e0260cb5d63" xlink:to="loc_srt_OwnershipDomain_663e3ddf-5fff-40a6-b98d-78a30bfb735a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_99b0842d-395e-48d2-924a-1fbab34ed441" xlink:href="cpix-20221231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_663e3ddf-5fff-40a6-b98d-78a30bfb735a" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_99b0842d-395e-48d2-924a-1fbab34ed441" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i8a6dd82d28514edaae720b691e1f5fd4_SignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_22267e53-4adf-4b50-a550-116f720b255b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_22267e53-4adf-4b50-a550-116f720b255b" xlink:to="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_daa6a5cb-0712-4194-be05-660b38c50906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_daa6a5cb-0712-4194-be05-660b38c50906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c69bddca-d1dd-4b3d-9ae5-3ed29ae56a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_Revenues_c69bddca-d1dd-4b3d-9ae5-3ed29ae56a45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_70fbfc46-92ac-4a98-92dc-1466629ea32b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_70fbfc46-92ac-4a98-92dc-1466629ea32b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_89e9da70-67f4-491a-bfcf-f56d4e2c4288" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_89e9da70-67f4-491a-bfcf-f56d4e2c4288" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2668ef8e-0d28-4cf0-8a34-3950ef5eb2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2668ef8e-0d28-4cf0-8a34-3950ef5eb2e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_8514901b-0fd3-4012-b950-9180f8f1faae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_8514901b-0fd3-4012-b950-9180f8f1faae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_90ee7d59-52d4-486a-919e-9115f09941cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_90ee7d59-52d4-486a-919e-9115f09941cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_22267e53-4adf-4b50-a550-116f720b255b" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7d0fd9b8-37a0-4c3d-9c26-06880b9d98ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:to="loc_srt_CounterpartyNameAxis_7d0fd9b8-37a0-4c3d-9c26-06880b9d98ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d0fd9b8-37a0-4c3d-9c26-06880b9d98ce_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7d0fd9b8-37a0-4c3d-9c26-06880b9d98ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7d0fd9b8-37a0-4c3d-9c26-06880b9d98ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31e3503d-3f79-443f-b80b-a7d23ff88d7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7d0fd9b8-37a0-4c3d-9c26-06880b9d98ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31e3503d-3f79-443f-b80b-a7d23ff88d7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember_5d6f6446-b174-4a77-a62c-095ce8725af7" xlink:href="cpix-20221231.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31e3503d-3f79-443f-b80b-a7d23ff88d7f" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdMember_5d6f6446-b174-4a77-a62c-095ce8725af7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dbd40a44-066a-4f5e-a75c-c72177bc25d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:to="loc_srt_StatementGeographicalAxis_dbd40a44-066a-4f5e-a75c-c72177bc25d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dbd40a44-066a-4f5e-a75c-c72177bc25d8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_dbd40a44-066a-4f5e-a75c-c72177bc25d8" xlink:to="loc_srt_SegmentGeographicalDomain_dbd40a44-066a-4f5e-a75c-c72177bc25d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_809453d4-871a-4d80-ac66-1f5338058a5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_dbd40a44-066a-4f5e-a75c-c72177bc25d8" xlink:to="loc_srt_SegmentGeographicalDomain_809453d4-871a-4d80-ac66-1f5338058a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_803f3ca2-f73f-481b-82ab-aa6c958bc10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_809453d4-871a-4d80-ac66-1f5338058a5d" xlink:to="loc_us-gaap_NonUsMember_803f3ca2-f73f-481b-82ab-aa6c958bc10b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b891f96f-e45c-49e7-bea7-76f2ed837b0e" xlink:href="cpix-20221231.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b891f96f-e45c-49e7-bea7-76f2ed837b0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_b891f96f-e45c-49e7-bea7-76f2ed837b0e_default" xlink:href="cpix-20221231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b891f96f-e45c-49e7-bea7-76f2ed837b0e" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_b891f96f-e45c-49e7-bea7-76f2ed837b0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_2807348f-a46c-4fbb-b2a4-67aa58438c40" xlink:href="cpix-20221231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b891f96f-e45c-49e7-bea7-76f2ed837b0e" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_2807348f-a46c-4fbb-b2a4-67aa58438c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_84ed6622-2105-4ce1-8fa9-1f333968d3c8" xlink:href="cpix-20221231.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain_2807348f-a46c-4fbb-b2a4-67aa58438c40" xlink:to="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_84ed6622-2105-4ce1-8fa9-1f333968d3c8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="extended" id="i44adc4d63d9c49a58bd21f8561a016b7_SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_713e393a-5951-4d4a-bcc3-039d9661afb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_989f8f90-de29-40e6-b40a-1782d89ae5d2" xlink:href="cpix-20221231.xsd#cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_713e393a-5951-4d4a-bcc3-039d9661afb8" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_989f8f90-de29-40e6-b40a-1782d89ae5d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9539773a-c516-40be-bc22-28ede0a4c71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_713e393a-5951-4d4a-bcc3-039d9661afb8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9539773a-c516-40be-bc22-28ede0a4c71d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ce400304-fed2-4204-b06b-98a6cc906362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9539773a-c516-40be-bc22-28ede0a4c71d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ce400304-fed2-4204-b06b-98a6cc906362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce400304-fed2-4204-b06b-98a6cc906362_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ce400304-fed2-4204-b06b-98a6cc906362" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ce400304-fed2-4204-b06b-98a6cc906362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78b30fb7-c4de-411f-8191-c411afee0fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ce400304-fed2-4204-b06b-98a6cc906362" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78b30fb7-c4de-411f-8191-c411afee0fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRightsMember_dff38342-c85f-4612-80c7-06c1dde9d1f6" xlink:href="cpix-20221231.xsd#cpix_ProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78b30fb7-c4de-411f-8191-c411afee0fc6" xlink:to="loc_cpix_ProductRightsMember_dff38342-c85f-4612-80c7-06c1dde9d1f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b585589f-0e3e-479a-9334-973133b5a3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78b30fb7-c4de-411f-8191-c411afee0fc6" xlink:to="loc_us-gaap_LicensingAgreementsMember_b585589f-0e3e-479a-9334-973133b5a3dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_a19900ab-426f-448c-8f59-9746ae433aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78b30fb7-c4de-411f-8191-c411afee0fc6" xlink:to="loc_us-gaap_PatentsMember_a19900ab-426f-448c-8f59-9746ae433aa7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#RediTrexVibativandSancusoNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails" xlink:type="extended" id="i5cec08827b5140198225893e24df08ec_RediTrexVibativandSancusoNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_dbd053da-cdfa-4670-8a3e-b00b31d3f2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_dbd053da-cdfa-4670-8a3e-b00b31d3f2a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6949c1af-98bb-4c1d-a85e-5e8d954c8640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6949c1af-98bb-4c1d-a85e-5e8d954c8640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2bbd8592-679e-4a8b-a0ea-f35f6e3be0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2bbd8592-679e-4a8b-a0ea-f35f6e3be0d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e948f306-a752-4209-b63f-b46d1fd3811e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e948f306-a752-4209-b63f-b46d1fd3811e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e6c34294-9982-487f-862b-debc309444c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e6c34294-9982-487f-862b-debc309444c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_24cf13bf-37fe-4e75-9ffe-c1cde8920ac5" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_24cf13bf-37fe-4e75-9ffe-c1cde8920ac5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_9c6e4b8b-4fbb-4d6d-a854-738802b4fef6" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_9c6e4b8b-4fbb-4d6d-a854-738802b4fef6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_57220274-97f0-41bc-b6ed-2c706ffdf693" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_57220274-97f0-41bc-b6ed-2c706ffdf693" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e68693-323c-4bb5-96e8-c23015a9c2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e68693-323c-4bb5-96e8-c23015a9c2bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_f8cf0625-fec2-4c36-90fe-9b37d91ac0ae" xlink:href="cpix-20221231.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_f8cf0625-fec2-4c36-90fe-9b37d91ac0ae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold_7b754664-5e7e-4bae-a475-9fbf93c504cf" xlink:href="cpix-20221231.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_TieredRoyaltyPaymentsThreshold_7b754664-5e7e-4bae-a475-9fbf93c504cf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0d7a61c0-4dc4-4b44-889b-81fa96c562b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0d7a61c0-4dc4-4b44-889b-81fa96c562b2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c50f54b5-d2ff-434d-86ad-681f7ca4d107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c50f54b5-d2ff-434d-86ad-681f7ca4d107" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_b0f007ee-456f-4f98-9e54-b22c17436d2b" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_b0f007ee-456f-4f98-9e54-b22c17436d2b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_0c9247d0-e234-42f5-9606-4703ba093e9f" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_0c9247d0-e234-42f5-9606-4703ba093e9f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_e369397d-9825-454e-a75c-a692469a6d92" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_e369397d-9825-454e-a75c-a692469a6d92" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining_ba7028bb-6263-428e-b081-fc1e5720b59e" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining_ba7028bb-6263-428e-b081-fc1e5720b59e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold_69767a71-a55b-47f1-984e-fea81019861b" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold_69767a71-a55b-47f1-984e-fea81019861b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_0c778467-742e-4156-beee-55fe7f1f19ca" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_0c778467-742e-4156-beee-55fe7f1f19ca" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_94dfbcb9-af2a-4b36-9337-4b201b70c95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_94dfbcb9-af2a-4b36-9337-4b201b70c95c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_7253c253-85fa-4fac-bb44-d08ff15b4209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_7253c253-85fa-4fac-bb44-d08ff15b4209" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6f36d1d7-cd15-4bd5-8448-bc11bf014e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_Goodwill_6f36d1d7-cd15-4bd5-8448-bc11bf014e26" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_df41e806-2db9-4db8-9040-afd25bfb9745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_df41e806-2db9-4db8-9040-afd25bfb9745" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_827b1d9d-fcb8-4c4d-8571-e1ea0fa21caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_827b1d9d-fcb8-4c4d-8571-e1ea0fa21caf" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_1a4a22ec-9c62-47a7-9474-6fcd5f971020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_1a4a22ec-9c62-47a7-9474-6fcd5f971020" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_19a070ac-a932-4571-8a0e-e5ac82d1bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_19a070ac-a932-4571-8a0e-e5ac82d1bfa5" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_4f6ea117-cfc7-42da-854d-998a6a42d12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_4f6ea117-cfc7-42da-854d-998a6a42d12d" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7e5bc428-4e7c-4319-bfe7-8e4dc4ee301b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_us-gaap_AwardTypeAxis_7e5bc428-4e7c-4319-bfe7-8e4dc4ee301b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e5bc428-4e7c-4319-bfe7-8e4dc4ee301b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7e5bc428-4e7c-4319-bfe7-8e4dc4ee301b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e5bc428-4e7c-4319-bfe7-8e4dc4ee301b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ca72ab-2243-417f-b74e-71b686e79e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7e5bc428-4e7c-4319-bfe7-8e4dc4ee301b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ca72ab-2243-417f-b74e-71b686e79e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_24a83941-417e-4710-9114-86c8dbd7f822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ca72ab-2243-417f-b74e-71b686e79e90" xlink:to="loc_us-gaap_RestrictedStockMember_24a83941-417e-4710-9114-86c8dbd7f822" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7887e648-4eb7-4af8-84cf-bc7bf4144b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7887e648-4eb7-4af8-84cf-bc7bf4144b23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7887e648-4eb7-4af8-84cf-bc7bf4144b23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7887e648-4eb7-4af8-84cf-bc7bf4144b23" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7887e648-4eb7-4af8-84cf-bc7bf4144b23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0847b8c-6da6-417c-84e1-8faa70b649bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7887e648-4eb7-4af8-84cf-bc7bf4144b23" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0847b8c-6da6-417c-84e1-8faa70b649bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_668c2ff8-babe-4255-b578-aace166f112f" xlink:href="cpix-20221231.xsd#cpix_MethotrexateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0847b8c-6da6-417c-84e1-8faa70b649bc" xlink:to="loc_cpix_MethotrexateMember_668c2ff8-babe-4255-b578-aace166f112f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_437d42f7-46f2-47be-9daf-2dce098b08fb" xlink:href="cpix-20221231.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0847b8c-6da6-417c-84e1-8faa70b649bc" xlink:to="loc_cpix_SancusoMember_437d42f7-46f2-47be-9daf-2dce098b08fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_a40ee1d2-7950-4371-b909-5cb02eec32b3" xlink:href="cpix-20221231.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0847b8c-6da6-417c-84e1-8faa70b649bc" xlink:to="loc_cpix_VIBATIVMember_a40ee1d2-7950-4371-b909-5cb02eec32b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_438cd78a-8e96-442b-a5e7-7650540aba50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_srt_CounterpartyNameAxis_438cd78a-8e96-442b-a5e7-7650540aba50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_438cd78a-8e96-442b-a5e7-7650540aba50_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_438cd78a-8e96-442b-a5e7-7650540aba50" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_438cd78a-8e96-442b-a5e7-7650540aba50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f6655b7-8246-4bc5-bc98-c07679b8c4cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_438cd78a-8e96-442b-a5e7-7650540aba50" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f6655b7-8246-4bc5-bc98-c07679b8c4cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember_8c354878-afa9-46aa-9601-8bd43a49c8e3" xlink:href="cpix-20221231.xsd#cpix_KyowaKirinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f6655b7-8246-4bc5-bc98-c07679b8c4cc" xlink:to="loc_cpix_KyowaKirinMember_8c354878-afa9-46aa-9601-8bd43a49c8e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_abc226aa-e288-49a8-8198-b2174345f0a0" xlink:href="cpix-20221231.xsd#cpix_NordicGroupBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f6655b7-8246-4bc5-bc98-c07679b8c4cc" xlink:to="loc_cpix_NordicGroupBVMember_abc226aa-e288-49a8-8198-b2174345f0a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_911c167d-3a27-47a5-a070-dd1076f4a782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_us-gaap_TypeOfArrangementAxis_911c167d-3a27-47a5-a070-dd1076f4a782" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_911c167d-3a27-47a5-a070-dd1076f4a782_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_911c167d-3a27-47a5-a070-dd1076f4a782" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_911c167d-3a27-47a5-a070-dd1076f4a782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a20501-1a40-48b7-bb2a-f01de04c82f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_911c167d-3a27-47a5-a070-dd1076f4a782" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a20501-1a40-48b7-bb2a-f01de04c82f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d0efb8d1-20e5-4dd8-84fd-299d9a31296b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a20501-1a40-48b7-bb2a-f01de04c82f2" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d0efb8d1-20e5-4dd8-84fd-299d9a31296b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_526ea7aa-1e5a-4761-9497-c03078e08fad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_srt_RangeAxis_526ea7aa-1e5a-4761-9497-c03078e08fad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_526ea7aa-1e5a-4761-9497-c03078e08fad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_526ea7aa-1e5a-4761-9497-c03078e08fad" xlink:to="loc_srt_RangeMember_526ea7aa-1e5a-4761-9497-c03078e08fad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c58ba579-123b-4f8f-a7a0-833d14b45a44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_526ea7aa-1e5a-4761-9497-c03078e08fad" xlink:to="loc_srt_RangeMember_c58ba579-123b-4f8f-a7a0-833d14b45a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fc752d75-ad62-4800-bbef-3c31043af7a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c58ba579-123b-4f8f-a7a0-833d14b45a44" xlink:to="loc_srt_MaximumMember_fc752d75-ad62-4800-bbef-3c31043af7a4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="extended" id="i76b84af62fa5410c9163199d73a0ca59_RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_18f83fb2-7013-43fe-822c-6d8e1f6ca604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_18f83fb2-7013-43fe-822c-6d8e1f6ca604" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_e637d8fd-1858-4092-859c-ab8258cd2ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:to="loc_us-gaap_PaymentsForRoyalties_e637d8fd-1858-4092-859c-ab8258cd2ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4859ff33-8fdc-4ea7-aaac-65e3a6a8495a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4859ff33-8fdc-4ea7-aaac-65e3a6a8495a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_5e975a64-1771-444c-978b-e03a38debdf7" xlink:href="cpix-20221231.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_5e975a64-1771-444c-978b-e03a38debdf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_96bf8620-cc25-4904-90ac-8b4b670bda20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c917ed17-276b-4de2-aa84-01e22f089a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c917ed17-276b-4de2-aa84-01e22f089a29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c5a89b5e-b520-4c5d-8645-dcb481474cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c917ed17-276b-4de2-aa84-01e22f089a29" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c5a89b5e-b520-4c5d-8645-dcb481474cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c5a89b5e-b520-4c5d-8645-dcb481474cc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c5a89b5e-b520-4c5d-8645-dcb481474cc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c5a89b5e-b520-4c5d-8645-dcb481474cc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c74825f-4754-494d-8c89-f43f058d8eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c5a89b5e-b520-4c5d-8645-dcb481474cc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c74825f-4754-494d-8c89-f43f058d8eae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_7e449286-178f-41c5-8a3b-51dd923256d8" xlink:href="cpix-20221231.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c74825f-4754-494d-8c89-f43f058d8eae" xlink:to="loc_cpix_VIBATIVMember_7e449286-178f-41c5-8a3b-51dd923256d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_56231a51-e860-47ef-9488-4b2a9f546dfb" xlink:href="cpix-20221231.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c74825f-4754-494d-8c89-f43f058d8eae" xlink:to="loc_cpix_SancusoMember_56231a51-e860-47ef-9488-4b2a9f546dfb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended" id="i86e32a24920e4c9fac6cc8c3a0c82004_RevenuesScheduleofNetProductRevenuesbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4196cb05-7576-46d9-a9b1-d576776617c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_691e523d-146a-4d09-81bd-13f1ae604678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4196cb05-7576-46d9-a9b1-d576776617c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_691e523d-146a-4d09-81bd-13f1ae604678" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3d9a88b2-5446-4488-b761-38df2061ed42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4196cb05-7576-46d9-a9b1-d576776617c6" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3d9a88b2-5446-4488-b761-38df2061ed42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab6d8a6c-ceee-49f9-a6a9-15a57d854843" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3d9a88b2-5446-4488-b761-38df2061ed42" xlink:to="loc_srt_ProductOrServiceAxis_ab6d8a6c-ceee-49f9-a6a9-15a57d854843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab6d8a6c-ceee-49f9-a6a9-15a57d854843_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ab6d8a6c-ceee-49f9-a6a9-15a57d854843" xlink:to="loc_srt_ProductsAndServicesDomain_ab6d8a6c-ceee-49f9-a6a9-15a57d854843_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ab6d8a6c-ceee-49f9-a6a9-15a57d854843" xlink:to="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_6d29844f-8d7c-45ff-863c-7c86185fae5b" xlink:href="cpix-20221231.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_KristaloseMember_6d29844f-8d7c-45ff-863c-7c86185fae5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_be048a82-56dc-4dce-9eaa-5a166d035fe1" xlink:href="cpix-20221231.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_SancusoMember_be048a82-56dc-4dce-9eaa-5a166d035fe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_32e42f55-1140-4821-8979-b10d4b4b806c" xlink:href="cpix-20221231.xsd#cpix_CaldolorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_CaldolorMember_32e42f55-1140-4821-8979-b10d4b4b806c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember_33b839ea-19d6-4dae-8224-14d578e330b4" xlink:href="cpix-20221231.xsd#cpix_ProductVibativMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_ProductVibativMember_33b839ea-19d6-4dae-8224-14d578e330b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_a6d13afd-642a-4c37-a091-3a9cd2075c52" xlink:href="cpix-20221231.xsd#cpix_AcetadoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_AcetadoteMember_a6d13afd-642a-4c37-a091-3a9cd2075c52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_c49ce94c-3ff2-406d-a943-01f52b3c077a" xlink:href="cpix-20221231.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_OmeclamoxPakMember_c49ce94c-3ff2-406d-a943-01f52b3c077a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_55a8af66-6bca-4f6c-a62e-715db51b033f" xlink:href="cpix-20221231.xsd#cpix_VaprisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_VaprisolMember_55a8af66-6bca-4f6c-a62e-715db51b033f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_9af80ad8-1796-44f6-b8b1-8748224a72b4" xlink:href="cpix-20221231.xsd#cpix_RediTrexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_RediTrexMember_9af80ad8-1796-44f6-b8b1-8748224a72b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_06a88533-0bcb-4b00-b119-f05af392894f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3d9a88b2-5446-4488-b761-38df2061ed42" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_06a88533-0bcb-4b00-b119-f05af392894f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06a88533-0bcb-4b00-b119-f05af392894f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_06a88533-0bcb-4b00-b119-f05af392894f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06a88533-0bcb-4b00-b119-f05af392894f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa1a00ab-1676-4258-a655-6ae19c7318c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_06a88533-0bcb-4b00-b119-f05af392894f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa1a00ab-1676-4258-a655-6ae19c7318c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_a2d0417a-d89c-44e5-9a10-38c99acadedc" xlink:href="cpix-20221231.xsd#cpix_OmeclamoxPakMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa1a00ab-1676-4258-a655-6ae19c7318c2" xlink:to="loc_cpix_OmeclamoxPakMember_a2d0417a-d89c-44e5-9a10-38c99acadedc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="i3425f457f9a1475d9719cee1f470d088_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aafa6af1-6aa8-439b-bac6-61d27dc9a2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRevenuesAbstract_6888e2bf-a69a-428b-b0f0-de9b4d6a04e1" xlink:href="cpix-20221231.xsd#cpix_ProductRevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aafa6af1-6aa8-439b-bac6-61d27dc9a2e1" xlink:to="loc_cpix_ProductRevenuesAbstract_6888e2bf-a69a-428b-b0f0-de9b4d6a04e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2774cac6-37db-424f-969a-88b6705544ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ProductRevenuesAbstract_6888e2bf-a69a-428b-b0f0-de9b4d6a04e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2774cac6-37db-424f-969a-88b6705544ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:href="cpix-20221231.xsd#cpix_OtherRevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aafa6af1-6aa8-439b-bac6-61d27dc9a2e1" xlink:to="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionUpfrontPayment_ff7a6fe6-78c3-4903-98af-0ac5d81a779e" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:to="loc_cpix_RevenueRecognitionUpfrontPayment_ff7a6fe6-78c3-4903-98af-0ac5d81a779e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_643ea9c4-7f7f-4504-9eab-a1269693798c" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_643ea9c4-7f7f-4504-9eab-a1269693798c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_2cc1fb6c-409d-431a-a3c7-d09db051124e" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_2cc1fb6c-409d-431a-a3c7-d09db051124e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_38bf98e8-3a86-4ba5-bb56-c29a9453e8aa" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionCumulativeUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:to="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_38bf98e8-3a86-4ba5-bb56-c29a9453e8aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments_00719341-9052-466f-9173-3bed3edbd5b6" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:to="loc_cpix_RevenueRecognitionMilestonePayments_00719341-9052-466f-9173-3bed3edbd5b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e77afff5-de10-4f42-bb8c-19a2f77a9d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aafa6af1-6aa8-439b-bac6-61d27dc9a2e1" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e77afff5-de10-4f42-bb8c-19a2f77a9d7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_624d2a6d-ef0d-44e6-bce7-03341a51d49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e77afff5-de10-4f42-bb8c-19a2f77a9d7e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_624d2a6d-ef0d-44e6-bce7-03341a51d49f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_624d2a6d-ef0d-44e6-bce7-03341a51d49f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_624d2a6d-ef0d-44e6-bce7-03341a51d49f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_624d2a6d-ef0d-44e6-bce7-03341a51d49f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_691971ae-8699-4e1c-810f-79252ad686b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_624d2a6d-ef0d-44e6-bce7-03341a51d49f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_691971ae-8699-4e1c-810f-79252ad686b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_f2ef6a18-85b1-4329-ba9e-111053c9fc65" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_691971ae-8699-4e1c-810f-79252ad686b0" xlink:to="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_f2ef6a18-85b1-4329-ba9e-111053c9fc65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_80c80745-763b-4b6d-9350-3f1e18569272" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e77afff5-de10-4f42-bb8c-19a2f77a9d7e" xlink:to="loc_srt_ProductOrServiceAxis_80c80745-763b-4b6d-9350-3f1e18569272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_80c80745-763b-4b6d-9350-3f1e18569272_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_80c80745-763b-4b6d-9350-3f1e18569272" xlink:to="loc_srt_ProductsAndServicesDomain_80c80745-763b-4b6d-9350-3f1e18569272_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d8bbf2f-af54-4cb6-b24f-00010da3fdcc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_80c80745-763b-4b6d-9350-3f1e18569272" xlink:to="loc_srt_ProductsAndServicesDomain_9d8bbf2f-af54-4cb6-b24f-00010da3fdcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_5f8cf489-7ee0-4d53-a851-3fd18fe80926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9d8bbf2f-af54-4cb6-b24f-00010da3fdcc" xlink:to="loc_us-gaap_GrantMember_5f8cf489-7ee0-4d53-a851-3fd18fe80926" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i38d6c6b592ec430db50d5e709875eee1_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_38c4e80d-d931-4abf-a7a5-ac6b4dba03ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_7803801c-0986-4c86-86ab-2dd180b6ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_38c4e80d-d931-4abf-a7a5-ac6b4dba03ec" xlink:to="loc_us-gaap_InventoryValuationReserves_7803801c-0986-4c86-86ab-2dd180b6ad54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_4f82e99d-8116-4d00-a84f-5cdde10093af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_38c4e80d-d931-4abf-a7a5-ac6b4dba03ec" xlink:to="loc_us-gaap_InventoryNoncurrent_4f82e99d-8116-4d00-a84f-5cdde10093af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a1545177-e16e-4c79-99e2-f899bb7a4900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_38c4e80d-d931-4abf-a7a5-ac6b4dba03ec" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a1545177-e16e-4c79-99e2-f899bb7a4900" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_88c6e94b-ff90-426f-95e1-abbd22942f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_38c4e80d-d931-4abf-a7a5-ac6b4dba03ec" xlink:to="loc_us-gaap_InventoryCurrentTable_88c6e94b-ff90-426f-95e1-abbd22942f06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f02fa9e7-bde1-4f71-86ce-48611b121515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_88c6e94b-ff90-426f-95e1-abbd22942f06" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f02fa9e7-bde1-4f71-86ce-48611b121515" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f02fa9e7-bde1-4f71-86ce-48611b121515_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f02fa9e7-bde1-4f71-86ce-48611b121515" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f02fa9e7-bde1-4f71-86ce-48611b121515_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d1c94ec-cd59-4f47-94ea-997e21b9c920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f02fa9e7-bde1-4f71-86ce-48611b121515" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d1c94ec-cd59-4f47-94ea-997e21b9c920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_064ec467-f0f4-49de-92f5-599e5da1f5bd" xlink:href="cpix-20221231.xsd#cpix_VIBATIVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d1c94ec-cd59-4f47-94ea-997e21b9c920" xlink:to="loc_cpix_VIBATIVMember_064ec467-f0f4-49de-92f5-599e5da1f5bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_db6efddb-0187-49a0-838b-9444a85738e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_88c6e94b-ff90-426f-95e1-abbd22942f06" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_db6efddb-0187-49a0-838b-9444a85738e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_db6efddb-0187-49a0-838b-9444a85738e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_db6efddb-0187-49a0-838b-9444a85738e0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_db6efddb-0187-49a0-838b-9444a85738e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e5c6b6a-fe52-4531-b60e-a4b25339fd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_db6efddb-0187-49a0-838b-9444a85738e0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e5c6b6a-fe52-4531-b60e-a4b25339fd4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_fa064d59-f0cb-4723-bb4a-3e9bd8e27a14" xlink:href="cpix-20221231.xsd#cpix_IfetrobanClinicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e5c6b6a-fe52-4531-b60e-a4b25339fd4d" xlink:to="loc_cpix_IfetrobanClinicalMember_fa064d59-f0cb-4723-bb4a-3e9bd8e27a14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WorkInProcessMember_493bbfc3-ad5f-41d4-ab18-9f91bae57a54" xlink:href="cpix-20221231.xsd#cpix_WorkInProcessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e5c6b6a-fe52-4531-b60e-a4b25339fd4d" xlink:to="loc_cpix_WorkInProcessMember_493bbfc3-ad5f-41d4-ab18-9f91bae57a54" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended" id="i00261e6c50134394bbca172b249999db_PropertyandEquipmentScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b2d49674-294a-4800-bce0-0835e60d4a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b2d49674-294a-4800-bce0-0835e60d4a6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74d8e9bb-4a3b-40eb-9a34-bf1cfc761254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74d8e9bb-4a3b-40eb-9a34-bf1cfc761254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9420a611-8639-4478-a311-48c6e4cacd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9420a611-8639-4478-a311-48c6e4cacd0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5e65c831-14fd-49b2-928f-5ecfc61b9e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5e65c831-14fd-49b2-928f-5ecfc61b9e03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61ccdeed-e0c6-4e69-b8df-59071c23d709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61ccdeed-e0c6-4e69-b8df-59071c23d709" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47fce53e-2a91-4a7c-9f12-b917870eca57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61ccdeed-e0c6-4e69-b8df-59071c23d709" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47fce53e-2a91-4a7c-9f12-b917870eca57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_47fce53e-2a91-4a7c-9f12-b917870eca57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47fce53e-2a91-4a7c-9f12-b917870eca57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_47fce53e-2a91-4a7c-9f12-b917870eca57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47fce53e-2a91-4a7c-9f12-b917870eca57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d5cf1422-3051-4718-9e98-74bc5f343d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:to="loc_us-gaap_ComputerEquipmentMember_d5cf1422-3051-4718-9e98-74bc5f343d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_305caba9-3134-4348-a00b-7a735cf66fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:to="loc_us-gaap_OfficeEquipmentMember_305caba9-3134-4348-a00b-7a735cf66fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_50a6e6c6-c90f-4a63-be93-db064be74994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_50a6e6c6-c90f-4a63-be93-db064be74994" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_96cd5bca-7c3e-4b89-8325-0e2fbfd1e50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_96cd5bca-7c3e-4b89-8325-0e2fbfd1e50d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e0107e4e-a8d3-4ad4-a51d-48869e88dd29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61ccdeed-e0c6-4e69-b8df-59071c23d709" xlink:to="loc_srt_RangeAxis_e0107e4e-a8d3-4ad4-a51d-48869e88dd29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0107e4e-a8d3-4ad4-a51d-48869e88dd29_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e0107e4e-a8d3-4ad4-a51d-48869e88dd29" xlink:to="loc_srt_RangeMember_e0107e4e-a8d3-4ad4-a51d-48869e88dd29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c72c2b6a-2f6a-438f-bbdc-5338ccf490c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e0107e4e-a8d3-4ad4-a51d-48869e88dd29" xlink:to="loc_srt_RangeMember_c72c2b6a-2f6a-438f-bbdc-5338ccf490c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1e0c6970-d18b-4107-9fb3-383668acf335" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c72c2b6a-2f6a-438f-bbdc-5338ccf490c9" xlink:to="loc_srt_MinimumMember_1e0c6970-d18b-4107-9fb3-383668acf335" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_758d836c-4671-4908-99d6-8b8bac9cadb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c72c2b6a-2f6a-438f-bbdc-5338ccf490c9" xlink:to="loc_srt_MaximumMember_758d836c-4671-4908-99d6-8b8bac9cadb8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="extended" id="iaaeccafd1e7b4c3dbf1fe5e303cb5616_IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_184c9705-2929-4fbf-8869-d3975e33b225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_184c9705-2929-4fbf-8869-d3975e33b225" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_20fee987-60cc-438c-948b-7a21549894f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_20fee987-60cc-438c-948b-7a21549894f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_08baf4a9-4291-4a7f-b7e8-378d69644944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_08baf4a9-4291-4a7f-b7e8-378d69644944" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ef1914bc-1919-400e-b371-06690ba37165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:to="loc_us-gaap_Goodwill_ef1914bc-1919-400e-b371-06690ba37165" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7add3059-7362-4ac3-8766-c06b3fc0d5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7add3059-7362-4ac3-8766-c06b3fc0d5f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc63a7f1-8ddd-4cca-846e-be537d9fe34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7add3059-7362-4ac3-8766-c06b3fc0d5f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc63a7f1-8ddd-4cca-846e-be537d9fe34b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc63a7f1-8ddd-4cca-846e-be537d9fe34b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc63a7f1-8ddd-4cca-846e-be537d9fe34b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cc63a7f1-8ddd-4cca-846e-be537d9fe34b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe732015-1e67-4e29-9bd4-c8f3e2497b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc63a7f1-8ddd-4cca-846e-be537d9fe34b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe732015-1e67-4e29-9bd4-c8f3e2497b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_71a11a2c-02c2-4834-b2f9-b3cb4698ce22" xlink:href="cpix-20221231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe732015-1e67-4e29-9bd4-c8f3e2497b5b" xlink:to="loc_cpix_ProductAndLicenseRightsMember_71a11a2c-02c2-4834-b2f9-b3cb4698ce22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_5e8210d4-3a87-4f8d-90d5-57172d589732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe732015-1e67-4e29-9bd4-c8f3e2497b5b" xlink:to="loc_us-gaap_PatentsMember_5e8210d4-3a87-4f8d-90d5-57172d589732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_c0104079-d4f2-4b3e-b9fa-41962288c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe732015-1e67-4e29-9bd4-c8f3e2497b5b" xlink:to="loc_us-gaap_TrademarksMember_c0104079-d4f2-4b3e-b9fa-41962288c21c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0aaa7728-0ed4-45b7-8eba-531f3662ed62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7add3059-7362-4ac3-8766-c06b3fc0d5f2" xlink:to="loc_srt_ProductOrServiceAxis_0aaa7728-0ed4-45b7-8eba-531f3662ed62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0aaa7728-0ed4-45b7-8eba-531f3662ed62_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0aaa7728-0ed4-45b7-8eba-531f3662ed62" xlink:to="loc_srt_ProductsAndServicesDomain_0aaa7728-0ed4-45b7-8eba-531f3662ed62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8febc1b1-7a1f-4fe0-b088-478925cc4bfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0aaa7728-0ed4-45b7-8eba-531f3662ed62" xlink:to="loc_srt_ProductsAndServicesDomain_8febc1b1-7a1f-4fe0-b088-478925cc4bfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_53eaea24-de93-418a-a5cc-4c2d0423dd15" xlink:href="cpix-20221231.xsd#cpix_KristaloseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8febc1b1-7a1f-4fe0-b088-478925cc4bfa" xlink:to="loc_cpix_KristaloseMember_53eaea24-de93-418a-a5cc-4c2d0423dd15" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="i7a4940c3139c439f99d6520bbb65cc92_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_202e4762-b975-4616-8f9b-c0bd8c5bdd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8be2394a-b54a-4b1d-9ada-14a617e33500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_202e4762-b975-4616-8f9b-c0bd8c5bdd2b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8be2394a-b54a-4b1d-9ada-14a617e33500" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2c1c12b4-d369-46d2-8e50-e5d1f6360784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_202e4762-b975-4616-8f9b-c0bd8c5bdd2b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2c1c12b4-d369-46d2-8e50-e5d1f6360784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1843f6ee-9ed9-4309-be3b-761e9efa2e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_202e4762-b975-4616-8f9b-c0bd8c5bdd2b" xlink:to="loc_us-gaap_Goodwill_1843f6ee-9ed9-4309-be3b-761e9efa2e11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_52b905ac-3c91-4dd4-8c0b-55848aea7f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_202e4762-b975-4616-8f9b-c0bd8c5bdd2b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_52b905ac-3c91-4dd4-8c0b-55848aea7f48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9111b8c-2497-4990-9518-5830e3bebe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_52b905ac-3c91-4dd4-8c0b-55848aea7f48" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9111b8c-2497-4990-9518-5830e3bebe0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f9111b8c-2497-4990-9518-5830e3bebe0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9111b8c-2497-4990-9518-5830e3bebe0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f9111b8c-2497-4990-9518-5830e3bebe0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e2a3595-67ae-4f2d-85c4-950f9f9d611a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9111b8c-2497-4990-9518-5830e3bebe0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e2a3595-67ae-4f2d-85c4-950f9f9d611a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_1c0f96e0-a487-4e26-b0c9-ccd57560024e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e2a3595-67ae-4f2d-85c4-950f9f9d611a" xlink:to="loc_us-gaap_PatentsMember_1c0f96e0-a487-4e26-b0c9-ccd57560024e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4417cb20-0690-4325-b312-d3f0b378b706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_52b905ac-3c91-4dd4-8c0b-55848aea7f48" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4417cb20-0690-4325-b312-d3f0b378b706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4417cb20-0690-4325-b312-d3f0b378b706_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4417cb20-0690-4325-b312-d3f0b378b706" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4417cb20-0690-4325-b312-d3f0b378b706_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11f311e9-43cf-4bdb-9bd5-c23568f58ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4417cb20-0690-4325-b312-d3f0b378b706" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11f311e9-43cf-4bdb-9bd5-c23568f58ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_2bc6c292-cb3f-46c1-9dec-af46aa1a5be4" xlink:href="cpix-20221231.xsd#cpix_SancusoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11f311e9-43cf-4bdb-9bd5-c23568f58ebf" xlink:to="loc_cpix_SancusoMember_2bc6c292-cb3f-46c1-9dec-af46aa1a5be4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#DebtLineofCreditDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="extended" id="i9a294a2b253b45e28513791fe1dfdb50_DebtLineofCreditDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_9b9ba369-9e46-44aa-bcf1-fbfa41cae49f" xlink:href="cpix-20221231.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_9b9ba369-9e46-44aa-bcf1-fbfa41cae49f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_5a7ad91c-95df-437a-8c4a-ed108765bcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_5a7ad91c-95df-437a-8c4a-ed108765bcfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_4788879d-500a-4c83-8f56-a0794ff9cd55" xlink:href="cpix-20221231.xsd#cpix_DebtInstrumentCovenantUnrestrictedCashThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_4788879d-500a-4c83-8f56-a0794ff9cd55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_594f9b75-3a21-4e0b-8eb8-fa3ae5b93179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_us-gaap_LongTermLineOfCredit_594f9b75-3a21-4e0b-8eb8-fa3ae5b93179" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_de7e8447-4fed-45c0-b1fd-9d9df9f584a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_de7e8447-4fed-45c0-b1fd-9d9df9f584a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_40cb8582-ac15-4f77-948d-2dcb6b18371f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_40cb8582-ac15-4f77-948d-2dcb6b18371f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_3fc05b37-adf1-4a7b-8450-d4920d4a42de" xlink:href="cpix-20221231.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_3fc05b37-adf1-4a7b-8450-d4920d4a42de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8e35ec77-0d4c-417f-9fea-c5325a843173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_CreditFacilityAxis_8e35ec77-0d4c-417f-9fea-c5325a843173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8e35ec77-0d4c-417f-9fea-c5325a843173_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_8e35ec77-0d4c-417f-9fea-c5325a843173" xlink:to="loc_us-gaap_CreditFacilityDomain_8e35ec77-0d4c-417f-9fea-c5325a843173_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6e14c12a-b2dd-4215-9316-a851c5443692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_8e35ec77-0d4c-417f-9fea-c5325a843173" xlink:to="loc_us-gaap_CreditFacilityDomain_6e14c12a-b2dd-4215-9316-a851c5443692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_898f4a89-7580-4a6c-8d64-0f51f199ea03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_6e14c12a-b2dd-4215-9316-a851c5443692" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_898f4a89-7580-4a6c-8d64-0f51f199ea03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_d41cb82c-5c88-4b5a-8d59-09f3db7622cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_d41cb82c-5c88-4b5a-8d59-09f3db7622cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_d41cb82c-5c88-4b5a-8d59-09f3db7622cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_d41cb82c-5c88-4b5a-8d59-09f3db7622cd" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_d41cb82c-5c88-4b5a-8d59-09f3db7622cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_0d4020df-1623-423d-8ad3-83ee25765ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_d41cb82c-5c88-4b5a-8d59-09f3db7622cd" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_0d4020df-1623-423d-8ad3-83ee25765ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_363249ef-d542-4312-85ec-5325ac7b61ea" xlink:href="cpix-20221231.xsd#cpix_PinnacleBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_0d4020df-1623-423d-8ad3-83ee25765ce6" xlink:to="loc_cpix_PinnacleBankMember_363249ef-d542-4312-85ec-5325ac7b61ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_33bde9ca-bdcc-4d53-8d4f-b21c76bc75d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_DebtInstrumentAxis_33bde9ca-bdcc-4d53-8d4f-b21c76bc75d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_33bde9ca-bdcc-4d53-8d4f-b21c76bc75d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_33bde9ca-bdcc-4d53-8d4f-b21c76bc75d6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_33bde9ca-bdcc-4d53-8d4f-b21c76bc75d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_33bde9ca-bdcc-4d53-8d4f-b21c76bc75d6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FifthAmendmentMember_35f35056-f6bf-4a80-b41c-50017f731213" xlink:href="cpix-20221231.xsd#cpix_FifthAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:to="loc_cpix_FifthAmendmentMember_35f35056-f6bf-4a80-b41c-50017f731213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_6d45f067-282f-4dc4-8941-b578557292a0" xlink:href="cpix-20221231.xsd#cpix_SecondAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:to="loc_cpix_SecondAmendmentMember_6d45f067-282f-4dc4-8941-b578557292a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_13c6ed82-e3ae-4b83-a479-8d4c5644fa84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:to="loc_us-gaap_LineOfCreditMember_13c6ed82-e3ae-4b83-a479-8d4c5644fa84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentProtectionProgramMember_dca36c5a-528a-4b7f-8e8b-6ecf47f5ba4b" xlink:href="cpix-20221231.xsd#cpix_PaymentProtectionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:to="loc_cpix_PaymentProtectionProgramMember_dca36c5a-528a-4b7f-8e8b-6ecf47f5ba4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NinthAmemdmentMember_e1191c6f-49aa-4f14-8ce8-0ab0149e546e" xlink:href="cpix-20221231.xsd#cpix_NinthAmemdmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:to="loc_cpix_NinthAmemdmentMember_e1191c6f-49aa-4f14-8ce8-0ab0149e546e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b31a1883-7fca-435e-8e54-17a14cc0c866" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_srt_RangeAxis_b31a1883-7fca-435e-8e54-17a14cc0c866" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b31a1883-7fca-435e-8e54-17a14cc0c866_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b31a1883-7fca-435e-8e54-17a14cc0c866" xlink:to="loc_srt_RangeMember_b31a1883-7fca-435e-8e54-17a14cc0c866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_643fd113-a3ce-4984-a645-cf465d04d8e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b31a1883-7fca-435e-8e54-17a14cc0c866" xlink:to="loc_srt_RangeMember_643fd113-a3ce-4984-a645-cf465d04d8e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_44a2b465-8975-4d7b-9c92-661d5ba3f6f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_643fd113-a3ce-4984-a645-cf465d04d8e3" xlink:to="loc_srt_MinimumMember_44a2b465-8975-4d7b-9c92-661d5ba3f6f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b289b7b9-7f06-4734-ab1b-ca2b38722896" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_643fd113-a3ce-4984-a645-cf465d04d8e3" xlink:to="loc_srt_MaximumMember_b289b7b9-7f06-4734-ab1b-ca2b38722896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5a655251-d0e1-452f-96dd-698e4dbf83bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5a655251-d0e1-452f-96dd-698e4dbf83bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5a655251-d0e1-452f-96dd-698e4dbf83bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5a655251-d0e1-452f-96dd-698e4dbf83bf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5a655251-d0e1-452f-96dd-698e4dbf83bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_877506ab-b6b5-4fb2-a083-78e3923452cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5a655251-d0e1-452f-96dd-698e4dbf83bf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_877506ab-b6b5-4fb2-a083-78e3923452cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_47600d6a-3d58-47c4-a944-71a853bfd454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_877506ab-b6b5-4fb2-a083-78e3923452cc" xlink:to="loc_us-gaap_LoansPayableMember_47600d6a-3d58-47c4-a944-71a853bfd454" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_521974e6-741f-42bd-8509-5251ed9c10e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_VariableRateAxis_521974e6-741f-42bd-8509-5251ed9c10e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_521974e6-741f-42bd-8509-5251ed9c10e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_521974e6-741f-42bd-8509-5251ed9c10e5" xlink:to="loc_us-gaap_VariableRateDomain_521974e6-741f-42bd-8509-5251ed9c10e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3be821de-f69a-480b-a6b6-f5e514925e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_521974e6-741f-42bd-8509-5251ed9c10e5" xlink:to="loc_us-gaap_VariableRateDomain_3be821de-f69a-480b-a6b6-f5e514925e93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFloorMember_8af19f19-3c2f-4862-9ba2-caedc99d5614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFloorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3be821de-f69a-480b-a6b6-f5e514925e93" xlink:to="loc_us-gaap_InterestRateFloorMember_8af19f19-3c2f-4862-9ba2-caedc99d5614" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="extended" id="i2433f2921832408caf599edd4d1c1136_ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_66f017bd-6bd7-494c-b4c2-b0be499f74d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:href="cpix-20221231.xsd#cpix_InitialPublicOfferingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_66f017bd-6bd7-494c-b4c2-b0be499f74d1" xlink:to="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_0d20f993-dcb9-4229-8c06-ae1da85be46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_0d20f993-dcb9-4229-8c06-ae1da85be46f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3c0fdc63-a073-4405-ae7f-a2c4a82120d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3c0fdc63-a073-4405-ae7f-a2c4a82120d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_94c41572-ba96-4b34-ada1-73be6752efd2" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_94c41572-ba96-4b34-ada1-73be6752efd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_6700633a-7212-48a7-bb6b-846aa4a38580" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_6700633a-7212-48a7-bb6b-846aa4a38580" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_1f59aff3-67aa-48cb-a6a0-301c5031d047" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_1f59aff3-67aa-48cb-a6a0-301c5031d047" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_55aae9dc-5260-49a7-86fd-bd9c1d9dd4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_55aae9dc-5260-49a7-86fd-bd9c1d9dd4bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_67f966c3-1c2c-4212-9471-cc560258d4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_67f966c3-1c2c-4212-9471-cc560258d4d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PreferredStockAbstract_d1aa818e-78aa-4ba6-bcd8-ab2d28bd580c" xlink:href="cpix-20221231.xsd#cpix_PreferredStockAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_66f017bd-6bd7-494c-b4c2-b0be499f74d1" xlink:to="loc_cpix_PreferredStockAbstract_d1aa818e-78aa-4ba6-bcd8-ab2d28bd580c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fc09a105-c407-49d8-b888-0c0063b5e760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_PreferredStockAbstract_d1aa818e-78aa-4ba6-bcd8-ab2d28bd580c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fc09a105-c407-49d8-b888-0c0063b5e760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0f8aefbd-bda5-4044-bc4e-131be8313368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_PreferredStockAbstract_d1aa818e-78aa-4ba6-bcd8-ab2d28bd580c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0f8aefbd-bda5-4044-bc4e-131be8313368" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CommonStockAbstract_0e4942ea-79b7-4f45-88de-bb94591d45b8" xlink:href="cpix-20221231.xsd#cpix_CommonStockAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_66f017bd-6bd7-494c-b4c2-b0be499f74d1" xlink:to="loc_cpix_CommonStockAbstract_0e4942ea-79b7-4f45-88de-bb94591d45b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d4414e7a-1f01-4970-8113-a53ee64d2934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_CommonStockAbstract_0e4942ea-79b7-4f45-88de-bb94591d45b8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d4414e7a-1f01-4970-8113-a53ee64d2934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_10f2efc7-9bf3-4f97-b9ae-0bbe26d4ca80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_66f017bd-6bd7-494c-b4c2-b0be499f74d1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_10f2efc7-9bf3-4f97-b9ae-0bbe26d4ca80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aacd2353-2f36-45a9-b041-95a71eadc91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10f2efc7-9bf3-4f97-b9ae-0bbe26d4ca80" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aacd2353-2f36-45a9-b041-95a71eadc91b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aacd2353-2f36-45a9-b041-95a71eadc91b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aacd2353-2f36-45a9-b041-95a71eadc91b" xlink:to="loc_us-gaap_EquityComponentDomain_aacd2353-2f36-45a9-b041-95a71eadc91b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c749c67-80e5-425f-aba0-d37c773f94c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aacd2353-2f36-45a9-b041-95a71eadc91b" xlink:to="loc_us-gaap_EquityComponentDomain_9c749c67-80e5-425f-aba0-d37c773f94c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_702c7aa9-5db6-4f1f-9f6e-3b464ced3f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9c749c67-80e5-425f-aba0-d37c773f94c4" xlink:to="loc_us-gaap_CommonStockMember_702c7aa9-5db6-4f1f-9f6e-3b464ced3f8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b06bdae5-78f5-43d9-9785-fb97af98795c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10f2efc7-9bf3-4f97-b9ae-0bbe26d4ca80" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b06bdae5-78f5-43d9-9785-fb97af98795c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b06bdae5-78f5-43d9-9785-fb97af98795c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b06bdae5-78f5-43d9-9785-fb97af98795c" xlink:to="loc_us-gaap_ClassOfStockDomain_b06bdae5-78f5-43d9-9785-fb97af98795c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0addf72c-9596-44c8-893f-bd407699c498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b06bdae5-78f5-43d9-9785-fb97af98795c" xlink:to="loc_us-gaap_ClassOfStockDomain_0addf72c-9596-44c8-893f-bd407699c498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf133be8-f46d-413e-b437-507d6d969d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0addf72c-9596-44c8-893f-bd407699c498" xlink:to="loc_us-gaap_CommonStockMember_cf133be8-f46d-413e-b437-507d6d969d3e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="extended" id="i402c0d33a84848d09ec692bd365ef745_ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c90375ff-f2c9-4ec5-bc96-09f5ff88dbee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c90375ff-f2c9-4ec5-bc96-09f5ff88dbee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_de0b7352-891b-4874-a6aa-f99981f9ce05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_de0b7352-891b-4874-a6aa-f99981f9ce05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_98205908-1f7b-47fd-b678-925db1734293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_98205908-1f7b-47fd-b678-925db1734293" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_43e4f424-6048-4a2c-98fa-c9fb1527b39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_43e4f424-6048-4a2c-98fa-c9fb1527b39e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_5a8659c5-ef97-4edf-9fc7-6598de24611c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_5a8659c5-ef97-4edf-9fc7-6598de24611c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_420399f8-e623-43b5-9857-39328671d04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5a8659c5-ef97-4edf-9fc7-6598de24611c" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_420399f8-e623-43b5-9857-39328671d04b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_420399f8-e623-43b5-9857-39328671d04b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_420399f8-e623-43b5-9857-39328671d04b" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_420399f8-e623-43b5-9857-39328671d04b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8e4a3935-7189-4419-95ba-87e95e24d84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_420399f8-e623-43b5-9857-39328671d04b" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8e4a3935-7189-4419-95ba-87e95e24d84e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_74dcd749-ab5f-4529-b27c-f9fafe63423c" xlink:href="cpix-20221231.xsd#cpix_ShareRepurchaseProgramAuthorizedIn2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8e4a3935-7189-4419-95ba-87e95e24d84e" xlink:to="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_74dcd749-ab5f-4529-b27c-f9fafe63423c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeAxis_02d05766-5f38-4710-be6f-023e36207ab3" xlink:href="cpix-20221231.xsd#cpix_SharesRepurchaseActivityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5a8659c5-ef97-4edf-9fc7-6598de24611c" xlink:to="loc_cpix_SharesRepurchaseActivityTypeAxis_02d05766-5f38-4710-be6f-023e36207ab3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain_02d05766-5f38-4710-be6f-023e36207ab3_default" xlink:href="cpix-20221231.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis_02d05766-5f38-4710-be6f-023e36207ab3" xlink:to="loc_cpix_SharesRepurchaseActivityTypeDomain_02d05766-5f38-4710-be6f-023e36207ab3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain_544be10f-7f7f-4ff5-b64b-4479961e1acd" xlink:href="cpix-20221231.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis_02d05766-5f38-4710-be6f-023e36207ab3" xlink:to="loc_cpix_SharesRepurchaseActivityTypeDomain_544be10f-7f7f-4ff5-b64b-4479961e1acd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_c64eb281-666f-4f7e-9dd1-00bdec867270" xlink:href="cpix-20221231.xsd#cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_SharesRepurchaseActivityTypeDomain_544be10f-7f7f-4ff5-b64b-4479961e1acd" xlink:to="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_c64eb281-666f-4f7e-9dd1-00bdec867270" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended" id="ic1e117d649a74fc9af7c9638eb67f8e7_IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_bfb74d5c-b24f-424b-8359-7e09c322868f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d4d9bed1-8c95-45c5-b3e6-e121564d0063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_bfb74d5c-b24f-424b-8359-7e09c322868f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d4d9bed1-8c95-45c5-b3e6-e121564d0063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c880a068-f288-4f06-b786-091bd6975002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_bfb74d5c-b24f-424b-8359-7e09c322868f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c880a068-f288-4f06-b786-091bd6975002" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_870b6cfe-a8a3-4b64-9e7a-b7f6ad028895" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c880a068-f288-4f06-b786-091bd6975002" xlink:to="loc_cpix_ExpirationTimePeriodAxis_870b6cfe-a8a3-4b64-9e7a-b7f6ad028895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_870b6cfe-a8a3-4b64-9e7a-b7f6ad028895_default" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_ExpirationTimePeriodAxis_870b6cfe-a8a3-4b64-9e7a-b7f6ad028895" xlink:to="loc_cpix_ExpirationTimePeriodDomain_870b6cfe-a8a3-4b64-9e7a-b7f6ad028895_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_0a8990c2-8436-488f-99af-e7627f577a4f" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_ExpirationTimePeriodAxis_870b6cfe-a8a3-4b64-9e7a-b7f6ad028895" xlink:to="loc_cpix_ExpirationTimePeriodDomain_0a8990c2-8436-488f-99af-e7627f577a4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_db8091ac-bff0-418a-b866-92771cfef682" xlink:href="cpix-20221231.xsd#cpix_ExpirationTermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_0a8990c2-8436-488f-99af-e7627f577a4f" xlink:to="loc_cpix_ExpirationTermOneMember_db8091ac-bff0-418a-b866-92771cfef682" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_7ad2900c-4114-4521-adb0-239c94345be3" xlink:href="cpix-20221231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_0a8990c2-8436-488f-99af-e7627f577a4f" xlink:to="loc_cpix_ExpirationTermTwoMember_7ad2900c-4114-4521-adb0-239c94345be3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember_73b9d5d9-40bd-4e48-9b4c-52c3ff25193d" xlink:href="cpix-20221231.xsd#cpix_IndefiniteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_0a8990c2-8436-488f-99af-e7627f577a4f" xlink:to="loc_cpix_IndefiniteMember_73b9d5d9-40bd-4e48-9b4c-52c3ff25193d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_88bc6972-204b-454c-885b-38068268e5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c880a068-f288-4f06-b786-091bd6975002" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_88bc6972-204b-454c-885b-38068268e5fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_88bc6972-204b-454c-885b-38068268e5fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_88bc6972-204b-454c-885b-38068268e5fd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_88bc6972-204b-454c-885b-38068268e5fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5cc9fa7e-07de-4e64-b46e-0798f20c5651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_88bc6972-204b-454c-885b-38068268e5fd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5cc9fa7e-07de-4e64-b46e-0798f20c5651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_92e5a469-0d6a-42c8-ad43-62dfae309f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5cc9fa7e-07de-4e64-b46e-0798f20c5651" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_92e5a469-0d6a-42c8-ad43-62dfae309f5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e9e4c16a-be7f-4f5d-a630-f51068ff71b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5cc9fa7e-07de-4e64-b46e-0798f20c5651" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e9e4c16a-be7f-4f5d-a630-f51068ff71b1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="extended" id="i3f8b123067d74ecd80e3715c564a2f13_IncomeTaxesScheduleoftaxcreditcarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_79a49b4c-3bba-4361-9c46-579ee68f17b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1ec23eb1-0448-43ec-bdf8-b431de249d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_79a49b4c-3bba-4361-9c46-579ee68f17b4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1ec23eb1-0448-43ec-bdf8-b431de249d64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_196a5ae9-4c1f-4bc9-9252-4697496b7590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_79a49b4c-3bba-4361-9c46-579ee68f17b4" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_196a5ae9-4c1f-4bc9-9252-4697496b7590" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_bc405a39-9f01-4592-8aaf-cab007d1aaeb" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_196a5ae9-4c1f-4bc9-9252-4697496b7590" xlink:to="loc_cpix_ExpirationTimePeriodAxis_bc405a39-9f01-4592-8aaf-cab007d1aaeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_bc405a39-9f01-4592-8aaf-cab007d1aaeb_default" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_ExpirationTimePeriodAxis_bc405a39-9f01-4592-8aaf-cab007d1aaeb" xlink:to="loc_cpix_ExpirationTimePeriodDomain_bc405a39-9f01-4592-8aaf-cab007d1aaeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_7fa8d34a-e3f6-4951-97bb-f31ba06fcd97" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_ExpirationTimePeriodAxis_bc405a39-9f01-4592-8aaf-cab007d1aaeb" xlink:to="loc_cpix_ExpirationTimePeriodDomain_7fa8d34a-e3f6-4951-97bb-f31ba06fcd97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_aac02f3b-cadd-43ab-a891-32fee840d5e5" xlink:href="cpix-20221231.xsd#cpix_ExpirationTermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_7fa8d34a-e3f6-4951-97bb-f31ba06fcd97" xlink:to="loc_cpix_ExpirationTermOneMember_aac02f3b-cadd-43ab-a891-32fee840d5e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_4277d55b-28b7-4c20-ab1f-015132b88e1f" xlink:href="cpix-20221231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ExpirationTimePeriodDomain_7fa8d34a-e3f6-4951-97bb-f31ba06fcd97" xlink:to="loc_cpix_ExpirationTermTwoMember_4277d55b-28b7-4c20-ab1f-015132b88e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_cd72e726-624f-4bc5-96b3-c85071a67138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_196a5ae9-4c1f-4bc9-9252-4697496b7590" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_cd72e726-624f-4bc5-96b3-c85071a67138" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_cd72e726-624f-4bc5-96b3-c85071a67138_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_cd72e726-624f-4bc5-96b3-c85071a67138" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_cd72e726-624f-4bc5-96b3-c85071a67138_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8c2291ad-9f49-4f4b-b02e-9d7a6782f3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_cd72e726-624f-4bc5-96b3-c85071a67138" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8c2291ad-9f49-4f4b-b02e-9d7a6782f3be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalAndStateMember_50ab0f65-ca16-4658-b705-86f75651c935" xlink:href="cpix-20221231.xsd#cpix_FederalAndStateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8c2291ad-9f49-4f4b-b02e-9d7a6782f3be" xlink:to="loc_cpix_FederalAndStateMember_50ab0f65-ca16-4658-b705-86f75651c935" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended" id="i83ec52407f51422588f484a569d5c635_StockBasedCompensationPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_eaf7f9b4-ccc5-4eab-a0d9-6a9b4159c7e8" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_eaf7f9b4-ccc5-4eab-a0d9-6a9b4159c7e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_de026bb2-6708-481b-adb9-9d36b6cc8ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_de026bb2-6708-481b-adb9-9d36b6cc8ed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_5bbd5222-f7d3-493b-945f-b18362fa016f" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_5bbd5222-f7d3-493b-945f-b18362fa016f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6ba0bfd6-cabc-4792-b2d1-a1b8d595a418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6ba0bfd6-cabc-4792-b2d1-a1b8d595a418" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_c8fb054c-2168-4a27-a616-6477f99a2f00" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_c8fb054c-2168-4a27-a616-6477f99a2f00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_67e9b780-dfa6-41c4-bb41-f407fce10c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_67e9b780-dfa6-41c4-bb41-f407fce10c2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4bc60c07-15c2-4fe3-bb55-832eb6fbaa80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4bc60c07-15c2-4fe3-bb55-832eb6fbaa80" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_665a4388-f952-4ec3-af27-19cd76b2582c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_665a4388-f952-4ec3-af27-19cd76b2582c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dab7f8d7-7ecb-4395-8038-474b498cf518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dab7f8d7-7ecb-4395-8038-474b498cf518" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb75f4fb-60eb-4a1b-b6bb-2cda9fc3b45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb75f4fb-60eb-4a1b-b6bb-2cda9fc3b45f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6345f537-5977-40ee-b569-08707636448b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6345f537-5977-40ee-b569-08707636448b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdcaf1e6-3148-44e1-a796-915681f1957c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdcaf1e6-3148-44e1-a796-915681f1957c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_434d113b-c126-410b-aca8-5897e71395b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_434d113b-c126-410b-aca8-5897e71395b2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2f1c7dfb-62bb-432a-911a-90cd46d3376d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2f1c7dfb-62bb-432a-911a-90cd46d3376d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_2c005a76-0264-4baf-9b14-bc1f5811b261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_2c005a76-0264-4baf-9b14-bc1f5811b261" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_182380e9-dee4-4d01-a7cc-b77a74cf42db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:to="loc_us-gaap_AwardTypeAxis_182380e9-dee4-4d01-a7cc-b77a74cf42db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_182380e9-dee4-4d01-a7cc-b77a74cf42db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_182380e9-dee4-4d01-a7cc-b77a74cf42db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_182380e9-dee4-4d01-a7cc-b77a74cf42db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c2eb3a6-dd6a-4d2e-ba72-89b2c59f306f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_182380e9-dee4-4d01-a7cc-b77a74cf42db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c2eb3a6-dd6a-4d2e-ba72-89b2c59f306f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b4f25964-14fd-4c8b-a646-010e4b97f163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c2eb3a6-dd6a-4d2e-ba72-89b2c59f306f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b4f25964-14fd-4c8b-a646-010e4b97f163" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b3207844-6178-450d-8c5d-3104b5138166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c2eb3a6-dd6a-4d2e-ba72-89b2c59f306f" xlink:to="loc_us-gaap_RestrictedStockMember_b3207844-6178-450d-8c5d-3104b5138166" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d635a610-0c59-4635-a4af-122a5d28e398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:to="loc_us-gaap_PlanNameAxis_d635a610-0c59-4635-a4af-122a5d28e398" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d635a610-0c59-4635-a4af-122a5d28e398_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d635a610-0c59-4635-a4af-122a5d28e398" xlink:to="loc_us-gaap_PlanNameDomain_d635a610-0c59-4635-a4af-122a5d28e398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1b5930db-e716-406d-9ea9-e6215c352532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d635a610-0c59-4635-a4af-122a5d28e398" xlink:to="loc_us-gaap_PlanNameDomain_1b5930db-e716-406d-9ea9-e6215c352532" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member_5ab42ab7-b072-405b-9670-3d68eda0c5e8" xlink:href="cpix-20221231.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1b5930db-e716-406d-9ea9-e6215c352532" xlink:to="loc_cpix_LongTermIncentiveCompensationPlan2007Member_5ab42ab7-b072-405b-9670-3d68eda0c5e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member_2cb04433-2d8c-4877-807f-5c95513ccedf" xlink:href="cpix-20221231.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1b5930db-e716-406d-9ea9-e6215c352532" xlink:to="loc_cpix_DirectorsIncentivePlan2007Member_2cb04433-2d8c-4877-807f-5c95513ccedf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e4ba74cd-96d7-4c57-a852-2633bda6efdc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:to="loc_srt_TitleOfIndividualAxis_e4ba74cd-96d7-4c57-a852-2633bda6efdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e4ba74cd-96d7-4c57-a852-2633bda6efdc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_e4ba74cd-96d7-4c57-a852-2633bda6efdc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e4ba74cd-96d7-4c57-a852-2633bda6efdc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_e4ba74cd-96d7-4c57-a852-2633bda6efdc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_f4e2b9c7-ddc1-4a9a-9e91-56e9e0d64ef8" xlink:href="cpix-20221231.xsd#cpix_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:to="loc_cpix_EmployeeMember_f4e2b9c7-ddc1-4a9a-9e91-56e9e0d64ef8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_f7b9a146-6c78-4197-95d5-4c7ee1551539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:to="loc_us-gaap_PrincipalOwnerMember_f7b9a146-6c78-4197-95d5-4c7ee1551539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember_ed5a97c0-b3e9-4412-b502-bbf8a21a0e88" xlink:href="cpix-20221231.xsd#cpix_NonprincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:to="loc_cpix_NonprincipalOwnerMember_ed5a97c0-b3e9-4412-b502-bbf8a21a0e88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_f4ddfe2e-4d34-4dce-8515-d7689b9c70f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:to="loc_srt_DirectorMember_f4ddfe2e-4d34-4dce-8515-d7689b9c70f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b789f136-b767-42ce-8f2f-15c5ff413ee6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:to="loc_srt_RangeAxis_b789f136-b767-42ce-8f2f-15c5ff413ee6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b789f136-b767-42ce-8f2f-15c5ff413ee6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b789f136-b767-42ce-8f2f-15c5ff413ee6" xlink:to="loc_srt_RangeMember_b789f136-b767-42ce-8f2f-15c5ff413ee6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11d37871-6d06-4f79-b2fb-ee13c8c995ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b789f136-b767-42ce-8f2f-15c5ff413ee6" xlink:to="loc_srt_RangeMember_11d37871-6d06-4f79-b2fb-ee13c8c995ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_981348f7-59ae-4003-9e29-8195243460c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11d37871-6d06-4f79-b2fb-ee13c8c995ee" xlink:to="loc_srt_MinimumMember_981348f7-59ae-4003-9e29-8195243460c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3865b9c6-bb1e-47a2-9b35-363d52508d8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11d37871-6d06-4f79-b2fb-ee13c8c995ee" xlink:to="loc_srt_MaximumMember_3865b9c6-bb1e-47a2-9b35-363d52508d8a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended" id="ie67864ddba4b4430b2868393e8e5d479_StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d33f5c-e6e9-476f-bdec-c46e789137c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_68bc8ce0-c9bf-47c9-aa60-cbe3dcde90a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d33f5c-e6e9-476f-bdec-c46e789137c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_68bc8ce0-c9bf-47c9-aa60-cbe3dcde90a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c1d90d-46b6-4ab8-b97d-12295cbe75be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d33f5c-e6e9-476f-bdec-c46e789137c9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c1d90d-46b6-4ab8-b97d-12295cbe75be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2f89b6f3-348a-4b66-991a-b731f8f61f69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c1d90d-46b6-4ab8-b97d-12295cbe75be" xlink:to="loc_srt_TitleOfIndividualAxis_2f89b6f3-348a-4b66-991a-b731f8f61f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2f89b6f3-348a-4b66-991a-b731f8f61f69_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2f89b6f3-348a-4b66-991a-b731f8f61f69" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2f89b6f3-348a-4b66-991a-b731f8f61f69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aefdb281-1ee5-434c-beea-fbcc5d9967b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2f89b6f3-348a-4b66-991a-b731f8f61f69" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aefdb281-1ee5-434c-beea-fbcc5d9967b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_aa7e897c-01e2-46c9-8613-dfbc15b66203" xlink:href="cpix-20221231.xsd#cpix_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aefdb281-1ee5-434c-beea-fbcc5d9967b7" xlink:to="loc_cpix_EmployeeMember_aa7e897c-01e2-46c9-8613-dfbc15b66203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonemployeeMember_45a1115a-8297-4639-80ee-afc6c9c65d43" xlink:href="cpix-20221231.xsd#cpix_NonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aefdb281-1ee5-434c-beea-fbcc5d9967b7" xlink:to="loc_cpix_NonemployeeMember_45a1115a-8297-4639-80ee-afc6c9c65d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_60a6daa2-5c7e-45dd-b26a-ba055a17172e" xlink:href="cpix-20221231.xsd#cpix_EmployeeNonemployeeandFoundationContributionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aefdb281-1ee5-434c-beea-fbcc5d9967b7" xlink:to="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_60a6daa2-5c7e-45dd-b26a-ba055a17172e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails" xlink:type="extended" id="icd82379be2f7479697940dddc8207243_StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48a668c-5380-4166-ba3a-453ab677e38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48a668c-5380-4166-ba3a-453ab677e38d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b519cf84-1959-443a-b97b-765328727a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b519cf84-1959-443a-b97b-765328727a13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8d0cbfbd-c39a-48df-9447-a047cbc8e166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8d0cbfbd-c39a-48df-9447-a047cbc8e166" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1d7586c6-495f-43be-9c2e-6325b8b1ca6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1d7586c6-495f-43be-9c2e-6325b8b1ca6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54560565-80be-4c3c-ac0f-061066dce3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54560565-80be-4c3c-ac0f-061066dce3ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b4d31500-a1e4-473f-9034-a09d359ca485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48a668c-5380-4166-ba3a-453ab677e38d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d34b9755-ee19-44fc-ac8d-fab36f67b89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d34b9755-ee19-44fc-ac8d-fab36f67b89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c3c086af-3b94-409f-b2dd-f0bcd931819d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c3c086af-3b94-409f-b2dd-f0bcd931819d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b1321d9c-9c5a-4f8c-8f7a-ddf19c44b400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b1321d9c-9c5a-4f8c-8f7a-ddf19c44b400" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_be97d0ac-b560-4fa9-854a-476be0f9dbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_be97d0ac-b560-4fa9-854a-476be0f9dbc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ad017af4-c592-43c8-8804-2435a92ffccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_206ee39d-dac1-41c5-9a8b-bbfa395b14b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48a668c-5380-4166-ba3a-453ab677e38d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_206ee39d-dac1-41c5-9a8b-bbfa395b14b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29c21d72-9c56-4763-a9c0-65f23b8051f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48a668c-5380-4166-ba3a-453ab677e38d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29c21d72-9c56-4763-a9c0-65f23b8051f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fe374aea-0dc1-49e7-90bb-fb8ebe068131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29c21d72-9c56-4763-a9c0-65f23b8051f8" xlink:to="loc_us-gaap_AwardTypeAxis_fe374aea-0dc1-49e7-90bb-fb8ebe068131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe374aea-0dc1-49e7-90bb-fb8ebe068131_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fe374aea-0dc1-49e7-90bb-fb8ebe068131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe374aea-0dc1-49e7-90bb-fb8ebe068131_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebd64470-4be3-49d4-9e61-4f3b26f179e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fe374aea-0dc1-49e7-90bb-fb8ebe068131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebd64470-4be3-49d4-9e61-4f3b26f179e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RestrictedIncentiveStockOptionsMember_74d06984-fa93-4992-b007-a5de01b8f645" xlink:href="cpix-20221231.xsd#cpix_RestrictedIncentiveStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebd64470-4be3-49d4-9e61-4f3b26f179e2" xlink:to="loc_cpix_RestrictedIncentiveStockOptionsMember_74d06984-fa93-4992-b007-a5de01b8f645" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="extended" id="i91a4fccd103347ef82cd609ecaa02083_StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2d2108c-ab87-4676-9eb8-e34629a27c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2d2108c-ab87-4676-9eb8-e34629a27c7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ed08e0e2-0a4e-44d9-ae2b-1b091ab083d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ed08e0e2-0a4e-44d9-ae2b-1b091ab083d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_58aa0779-6786-4dce-b86a-db2c536696e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_58aa0779-6786-4dce-b86a-db2c536696e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3884f770-2e1c-43fb-b2be-efe291a911c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3884f770-2e1c-43fb-b2be-efe291a911c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_04fce73b-063e-43e9-8bfa-5980e7b92a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_04fce73b-063e-43e9-8bfa-5980e7b92a5f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c63d9af0-fa50-4702-984f-20f2809f2e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2d2108c-ab87-4676-9eb8-e34629a27c7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_36cdc9ca-ccd6-4ce0-b951-e1781192f374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_36cdc9ca-ccd6-4ce0-b951-e1781192f374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11ac44a8-7445-4592-997e-ea01b108ef5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11ac44a8-7445-4592-997e-ea01b108ef5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4241b1d6-2224-4c98-be4c-e421a96209c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4241b1d6-2224-4c98-be4c-e421a96209c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7dafecfd-81eb-43a0-9cfa-50116c66131c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7dafecfd-81eb-43a0-9cfa-50116c66131c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e69e3d80-a95e-4438-9bf5-10bbef3ce373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d95319-8558-430d-83e4-f6ea9abe22f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2d2108c-ab87-4676-9eb8-e34629a27c7e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d95319-8558-430d-83e4-f6ea9abe22f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d29d21d-7866-43dc-8cbf-6c8666276fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d95319-8558-430d-83e4-f6ea9abe22f4" xlink:to="loc_us-gaap_AwardTypeAxis_2d29d21d-7866-43dc-8cbf-6c8666276fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d29d21d-7866-43dc-8cbf-6c8666276fd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2d29d21d-7866-43dc-8cbf-6c8666276fd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d29d21d-7866-43dc-8cbf-6c8666276fd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e69955c1-542d-471a-8734-e1c39d8d1582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2d29d21d-7866-43dc-8cbf-6c8666276fd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e69955c1-542d-471a-8734-e1c39d8d1582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_214fae82-c34a-4e6f-b629-cfbadc99feb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e69955c1-542d-471a-8734-e1c39d8d1582" xlink:to="loc_us-gaap_RestrictedStockMember_214fae82-c34a-4e6f-b629-cfbadc99feb5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i4049f7f2c52e4895916f6652ce104569_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea_51e820bc-4fe5-40e3-aeb5-9169c642e3aa" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_cpix_LesseeOperatingLeaseLeasedArea_51e820bc-4fe5-40e3-aeb5-9169c642e3aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f06353a2-e3b5-4fd6-9132-4fd8a1a44cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f06353a2-e3b5-4fd6-9132-4fd8a1a44cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_c213b133-359f-44aa-ac72-4fb0678748c2" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_c213b133-359f-44aa-ac72-4fb0678748c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0274bb70-e6b5-4f65-b51d-0acd4690decc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0274bb70-e6b5-4f65-b51d-0acd4690decc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent_c1eabe82-7a5f-44e0-a78a-f719bcc35b83" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_cpix_LesseeOperatingLeaseBaseRent_c1eabe82-7a5f-44e0-a78a-f719bcc35b83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseRentIncrease_b29eb0ce-eee7-4d51-be66-1ac935e998f0" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseRentIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_cpix_LesseeOperatingLeaseRentIncrease_b29eb0ce-eee7-4d51-be66-1ac935e998f0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_19dc7e6d-bdc0-4a9c-a154-9c86a1644fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_19dc7e6d-bdc0-4a9c-a154-9c86a1644fbc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6dde928b-21d6-4d1b-abf9-28f26a320a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6dde928b-21d6-4d1b-abf9-28f26a320a5a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9b3676c8-2d3c-48e8-a7d4-d8d4621638f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9b3676c8-2d3c-48e8-a7d4-d8d4621638f1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_133e29d5-19a6-46b2-ad2e-62aebf937341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_133e29d5-19a6-46b2-ad2e-62aebf937341" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b695e479-6232-41df-a40c-e98fca32ee9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b695e479-6232-41df-a40c-e98fca32ee9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b695e479-6232-41df-a40c-e98fca32ee9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b695e479-6232-41df-a40c-e98fca32ee9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b695e479-6232-41df-a40c-e98fca32ee9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37f2fc71-83be-430c-87c5-b4f649c3a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b695e479-6232-41df-a40c-e98fca32ee9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37f2fc71-83be-430c-87c5-b4f649c3a13f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_e1dd47d1-9d85-426b-8fb9-4fbbe7538498" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37f2fc71-83be-430c-87c5-b4f649c3a13f" xlink:to="loc_srt_OfficeBuildingMember_e1dd47d1-9d85-426b-8fb9-4fbbe7538498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_17327fd2-e69b-4fd3-ad60-f7903f8fa74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:to="loc_us-gaap_LeaseContractualTermAxis_17327fd2-e69b-4fd3-ad60-f7903f8fa74f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_17327fd2-e69b-4fd3-ad60-f7903f8fa74f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_17327fd2-e69b-4fd3-ad60-f7903f8fa74f" xlink:to="loc_us-gaap_LeaseContractualTermDomain_17327fd2-e69b-4fd3-ad60-f7903f8fa74f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_824fd777-bd0c-49e9-b5d0-a1cdded81a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_17327fd2-e69b-4fd3-ad60-f7903f8fa74f" xlink:to="loc_us-gaap_LeaseContractualTermDomain_824fd777-bd0c-49e9-b5d0-a1cdded81a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_a704de9e-3d27-4b0b-91bd-5105521e2d7f" xlink:href="cpix-20221231.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_824fd777-bd0c-49e9-b5d0-a1cdded81a18" xlink:to="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_a704de9e-3d27-4b0b-91bd-5105521e2d7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fe6ad33c-05b3-41df-9ec6-e0d7e7864202" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:to="loc_srt_CounterpartyNameAxis_fe6ad33c-05b3-41df-9ec6-e0d7e7864202" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe6ad33c-05b3-41df-9ec6-e0d7e7864202_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fe6ad33c-05b3-41df-9ec6-e0d7e7864202" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe6ad33c-05b3-41df-9ec6-e0d7e7864202_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71fa0de1-0773-48b2-829f-54a7c9dc6c93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fe6ad33c-05b3-41df-9ec6-e0d7e7864202" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71fa0de1-0773-48b2-829f-54a7c9dc6c93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_A1600WestEndAvenuePartnersLLCMember_1d87227a-3096-4c6d-bfeb-16d7a698e819" xlink:href="cpix-20221231.xsd#cpix_A1600WestEndAvenuePartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71fa0de1-0773-48b2-829f-54a7c9dc6c93" xlink:to="loc_cpix_A1600WestEndAvenuePartnersLLCMember_1d87227a-3096-4c6d-bfeb-16d7a698e819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CETMember_9ce1335a-a238-441a-9537-b9eca3c20025" xlink:href="cpix-20221231.xsd#cpix_CETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71fa0de1-0773-48b2-829f-54a7c9dc6c93" xlink:to="loc_cpix_CETMember_9ce1335a-a238-441a-9537-b9eca3c20025" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended" id="i4a3f51c69446411d8b4091f67da28b83_MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_10b8812b-c5c3-4b3d-91bb-a9bff9f6284e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6628b222-3b5b-43e3-90bc-16d7ff214b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_10b8812b-c5c3-4b3d-91bb-a9bff9f6284e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6628b222-3b5b-43e3-90bc-16d7ff214b2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_10b8812b-c5c3-4b3d-91bb-a9bff9f6284e" xlink:to="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0b4ddd24-4be2-4e77-8342-bfa453fa0a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0b4ddd24-4be2-4e77-8342-bfa453fa0a21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0b4ddd24-4be2-4e77-8342-bfa453fa0a21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0b4ddd24-4be2-4e77-8342-bfa453fa0a21" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0b4ddd24-4be2-4e77-8342-bfa453fa0a21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_30508235-0144-422a-b80b-6a9ba000d747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0b4ddd24-4be2-4e77-8342-bfa453fa0a21" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_30508235-0144-422a-b80b-6a9ba000d747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_dcb442bf-8ef6-4373-908e-483caff49b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_30508235-0144-422a-b80b-6a9ba000d747" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_dcb442bf-8ef6-4373-908e-483caff49b67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33f0ed98-58aa-4c84-98f6-71d25a41be56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33f0ed98-58aa-4c84-98f6-71d25a41be56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_33f0ed98-58aa-4c84-98f6-71d25a41be56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33f0ed98-58aa-4c84-98f6-71d25a41be56" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_33f0ed98-58aa-4c84-98f6-71d25a41be56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92a9187a-16e4-46fa-b4a4-ce8d84cf60b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33f0ed98-58aa-4c84-98f6-71d25a41be56" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92a9187a-16e4-46fa-b4a4-ce8d84cf60b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember_149039c3-bb8e-4d07-bc93-c7ee3fc23532" xlink:href="cpix-20221231.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92a9187a-16e4-46fa-b4a4-ce8d84cf60b8" xlink:to="loc_cpix_SalesRevenueGoodsGrossMember_149039c3-bb8e-4d07-bc93-c7ee3fc23532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_7fa54987-6ec3-4165-9e52-b75dec0467df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92a9187a-16e4-46fa-b4a4-ce8d84cf60b8" xlink:to="loc_us-gaap_AccountsReceivableMember_7fa54987-6ec3-4165-9e52-b75dec0467df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fe26cb1c-de4b-4442-8e3c-3251c2c080a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:to="loc_srt_MajorCustomersAxis_fe26cb1c-de4b-4442-8e3c-3251c2c080a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fe26cb1c-de4b-4442-8e3c-3251c2c080a4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_fe26cb1c-de4b-4442-8e3c-3251c2c080a4" xlink:to="loc_srt_NameOfMajorCustomerDomain_fe26cb1c-de4b-4442-8e3c-3251c2c080a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_fe26cb1c-de4b-4442-8e3c-3251c2c080a4" xlink:to="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember_8f2e5466-c3d4-4575-a6bc-d36dc26db880" xlink:href="cpix-20221231.xsd#cpix_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:to="loc_cpix_CustomerOneMember_8f2e5466-c3d4-4575-a6bc-d36dc26db880" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember_9ed53059-0885-409a-a2ad-5b649417186f" xlink:href="cpix-20221231.xsd#cpix_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:to="loc_cpix_CustomerTwoMember_9ed53059-0885-409a-a2ad-5b649417186f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember_42390a9c-d1e0-422d-8ce7-7ce1cd8f9d49" xlink:href="cpix-20221231.xsd#cpix_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:to="loc_cpix_CustomerThreeMember_42390a9c-d1e0-422d-8ce7-7ce1cd8f9d49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Customer12And3Member_cd8bfc70-6521-48c2-8975-7bed7b7c4807" xlink:href="cpix-20221231.xsd#cpix_Customer12And3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:to="loc_cpix_Customer12And3Member_cd8bfc70-6521-48c2-8975-7bed7b7c4807" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended" id="ie1d8de08a2614f15af6f757c8211ba09_ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems_e02aae50-3c9d-4d53-b1d9-4735567e0cf6" xlink:href="cpix-20221231.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_03f026ee-758d-46b9-a57e-7b2307fd6f4a" xlink:href="cpix-20221231.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_e02aae50-3c9d-4d53-b1d9-4735567e0cf6" xlink:to="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_03f026ee-758d-46b9-a57e-7b2307fd6f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable_136704e0-6b9b-4035-a852-3199cc434887" xlink:href="cpix-20221231.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_e02aae50-3c9d-4d53-b1d9-4735567e0cf6" xlink:to="loc_cpix_ManufacturingandSupplyAgreementTable_136704e0-6b9b-4035-a852-3199cc434887" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d3277d32-ae18-4251-9dfd-1ef74f7de6c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_136704e0-6b9b-4035-a852-3199cc434887" xlink:to="loc_srt_RangeAxis_d3277d32-ae18-4251-9dfd-1ef74f7de6c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3277d32-ae18-4251-9dfd-1ef74f7de6c6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d3277d32-ae18-4251-9dfd-1ef74f7de6c6" xlink:to="loc_srt_RangeMember_d3277d32-ae18-4251-9dfd-1ef74f7de6c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b8dd36d-e150-4e79-83fc-87af6b0e4fbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d3277d32-ae18-4251-9dfd-1ef74f7de6c6" xlink:to="loc_srt_RangeMember_7b8dd36d-e150-4e79-83fc-87af6b0e4fbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6992c413-e90a-4ad2-aba7-b7bc784043a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7b8dd36d-e150-4e79-83fc-87af6b0e4fbe" xlink:to="loc_srt_MinimumMember_6992c413-e90a-4ad2-aba7-b7bc784043a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eb2a2d52-6abb-4805-a692-6233e8828889" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7b8dd36d-e150-4e79-83fc-87af6b0e4fbe" xlink:to="loc_srt_MaximumMember_eb2a2d52-6abb-4805-a692-6233e8828889" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ica29b3abb24e410581eb3cf84e858379_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_648a0e9f-cf1f-493d-9503-c4a53adf5659" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_648a0e9f-cf1f-493d-9503-c4a53adf5659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_028269ef-7990-4a80-b941-619d1e9964d6" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_028269ef-7990-4a80-b941-619d1e9964d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTerm_3319ef1d-accb-4082-b10b-52b9607eec65" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTerm_3319ef1d-accb-4082-b10b-52b9607eec65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_938066b3-9ae7-4678-b14a-7049b984ca26" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_938066b3-9ae7-4678-b14a-7049b984ca26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount_325db824-c44d-4ed9-9f3b-852b35a4bbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_us-gaap_GainContingencyUnrecordedAmount_325db824-c44d-4ed9-9f3b-852b35a4bbca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bc61ab94-5b83-4de8-b0b3-d06fc589cd7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:to="loc_srt_CounterpartyNameAxis_bc61ab94-5b83-4de8-b0b3-d06fc589cd7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc61ab94-5b83-4de8-b0b3-d06fc589cd7c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bc61ab94-5b83-4de8-b0b3-d06fc589cd7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc61ab94-5b83-4de8-b0b3-d06fc589cd7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5236743-ac42-4552-80cd-f4c399083804" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bc61ab94-5b83-4de8-b0b3-d06fc589cd7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5236743-ac42-4552-80cd-f4c399083804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember_bb8d2ac2-c6ff-4d95-80ae-7e6f78bc27cf" xlink:href="cpix-20221231.xsd#cpix_KyowaKirinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5236743-ac42-4552-80cd-f4c399083804" xlink:to="loc_cpix_KyowaKirinMember_bb8d2ac2-c6ff-4d95-80ae-7e6f78bc27cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_6c515772-310a-465a-a34d-c29a43bbeb26" xlink:href="cpix-20221231.xsd#cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5236743-ac42-4552-80cd-f4c399083804" xlink:to="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_6c515772-310a-465a-a34d-c29a43bbeb26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3d702c31-b31e-40db-a479-4fa3bc5bb6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3d702c31-b31e-40db-a479-4fa3bc5bb6e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d702c31-b31e-40db-a479-4fa3bc5bb6e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d702c31-b31e-40db-a479-4fa3bc5bb6e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d702c31-b31e-40db-a479-4fa3bc5bb6e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d8e930f-d43a-4595-8a51-2fe8da4658af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d702c31-b31e-40db-a479-4fa3bc5bb6e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d8e930f-d43a-4595-8a51-2fe8da4658af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_7803ceee-63b8-4283-beab-38fe5e125ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d8e930f-d43a-4595-8a51-2fe8da4658af" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_7803ceee-63b8-4283-beab-38fe5e125ad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_318659f8-b684-465f-ac7e-02078a2a1a79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:to="loc_srt_RangeAxis_318659f8-b684-465f-ac7e-02078a2a1a79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_318659f8-b684-465f-ac7e-02078a2a1a79_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_318659f8-b684-465f-ac7e-02078a2a1a79" xlink:to="loc_srt_RangeMember_318659f8-b684-465f-ac7e-02078a2a1a79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c2623a01-4f0b-439d-8a38-0c9820ba239d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_318659f8-b684-465f-ac7e-02078a2a1a79" xlink:to="loc_srt_RangeMember_c2623a01-4f0b-439d-8a38-0c9820ba239d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9fcf7f59-cd4c-411e-889d-fa19b6e8fbbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c2623a01-4f0b-439d-8a38-0c9820ba239d" xlink:to="loc_srt_MinimumMember_9fcf7f59-cd4c-411e-889d-fa19b6e8fbbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f1a888b4-7952-4d00-b473-cfc1ef80e295" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c2623a01-4f0b-439d-8a38-0c9820ba239d" xlink:to="loc_srt_MaximumMember_f1a888b4-7952-4d00-b473-cfc1ef80e295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_cd9c4f45-5481-4e4f-905e-35d190a2e687" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:to="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_cd9c4f45-5481-4e4f-905e-35d190a2e687" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_cd9c4f45-5481-4e4f-905e-35d190a2e687_default" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_cd9c4f45-5481-4e4f-905e-35d190a2e687" xlink:to="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_cd9c4f45-5481-4e4f-905e-35d190a2e687_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_874cea0a-4fef-452b-9727-74b098acdadb" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_cd9c4f45-5481-4e4f-905e-35d190a2e687" xlink:to="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_874cea0a-4fef-452b-9727-74b098acdadb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Within30DaysOfFirstSNDAFilingMember_e67395ae-47d4-4302-b755-a66030cab6cf" xlink:href="cpix-20221231.xsd#cpix_Within30DaysOfFirstSNDAFilingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_874cea0a-4fef-452b-9727-74b098acdadb" xlink:to="loc_cpix_Within30DaysOfFirstSNDAFilingMember_e67395ae-47d4-4302-b755-a66030cab6cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FollowingApprovalOfFirstSNDAMember_462b1f6e-a61e-4150-af18-451b449730cc" xlink:href="cpix-20221231.xsd#cpix_FollowingApprovalOfFirstSNDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_874cea0a-4fef-452b-9727-74b098acdadb" xlink:to="loc_cpix_FollowingApprovalOfFirstSNDAMember_462b1f6e-a61e-4150-af18-451b449730cc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended" id="iea4b57ac84544836bf93cd9758d8570c_ValuationandQualifyingAccountsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_79cc44f4-584c-4837-aa32-f4077b167c69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_79cc44f4-584c-4837-aa32-f4077b167c69" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e06032e3-3746-41e7-b135-ee8109b4a272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e06032e3-3746-41e7-b135-ee8109b4a272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_b31fe19d-22e4-4192-9a73-903f8caad503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_b31fe19d-22e4-4192-9a73-903f8caad503" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_41704278-72bb-4ea4-9ff3-3f1ca745daea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_41704278-72bb-4ea4-9ff3-3f1ca745daea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_90441133-9be9-487b-8bcd-a9a3b4a09d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_90441133-9be9-487b-8bcd-a9a3b4a09d15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c3d900bf-0b12-4d31-b763-af70d01e0e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ef3d3457-9499-4bd5-86e1-bc1b9c3a401e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_79cc44f4-584c-4837-aa32-f4077b167c69" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ef3d3457-9499-4bd5-86e1-bc1b9c3a401e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_eb62f759-8cdb-4b37-8f6f-e0700df14bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ef3d3457-9499-4bd5-86e1-bc1b9c3a401e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_eb62f759-8cdb-4b37-8f6f-e0700df14bec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_eb62f759-8cdb-4b37-8f6f-e0700df14bec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_eb62f759-8cdb-4b37-8f6f-e0700df14bec" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_eb62f759-8cdb-4b37-8f6f-e0700df14bec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3dd02d38-8ef4-4978-9cb3-1f40e6cec0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_eb62f759-8cdb-4b37-8f6f-e0700df14bec" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3dd02d38-8ef4-4978-9cb3-1f40e6cec0a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_d3a507db-c6da-45ec-a00d-c1adb16bd4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3dd02d38-8ef4-4978-9cb3-1f40e6cec0a5" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_d3a507db-c6da-45ec-a00d-c1adb16bd4ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_59111c75-aaf0-472b-ae35-c795fa27dd57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3dd02d38-8ef4-4978-9cb3-1f40e6cec0a5" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_59111c75-aaf0-472b-ae35-c795fa27dd57" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>cpix-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f3294900-4a6d-4934-9914-8de8a2261475,g:98ef8ed7-f771-4377-a070-411ae3070b66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cpix_ProductRevenuesAbstract_14c63fae-4b96-49b8-8b0c-4ec0cf82fedd_terseLabel_en-US" xlink:label="lab_cpix_ProductRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues</link:label>
    <link:label id="lab_cpix_ProductRevenuesAbstract_label_en-US" xlink:label="lab_cpix_ProductRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues [Abstract]</link:label>
    <link:label id="lab_cpix_ProductRevenuesAbstract_documentation_en-US" xlink:label="lab_cpix_ProductRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRevenuesAbstract" xlink:href="cpix-20221231.xsd#cpix_ProductRevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductRevenuesAbstract" xlink:to="lab_cpix_ProductRevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0fab8169-800e-466c-892f-44534540b950_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IfetrobanClinicalMember_2aae18c4-1234-43be-82ba-b171d74c0eea_terseLabel_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_label_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical [Member]</link:label>
    <link:label id="lab_cpix_IfetrobanClinicalMember_documentation_en-US" xlink:label="lab_cpix_IfetrobanClinicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ifetroban Clinical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember" xlink:href="cpix-20221231.xsd#cpix_IfetrobanClinicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IfetrobanClinicalMember" xlink:to="lab_cpix_IfetrobanClinicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeDomain_051757a2-b60d-43c4-851c-ce6395e4e771_terseLabel_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Domain]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeDomain_label_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Domain]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeDomain_documentation_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Shares Repurchase Activity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain" xlink:href="cpix-20221231.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharesRepurchaseActivityTypeDomain" xlink:to="lab_cpix_SharesRepurchaseActivityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_229f0654-73b9-41ba-a166-7d6eda26f743_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d41e9b6b-21a6-425d-80eb-8c68f1781997_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a5a4f1fb-280b-41fb-942b-fc2df2f6fd2c_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_ca7dcb35-c864-4ab8-b5f5-a05482109caf_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_519ac6ec-ccc5-4e04-8979-00b22ac59cba_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_da4f34e4-e56e-4b21-b94b-516336827810_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_36859752-262f-415e-ac02-591ef7f7aa24_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_cf3841fb-c27f-4efd-af3a-db78995122f2_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of real estate property</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_b246597f-08f5-4662-affc-96558e83d8ea_terseLabel_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumberland Emerging Technologies, Inc (CET)</link:label>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_label_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumberland Emerging Technologies, Inc [Member]</link:label>
    <link:label id="lab_cpix_CumberlandEmergingTechnologiesIncMember_documentation_en-US" xlink:label="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumberland Emerging Technologies, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember" xlink:href="cpix-20221231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CumberlandEmergingTechnologiesIncMember" xlink:to="lab_cpix_CumberlandEmergingTechnologiesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_9ec94e5f-0ff9-4519-87cb-bb4ea58cdc9d_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (Increase) in cash surrender value of life insurance policies over premiums paid</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:href="cpix-20221231.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_Customer12And3Member_3a2af797-26fe-4883-8690-b687c9342f61_terseLabel_en-US" xlink:label="lab_cpix_Customer12And3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1, 2, and 3</link:label>
    <link:label id="lab_cpix_Customer12And3Member_label_en-US" xlink:label="lab_cpix_Customer12And3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1, 2, and 3 [Member]</link:label>
    <link:label id="lab_cpix_Customer12And3Member_documentation_en-US" xlink:label="lab_cpix_Customer12And3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1, 2, and 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Customer12And3Member" xlink:href="cpix-20221231.xsd#cpix_Customer12And3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_Customer12And3Member" xlink:to="lab_cpix_Customer12And3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c024797b-9157-4823-8875-f8bfa51592b6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_86ebce57-a491-435b-baa3-35c8a840d908_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_5a3fa93f-3c5b-49bd-a113-b196e7361209_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NumeratorAbstract_15edf05a-e16c-449a-a48a-fc0a60fb176c_verboseLabel_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_label_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_cpix_NumeratorAbstract_documentation_en-US" xlink:label="lab_cpix_NumeratorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract" xlink:href="cpix-20221231.xsd#cpix_NumeratorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NumeratorAbstract" xlink:to="lab_cpix_NumeratorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_21599ed3-f86e-445a-80b2-ec1c16dcfaff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_51fadbb9-e71e-46c1-8e3e-5fd2bf4b1c1f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party expense</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f2bb9787-a7e4-423c-ae5c-45f26901cc29_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_6060cf41-7568-4b56-8429-6d0eabf49fcd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_a62b0a02-7758-45e2-9263-9fdc64da39b8_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional payments to acquire businesses</link:label>
    <link:label id="lab_us-gaap_OtherPaymentsToAcquireBusinesses_label_en-US" xlink:label="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Payments to Acquire Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="lab_us-gaap_OtherPaymentsToAcquireBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2c893988-3005-46e8-872f-330a137d3158_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_ecbe2e25-2a32-4451-805b-a2e31227ac69_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation assets</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationPlanAssets" xlink:to="lab_us-gaap_DeferredCompensationPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_5952fbf8-36e7-4612-9393-0114c74d18e2_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of accrued contingent consideration</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Accrued, Current</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Accrued, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:href="cpix-20221231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_582830e4-b570-4026-805e-18942da2e626_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, underwriting discounts</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Shares, Underwriting Discounts</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Shares, Underwriting Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:to="lab_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_80d5b0b8-bac3-49dc-a989-db02b0429e2a_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_label_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:label id="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_documentation_en-US" xlink:label="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing agreements, number of primary suppliers for each product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:href="cpix-20221231.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:to="lab_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_b330194b-6b10-4c8c-aa01-69ba2d1f50eb_terseLabel_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, including amortization related to leasehold improvements</link:label>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_label_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Including Amortization Related to Leasehold Improvements</link:label>
    <link:label id="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_documentation_en-US" xlink:label="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Including Amortization Related to Leasehold Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:href="cpix-20221231.xsd#cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:to="lab_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_96bbae4a-8078-4664-ad12-74c5712cdb30_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_c2960ca2-b017-4793-887c-27ebfe27b991_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmploymentAgreementsAbstract_label_en-US" xlink:label="lab_cpix_EmploymentAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements [Abstract]</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsAbstract_documentation_en-US" xlink:label="lab_cpix_EmploymentAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsAbstract" xlink:href="cpix-20221231.xsd#cpix_EmploymentAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmploymentAgreementsAbstract" xlink:to="lab_cpix_EmploymentAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1c4cd9ab-a632-457a-bb5c-8313d8572ea7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9d19d180-addb-462d-b4db-b395fd8125c4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_6e485d47-f43a-4856-bca1-46704135b0b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_e2ebd3bb-20df-43bc-84df-2a29c86ce248_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseBaseRent_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Base Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseBaseRent" xlink:to="lab_cpix_LesseeOperatingLeaseBaseRent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_a791f509-04ad-437d-b9a0-6ef4b3884d6c_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs [Member]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Federal Small Business Grant Programs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:to="lab_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_42bfc2fe-7449-4a4c-8acc-57fc5381e63e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period, acquisitions (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4e34bf67-a532-4e07-ba2f-eef2df992fe4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and other</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_c55d7655-6cfb-45f0-8654-9ee0f99a1636_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty payments, threshold</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Threshold</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsThreshold_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold" xlink:href="cpix-20221231.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsThreshold" xlink:to="lab_cpix_TieredRoyaltyPaymentsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e8233f8b-38bb-462d-a1f8-3adfa3aab4dc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c80962e8-c9c4-4d55-8553-a75f4effb01e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_e61d2f32-fa33-40ed-8892-42ebf92988f3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2dc74951-388e-412b-8d42-7d16b61036f2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average volatility rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1fabca43-0313-433a-bf5e-828606b77988_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IntercompanyLoansPayableConvertedAmount_7f98cdc2-c0b5-4816-b498-058ffcadad36_terseLabel_en-US" xlink:label="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of intercompany loans payable</link:label>
    <link:label id="lab_cpix_IntercompanyLoansPayableConvertedAmount_label_en-US" xlink:label="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Loans Payable, Converted Amount</link:label>
    <link:label id="lab_cpix_IntercompanyLoansPayableConvertedAmount_documentation_en-US" xlink:label="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Loans Payable, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IntercompanyLoansPayableConvertedAmount" xlink:href="cpix-20221231.xsd#cpix_IntercompanyLoansPayableConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IntercompanyLoansPayableConvertedAmount" xlink:to="lab_cpix_IntercompanyLoansPayableConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b91a5179-10d8-4e6c-b1ed-04b600296c4a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities, Payments Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_f465b508-cf7d-4ff4-a5fa-1ca00bb5ff2b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_64f3420e-a8cf-4b12-b014-f7f305464cf5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4386969f-758f-477e-b873-06191e3ab153_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DenominatorAbstract_df438419-7528-4950-bc17-70bfca9c8515_verboseLabel_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_label_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_cpix_DenominatorAbstract_documentation_en-US" xlink:label="lab_cpix_DenominatorAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract" xlink:href="cpix-20221231.xsd#cpix_DenominatorAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DenominatorAbstract" xlink:to="lab_cpix_DenominatorAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_80478f1d-4b18-415b-9697-1ee986e66713_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_a21bef49-56af-4383-90c3-c0b3fc5bba15_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FifthAmendmentMember_c7192d5a-9783-405d-9ca2-d85203002280_terseLabel_en-US" xlink:label="lab_cpix_FifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Amendment</link:label>
    <link:label id="lab_cpix_FifthAmendmentMember_label_en-US" xlink:label="lab_cpix_FifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Amendment [Member]</link:label>
    <link:label id="lab_cpix_FifthAmendmentMember_documentation_en-US" xlink:label="lab_cpix_FifthAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fifth Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FifthAmendmentMember" xlink:href="cpix-20221231.xsd#cpix_FifthAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FifthAmendmentMember" xlink:to="lab_cpix_FifthAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_b8100884-96a3-4598-9a06-22bdab03bd1e_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_e9cc5eee-9a1f-4158-b653-c89b2d887e5a_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermTwoMember_163f434e-bda2-4b83-8656-dcc0b151f5bf_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024-2042</link:label>
    <link:label id="lab_cpix_ExpirationTermTwoMember_label_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Two [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermTwoMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember" xlink:href="cpix-20221231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermTwoMember" xlink:to="lab_cpix_ExpirationTermTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_768e86dc-5e70-43d9-99e0-42d6226960fe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_c5a61bf2-1b42-479d-904a-ef9bcacaff0e_terseLabel_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration, payment period</link:label>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_label_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Payment Period</link:label>
    <link:label id="lab_cpix_FinancialConsiderationPaymentPeriod_documentation_en-US" xlink:label="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod" xlink:href="cpix-20221231.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FinancialConsiderationPaymentPeriod" xlink:to="lab_cpix_FinancialConsiderationPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_0ee41e89-91b5-44e0-8aaa-f45cfeb7511d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_19c74798-c2cf-4909-b4a5-1a60acc05c07_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_6be92e08-8394-46aa-bf61-00ea06394cb5_terseLabel_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unpaid invoices for purchases of intangibles</link:label>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_label_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of Intangible Assets Incurred But Not Yet Paid</link:label>
    <link:label id="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of Intangible Assets Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:href="cpix-20221231.xsd#cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:to="lab_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f08c8e75-c172-4baf-93d0-5abd25ba7cb4_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e35965db-23e3-4f73-8906-dc7825bdf5f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-Continuing operations-diluted</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9fa75ef9-54a2-4d48-aca2-1e4a0de204a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options shares forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_70edc429-c7fe-4172-aa2a-0dc514d35fc2_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Domain]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_label_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Domain]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodDomain_documentation_en-US" xlink:label="lab_cpix_ExpirationTimePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Expiration Time Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTimePeriodDomain" xlink:to="lab_cpix_ExpirationTimePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_85be24a2-1437-4e74-886e-d24aae2d58b3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_51f8c1dd-1f55-482d-9691-953ce30b1447_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_6b626d82-a068-45a1-8548-c399f02d1476_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4ab581aa-daff-4a42-8348-f70c764ce865_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_fcad36a8-0a2f-4adf-8372-8d90199272c1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock &#8211; no par value; 100,000,000 shares authorized; 14,366,316 and 14,742,754 shares issued and outstanding as of December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d859167d-6f29-419c-9cff-351b273462c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_49a751c4-51e2-4d7b-ab17-ea1c37286b16_terseLabel_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, product returns, administrative fees and service fees</link:label>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales-Related Liabilities, Current</link:label>
    <link:label id="lab_cpix_ProductSalesRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales-Related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:href="cpix-20221231.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:to="lab_cpix_ProductSalesRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LeaseLiability_25cd9227-95a1-4d42-b114-e7df6d7eef10_totalLabel_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_cpix_LeaseLiability_label_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_cpix_LeaseLiability_documentation_en-US" xlink:label="lab_cpix_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability" xlink:href="cpix-20221231.xsd#cpix_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LeaseLiability" xlink:to="lab_cpix_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_2d06bd80-8a51-4c57-bdc8-ee555ae9204d_terseLabel_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option</link:label>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_label_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option [Member]</link:label>
    <link:label id="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember_documentation_en-US" xlink:label="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broadwest Lease, Five Year Renewal Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:href="cpix-20221231.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:to="lab_cpix_BroadwestLeaseFiveYearRenewalOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_3f4685f0-6bd7-4f0b-8312-ceada70b3889_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options and related tax benefit</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Sale of Parent Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NinthAmemdmentMember_3205d780-367e-401d-93b8-c1d3a6cfc22a_terseLabel_en-US" xlink:label="lab_cpix_NinthAmemdmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ninth Amemdment</link:label>
    <link:label id="lab_cpix_NinthAmemdmentMember_label_en-US" xlink:label="lab_cpix_NinthAmemdmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ninth Amemdment [Member]</link:label>
    <link:label id="lab_cpix_NinthAmemdmentMember_documentation_en-US" xlink:label="lab_cpix_NinthAmemdmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ninth Amemdment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NinthAmemdmentMember" xlink:href="cpix-20221231.xsd#cpix_NinthAmemdmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NinthAmemdmentMember" xlink:to="lab_cpix_NinthAmemdmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d5d69c73-50bb-42b1-8ffc-620311e39163_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_51c885e4-c3ba-4b18-9436-aec53c688df2_terseLabel_en-US" xlink:label="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets, useful lives</link:label>
    <link:label id="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:href="cpix-20221231.xsd#cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:to="lab_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OtherRevenuesAbstract_fb21a8a5-92ca-4356-9767-44be96b2ceaa_terseLabel_en-US" xlink:label="lab_cpix_OtherRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_cpix_OtherRevenuesAbstract_label_en-US" xlink:label="lab_cpix_OtherRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Abstract]</link:label>
    <link:label id="lab_cpix_OtherRevenuesAbstract_documentation_en-US" xlink:label="lab_cpix_OtherRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherRevenuesAbstract" xlink:href="cpix-20221231.xsd#cpix_OtherRevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OtherRevenuesAbstract" xlink:to="lab_cpix_OtherRevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_6ddab7a1-4bfd-42cc-852c-13ccffaac5f7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_876d88c9-7a99-4f32-954e-19aca4960969_terseLabel_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Goods, Gross</link:label>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_label_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Goods, Gross [Member]</link:label>
    <link:label id="lab_cpix_SalesRevenueGoodsGrossMember_documentation_en-US" xlink:label="lab_cpix_SalesRevenueGoodsGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Goods, Gross [Member] [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember" xlink:href="cpix-20221231.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SalesRevenueGoodsGrossMember" xlink:to="lab_cpix_SalesRevenueGoodsGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CashPaidDuringYearForAbstract_8d0e27ee-b3a6-47d5-af40-1ee75f59b6ba_terseLabel_en-US" xlink:label="lab_cpix_CashPaidDuringYearForAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid (refunded) during the year for:</link:label>
    <link:label id="lab_cpix_CashPaidDuringYearForAbstract_label_en-US" xlink:label="lab_cpix_CashPaidDuringYearForAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During Year For [Abstract]</link:label>
    <link:label id="lab_cpix_CashPaidDuringYearForAbstract_documentation_en-US" xlink:label="lab_cpix_CashPaidDuringYearForAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During Year For [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CashPaidDuringYearForAbstract" xlink:href="cpix-20221231.xsd#cpix_CashPaidDuringYearForAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CashPaidDuringYearForAbstract" xlink:to="lab_cpix_CashPaidDuringYearForAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VaprisolMember_df02c3d3-d877-4fbb-aa5b-2e6c5d648677_verboseLabel_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol</link:label>
    <link:label id="lab_cpix_VaprisolMember_label_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:label id="lab_cpix_VaprisolMember_documentation_en-US" xlink:label="lab_cpix_VaprisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaprisol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember" xlink:href="cpix-20221231.xsd#cpix_VaprisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VaprisolMember" xlink:to="lab_cpix_VaprisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining_658ac3eb-2675-411f-937a-708fedfcfe25_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments, remaining</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Remaining</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_20a32a9b-6bd1-45e7-9785-3d25b8732e08_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_3beae7ab-75f5-4bed-b74b-b10452555e42_terseLabel_en-US" xlink:label="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation</link:label>
    <link:label id="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_label_en-US" xlink:label="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation [Member]</link:label>
    <link:label id="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_documentation_en-US" xlink:label="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:href="cpix-20221231.xsd#cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:to="lab_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c55f815f-ba9a-487e-b12b-27492ac46b91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4c0d2846-b2bc-47d5-b34a-d5f93aa7b024_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_c5b905c8-f7b8-4cf9-9ec2-d3f117013593_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue contributed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_e0a0be14-a19c-4482-88e3-7057b6c63e5f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted stock activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_61d964ac-5bfe-4e40-9109-308e3d165a77_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a1cd10c2-c883-466a-af01-68b0b6db8eac_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateFloorMember_74413a34-d1e0-4e9b-a2a5-712405f959d5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateFloorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Floor</link:label>
    <link:label id="lab_us-gaap_InterestRateFloorMember_label_en-US" xlink:label="lab_us-gaap_InterestRateFloorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Floor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFloorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFloorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFloorMember" xlink:to="lab_us-gaap_InterestRateFloorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_696546a7-5787-4ddc-8a69-1dbebeb4e6ea_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_8353e938-27b0-44a7-ba35-29b0d51ea25a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f68758b0-d9c9-4341-be2d-d222f495f5f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_13dfb953-d090-42e7-a7f1-7db12a382eda_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_ec5ee7cf-269e-4905-99c7-7f709661b640_terseLabel_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, eligibility, minimum employee service time for participation eligibility</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_label_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_documentation_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:href="cpix-20221231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:to="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_fbdf8b26-c9d9-4bcc-9120-4f53343d7c5b_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ca7b8874-c671-4c28-ae95-71d31ffd85f2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c83eabcf-f72d-4d63-9e84-4d3979b06c02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6be4a427-06c0-4c8d-997f-582ea22e4fe7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_3984c598-bcf3-4ba2-8ae2-7df1ece69c83_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6923cb9b-5002-4c09-b142-50f272ba101d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_OmeclamoxPakMember_f8be24ab-8c38-469a-b1d6-e07bf2446da4_verboseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_4aca7e09-b516-4f7b-b5e2-32ac91c52248_terseLabel_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_label_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:label id="lab_cpix_OmeclamoxPakMember_documentation_en-US" xlink:label="lab_cpix_OmeclamoxPakMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omeclamox-Pak [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember" xlink:href="cpix-20221231.xsd#cpix_OmeclamoxPakMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_OmeclamoxPakMember" xlink:to="lab_cpix_OmeclamoxPakMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FollowingApprovalOfFirstSNDAMember_66d50fbc-f7b8-44ea-a647-0e8a932a784c_terseLabel_en-US" xlink:label="lab_cpix_FollowingApprovalOfFirstSNDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Following Approval Of First sNDA</link:label>
    <link:label id="lab_cpix_FollowingApprovalOfFirstSNDAMember_label_en-US" xlink:label="lab_cpix_FollowingApprovalOfFirstSNDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Following Approval Of First sNDA [Member]</link:label>
    <link:label id="lab_cpix_FollowingApprovalOfFirstSNDAMember_documentation_en-US" xlink:label="lab_cpix_FollowingApprovalOfFirstSNDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Following Approval Of First sNDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FollowingApprovalOfFirstSNDAMember" xlink:href="cpix-20221231.xsd#cpix_FollowingApprovalOfFirstSNDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FollowingApprovalOfFirstSNDAMember" xlink:to="lab_cpix_FollowingApprovalOfFirstSNDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_939f7adf-c0c2-4bd1-a27a-830589aa3342_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6d2d171e-cc19-4e7b-b460-7a7fd06febdc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_1ff185e3-2e2d-4245-89bf-ab8261198fe3_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_7fd7cf8e-1774-4ca5-a8ba-0913a9d41b4b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a84670c4-6b62-42bc-9a3e-fd519b153ff1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0c2f61cc-a1aa-4d58-b8a0-ebde232d7a8a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_edc96c2c-c473-42da-a55e-1d09fe0880d7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4c1e5170-89b6-4bd2-b149-f34f37e314dc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_03bd15fa-8fe5-4da0-9821-f1c6d556454e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_c739a607-2c16-4210-af1f-db83d5503997_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b1cb18df-7058-47e4-940c-6cd3d8323b85_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_69e977fd-ff65-4f8e-8352-2e7a5e7eaf77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_e23b2d8b-5c12-4b35-baa4-0ded4722753f_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RestrictedIncentiveStockOptionsMember_b8cefccf-0e28-4022-b003-6e720ab5f738_terseLabel_en-US" xlink:label="lab_cpix_RestrictedIncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Incentive Stock Options</link:label>
    <link:label id="lab_cpix_RestrictedIncentiveStockOptionsMember_label_en-US" xlink:label="lab_cpix_RestrictedIncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Incentive Stock Options [Member]</link:label>
    <link:label id="lab_cpix_RestrictedIncentiveStockOptionsMember_documentation_en-US" xlink:label="lab_cpix_RestrictedIncentiveStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Incentive Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RestrictedIncentiveStockOptionsMember" xlink:href="cpix-20221231.xsd#cpix_RestrictedIncentiveStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RestrictedIncentiveStockOptionsMember" xlink:to="lab_cpix_RestrictedIncentiveStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_88573532-19c9-4de2-ba37-7137b2264b03_terseLabel_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_label_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five and After</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_documentation_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five and After</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:href="cpix-20221231.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:to="lab_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a0721ab-e92e-447d-9f15-883312869c93_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_09a226e4-afbf-4123-9ad8-7353d8192ad9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning of period, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_84790ce7-e2a6-4c11-97dd-d71cd56a791e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, end of period, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_7fda7d28-9c04-4ad0-9559-44870b4725d0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_e682405e-bb5a-46b8-aa42-330ffcbab69e_totalLabel_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets, before valuation allowance</link:label>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_label_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Assets, Gross</link:label>
    <link:label id="lab_cpix_NetDeferredTaxAssetsGross_documentation_en-US" xlink:label="lab_cpix_NetDeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross" xlink:href="cpix-20221231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NetDeferredTaxAssetsGross" xlink:to="lab_cpix_NetDeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_f7463a67-fb1e-4cf9-b682-a73f696a2be1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_822ff281-c1ea-46af-8956-f5e2c052f25d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4dc1446e-55b0-46c9-be3d-882915fc2e5d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_39f9da7a-dbd5-4c1e-a08e-a85b98a9556d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable investment funding</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerTwoMember_f79d7583-3d30-4dac-838b-ff1b6014afa0_terseLabel_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2</link:label>
    <link:label id="lab_cpix_CustomerTwoMember_label_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:label id="lab_cpix_CustomerTwoMember_documentation_en-US" xlink:label="lab_cpix_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember" xlink:href="cpix-20221231.xsd#cpix_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerTwoMember" xlink:to="lab_cpix_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_c16a64c5-3a12-4d3e-8103-af1549b31121_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_31675bf6-1b0d-4585-b1ef-10ea70db0e64_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_cdd6b817-c555-4fc8-9201-d48f0298140c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current and Other Long-term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_2f3cd9b9-0ec0-4fb0-9fe4-7eb8634dc4f4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_e9187dd5-ca74-479b-b398-9c211065badb_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal terms</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:to="lab_cpix_LesseeOperatingLeaseNumberOfRenewalTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_36f62636-8e72-4af9-95bb-cab583107eb6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_5d0ffa10-8447-4b76-b539-6909c0d64edc_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, price per share</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Price Per Share, New Issues</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Price Per Share, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:to="lab_cpix_StockIssuedDuringPeriodPricePerShareNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_1030d191-bdec-4759-9d2d-a483dd8bdc2f_terseLabel_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007</link:label>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_label_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007 [Member]</link:label>
    <link:label id="lab_cpix_LongTermIncentiveCompensationPlan2007Member_documentation_en-US" xlink:label="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Incentive Compensation Plan 2007 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:href="cpix-20221231.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:to="lab_cpix_LongTermIncentiveCompensationPlan2007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7825c9be-d23c-4b67-aa58-904cb77eafc8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5104c6d9-bd2b-40af-98a9-cdbacd4187f2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share attributable to common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_8eec572f-6b44-4006-a7e1-fdf13bb364aa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_949f96bb-3af8-4ae6-8b0e-3bc68f56b7ee_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_0022e01a-04a2-44c2-afa8-e1819537d875_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash contributions</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Cash Contributions</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Cash Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:to="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FinancialConsiderationNumberOfInstallments_cbb39d8b-061a-4df2-854f-f2e730cbdce5_terseLabel_en-US" xlink:label="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of quarterly installments</link:label>
    <link:label id="lab_cpix_FinancialConsiderationNumberOfInstallments_label_en-US" xlink:label="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Number of Installments</link:label>
    <link:label id="lab_cpix_FinancialConsiderationNumberOfInstallments_documentation_en-US" xlink:label="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Consideration, Number of Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationNumberOfInstallments" xlink:href="cpix-20221231.xsd#cpix_FinancialConsiderationNumberOfInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FinancialConsiderationNumberOfInstallments" xlink:to="lab_cpix_FinancialConsiderationNumberOfInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8da7a571-950c-434c-b137-787ded7a10ab_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4190ee47-e0b5-46fe-90a5-af384ac2282b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_41c21b73-d462-48af-b786-576ecae0f087_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_93cf0d7e-9859-4e6d-a5a8-0eaaaed57f2b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8d8b7dc3-dce3-4c5d-a468-f46b991bbb43_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase program, number of shares authorized to be repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PinnacleBankMember_5984ab46-f9a1-45d8-8100-69c2b5bddbf7_terseLabel_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_label_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:label id="lab_cpix_PinnacleBankMember_documentation_en-US" xlink:label="lab_cpix_PinnacleBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember" xlink:href="cpix-20221231.xsd#cpix_PinnacleBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PinnacleBankMember" xlink:to="lab_cpix_PinnacleBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_444c32af-1e3e-450d-874f-6d4fb3b4c758_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee wages and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_7c0b7d2d-f6ea-4b7d-a16e-370e3345cc59_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff108197-04bc-4b05-884e-49ef0793df7a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_78e0b89d-7f2b-41eb-8fa3-11fed14a0d75_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b71332da-6aa1-4b36-ae4c-7ac3c64f24b4_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CommonStockAbstract_d0cc1fe4-d9bd-4dfc-bb2c-54af157360e3_terseLabel_en-US" xlink:label="lab_cpix_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:label id="lab_cpix_CommonStockAbstract_label_en-US" xlink:label="lab_cpix_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:label id="lab_cpix_CommonStockAbstract_documentation_en-US" xlink:label="lab_cpix_CommonStockAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CommonStockAbstract" xlink:href="cpix-20221231.xsd#cpix_CommonStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CommonStockAbstract" xlink:to="lab_cpix_CommonStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyUnrecordedAmount_174a4f31-1a9c-45f1-83ec-badf4d506f95_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain contingency, unrecorded amount</link:label>
    <link:label id="lab_us-gaap_GainContingencyUnrecordedAmount_label_en-US" xlink:label="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Unrecorded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyUnrecordedAmount" xlink:to="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5bc25fcd-980d-4ed1-bc1b-4ee13c21a1c9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2847b9d7-c79f-4b6f-a2a2-681534000dbd_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_1e19ad16-cffa-4583-85e3-ec0c9944dec9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a85fb8d0-6b3f-4597-b12c-2f0bdcb8c0c6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CETMember_7359c79d-724d-49c8-ba56-9539c14a4881_terseLabel_en-US" xlink:label="lab_cpix_CETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CET</link:label>
    <link:label id="lab_cpix_CETMember_label_en-US" xlink:label="lab_cpix_CETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CET [Member]</link:label>
    <link:label id="lab_cpix_CETMember_documentation_en-US" xlink:label="lab_cpix_CETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CET</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CETMember" xlink:href="cpix-20221231.xsd#cpix_CETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CETMember" xlink:to="lab_cpix_CETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_79b7a99b-ce56-4eec-b9c8-fbf719faa53d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_28d21fb5-5214-4133-aa5f-2bc281e0793a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bfd94179-607c-4d72-8c0b-3273407b8df1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f84c1152-268b-4379-b831-b2dcb21489fb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to share-based payments, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment_082c8546-2562-4189-8a46-46c39e981eb3_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative upfront payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment_label_en-US" xlink:label="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Cumulative Upfront Payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Cumulative Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionCumulativeUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:to="lab_cpix_RevenueRecognitionCumulativeUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_aa5de3d0-9b1a-466e-affc-180c7d7035a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_5fd51f2d-900d-4b85-8a09-81de8399d196_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted shares receivable (in shares)</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_5f39a288-67ea-4019-ac1f-8187b3af1451_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_9b57e878-ef46-411f-ac71-c9e0772f1d76_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_335d9c2e-5570-4b2f-b908-b2db2f06dda2_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_d4a9a33d-9cad-40a5-81f8-70d5140b45f3_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ManufacturedProductOtherMember_label_en-US" xlink:label="lab_us-gaap_ManufacturedProductOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufactured Product, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturedProductOtherMember" xlink:to="lab_us-gaap_ManufacturedProductOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_99d749ce-f82b-46c9-a9d5-068c088b67b2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b7ce9dbf-1223-475f-9c85-64ebc46271f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_11cfe470-ebc4-4000-a9e5-d2ad55b8353f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue_68196d52-1241-4606-b0b3-bcb2b2bc3957_terseLabel_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of common stock - Methotrexate</link:label>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue_1302805d-0032-4413-a275-b94714c65f3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of common stock - Methotrexate</link:label>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Redeemed or Called During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f3080e99-4adf-41d9-b421-5ca7684036ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-Discontinued operations-basic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_6379eb12-df36-4d6e-b56d-bedd590d5034_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving line of credit</link:label>
    <link:label id="lab_us-gaap_LongTermLineOfCredit_label_en-US" xlink:label="lab_us-gaap_LongTermLineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLineOfCredit" xlink:to="lab_us-gaap_LongTermLineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_28f2f482-5da8-4934-8fa8-748d65df710e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_A1600WestEndAvenuePartnersLLCMember_d150c33a-f1d4-43d1-bfc0-d069a265d44b_terseLabel_en-US" xlink:label="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1600 West End Avenue Partners, LLC</link:label>
    <link:label id="lab_cpix_A1600WestEndAvenuePartnersLLCMember_label_en-US" xlink:label="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1600 West End Avenue Partners, LLC [Member]</link:label>
    <link:label id="lab_cpix_A1600WestEndAvenuePartnersLLCMember_documentation_en-US" xlink:label="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1600 West End Avenue Partners, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:href="cpix-20221231.xsd#cpix_A1600WestEndAvenuePartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:to="lab_cpix_A1600WestEndAvenuePartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_bf201e7d-0d0b-4a07-ac3b-3c6627d8bc66_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficeBuildingMember_e84718e8-1cfb-432b-9766-cf5da82e1397_terseLabel_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building</link:label>
    <link:label id="lab_srt_OfficeBuildingMember_label_en-US" xlink:label="lab_srt_OfficeBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficeBuildingMember" xlink:to="lab_srt_OfficeBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_4dea4fba-f2d6-406d-93ef-7de2e7323620_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_50aec9ae-e875-4425-a3fc-7f4a5366643b_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bdd9ea13-1017-4a92-8b23-13b8a6ff19ec_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5107a2c5-c4af-438c-bbfd-b7d85004eead_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3afb8785-f0fb-4d29-bfac-2798a397e021_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_761fe840-d961-495f-b97e-0a32b171a19b_terseLabel_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Domain]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_label_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd [Member]</link:label>
    <link:label id="lab_cpix_WinHealthInvestmentSingaporeLtdMember_documentation_en-US" xlink:label="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WinHealth Investment (Singapore) Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:href="cpix-20221231.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:to="lab_cpix_WinHealthInvestmentSingaporeLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_96141a59-72c2-448d-8e23-bc11fe0697ff_terseLabel_en-US" xlink:label="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program Authorized in 2010</link:label>
    <link:label id="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_label_en-US" xlink:label="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program Authorized in 2010 [Member]</link:label>
    <link:label id="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_documentation_en-US" xlink:label="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program Authorized in 2010 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:href="cpix-20221231.xsd#cpix_ShareRepurchaseProgramAuthorizedIn2010Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:to="lab_cpix_ShareRepurchaseProgramAuthorizedIn2010Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_86dce1de-bc82-4f7d-858e-4b6c87306e6c_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_42aaf439-810a-4b13-9a1d-9dff6006cf0e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life insurance policy proceeds received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLifeInsurancePolicies_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:to="lab_us-gaap_ProceedsFromLifeInsurancePolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a98fd66c-5d6d-418f-a8bb-72dcd2c40167_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_c3703949-9a94-4d90-b56f-366415e62bb1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductVibativMember_c754613b-9ffb-48bf-b782-79a1aee3d274_terseLabel_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor</link:label>
    <link:label id="lab_cpix_ProductVibativMember_label_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Vibativ [Member]</link:label>
    <link:label id="lab_cpix_ProductVibativMember_documentation_en-US" xlink:label="lab_cpix_ProductVibativMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Vibativ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember" xlink:href="cpix-20221231.xsd#cpix_ProductVibativMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductVibativMember" xlink:to="lab_cpix_ProductVibativMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_fdbf5a52-01fb-4c02-8a9d-fc47e2e5ab42_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_419d850c-618e-4c74-b46f-a2802b361383_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_0be6401e-733f-4fd3-9a42-b55ba5d8f984_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of rent expense and sublease income</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rent Expense and Sublease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:href="cpix-20221231.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:to="lab_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_15b44309-3cdd-4854-a5ed-63445ea1700c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, other than goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_af96c384-3ed2-47fb-be33-6d335b2e21e2_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_97469426-7172-4983-8274-b4bfbfb02952_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_b94ab12e-835d-4a5e-a764-074f7c0fded5_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder, percent</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shareholder, Percent</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shareholder, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_aae95537-9b29-49dd-940d-b75c84f49f99_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_label_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementTable_documentation_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable" xlink:href="cpix-20221231.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable" xlink:to="lab_cpix_ManufacturingandSupplyAgreementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_620a4b4d-3960-4ab8-b67d-0637b605f043_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_85ca2aaf-f81e-4cdb-9261-5a2c84e6c7ba_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b09f88b5-4408-423b-8be9-230d4e1e3599_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_7bf1f9ec-0fee-4251-b48b-a969f2f38bbe_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_3db6714b-6dd7-4611-a829-ef9535f8c81f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences associated with general business credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_e6dc69af-35d0-4567-9086-65f03c101e17_negatedTerseLabel_en-US" xlink:label="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums paid for life insurance policies</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Proceeds from Life Insurance Policy</link:label>
    <link:label id="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Proceeds from Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:href="cpix-20221231.xsd#cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:to="lab_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_5ce43315-436d-4457-8b46-2e648e60e3f3_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased area</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseLeasedArea_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leased Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseLeasedArea" xlink:to="lab_cpix_LesseeOperatingLeaseLeasedArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e8194b3b-dab5-4b62-9d9c-98b9dd769eed_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_16762157-466f-4d87-a679-ce96159c7a00_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_7e3ac471-3255-42b4-bfba-af86d24db99d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0d2c978d-38f4-4641-9a62-9a533e7ba622_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_3493234a-3b9c-4584-a2e8-768a115f96ac_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c7e71f90-2277-4cf6-8291-101fa276d7bc_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income tax expense</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_80c2d0b5-4933-4e6d-b3dc-b5a0078c1f1f_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of federal and state net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_f44ced7c-3a68-4d59-a5de-668e4612ae85_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_b56138a2-da4c-4d01-a720-9b8d8e40976e_terseLabel_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Domain]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_label_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Domain]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentDomain_documentation_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:href="cpix-20221231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:to="lab_cpix_AccountsReceivableAllowancesByComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ff262e1a-ac7c-4dad-8667-bd65aa961614_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_e5d8144e-ee2c-46e0-88a7-2883e4c1153c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex&#174;, Vibativ&#174; and Sancuso&#174;</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LesseeOperatingLeaseRentIncrease_aa6149d1-a75e-4bc5-8a0e-ac0aa396bf78_terseLabel_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent increase</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseRentIncrease_label_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Increase</link:label>
    <link:label id="lab_cpix_LesseeOperatingLeaseRentIncrease_documentation_en-US" xlink:label="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Rent Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseRentIncrease" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseRentIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LesseeOperatingLeaseRentIncrease" xlink:to="lab_cpix_LesseeOperatingLeaseRentIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a3aceb57-0788-442f-a3f1-3f733cfe2648_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_35ad886a-236a-4598-9385-76a4c7dbe491_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_58fbe84d-bcf1-4497-9b7c-47a8722e6737_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues from customers outside the United States</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_2cc5b144-c125-4c3f-872b-f9af6cda02fb_terseLabel_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Owner</link:label>
    <link:label id="lab_us-gaap_PrincipalOwnerMember_label_en-US" xlink:label="lab_us-gaap_PrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrincipalOwnerMember" xlink:to="lab_us-gaap_PrincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_15afb0ac-9058-4f49-8b37-1c230149cd54_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities incurred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_52ad5a9d-d08f-4c20-8b91-850a15459504_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e90e0b96-260b-4eaf-9fab-dfbef6776987_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ba22ad2b-68fc-40c3-a512-61ecbed66d32_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_ada99071-565c-4453-97ee-39431c632b3f_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in non-cash contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e906ea96-cfd1-4612-ad90-b10faf561f7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_20a51a47-0442-4911-a21c-458bfce56d5e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods, net of reserve</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_e4355b99-163f-4be3-bccf-ea41bdaaf000_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_81dcbd5e-6fd7-4af0-8af4-b0db53ddf35c_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_5104ce29-40fc-47c2-bf66-9bffa3b7e38a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d0ab29aa-15ef-4143-994f-83a9eafc7589_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3b22bd31-ea55-485e-8843-0e2fd6e538c4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_2d5a9d55-48bd-48f9-9523-fda4004f4acb_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments associated with international agreements</link:label>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_label_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Payments</link:label>
    <link:label id="lab_cpix_RevenueRecognitionMilestonePayments_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionMilestonePayments" xlink:to="lab_cpix_RevenueRecognitionMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_008cc7ca-537d-435a-858e-cbdce3aa8660_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_6747925e-a4e9-41a5-b164-5c10b4f33103_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment credit due</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_bbfb6678-f87e-4086-a93a-a5312e2c9593_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_4c5ebee5-ae36-477d-9e28-804697a9ea12_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_c7948f9b-0699-464e-9a72-883f03d721f0_terseLabel_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_label_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements [Text Block]</link:label>
    <link:label id="lab_cpix_EmploymentAgreementsTextBlock_documentation_en-US" xlink:label="lab_cpix_EmploymentAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employment Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsTextBlock" xlink:href="cpix-20221231.xsd#cpix_EmploymentAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmploymentAgreementsTextBlock" xlink:to="lab_cpix_EmploymentAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4afa851a-00c2-4d05-b341-cbc141de5946_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_559966b2-d5eb-4b9f-999d-7893dd0c99aa_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_bb5e3666-9b54-499a-a6c8-724e2771702a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_5ae31cb2-2e0d-4a0c-b2ae-3affc53e2bca_terseLabel_en-US" xlink:label="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options</link:label>
    <link:label id="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_label_en-US" xlink:label="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_documentation_en-US" xlink:label="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:href="cpix-20221231.xsd#cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:to="lab_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KyowaKirinMember_5b96b5a7-b75c-48ef-aa90-1f4dcfa7564b_terseLabel_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin</link:label>
    <link:label id="lab_cpix_KyowaKirinMember_label_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin [Member]</link:label>
    <link:label id="lab_cpix_KyowaKirinMember_documentation_en-US" xlink:label="lab_cpix_KyowaKirinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember" xlink:href="cpix-20221231.xsd#cpix_KyowaKirinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KyowaKirinMember" xlink:to="lab_cpix_KyowaKirinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_f49dca05-dbe2-4665-9b41-1cd806c586b0_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_97c6b1db-6d19-49fd-a281-852725a8de4a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a9bb8e7d-d9be-4d13-abf9-5ce2db86ad47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_72f907cc-f355-4ff2-8301-2e239aa0fd05_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred charges</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Charges</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsDeferredCharges_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsDeferredCharges" xlink:to="lab_cpix_DeferredTaxAssetsDeferredCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_b710e7d8-5fe7-4694-b999-67d4f2c5c830_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_9b597182-1edf-414d-ac09-e8ffe507b771_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_0a40d0ea-7774-4c89-a9ef-d3365fafb821_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_9ea03294-3393-43c4-be75-55fb4ede9d2c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment of royalty during the period</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_MethotrexateMember_17819811-4b01-414d-abfd-614eb449a871_terseLabel_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate</link:label>
    <link:label id="lab_cpix_MethotrexateMember_label_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:label id="lab_cpix_MethotrexateMember_documentation_en-US" xlink:label="lab_cpix_MethotrexateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Methotrexate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember" xlink:href="cpix-20221231.xsd#cpix_MethotrexateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_MethotrexateMember" xlink:to="lab_cpix_MethotrexateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5b6a66fb-44d9-42ec-94f5-191e85236eec_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_cc53517d-0f96-4368-96ef-0cda3a3919ee_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_label_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:label id="lab_cpix_ExpirationTimePeriodAxis_documentation_en-US" xlink:label="lab_cpix_ExpirationTimePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration Time Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTimePeriodAxis" xlink:to="lab_cpix_ExpirationTimePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2aa6afa5-2e08-4949-881f-5849e2c6c105_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c6ef0324-16d2-4d78-9961-466944df2568_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8d81fa3a-7e88-4121-83b9-747834edbe8c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities affecting operating activities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_451f5941-da4e-40fd-900a-c25891cadf17_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_34cd36e3-41cd-4ae5-93ed-128abe183830_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_5ec91356-caff-434c-ace0-18affeae6363_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, gross proceeds</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Gross Proceeds from Initial Public Offering</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Gross Proceeds from Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:to="lab_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FederalAndStateMember_bf6d0ba5-a037-4204-8fcc-05f2acac8c6f_terseLabel_en-US" xlink:label="lab_cpix_FederalAndStateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal And State</link:label>
    <link:label id="lab_cpix_FederalAndStateMember_label_en-US" xlink:label="lab_cpix_FederalAndStateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal And State [Member]</link:label>
    <link:label id="lab_cpix_FederalAndStateMember_documentation_en-US" xlink:label="lab_cpix_FederalAndStateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal And State</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalAndStateMember" xlink:href="cpix-20221231.xsd#cpix_FederalAndStateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FederalAndStateMember" xlink:to="lab_cpix_FederalAndStateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0a6be77b-1278-47fe-971e-3fbf5f5e535f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_14e3b36c-9d2f-4654-982f-a620c4284260_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_63229fbd-b08d-4806-96b4-8b79bcdb3055_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_5a46db6d-0435-4e91-96a6-d01b61e88378_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, amount</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_deb32fa9-0d4d-4da6-906f-a2f5d6db6c05_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_a560e433-e5ce-495e-9ace-7cc310f4ab19_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments, maximum</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_bf1034c0-8dc5-473c-9efd-564c890d48b2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_db453c48-1748-4bb4-92fd-d1646e70d779_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2bb9dba8-7574-4502-987b-5341c8e5f852_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability to be paid</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5ce99507-afd0-4647-b874-b617cd4df379_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1220642f-893a-4851-9d85-a822dc72ad5a_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6f0b925e-e945-4f4c-b756-52234eeb10a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_215bcc90-0e6b-46d4-b6a2-c2672867a7ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b4133ba6-f716-42ce-89b4-9499b6a9cd2a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_6a27f432-07e7-4400-a9f8-c17359df4b17_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Tax Credit Carryforwards [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:to="lab_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d2d7cc0c-d9c2-443e-860e-9907dc4594fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_65ef3f8d-68ea-457a-b347-50070af5b63f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period, acquisitions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionUpfrontPayment_607934db-5eb2-42ab-90de-b38fb31be2bc_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, upfront payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionUpfrontPayment_label_en-US" xlink:label="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Upfront Payment</link:label>
    <link:label id="lab_cpix_RevenueRecognitionUpfrontPayment_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionUpfrontPayment" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionUpfrontPayment" xlink:to="lab_cpix_RevenueRecognitionUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_a07bcb5b-9186-481f-8093-9531011fe58d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_82eae0c9-5697-4dcf-bbc0-7b765f4424fa_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ed3d5a85-1b71-4a46-9b6e-77911e2d6388_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_eb827bab-53ff-4a5d-9d98-d111e6de40f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5d6b1807-e4b4-4ed3-8fad-3492bfc11233_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_08b852bc-e9f1-4e0e-b4a5-774f67c418b4_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_225b6fdf-f366-4200-ac3b-ee3c7180defc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unpaid invoices for offering costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_b6dae9e0-ff30-4d58-93fa-88d4df6af363_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8bebb1aa-da6d-4293-b77a-2bbbc6d9a45a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settlement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_8b44dcbd-fc75-451f-8577-4055d76fcf64_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_bc11273d-b8ff-4aa5-8274-949d09c5b5ee_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_88301970-f6a9-4bf9-8cb3-1c1d7b4960e6_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_21fe96c0-95d1-4646-ab18-834e3c1bcfdb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities_73c478bc-2ed7-44c2-9566-92702dd6f837_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Operating Lease Liabilities</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:to="lab_cpix_DeferredTaxAssetOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1cf27491-3223-44b6-96a2-86bf19c7fef5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_81fbdd9f-8057-4daa-afb3-fc5dfc983ad7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_f8e8330a-0a4f-4d6c-9c72-28365101bdd7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for accounts receivable</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_bc880264-e358-4f49-9687-e383f12d5761_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_e5b65c70-cf7c-4c51-89c4-4f177ed77285_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_c856e485-eb55-45fa-aaf1-648889b28ca7_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, exercise price as percent of weighted-average grant date fair value</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_ad33110e-5101-426d-8866-8fd9d11a4757_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AuditorInformationAbstract_label_en-US" xlink:label="lab_cpix_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_cpix_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_cpix_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AuditorInformationAbstract" xlink:href="cpix-20221231.xsd#cpix_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AuditorInformationAbstract" xlink:to="lab_cpix_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_132a1613-10c5-46dd-afbc-2a44aeda3b14_terseLabel_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_label_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals [Member]</link:label>
    <link:label id="lab_cpix_GloriaPharmaceuticalsMember_documentation_en-US" xlink:label="lab_cpix_GloriaPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gloria Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember" xlink:href="cpix-20221231.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_GloriaPharmaceuticalsMember" xlink:to="lab_cpix_GloriaPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d45bed2b-f223-44a5-a495-ccd8ba107080_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_ca491d39-e7dd-417f-a950-958b5cdbd48f_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, potential upfront payment related to product sales</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_label_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payment Related to Product Sales</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payment Related to Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:to="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_eb8bf1a9-c41d-4867-8157-6c91c599178b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_35d2a85c-17b5-437c-a8e9-bf60dc0a92d3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d75438fa-095e-467e-aeab-5038d4018739_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, beginning of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_14585275-ab3c-486d-b810-331a244ad8f5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_fe3ff0a5-0245-4b0c-8448-f998c6e2e59d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_a7e9e6d5-de3c-4f2e-9a21-39e58850c13c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_5ba5f3e9-a35b-41d4-aa85-1fd0bbd1bc48_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7064e3b6-246f-4ca0-ad62-82d8dc58082f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8cf52281-711b-4219-94a9-f50092ba54d6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_b3dfa783-0b9e-4fd4-88fa-b41dac9af0a1_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_8688063d-bf9f-4a1c-9b69-4522aa8d56ed_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_label_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements [Text Block]</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock_documentation_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:href="cpix-20221231.xsd#cpix_ManufacturingAndSupplyAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:to="lab_cpix_ManufacturingAndSupplyAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_47fcccf0-9bee-4f1f-ae51-549c1d47f018_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_32af0cbd-20e8-48c9-b329-be600b4981f3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_09a01034-a9aa-4848-bbf1-ab70b338eadc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_f2a4e609-bc5d-4abf-8306-6555fbd1bdef_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_a57e139f-10a5-4537-8d4a-43d10a1cfe76_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleOfDistributionCostsTableTextBlock_8b5987d7-1b92-4e9b-bf16-c6e5c0daa8db_terseLabel_en-US" xlink:label="lab_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Distribution Costs</link:label>
    <link:label id="lab_cpix_ScheduleOfDistributionCostsTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Distribution Costs [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleOfDistributionCostsTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Distribution Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:href="cpix-20221231.xsd#cpix_ScheduleOfDistributionCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:to="lab_cpix_ScheduleOfDistributionCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7d64a131-c850-41c9-877c-1d6e688697d9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_06fbbb88-ab46-4d3a-b1e9-db2ed735d896_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CaldolorMember_2f7f06ea-9a54-4e70-9950-243ff49cb55e_terseLabel_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vibativ</link:label>
    <link:label id="lab_cpix_CaldolorMember_label_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor [Member]</link:label>
    <link:label id="lab_cpix_CaldolorMember_documentation_en-US" xlink:label="lab_cpix_CaldolorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caldolor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember" xlink:href="cpix-20221231.xsd#cpix_CaldolorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CaldolorMember" xlink:to="lab_cpix_CaldolorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_60e14f08-61bd-4b6a-af94-efb9a22650e3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_1a67ce1d-967b-496a-8f21-96407d7f9538_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ec4f1de3-e026-439c-b182-f3865fbe4f5b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_976368a6-5699-471e-b085-bc3ee3c0901a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6a4756f1-0cff-4de1-945e-e99eba31ff4c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_26f1ec03-6840-4389-8d1c-394542ee9e9f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_ffe2fe92-e994-4bbb-ade9-8899739e3deb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_40796714-3224-4e52-a224-099164798954_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6ad8fc3c-453d-4920-bc4d-72496d7f922f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_eff16695-468c-40fd-bb17-60f9112d218b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative compensation costs incurred on deductible equity awards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_eb0d6a4b-9722-472c-b3ba-040b12288ac6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_b65fd110-9ea6-4698-8c1c-87f81da0f557_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9ad07de7-13c9-441c-8048-5e136588fb56_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_316c4367-5dcd-4a46-9e5b-d3ab92a1b247_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, common shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_214f6c7f-f5cc-4d2a-8a73-7f5756d6a3f3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, common shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_29ca8775-0d11-488b-8d2e-c16c39ebd9b5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial investment amount</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_bd269320-c23c-48d3-994c-a3162f3ddeef_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_3ff78e56-6a37-4e40-9943-701d02f06e3b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d70c5ce2-80ae-4037-9a01-3fa935795462_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_440e17b8-af76-4a28-8c86-22a592c8fd50_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_f559ccc3-daf1-4cfc-b271-ebecd8f1987c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_21f8cea2-cf2d-4e21-8961-e596eb374f95_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d7024e5d-6494-4320-89d3-0360e30be783_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6cff3119-5347-4e83-9efc-583462c6ff8d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_30c844a2-620d-48f9-b390-d140ee19cf4d_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_ce02b7a2-1b00-4d59-8672-1e378d7e053e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_acf0d48a-cf4e-4e8a-aef5-76c225c495d3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_92cc3c30-1294-4bd0-89bb-107ee77f428d_terseLabel_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charitable contribution of shares (in shares)</link:label>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_label_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Shares</link:label>
    <link:label id="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares_documentation_en-US" xlink:label="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:href="cpix-20221231.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:to="lab_cpix_SharebasedCompensationCharitableContributionofSharesShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5414bff5-1052-4353-b5f1-a0f19b30ef3f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cf8872c0-f4fb-442f-ac4a-d74bcbc7f7fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_d82271e5-490b-44d4-8e98-4d7ecba01c1a_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_78660b5c-4f89-495f-8161-f7e18085f9a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_796fd70b-627c-4b66-9e0f-e051afcfce6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_19b31772-ac80-49fb-ac79-6743840d97f2_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Rights</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8f93627a-d389-49d8-b669-f45d5e51cef8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_86092fc0-2b78-4b47-a6fb-d99b0665a29e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6055304c-fd80-4587-890b-af82ff028f77_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2f3acd1b-0746-4d67-bc5b-100fffa9b35e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_83b803d1-6176-400f-9fdc-519826f717ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_100b0d0e-e3b4-47d4-8150-3bbfcf6e2f8b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Concentrations</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9d31d349-4de1-4693-a04f-bf07270c4b0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories, current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AcetadoteMember_3c315a76-6e1f-4d52-801a-768e1888870a_terseLabel_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote</link:label>
    <link:label id="lab_cpix_AcetadoteMember_label_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote [Member]</link:label>
    <link:label id="lab_cpix_AcetadoteMember_documentation_en-US" xlink:label="lab_cpix_AcetadoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acetadote.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember" xlink:href="cpix-20221231.xsd#cpix_AcetadoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AcetadoteMember" xlink:to="lab_cpix_AcetadoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1435bba3-80eb-453a-80b3-9f55287824a0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_fc1a1818-ef46-4d62-86a6-f35109703712_terseLabel_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods</link:label>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_label_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Cash Discounts and Damaged Goods [Member]</link:label>
    <link:label id="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_documentation_en-US" xlink:label="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Cash Discounts and Damaged Goods [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:href="cpix-20221231.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:to="lab_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_43573344-b4a9-46c3-b2f0-ebc48a24a135_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_958c8607-ecb3-428f-b1aa-e3174e25204a_verboseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_c5c8ac6e-b43d-46ad-a3d0-60b8316d9b99_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsAbstract_label_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements [Abstract]</link:label>
    <link:label id="lab_cpix_ManufacturingAndSupplyAgreementsAbstract_documentation_en-US" xlink:label="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:href="cpix-20221231.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:to="lab_cpix_ManufacturingAndSupplyAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NordicGroupBVMember_387e1ea4-ab3f-4c80-baaf-7d6e7f73d910_terseLabel_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_label_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V. [Member]</link:label>
    <link:label id="lab_cpix_NordicGroupBVMember_documentation_en-US" xlink:label="lab_cpix_NordicGroupBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nordic Group B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember" xlink:href="cpix-20221231.xsd#cpix_NordicGroupBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NordicGroupBVMember" xlink:to="lab_cpix_NordicGroupBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_bf0b54a9-fc36-4d5b-9cca-b4fa43f2aeee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-Discontinued operations-diluted</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_86400fc6-e609-431e-91a9-e9d1a0d3bcab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_a7ca0a42-a82c-48f0-be55-c87805d0b2ca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_9eee5d97-0ad0-45c1-bcec-78aedaf56335_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_d84ec5c8-a77d-4e49-8665-8215f9789e00_terseLabel_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum increase to line of credit</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_label_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:label id="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_documentation_en-US" xlink:label="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Additional Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:href="cpix-20221231.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:to="lab_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_00b752c7-fba2-418c-bed4-b82b694090d9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ba9f4bb5-f868-4a34-aeff-36d2a174ad6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted, weighted-average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3ae74003-ae61-44f6-8198-d5d402a2aefe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of anti-dilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ExpirationTermOneMember_febb3d78-3fb1-468b-84e5-bd3fa182830f_terseLabel_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_cpix_ExpirationTermOneMember_label_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term One [Member]</link:label>
    <link:label id="lab_cpix_ExpirationTermOneMember_documentation_en-US" xlink:label="lab_cpix_ExpirationTermOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration, Term One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember" xlink:href="cpix-20221231.xsd#cpix_ExpirationTermOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ExpirationTermOneMember" xlink:to="lab_cpix_ExpirationTermOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockTransactionDate_a7189bab-db55-47bd-a7f0-d56c4aa032ef_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, effective date</link:label>
    <link:label id="lab_us-gaap_SaleOfStockTransactionDate_label_en-US" xlink:label="lab_us-gaap_SaleOfStockTransactionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Transaction Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockTransactionDate" xlink:to="lab_us-gaap_SaleOfStockTransactionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_31ec4fba-4967-4a6b-a484-2fbd22b0ddcf_terseLabel_en-US" xlink:label="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial consideration</link:label>
    <link:label id="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_label_en-US" xlink:label="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:to="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncome_45fd2da7-7a69-47c9-b012-17829f9f6cb3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_OtherIncome_label_en-US" xlink:label="lab_us-gaap_OtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncome" xlink:to="lab_us-gaap_OtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f2c73bb2-81ea-4f88-8112-46715b52e8bd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmployeeNonemployeeandFoundationContributionMember_0a174d9e-611a-45de-bbe2-9b526bbe564b_terseLabel_en-US" xlink:label="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee, Nonemployee and Foundation Contribution</link:label>
    <link:label id="lab_cpix_EmployeeNonemployeeandFoundationContributionMember_label_en-US" xlink:label="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee, Nonemployee and Foundation Contribution [Member]</link:label>
    <link:label id="lab_cpix_EmployeeNonemployeeandFoundationContributionMember_documentation_en-US" xlink:label="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee, Nonemployee and Foundation Contribution [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:href="cpix-20221231.xsd#cpix_EmployeeNonemployeeandFoundationContributionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:to="lab_cpix_EmployeeNonemployeeandFoundationContributionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4e56e36-f1f8-481c-aa82-ec71e9ecef2d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94b014a5-7067-49a8-99f9-c194f4402f6c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_019529ce-acfb-4c9c-8306-2c56bf8d1c1b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_DeferredOtherTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredOtherTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TextBlockAbstract_label_en-US" xlink:label="lab_us-gaap_TextBlockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Text Block [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TextBlockAbstract" xlink:to="lab_us-gaap_TextBlockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_0a3948da-775d-4f45-84f0-d9d5ba34bed6_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ba3eb061-b59f-4e4e-be4c-5cd522f6417a_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7a551314-6599-4f4f-8951-87fab298270a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ec8c5171-eb1a-4dec-9f92-07f00de2319a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss at subsidiary allocated to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d10a679a-5774-4247-a557-ef5b9383f0d7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d77bd800-4c9a-40b9-ae63-fdeca04b22e1_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_edc2cde2-4448-4abf-b36e-5e438946a356_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_a728fcde-4758-4968-84e0-0d05e15ea826_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeAxis_05391776-ad27-4841-9fc7-b9e69e18c438_terseLabel_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Axis]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeAxis_label_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Axis]</link:label>
    <link:label id="lab_cpix_SharesRepurchaseActivityTypeAxis_documentation_en-US" xlink:label="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Repurchase Activity, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeAxis" xlink:href="cpix-20221231.xsd#cpix_SharesRepurchaseActivityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis" xlink:to="lab_cpix_SharesRepurchaseActivityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_309044f8-7a3d-4975-b54f-49723d4f8ad9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current deferred charges</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_VIBATIVMember_ff461548-5c00-46b5-8739-d50d9b77ed95_terseLabel_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:label id="lab_cpix_VIBATIVMember_label_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV [Member]</link:label>
    <link:label id="lab_cpix_VIBATIVMember_documentation_en-US" xlink:label="lab_cpix_VIBATIVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIBATIV</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember" xlink:href="cpix-20221231.xsd#cpix_VIBATIVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_VIBATIVMember" xlink:to="lab_cpix_VIBATIVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8768edb5-f0bd-49f0-b04b-2e5550ba375c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a4a8d7de-485d-4231-bf61-49f0653f7ed3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_4f6d47f5-dffc-4cef-98f2-2d10e4332bb7_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerOneMember_af51ca16-8536-46fb-816e-a76b93e81e90_terseLabel_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1</link:label>
    <link:label id="lab_cpix_CustomerOneMember_label_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:label id="lab_cpix_CustomerOneMember_documentation_en-US" xlink:label="lab_cpix_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember" xlink:href="cpix-20221231.xsd#cpix_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerOneMember" xlink:to="lab_cpix_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_a0d61bc4-3ba7-44e2-b597-cd27097c462c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities from continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_3afa90c6-c408-48e7-a248-dd10e0035378_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_68a47456-9881-48d4-a351-21f315a3de14_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_e6fdb269-8a55-43bc-b89d-ca9e8bb0a4db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6cd5da96-4d22-48c3-ae4a-eeac1ba54760_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_7e60cb4b-b0ee-4fc6-aeb7-8e4e81f6947c_terseLabel_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, useful life</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_label_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Useful Lives, (Textual)</link:label>
    <link:label id="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_documentation_en-US" xlink:label="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Useful Lives, (Textual)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:href="cpix-20221231.xsd#cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:to="lab_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0aeb84ec-ff91-410f-bb67-9be48476c02d_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_4a503f31-6482-4ad9-9e8f-66e895e87dfb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_734c70f6-ba5a-49d5-8728-ba1b22408c9f_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty, percent</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_b63d5fed-21a6-4890-acec-d3f7e3677455_terseLabel_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_label_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited [Member]</link:label>
    <link:label id="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_documentation_en-US" xlink:label="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HongKong WinHealth Pharma Group Co. Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:href="cpix-20221231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:to="lab_cpix_HongKongWinHealthPharmaGroupCoLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_fe1f765b-987c-486b-9f41-ea62c53342b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on line of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9cd63246-97b7-4338-b026-556bb44017f2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_c0dd04c0-8af3-4a69-8969-7c30c63adcc5_terseLabel_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue, potential upfront payments related to regulatory approval</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_label_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval</link:label>
    <link:label id="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_documentation_en-US" xlink:label="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:to="lab_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NonemployeeMember_ae03626c-7351-4d65-89ea-1c821d80c1bd_terseLabel_en-US" xlink:label="lab_cpix_NonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee</link:label>
    <link:label id="lab_cpix_NonemployeeMember_label_en-US" xlink:label="lab_cpix_NonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee [Member]</link:label>
    <link:label id="lab_cpix_NonemployeeMember_documentation_en-US" xlink:label="lab_cpix_NonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonemployeeMember" xlink:href="cpix-20221231.xsd#cpix_NonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NonemployeeMember" xlink:to="lab_cpix_NonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_c57dc5c7-127c-4261-b400-ea6a7cbe3d18_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for expired product</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:to="lab_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9282d240-ac04-4438-a898-e6c60ed9860f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_7d462bd1-bfe0-4285-9e10-9cfc9e95d00e_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in CET</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPurchaseOfShares_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:href="cpix-20221231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:to="lab_cpix_SubsidiaryInvestmentPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_3fe23f10-7e29-441f-aa1f-a7b52313619d_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_16dd0b5d-0173-4ece-8554-a087c2b24611_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7abcb5a7-142c-45e6-a657-2feb64f4b1e5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9b6b5e9a-2f37-43d5-8e47-7571db7d696d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SecondAmendmentMember_8ed59e5e-7feb-4884-ab28-c202c2180541_terseLabel_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_label_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment [Member]</link:label>
    <link:label id="lab_cpix_SecondAmendmentMember_documentation_en-US" xlink:label="lab_cpix_SecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember" xlink:href="cpix-20221231.xsd#cpix_SecondAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SecondAmendmentMember" xlink:to="lab_cpix_SecondAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_e65787a2-0685-4d72-a902-4062c25d690f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_db27feb2-bf71-468a-bb2f-941f9dccf8dd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-ived intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4a3a7daa-10ac-4dfe-bd9a-21686b0bfea6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_05366d8f-9934-43d8-af3d-abaebc8bc7e2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax expense (net of federal income tax benefit)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0c0385cf-a3ce-4a11-892e-eb795b3aebbf_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_18c5ce18-a216-4130-b750-92b067c66296_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_7c9f6022-50a4-405f-894c-e629e7432dbe_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_08526f72-b768-4e13-bc6e-0e3a8df5ed2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of expected amortization expense of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_d9532d56-5c0a-4208-832e-c63f99413494_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_78337a0f-629c-4530-ba5a-8491f4d3e8a6_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fead9d85-b781-41b0-afe1-e24dbc386879_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_1903f767-4bf8-412b-b0f3-978fda1245c5_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of equity compensation plans available for future grants</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:to="lab_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_bff88176-06fc-4c35-a662-4432988c49b7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0535a1d0-44e7-4641-8476-874497852c4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_19898020-4ada-42ae-ace6-27d5c2869cff_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, allowances, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7983f77f-b665-4059-8c0c-fda6e6460a40_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares forfeited, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c82d4405-d0b6-4b7b-b955-df1575ed057f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of accrued contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_8507f20f-9309-4189-9e87-1e4d9becaa00_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, number of shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_4e0f3fd3-da0f-4425-aaab-ce59a53c39f4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0b1d31c0-b1b8-4222-953f-1525d2c622a6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_0d99da23-f9a5-47fd-acc3-00b2b2b2dd8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net product revenues by product</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_9c096098-a108-4fde-8993-ce8f59ed04ca_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_6d03f058-41cf-493b-9251-b697c0101c45_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a9f05093-14b6-49e2-ac3d-ff75dc4185c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_75438b0f-c3bf-4951-83c7-7ea1e2e58a02_terseLabel_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed cash contributions</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_label_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions</link:label>
    <link:label id="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_documentation_en-US" xlink:label="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:to="lab_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1046c3a6-b8df-4c87-8638-cc3cda0a09e2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_b0bef09a-a08d-40df-b275-e8e3bf53f829_terseLabel_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, eligibiilty, minimum employee age</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_label_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Age</link:label>
    <link:label id="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_documentation_en-US" xlink:label="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Eligibility, Minimum Employee Age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:href="cpix-20221231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:to="lab_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ecc0557e-abc4-4bd8-9450-1e0970ae8dd0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_4810c4ab-4390-42c3-94f7-5c8778f7f1d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_b9caec22-6e3a-49d1-be5d-5d7383cb18f3_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold [Axis]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold [Axis]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:to="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_d91d78f0-0247-4c9f-9071-ddf5b98fbb4b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_776a0ff2-d28c-4287-b9c0-5fca86a181ea_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_8e954b6f-0d0d-4a3c-abe6-ce521263671c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dcb35883-95c1-4289-a7aa-25fa12d70b90_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_1e73c49f-70e2-48b4-aebc-12a622fc8f01_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_946ab2eb-0021-47f6-9711-53b510a63509_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_1afec8ca-93f7-4feb-96a9-a216b2f05e07_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d565da80-d14d-4a14-a3d3-745c9789d8a7_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_b86135c1-5804-4b51-9d45-f31b8761ccbb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_54ed0d54-d4e5-4dfb-a9c1-99b92c998f01_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_18ff7aa4-e126-4381-b616-139b660c580b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_f73b155f-52c3-4f31-a93e-aa84adfad13e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Products Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d964f11f-8f83-49f6-8a48-3551762347d5_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CreditIssuedForMilestonePayable_944e06b9-bba9-4561-8366-b2337272f622_terseLabel_en-US" xlink:label="lab_cpix_CreditIssuedForMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex forgiveness of milestone payable</link:label>
    <link:label id="lab_cpix_CreditIssuedForMilestonePayable_label_en-US" xlink:label="lab_cpix_CreditIssuedForMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Issued for Milestone Payable</link:label>
    <link:label id="lab_cpix_CreditIssuedForMilestonePayable_documentation_en-US" xlink:label="lab_cpix_CreditIssuedForMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Issued for Milestone Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CreditIssuedForMilestonePayable" xlink:href="cpix-20221231.xsd#cpix_CreditIssuedForMilestonePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CreditIssuedForMilestonePayable" xlink:to="lab_cpix_CreditIssuedForMilestonePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_30454e87-1c8f-4acf-95dc-a90f0ea0ef10_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to share-based payments</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_7870a514-56de-451e-84de-5edb8badf2bc_terseLabel_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of depreciation expense</link:label>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Depreciation Expense [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Depreciation Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:href="cpix-20221231.xsd#cpix_ScheduleofDepreciationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:to="lab_cpix_ScheduleofDepreciationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_31460d60-4f06-4c4c-87ad-015b6acf96bb_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ca302ce-b1d1-46bd-9a08-69398405b6b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_WorkInProcessMember_24a56c26-7851-4262-a65f-9433bfbe4307_terseLabel_en-US" xlink:label="lab_cpix_WorkInProcessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in Process</link:label>
    <link:label id="lab_cpix_WorkInProcessMember_label_en-US" xlink:label="lab_cpix_WorkInProcessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in Process [Member]</link:label>
    <link:label id="lab_cpix_WorkInProcessMember_documentation_en-US" xlink:label="lab_cpix_WorkInProcessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WorkInProcessMember" xlink:href="cpix-20221231.xsd#cpix_WorkInProcessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_WorkInProcessMember" xlink:to="lab_cpix_WorkInProcessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0a005383-e73b-46b6-bc11-8c8bb2c3ef71_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues concentration from major customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_eb5eea58-ac9e-4693-ad05-ee2c562370b2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_e7b3f68a-7c20-48db-b906-8b053743cd58_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_20a468fa-a329-4efe-98dd-7ed5fcb8d5fc_terseLabel_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_label_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:label id="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_documentation_en-US" xlink:label="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:href="cpix-20221231.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:to="lab_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CustomerThreeMember_992eacff-dba4-4596-a6f9-918e81080921_terseLabel_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3</link:label>
    <link:label id="lab_cpix_CustomerThreeMember_label_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:label id="lab_cpix_CustomerThreeMember_documentation_en-US" xlink:label="lab_cpix_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember" xlink:href="cpix-20221231.xsd#cpix_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CustomerThreeMember" xlink:to="lab_cpix_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_17b25db6-f37c-4a44-9e80-bfc319d82cf9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_RediTrexMember_4f28cc1f-b768-4e9b-8e29-f4baec798874_terseLabel_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:label id="lab_cpix_RediTrexMember_label_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex [Member]</link:label>
    <link:label id="lab_cpix_RediTrexMember_documentation_en-US" xlink:label="lab_cpix_RediTrexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RediTrex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember" xlink:href="cpix-20221231.xsd#cpix_RediTrexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_RediTrexMember" xlink:to="lab_cpix_RediTrexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_47440aa3-d0d0-46ba-b489-930d5d4a307e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_99d25601-0f6e-4a1f-a1dc-b0b6a10e8c4c_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments, receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f577bc02-a048-4b36-bb29-6372bc5fcc13_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_78412dbf-e53d-47eb-85be-55a5dadfc67d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9cdd12a4-24c9-44e0-82f2-3fbc14ceb2b6_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ContributionOfCashAdditionalSharesPurchased_f9c5d47b-6227-4837-8722-825fb08f6e1e_terseLabel_en-US" xlink:label="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of cash</link:label>
    <link:label id="lab_cpix_ContributionOfCashAdditionalSharesPurchased_label_en-US" xlink:label="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of Cash, Additional Shares Purchased</link:label>
    <link:label id="lab_cpix_ContributionOfCashAdditionalSharesPurchased_documentation_en-US" xlink:label="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of Cash, Additional Shares Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:href="cpix-20221231.xsd#cpix_ContributionOfCashAdditionalSharesPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:to="lab_cpix_ContributionOfCashAdditionalSharesPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromCollaborationArrangement_d3c8dfba-9eac-4479-94d5-e99cf9fa3bad_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of RediTrex</link:label>
    <link:label id="lab_cpix_ProceedsFromCollaborationArrangement_label_en-US" xlink:label="lab_cpix_ProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaboration Arrangement</link:label>
    <link:label id="lab_cpix_ProceedsFromCollaborationArrangement_documentation_en-US" xlink:label="lab_cpix_ProceedsFromCollaborationArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaboration Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromCollaborationArrangement" xlink:href="cpix-20221231.xsd#cpix_ProceedsFromCollaborationArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromCollaborationArrangement" xlink:to="lab_cpix_ProceedsFromCollaborationArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_53212187-952b-4023-bee0-c15ab98ae196_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_c4e8d116-a8f1-46d7-9198-93f8e3e1e442_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_aecd7785-2dde-4082-a27f-696d05fe1758_terseLabel_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered royalty payments (percentage)</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_label_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:label id="lab_cpix_TieredRoyaltyPaymentsPercentage_documentation_en-US" xlink:label="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tiered Royalty Payments, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:href="cpix-20221231.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_TieredRoyaltyPaymentsPercentage" xlink:to="lab_cpix_TieredRoyaltyPaymentsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_2632877f-b1ab-455c-aea7-54631fd1d954_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0578925b-1336-4f20-9a05-ef0bb00ea6c5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0e3bd4b6-4d52-432f-9233-e553864d5334_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_b3f93bf7-da32-42c2-843a-f845dbed397a_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss and tax credits</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:to="lab_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_e59f3130-3824-46b1-8efb-4b7f0ad498c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_feea1e5d-e3e3-40df-be68-79ef48b629ee_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2d3d4ab9-f9c2-4080-8866-ff755b0403b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_6aea124c-efe2-41c3-96c7-8f63a9149d69_negatedTerseLabel_en-US" xlink:label="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Operating Lease Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:to="lab_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_34de9970-31a0-477a-97f1-03cae43ea93a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_6ee07017-8847-4c0e-bc12-481f98c2c9bb_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum sublease income under noncancelable operating subleases</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductionAndDistributionCosts_c69715d6-c2f3-4082-a657-defdd9596eb0_terseLabel_en-US" xlink:label="lab_us-gaap_ProductionAndDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution costs</link:label>
    <link:label id="lab_us-gaap_ProductionAndDistributionCosts_label_en-US" xlink:label="lab_us-gaap_ProductionAndDistributionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Production and Distribution Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionAndDistributionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionAndDistributionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductionAndDistributionCosts" xlink:to="lab_us-gaap_ProductionAndDistributionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7dd980e7-352c-4985-b4c4-d6cb5977f370_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_a933654d-04bb-45f0-bb99-e304360ba64a_terseLabel_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_label_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:label id="lab_cpix_AccountsReceivableAllowancesByComponentAxis_documentation_en-US" xlink:label="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowances by Component [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:href="cpix-20221231.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:to="lab_cpix_AccountsReceivableAllowancesByComponentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d8f64f64-542d-42f7-af41-cc867abb1ede_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_21be9fc9-322e-4518-ac27-9b1218ecbd00_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_e00a065a-9ab0-454a-80d0-012ce1d38db2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTerm_6e31deff-df76-4a54-8259-44d2f92f948f_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, term</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTerm_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Term</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsTerm_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTerm" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsTerm" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NoncashOrPartNoncashGainOnTransaction_4c0b79df-8c85-4acf-8541-e9e5da33e51c_negatedTerseLabel_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash gain on RediTrex transaction</link:label>
    <link:label id="lab_cpix_NoncashOrPartNoncashGainOnTransaction_label_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash, Gain on Transaction</link:label>
    <link:label id="lab_cpix_NoncashOrPartNoncashGainOnTransaction_documentation_en-US" xlink:label="lab_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash, Gain on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:href="cpix-20221231.xsd#cpix_NoncashOrPartNoncashGainOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:to="lab_cpix_NoncashOrPartNoncashGainOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4e902d1e-c0b3-426e-a49b-11d44e7e55c8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_290a4de6-6fe0-4bf2-82de-7446c5c64752_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9476140e-2e74-41f7-8e6e-3422e292ea14_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_ae06322a-c18f-48c8-aeba-5f2ef84b43b0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_76168238-204a-4d53-be68-17ad8ac4eeca_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_201bd806-0375-410e-ad06-c22e0d0a561b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9d08bebe-edd4-483c-9b0b-2574bc2fc343_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_89c34a36-86d7-4537-9d80-c78d0531f3b4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid, other current assets and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold_33c950b0-aabf-4715-98f0-97c5ce89c287_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments, annual net revenue threshold</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Annual Net Revenue Threshold</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Annual Net Revenue Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_aa6a3bda-9efd-4388-9d12-c9d18d742c80_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-Continuing operations-basic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_80eca95d-899c-43fe-b2fe-1fd73e61c072_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_KristaloseMember_98ff84a2-656b-46f9-86cc-fefc7b0dc316_terseLabel_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose</link:label>
    <link:label id="lab_cpix_KristaloseMember_label_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose [Member]</link:label>
    <link:label id="lab_cpix_KristaloseMember_documentation_en-US" xlink:label="lab_cpix_KristaloseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kristalose.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember" xlink:href="cpix-20221231.xsd#cpix_KristaloseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_KristaloseMember" xlink:to="lab_cpix_KristaloseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PreferredStockAbstract_b5bd5158-e6c8-48e4-b995-4b40781faa52_terseLabel_en-US" xlink:label="lab_cpix_PreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Abstract]</link:label>
    <link:label id="lab_cpix_PreferredStockAbstract_label_en-US" xlink:label="lab_cpix_PreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Abstract]</link:label>
    <link:label id="lab_cpix_PreferredStockAbstract_documentation_en-US" xlink:label="lab_cpix_PreferredStockAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PreferredStockAbstract" xlink:href="cpix-20221231.xsd#cpix_PreferredStockAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PreferredStockAbstract" xlink:to="lab_cpix_PreferredStockAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_28a56a0a-36d8-4f14-9e25-67e158a9b84d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c7872a11-834b-40b4-8e5f-fb24ad6b8638_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3c31edb9-6cb4-4a48-b354-0a458035bf61_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_80815014-b249-4a83-bcc5-f845cb574371_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9e437adb-9d65-49d9-bb99-a2fdb0446b71_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_635757f7-3c4b-4f39-9ee7-3551c980ab76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_bf3b68e5-686c-46ce-b656-7c045eb8f29e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating profit of acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy_8554cc9f-726b-4187-8185-0739808fd1f0_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from surrender of life insurance policies</link:label>
    <link:label id="lab_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy_label_en-US" xlink:label="lab_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Surrender of Life Insurance Policy</link:label>
    <link:label id="lab_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy_documentation_en-US" xlink:label="lab_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Surrender of Life Insurance Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy" xlink:href="cpix-20221231.xsd#cpix_ProceedsFromSurrenderOfLifeInsurancePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy" xlink:to="lab_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b4da72c4-51a1-4faa-ad4c-1ff7e2282d08_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c037bb6b-e0c2-4c62-84a4-68b55f862398_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9c3f7a3c-aa95-4fd9-9a0b-cb3c72860b4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ee4f3c85-7659-40db-aa1d-e50d8cf19fa1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6f415e12-b89e-4937-a50d-3287b5b84318_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, weighted-average exercise price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PaymentProtectionProgramMember_ca91d337-66a8-44e3-8ff3-9ed7be99e5c1_terseLabel_en-US" xlink:label="lab_cpix_PaymentProtectionProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Protection Program</link:label>
    <link:label id="lab_cpix_PaymentProtectionProgramMember_label_en-US" xlink:label="lab_cpix_PaymentProtectionProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Protection Program [Member]</link:label>
    <link:label id="lab_cpix_PaymentProtectionProgramMember_documentation_en-US" xlink:label="lab_cpix_PaymentProtectionProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Protection Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentProtectionProgramMember" xlink:href="cpix-20221231.xsd#cpix_PaymentProtectionProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PaymentProtectionProgramMember" xlink:to="lab_cpix_PaymentProtectionProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_58ca2228-094a-4094-a3be-ba859bc9bcd2_terseLabel_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of balance sheet classification</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cpix-20221231.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cpix_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_8663c69b-a779-4dcd-a5b6-88f4016bb4cb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consigned inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_label_en-US" xlink:label="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:to="lab_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_10f1bdfb-3376-4961-8a9f-b9616b417d55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of quarterly financial information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_19f7f49f-0159-468e-bd43-7475a426e81f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_e9b921d7-d24f-4a64-b858-1803f953e029_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_96bbdd88-0086-478a-84a3-42942877c184_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_e5d1c361-4093-4b2e-a5f0-1c341081cce7_terseLabel_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors&#8217; Incentive Plan 2007</link:label>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_label_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors&#8217; Incentive Plan 2007 [Member]</link:label>
    <link:label id="lab_cpix_DirectorsIncentivePlan2007Member_documentation_en-US" xlink:label="lab_cpix_DirectorsIncentivePlan2007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors&#8217; Incentive Plan 2007 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member" xlink:href="cpix-20221231.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DirectorsIncentivePlan2007Member" xlink:to="lab_cpix_DirectorsIncentivePlan2007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_cf92d41e-a838-4139-bc27-d21afe470f8f_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_ad1724aa-8e0c-4ad4-8834-efd33002cb10_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_c3fd6924-b76d-4434-a9a4-82aad5a404db_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance for deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_070efd3d-0de5-4ba8-8cf0-f92bb5d2d69f_terseLabel_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Line Items]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_label_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and Supply Agreement [Line Items]</link:label>
    <link:label id="lab_cpix_ManufacturingandSupplyAgreementLineItems_documentation_en-US" xlink:label="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Manufacturing and Supply Agreement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems" xlink:href="cpix-20221231.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems" xlink:to="lab_cpix_ManufacturingandSupplyAgreementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_NonprincipalOwnerMember_8fa4bdff-1d69-4534-ae72-35dd83b5d9d4_terseLabel_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonPrincipal Owner</link:label>
    <link:label id="lab_cpix_NonprincipalOwnerMember_label_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonPrincipal Owner [Member]</link:label>
    <link:label id="lab_cpix_NonprincipalOwnerMember_documentation_en-US" xlink:label="lab_cpix_NonprincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonPrincipal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember" xlink:href="cpix-20221231.xsd#cpix_NonprincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_NonprincipalOwnerMember" xlink:to="lab_cpix_NonprincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_1056ed03-0034-4680-acdf-630aecf67e4f_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_0da47d8f-8a37-4f8d-acda-5b3ee2ff1b83_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c5e76e3a-60d9-460d-86f1-7757ab52f713_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_f48d7381-70bd-4d20-89c8-51529c79b98e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_4b37ed93-5b68-456d-92b5-cbd69fc78224_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_b2176fee-3c41-4a3a-abd1-306e1abed49a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_85a9d1a3-1b81-4fe4-bdc0-0c31c264ad71_terseLabel_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and License Rights</link:label>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_label_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and License Rights [Member]</link:label>
    <link:label id="lab_cpix_ProductAndLicenseRightsMember_documentation_en-US" xlink:label="lab_cpix_ProductAndLicenseRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and License Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember" xlink:href="cpix-20221231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductAndLicenseRightsMember" xlink:to="lab_cpix_ProductAndLicenseRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_0705758b-8145-4273-93c5-d06e99d399fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_f6de4d61-4a14-41c3-a614-c27fd133b2af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_b4dbf3a8-8f15-482f-aef5-b3cb2a9c5c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_fb4994c5-c6a9-42be-ae8b-c373e254875f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_795fcdef-2a89-4b40-bd87-a8c8563989b8_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProductRightsMember_dcd600f0-6894-4880-abd6-4dcbc7614d36_verboseLabel_en-US" xlink:label="lab_cpix_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights</link:label>
    <link:label id="lab_cpix_ProductRightsMember_label_en-US" xlink:label="lab_cpix_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights [Member]</link:label>
    <link:label id="lab_cpix_ProductRightsMember_documentation_en-US" xlink:label="lab_cpix_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRightsMember" xlink:href="cpix-20221231.xsd#cpix_ProductRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProductRightsMember" xlink:to="lab_cpix_ProductRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_00207ac2-51e2-4106-b82c-a7b28a0fc9a5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_579affc4-f1dc-4fe6-a9a9-5847c6a4024b_terseLabel_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted cash threshold</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_label_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash Threshold</link:label>
    <link:label id="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_documentation_en-US" xlink:label="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Unrestricted Cash Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:href="cpix-20221231.xsd#cpix_DebtInstrumentCovenantUnrestrictedCashThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:to="lab_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_22e7fb13-64a5-40b2-a438-817b127bc018_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of deferred tax assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_113ec375-6900-419b-8db5-02f6dc8b087c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_660c04ec-cbc3-4d83-94a0-5030f3476463_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangements [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_93526227-9a9f-4129-828c-14cf3113d990_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_255ae88b-29c5-4916-83b9-f9d52db56e3d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_d911d375-8a1a-4253-a280-c38ab5462366_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available under current repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_759816f7-da7d-46df-8cdd-c6ce6e64833c_terseLabel_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income - gain on insurance proceeds</link:label>
    <link:label id="lab_us-gaap_InsuredEventGainLoss_label_en-US" xlink:label="lab_us-gaap_InsuredEventGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insured Event, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuredEventGainLoss" xlink:to="lab_us-gaap_InsuredEventGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccruedLiabilitiesStockPayable_67badbb4-f354-49b1-8ade-b0f68d7e3c74_terseLabel_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStockPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso related liabilities</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesStockPayable_label_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStockPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Stock Payable</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesStockPayable_documentation_en-US" xlink:label="lab_cpix_AccruedLiabilitiesStockPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Stock Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStockPayable" xlink:href="cpix-20221231.xsd#cpix_AccruedLiabilitiesStockPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccruedLiabilitiesStockPayable" xlink:to="lab_cpix_AccruedLiabilitiesStockPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_380413bc-f021-4d99-85ef-cdbe1d1978e8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_0ace6c73-7c9b-425c-bd45-5421cd75402e_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_6eb19649-4cf6-4756-9a18-af3930e8dbff_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_5641492a-675a-4c49-8313-4f7ae970a856_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_b3532487-4872-45aa-9d0e-b7315be16d8c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill amount to be deducted for tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_2c96b0b4-3f38-4057-9fb6-2ec6f713fd6f_terseLabel_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange for consideration, amount</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_label_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:label id="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_documentation_en-US" xlink:label="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary Investment, Payments For Return Of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:href="cpix-20221231.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:to="lab_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_862a70ab-9ca1-4792-af96-ed840c1c17de_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7d94aa29-50a1-4753-b624-3119270fa176_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_b110dc5c-6489-45e5-8514-4cfe25cf3d74_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ec6a9cc0-e94e-4667-b1fa-adbdaf3f5248_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_2aef8865-d450-4147-92c9-c6cafbe230e4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_SancusoMember_f171d189-df85-4a9f-b489-93f469931e42_terseLabel_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso</link:label>
    <link:label id="lab_cpix_SancusoMember_label_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso [Member]</link:label>
    <link:label id="lab_cpix_SancusoMember_documentation_en-US" xlink:label="lab_cpix_SancusoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sancuso</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember" xlink:href="cpix-20221231.xsd#cpix_SancusoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_SancusoMember" xlink:to="lab_cpix_SancusoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8356a065-3f7c-48c8-b7cc-fc167f387882_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_f6dd4b36-abd3-4fb6-a58e-e32e53af5e61_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_ca6d12cb-b638-4d83-b6bf-c486afa13887_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_43f316a0-fc4e-4b18-b1f3-a1cde6568dc0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1b129807-962f-459a-982b-a67f90859cbf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_561715b4-2714-4871-a034-11443c73a273_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options shares vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_77aa12f3-06da-40a1-942a-2f3acc2389a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_1ae66f8d-96e6-407e-87fc-e198618fbe3f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_7351eaf3-9aa8-4073-b9fc-e0bc3fdc984b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingGainsLosses_333db933-3606-4e0d-ae95-ebc4fd079f1d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investment gains</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingGainsLosses_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingGainsLosses" xlink:to="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_a036e2c0-6588-4b9b-a9bb-ae7a59cd0302_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_HarbinGloriaPharmaceuticalsCoMember_84b8e2bb-92ef-4cdc-9f18-ea680f7007df_terseLabel_en-US" xlink:label="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbin Gloria Pharmaceuticals Co</link:label>
    <link:label id="lab_cpix_HarbinGloriaPharmaceuticalsCoMember_label_en-US" xlink:label="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbin Gloria Pharmaceuticals Co [Member]</link:label>
    <link:label id="lab_cpix_HarbinGloriaPharmaceuticalsCoMember_documentation_en-US" xlink:label="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Harbin Gloria Pharmaceuticals Co [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:href="cpix-20221231.xsd#cpix_HarbinGloriaPharmaceuticalsCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:to="lab_cpix_HarbinGloriaPharmaceuticalsCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_168617bb-b346-4fa6-b40a-05107a1d66e8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_935c7553-874f-4fb6-a052-fd5b5b42aad8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_59e3e82c-9f8d-4879-b2d1-ba428b4866ec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_d38cd1b3-717d-4f68-95bd-9b4bb416b3c6_terseLabel_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued inventory purchases</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_label_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Inventory Purchases</link:label>
    <link:label id="lab_cpix_AccruedLiabilitiesInventoryPurchases_documentation_en-US" xlink:label="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Inventory Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases" xlink:href="cpix-20221231.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_AccruedLiabilitiesInventoryPurchases" xlink:to="lab_cpix_AccruedLiabilitiesInventoryPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9a5e5a34-2bc7-400a-b0c0-20a746f0073c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_26478eff-f7b5-4949-a107-9d32d7a5dd28_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_59a21046-9a48-4f0e-b340-a051ab7be9ca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of operating lease liability maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0ef78e86-5db1-437c-bc52-e9454587e179_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5363241f-9e21-488d-a121-1d8a7cf488da_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_47245479-d371-4cbd-b162-496ba0573e73_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_1f15e02d-88aa-4240-99bd-9eb4d03ad093_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on forgiveness of debt</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_696eac17-d667-495a-a69a-8c3aa066d390_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_78033ed8-b9a9-4114-82d3-de0a4cf4fe25_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_EmployeeMember_8bcaaf7f-a2c0-46e6-be54-6939e1e3a953_terseLabel_en-US" xlink:label="lab_cpix_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_cpix_EmployeeMember_label_en-US" xlink:label="lab_cpix_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_cpix_EmployeeMember_documentation_en-US" xlink:label="lab_cpix_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember" xlink:href="cpix-20221231.xsd#cpix_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_EmployeeMember" xlink:to="lab_cpix_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_441a6bce-e3e1-46aa-8294-8f4ccdd3071a_terseLabel_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration earned and accrued</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_label_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:label id="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_documentation_en-US" xlink:label="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:href="cpix-20221231.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:to="lab_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_3d7473d3-8132-4b3b-bc9e-8ee2f4b44d05_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b68bc79e-fbc1-4fc6-829d-46006ac6c678_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options shares vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_e4335fdd-0a4a-4ea3-ae14-8df2fb6085de_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_71b0f16a-2b90-48dc-a4c3-733b2dfe15eb_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_89b20f32-e14c-4623-a475-990de41f3e08_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_8672c265-5e91-488b-a80a-165a8e092e3d_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">less non-current inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_17f270c5-a45a-40a4-9213-2f2de2f455f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_531138a6-5e38-4261-9198-91744f7418b4_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory reserves, obsolescence and discontinuance</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_d1a5cd97-54e4-4884-8e1e-dafd0ce8ec26_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ProceedsFromSettlementOfPatentLitigation_c79888af-02e3-44f2-b46f-f1fa5d922c07_terseLabel_en-US" xlink:label="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of patent litigation</link:label>
    <link:label id="lab_cpix_ProceedsFromSettlementOfPatentLitigation_label_en-US" xlink:label="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Settlement of Patent Litigation</link:label>
    <link:label id="lab_cpix_ProceedsFromSettlementOfPatentLitigation_documentation_en-US" xlink:label="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Settlement of Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:href="cpix-20221231.xsd#cpix_ProceedsFromSettlementOfPatentLitigation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:to="lab_cpix_ProceedsFromSettlementOfPatentLitigation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_7634e749-d820-4673-8a7f-041e7f3579c8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fcaf7b29-e7d7-491c-81df-17597240ecd1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares vested, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_07d7c48b-d2dd-4aeb-94d3-18fe64c5ea39_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3a39973e-9f7a-4d85-ae3f-3ee36dcc4e16_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance under equity compensation plans</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_5e1f1eb7-a91d-4fa9-a0f8-15852b06d4c0_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected sales milestone payments</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares_00345ecd-10cc-4b17-8f55-ae320953637d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Redeemed or Called During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_f97b4c94-a7c5-4325-85df-2893f67672de_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock_e0fae3ff-d287-4adc-a767-9ccaaf7e353a_terseLabel_en-US" xlink:label="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Advertising Costs</link:label>
    <link:label id="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock_label_en-US" xlink:label="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Advertising Costs [Table Text Block]</link:label>
    <link:label id="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock_documentation_en-US" xlink:label="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Advertising Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:href="cpix-20221231.xsd#cpix_ScheduleOfAdvertisingCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:to="lab_cpix_ScheduleOfAdvertisingCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNoParValue_81eedb17-8b49-46d4-ac1d-c4d13f31eee2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, no par value (dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockNoParValue_label_en-US" xlink:label="lab_us-gaap_CommonStockNoParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, No Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_f98c7a1e-e18c-459e-845d-cc3bf630e3a7_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:to="lab_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_16215555-b74f-45e2-8ceb-ce11984119b3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effective tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1fadd965-9cfc-4fbe-aff0-4c67e98b5b7e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_InitialPublicOfferingAbstract_4efe8bfb-b65e-4735-8e75-8ae496257f6f_terseLabel_en-US" xlink:label="lab_cpix_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Abstract]</link:label>
    <link:label id="lab_cpix_InitialPublicOfferingAbstract_label_en-US" xlink:label="lab_cpix_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Abstract]</link:label>
    <link:label id="lab_cpix_InitialPublicOfferingAbstract_documentation_en-US" xlink:label="lab_cpix_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InitialPublicOfferingAbstract" xlink:href="cpix-20221231.xsd#cpix_InitialPublicOfferingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_InitialPublicOfferingAbstract" xlink:to="lab_cpix_InitialPublicOfferingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_2939db7c-b9a2-44df-aab1-292b60e6d3c2_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_b9636766-7493-4078-a6e9-8e18e706710b_terseLabel_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold [Domain]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_label_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold [Domain]</link:label>
    <link:label id="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_documentation_en-US" xlink:label="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Threshold [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:to="lab_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_62849cc4-5f9a-4e05-ba0b-c0aab423c807_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_d25b412d-475d-42e9-a790-c697667947a6_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_c99f6a61-4ecf-4e28-930e-c627bd46bd1f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_01c693f8-b2c5-4547-a12a-52bb468b88c1_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ba6c48c7-c40f-461f-b738-325767b738a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- average grant-date fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f0a5ca42-e4d1-4291-b85d-4629d2b07466_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e5275ea1-5194-4563-a9dc-aadc97e6a0da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_ed696166-2569-4fc2-915d-b79ee19a760e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_IndefiniteMember_450150f9-82ce-4e55-bc86-c0a37ffac88a_terseLabel_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite Period</link:label>
    <link:label id="lab_cpix_IndefiniteMember_label_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite [Member]</link:label>
    <link:label id="lab_cpix_IndefiniteMember_documentation_en-US" xlink:label="lab_cpix_IndefiniteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember" xlink:href="cpix-20221231.xsd#cpix_IndefiniteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_IndefiniteMember" xlink:to="lab_cpix_IndefiniteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_b5f85df5-4bca-400e-a119-bfcdf5654012_terseLabel_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and Other Current Assets</link:label>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and Other Current Assets, Policy [Policy Text Block]</link:label>
    <link:label id="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and Other Current Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:href="cpix-20221231.xsd#cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:to="lab_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_88488020-1dac-4fbc-9cad-c0b2077d255d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_f40f6438-18ae-4ca8-9402-b1f0004a5c05_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5ff3b031-f1a9-42a7-9fcf-0c01caee14c3_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ebdd9d63-1184-4e09-afd0-c33048cd3c0c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_1a4a002a-d2c4-4b57-9467-966a23bc6dd1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_e244afc8-c4f2-48f5-8109-383dcf385505_terseLabel_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment and intangibles</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_label_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property and Equipment and Intangibles</link:label>
    <link:label id="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_documentation_en-US" xlink:label="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property and Equipment and Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:to="lab_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_2c0e33a4-0313-49ef-88f9-f1c5c17d46b6_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eb2ce3b3-63b3-4d0a-82c1-6acea0d8189f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_79144c6e-a961-406c-87e7-36077127a5c4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial public offering, net proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e936328c-d1e6-4cf1-959c-06c5ca1bbb50_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a326b2cc-6e09-478b-bcfd-f27990331a63_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7323a2f8-b4f1-4047-80f4-02e85f9ce25a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_f96b7ece-1b29-4592-89a9-3fc34df40c1f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b424b044-99f8-4951-8083-84b746d4c31d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ed515c06-59df-4f86-8c72-60a83b4b4a64_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_95d4118d-e2b1-4fdc-a74b-ce8589d875d7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e17d9056-b9fa-4358-921e-e5b0e4ce5e91_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_30b5b046-f53d-49bc-aaa6-d771b8ea49b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of numerator and denominator in earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_Within30DaysOfFirstSNDAFilingMember_915c1b80-c4f4-4644-ae7e-fa1880fa158a_terseLabel_en-US" xlink:label="lab_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within 30 Days Of First sNDA Filing</link:label>
    <link:label id="lab_cpix_Within30DaysOfFirstSNDAFilingMember_label_en-US" xlink:label="lab_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within 30 Days Of First sNDA Filing [Member]</link:label>
    <link:label id="lab_cpix_Within30DaysOfFirstSNDAFilingMember_documentation_en-US" xlink:label="lab_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within 30 Days Of First sNDA Filing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:href="cpix-20221231.xsd#cpix_Within30DaysOfFirstSNDAFilingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:to="lab_cpix_Within30DaysOfFirstSNDAFilingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_94cecefe-7721-42ec-bbca-7a446d3b5b3e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of operating lease assets and liabilities through adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_e4030c0c-d33c-4d4d-8835-9f4066a672d3_terseLabel_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, sale of corporate securities (up to)</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_label_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</link:label>
    <link:label id="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_documentation_en-US" xlink:label="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:to="lab_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_4742d45a-9e09-412a-9cf6-698ae05cf7a5_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>cpix-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f3294900-4a6d-4934-9914-8de8a2261475,g:98ef8ed7-f771-4377-a070-411ae3070b66-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="simple" xlink:href="cpix-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9ff1281f-2500-4e61-bd9b-38e567f2e242" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_DocumentType_9ff1281f-2500-4e61-bd9b-38e567f2e242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6691783c-9acf-4e3b-8f5e-bd60f06027ca" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_DocumentAnnualReport_6691783c-9acf-4e3b-8f5e-bd60f06027ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9682c964-fd07-42d7-9453-9be533d7a2e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_DocumentPeriodEndDate_9682c964-fd07-42d7-9453-9be533d7a2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e298c638-235a-46b0-b028-083fa1cd196b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_DocumentTransitionReport_e298c638-235a-46b0-b028-083fa1cd196b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5b5fe18a-be1c-4d8c-90e0-b2c05a5b7b4e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityRegistrantName_5b5fe18a-be1c-4d8c-90e0-b2c05a5b7b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e345137a-e4c0-4e86-8952-e753c8eb42f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e345137a-e4c0-4e86-8952-e753c8eb42f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3623b866-156e-4f23-9a48-bc8123503f33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityTaxIdentificationNumber_3623b866-156e-4f23-9a48-bc8123503f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d664feda-235d-4952-b9df-50eb7423f545" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityFileNumber_d664feda-235d-4952-b9df-50eb7423f545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1b393004-cad3-4955-b2ab-1eb914571d65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityCentralIndexKey_1b393004-cad3-4955-b2ab-1eb914571d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_50bc195e-73a6-4fca-96a7-29077bae9296" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_CurrentFiscalYearEndDate_50bc195e-73a6-4fca-96a7-29077bae9296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7c8ad454-70fa-418d-934f-de826fc75658" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_DocumentFiscalYearFocus_7c8ad454-70fa-418d-934f-de826fc75658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_eb212d4a-2a73-4aba-ad14-54405396058f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_DocumentFiscalPeriodFocus_eb212d4a-2a73-4aba-ad14-54405396058f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_748a87ea-1de4-47cf-a622-ede9c86eb2ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_AmendmentFlag_748a87ea-1de4-47cf-a622-ede9c86eb2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e3cd534d-6712-4a36-986a-88cd267c03b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityAddressAddressLine1_e3cd534d-6712-4a36-986a-88cd267c03b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_2580e21f-3bc0-4381-a389-5164a39f9dff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityAddressAddressLine2_2580e21f-3bc0-4381-a389-5164a39f9dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_aac8b0dc-7d6e-4e7f-96ac-215de644b87e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityAddressCityOrTown_aac8b0dc-7d6e-4e7f-96ac-215de644b87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4f05845b-7307-4069-8f8d-e00c9109bb0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityAddressStateOrProvince_4f05845b-7307-4069-8f8d-e00c9109bb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_026f8bc3-855c-426d-aa11-8e9773b6336c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityAddressPostalZipCode_026f8bc3-855c-426d-aa11-8e9773b6336c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3e05146d-33d8-4e6d-b676-4678c4be93f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_CityAreaCode_3e05146d-33d8-4e6d-b676-4678c4be93f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b6d3fdca-b4a2-4f76-b886-f78c6ec15584" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_LocalPhoneNumber_b6d3fdca-b4a2-4f76-b886-f78c6ec15584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6500e545-df5b-49f1-952d-18367afc8800" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_Security12bTitle_6500e545-df5b-49f1-952d-18367afc8800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a8599761-d690-4db7-aaa4-3c4a001922f8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_TradingSymbol_a8599761-d690-4db7-aaa4-3c4a001922f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_dc433d22-da71-4e21-9a25-8697db7f9f26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_SecurityExchangeName_dc433d22-da71-4e21-9a25-8697db7f9f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a6048bcc-a19a-415c-ac91-244b74e9cccf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityFilerCategory_a6048bcc-a19a-415c-ac91-244b74e9cccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e9379dcf-2fe5-465f-b98e-6ac04c4fe717" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityEmergingGrowthCompany_e9379dcf-2fe5-465f-b98e-6ac04c4fe717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c40a4445-fd67-4ebf-9e65-cf614f18b1ad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntitySmallBusiness_c40a4445-fd67-4ebf-9e65-cf614f18b1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bdeb228e-fd52-4a99-9941-079e0f07fee0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityShellCompany_bdeb228e-fd52-4a99-9941-079e0f07fee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f114a3ad-f05b-463c-9c1b-0b51470c7244" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f114a3ad-f05b-463c-9c1b-0b51470c7244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_de27eadd-2456-498c-800c-1ce4582a233b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityVoluntaryFilers_de27eadd-2456-498c-800c-1ce4582a233b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a55d8dd1-7ec0-43c7-8c7c-8d80d182d457" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityCurrentReportingStatus_a55d8dd1-7ec0-43c7-8c7c-8d80d182d457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ba45a73f-704e-4bf7-a814-f3cdafa0bb09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityInteractiveDataCurrent_ba45a73f-704e-4bf7-a814-f3cdafa0bb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_ce421767-0985-4504-b831-31a9c6fdcc13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityPublicFloat_ce421767-0985-4504-b831-31a9c6fdcc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_671cc9cd-a62e-4eb4-8029-af180267f256" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_671cc9cd-a62e-4eb4-8029-af180267f256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1d9b21c2-c016-45d5-bbcb-a4116e59c6ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97afe36c-a3ae-4cf6-ad1c-c81331cf6292" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1d9b21c2-c016-45d5-bbcb-a4116e59c6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/AuditInformation" xlink:type="simple" xlink:href="cpix-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AuditorInformationAbstract_367b2c0a-ffe6-4a76-b57d-6c896fde790b" xlink:href="cpix-20221231.xsd#cpix_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_8650c571-1bbb-421e-92d5-3903f006cd82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AuditorInformationAbstract_367b2c0a-ffe6-4a76-b57d-6c896fde790b" xlink:to="loc_dei_AuditorName_8650c571-1bbb-421e-92d5-3903f006cd82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_a1af6317-dce1-4dcf-9bf4-be3d7ca85e40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AuditorInformationAbstract_367b2c0a-ffe6-4a76-b57d-6c896fde790b" xlink:to="loc_dei_AuditorLocation_a1af6317-dce1-4dcf-9bf4-be3d7ca85e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_d5e7060e-21e7-49a0-bdb8-d60f6cf58bad" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AuditorInformationAbstract_367b2c0a-ffe6-4a76-b57d-6c896fde790b" xlink:to="loc_dei_AuditorFirmId_d5e7060e-21e7-49a0-bdb8-d60f6cf58bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cpix-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_995c1a1b-a2e2-41c7-8460-f6a93bef2c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_75a61b53-288d-4dd5-b9f1-ddcd71736da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_995c1a1b-a2e2-41c7-8460-f6a93bef2c3b" xlink:to="loc_us-gaap_AssetsAbstract_75a61b53-288d-4dd5-b9f1-ddcd71736da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f4ca5e44-99a4-4179-bb4f-d61aecebcb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75a61b53-288d-4dd5-b9f1-ddcd71736da0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f4ca5e44-99a4-4179-bb4f-d61aecebcb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c9ecb96-dda2-4aae-bcfa-079406953cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ca5e44-99a4-4179-bb4f-d61aecebcb64" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c9ecb96-dda2-4aae-bcfa-079406953cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ec6dbecf-b4f8-4cf0-ab54-00799771469e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ca5e44-99a4-4179-bb4f-d61aecebcb64" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ec6dbecf-b4f8-4cf0-ab54-00799771469e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_90f2ce7a-b35e-4632-a22c-c20c53577022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ca5e44-99a4-4179-bb4f-d61aecebcb64" xlink:to="loc_us-gaap_InventoryNet_90f2ce7a-b35e-4632-a22c-c20c53577022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8be93d59-324d-4a88-bfac-a27706d8ada0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ca5e44-99a4-4179-bb4f-d61aecebcb64" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8be93d59-324d-4a88-bfac-a27706d8ada0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4649b3a1-79dd-4510-976e-168ad0403e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4ca5e44-99a4-4179-bb4f-d61aecebcb64" xlink:to="loc_us-gaap_AssetsCurrent_4649b3a1-79dd-4510-976e-168ad0403e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_5be2aed2-fccf-471b-a3a2-a31942d92abb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75a61b53-288d-4dd5-b9f1-ddcd71736da0" xlink:to="loc_us-gaap_InventoryNoncurrent_5be2aed2-fccf-471b-a3a2-a31942d92abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68fabbb2-c8d3-4b9c-966e-a823fb6f11d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75a61b53-288d-4dd5-b9f1-ddcd71736da0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68fabbb2-c8d3-4b9c-966e-a823fb6f11d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b825eb83-8054-4a85-9773-d262384715f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75a61b53-288d-4dd5-b9f1-ddcd71736da0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b825eb83-8054-4a85-9773-d262384715f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3230e79c-6977-4652-8714-41285e4b7375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75a61b53-288d-4dd5-b9f1-ddcd71736da0" xlink:to="loc_us-gaap_Goodwill_3230e79c-6977-4652-8714-41285e4b7375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5f6ba0b5-0a60-464d-836c-4328668a4721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75a61b53-288d-4dd5-b9f1-ddcd71736da0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5f6ba0b5-0a60-464d-836c-4328668a4721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d23b452b-c219-4e14-bd33-f2d0a3a114ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75a61b53-288d-4dd5-b9f1-ddcd71736da0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d23b452b-c219-4e14-bd33-f2d0a3a114ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_07765df3-8a1a-4d25-b5e5-783456f80376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_75a61b53-288d-4dd5-b9f1-ddcd71736da0" xlink:to="loc_us-gaap_Assets_07765df3-8a1a-4d25-b5e5-783456f80376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a207eece-6e80-4eff-ba9c-874ef6883308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_995c1a1b-a2e2-41c7-8460-f6a93bef2c3b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a207eece-6e80-4eff-ba9c-874ef6883308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_fc9a8d29-a99e-4f02-9cee-363abd88740d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a207eece-6e80-4eff-ba9c-874ef6883308" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_fc9a8d29-a99e-4f02-9cee-363abd88740d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_52f61af9-c8ea-4c97-aa2a-ef860145cde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc9a8d29-a99e-4f02-9cee-363abd88740d" xlink:to="loc_us-gaap_AccountsPayableCurrent_52f61af9-c8ea-4c97-aa2a-ef860145cde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e21b3526-95d2-4382-b323-cbd1727f3205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc9a8d29-a99e-4f02-9cee-363abd88740d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e21b3526-95d2-4382-b323-cbd1727f3205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a8eb4730-371f-44c0-a741-59f9712ef608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc9a8d29-a99e-4f02-9cee-363abd88740d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a8eb4730-371f-44c0-a741-59f9712ef608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a7622d53-bdd8-4aea-8127-75babf5ad3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_fc9a8d29-a99e-4f02-9cee-363abd88740d" xlink:to="loc_us-gaap_LiabilitiesCurrent_a7622d53-bdd8-4aea-8127-75babf5ad3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_2e8a36e3-d2a8-466a-bc49-323ac2c7b0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a207eece-6e80-4eff-ba9c-874ef6883308" xlink:to="loc_us-gaap_LongTermLineOfCredit_2e8a36e3-d2a8-466a-bc49-323ac2c7b0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3dc88154-82d0-42b7-ac06-ecbe49a8ebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a207eece-6e80-4eff-ba9c-874ef6883308" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3dc88154-82d0-42b7-ac06-ecbe49a8ebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_cf5fa7a3-3291-4967-b5df-e556b3dab211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a207eece-6e80-4eff-ba9c-874ef6883308" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_cf5fa7a3-3291-4967-b5df-e556b3dab211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_03352afb-0a65-4da6-80f2-a14474138814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a207eece-6e80-4eff-ba9c-874ef6883308" xlink:to="loc_us-gaap_Liabilities_03352afb-0a65-4da6-80f2-a14474138814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b5c1f58c-7918-487e-b7aa-7228e9c0b809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a207eece-6e80-4eff-ba9c-874ef6883308" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b5c1f58c-7918-487e-b7aa-7228e9c0b809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d7506306-bddb-4975-922f-d32653f6d117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a207eece-6e80-4eff-ba9c-874ef6883308" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d7506306-bddb-4975-922f-d32653f6d117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5ad17ab1-6d2f-4d65-811f-d198ff0591e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d7506306-bddb-4975-922f-d32653f6d117" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5ad17ab1-6d2f-4d65-811f-d198ff0591e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_65f6e08c-2840-429a-960e-3160c0770d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5ad17ab1-6d2f-4d65-811f-d198ff0591e2" xlink:to="loc_us-gaap_CommonStockValueOutstanding_65f6e08c-2840-429a-960e-3160c0770d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_142f3d13-2db5-4fb4-9794-bc3043597451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5ad17ab1-6d2f-4d65-811f-d198ff0591e2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_142f3d13-2db5-4fb4-9794-bc3043597451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9203c73c-00e1-4141-b0f0-a01245b2d443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5ad17ab1-6d2f-4d65-811f-d198ff0591e2" xlink:to="loc_us-gaap_StockholdersEquity_9203c73c-00e1-4141-b0f0-a01245b2d443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a1703957-9f7f-48d5-acb7-03256b8b6ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d7506306-bddb-4975-922f-d32653f6d117" xlink:to="loc_us-gaap_MinorityInterest_a1703957-9f7f-48d5-acb7-03256b8b6ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59f8f9d6-a648-4018-b0c7-d45ca7247a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d7506306-bddb-4975-922f-d32653f6d117" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59f8f9d6-a648-4018-b0c7-d45ca7247a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_de3ff78d-02a3-4240-b97f-96ff019190c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a207eece-6e80-4eff-ba9c-874ef6883308" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_de3ff78d-02a3-4240-b97f-96ff019190c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cpix-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_520af5c7-3f87-496b-86b4-1fa8821ad023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNoParValue_1dd41974-336c-4b14-89c5-20250ecf31ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_520af5c7-3f87-496b-86b4-1fa8821ad023" xlink:to="loc_us-gaap_CommonStockNoParValue_1dd41974-336c-4b14-89c5-20250ecf31ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_569d7f19-79ba-41d5-b69b-79e2ce6433d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_520af5c7-3f87-496b-86b4-1fa8821ad023" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_569d7f19-79ba-41d5-b69b-79e2ce6433d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c99e55d4-c1d2-47a7-8e75-4b1f0811d483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_520af5c7-3f87-496b-86b4-1fa8821ad023" xlink:to="loc_us-gaap_CommonStockSharesIssued_c99e55d4-c1d2-47a7-8e75-4b1f0811d483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1f88b93e-19dd-4852-9022-4894e96af813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_520af5c7-3f87-496b-86b4-1fa8821ad023" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1f88b93e-19dd-4852-9022-4894e96af813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cpix-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f9ee0e1c-6986-4e53-963d-2ba8e527cca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9304a0e2-a0c2-4977-b784-1e6ffa05caba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f9ee0e1c-6986-4e53-963d-2ba8e527cca1" xlink:to="loc_us-gaap_StatementTable_9304a0e2-a0c2-4977-b784-1e6ffa05caba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_24c982f4-ee9a-4011-baca-308c6a3a217f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9304a0e2-a0c2-4977-b784-1e6ffa05caba" xlink:to="loc_srt_ProductOrServiceAxis_24c982f4-ee9a-4011-baca-308c6a3a217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5099d65c-7543-40c7-96e4-bf3faf8572a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_24c982f4-ee9a-4011-baca-308c6a3a217f" xlink:to="loc_srt_ProductsAndServicesDomain_5099d65c-7543-40c7-96e4-bf3faf8572a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_75bbebba-1dab-48b9-8de1-2a76478c22df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5099d65c-7543-40c7-96e4-bf3faf8572a2" xlink:to="loc_us-gaap_ProductMember_75bbebba-1dab-48b9-8de1-2a76478c22df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturedProductOtherMember_60115f0b-993d-4a2a-ba31-43f0fc07a68c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturedProductOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5099d65c-7543-40c7-96e4-bf3faf8572a2" xlink:to="loc_us-gaap_ManufacturedProductOtherMember_60115f0b-993d-4a2a-ba31-43f0fc07a68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9304a0e2-a0c2-4977-b784-1e6ffa05caba" xlink:to="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a560a093-25be-4638-8d0b-e26a1db91f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_RevenuesAbstract_a560a093-25be-4638-8d0b-e26a1db91f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9151ee6b-0d75-4b54-90b4-13449e158f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a560a093-25be-4638-8d0b-e26a1db91f2e" xlink:to="loc_us-gaap_Revenues_9151ee6b-0d75-4b54-90b4-13449e158f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_356d4bf9-a10e-40f9-a585-159147cfff18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_356d4bf9-a10e-40f9-a585-159147cfff18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_d611f36c-a654-41e7-a71e-40d9d973e3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_SellingAndMarketingExpense_d611f36c-a654-41e7-a71e-40d9d973e3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f2e35393-e0e5-450b-89ea-326b972f3b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f2e35393-e0e5-450b-89ea-326b972f3b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_08430f5a-5543-4e34-8575-0279b433b7ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_08430f5a-5543-4e34-8575-0279b433b7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ad03585c-0138-408a-95ec-0e8bd0857acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ad03585c-0138-408a-95ec-0e8bd0857acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_fce0f67c-bf01-4e81-be91-76fc9fb3035e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_84123000-1ba8-4498-8c69-d96f64aeca8a" xlink:to="loc_us-gaap_CostsAndExpenses_fce0f67c-bf01-4e81-be91-76fc9fb3035e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ea328df7-8a4f-45dc-98d5-8fb8b37e1fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_OperatingIncomeLoss_ea328df7-8a4f-45dc-98d5-8fb8b37e1fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e7932b01-f1eb-43c3-be21-aefb4c20c41a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e7932b01-f1eb-43c3-be21-aefb4c20c41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncome_a9a11545-5602-48af-8b5a-ba2458cd331f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_OtherIncome_a9a11545-5602-48af-8b5a-ba2458cd331f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuredEventGainLoss_bb1214c3-57cf-44a5-8710-08eef18a2155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuredEventGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_InsuredEventGainLoss_bb1214c3-57cf-44a5-8710-08eef18a2155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bbe51062-8cda-41cf-a433-f201aa64ac7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_InterestExpense_bbe51062-8cda-41cf-a433-f201aa64ac7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d046fb62-732e-4ef7-aa43-78e61eb1e361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d046fb62-732e-4ef7-aa43-78e61eb1e361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ccdc04ce-8ae1-49aa-9b98-d13a0a614f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ccdc04ce-8ae1-49aa-9b98-d13a0a614f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f721959a-98bc-45f4-a40a-5812070ee31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f721959a-98bc-45f4-a40a-5812070ee31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9280d99d-8daa-4cb8-ae81-6b32771cc2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9280d99d-8daa-4cb8-ae81-6b32771cc2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_356aad5f-5112-473b-b704-f1f7d8d73ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_ProfitLoss_356aad5f-5112-473b-b704-f1f7d8d73ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6bae5eaf-133c-4008-a80b-f271c9247bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6bae5eaf-133c-4008-a80b-f271c9247bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_725d4db8-0ee8-4a83-8573-0ebd691b4ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_NetIncomeLoss_725d4db8-0ee8-4a83-8573-0ebd691b4ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e12f7eba-9927-4b5e-a1c4-790fd6df7001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e12f7eba-9927-4b5e-a1c4-790fd6df7001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_a89fc7c8-7c3c-43a3-8f90-ecb023d39634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_a89fc7c8-7c3c-43a3-8f90-ecb023d39634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3b9dd7e5-928b-4887-8f50-27c52d3a6917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_EarningsPerShareBasic_3b9dd7e5-928b-4887-8f50-27c52d3a6917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_64673057-acc2-4fec-9ca9-fb89733bb8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_64673057-acc2-4fec-9ca9-fb89733bb8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_024fc8cb-7bd8-4644-894f-34d38d7edcc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_024fc8cb-7bd8-4644-894f-34d38d7edcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1b00fbac-4333-4105-b20c-fd2cf28464ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc15eb6e-5426-45db-8e72-498e49e161bb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1b00fbac-4333-4105-b20c-fd2cf28464ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_655eb915-1dd5-4155-926b-9f840df65713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b913405e-6702-4d4e-9354-a6597af75bf8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_655eb915-1dd5-4155-926b-9f840df65713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fd4b2f9f-312a-4bef-9ffb-e12af42c8fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_655eb915-1dd5-4155-926b-9f840df65713" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fd4b2f9f-312a-4bef-9ffb-e12af42c8fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5493f149-727a-415c-a52d-fc230a7bae9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_655eb915-1dd5-4155-926b-9f840df65713" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5493f149-727a-415c-a52d-fc230a7bae9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cpix-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b6fdcd69-c86c-419f-8547-5ff618dcd6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f390fe6a-14a3-4d33-8c7d-5a558edbcfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6fdcd69-c86c-419f-8547-5ff618dcd6ce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f390fe6a-14a3-4d33-8c7d-5a558edbcfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_61542c72-e242-47a8-96a6-1cb926f64e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f390fe6a-14a3-4d33-8c7d-5a558edbcfd8" xlink:to="loc_us-gaap_ProfitLoss_61542c72-e242-47a8-96a6-1cb926f64e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b010acd7-2c90-45aa-b84c-cfec984e5df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f390fe6a-14a3-4d33-8c7d-5a558edbcfd8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b010acd7-2c90-45aa-b84c-cfec984e5df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d84fbd40-1157-4b79-bec2-be2173beb37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f390fe6a-14a3-4d33-8c7d-5a558edbcfd8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d84fbd40-1157-4b79-bec2-be2173beb37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f390fe6a-14a3-4d33-8c7d-5a558edbcfd8" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f2c4c5cd-257a-4c98-8d36-dbe6caf928b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f2c4c5cd-257a-4c98-8d36-dbe6caf928b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bce5dffa-b549-4c88-b64f-f3f02c3ebab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bce5dffa-b549-4c88-b64f-f3f02c3ebab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_49074bc6-b40f-48ba-aacc-2205db9d8a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:to="loc_us-gaap_ShareBasedCompensation_49074bc6-b40f-48ba-aacc-2205db9d8a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_95374e2a-441b-4a2d-be64-1d1cdf644686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_95374e2a-441b-4a2d-be64-1d1cdf644686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_db661424-3585-45ec-89d2-b1e93e3a5966" xlink:href="cpix-20221231.xsd#cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:to="loc_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy_db661424-3585-45ec-89d2-b1e93e3a5966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_51929a0a-045a-4f16-a42f-91e5f85897ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_51929a0a-045a-4f16-a42f-91e5f85897ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NoncashOrPartNoncashGainOnTransaction_e3fc6b6c-dffc-4b3d-a177-6eec87527bc6" xlink:href="cpix-20221231.xsd#cpix_NoncashOrPartNoncashGainOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:to="loc_cpix_NoncashOrPartNoncashGainOnTransaction_e3fc6b6c-dffc-4b3d-a177-6eec87527bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_aa2bdcb5-15d5-4dca-b871-6a2381f84c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_aa2bdcb5-15d5-4dca-b871-6a2381f84c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_86a9cc7c-b6a0-4ec3-95b9-0572e540b0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_86a9cc7c-b6a0-4ec3-95b9-0572e540b0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4bd8bb-2df6-4d04-bab6-d3c74d714873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cdac1d3d-7eb0-4758-94fc-e6401cd7dc5e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4bd8bb-2df6-4d04-bab6-d3c74d714873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_16fc0906-4c6f-4c7b-b638-81d129827e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4bd8bb-2df6-4d04-bab6-d3c74d714873" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_16fc0906-4c6f-4c7b-b638-81d129827e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f214c1e2-97c9-4ead-b1d1-499e2fabe27a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4bd8bb-2df6-4d04-bab6-d3c74d714873" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f214c1e2-97c9-4ead-b1d1-499e2fabe27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2ae6812e-ed44-4425-b4ff-fd5398d6b57d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4bd8bb-2df6-4d04-bab6-d3c74d714873" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_2ae6812e-ed44-4425-b4ff-fd5398d6b57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f2cf2cb7-c0e0-40b2-872c-813a2c6d13bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4bd8bb-2df6-4d04-bab6-d3c74d714873" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f2cf2cb7-c0e0-40b2-872c-813a2c6d13bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_628d4198-20ae-4118-9bd5-eec3bea639f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4bd8bb-2df6-4d04-bab6-d3c74d714873" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_628d4198-20ae-4118-9bd5-eec3bea639f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_771616e0-7e60-4f06-b6be-62490ea4e9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ce4bd8bb-2df6-4d04-bab6-d3c74d714873" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_771616e0-7e60-4f06-b6be-62490ea4e9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_fd7e944f-fdbc-4fde-8235-a387c8b2a31d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f390fe6a-14a3-4d33-8c7d-5a558edbcfd8" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_fd7e944f-fdbc-4fde-8235-a387c8b2a31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5cb04293-03f6-4fd9-aabc-89d4b7283267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f390fe6a-14a3-4d33-8c7d-5a558edbcfd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5cb04293-03f6-4fd9-aabc-89d4b7283267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6fdcd69-c86c-419f-8547-5ff618dcd6ce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_734aae55-75d7-442a-9ee7-7334440899c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_734aae55-75d7-442a-9ee7-7334440899c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_281a0cdd-6e49-4504-8509-1cebed287e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_281a0cdd-6e49-4504-8509-1cebed287e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromCollaborationArrangement_24e875de-ee62-4c50-b2b6-05741e9be479" xlink:href="cpix-20221231.xsd#cpix_ProceedsFromCollaborationArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:to="loc_cpix_ProceedsFromCollaborationArrangement_24e875de-ee62-4c50-b2b6-05741e9be479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy_f2a6ea97-606c-4985-9469-8c3cbe597fa1" xlink:href="cpix-20221231.xsd#cpix_ProceedsFromSurrenderOfLifeInsurancePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:to="loc_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy_f2a6ea97-606c-4985-9469-8c3cbe597fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_df6f4062-802f-4579-a36b-6e06e10f4944" xlink:href="cpix-20221231.xsd#cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:to="loc_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy_df6f4062-802f-4579-a36b-6e06e10f4944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLifeInsurancePolicies_38aa2d35-4218-4d02-81fe-2d55f6314f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLifeInsurancePolicies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:to="loc_us-gaap_ProceedsFromLifeInsurancePolicies_38aa2d35-4218-4d02-81fe-2d55f6314f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProceedsFromSettlementOfPatentLitigation_393b8f9c-15cd-4b25-a18c-470be6d4accf" xlink:href="cpix-20221231.xsd#cpix_ProceedsFromSettlementOfPatentLitigation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:to="loc_cpix_ProceedsFromSettlementOfPatentLitigation_393b8f9c-15cd-4b25-a18c-470be6d4accf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_667d9a66-fd81-4eda-a64c-de74c7957ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_667d9a66-fd81-4eda-a64c-de74c7957ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_57efe0b9-a6fb-40ac-9338-69cc1ea1687d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_57efe0b9-a6fb-40ac-9338-69cc1ea1687d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7d51259-1839-4443-9873-4737c75613e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_885dbcf2-54d3-44b3-9262-4d29c58cc741" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f7d51259-1839-4443-9873-4737c75613e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a57daf03-1f4a-4032-989b-3f1ad64e362e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6fdcd69-c86c-419f-8547-5ff618dcd6ce" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a57daf03-1f4a-4032-989b-3f1ad64e362e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_b83fc056-6d89-4a86-80ce-061588eca88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a57daf03-1f4a-4032-989b-3f1ad64e362e" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_b83fc056-6d89-4a86-80ce-061588eca88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_ca5731d8-2dc5-4c56-a165-557638468c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a57daf03-1f4a-4032-989b-3f1ad64e362e" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_ca5731d8-2dc5-4c56-a165-557638468c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04d67f4b-3d51-4e66-9f96-f2090a770718" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a57daf03-1f4a-4032-989b-3f1ad64e362e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_04d67f4b-3d51-4e66-9f96-f2090a770718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_eedf0226-0790-4e7b-85f4-a5b510d044dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a57daf03-1f4a-4032-989b-3f1ad64e362e" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_eedf0226-0790-4e7b-85f4-a5b510d044dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a2eed12-e6c5-4bad-ab6c-c01a24d6989f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a57daf03-1f4a-4032-989b-3f1ad64e362e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1a2eed12-e6c5-4bad-ab6c-c01a24d6989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_223174b7-24eb-4801-a440-67449ab4c281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6fdcd69-c86c-419f-8547-5ff618dcd6ce" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_223174b7-24eb-4801-a440-67449ab4c281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41f52ad3-8139-451d-83e5-5f39b1042093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6fdcd69-c86c-419f-8547-5ff618dcd6ce" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41f52ad3-8139-451d-83e5-5f39b1042093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_996df941-d2e9-4324-b43c-dcd8a6d4ec29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6fdcd69-c86c-419f-8547-5ff618dcd6ce" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_996df941-d2e9-4324-b43c-dcd8a6d4ec29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_d0c9831b-1aff-46c3-b85c-51cfb2089645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b6fdcd69-c86c-419f-8547-5ff618dcd6ce" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_d0c9831b-1aff-46c3-b85c-51cfb2089645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CashPaidDuringYearForAbstract_d955d2a1-1ba0-4de4-98fe-ac838223fa53" xlink:href="cpix-20221231.xsd#cpix_CashPaidDuringYearForAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d0c9831b-1aff-46c3-b85c-51cfb2089645" xlink:to="loc_cpix_CashPaidDuringYearForAbstract_d955d2a1-1ba0-4de4-98fe-ac838223fa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ae0ebe1b-caf0-4402-918c-3a6be07f16c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CashPaidDuringYearForAbstract_d955d2a1-1ba0-4de4-98fe-ac838223fa53" xlink:to="loc_us-gaap_InterestPaidNet_ae0ebe1b-caf0-4402-918c-3a6be07f16c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_01ced9d2-bb20-411c-9278-8e6eb8b3bd88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CashPaidDuringYearForAbstract_d955d2a1-1ba0-4de4-98fe-ac838223fa53" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_01ced9d2-bb20-411c-9278-8e6eb8b3bd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c4d99f96-6c3f-4f36-9a46-54311a79c6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d0c9831b-1aff-46c3-b85c-51cfb2089645" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c4d99f96-6c3f-4f36-9a46-54311a79c6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_13c19c17-a990-4df8-9555-bb72628e4182" xlink:href="cpix-20221231.xsd#cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c4d99f96-6c3f-4f36-9a46-54311a79c6ad" xlink:to="loc_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid_13c19c17-a990-4df8-9555-bb72628e4182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_80a3dc2f-dcda-471b-be88-a41ae7a88058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c4d99f96-6c3f-4f36-9a46-54311a79c6ad" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_80a3dc2f-dcda-471b-be88-a41ae7a88058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9dc7c7ec-56f2-4868-8f27-77c9441cc76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c4d99f96-6c3f-4f36-9a46-54311a79c6ad" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9dc7c7ec-56f2-4868-8f27-77c9441cc76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CreditIssuedForMilestonePayable_f5c009b4-3457-49ea-b624-834b13706bc5" xlink:href="cpix-20221231.xsd#cpix_CreditIssuedForMilestonePayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c4d99f96-6c3f-4f36-9a46-54311a79c6ad" xlink:to="loc_cpix_CreditIssuedForMilestonePayable_f5c009b4-3457-49ea-b624-834b13706bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_bd1360fa-eedc-4bd1-acfd-0d5d3c48328e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_c4d99f96-6c3f-4f36-9a46-54311a79c6ad" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_bd1360fa-eedc-4bd1-acfd-0d5d3c48328e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="cpix-20221231.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_786b50e4-add9-440f-ac5c-56f88918ffb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ee2a8d2-e3c7-4925-a6e8-9fc6735beb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_786b50e4-add9-440f-ac5c-56f88918ffb7" xlink:to="loc_us-gaap_StatementTable_2ee2a8d2-e3c7-4925-a6e8-9fc6735beb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fde97187-8844-4077-8a47-f0d18f7bb54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ee2a8d2-e3c7-4925-a6e8-9fc6735beb4c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fde97187-8844-4077-8a47-f0d18f7bb54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c19329a0-4cfb-4d19-817c-304bb598a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fde97187-8844-4077-8a47-f0d18f7bb54f" xlink:to="loc_us-gaap_EquityComponentDomain_c19329a0-4cfb-4d19-817c-304bb598a84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e4fe6a16-abed-486c-bb3c-b1aceba101a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c19329a0-4cfb-4d19-817c-304bb598a84a" xlink:to="loc_us-gaap_CommonStockMember_e4fe6a16-abed-486c-bb3c-b1aceba101a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_45a168d8-7291-43ca-bf42-da0baedce858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c19329a0-4cfb-4d19-817c-304bb598a84a" xlink:to="loc_us-gaap_RetainedEarningsMember_45a168d8-7291-43ca-bf42-da0baedce858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_2eb9de6e-5cba-487d-87cb-253c093955ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c19329a0-4cfb-4d19-817c-304bb598a84a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_2eb9de6e-5cba-487d-87cb-253c093955ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_55fed691-fa85-4d7a-8243-3592475270a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ee2a8d2-e3c7-4925-a6e8-9fc6735beb4c" xlink:to="loc_us-gaap_StatementLineItems_55fed691-fa85-4d7a-8243-3592475270a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55fed691-fa85-4d7a-8243-3592475270a1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_29a950f4-ecf6-4f58-9f2e-5160fd7e5d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_29a950f4-ecf6-4f58-9f2e-5160fd7e5d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7cb3bc0-18e0-4513-94f2-02f0758198e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d7cb3bc0-18e0-4513-94f2-02f0758198e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3f7a243f-cb40-4f68-87ae-8921cf2a97da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_NetIncomeLoss_3f7a243f-cb40-4f68-87ae-8921cf2a97da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_15b00173-d7af-4e84-86ee-9a06009c5dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_15b00173-d7af-4e84-86ee-9a06009c5dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_52246a98-41c9-4ea4-8be8-f0531be476d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_ProfitLoss_52246a98-41c9-4ea4-8be8-f0531be476d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_cbab720b-b704-4c40-94d4-68f69f979b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodShares_cbab720b-b704-4c40-94d4-68f69f979b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_38428cf0-70d5-4792-994d-092a787bc456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_38428cf0-70d5-4792-994d-092a787bc456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_71ad5ba4-7225-4288-b800-15f451f33409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_71ad5ba4-7225-4288-b800-15f451f33409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_919348d2-3247-4c2e-b289-b76a7f504a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_919348d2-3247-4c2e-b289-b76a7f504a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_d8404652-eb7f-4d6a-b7e5-45adb4e1f18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_d8404652-eb7f-4d6a-b7e5-45adb4e1f18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_b05f5a73-6937-4943-b63b-d26b4fbbf7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_b05f5a73-6937-4943-b63b-d26b4fbbf7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0c7c41bb-6ff9-44c5-92fb-c6c388b28870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0c7c41bb-6ff9-44c5-92fb-c6c388b28870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_210bb1f5-ca2a-44e5-9f46-7ece3a6d24c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_88046fb2-3431-468b-9ebb-02b11b401a58" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_210bb1f5-ca2a-44e5-9f46-7ece3a6d24c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="simple" xlink:href="cpix-20221231.xsd#ValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_32af0230-f7ad-46be-a711-61eee775ec59" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_5f80493b-b41b-492a-9b05-f3807c6a318b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_32af0230-f7ad-46be-a711-61eee775ec59" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_5f80493b-b41b-492a-9b05-f3807c6a318b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Organization" xlink:type="simple" xlink:href="cpix-20221231.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b96a72d-2642-4bb0-a936-cc27be0405b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7f224779-fd2b-44b4-a63f-74b82f732a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b96a72d-2642-4bb0-a936-cc27be0405b8" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7f224779-fd2b-44b4-a63f-74b82f732a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="cpix-20221231.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1be362c5-1c49-499c-8ccc-1020bc42134d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f46b90e7-e134-4879-b781-5b49e9f253ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1be362c5-1c49-499c-8ccc-1020bc42134d" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f46b90e7-e134-4879-b781-5b49e9f253ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancuso" xlink:type="simple" xlink:href="cpix-20221231.xsd#RediTrexVibativandSancuso"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexVibativandSancuso" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_77a48a60-6538-4e8f-9874-7bf0083c8717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_499115d4-87b5-4e0b-86ab-494b66443ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_77a48a60-6538-4e8f-9874-7bf0083c8717" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_499115d4-87b5-4e0b-86ab-494b66443ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Revenues" xlink:type="simple" xlink:href="cpix-20221231.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_363e8747-fc67-436d-bc6e-9b934f96ea1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_e30a0cff-e376-4292-9156-bb6207302e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_363e8747-fc67-436d-bc6e-9b934f96ea1e" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_e30a0cff-e376-4292-9156-bb6207302e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Inventories" xlink:type="simple" xlink:href="cpix-20221231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_76955f90-57a1-4371-bd22-76ca49601cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_ba121af5-a557-4c41-aa7b-c67399df5a73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_76955f90-57a1-4371-bd22-76ca49601cf7" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_ba121af5-a557-4c41-aa7b-c67399df5a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="cpix-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a546cd85-82c0-4813-b9ed-8a1c61273687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fffb7fec-1f93-461e-b0ec-f290ea1eb082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a546cd85-82c0-4813-b9ed-8a1c61273687" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_fffb7fec-1f93-461e-b0ec-f290ea1eb082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="cpix-20221231.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8fc0ff9c-d3b4-4279-a26e-a85e7d80f9b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b3954367-f32c-4663-a718-74d1a5391531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8fc0ff9c-d3b4-4279-a26e-a85e7d80f9b3" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_b3954367-f32c-4663-a718-74d1a5391531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="simple" xlink:href="cpix-20221231.xsd#OtherCurrentandOtherLongtermLiabilities"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_cf145d99-80fd-432e-afe5-8398d344277c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_cd0f7934-73d7-414c-a445-730fa900b096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_cf145d99-80fd-432e-afe5-8398d344277c" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_cd0f7934-73d7-414c-a445-730fa900b096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Debt" xlink:type="simple" xlink:href="cpix-20221231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_087ab82c-4806-483d-a7f3-eaac483d4c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_de967a93-e512-4d7e-b6f3-325ef1023750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_087ab82c-4806-483d-a7f3-eaac483d4c11" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_de967a93-e512-4d7e-b6f3-325ef1023750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cpix-20221231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_81db26a9-1168-4379-9d75-614260897a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7bcc1c48-04aa-40f7-9436-3588ea1e15e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_81db26a9-1168-4379-9d75-614260897a8e" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7bcc1c48-04aa-40f7-9436-3588ea1e15e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="simple" xlink:href="cpix-20221231.xsd#EarningsLossPerShare"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_594b3373-fbe2-4c29-9540-4922c2e7616e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_4a3020e8-1bb1-4bee-bcfd-31c1c0f07133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_594b3373-fbe2-4c29-9540-4922c2e7616e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_4a3020e8-1bb1-4bee-bcfd-31c1c0f07133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_870da7b9-789e-4280-b04a-7cddf1827c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_30d7cef8-5518-42e2-83d1-c2418091f8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_870da7b9-789e-4280-b04a-7cddf1827c2f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_30d7cef8-5518-42e2-83d1-c2418091f8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="cpix-20221231.xsd#StockBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce704cf4-d682-4f88-9b72-6e32fed75906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_14bf6657-5ed4-46d4-84d7-78b50fa6f756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce704cf4-d682-4f88-9b72-6e32fed75906" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_14bf6657-5ed4-46d4-84d7-78b50fa6f756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="cpix-20221231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_e1b3aeaa-d86e-4ffa-927d-7621276ae64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5c2ce7ba-417a-40a9-ae94-92b6a5840da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_e1b3aeaa-d86e-4ffa-927d-7621276ae64e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_5c2ce7ba-417a-40a9-ae94-92b6a5840da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/Leases" xlink:type="simple" xlink:href="cpix-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3f5209c0-a608-4165-bd76-580f13e3ed3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_84604c25-512f-437b-934e-d47d4811aeba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3f5209c0-a608-4165-bd76-580f13e3ed3e" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_84604c25-512f-437b-934e-d47d4811aeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="simple" xlink:href="cpix-20221231.xsd#MarketConcentrations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_558be59b-5063-46d0-a92f-9ea0a97a83c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_cfec61d8-c887-4872-a5c5-733e5bd69e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_558be59b-5063-46d0-a92f-9ea0a97a83c6" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_cfec61d8-c887-4872-a5c5-733e5bd69e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="simple" xlink:href="cpix-20221231.xsd#ManufacturingandSupplyAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_845ca92b-4313-4d34-9312-e681d7e89dbf" xlink:href="cpix-20221231.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock_73a76758-2ef8-44ca-94e2-73b2e819ee6b" xlink:href="cpix-20221231.xsd#cpix_ManufacturingAndSupplyAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_845ca92b-4313-4d34-9312-e681d7e89dbf" xlink:to="loc_cpix_ManufacturingAndSupplyAgreementsTextBlock_73a76758-2ef8-44ca-94e2-73b2e819ee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="simple" xlink:href="cpix-20221231.xsd#EmploymentAgreements"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmploymentAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsAbstract_206d6362-36a0-4126-a924-a4dbad4a0fe7" xlink:href="cpix-20221231.xsd#cpix_EmploymentAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmploymentAgreementsTextBlock_35857723-ade9-4dbd-a6c1-f9ca6e3ac715" xlink:href="cpix-20221231.xsd#cpix_EmploymentAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_EmploymentAgreementsAbstract_206d6362-36a0-4126-a924-a4dbad4a0fe7" xlink:to="loc_cpix_EmploymentAgreementsTextBlock_35857723-ade9-4dbd-a6c1-f9ca6e3ac715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="cpix-20221231.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_00f04970-4f0d-44da-81d5-c45f00008bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_f61b121c-3389-408f-b0f1-5acd2a0a2216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_00f04970-4f0d-44da-81d5-c45f00008bf3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_f61b121c-3389-408f-b0f1-5acd2a0a2216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cpix-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55e7013f-f623-48e9-aa9e-7c793a4d7f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_05875d12-8143-4557-bacb-3f4471339001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55e7013f-f623-48e9-aa9e-7c793a4d7f80" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_05875d12-8143-4557-bacb-3f4471339001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="simple" xlink:href="cpix-20221231.xsd#QuarterlyFinancialInformationUnaudited"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_09980b45-509f-4ea1-ae19-c88c6478773c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_4b620b94-655c-40e7-a2c9-cad0861c8b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_09980b45-509f-4ea1-ae19-c88c6478773c" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_4b620b94-655c-40e7-a2c9-cad0861c8b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cpix-20221231.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_e2c6660b-7f08-4849-8535-d144c6a4c7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_e2c6660b-7f08-4849-8535-d144c6a4c7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_93625069-3032-47fa-bb38-9f27c6fa0aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_UseOfEstimates_93625069-3032-47fa-bb38-9f27c6fa0aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ee4b728b-b590-49cc-ae8f-0233b0c430a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_ee4b728b-b590-49cc-ae8f-0233b0c430a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_87adcf2d-c25b-407a-9018-5d8027e0087b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_87adcf2d-c25b-407a-9018-5d8027e0087b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_eb3446a4-3b24-4295-a2e0-c90ea4555e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_eb3446a4-3b24-4295-a2e0-c90ea4555e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_404915fc-4570-4613-8566-3387930b54dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_404915fc-4570-4613-8566-3387930b54dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_03c19b82-eee6-47c5-b9ca-1af03874ae24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_03c19b82-eee6-47c5-b9ca-1af03874ae24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_d1c953bf-f9fa-4940-bdc9-03085b950c7d" xlink:href="cpix-20221231.xsd#cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock_d1c953bf-f9fa-4940-bdc9-03085b950c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_eca27d17-a654-47a4-9833-bef238ee9591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_eca27d17-a654-47a4-9833-bef238ee9591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_5ec99fd7-8647-4cab-8b38-7a358a8384c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_5ec99fd7-8647-4cab-8b38-7a358a8384c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a428addb-ccc6-41c6-8878-1b5e8cabac17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a428addb-ccc6-41c6-8878-1b5e8cabac17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_44d8912d-351e-48c2-8160-c751a4f0fd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_44d8912d-351e-48c2-8160-c751a4f0fd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_2b8c2da4-a7af-457e-a1df-26bae401c4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_2b8c2da4-a7af-457e-a1df-26bae401c4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_e045d37f-c31b-472d-afbb-875d43388ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_e045d37f-c31b-472d-afbb-875d43388ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e134b1fe-a086-4403-b710-8238db15822a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e134b1fe-a086-4403-b710-8238db15822a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_fcd162b6-f7d8-4a2e-99d2-5680f7a3b102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_fcd162b6-f7d8-4a2e-99d2-5680f7a3b102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2fcd6fac-3049-4e5b-90ab-898ad02317f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2fcd6fac-3049-4e5b-90ab-898ad02317f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a8d644a0-fa48-4f0d-b18a-d3e23aae3808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a8d644a0-fa48-4f0d-b18a-d3e23aae3808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_d95531f7-6783-4270-9e9e-2594c36174b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_d95531f7-6783-4270-9e9e-2594c36174b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_afc927ea-476b-45ed-a28c-e1c539e0aa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_afc927ea-476b-45ed-a28c-e1c539e0aa0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1785e529-cbda-4406-98c8-b522d5115417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7680dd7-66d9-484e-8992-f542d9a67522" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1785e529-cbda-4406-98c8-b522d5115417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4d3e213f-b603-43c9-b22a-83a3836f42a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_3f5ed2f2-44a4-446d-b7e2-f63e527a130a" xlink:href="cpix-20221231.xsd#cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d3e213f-b603-43c9-b22a-83a3836f42a8" xlink:to="loc_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock_3f5ed2f2-44a4-446d-b7e2-f63e527a130a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfDistributionCostsTableTextBlock_8c0bcf0e-5ebc-4288-81e1-42ccbc84af90" xlink:href="cpix-20221231.xsd#cpix_ScheduleOfDistributionCostsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d3e213f-b603-43c9-b22a-83a3836f42a8" xlink:to="loc_cpix_ScheduleOfDistributionCostsTableTextBlock_8c0bcf0e-5ebc-4288-81e1-42ccbc84af90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleOfAdvertisingCostsTableTextBlock_e9d9b501-5272-4695-9425-1b4cdf977f66" xlink:href="cpix-20221231.xsd#cpix_ScheduleOfAdvertisingCostsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4d3e213f-b603-43c9-b22a-83a3836f42a8" xlink:to="loc_cpix_ScheduleOfAdvertisingCostsTableTextBlock_e9d9b501-5272-4695-9425-1b4cdf977f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#RediTrexVibativandSancusoTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_101e1614-2ce3-4d4f-a508-8a9003d6a94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_59cf7a93-1b1d-44ac-b49a-30647ecc5f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_101e1614-2ce3-4d4f-a508-8a9003d6a94f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_59cf7a93-1b1d-44ac-b49a-30647ecc5f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_38aa47d0-3f41-46be-a7e4-82e6b3f3ed23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_101e1614-2ce3-4d4f-a508-8a9003d6a94f" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_38aa47d0-3f41-46be-a7e4-82e6b3f3ed23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8195a75c-2ed2-4cfc-931c-7dc4dbfa567e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_0701405d-88c6-4f4d-9f5e-d14815ed6434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8195a75c-2ed2-4cfc-931c-7dc4dbfa567e" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_0701405d-88c6-4f4d-9f5e-d14815ed6434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_20f0500e-1d31-40f3-b66a-b79b822fd0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7a8cde90-6eb3-4b2e-898b-2c69c1928e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_20f0500e-1d31-40f3-b66a-b79b822fd0ee" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_7a8cde90-6eb3-4b2e-898b-2c69c1928e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e42fc9b4-132c-4287-bf2c-5e1e0690fa41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_06c603f2-92a7-4bd5-9d85-225cf03d1d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e42fc9b4-132c-4287-bf2c-5e1e0690fa41" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_06c603f2-92a7-4bd5-9d85-225cf03d1d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock_afbcace4-95f9-4a1e-bad7-153cf728a815" xlink:href="cpix-20221231.xsd#cpix_ScheduleofDepreciationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e42fc9b4-132c-4287-bf2c-5e1e0690fa41" xlink:to="loc_cpix_ScheduleofDepreciationExpenseTableTextBlock_afbcace4-95f9-4a1e-bad7-153cf728a815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_761d09c5-fbcd-409e-83ca-e100d97bf8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_253bce8c-ac04-4137-956c-1b90a93c7c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_761d09c5-fbcd-409e-83ca-e100d97bf8b1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_253bce8c-ac04-4137-956c-1b90a93c7c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_a86e5550-dce2-4cc4-8151-0ece2ec6c3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_761d09c5-fbcd-409e-83ca-e100d97bf8b1" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_a86e5550-dce2-4cc4-8151-0ece2ec6c3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#OtherCurrentandOtherLongtermLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_bd1fc0f6-c0ef-4e23-a294-2138531af668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ab39f7f0-4173-4209-aed2-ae0164cb3db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_bd1fc0f6-c0ef-4e23-a294-2138531af668" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ab39f7f0-4173-4209-aed2-ae0164cb3db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_9401a0a4-518c-4e44-8a7d-bb1a611b6621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_bd1fc0f6-c0ef-4e23-a294-2138531af668" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_9401a0a4-518c-4e44-8a7d-bb1a611b6621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#EarningsLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ada84fa9-9772-40ff-bfc6-ecdec4bafe97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_21c22889-4361-4b11-a7ef-5641b21bda56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ada84fa9-9772-40ff-bfc6-ecdec4bafe97" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_21c22889-4361-4b11-a7ef-5641b21bda56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4726078c-cb57-4d89-83e4-3838f3a4c764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ada84fa9-9772-40ff-bfc6-ecdec4bafe97" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4726078c-cb57-4d89-83e4-3838f3a4c764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0235c301-69b8-4973-b502-989f35bef60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_12792283-4ce2-439f-92a3-8803037b7d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0235c301-69b8-4973-b502-989f35bef60e" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_12792283-4ce2-439f-92a3-8803037b7d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_5362795e-f753-45b4-abcb-546db37195ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0235c301-69b8-4973-b502-989f35bef60e" xlink:to="loc_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_5362795e-f753-45b4-abcb-546db37195ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_fe6b33c4-767b-4e1a-a882-bdf3002eb12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0235c301-69b8-4973-b502-989f35bef60e" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_fe6b33c4-767b-4e1a-a882-bdf3002eb12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_82dce2bb-5755-42ce-ad71-d90316882bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0235c301-69b8-4973-b502-989f35bef60e" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_82dce2bb-5755-42ce-ad71-d90316882bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_9aecf22a-e533-48a9-b499-18463968752e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0235c301-69b8-4973-b502-989f35bef60e" xlink:to="loc_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock_9aecf22a-e533-48a9-b499-18463968752e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#StockBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f363d040-dc58-4094-b3d9-a99a39fea92d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2834dfcf-5385-4303-8610-f5ed70a401cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f363d040-dc58-4094-b3d9-a99a39fea92d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2834dfcf-5385-4303-8610-f5ed70a401cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_09e5a527-31f2-40c0-b0e2-79992bc77482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f363d040-dc58-4094-b3d9-a99a39fea92d" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_09e5a527-31f2-40c0-b0e2-79992bc77482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c9d01dc0-134f-40b9-8ccb-2d5e82cd0c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_cad8afd9-6d05-4498-9f4e-5634c621f483" xlink:href="cpix-20221231.xsd#cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c9d01dc0-134f-40b9-8ccb-2d5e82cd0c7b" xlink:to="loc_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock_cad8afd9-6d05-4498-9f4e-5634c621f483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_ca8980b1-83b1-47bf-8e54-98504b65a66f" xlink:href="cpix-20221231.xsd#cpix_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c9d01dc0-134f-40b9-8ccb-2d5e82cd0c7b" xlink:to="loc_cpix_AssetsAndLiabilitiesLesseeTableTextBlock_ca8980b1-83b1-47bf-8e54-98504b65a66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b2a531f5-ad74-4bfb-a3ae-5bac3c89a09f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c9d01dc0-134f-40b9-8ccb-2d5e82cd0c7b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b2a531f5-ad74-4bfb-a3ae-5bac3c89a09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#MarketConcentrationsTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_1b957368-20c6-4a19-87e4-e24f33a2a695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_fe1bfa51-90c7-40fe-8120-748e422dbce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_1b957368-20c6-4a19-87e4-e24f33a2a695" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_fe1bfa51-90c7-40fe-8120-748e422dbce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" xlink:href="cpix-20221231.xsd#QuarterlyFinancialInformationUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_981d3225-90c4-4cb2-9123-eab00583fa81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_dbd93b76-5b59-4ef2-b15b-ca2808e7d0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_981d3225-90c4-4cb2-9123-eab00583fa81" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_dbd93b76-5b59-4ef2-b15b-ca2808e7d0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#OrganizationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65181570-b88b-46a6-8786-e2db1a201a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_65181570-b88b-46a6-8786-e2db1a201a4b" xlink:to="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_415b9f0e-36f5-43a4-b351-07984bd82ea7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:to="loc_dei_LegalEntityAxis_415b9f0e-36f5-43a4-b351-07984bd82ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5e28d212-51af-4840-aefb-4db6ffa964d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_415b9f0e-36f5-43a4-b351-07984bd82ea7" xlink:to="loc_dei_EntityDomain_5e28d212-51af-4840-aefb-4db6ffa964d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_8c6cbbfc-6451-4eaa-a332-f2eb10dc7653" xlink:href="cpix-20221231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5e28d212-51af-4840-aefb-4db6ffa964d0" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_8c6cbbfc-6451-4eaa-a332-f2eb10dc7653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_560d39e0-8551-454e-a8c0-0e498cd86971" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:to="loc_srt_CounterpartyNameAxis_560d39e0-8551-454e-a8c0-0e498cd86971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_078e820e-d5fe-43ce-8525-b2f3c458e01a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_560d39e0-8551-454e-a8c0-0e498cd86971" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_078e820e-d5fe-43ce-8525-b2f3c458e01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_c49ac435-5569-49e9-be4e-b093c8f7065b" xlink:href="cpix-20221231.xsd#cpix_HarbinGloriaPharmaceuticalsCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_078e820e-d5fe-43ce-8525-b2f3c458e01a" xlink:to="loc_cpix_HarbinGloriaPharmaceuticalsCoMember_c49ac435-5569-49e9-be4e-b093c8f7065b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_f241153e-d73d-40a2-b26f-9d3142bf523d" xlink:href="cpix-20221231.xsd#cpix_HongKongWinHealthPharmaGroupCoLimitedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_078e820e-d5fe-43ce-8525-b2f3c458e01a" xlink:to="loc_cpix_HongKongWinHealthPharmaGroupCoLimitedMember_f241153e-d73d-40a2-b26f-9d3142bf523d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_GloriaPharmaceuticalsMember_295c8b28-78ff-445f-8a31-3e0fd9f985d3" xlink:href="cpix-20221231.xsd#cpix_GloriaPharmaceuticalsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_078e820e-d5fe-43ce-8525-b2f3c458e01a" xlink:to="loc_cpix_GloriaPharmaceuticalsMember_295c8b28-78ff-445f-8a31-3e0fd9f985d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_2811e01e-cb15-4c18-ba3f-3e0260cb5d63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:to="loc_srt_OwnershipAxis_2811e01e-cb15-4c18-ba3f-3e0260cb5d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_663e3ddf-5fff-40a6-b98d-78a30bfb735a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_2811e01e-cb15-4c18-ba3f-3e0260cb5d63" xlink:to="loc_srt_OwnershipDomain_663e3ddf-5fff-40a6-b98d-78a30bfb735a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CumberlandEmergingTechnologiesIncMember_99b0842d-395e-48d2-924a-1fbab34ed441" xlink:href="cpix-20221231.xsd#cpix_CumberlandEmergingTechnologiesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_663e3ddf-5fff-40a6-b98d-78a30bfb735a" xlink:to="loc_cpix_CumberlandEmergingTechnologiesIncMember_99b0842d-395e-48d2-924a-1fbab34ed441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_285ffdd9-f89b-4eac-b348-2101ec07dd44" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_df971cd6-3d72-46b9-9a92-24ac4d80841d" xlink:to="loc_dei_EntityInformationLineItems_285ffdd9-f89b-4eac-b348-2101ec07dd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_285ffdd9-f89b-4eac-b348-2101ec07dd44" xlink:to="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_2ac2b9bf-07b9-4831-829f-43e26ad508e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest_2ac2b9bf-07b9-4831-829f-43e26ad508e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d6253f9f-2c13-4751-9370-e93267edb112" xlink:href="cpix-20221231.xsd#cpix_SubsidiaryInvestmentPurchaseOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_SubsidiaryInvestmentPurchaseOfShares_d6253f9f-2c13-4751-9370-e93267edb112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ContributionOfCashAdditionalSharesPurchased_5c1ba1d3-38b0-4477-a493-4876e8de44e8" xlink:href="cpix-20221231.xsd#cpix_ContributionOfCashAdditionalSharesPurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_ContributionOfCashAdditionalSharesPurchased_5c1ba1d3-38b0-4477-a493-4876e8de44e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IntercompanyLoansPayableConvertedAmount_92cf3db8-a9f5-4925-a623-1a670f0a6868" xlink:href="cpix-20221231.xsd#cpix_IntercompanyLoansPayableConvertedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_IntercompanyLoansPayableConvertedAmount_92cf3db8-a9f5-4925-a623-1a670f0a6868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_48e52e1b-93ae-48d9-981b-52bbba36efe4" xlink:href="cpix-20221231.xsd#cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital_48e52e1b-93ae-48d9-981b-52bbba36efe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ab9efc7f-780c-4b8f-9030-a0459de9373a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ab9efc7f-780c-4b8f-9030-a0459de9373a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9fa8574f-3e07-4ccf-8bd2-d584d761ff73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9fa8574f-3e07-4ccf-8bd2-d584d761ff73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_8f1d4e3f-b79a-4c81-abc2-35edcad17002" xlink:href="cpix-20221231.xsd#cpix_SharebasedCompensationCharitableContributionofSharesShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_SharebasedCompensationCharitableContributionofSharesShares_8f1d4e3f-b79a-4c81-abc2-35edcad17002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_99fa45e2-1b51-4949-a340-8350d46e8e2c" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions_99fa45e2-1b51-4949-a340-8350d46e8e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_08198cf8-173e-485e-88b6-963bd77a9eba" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_5e771935-dac9-4fdc-8eaf-1cd33f0eccd3" xlink:to="loc_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions_08198cf8-173e-485e-88b6-963bd77a9eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_888a7a03-c00a-468d-b7fe-d65630aadb50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_888a7a03-c00a-468d-b7fe-d65630aadb50" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7d0fd9b8-37a0-4c3d-9c26-06880b9d98ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:to="loc_srt_CounterpartyNameAxis_7d0fd9b8-37a0-4c3d-9c26-06880b9d98ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31e3503d-3f79-443f-b80b-a7d23ff88d7f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7d0fd9b8-37a0-4c3d-9c26-06880b9d98ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31e3503d-3f79-443f-b80b-a7d23ff88d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WinHealthInvestmentSingaporeLtdMember_5d6f6446-b174-4a77-a62c-095ce8725af7" xlink:href="cpix-20221231.xsd#cpix_WinHealthInvestmentSingaporeLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_31e3503d-3f79-443f-b80b-a7d23ff88d7f" xlink:to="loc_cpix_WinHealthInvestmentSingaporeLtdMember_5d6f6446-b174-4a77-a62c-095ce8725af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dbd40a44-066a-4f5e-a75c-c72177bc25d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:to="loc_srt_StatementGeographicalAxis_dbd40a44-066a-4f5e-a75c-c72177bc25d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_809453d4-871a-4d80-ac66-1f5338058a5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_dbd40a44-066a-4f5e-a75c-c72177bc25d8" xlink:to="loc_srt_SegmentGeographicalDomain_809453d4-871a-4d80-ac66-1f5338058a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_803f3ca2-f73f-481b-82ab-aa6c958bc10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_809453d4-871a-4d80-ac66-1f5338058a5d" xlink:to="loc_us-gaap_NonUsMember_803f3ca2-f73f-481b-82ab-aa6c958bc10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b891f96f-e45c-49e7-bea7-76f2ed837b0e" xlink:href="cpix-20221231.xsd#cpix_AccountsReceivableAllowancesByComponentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b891f96f-e45c-49e7-bea7-76f2ed837b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccountsReceivableAllowancesByComponentDomain_2807348f-a46c-4fbb-b2a4-67aa58438c40" xlink:href="cpix-20221231.xsd#cpix_AccountsReceivableAllowancesByComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentAxis_b891f96f-e45c-49e7-bea7-76f2ed837b0e" xlink:to="loc_cpix_AccountsReceivableAllowancesByComponentDomain_2807348f-a46c-4fbb-b2a4-67aa58438c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_84ed6622-2105-4ce1-8fa9-1f333968d3c8" xlink:href="cpix-20221231.xsd#cpix_ChargebacksCashDiscountsAndDamagedGoodsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_AccountsReceivableAllowancesByComponentDomain_2807348f-a46c-4fbb-b2a4-67aa58438c40" xlink:to="loc_cpix_ChargebacksCashDiscountsAndDamagedGoodsMember_84ed6622-2105-4ce1-8fa9-1f333968d3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_22267e53-4adf-4b50-a550-116f720b255b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_78fb3919-45da-4e52-98e0-2a62e68afea2" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_22267e53-4adf-4b50-a550-116f720b255b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_22267e53-4adf-4b50-a550-116f720b255b" xlink:to="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_daa6a5cb-0712-4194-be05-660b38c50906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_daa6a5cb-0712-4194-be05-660b38c50906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_c69bddca-d1dd-4b3d-9ae5-3ed29ae56a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_Revenues_c69bddca-d1dd-4b3d-9ae5-3ed29ae56a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_70fbfc46-92ac-4a98-92dc-1466629ea32b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_70fbfc46-92ac-4a98-92dc-1466629ea32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_89e9da70-67f4-491a-bfcf-f56d4e2c4288" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities_89e9da70-67f4-491a-bfcf-f56d4e2c4288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2668ef8e-0d28-4cf0-8a34-3950ef5eb2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2668ef8e-0d28-4cf0-8a34-3950ef5eb2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_8514901b-0fd3-4012-b950-9180f8f1faae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_8514901b-0fd3-4012-b950-9180f8f1faae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_90ee7d59-52d4-486a-919e-9115f09941cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_d2845f3c-73f2-4b28-b32f-0f98c1825cf2" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_90ee7d59-52d4-486a-919e-9115f09941cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5c6c0e56-f7b3-478c-850b-f2818e852167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9539773a-c516-40be-bc22-28ede0a4c71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5c6c0e56-f7b3-478c-850b-f2818e852167" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9539773a-c516-40be-bc22-28ede0a4c71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ce400304-fed2-4204-b06b-98a6cc906362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9539773a-c516-40be-bc22-28ede0a4c71d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ce400304-fed2-4204-b06b-98a6cc906362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78b30fb7-c4de-411f-8191-c411afee0fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ce400304-fed2-4204-b06b-98a6cc906362" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78b30fb7-c4de-411f-8191-c411afee0fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRightsMember_dff38342-c85f-4612-80c7-06c1dde9d1f6" xlink:href="cpix-20221231.xsd#cpix_ProductRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78b30fb7-c4de-411f-8191-c411afee0fc6" xlink:to="loc_cpix_ProductRightsMember_dff38342-c85f-4612-80c7-06c1dde9d1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b585589f-0e3e-479a-9334-973133b5a3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78b30fb7-c4de-411f-8191-c411afee0fc6" xlink:to="loc_us-gaap_LicensingAgreementsMember_b585589f-0e3e-479a-9334-973133b5a3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_a19900ab-426f-448c-8f59-9746ae433aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_78b30fb7-c4de-411f-8191-c411afee0fc6" xlink:to="loc_us-gaap_PatentsMember_a19900ab-426f-448c-8f59-9746ae433aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_713e393a-5951-4d4a-bcc3-039d9661afb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9539773a-c516-40be-bc22-28ede0a4c71d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_713e393a-5951-4d4a-bcc3-039d9661afb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_989f8f90-de29-40e6-b40a-1782d89ae5d2" xlink:href="cpix-20221231.xsd#cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_713e393a-5951-4d4a-bcc3-039d9661afb8" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual_989f8f90-de29-40e6-b40a-1782d89ae5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#SignificantAccountingPoliciesScheduleofDistributionCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fa3fdb28-a4e1-4190-b70d-e462a3dbf8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductionAndDistributionCosts_c92cb35c-bebd-4477-8269-e04d579f8dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductionAndDistributionCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa3fdb28-a4e1-4190-b70d-e462a3dbf8c7" xlink:to="loc_us-gaap_ProductionAndDistributionCosts_c92cb35c-bebd-4477-8269-e04d579f8dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ba76fcb6-e0b4-4363-8845-8262e669083e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_93bee4b0-a7c6-4033-80e2-a52bde61f2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba76fcb6-e0b4-4363-8845-8262e669083e" xlink:to="loc_us-gaap_AdvertisingExpense_93bee4b0-a7c6-4033-80e2-a52bde61f2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#RediTrexVibativandSancusoNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e22451e1-743e-4e8e-83c2-9bce3592bf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e22451e1-743e-4e8e-83c2-9bce3592bf2c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7e5bc428-4e7c-4319-bfe7-8e4dc4ee301b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_us-gaap_AwardTypeAxis_7e5bc428-4e7c-4319-bfe7-8e4dc4ee301b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ca72ab-2243-417f-b74e-71b686e79e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7e5bc428-4e7c-4319-bfe7-8e4dc4ee301b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ca72ab-2243-417f-b74e-71b686e79e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_24a83941-417e-4710-9114-86c8dbd7f822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48ca72ab-2243-417f-b74e-71b686e79e90" xlink:to="loc_us-gaap_RestrictedStockMember_24a83941-417e-4710-9114-86c8dbd7f822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7887e648-4eb7-4af8-84cf-bc7bf4144b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7887e648-4eb7-4af8-84cf-bc7bf4144b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0847b8c-6da6-417c-84e1-8faa70b649bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7887e648-4eb7-4af8-84cf-bc7bf4144b23" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0847b8c-6da6-417c-84e1-8faa70b649bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MethotrexateMember_668c2ff8-babe-4255-b578-aace166f112f" xlink:href="cpix-20221231.xsd#cpix_MethotrexateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0847b8c-6da6-417c-84e1-8faa70b649bc" xlink:to="loc_cpix_MethotrexateMember_668c2ff8-babe-4255-b578-aace166f112f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_437d42f7-46f2-47be-9daf-2dce098b08fb" xlink:href="cpix-20221231.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0847b8c-6da6-417c-84e1-8faa70b649bc" xlink:to="loc_cpix_SancusoMember_437d42f7-46f2-47be-9daf-2dce098b08fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_a40ee1d2-7950-4371-b909-5cb02eec32b3" xlink:href="cpix-20221231.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0847b8c-6da6-417c-84e1-8faa70b649bc" xlink:to="loc_cpix_VIBATIVMember_a40ee1d2-7950-4371-b909-5cb02eec32b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_438cd78a-8e96-442b-a5e7-7650540aba50" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_srt_CounterpartyNameAxis_438cd78a-8e96-442b-a5e7-7650540aba50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f6655b7-8246-4bc5-bc98-c07679b8c4cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_438cd78a-8e96-442b-a5e7-7650540aba50" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f6655b7-8246-4bc5-bc98-c07679b8c4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember_8c354878-afa9-46aa-9601-8bd43a49c8e3" xlink:href="cpix-20221231.xsd#cpix_KyowaKirinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f6655b7-8246-4bc5-bc98-c07679b8c4cc" xlink:to="loc_cpix_KyowaKirinMember_8c354878-afa9-46aa-9601-8bd43a49c8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NordicGroupBVMember_abc226aa-e288-49a8-8198-b2174345f0a0" xlink:href="cpix-20221231.xsd#cpix_NordicGroupBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f6655b7-8246-4bc5-bc98-c07679b8c4cc" xlink:to="loc_cpix_NordicGroupBVMember_abc226aa-e288-49a8-8198-b2174345f0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_911c167d-3a27-47a5-a070-dd1076f4a782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_us-gaap_TypeOfArrangementAxis_911c167d-3a27-47a5-a070-dd1076f4a782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a20501-1a40-48b7-bb2a-f01de04c82f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_911c167d-3a27-47a5-a070-dd1076f4a782" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a20501-1a40-48b7-bb2a-f01de04c82f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d0efb8d1-20e5-4dd8-84fd-299d9a31296b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e4a20501-1a40-48b7-bb2a-f01de04c82f2" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d0efb8d1-20e5-4dd8-84fd-299d9a31296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_526ea7aa-1e5a-4761-9497-c03078e08fad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_srt_RangeAxis_526ea7aa-1e5a-4761-9497-c03078e08fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c58ba579-123b-4f8f-a7a0-833d14b45a44" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_526ea7aa-1e5a-4761-9497-c03078e08fad" xlink:to="loc_srt_RangeMember_c58ba579-123b-4f8f-a7a0-833d14b45a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fc752d75-ad62-4800-bbef-3c31043af7a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c58ba579-123b-4f8f-a7a0-833d14b45a44" xlink:to="loc_srt_MaximumMember_fc752d75-ad62-4800-bbef-3c31043af7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_958ec7e0-4b2f-467a-a568-63a6f5148208" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_dbd053da-cdfa-4670-8a3e-b00b31d3f2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_dbd053da-cdfa-4670-8a3e-b00b31d3f2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6949c1af-98bb-4c1d-a85e-5e8d954c8640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6949c1af-98bb-4c1d-a85e-5e8d954c8640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2bbd8592-679e-4a8b-a0ea-f35f6e3be0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2bbd8592-679e-4a8b-a0ea-f35f6e3be0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e948f306-a752-4209-b63f-b46d1fd3811e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_e948f306-a752-4209-b63f-b46d1fd3811e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e6c34294-9982-487f-862b-debc309444c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_e6c34294-9982-487f-862b-debc309444c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_24cf13bf-37fe-4e75-9ffe-c1cde8920ac5" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable_24cf13bf-37fe-4e75-9ffe-c1cde8920ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_9c6e4b8b-4fbb-4d6d-a854-738802b4fef6" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable_9c6e4b8b-4fbb-4d6d-a854-738802b4fef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_57220274-97f0-41bc-b6ed-2c706ffdf693" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue_57220274-97f0-41bc-b6ed-2c706ffdf693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e68693-323c-4bb5-96e8-c23015a9c2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_81e68693-323c-4bb5-96e8-c23015a9c2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsPercentage_f8cf0625-fec2-4c36-90fe-9b37d91ac0ae" xlink:href="cpix-20221231.xsd#cpix_TieredRoyaltyPaymentsPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_TieredRoyaltyPaymentsPercentage_f8cf0625-fec2-4c36-90fe-9b37d91ac0ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TieredRoyaltyPaymentsThreshold_7b754664-5e7e-4bae-a475-9fbf93c504cf" xlink:href="cpix-20221231.xsd#cpix_TieredRoyaltyPaymentsThreshold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_TieredRoyaltyPaymentsThreshold_7b754664-5e7e-4bae-a475-9fbf93c504cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0d7a61c0-4dc4-4b44-889b-81fa96c562b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_0d7a61c0-4dc4-4b44-889b-81fa96c562b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c50f54b5-d2ff-434d-86ad-681f7ca4d107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_c50f54b5-d2ff-434d-86ad-681f7ca4d107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_b0f007ee-456f-4f98-9e54-b22c17436d2b" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment_b0f007ee-456f-4f98-9e54-b22c17436d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_0c9247d0-e234-42f5-9606-4703ba093e9f" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_0c9247d0-e234-42f5-9606-4703ba093e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_e369397d-9825-454e-a75c-a692469a6d92" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected_e369397d-9825-454e-a75c-a692469a6d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining_ba7028bb-6263-428e-b081-fc1e5720b59e" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining_ba7028bb-6263-428e-b081-fc1e5720b59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold_69767a71-a55b-47f1-984e-fea81019861b" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold_69767a71-a55b-47f1-984e-fea81019861b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_0c778467-742e-4156-beee-55fe7f1f19ca" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_0c778467-742e-4156-beee-55fe7f1f19ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_94dfbcb9-af2a-4b36-9337-4b201b70c95c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_94dfbcb9-af2a-4b36-9337-4b201b70c95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_7253c253-85fa-4fac-bb44-d08ff15b4209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_7253c253-85fa-4fac-bb44-d08ff15b4209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6f36d1d7-cd15-4bd5-8448-bc11bf014e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_Goodwill_6f36d1d7-cd15-4bd5-8448-bc11bf014e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_df41e806-2db9-4db8-9040-afd25bfb9745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_df41e806-2db9-4db8-9040-afd25bfb9745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPaymentsToAcquireBusinesses_827b1d9d-fcb8-4c4d-8571-e1ea0fa21caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_OtherPaymentsToAcquireBusinesses_827b1d9d-fcb8-4c4d-8571-e1ea0fa21caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_1a4a22ec-9c62-47a7-9474-6fcd5f971020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_1a4a22ec-9c62-47a7-9474-6fcd5f971020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_19a070ac-a932-4571-8a0e-e5ac82d1bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_19a070ac-a932-4571-8a0e-e5ac82d1bfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_4f6ea117-cfc7-42da-854d-998a6a42d12d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7a444bb2-b30f-48df-91e1-3747ed52b866" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_4f6ea117-cfc7-42da-854d-998a6a42d12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_afefbf5b-2df1-471b-ba9b-ab4df66996d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c917ed17-276b-4de2-aa84-01e22f089a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_afefbf5b-2df1-471b-ba9b-ab4df66996d4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c917ed17-276b-4de2-aa84-01e22f089a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c5a89b5e-b520-4c5d-8645-dcb481474cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c917ed17-276b-4de2-aa84-01e22f089a29" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c5a89b5e-b520-4c5d-8645-dcb481474cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c74825f-4754-494d-8c89-f43f058d8eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c5a89b5e-b520-4c5d-8645-dcb481474cc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c74825f-4754-494d-8c89-f43f058d8eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_7e449286-178f-41c5-8a3b-51dd923256d8" xlink:href="cpix-20221231.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c74825f-4754-494d-8c89-f43f058d8eae" xlink:to="loc_cpix_VIBATIVMember_7e449286-178f-41c5-8a3b-51dd923256d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_56231a51-e860-47ef-9488-4b2a9f546dfb" xlink:href="cpix-20221231.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6c74825f-4754-494d-8c89-f43f058d8eae" xlink:to="loc_cpix_SancusoMember_56231a51-e860-47ef-9488-4b2a9f546dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c917ed17-276b-4de2-aa84-01e22f089a29" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_18f83fb2-7013-43fe-822c-6d8e1f6ca604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_18f83fb2-7013-43fe-822c-6d8e1f6ca604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_e637d8fd-1858-4092-859c-ab8258cd2ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:to="loc_us-gaap_PaymentsForRoyalties_e637d8fd-1858-4092-859c-ab8258cd2ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4859ff33-8fdc-4ea7-aaac-65e3a6a8495a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4859ff33-8fdc-4ea7-aaac-65e3a6a8495a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_5e975a64-1771-444c-978b-e03a38debdf7" xlink:href="cpix-20221231.xsd#cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses_5e975a64-1771-444c-978b-e03a38debdf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_96bf8620-cc25-4904-90ac-8b4b670bda20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_da5d987d-f719-4825-b5c0-0635500b7126" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_96bf8620-cc25-4904-90ac-8b4b670bda20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoProFormaResultsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#RediTrexVibativandSancusoProFormaResultsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoProFormaResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f84b75a8-245f-413e-8079-dc2eec721ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_c22ee267-b9b5-4cf9-89b9-a539e65625b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f84b75a8-245f-413e-8079-dc2eec721ce4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_c22ee267-b9b5-4cf9-89b9-a539e65625b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2d74e7f9-61d6-4003-aaab-59a06b576bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f84b75a8-245f-413e-8079-dc2eec721ce4" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2d74e7f9-61d6-4003-aaab-59a06b576bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#RevenuesScheduleofNetProductRevenuesbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d0bbbb6f-276e-44a2-93aa-4de46457809c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3d9a88b2-5446-4488-b761-38df2061ed42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d0bbbb6f-276e-44a2-93aa-4de46457809c" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3d9a88b2-5446-4488-b761-38df2061ed42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab6d8a6c-ceee-49f9-a6a9-15a57d854843" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3d9a88b2-5446-4488-b761-38df2061ed42" xlink:to="loc_srt_ProductOrServiceAxis_ab6d8a6c-ceee-49f9-a6a9-15a57d854843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ab6d8a6c-ceee-49f9-a6a9-15a57d854843" xlink:to="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_6d29844f-8d7c-45ff-863c-7c86185fae5b" xlink:href="cpix-20221231.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_KristaloseMember_6d29844f-8d7c-45ff-863c-7c86185fae5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_be048a82-56dc-4dce-9eaa-5a166d035fe1" xlink:href="cpix-20221231.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_SancusoMember_be048a82-56dc-4dce-9eaa-5a166d035fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CaldolorMember_32e42f55-1140-4821-8979-b10d4b4b806c" xlink:href="cpix-20221231.xsd#cpix_CaldolorMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_CaldolorMember_32e42f55-1140-4821-8979-b10d4b4b806c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductVibativMember_33b839ea-19d6-4dae-8224-14d578e330b4" xlink:href="cpix-20221231.xsd#cpix_ProductVibativMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_ProductVibativMember_33b839ea-19d6-4dae-8224-14d578e330b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AcetadoteMember_a6d13afd-642a-4c37-a091-3a9cd2075c52" xlink:href="cpix-20221231.xsd#cpix_AcetadoteMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_AcetadoteMember_a6d13afd-642a-4c37-a091-3a9cd2075c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_c49ce94c-3ff2-406d-a943-01f52b3c077a" xlink:href="cpix-20221231.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_OmeclamoxPakMember_c49ce94c-3ff2-406d-a943-01f52b3c077a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VaprisolMember_55a8af66-6bca-4f6c-a62e-715db51b033f" xlink:href="cpix-20221231.xsd#cpix_VaprisolMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_VaprisolMember_55a8af66-6bca-4f6c-a62e-715db51b033f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RediTrexMember_9af80ad8-1796-44f6-b8b1-8748224a72b4" xlink:href="cpix-20221231.xsd#cpix_RediTrexMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_80b260c9-94ca-4629-8202-9a0ab8180273" xlink:to="loc_cpix_RediTrexMember_9af80ad8-1796-44f6-b8b1-8748224a72b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_06a88533-0bcb-4b00-b119-f05af392894f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3d9a88b2-5446-4488-b761-38df2061ed42" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_06a88533-0bcb-4b00-b119-f05af392894f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa1a00ab-1676-4258-a655-6ae19c7318c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_06a88533-0bcb-4b00-b119-f05af392894f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa1a00ab-1676-4258-a655-6ae19c7318c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OmeclamoxPakMember_a2d0417a-d89c-44e5-9a10-38c99acadedc" xlink:href="cpix-20221231.xsd#cpix_OmeclamoxPakMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_aa1a00ab-1676-4258-a655-6ae19c7318c2" xlink:to="loc_cpix_OmeclamoxPakMember_a2d0417a-d89c-44e5-9a10-38c99acadedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4196cb05-7576-46d9-a9b1-d576776617c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3d9a88b2-5446-4488-b761-38df2061ed42" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4196cb05-7576-46d9-a9b1-d576776617c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_691e523d-146a-4d09-81bd-13f1ae604678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_4196cb05-7576-46d9-a9b1-d576776617c6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_691e523d-146a-4d09-81bd-13f1ae604678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b68ba3f7-8caa-4f25-9cc5-d5e69574df43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e77afff5-de10-4f42-bb8c-19a2f77a9d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b68ba3f7-8caa-4f25-9cc5-d5e69574df43" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e77afff5-de10-4f42-bb8c-19a2f77a9d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_624d2a6d-ef0d-44e6-bce7-03341a51d49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e77afff5-de10-4f42-bb8c-19a2f77a9d7e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_624d2a6d-ef0d-44e6-bce7-03341a51d49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_691971ae-8699-4e1c-810f-79252ad686b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_624d2a6d-ef0d-44e6-bce7-03341a51d49f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_691971ae-8699-4e1c-810f-79252ad686b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_f2ef6a18-85b1-4329-ba9e-111053c9fc65" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_691971ae-8699-4e1c-810f-79252ad686b0" xlink:to="loc_cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember_f2ef6a18-85b1-4329-ba9e-111053c9fc65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_80c80745-763b-4b6d-9350-3f1e18569272" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e77afff5-de10-4f42-bb8c-19a2f77a9d7e" xlink:to="loc_srt_ProductOrServiceAxis_80c80745-763b-4b6d-9350-3f1e18569272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9d8bbf2f-af54-4cb6-b24f-00010da3fdcc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_80c80745-763b-4b6d-9350-3f1e18569272" xlink:to="loc_srt_ProductsAndServicesDomain_9d8bbf2f-af54-4cb6-b24f-00010da3fdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_5f8cf489-7ee0-4d53-a851-3fd18fe80926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9d8bbf2f-af54-4cb6-b24f-00010da3fdcc" xlink:to="loc_us-gaap_GrantMember_5f8cf489-7ee0-4d53-a851-3fd18fe80926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aafa6af1-6aa8-439b-bac6-61d27dc9a2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_e77afff5-de10-4f42-bb8c-19a2f77a9d7e" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aafa6af1-6aa8-439b-bac6-61d27dc9a2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductRevenuesAbstract_6888e2bf-a69a-428b-b0f0-de9b4d6a04e1" xlink:href="cpix-20221231.xsd#cpix_ProductRevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aafa6af1-6aa8-439b-bac6-61d27dc9a2e1" xlink:to="loc_cpix_ProductRevenuesAbstract_6888e2bf-a69a-428b-b0f0-de9b4d6a04e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2774cac6-37db-424f-969a-88b6705544ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ProductRevenuesAbstract_6888e2bf-a69a-428b-b0f0-de9b4d6a04e1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2774cac6-37db-424f-969a-88b6705544ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:href="cpix-20221231.xsd#cpix_OtherRevenuesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_aafa6af1-6aa8-439b-bac6-61d27dc9a2e1" xlink:to="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionUpfrontPayment_ff7a6fe6-78c3-4903-98af-0ac5d81a779e" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:to="loc_cpix_RevenueRecognitionUpfrontPayment_ff7a6fe6-78c3-4903-98af-0ac5d81a779e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_643ea9c4-7f7f-4504-9eab-a1269693798c" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval_643ea9c4-7f7f-4504-9eab-a1269693798c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_2cc1fb6c-409d-431a-a3c7-d09db051124e" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:to="loc_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales_2cc1fb6c-409d-431a-a3c7-d09db051124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_38bf98e8-3a86-4ba5-bb56-c29a9453e8aa" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionCumulativeUpfrontPayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:to="loc_cpix_RevenueRecognitionCumulativeUpfrontPayment_38bf98e8-3a86-4ba5-bb56-c29a9453e8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RevenueRecognitionMilestonePayments_00719341-9052-466f-9173-3bed3edbd5b6" xlink:href="cpix-20221231.xsd#cpix_RevenueRecognitionMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_OtherRevenuesAbstract_b0dcdbc5-93d2-4d6f-87e7-70a088bd01bc" xlink:to="loc_cpix_RevenueRecognitionMilestonePayments_00719341-9052-466f-9173-3bed3edbd5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_809c829f-9b91-45e6-baa0-ad585a2a1e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d1f0e651-4ae3-4cdf-a99b-4d572acb6b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_809c829f-9b91-45e6-baa0-ad585a2a1e2c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_d1f0e651-4ae3-4cdf-a99b-4d572acb6b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_bc2d702e-fe14-4b77-ba63-522d3433407d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_809c829f-9b91-45e6-baa0-ad585a2a1e2c" xlink:to="loc_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment_bc2d702e-fe14-4b77-ba63-522d3433407d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1fcd8ae8-6e2c-48e0-8b13-d8d663b7d1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_809c829f-9b91-45e6-baa0-ad585a2a1e2c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_1fcd8ae8-6e2c-48e0-8b13-d8d663b7d1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_12b9aea0-898d-4689-bbd1-3c7c9008288b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_809c829f-9b91-45e6-baa0-ad585a2a1e2c" xlink:to="loc_us-gaap_InventoryGross_12b9aea0-898d-4689-bbd1-3c7c9008288b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_7b85fa7d-7b24-4b25-b2cc-eb50ad46a302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_809c829f-9b91-45e6-baa0-ad585a2a1e2c" xlink:to="loc_us-gaap_InventoryNoncurrent_7b85fa7d-7b24-4b25-b2cc-eb50ad46a302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_30071f7e-3cc7-45c7-8eea-3fe36dcb737b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_809c829f-9b91-45e6-baa0-ad585a2a1e2c" xlink:to="loc_us-gaap_InventoryNet_30071f7e-3cc7-45c7-8eea-3fe36dcb737b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c43a5464-435c-43f5-9350-8dc588cefac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_88c6e94b-ff90-426f-95e1-abbd22942f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c43a5464-435c-43f5-9350-8dc588cefac8" xlink:to="loc_us-gaap_InventoryCurrentTable_88c6e94b-ff90-426f-95e1-abbd22942f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f02fa9e7-bde1-4f71-86ce-48611b121515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_88c6e94b-ff90-426f-95e1-abbd22942f06" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f02fa9e7-bde1-4f71-86ce-48611b121515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d1c94ec-cd59-4f47-94ea-997e21b9c920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f02fa9e7-bde1-4f71-86ce-48611b121515" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d1c94ec-cd59-4f47-94ea-997e21b9c920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_VIBATIVMember_064ec467-f0f4-49de-92f5-599e5da1f5bd" xlink:href="cpix-20221231.xsd#cpix_VIBATIVMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5d1c94ec-cd59-4f47-94ea-997e21b9c920" xlink:to="loc_cpix_VIBATIVMember_064ec467-f0f4-49de-92f5-599e5da1f5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_db6efddb-0187-49a0-838b-9444a85738e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_88c6e94b-ff90-426f-95e1-abbd22942f06" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_db6efddb-0187-49a0-838b-9444a85738e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e5c6b6a-fe52-4531-b60e-a4b25339fd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_db6efddb-0187-49a0-838b-9444a85738e0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e5c6b6a-fe52-4531-b60e-a4b25339fd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IfetrobanClinicalMember_fa064d59-f0cb-4723-bb4a-3e9bd8e27a14" xlink:href="cpix-20221231.xsd#cpix_IfetrobanClinicalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e5c6b6a-fe52-4531-b60e-a4b25339fd4d" xlink:to="loc_cpix_IfetrobanClinicalMember_fa064d59-f0cb-4723-bb4a-3e9bd8e27a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_WorkInProcessMember_493bbfc3-ad5f-41d4-ab18-9f91bae57a54" xlink:href="cpix-20221231.xsd#cpix_WorkInProcessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_6e5c6b6a-fe52-4531-b60e-a4b25339fd4d" xlink:to="loc_cpix_WorkInProcessMember_493bbfc3-ad5f-41d4-ab18-9f91bae57a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_38c4e80d-d931-4abf-a7a5-ac6b4dba03ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_88c6e94b-ff90-426f-95e1-abbd22942f06" xlink:to="loc_us-gaap_InventoryLineItems_38c4e80d-d931-4abf-a7a5-ac6b4dba03ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_7803801c-0986-4c86-86ab-2dd180b6ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_38c4e80d-d931-4abf-a7a5-ac6b4dba03ec" xlink:to="loc_us-gaap_InventoryValuationReserves_7803801c-0986-4c86-86ab-2dd180b6ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_4f82e99d-8116-4d00-a84f-5cdde10093af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_38c4e80d-d931-4abf-a7a5-ac6b4dba03ec" xlink:to="loc_us-gaap_InventoryNoncurrent_4f82e99d-8116-4d00-a84f-5cdde10093af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a1545177-e16e-4c79-99e2-f899bb7a4900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_38c4e80d-d931-4abf-a7a5-ac6b4dba03ec" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_a1545177-e16e-4c79-99e2-f899bb7a4900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#PropertyandEquipmentScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d1bceeb3-1187-4aee-ac4b-56cb1c93d5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61ccdeed-e0c6-4e69-b8df-59071c23d709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d1bceeb3-1187-4aee-ac4b-56cb1c93d5d9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61ccdeed-e0c6-4e69-b8df-59071c23d709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47fce53e-2a91-4a7c-9f12-b917870eca57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61ccdeed-e0c6-4e69-b8df-59071c23d709" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47fce53e-2a91-4a7c-9f12-b917870eca57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_47fce53e-2a91-4a7c-9f12-b917870eca57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_d5cf1422-3051-4718-9e98-74bc5f343d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:to="loc_us-gaap_ComputerEquipmentMember_d5cf1422-3051-4718-9e98-74bc5f343d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_305caba9-3134-4348-a00b-7a735cf66fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:to="loc_us-gaap_OfficeEquipmentMember_305caba9-3134-4348-a00b-7a735cf66fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_50a6e6c6-c90f-4a63-be93-db064be74994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_50a6e6c6-c90f-4a63-be93-db064be74994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_96cd5bca-7c3e-4b89-8325-0e2fbfd1e50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ca4c2bc5-d039-4850-85dd-c0acc9f17ea4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_96cd5bca-7c3e-4b89-8325-0e2fbfd1e50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e0107e4e-a8d3-4ad4-a51d-48869e88dd29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61ccdeed-e0c6-4e69-b8df-59071c23d709" xlink:to="loc_srt_RangeAxis_e0107e4e-a8d3-4ad4-a51d-48869e88dd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c72c2b6a-2f6a-438f-bbdc-5338ccf490c9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e0107e4e-a8d3-4ad4-a51d-48869e88dd29" xlink:to="loc_srt_RangeMember_c72c2b6a-2f6a-438f-bbdc-5338ccf490c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1e0c6970-d18b-4107-9fb3-383668acf335" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c72c2b6a-2f6a-438f-bbdc-5338ccf490c9" xlink:to="loc_srt_MinimumMember_1e0c6970-d18b-4107-9fb3-383668acf335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_758d836c-4671-4908-99d6-8b8bac9cadb8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c72c2b6a-2f6a-438f-bbdc-5338ccf490c9" xlink:to="loc_srt_MaximumMember_758d836c-4671-4908-99d6-8b8bac9cadb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61ccdeed-e0c6-4e69-b8df-59071c23d709" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b2d49674-294a-4800-bce0-0835e60d4a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b2d49674-294a-4800-bce0-0835e60d4a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74d8e9bb-4a3b-40eb-9a34-bf1cfc761254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_74d8e9bb-4a3b-40eb-9a34-bf1cfc761254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9420a611-8639-4478-a311-48c6e4cacd0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9420a611-8639-4478-a311-48c6e4cacd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5e65c831-14fd-49b2-928f-5ecfc61b9e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e567df7c-0e02-405b-b117-d1a44a9ef322" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5e65c831-14fd-49b2-928f-5ecfc61b9e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#PropertyandEquipmentDepreciationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_95b42c5b-da65-4fe7-9c94-87ff1a4279af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_622ace37-c092-401c-b436-f0d64f8b4dbf" xlink:href="cpix-20221231.xsd#cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_95b42c5b-da65-4fe7-9c94-87ff1a4279af" xlink:to="loc_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements_622ace37-c092-401c-b436-f0d64f8b4dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42edc5d5-4df4-470c-a602-1d3198c8efbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7add3059-7362-4ac3-8766-c06b3fc0d5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42edc5d5-4df4-470c-a602-1d3198c8efbc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7add3059-7362-4ac3-8766-c06b3fc0d5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc63a7f1-8ddd-4cca-846e-be537d9fe34b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7add3059-7362-4ac3-8766-c06b3fc0d5f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc63a7f1-8ddd-4cca-846e-be537d9fe34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe732015-1e67-4e29-9bd4-c8f3e2497b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cc63a7f1-8ddd-4cca-846e-be537d9fe34b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe732015-1e67-4e29-9bd4-c8f3e2497b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductAndLicenseRightsMember_71a11a2c-02c2-4834-b2f9-b3cb4698ce22" xlink:href="cpix-20221231.xsd#cpix_ProductAndLicenseRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe732015-1e67-4e29-9bd4-c8f3e2497b5b" xlink:to="loc_cpix_ProductAndLicenseRightsMember_71a11a2c-02c2-4834-b2f9-b3cb4698ce22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_5e8210d4-3a87-4f8d-90d5-57172d589732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe732015-1e67-4e29-9bd4-c8f3e2497b5b" xlink:to="loc_us-gaap_PatentsMember_5e8210d4-3a87-4f8d-90d5-57172d589732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_c0104079-d4f2-4b3e-b9fa-41962288c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fe732015-1e67-4e29-9bd4-c8f3e2497b5b" xlink:to="loc_us-gaap_TrademarksMember_c0104079-d4f2-4b3e-b9fa-41962288c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0aaa7728-0ed4-45b7-8eba-531f3662ed62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7add3059-7362-4ac3-8766-c06b3fc0d5f2" xlink:to="loc_srt_ProductOrServiceAxis_0aaa7728-0ed4-45b7-8eba-531f3662ed62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8febc1b1-7a1f-4fe0-b088-478925cc4bfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0aaa7728-0ed4-45b7-8eba-531f3662ed62" xlink:to="loc_srt_ProductsAndServicesDomain_8febc1b1-7a1f-4fe0-b088-478925cc4bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KristaloseMember_53eaea24-de93-418a-a5cc-4c2d0423dd15" xlink:href="cpix-20221231.xsd#cpix_KristaloseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8febc1b1-7a1f-4fe0-b088-478925cc4bfa" xlink:to="loc_cpix_KristaloseMember_53eaea24-de93-418a-a5cc-4c2d0423dd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7add3059-7362-4ac3-8766-c06b3fc0d5f2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_184c9705-2929-4fbf-8869-d3975e33b225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_184c9705-2929-4fbf-8869-d3975e33b225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_20fee987-60cc-438c-948b-7a21549894f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_20fee987-60cc-438c-948b-7a21549894f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_08baf4a9-4291-4a7f-b7e8-378d69644944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_08baf4a9-4291-4a7f-b7e8-378d69644944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ef1914bc-1919-400e-b371-06690ba37165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_3ce7456d-50cb-4132-acc0-42a8254b3d38" xlink:to="loc_us-gaap_Goodwill_ef1914bc-1919-400e-b371-06690ba37165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38ac5503-3943-4a38-b9ad-1fd06c72a8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_52b905ac-3c91-4dd4-8c0b-55848aea7f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_38ac5503-3943-4a38-b9ad-1fd06c72a8d6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_52b905ac-3c91-4dd4-8c0b-55848aea7f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9111b8c-2497-4990-9518-5830e3bebe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_52b905ac-3c91-4dd4-8c0b-55848aea7f48" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9111b8c-2497-4990-9518-5830e3bebe0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e2a3595-67ae-4f2d-85c4-950f9f9d611a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f9111b8c-2497-4990-9518-5830e3bebe0f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e2a3595-67ae-4f2d-85c4-950f9f9d611a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_1c0f96e0-a487-4e26-b0c9-ccd57560024e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4e2a3595-67ae-4f2d-85c4-950f9f9d611a" xlink:to="loc_us-gaap_PatentsMember_1c0f96e0-a487-4e26-b0c9-ccd57560024e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4417cb20-0690-4325-b312-d3f0b378b706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_52b905ac-3c91-4dd4-8c0b-55848aea7f48" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4417cb20-0690-4325-b312-d3f0b378b706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11f311e9-43cf-4bdb-9bd5-c23568f58ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4417cb20-0690-4325-b312-d3f0b378b706" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11f311e9-43cf-4bdb-9bd5-c23568f58ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SancusoMember_2bc6c292-cb3f-46c1-9dec-af46aa1a5be4" xlink:href="cpix-20221231.xsd#cpix_SancusoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_11f311e9-43cf-4bdb-9bd5-c23568f58ebf" xlink:to="loc_cpix_SancusoMember_2bc6c292-cb3f-46c1-9dec-af46aa1a5be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_202e4762-b975-4616-8f9b-c0bd8c5bdd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_52b905ac-3c91-4dd4-8c0b-55848aea7f48" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_202e4762-b975-4616-8f9b-c0bd8c5bdd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8be2394a-b54a-4b1d-9ada-14a617e33500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_202e4762-b975-4616-8f9b-c0bd8c5bdd2b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8be2394a-b54a-4b1d-9ada-14a617e33500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2c1c12b4-d369-46d2-8e50-e5d1f6360784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_202e4762-b975-4616-8f9b-c0bd8c5bdd2b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_2c1c12b4-d369-46d2-8e50-e5d1f6360784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1843f6ee-9ed9-4309-be3b-761e9efa2e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_202e4762-b975-4616-8f9b-c0bd8c5bdd2b" xlink:to="loc_us-gaap_Goodwill_1843f6ee-9ed9-4309-be3b-761e9efa2e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd084ad4-fc2d-4d98-89b3-a1b6f4ed9e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8e7b3919-f62c-4e39-b727-d502f9e4f899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd084ad4-fc2d-4d98-89b3-a1b6f4ed9e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_8e7b3919-f62c-4e39-b727-d502f9e4f899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7d3e7063-478e-4023-8417-62354013d203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd084ad4-fc2d-4d98-89b3-a1b6f4ed9e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7d3e7063-478e-4023-8417-62354013d203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_daec8d8c-27bb-4eca-ae95-a723e314c236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd084ad4-fc2d-4d98-89b3-a1b6f4ed9e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_daec8d8c-27bb-4eca-ae95-a723e314c236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5907437a-e5ed-4cc2-9081-9f90d0dd221a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd084ad4-fc2d-4d98-89b3-a1b6f4ed9e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_5907437a-e5ed-4cc2-9081-9f90d0dd221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_326c2ff5-2635-420e-bc8f-59c939e18274" xlink:href="cpix-20221231.xsd#cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd084ad4-fc2d-4d98-89b3-a1b6f4ed9e77" xlink:to="loc_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter_326c2ff5-2635-420e-bc8f-59c939e18274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_462a54ba-24f4-4d5e-9f64-7569a3f0ab41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd084ad4-fc2d-4d98-89b3-a1b6f4ed9e77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_462a54ba-24f4-4d5e-9f64-7569a3f0ab41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrentAbstract_49e9ad58-373a-443d-8aed-6bfc52afe1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_c5196d7d-cb6c-4b50-a6e1-cf5e01c97829" xlink:href="cpix-20221231.xsd#cpix_ProductSalesRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_49e9ad58-373a-443d-8aed-6bfc52afe1c2" xlink:to="loc_cpix_ProductSalesRelatedLiabilitiesCurrent_c5196d7d-cb6c-4b50-a6e1-cf5e01c97829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2d773ac3-92d5-436b-bd81-6d71f2819b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_49e9ad58-373a-443d-8aed-6bfc52afe1c2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2d773ac3-92d5-436b-bd81-6d71f2819b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesStockPayable_7a962ab4-ae24-425a-9b50-f41f19627635" xlink:href="cpix-20221231.xsd#cpix_AccruedLiabilitiesStockPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_49e9ad58-373a-443d-8aed-6bfc52afe1c2" xlink:to="loc_cpix_AccruedLiabilitiesStockPayable_7a962ab4-ae24-425a-9b50-f41f19627635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_d1900138-e0dd-4ad9-840c-5cf96bc3721a" xlink:href="cpix-20221231.xsd#cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_49e9ad58-373a-443d-8aed-6bfc52afe1c2" xlink:to="loc_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent_d1900138-e0dd-4ad9-840c-5cf96bc3721a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2e20049-b34b-42ca-b687-e79861f1f851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_49e9ad58-373a-443d-8aed-6bfc52afe1c2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e2e20049-b34b-42ca-b687-e79861f1f851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_AccruedLiabilitiesInventoryPurchases_b5e05645-ce27-453c-818b-4f91322ced5c" xlink:href="cpix-20221231.xsd#cpix_AccruedLiabilitiesInventoryPurchases"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_49e9ad58-373a-443d-8aed-6bfc52afe1c2" xlink:to="loc_cpix_AccruedLiabilitiesInventoryPurchases_b5e05645-ce27-453c-818b-4f91322ced5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_59c028b2-802d-4d31-b745-34ebc3ff4c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_49e9ad58-373a-443d-8aed-6bfc52afe1c2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_59c028b2-802d-4d31-b745-34ebc3ff4c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ac7d49ac-b0f6-4d5a-8281-097287235df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesCurrentAbstract_49e9ad58-373a-443d-8aed-6bfc52afe1c2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ac7d49ac-b0f6-4d5a-8281-097287235df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_382077b4-ae33-4152-aefc-76d8d0a22ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_730d8f0e-5bbd-458a-af80-38e6ae14addc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_382077b4-ae33-4152-aefc-76d8d0a22ad1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_730d8f0e-5bbd-458a-af80-38e6ae14addc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_56060973-7432-4fcd-9f48-6c090683b7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_382077b4-ae33-4152-aefc-76d8d0a22ad1" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_56060973-7432-4fcd-9f48-6c090683b7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_0d4f6e51-a8d7-492d-b86d-1e6020281eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_382077b4-ae33-4152-aefc-76d8d0a22ad1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_0d4f6e51-a8d7-492d-b86d-1e6020281eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9da26bff-7956-4331-90b5-bfe1eb0f5676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_382077b4-ae33-4152-aefc-76d8d0a22ad1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9da26bff-7956-4331-90b5-bfe1eb0f5676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#DebtLineofCreditDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DebtLineofCreditDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d81a7476-cbdf-4c60-b126-209ee59afa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d81a7476-cbdf-4c60-b126-209ee59afa8f" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_8e35ec77-0d4c-417f-9fea-c5325a843173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_CreditFacilityAxis_8e35ec77-0d4c-417f-9fea-c5325a843173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6e14c12a-b2dd-4215-9316-a851c5443692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_8e35ec77-0d4c-417f-9fea-c5325a843173" xlink:to="loc_us-gaap_CreditFacilityDomain_6e14c12a-b2dd-4215-9316-a851c5443692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_898f4a89-7580-4a6c-8d64-0f51f199ea03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_6e14c12a-b2dd-4215-9316-a851c5443692" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_898f4a89-7580-4a6c-8d64-0f51f199ea03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_d41cb82c-5c88-4b5a-8d59-09f3db7622cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_d41cb82c-5c88-4b5a-8d59-09f3db7622cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_0d4020df-1623-423d-8ad3-83ee25765ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_d41cb82c-5c88-4b5a-8d59-09f3db7622cd" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_0d4020df-1623-423d-8ad3-83ee25765ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PinnacleBankMember_363249ef-d542-4312-85ec-5325ac7b61ea" xlink:href="cpix-20221231.xsd#cpix_PinnacleBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_0d4020df-1623-423d-8ad3-83ee25765ce6" xlink:to="loc_cpix_PinnacleBankMember_363249ef-d542-4312-85ec-5325ac7b61ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_33bde9ca-bdcc-4d53-8d4f-b21c76bc75d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_DebtInstrumentAxis_33bde9ca-bdcc-4d53-8d4f-b21c76bc75d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_33bde9ca-bdcc-4d53-8d4f-b21c76bc75d6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FifthAmendmentMember_35f35056-f6bf-4a80-b41c-50017f731213" xlink:href="cpix-20221231.xsd#cpix_FifthAmendmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:to="loc_cpix_FifthAmendmentMember_35f35056-f6bf-4a80-b41c-50017f731213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SecondAmendmentMember_6d45f067-282f-4dc4-8941-b578557292a0" xlink:href="cpix-20221231.xsd#cpix_SecondAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:to="loc_cpix_SecondAmendmentMember_6d45f067-282f-4dc4-8941-b578557292a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_13c6ed82-e3ae-4b83-a479-8d4c5644fa84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:to="loc_us-gaap_LineOfCreditMember_13c6ed82-e3ae-4b83-a479-8d4c5644fa84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PaymentProtectionProgramMember_dca36c5a-528a-4b7f-8e8b-6ecf47f5ba4b" xlink:href="cpix-20221231.xsd#cpix_PaymentProtectionProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:to="loc_cpix_PaymentProtectionProgramMember_dca36c5a-528a-4b7f-8e8b-6ecf47f5ba4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NinthAmemdmentMember_e1191c6f-49aa-4f14-8ce8-0ab0149e546e" xlink:href="cpix-20221231.xsd#cpix_NinthAmemdmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_88049202-1dcc-4ca2-b7bc-cf1f93e06efd" xlink:to="loc_cpix_NinthAmemdmentMember_e1191c6f-49aa-4f14-8ce8-0ab0149e546e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b31a1883-7fca-435e-8e54-17a14cc0c866" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_srt_RangeAxis_b31a1883-7fca-435e-8e54-17a14cc0c866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_643fd113-a3ce-4984-a645-cf465d04d8e3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b31a1883-7fca-435e-8e54-17a14cc0c866" xlink:to="loc_srt_RangeMember_643fd113-a3ce-4984-a645-cf465d04d8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_44a2b465-8975-4d7b-9c92-661d5ba3f6f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_643fd113-a3ce-4984-a645-cf465d04d8e3" xlink:to="loc_srt_MinimumMember_44a2b465-8975-4d7b-9c92-661d5ba3f6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b289b7b9-7f06-4734-ab1b-ca2b38722896" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_643fd113-a3ce-4984-a645-cf465d04d8e3" xlink:to="loc_srt_MaximumMember_b289b7b9-7f06-4734-ab1b-ca2b38722896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5a655251-d0e1-452f-96dd-698e4dbf83bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5a655251-d0e1-452f-96dd-698e4dbf83bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_877506ab-b6b5-4fb2-a083-78e3923452cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5a655251-d0e1-452f-96dd-698e4dbf83bf" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_877506ab-b6b5-4fb2-a083-78e3923452cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_47600d6a-3d58-47c4-a944-71a853bfd454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_877506ab-b6b5-4fb2-a083-78e3923452cc" xlink:to="loc_us-gaap_LoansPayableMember_47600d6a-3d58-47c4-a944-71a853bfd454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_521974e6-741f-42bd-8509-5251ed9c10e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_VariableRateAxis_521974e6-741f-42bd-8509-5251ed9c10e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_3be821de-f69a-480b-a6b6-f5e514925e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_521974e6-741f-42bd-8509-5251ed9c10e5" xlink:to="loc_us-gaap_VariableRateDomain_3be821de-f69a-480b-a6b6-f5e514925e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFloorMember_8af19f19-3c2f-4862-9ba2-caedc99d5614" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateFloorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3be821de-f69a-480b-a6b6-f5e514925e93" xlink:to="loc_us-gaap_InterestRateFloorMember_8af19f19-3c2f-4862-9ba2-caedc99d5614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5f901001-9b71-4d86-9445-3c60cdbaced2" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_9b9ba369-9e46-44aa-bcf1-fbfa41cae49f" xlink:href="cpix-20221231.xsd#cpix_LineOfCreditFacilityAdditionalBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity_9b9ba369-9e46-44aa-bcf1-fbfa41cae49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_5a7ad91c-95df-437a-8c4a-ed108765bcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_5a7ad91c-95df-437a-8c4a-ed108765bcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_4788879d-500a-4c83-8f56-a0794ff9cd55" xlink:href="cpix-20221231.xsd#cpix_DebtInstrumentCovenantUnrestrictedCashThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold_4788879d-500a-4c83-8f56-a0794ff9cd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLineOfCredit_594f9b75-3a21-4e0b-8eb8-fa3ae5b93179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_us-gaap_LongTermLineOfCredit_594f9b75-3a21-4e0b-8eb8-fa3ae5b93179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_de7e8447-4fed-45c0-b1fd-9d9df9f584a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_de7e8447-4fed-45c0-b1fd-9d9df9f584a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_40cb8582-ac15-4f77-948d-2dcb6b18371f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_40cb8582-ac15-4f77-948d-2dcb6b18371f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_3fc05b37-adf1-4a7b-8450-d4920d4a42de" xlink:href="cpix-20221231.xsd#cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_82be1a6f-ec8a-4c03-a1d6-a272ec38b490" xlink:to="loc_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived_3fc05b37-adf1-4a7b-8450-d4920d4a42de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_cdb582ee-e1a6-4b84-b5d8-4b897b5297b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_10f2efc7-9bf3-4f97-b9ae-0bbe26d4ca80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cdb582ee-e1a6-4b84-b5d8-4b897b5297b0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_10f2efc7-9bf3-4f97-b9ae-0bbe26d4ca80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aacd2353-2f36-45a9-b041-95a71eadc91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10f2efc7-9bf3-4f97-b9ae-0bbe26d4ca80" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aacd2353-2f36-45a9-b041-95a71eadc91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c749c67-80e5-425f-aba0-d37c773f94c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aacd2353-2f36-45a9-b041-95a71eadc91b" xlink:to="loc_us-gaap_EquityComponentDomain_9c749c67-80e5-425f-aba0-d37c773f94c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_702c7aa9-5db6-4f1f-9f6e-3b464ced3f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9c749c67-80e5-425f-aba0-d37c773f94c4" xlink:to="loc_us-gaap_CommonStockMember_702c7aa9-5db6-4f1f-9f6e-3b464ced3f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b06bdae5-78f5-43d9-9785-fb97af98795c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10f2efc7-9bf3-4f97-b9ae-0bbe26d4ca80" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b06bdae5-78f5-43d9-9785-fb97af98795c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0addf72c-9596-44c8-893f-bd407699c498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b06bdae5-78f5-43d9-9785-fb97af98795c" xlink:to="loc_us-gaap_ClassOfStockDomain_0addf72c-9596-44c8-893f-bd407699c498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf133be8-f46d-413e-b437-507d6d969d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0addf72c-9596-44c8-893f-bd407699c498" xlink:to="loc_us-gaap_CommonStockMember_cf133be8-f46d-413e-b437-507d6d969d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_66f017bd-6bd7-494c-b4c2-b0be499f74d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_10f2efc7-9bf3-4f97-b9ae-0bbe26d4ca80" xlink:to="loc_us-gaap_ClassOfStockLineItems_66f017bd-6bd7-494c-b4c2-b0be499f74d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:href="cpix-20221231.xsd#cpix_InitialPublicOfferingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_66f017bd-6bd7-494c-b4c2-b0be499f74d1" xlink:to="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockTransactionDate_0d20f993-dcb9-4229-8c06-ae1da85be46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockTransactionDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_us-gaap_SaleOfStockTransactionDate_0d20f993-dcb9-4229-8c06-ae1da85be46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3c0fdc63-a073-4405-ae7f-a2c4a82120d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3c0fdc63-a073-4405-ae7f-a2c4a82120d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_94c41572-ba96-4b34-ada1-73be6752efd2" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodPricePerShareNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_cpix_StockIssuedDuringPeriodPricePerShareNewIssues_94c41572-ba96-4b34-ada1-73be6752efd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_6700633a-7212-48a7-bb6b-846aa4a38580" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering_6700633a-7212-48a7-bb6b-846aa4a38580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_1f59aff3-67aa-48cb-a6a0-301c5031d047" xlink:href="cpix-20221231.xsd#cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts_1f59aff3-67aa-48cb-a6a0-301c5031d047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_55aae9dc-5260-49a7-86fd-bd9c1d9dd4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_55aae9dc-5260-49a7-86fd-bd9c1d9dd4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_67f966c3-1c2c-4212-9471-cc560258d4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_InitialPublicOfferingAbstract_2ea9d22a-3fb0-4ca7-8e70-addd5fab37a5" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_67f966c3-1c2c-4212-9471-cc560258d4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_PreferredStockAbstract_d1aa818e-78aa-4ba6-bcd8-ab2d28bd580c" xlink:href="cpix-20221231.xsd#cpix_PreferredStockAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_66f017bd-6bd7-494c-b4c2-b0be499f74d1" xlink:to="loc_cpix_PreferredStockAbstract_d1aa818e-78aa-4ba6-bcd8-ab2d28bd580c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fc09a105-c407-49d8-b888-0c0063b5e760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_PreferredStockAbstract_d1aa818e-78aa-4ba6-bcd8-ab2d28bd580c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fc09a105-c407-49d8-b888-0c0063b5e760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0f8aefbd-bda5-4044-bc4e-131be8313368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_PreferredStockAbstract_d1aa818e-78aa-4ba6-bcd8-ab2d28bd580c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0f8aefbd-bda5-4044-bc4e-131be8313368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CommonStockAbstract_0e4942ea-79b7-4f45-88de-bb94591d45b8" xlink:href="cpix-20221231.xsd#cpix_CommonStockAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_66f017bd-6bd7-494c-b4c2-b0be499f74d1" xlink:to="loc_cpix_CommonStockAbstract_0e4942ea-79b7-4f45-88de-bb94591d45b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d4414e7a-1f01-4970-8113-a53ee64d2934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CommonStockAbstract_0e4942ea-79b7-4f45-88de-bb94591d45b8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d4414e7a-1f01-4970-8113-a53ee64d2934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3e3c0918-2bee-4638-899e-7a66e5be972d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_5a8659c5-ef97-4edf-9fc7-6598de24611c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3e3c0918-2bee-4638-899e-7a66e5be972d" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_5a8659c5-ef97-4edf-9fc7-6598de24611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_420399f8-e623-43b5-9857-39328671d04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5a8659c5-ef97-4edf-9fc7-6598de24611c" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_420399f8-e623-43b5-9857-39328671d04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_8e4a3935-7189-4419-95ba-87e95e24d84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_420399f8-e623-43b5-9857-39328671d04b" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_8e4a3935-7189-4419-95ba-87e95e24d84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_74dcd749-ab5f-4529-b27c-f9fafe63423c" xlink:href="cpix-20221231.xsd#cpix_ShareRepurchaseProgramAuthorizedIn2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_8e4a3935-7189-4419-95ba-87e95e24d84e" xlink:to="loc_cpix_ShareRepurchaseProgramAuthorizedIn2010Member_74dcd749-ab5f-4529-b27c-f9fafe63423c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeAxis_02d05766-5f38-4710-be6f-023e36207ab3" xlink:href="cpix-20221231.xsd#cpix_SharesRepurchaseActivityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5a8659c5-ef97-4edf-9fc7-6598de24611c" xlink:to="loc_cpix_SharesRepurchaseActivityTypeAxis_02d05766-5f38-4710-be6f-023e36207ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseActivityTypeDomain_544be10f-7f7f-4ff5-b64b-4479961e1acd" xlink:href="cpix-20221231.xsd#cpix_SharesRepurchaseActivityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_SharesRepurchaseActivityTypeAxis_02d05766-5f38-4710-be6f-023e36207ab3" xlink:to="loc_cpix_SharesRepurchaseActivityTypeDomain_544be10f-7f7f-4ff5-b64b-4479961e1acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_c64eb281-666f-4f7e-9dd1-00bdec867270" xlink:href="cpix-20221231.xsd#cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_SharesRepurchaseActivityTypeDomain_544be10f-7f7f-4ff5-b64b-4479961e1acd" xlink:to="loc_cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember_c64eb281-666f-4f7e-9dd1-00bdec867270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_5a8659c5-ef97-4edf-9fc7-6598de24611c" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c90375ff-f2c9-4ec5-bc96-09f5ff88dbee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c90375ff-f2c9-4ec5-bc96-09f5ff88dbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_de0b7352-891b-4874-a6aa-f99981f9ce05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_de0b7352-891b-4874-a6aa-f99981f9ce05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_98205908-1f7b-47fd-b678-925db1734293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_98205908-1f7b-47fd-b678-925db1734293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_43e4f424-6048-4a2c-98fa-c9fb1527b39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ce6b3638-d10d-45ad-9d2e-310c0e94b392" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_43e4f424-6048-4a2c-98fa-c9fb1527b39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6849b32f-472e-4aca-9b43-8fc053817fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NumeratorAbstract_3e0f70fa-9a57-4003-95f8-eefd1210c0c2" xlink:href="cpix-20221231.xsd#cpix_NumeratorAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6849b32f-472e-4aca-9b43-8fc053817fd2" xlink:to="loc_cpix_NumeratorAbstract_3e0f70fa-9a57-4003-95f8-eefd1210c0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cf7adf88-c397-44af-9bd1-e021e6428c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_3e0f70fa-9a57-4003-95f8-eefd1210c0c2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_cf7adf88-c397-44af-9bd1-e021e6428c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_80bdb2df-a3e2-4cad-8fda-1f910091e1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_3e0f70fa-9a57-4003-95f8-eefd1210c0c2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_80bdb2df-a3e2-4cad-8fda-1f910091e1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_74ab32a3-78ba-46ac-b62c-fb07f2ccb7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_3e0f70fa-9a57-4003-95f8-eefd1210c0c2" xlink:to="loc_us-gaap_ProfitLoss_74ab32a3-78ba-46ac-b62c-fb07f2ccb7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_20887ff5-6d7b-4d91-a28a-fa1f03f8a046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_3e0f70fa-9a57-4003-95f8-eefd1210c0c2" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_20887ff5-6d7b-4d91-a28a-fa1f03f8a046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5ae31428-94f3-44a3-a4b9-0a1b93a92108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_NumeratorAbstract_3e0f70fa-9a57-4003-95f8-eefd1210c0c2" xlink:to="loc_us-gaap_NetIncomeLoss_5ae31428-94f3-44a3-a4b9-0a1b93a92108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DenominatorAbstract_8ba71762-5230-438c-b952-e02f0233a3ac" xlink:href="cpix-20221231.xsd#cpix_DenominatorAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6849b32f-472e-4aca-9b43-8fc053817fd2" xlink:to="loc_cpix_DenominatorAbstract_8ba71762-5230-438c-b952-e02f0233a3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f271a800-3f55-49b0-afae-ddda1fc21dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_8ba71762-5230-438c-b952-e02f0233a3ac" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_f271a800-3f55-49b0-afae-ddda1fc21dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a43693bf-48c7-42c9-a444-670d97af226e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_DenominatorAbstract_8ba71762-5230-438c-b952-e02f0233a3ac" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a43693bf-48c7-42c9-a444-670d97af226e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c403c89e-c75d-48a1-bab8-f563308ce68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_df8aa6c0-ad62-4d39-87c3-6ac981eb12d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c403c89e-c75d-48a1-bab8-f563308ce68e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_df8aa6c0-ad62-4d39-87c3-6ac981eb12d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_79a8e0aa-e9cf-493a-afb4-fe9990fcabf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79a8e0aa-e9cf-493a-afb4-fe9990fcabf3" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_e8fe597e-eae9-44f4-add0-640282354648" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_e8fe597e-eae9-44f4-add0-640282354648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_8faef17c-4347-495c-9a9a-508ce14a74e7" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles_8faef17c-4347-495c-9a9a-508ce14a74e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities_d747c878-5eb3-42e2-a19d-cbc9eb6ddbe7" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetOperatingLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_cpix_DeferredTaxAssetOperatingLeaseLiabilities_d747c878-5eb3-42e2-a19d-cbc9eb6ddbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a5bda8bb-ca35-4b02-8055-61c32cf8a5d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_a5bda8bb-ca35-4b02-8055-61c32cf8a5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6999a55e-867a-46b5-94a8-404cfc1765ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_6999a55e-867a-46b5-94a8-404cfc1765ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4e6070e6-9b86-40c8-9bea-ecda8bc9c109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_4e6070e6-9b86-40c8-9bea-ecda8bc9c109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_a3d18e66-0003-4a02-8fdc-85ebeec987b6" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct_a3d18e66-0003-4a02-8fdc-85ebeec987b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_277cf9da-acd2-49a9-be9c-f6ddd9b422f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_277cf9da-acd2-49a9-be9c-f6ddd9b422f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxAssetsDeferredCharges_48ac0a2e-1166-4768-a24c-5911628be2e2" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxAssetsDeferredCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_cpix_DeferredTaxAssetsDeferredCharges_48ac0a2e-1166-4768-a24c-5911628be2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f3ec6ece-fdc7-428d-8a28-65a6b203362f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f3ec6ece-fdc7-428d-8a28-65a6b203362f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6a4f3142-4cfc-4d51-9a69-7fc784bcc6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_a5064fcd-0e19-4a49-9c7e-fb75501b1c1e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6a4f3142-4cfc-4d51-9a69-7fc784bcc6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_712bae61-66a0-41a5-a396-eae2f76de4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_79a8e0aa-e9cf-493a-afb4-fe9990fcabf3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_712bae61-66a0-41a5-a396-eae2f76de4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_a3f12f4b-b1af-4182-bc3e-e2e2b867976f" xlink:href="cpix-20221231.xsd#cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_712bae61-66a0-41a5-a396-eae2f76de4db" xlink:to="loc_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets_a3f12f4b-b1af-4182-bc3e-e2e2b867976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_15354076-4470-40d6-9feb-1b024192140d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_712bae61-66a0-41a5-a396-eae2f76de4db" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_15354076-4470-40d6-9feb-1b024192140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NetDeferredTaxAssetsGross_cd8061dc-07dc-4396-9cc2-0e84afd8e9d6" xlink:href="cpix-20221231.xsd#cpix_NetDeferredTaxAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_712bae61-66a0-41a5-a396-eae2f76de4db" xlink:to="loc_cpix_NetDeferredTaxAssetsGross_cd8061dc-07dc-4396-9cc2-0e84afd8e9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_15b08841-dea7-4658-a3da-50c86df68398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_712bae61-66a0-41a5-a396-eae2f76de4db" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_15b08841-dea7-4658-a3da-50c86df68398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7988eac8-1bf8-4379-b17c-84fdc49a9c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_712bae61-66a0-41a5-a396-eae2f76de4db" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_7988eac8-1bf8-4379-b17c-84fdc49a9c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_228b7def-296c-402c-8a1b-11772b5f46be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c880a068-f288-4f06-b786-091bd6975002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_228b7def-296c-402c-8a1b-11772b5f46be" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c880a068-f288-4f06-b786-091bd6975002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_870b6cfe-a8a3-4b64-9e7a-b7f6ad028895" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c880a068-f288-4f06-b786-091bd6975002" xlink:to="loc_cpix_ExpirationTimePeriodAxis_870b6cfe-a8a3-4b64-9e7a-b7f6ad028895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_0a8990c2-8436-488f-99af-e7627f577a4f" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodAxis_870b6cfe-a8a3-4b64-9e7a-b7f6ad028895" xlink:to="loc_cpix_ExpirationTimePeriodDomain_0a8990c2-8436-488f-99af-e7627f577a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_db8091ac-bff0-418a-b866-92771cfef682" xlink:href="cpix-20221231.xsd#cpix_ExpirationTermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_0a8990c2-8436-488f-99af-e7627f577a4f" xlink:to="loc_cpix_ExpirationTermOneMember_db8091ac-bff0-418a-b866-92771cfef682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_7ad2900c-4114-4521-adb0-239c94345be3" xlink:href="cpix-20221231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_0a8990c2-8436-488f-99af-e7627f577a4f" xlink:to="loc_cpix_ExpirationTermTwoMember_7ad2900c-4114-4521-adb0-239c94345be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_IndefiniteMember_73b9d5d9-40bd-4e48-9b4c-52c3ff25193d" xlink:href="cpix-20221231.xsd#cpix_IndefiniteMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_0a8990c2-8436-488f-99af-e7627f577a4f" xlink:to="loc_cpix_IndefiniteMember_73b9d5d9-40bd-4e48-9b4c-52c3ff25193d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_88bc6972-204b-454c-885b-38068268e5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c880a068-f288-4f06-b786-091bd6975002" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_88bc6972-204b-454c-885b-38068268e5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5cc9fa7e-07de-4e64-b46e-0798f20c5651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_88bc6972-204b-454c-885b-38068268e5fd" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5cc9fa7e-07de-4e64-b46e-0798f20c5651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_92e5a469-0d6a-42c8-ad43-62dfae309f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5cc9fa7e-07de-4e64-b46e-0798f20c5651" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_92e5a469-0d6a-42c8-ad43-62dfae309f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e9e4c16a-be7f-4f5d-a630-f51068ff71b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5cc9fa7e-07de-4e64-b46e-0798f20c5651" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e9e4c16a-be7f-4f5d-a630-f51068ff71b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_bfb74d5c-b24f-424b-8359-7e09c322868f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c880a068-f288-4f06-b786-091bd6975002" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_bfb74d5c-b24f-424b-8359-7e09c322868f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_d4d9bed1-8c95-45c5-b3e6-e121564d0063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_bfb74d5c-b24f-424b-8359-7e09c322868f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_d4d9bed1-8c95-45c5-b3e6-e121564d0063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_90d9c5fd-ed34-4379-a7aa-6720c8e89eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eedaac6e-7029-4b13-bf2b-329feb7c125f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_90d9c5fd-ed34-4379-a7aa-6720c8e89eb8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eedaac6e-7029-4b13-bf2b-329feb7c125f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_668379cb-4fbd-4ff4-9972-0588a3932698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eedaac6e-7029-4b13-bf2b-329feb7c125f" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_668379cb-4fbd-4ff4-9972-0588a3932698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b7218783-81ed-4646-827e-d1e4f104353c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eedaac6e-7029-4b13-bf2b-329feb7c125f" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b7218783-81ed-4646-827e-d1e4f104353c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_05cf330a-6d7d-4e3b-806b-f49db158be3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_eedaac6e-7029-4b13-bf2b-329feb7c125f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_05cf330a-6d7d-4e3b-806b-f49db158be3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a47fe1eb-14a8-45f2-a7cf-2e7639ee5fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_90d9c5fd-ed34-4379-a7aa-6720c8e89eb8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a47fe1eb-14a8-45f2-a7cf-2e7639ee5fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e616dacf-0880-49f7-97b5-194598008840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a47fe1eb-14a8-45f2-a7cf-2e7639ee5fa5" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e616dacf-0880-49f7-97b5-194598008840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0b24ca30-d033-42e2-8e74-7407d957e2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a47fe1eb-14a8-45f2-a7cf-2e7639ee5fa5" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0b24ca30-d033-42e2-8e74-7407d957e2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOtherTaxExpenseBenefit_263abe68-c0c1-4d20-b3c6-2cddbd25d606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_a47fe1eb-14a8-45f2-a7cf-2e7639ee5fa5" xlink:to="loc_us-gaap_DeferredOtherTaxExpenseBenefit_263abe68-c0c1-4d20-b3c6-2cddbd25d606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1df638d5-9e33-413d-a80d-18dc2e73cc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_90d9c5fd-ed34-4379-a7aa-6720c8e89eb8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1df638d5-9e33-413d-a80d-18dc2e73cc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d245b725-d98d-4e89-a668-4977fea8a0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9fbd8456-d0b5-45fd-a849-e9bb98024510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d245b725-d98d-4e89-a668-4977fea8a0fe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9fbd8456-d0b5-45fd-a849-e9bb98024510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_04d72e1e-2237-4c05-b707-40d516100ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d245b725-d98d-4e89-a668-4977fea8a0fe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_04d72e1e-2237-4c05-b707-40d516100ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f3570744-3936-45c4-8635-53b91d4c8a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d245b725-d98d-4e89-a668-4977fea8a0fe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_f3570744-3936-45c4-8635-53b91d4c8a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1ba99390-f190-4318-9e07-f6987553372a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d245b725-d98d-4e89-a668-4977fea8a0fe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1ba99390-f190-4318-9e07-f6987553372a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_b2af0efd-1e03-4b8a-9fee-f74882827b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d245b725-d98d-4e89-a668-4977fea8a0fe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_b2af0efd-1e03-4b8a-9fee-f74882827b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e0be3150-2977-4f1b-8889-edfb152655fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d245b725-d98d-4e89-a668-4977fea8a0fe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e0be3150-2977-4f1b-8889-edfb152655fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_054fdcd5-8d2c-4857-b15a-2352e5783250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d245b725-d98d-4e89-a668-4977fea8a0fe" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_054fdcd5-8d2c-4857-b15a-2352e5783250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_a20f24d3-d9c4-4bb2-b95e-8ec0d72bc1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_196a5ae9-4c1f-4bc9-9252-4697496b7590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_a20f24d3-d9c4-4bb2-b95e-8ec0d72bc1ff" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_196a5ae9-4c1f-4bc9-9252-4697496b7590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodAxis_bc405a39-9f01-4592-8aaf-cab007d1aaeb" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_196a5ae9-4c1f-4bc9-9252-4697496b7590" xlink:to="loc_cpix_ExpirationTimePeriodAxis_bc405a39-9f01-4592-8aaf-cab007d1aaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTimePeriodDomain_7fa8d34a-e3f6-4951-97bb-f31ba06fcd97" xlink:href="cpix-20221231.xsd#cpix_ExpirationTimePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodAxis_bc405a39-9f01-4592-8aaf-cab007d1aaeb" xlink:to="loc_cpix_ExpirationTimePeriodDomain_7fa8d34a-e3f6-4951-97bb-f31ba06fcd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermOneMember_aac02f3b-cadd-43ab-a891-32fee840d5e5" xlink:href="cpix-20221231.xsd#cpix_ExpirationTermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_7fa8d34a-e3f6-4951-97bb-f31ba06fcd97" xlink:to="loc_cpix_ExpirationTermOneMember_aac02f3b-cadd-43ab-a891-32fee840d5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ExpirationTermTwoMember_4277d55b-28b7-4c20-ab1f-015132b88e1f" xlink:href="cpix-20221231.xsd#cpix_ExpirationTermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ExpirationTimePeriodDomain_7fa8d34a-e3f6-4951-97bb-f31ba06fcd97" xlink:to="loc_cpix_ExpirationTermTwoMember_4277d55b-28b7-4c20-ab1f-015132b88e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_cd72e726-624f-4bc5-96b3-c85071a67138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_196a5ae9-4c1f-4bc9-9252-4697496b7590" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_cd72e726-624f-4bc5-96b3-c85071a67138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8c2291ad-9f49-4f4b-b02e-9d7a6782f3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_cd72e726-624f-4bc5-96b3-c85071a67138" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8c2291ad-9f49-4f4b-b02e-9d7a6782f3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FederalAndStateMember_50ab0f65-ca16-4658-b705-86f75651c935" xlink:href="cpix-20221231.xsd#cpix_FederalAndStateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_8c2291ad-9f49-4f4b-b02e-9d7a6782f3be" xlink:to="loc_cpix_FederalAndStateMember_50ab0f65-ca16-4658-b705-86f75651c935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_79a49b4c-3bba-4361-9c46-579ee68f17b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_196a5ae9-4c1f-4bc9-9252-4697496b7590" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_79a49b4c-3bba-4361-9c46-579ee68f17b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1ec23eb1-0448-43ec-bdf8-b431de249d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_79a49b4c-3bba-4361-9c46-579ee68f17b4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1ec23eb1-0448-43ec-bdf8-b431de249d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#StockBasedCompensationPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10ae5edf-65ad-46a5-a43f-3890398ba3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10ae5edf-65ad-46a5-a43f-3890398ba3f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_182380e9-dee4-4d01-a7cc-b77a74cf42db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:to="loc_us-gaap_AwardTypeAxis_182380e9-dee4-4d01-a7cc-b77a74cf42db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c2eb3a6-dd6a-4d2e-ba72-89b2c59f306f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_182380e9-dee4-4d01-a7cc-b77a74cf42db" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c2eb3a6-dd6a-4d2e-ba72-89b2c59f306f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b4f25964-14fd-4c8b-a646-010e4b97f163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c2eb3a6-dd6a-4d2e-ba72-89b2c59f306f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b4f25964-14fd-4c8b-a646-010e4b97f163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b3207844-6178-450d-8c5d-3104b5138166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1c2eb3a6-dd6a-4d2e-ba72-89b2c59f306f" xlink:to="loc_us-gaap_RestrictedStockMember_b3207844-6178-450d-8c5d-3104b5138166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d635a610-0c59-4635-a4af-122a5d28e398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:to="loc_us-gaap_PlanNameAxis_d635a610-0c59-4635-a4af-122a5d28e398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1b5930db-e716-406d-9ea9-e6215c352532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d635a610-0c59-4635-a4af-122a5d28e398" xlink:to="loc_us-gaap_PlanNameDomain_1b5930db-e716-406d-9ea9-e6215c352532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LongTermIncentiveCompensationPlan2007Member_5ab42ab7-b072-405b-9670-3d68eda0c5e8" xlink:href="cpix-20221231.xsd#cpix_LongTermIncentiveCompensationPlan2007Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1b5930db-e716-406d-9ea9-e6215c352532" xlink:to="loc_cpix_LongTermIncentiveCompensationPlan2007Member_5ab42ab7-b072-405b-9670-3d68eda0c5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DirectorsIncentivePlan2007Member_2cb04433-2d8c-4877-807f-5c95513ccedf" xlink:href="cpix-20221231.xsd#cpix_DirectorsIncentivePlan2007Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1b5930db-e716-406d-9ea9-e6215c352532" xlink:to="loc_cpix_DirectorsIncentivePlan2007Member_2cb04433-2d8c-4877-807f-5c95513ccedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e4ba74cd-96d7-4c57-a852-2633bda6efdc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:to="loc_srt_TitleOfIndividualAxis_e4ba74cd-96d7-4c57-a852-2633bda6efdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_e4ba74cd-96d7-4c57-a852-2633bda6efdc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_f4e2b9c7-ddc1-4a9a-9e91-56e9e0d64ef8" xlink:href="cpix-20221231.xsd#cpix_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:to="loc_cpix_EmployeeMember_f4e2b9c7-ddc1-4a9a-9e91-56e9e0d64ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrincipalOwnerMember_f7b9a146-6c78-4197-95d5-4c7ee1551539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalOwnerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:to="loc_us-gaap_PrincipalOwnerMember_f7b9a146-6c78-4197-95d5-4c7ee1551539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonprincipalOwnerMember_ed5a97c0-b3e9-4412-b502-bbf8a21a0e88" xlink:href="cpix-20221231.xsd#cpix_NonprincipalOwnerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:to="loc_cpix_NonprincipalOwnerMember_ed5a97c0-b3e9-4412-b502-bbf8a21a0e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_f4ddfe2e-4d34-4dce-8515-d7689b9c70f8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0589db5d-5d1c-437e-b52f-f8d0e8d0be3d" xlink:to="loc_srt_DirectorMember_f4ddfe2e-4d34-4dce-8515-d7689b9c70f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b789f136-b767-42ce-8f2f-15c5ff413ee6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:to="loc_srt_RangeAxis_b789f136-b767-42ce-8f2f-15c5ff413ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11d37871-6d06-4f79-b2fb-ee13c8c995ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b789f136-b767-42ce-8f2f-15c5ff413ee6" xlink:to="loc_srt_RangeMember_11d37871-6d06-4f79-b2fb-ee13c8c995ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_981348f7-59ae-4003-9e29-8195243460c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_11d37871-6d06-4f79-b2fb-ee13c8c995ee" xlink:to="loc_srt_MinimumMember_981348f7-59ae-4003-9e29-8195243460c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3865b9c6-bb1e-47a2-9b35-363d52508d8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_11d37871-6d06-4f79-b2fb-ee13c8c995ee" xlink:to="loc_srt_MaximumMember_3865b9c6-bb1e-47a2-9b35-363d52508d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6832f77b-3152-4103-b282-95b44c74f65f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_eaf7f9b4-ccc5-4eab-a0d9-6a9b4159c7e8" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants_eaf7f9b4-ccc5-4eab-a0d9-6a9b4159c7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_de026bb2-6708-481b-adb9-9d36b6cc8ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_de026bb2-6708-481b-adb9-9d36b6cc8ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_5bbd5222-f7d3-493b-945f-b18362fa016f" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue_5bbd5222-f7d3-493b-945f-b18362fa016f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6ba0bfd6-cabc-4792-b2d1-a1b8d595a418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6ba0bfd6-cabc-4792-b2d1-a1b8d595a418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_c8fb054c-2168-4a27-a616-6477f99a2f00" xlink:href="cpix-20221231.xsd#cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent_c8fb054c-2168-4a27-a616-6477f99a2f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_67e9b780-dfa6-41c4-bb41-f407fce10c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_67e9b780-dfa6-41c4-bb41-f407fce10c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4bc60c07-15c2-4fe3-bb55-832eb6fbaa80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4bc60c07-15c2-4fe3-bb55-832eb6fbaa80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_665a4388-f952-4ec3-af27-19cd76b2582c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_665a4388-f952-4ec3-af27-19cd76b2582c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dab7f8d7-7ecb-4395-8038-474b498cf518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dab7f8d7-7ecb-4395-8038-474b498cf518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb75f4fb-60eb-4a1b-b6bb-2cda9fc3b45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eb75f4fb-60eb-4a1b-b6bb-2cda9fc3b45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6345f537-5977-40ee-b569-08707636448b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_6345f537-5977-40ee-b569-08707636448b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdcaf1e6-3148-44e1-a796-915681f1957c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bdcaf1e6-3148-44e1-a796-915681f1957c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_434d113b-c126-410b-aca8-5897e71395b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_434d113b-c126-410b-aca8-5897e71395b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2f1c7dfb-62bb-432a-911a-90cd46d3376d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2f1c7dfb-62bb-432a-911a-90cd46d3376d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_2c005a76-0264-4baf-9b14-bc1f5811b261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3dc6ac90-edd8-4b16-bef6-9ea730499fb9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_2c005a76-0264-4baf-9b14-bc1f5811b261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_068af90a-085c-42f7-9c85-5c36717b8b49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c1d90d-46b6-4ab8-b97d-12295cbe75be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_068af90a-085c-42f7-9c85-5c36717b8b49" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c1d90d-46b6-4ab8-b97d-12295cbe75be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2f89b6f3-348a-4b66-991a-b731f8f61f69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c1d90d-46b6-4ab8-b97d-12295cbe75be" xlink:to="loc_srt_TitleOfIndividualAxis_2f89b6f3-348a-4b66-991a-b731f8f61f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aefdb281-1ee5-434c-beea-fbcc5d9967b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2f89b6f3-348a-4b66-991a-b731f8f61f69" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aefdb281-1ee5-434c-beea-fbcc5d9967b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeMember_aa7e897c-01e2-46c9-8613-dfbc15b66203" xlink:href="cpix-20221231.xsd#cpix_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aefdb281-1ee5-434c-beea-fbcc5d9967b7" xlink:to="loc_cpix_EmployeeMember_aa7e897c-01e2-46c9-8613-dfbc15b66203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_NonemployeeMember_45a1115a-8297-4639-80ee-afc6c9c65d43" xlink:href="cpix-20221231.xsd#cpix_NonemployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aefdb281-1ee5-434c-beea-fbcc5d9967b7" xlink:to="loc_cpix_NonemployeeMember_45a1115a-8297-4639-80ee-afc6c9c65d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_60a6daa2-5c7e-45dd-b26a-ba055a17172e" xlink:href="cpix-20221231.xsd#cpix_EmployeeNonemployeeandFoundationContributionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aefdb281-1ee5-434c-beea-fbcc5d9967b7" xlink:to="loc_cpix_EmployeeNonemployeeandFoundationContributionMember_60a6daa2-5c7e-45dd-b26a-ba055a17172e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d33f5c-e6e9-476f-bdec-c46e789137c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_87c1d90d-46b6-4ab8-b97d-12295cbe75be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d33f5c-e6e9-476f-bdec-c46e789137c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_68bc8ce0-c9bf-47c9-aa60-cbe3dcde90a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_07d33f5c-e6e9-476f-bdec-c46e789137c9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_68bc8ce0-c9bf-47c9-aa60-cbe3dcde90a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f53a49-6497-46e1-863e-a0f9209aa2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29c21d72-9c56-4763-a9c0-65f23b8051f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1f53a49-6497-46e1-863e-a0f9209aa2e0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29c21d72-9c56-4763-a9c0-65f23b8051f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fe374aea-0dc1-49e7-90bb-fb8ebe068131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29c21d72-9c56-4763-a9c0-65f23b8051f8" xlink:to="loc_us-gaap_AwardTypeAxis_fe374aea-0dc1-49e7-90bb-fb8ebe068131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebd64470-4be3-49d4-9e61-4f3b26f179e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fe374aea-0dc1-49e7-90bb-fb8ebe068131" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebd64470-4be3-49d4-9e61-4f3b26f179e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_RestrictedIncentiveStockOptionsMember_74d06984-fa93-4992-b007-a5de01b8f645" xlink:href="cpix-20221231.xsd#cpix_RestrictedIncentiveStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ebd64470-4be3-49d4-9e61-4f3b26f179e2" xlink:to="loc_cpix_RestrictedIncentiveStockOptionsMember_74d06984-fa93-4992-b007-a5de01b8f645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48a668c-5380-4166-ba3a-453ab677e38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29c21d72-9c56-4763-a9c0-65f23b8051f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48a668c-5380-4166-ba3a-453ab677e38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48a668c-5380-4166-ba3a-453ab677e38d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b519cf84-1959-443a-b97b-765328727a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b519cf84-1959-443a-b97b-765328727a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8d0cbfbd-c39a-48df-9447-a047cbc8e166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8d0cbfbd-c39a-48df-9447-a047cbc8e166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1d7586c6-495f-43be-9c2e-6325b8b1ca6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1d7586c6-495f-43be-9c2e-6325b8b1ca6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54560565-80be-4c3c-ac0f-061066dce3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_54560565-80be-4c3c-ac0f-061066dce3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b4d31500-a1e4-473f-9034-a09d359ca485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a92912e7-86e9-41cd-90fb-58c404acb080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b4d31500-a1e4-473f-9034-a09d359ca485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48a668c-5380-4166-ba3a-453ab677e38d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d34b9755-ee19-44fc-ac8d-fab36f67b89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d34b9755-ee19-44fc-ac8d-fab36f67b89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c3c086af-3b94-409f-b2dd-f0bcd931819d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c3c086af-3b94-409f-b2dd-f0bcd931819d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b1321d9c-9c5a-4f8c-8f7a-ddf19c44b400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b1321d9c-9c5a-4f8c-8f7a-ddf19c44b400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_be97d0ac-b560-4fa9-854a-476be0f9dbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_be97d0ac-b560-4fa9-854a-476be0f9dbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ad017af4-c592-43c8-8804-2435a92ffccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7772ff51-29d3-420a-8bbc-06e30294f95e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ad017af4-c592-43c8-8804-2435a92ffccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_206ee39d-dac1-41c5-9a8b-bbfa395b14b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c48a668c-5380-4166-ba3a-453ab677e38d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_206ee39d-dac1-41c5-9a8b-bbfa395b14b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d2257f59-aafe-4034-9e3c-c477f0e58530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d95319-8558-430d-83e4-f6ea9abe22f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d2257f59-aafe-4034-9e3c-c477f0e58530" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d95319-8558-430d-83e4-f6ea9abe22f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d29d21d-7866-43dc-8cbf-6c8666276fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d95319-8558-430d-83e4-f6ea9abe22f4" xlink:to="loc_us-gaap_AwardTypeAxis_2d29d21d-7866-43dc-8cbf-6c8666276fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e69955c1-542d-471a-8734-e1c39d8d1582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2d29d21d-7866-43dc-8cbf-6c8666276fd9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e69955c1-542d-471a-8734-e1c39d8d1582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_214fae82-c34a-4e6f-b629-cfbadc99feb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e69955c1-542d-471a-8734-e1c39d8d1582" xlink:to="loc_us-gaap_RestrictedStockMember_214fae82-c34a-4e6f-b629-cfbadc99feb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2d2108c-ab87-4676-9eb8-e34629a27c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_84d95319-8558-430d-83e4-f6ea9abe22f4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2d2108c-ab87-4676-9eb8-e34629a27c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2d2108c-ab87-4676-9eb8-e34629a27c7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ed08e0e2-0a4e-44d9-ae2b-1b091ab083d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ed08e0e2-0a4e-44d9-ae2b-1b091ab083d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_58aa0779-6786-4dce-b86a-db2c536696e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_58aa0779-6786-4dce-b86a-db2c536696e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3884f770-2e1c-43fb-b2be-efe291a911c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3884f770-2e1c-43fb-b2be-efe291a911c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_04fce73b-063e-43e9-8bfa-5980e7b92a5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_04fce73b-063e-43e9-8bfa-5980e7b92a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c63d9af0-fa50-4702-984f-20f2809f2e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_e7ce31ec-e300-4de9-a6e0-38e0516040c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c63d9af0-fa50-4702-984f-20f2809f2e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a2d2108c-ab87-4676-9eb8-e34629a27c7e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_36cdc9ca-ccd6-4ce0-b951-e1781192f374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_36cdc9ca-ccd6-4ce0-b951-e1781192f374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11ac44a8-7445-4592-997e-ea01b108ef5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11ac44a8-7445-4592-997e-ea01b108ef5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4241b1d6-2224-4c98-be4c-e421a96209c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_4241b1d6-2224-4c98-be4c-e421a96209c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7dafecfd-81eb-43a0-9cfa-50116c66131c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7dafecfd-81eb-43a0-9cfa-50116c66131c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e69e3d80-a95e-4438-9bf5-10bbef3ce373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_fd69b42f-9b7f-4988-8c82-e0f2df65d71c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e69e3d80-a95e-4438-9bf5-10bbef3ce373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_24cb3afc-cce7-4735-b38f-8cb53107834d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_e8b79ffe-1ce2-4a8b-918c-ba138d2cc36b" xlink:href="cpix-20221231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_24cb3afc-cce7-4735-b38f-8cb53107834d" xlink:to="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge_e8b79ffe-1ce2-4a8b-918c-ba138d2cc36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_27a3ab5b-5ca5-4532-8870-0b7f086af870" xlink:href="cpix-20221231.xsd#cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_24cb3afc-cce7-4735-b38f-8cb53107834d" xlink:to="loc_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility_27a3ab5b-5ca5-4532-8870-0b7f086af870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_6890b4de-a85c-4aed-b3a3-9ba91fb1a4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_24cb3afc-cce7-4735-b38f-8cb53107834d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_6890b4de-a85c-4aed-b3a3-9ba91fb1a4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_a4199567-fcf4-4ff5-9c38-dc0a6426a0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_24cb3afc-cce7-4735-b38f-8cb53107834d" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_a4199567-fcf4-4ff5-9c38-dc0a6426a0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_307c5619-ee03-4026-91aa-4aaa93882b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_24cb3afc-cce7-4735-b38f-8cb53107834d" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_307c5619-ee03-4026-91aa-4aaa93882b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_90888b07-9d7a-4280-b6ef-b4bb3e0c7b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_90888b07-9d7a-4280-b6ef-b4bb3e0c7b1a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b695e479-6232-41df-a40c-e98fca32ee9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b695e479-6232-41df-a40c-e98fca32ee9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37f2fc71-83be-430c-87c5-b4f649c3a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b695e479-6232-41df-a40c-e98fca32ee9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37f2fc71-83be-430c-87c5-b4f649c3a13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficeBuildingMember_e1dd47d1-9d85-426b-8fb9-4fbbe7538498" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficeBuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37f2fc71-83be-430c-87c5-b4f649c3a13f" xlink:to="loc_srt_OfficeBuildingMember_e1dd47d1-9d85-426b-8fb9-4fbbe7538498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_17327fd2-e69b-4fd3-ad60-f7903f8fa74f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:to="loc_us-gaap_LeaseContractualTermAxis_17327fd2-e69b-4fd3-ad60-f7903f8fa74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_824fd777-bd0c-49e9-b5d0-a1cdded81a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_17327fd2-e69b-4fd3-ad60-f7903f8fa74f" xlink:to="loc_us-gaap_LeaseContractualTermDomain_824fd777-bd0c-49e9-b5d0-a1cdded81a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_a704de9e-3d27-4b0b-91bd-5105521e2d7f" xlink:href="cpix-20221231.xsd#cpix_BroadwestLeaseFiveYearRenewalOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_824fd777-bd0c-49e9-b5d0-a1cdded81a18" xlink:to="loc_cpix_BroadwestLeaseFiveYearRenewalOptionMember_a704de9e-3d27-4b0b-91bd-5105521e2d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fe6ad33c-05b3-41df-9ec6-e0d7e7864202" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:to="loc_srt_CounterpartyNameAxis_fe6ad33c-05b3-41df-9ec6-e0d7e7864202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71fa0de1-0773-48b2-829f-54a7c9dc6c93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fe6ad33c-05b3-41df-9ec6-e0d7e7864202" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71fa0de1-0773-48b2-829f-54a7c9dc6c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_A1600WestEndAvenuePartnersLLCMember_1d87227a-3096-4c6d-bfeb-16d7a698e819" xlink:href="cpix-20221231.xsd#cpix_A1600WestEndAvenuePartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71fa0de1-0773-48b2-829f-54a7c9dc6c93" xlink:to="loc_cpix_A1600WestEndAvenuePartnersLLCMember_1d87227a-3096-4c6d-bfeb-16d7a698e819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CETMember_9ce1335a-a238-441a-9537-b9eca3c20025" xlink:href="cpix-20221231.xsd#cpix_CETMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71fa0de1-0773-48b2-829f-54a7c9dc6c93" xlink:to="loc_cpix_CETMember_9ce1335a-a238-441a-9537-b9eca3c20025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6de20ab2-0db0-478d-8668-7bd7556aa0e0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseLeasedArea_51e820bc-4fe5-40e3-aeb5-9169c642e3aa" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseLeasedArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_cpix_LesseeOperatingLeaseLeasedArea_51e820bc-4fe5-40e3-aeb5-9169c642e3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f06353a2-e3b5-4fd6-9132-4fd8a1a44cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_f06353a2-e3b5-4fd6-9132-4fd8a1a44cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_c213b133-359f-44aa-ac72-4fb0678748c2" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseNumberOfRenewalTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_cpix_LesseeOperatingLeaseNumberOfRenewalTerms_c213b133-359f-44aa-ac72-4fb0678748c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0274bb70-e6b5-4f65-b51d-0acd4690decc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0274bb70-e6b5-4f65-b51d-0acd4690decc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseBaseRent_c1eabe82-7a5f-44e0-a78a-f719bcc35b83" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseBaseRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_cpix_LesseeOperatingLeaseBaseRent_c1eabe82-7a5f-44e0-a78a-f719bcc35b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LesseeOperatingLeaseRentIncrease_b29eb0ce-eee7-4d51-be66-1ac935e998f0" xlink:href="cpix-20221231.xsd#cpix_LesseeOperatingLeaseRentIncrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_cpix_LesseeOperatingLeaseRentIncrease_b29eb0ce-eee7-4d51-be66-1ac935e998f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_19dc7e6d-bdc0-4a9c-a154-9c86a1644fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_19dc7e6d-bdc0-4a9c-a154-9c86a1644fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6dde928b-21d6-4d1b-abf9-28f26a320a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6dde928b-21d6-4d1b-abf9-28f26a320a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9b3676c8-2d3c-48e8-a7d4-d8d4621638f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9b3676c8-2d3c-48e8-a7d4-d8d4621638f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_133e29d5-19a6-46b2-ad2e-62aebf937341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_914dba70-c6c6-438c-838b-7824ac252578" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_133e29d5-19a6-46b2-ad2e-62aebf937341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#LeasesScheduleofRentExpenseandSubleaseIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ac234089-37a3-4aee-a031-4168e0144bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_0b74e914-a87d-4ce0-9d17-c7dde6246e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac234089-37a3-4aee-a031-4168e0144bbd" xlink:to="loc_us-gaap_OperatingLeaseExpense_0b74e914-a87d-4ce0-9d17-c7dde6246e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_8f643841-db39-400f-8039-7e58f94459eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ac234089-37a3-4aee-a031-4168e0144bbd" xlink:to="loc_us-gaap_SubleaseIncome_8f643841-db39-400f-8039-7e58f94459eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#LeasesLeasePositionDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TextBlockAbstract_8a7d687f-d3a8-4603-ae09-7532f25ebc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7b62d953-09ac-45a3-a684-0074dba4a878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_8a7d687f-d3a8-4603-ae09-7532f25ebc9e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7b62d953-09ac-45a3-a684-0074dba4a878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_bc228dc6-fce3-44e4-ae51-a853f5a2070c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_8a7d687f-d3a8-4603-ae09-7532f25ebc9e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_bc228dc6-fce3-44e4-ae51-a853f5a2070c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9a8adc39-21ea-4cc8-bba1-d6cd1db20b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_8a7d687f-d3a8-4603-ae09-7532f25ebc9e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9a8adc39-21ea-4cc8-bba1-d6cd1db20b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_LeaseLiability_49c931bc-bd27-4dc6-bbb0-7ffaff4fc05c" xlink:href="cpix-20221231.xsd#cpix_LeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TextBlockAbstract_8a7d687f-d3a8-4603-ae09-7532f25ebc9e" xlink:to="loc_cpix_LeaseLiability_49c931bc-bd27-4dc6-bbb0-7ffaff4fc05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_07668446-9176-4b63-ae39-33f4a40a09f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_07668446-9176-4b63-ae39-33f4a40a09f8" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_be62a157-fde2-46bb-bc33-e2a3a5a19636" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_be62a157-fde2-46bb-bc33-e2a3a5a19636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0bd51938-88d9-432e-84a8-f62a86714f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0bd51938-88d9-432e-84a8-f62a86714f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_20cf7b94-23b6-4835-9d1f-102b2a40732b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_20cf7b94-23b6-4835-9d1f-102b2a40732b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_62b1262e-e88e-4367-850c-6cb9160c838b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_62b1262e-e88e-4367-850c-6cb9160c838b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_afe7b54a-e531-4dcb-9fd1-24d98024b550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_afe7b54a-e531-4dcb-9fd1-24d98024b550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2e1dce93-176b-4dc6-8ce9-1ff5fdaebaf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2e1dce93-176b-4dc6-8ce9-1ff5fdaebaf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f4b3ad3-90f4-4fd5-bb7d-599a52314c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f4b3ad3-90f4-4fd5-bb7d-599a52314c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_28cc1c9b-9dcb-4c30-b0df-634c6de0c66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_28cc1c9b-9dcb-4c30-b0df-634c6de0c66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_900bc885-e825-4676-8f55-6c22e4480103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_7d0d1c44-a17c-4c40-97b9-78d713068dd2" xlink:to="loc_us-gaap_OperatingLeaseLiability_900bc885-e825-4676-8f55-6c22e4480103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="simple" xlink:href="cpix-20221231.xsd#LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_c302dd03-b784-4333-a0c3-59dd7ba2c916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_c302dd03-b784-4333-a0c3-59dd7ba2c916" xlink:to="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0b4ddd24-4be2-4e77-8342-bfa453fa0a21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0b4ddd24-4be2-4e77-8342-bfa453fa0a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_30508235-0144-422a-b80b-6a9ba000d747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0b4ddd24-4be2-4e77-8342-bfa453fa0a21" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_30508235-0144-422a-b80b-6a9ba000d747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_dcb442bf-8ef6-4373-908e-483caff49b67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_30508235-0144-422a-b80b-6a9ba000d747" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_dcb442bf-8ef6-4373-908e-483caff49b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33f0ed98-58aa-4c84-98f6-71d25a41be56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33f0ed98-58aa-4c84-98f6-71d25a41be56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92a9187a-16e4-46fa-b4a4-ce8d84cf60b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_33f0ed98-58aa-4c84-98f6-71d25a41be56" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92a9187a-16e4-46fa-b4a4-ce8d84cf60b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_SalesRevenueGoodsGrossMember_149039c3-bb8e-4d07-bc93-c7ee3fc23532" xlink:href="cpix-20221231.xsd#cpix_SalesRevenueGoodsGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92a9187a-16e4-46fa-b4a4-ce8d84cf60b8" xlink:to="loc_cpix_SalesRevenueGoodsGrossMember_149039c3-bb8e-4d07-bc93-c7ee3fc23532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_7fa54987-6ec3-4165-9e52-b75dec0467df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92a9187a-16e4-46fa-b4a4-ce8d84cf60b8" xlink:to="loc_us-gaap_AccountsReceivableMember_7fa54987-6ec3-4165-9e52-b75dec0467df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fe26cb1c-de4b-4442-8e3c-3251c2c080a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:to="loc_srt_MajorCustomersAxis_fe26cb1c-de4b-4442-8e3c-3251c2c080a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_fe26cb1c-de4b-4442-8e3c-3251c2c080a4" xlink:to="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerOneMember_8f2e5466-c3d4-4575-a6bc-d36dc26db880" xlink:href="cpix-20221231.xsd#cpix_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:to="loc_cpix_CustomerOneMember_8f2e5466-c3d4-4575-a6bc-d36dc26db880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerTwoMember_9ed53059-0885-409a-a2ad-5b649417186f" xlink:href="cpix-20221231.xsd#cpix_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:to="loc_cpix_CustomerTwoMember_9ed53059-0885-409a-a2ad-5b649417186f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CustomerThreeMember_42390a9c-d1e0-422d-8ce7-7ce1cd8f9d49" xlink:href="cpix-20221231.xsd#cpix_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:to="loc_cpix_CustomerThreeMember_42390a9c-d1e0-422d-8ce7-7ce1cd8f9d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Customer12And3Member_cd8bfc70-6521-48c2-8975-7bed7b7c4807" xlink:href="cpix-20221231.xsd#cpix_Customer12And3Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_361c18e4-a8ba-4433-aaab-d5c824451843" xlink:to="loc_cpix_Customer12And3Member_cd8bfc70-6521-48c2-8975-7bed7b7c4807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_10b8812b-c5c3-4b3d-91bb-a9bff9f6284e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_560ecddf-2e63-42c9-ae38-87df639e9abd" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_10b8812b-c5c3-4b3d-91bb-a9bff9f6284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6628b222-3b5b-43e3-90bc-16d7ff214b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_10b8812b-c5c3-4b3d-91bb-a9bff9f6284e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6628b222-3b5b-43e3-90bc-16d7ff214b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_1bb33107-d286-41cf-ba66-d180e33ab189" xlink:href="cpix-20221231.xsd#cpix_ManufacturingAndSupplyAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementTable_136704e0-6b9b-4035-a852-3199cc434887" xlink:href="cpix-20221231.xsd#cpix_ManufacturingandSupplyAgreementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingAndSupplyAgreementsAbstract_1bb33107-d286-41cf-ba66-d180e33ab189" xlink:to="loc_cpix_ManufacturingandSupplyAgreementTable_136704e0-6b9b-4035-a852-3199cc434887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d3277d32-ae18-4251-9dfd-1ef74f7de6c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_136704e0-6b9b-4035-a852-3199cc434887" xlink:to="loc_srt_RangeAxis_d3277d32-ae18-4251-9dfd-1ef74f7de6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b8dd36d-e150-4e79-83fc-87af6b0e4fbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d3277d32-ae18-4251-9dfd-1ef74f7de6c6" xlink:to="loc_srt_RangeMember_7b8dd36d-e150-4e79-83fc-87af6b0e4fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6992c413-e90a-4ad2-aba7-b7bc784043a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7b8dd36d-e150-4e79-83fc-87af6b0e4fbe" xlink:to="loc_srt_MinimumMember_6992c413-e90a-4ad2-aba7-b7bc784043a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_eb2a2d52-6abb-4805-a692-6233e8828889" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7b8dd36d-e150-4e79-83fc-87af6b0e4fbe" xlink:to="loc_srt_MaximumMember_eb2a2d52-6abb-4805-a692-6233e8828889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingandSupplyAgreementLineItems_e02aae50-3c9d-4d53-b1d9-4735567e0cf6" xlink:href="cpix-20221231.xsd#cpix_ManufacturingandSupplyAgreementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementTable_136704e0-6b9b-4035-a852-3199cc434887" xlink:to="loc_cpix_ManufacturingandSupplyAgreementLineItems_e02aae50-3c9d-4d53-b1d9-4735567e0cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_03f026ee-758d-46b9-a57e-7b2307fd6f4a" xlink:href="cpix-20221231.xsd#cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_ManufacturingandSupplyAgreementLineItems_e02aae50-3c9d-4d53-b1d9-4735567e0cf6" xlink:to="loc_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct_03f026ee-758d-46b9-a57e-7b2307fd6f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8790fa08-691f-4f1a-b0a7-c95ec9be67e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_233bef8e-9f34-4e38-a7dd-70f3e97a96fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8790fa08-691f-4f1a-b0a7-c95ec9be67e1" xlink:to="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_233bef8e-9f34-4e38-a7dd-70f3e97a96fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationPaymentPeriod_bcdc868b-8cff-43ba-a5f1-2b5545727473" xlink:href="cpix-20221231.xsd#cpix_FinancialConsiderationPaymentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8790fa08-691f-4f1a-b0a7-c95ec9be67e1" xlink:to="loc_cpix_FinancialConsiderationPaymentPeriod_bcdc868b-8cff-43ba-a5f1-2b5545727473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FinancialConsiderationNumberOfInstallments_09272b3e-3a3f-4c7d-8b47-eb04fab89116" xlink:href="cpix-20221231.xsd#cpix_FinancialConsiderationNumberOfInstallments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8790fa08-691f-4f1a-b0a7-c95ec9be67e1" xlink:to="loc_cpix_FinancialConsiderationNumberOfInstallments_09272b3e-3a3f-4c7d-8b47-eb04fab89116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_639eec5c-94e2-4696-863d-1b5a72158ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_639eec5c-94e2-4696-863d-1b5a72158ee6" xlink:to="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bc61ab94-5b83-4de8-b0b3-d06fc589cd7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:to="loc_srt_CounterpartyNameAxis_bc61ab94-5b83-4de8-b0b3-d06fc589cd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5236743-ac42-4552-80cd-f4c399083804" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bc61ab94-5b83-4de8-b0b3-d06fc589cd7c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5236743-ac42-4552-80cd-f4c399083804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_KyowaKirinMember_bb8d2ac2-c6ff-4d95-80ae-7e6f78bc27cf" xlink:href="cpix-20221231.xsd#cpix_KyowaKirinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5236743-ac42-4552-80cd-f4c399083804" xlink:to="loc_cpix_KyowaKirinMember_bb8d2ac2-c6ff-4d95-80ae-7e6f78bc27cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_6c515772-310a-465a-a34d-c29a43bbeb26" xlink:href="cpix-20221231.xsd#cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5236743-ac42-4552-80cd-f4c399083804" xlink:to="loc_cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember_6c515772-310a-465a-a34d-c29a43bbeb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3d702c31-b31e-40db-a479-4fa3bc5bb6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3d702c31-b31e-40db-a479-4fa3bc5bb6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d8e930f-d43a-4595-8a51-2fe8da4658af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d702c31-b31e-40db-a479-4fa3bc5bb6e4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d8e930f-d43a-4595-8a51-2fe8da4658af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_7803ceee-63b8-4283-beab-38fe5e125ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0d8e930f-d43a-4595-8a51-2fe8da4658af" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_7803ceee-63b8-4283-beab-38fe5e125ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_318659f8-b684-465f-ac7e-02078a2a1a79" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:to="loc_srt_RangeAxis_318659f8-b684-465f-ac7e-02078a2a1a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c2623a01-4f0b-439d-8a38-0c9820ba239d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_318659f8-b684-465f-ac7e-02078a2a1a79" xlink:to="loc_srt_RangeMember_c2623a01-4f0b-439d-8a38-0c9820ba239d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9fcf7f59-cd4c-411e-889d-fa19b6e8fbbb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c2623a01-4f0b-439d-8a38-0c9820ba239d" xlink:to="loc_srt_MinimumMember_9fcf7f59-cd4c-411e-889d-fa19b6e8fbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f1a888b4-7952-4d00-b473-cfc1ef80e295" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c2623a01-4f0b-439d-8a38-0c9820ba239d" xlink:to="loc_srt_MaximumMember_f1a888b4-7952-4d00-b473-cfc1ef80e295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_cd9c4f45-5481-4e4f-905e-35d190a2e687" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:to="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_cd9c4f45-5481-4e4f-905e-35d190a2e687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_874cea0a-4fef-452b-9727-74b098acdadb" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementMilestonePaymentThresholdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis_cd9c4f45-5481-4e4f-905e-35d190a2e687" xlink:to="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_874cea0a-4fef-452b-9727-74b098acdadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_Within30DaysOfFirstSNDAFilingMember_e67395ae-47d4-4302-b755-a66030cab6cf" xlink:href="cpix-20221231.xsd#cpix_Within30DaysOfFirstSNDAFilingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_874cea0a-4fef-452b-9727-74b098acdadb" xlink:to="loc_cpix_Within30DaysOfFirstSNDAFilingMember_e67395ae-47d4-4302-b755-a66030cab6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_FollowingApprovalOfFirstSNDAMember_462b1f6e-a61e-4150-af18-451b449730cc" xlink:href="cpix-20221231.xsd#cpix_FollowingApprovalOfFirstSNDAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cpix_CollaborativeArrangementMilestonePaymentThresholdDomain_874cea0a-4fef-452b-9727-74b098acdadb" xlink:to="loc_cpix_FollowingApprovalOfFirstSNDAMember_462b1f6e-a61e-4150-af18-451b449730cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ed970da-0c68-49ef-a7d3-93d4199a8411" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_648a0e9f-cf1f-493d-9503-c4a53adf5659" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum_648a0e9f-cf1f-493d-9503-c4a53adf5659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_028269ef-7990-4a80-b941-619d1e9964d6" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent_028269ef-7990-4a80-b941-619d1e9964d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsTerm_3319ef1d-accb-4082-b10b-52b9607eec65" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsTerm_3319ef1d-accb-4082-b10b-52b9607eec65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_938066b3-9ae7-4678-b14a-7049b984ca26" xlink:href="cpix-20221231.xsd#cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable_938066b3-9ae7-4678-b14a-7049b984ca26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount_325db824-c44d-4ed9-9f3b-852b35a4bbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_cdbb8884-b1e0-438d-b485-8b93a5d8b985" xlink:to="loc_us-gaap_GainContingencyUnrecordedAmount_325db824-c44d-4ed9-9f3b-852b35a4bbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8a4c1177-371f-4c18-a73b-151f43d3735e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_56fbfb41-91c2-4292-8113-fbdd619bbb14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8a4c1177-371f-4c18-a73b-151f43d3735e" xlink:to="loc_us-gaap_Revenues_56fbfb41-91c2-4292-8113-fbdd619bbb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7d15a568-c128-4b57-80cf-95625071b263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8a4c1177-371f-4c18-a73b-151f43d3735e" xlink:to="loc_us-gaap_OperatingIncomeLoss_7d15a568-c128-4b57-80cf-95625071b263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_96553c68-189a-4cec-aa1f-d35b4811b6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8a4c1177-371f-4c18-a73b-151f43d3735e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_96553c68-189a-4cec-aa1f-d35b4811b6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_674403fc-f8a8-4d11-be22-b5e005133845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8a4c1177-371f-4c18-a73b-151f43d3735e" xlink:to="loc_us-gaap_NetIncomeLoss_674403fc-f8a8-4d11-be22-b5e005133845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_da7c9541-7b21-4074-898f-1ef59f742900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_8a4c1177-371f-4c18-a73b-151f43d3735e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_da7c9541-7b21-4074-898f-1ef59f742900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7f86f369-5177-4739-9fda-eb3fc7d654c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da7c9541-7b21-4074-898f-1ef59f742900" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7f86f369-5177-4739-9fda-eb3fc7d654c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_abbcd71c-fd78-48b7-a404-22a1b86414a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da7c9541-7b21-4074-898f-1ef59f742900" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_abbcd71c-fd78-48b7-a404-22a1b86414a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c954b940-343f-4b74-b02a-990ab45707f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da7c9541-7b21-4074-898f-1ef59f742900" xlink:to="loc_us-gaap_EarningsPerShareBasic_c954b940-343f-4b74-b02a-990ab45707f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_937a6edb-d781-4798-a6f0-de87fdfbf2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da7c9541-7b21-4074-898f-1ef59f742900" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_937a6edb-d781-4798-a6f0-de87fdfbf2a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_fea56411-9fa3-4ceb-a522-6a67e41b1c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da7c9541-7b21-4074-898f-1ef59f742900" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_fea56411-9fa3-4ceb-a522-6a67e41b1c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_96924c26-0bb8-4ac0-bc5d-526df14fe4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da7c9541-7b21-4074-898f-1ef59f742900" xlink:to="loc_us-gaap_EarningsPerShareDiluted_96924c26-0bb8-4ac0-bc5d-526df14fe4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="cpix-20221231.xsd#ValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_b1c3403e-1261-469f-ab46-532f0acd8efb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ef3d3457-9499-4bd5-86e1-bc1b9c3a401e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_b1c3403e-1261-469f-ab46-532f0acd8efb" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ef3d3457-9499-4bd5-86e1-bc1b9c3a401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_eb62f759-8cdb-4b37-8f6f-e0700df14bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ef3d3457-9499-4bd5-86e1-bc1b9c3a401e" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_eb62f759-8cdb-4b37-8f6f-e0700df14bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3dd02d38-8ef4-4978-9cb3-1f40e6cec0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_eb62f759-8cdb-4b37-8f6f-e0700df14bec" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3dd02d38-8ef4-4978-9cb3-1f40e6cec0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_d3a507db-c6da-45ec-a00d-c1adb16bd4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3dd02d38-8ef4-4978-9cb3-1f40e6cec0a5" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_d3a507db-c6da-45ec-a00d-c1adb16bd4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_59111c75-aaf0-472b-ae35-c795fa27dd57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_3dd02d38-8ef4-4978-9cb3-1f40e6cec0a5" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_59111c75-aaf0-472b-ae35-c795fa27dd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_79cc44f4-584c-4837-aa32-f4077b167c69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ef3d3457-9499-4bd5-86e1-bc1b9c3a401e" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_79cc44f4-584c-4837-aa32-f4077b167c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_79cc44f4-584c-4837-aa32-f4077b167c69" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_e06032e3-3746-41e7-b135-ee8109b4a272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_e06032e3-3746-41e7-b135-ee8109b4a272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_b31fe19d-22e4-4192-9a73-903f8caad503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_b31fe19d-22e4-4192-9a73-903f8caad503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_41704278-72bb-4ea4-9ff3-3f1ca745daea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_41704278-72bb-4ea4-9ff3-3f1ca745daea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_90441133-9be9-487b-8bcd-a9a3b4a09d15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_90441133-9be9-487b-8bcd-a9a3b4a09d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c3d900bf-0b12-4d31-b763-af70d01e0e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_59726f02-a364-410d-92f2-dbe4a6880a3b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c3d900bf-0b12-4d31-b763-af70d01e0e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cpix-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cpix-20221231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOI(\X#16M]#%/,"< >6C9) ') KUJ@ HKR77OVZ/V5-"\:77PZB^+4.L:[8
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MK/?.Y[N[[I&/=F)K]+_^"S*))_P34^)@=0<0:61D=QJUGBOSX^,G_*P)9_\
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MS7431_;HC) 2-LK.6=3SBY(Z4 ?N#7XQ?\$B(TB_X*Y^(HHD"JO_  D@50.
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MJ'QC^Q__ ,%BO#?QW^)7@RXUWPMI/A>"+0;+(!6SG@DBN9;8M\@F69YCSC<
M%)4,&'$?\&Y7_)UOC;_LGLG_ *76E?HG\8_AA^S#^WYJGCC]F?XT>"H;V_\
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M+->H_P#!''X$^%_@O^PAX.U;2]*ACU;QC9_V[KE\$'F7+3,QA#'KM2#RU Z
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M'_@X?_9836_!/AO]KGPSI@-UHDJZ)XH>-.6M)6+6LS>R3%X\]2;A!T%>7_\
M!N%_R<7\0/\ L2H__2N*OU4^/'P>\,?M _!KQ-\%O&,>=.\2Z/-8S2;=QA9U
M^290?XD?:Z_[2"@#R'_@E;^T^G[5/[&'A?Q=J5^)M>T*'^PO$F6RQNK9542-
M[R1&*4]LR$=JU_V8M!TGXK?%WQO^V5<V$3G79AX9\$W90%AH.GRNIE5NNVYO
M#<S _P 42VYK\MO^";'CS]H7]G[]H/XA?L!Z'8W<&N^.WD\.23VY_P"0'?6\
MS1SZDN?X8K,WD@('SLD/:OVJ\%>#_#OP]\'Z5X"\(Z:EGI6BZ=#8Z;:1_=A@
MB01QH/HJ@4 ?CQ_P<7*H_;,\)L%&3\,;3)QU_P")CJ%?J#X@^*'P]UWXE>%O
MV3/$6FZ3K3>*/!-]J6M:/?1K.$LX/LT:>9&V1MD:9@-PY\IL=#7Y?_\ !Q?_
M ,GE^$O^R8VO_IQU"OOCX1_L _"_X%_M<>%_VCO@?X1;2;/4_ E_IOBFUBNG
MDA-PQM'MYE$C$H6"2JP'RG:AP#DD ]A_9=^!6G_LT_!+3/@EHMPLFGZ)?:C_
M &7M9CLM)K^XG@C8MR66*5%8]V4]JF_:.^!'AK]I/X72?"3QF$?2+O6M+O-3
MMI8]Z74%I?V]V]NPR/ED$)C)[!R:VO!_Q*\->.O$/B7P[X<F:>3PIJZ:9JLZ
M[3&+MK:&Y:)2"<E8[B+=TP6QU!KH* /SX_X.);*STW]C/P5I^G6D4%O!\1;6
M.""&,*D:#3KX!54<  #  Z5Z9_P2?^'_ (.^*O\ P2:\#_#KX@:!;ZIHVLZ?
MK5KJ-C=1ADEC;5[T'KT(Z@CD$ C! KSC_@XQ_P"3/_!__92K?_TWWU>P?\$7
MO^4:'PS_ .N>K_\ IXO: /G7_@L%^T)XU_8N_9%^&7[$/PO\7SQW^H^%8--U
MS7;7,,SZ;8V\-MM7!S']H?.[!^[&R]'-?2?_  2*^!'A?X(?L(^!Y]'TJ&/4
M?%NDQ^(-;O5C DNI+H>;%N/<)"T:*.@"YZDD_)G_  <>_!KQ+<R_#SX^Z=8R
M3:5;07.AZI,BDBVE9A-;[O0.//&?5 .XK[?_ .";GC/2?'?[!?PEUK1KA)(K
M?P-8:=(4.<2VD0M95^H>%A^% 'PG_P %V=$UC]F/]I_X8_MA? [4Y/#_ (HU
M:WNX;W4-.PAEGLF@V22#I)OBN/*8-D,D05@1Q7VU\%].\!_MR>'O@I^VMXET
M>TDET;PS?7=CI$L'F1VNJW7V6.25"Q_Y8M;7"+D9S(K9!45\7?\ !R3XMTZ\
MU3X2_#FRE$NHQ1ZM?SVZ<NL<C6L41QU^9HY@/]RONO\ X)Z_!SQ!\ OV*_AU
M\*O%EJUOJNG>'UEU*UD&&MY[B1[F2)O]I&F*'W4T ?F=_P '&/\ R>'X0_[)
MI;?^G"_K]2/B]^SSX,_:'^&_A73/$MG;K?>'=:T?7=#U-[</+9W%I<0SG8>"
M/,2-HFY^[(?05^6__!QC_P GA^$/^R:6W_IPOZ_8CPO_ ,BSIW_7A#_Z * +
M-[>V>FV<NHZA=1P6\$323S2N%2-%&69B>   237XP>/OVWOBK\(_^"LVB?M>
M_$;3[W3/"OB:VM3I-K."!/X.N0889@G7)53=;/\ GLIK]*?V^?$OBS6? >E?
MLV?#30)]7\0?$J]>RNM.M+^.UE&A0!9-4D$LA"Q[H"+8,>CWB8R>*^-?^"U?
MP2^,/QA^!FB_&>Z_96D\)K\.$,%Y?0>);&[7^RYF2,1^5 =V(Y?+(P,(K2$X
M'- 'ZA6US;WEO'=VDZ2Q2H'BEC8,KJ1D$$<$$=Z_&+_@XJ15_;;\,E5 +?"V
MQ+$#J?[1U(?TK[C_ ."*?[4__#1G[&NF^%=>U+SO$7P^==#U(.^7DM57-G,?
M8PCR\GDM YKX=_X.*_\ D]KPO_V2RQ_].6I4 ?LMHZ)'I%K'&H55MD"J!P!M
M%6:@TK_D%VW_ %[I_P"@BN:\$?%S0/'WQ"\8> M!C\QO!EY:66I7:RAE-W-;
MBX:$ #@I')"2<]9,8&WD ZROQA_X(8(D7_!2CQ-'&H55\+:R%4#@#[9;U^SU
M?AK_ ,$H_@_I/QS_ &Y_&GP_U7Q1X@T0W'A37&M-6\,Z]<Z?=VD_VF%4E62W
MD0N%+;O+?=&Q W*<"@#TC_@X,MO"/AO]K'P%XB^&LB6?C270!/JLVD'9=;TN
M<6<Q,?S>;D2!6^]A$[!:_3/7Y_&.H?L87MS\2K8Q^()_AA(VOPN@&V\.G$SJ
M1T'[PL,5^1G[-_B>7_@G/_P4SN?#G[</A6S\1'[<MK/XNUZW-W-9[V!M=9MY
M9MS;<;=QSN5&<??CVU^R7QSN;>\^ 7C&\L[A)8I?!^H/%+&X974VLA# C@@C
MG- 'Y7_\&Y^HZ?I'QI^)FJZM?0VMK;>"X9;FYN)0D<4:W(+.S' 50 22> !7
MWUX0\$?#W]M!_A3^VMH>D:9;:KX>\2ZC=Z5J\4!6:\T@_;K-(&;!+;E:";#<
M*RMMVAB#^9O_  1%_9E^"W[4_P 0?B/\/OC=X0&K:>/",1MPMU)#);R-<!?,
M1HV!##J,Y&1R#7ZA_LZZ+9?L/?L3Z/X3^)5Q+Y7@P76GHPV>;?DZC+%:",$A
M2\^^'8"1S*H..< ';>"?V?/!WA'XZ^-/VA'L[>X\0^+ELK87K6X\RTLK:VCC
M6!6.2 T@DD;& V4!!V U^37PY_Y6!KC_ +*SJG_HJXK]I*_%OX<_\K UQ_V5
MG5/_ $5<4 ?K)X@_9Y\&:Q^T7X=_:5M+.WM=?T71+[2;NXCMP)+ZUN/*94=Q
MR?+>/*YS@2.!C-?DM^VY!"?^"^-G"8EV/\2O!6Y<<'-MI>?SK]J:_%O]NR"7
M2O\ @O1INHZ@ABAE^(7@N>.1^ T:P::I;Z HP_ T ?M)7AO_  3QL++3_P!G
MF\AL;2.%#\2/&&5C0*./$6H*.GHJJ/H!7N5>(_\ !/.2.\_9DM]<MW#0:KXT
M\4ZA:..CP3^(-0DB<>H9&5@?1A0!^9_[,Z)'_P '!NI+&H _X6CXM. .YM]1
M)KUG_@Y"TCX<6^G_  RU^&&SB\7RW5]$TL047$NGJL9_>$<E%E(V9Z%Y-O5J
M\0^%'@?1?B1_P7@U_P $^(;K4X+._P#B;XJ6:;1M9N=/N4VPW[@QW%M)'+&<
MJ,[6&1E3E20<GXE^&_$W_!-[_@I98:O^UAH4OQ0\-)=":RU7Q:AU&6_TF1B(
M[J,SEA]I@(SM/ >-@,*ZM0!^M/[!&H?$?Q)^Q3\-]0^-"W$VO7?A&V.HG403
M-,A4B)I=W)=H?++;N22<\YK\>OCS^RI\9?V+]%^'/[>OP+UJ[ATG5VCO(]1M
M8P&T/4P[@P2 #:8)0#MR-I!>)ATW_NKX1\6>&O'GA;3O&O@W68-1TG5K**[T
MV_M7W1W$$BAD=3Z%2#7BO[*GPU\$?&'_ ()_^&/AA\2/#\&JZ'K?AA[74K"X
M7*R1M(_0]58'#*PP58!@00#0!YQX._;9\ ?M[?\ !,;XG^.+&&VMM>L/AKK-
MKXO\/;LFRN_[.G(=0>3#)@O&W/0J3N1L?5'PWMX+3X=Z#:VL*QQ1:+:I'&@P
M%40J  .PQ7X8_M/_  5^/W_!)7]H#Q'X1\)ZO<7/A+QSX:U+2M.U&X0F#6=)
MNHFBDAF"X N(#(I.,8=4<#8X!_='X?\ _(AZ)_V"+;_T4M &O1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2.JNI1U!4C!!'!%
M+10!\?\ B?\ X)&^$?!OQP?]HW]BWXVZM\'O$\YD^V6FGZ7%J&E3JY#/']DD
M9,1LP!,>\Q@A2B*5%>B_\,Q_M,_$:P_X1K]HC]L674?#\PVZEHW@3PBF@OJ,
M?>*:[\^>98V'#"$PL02-V#7O=% &1I_@'P1I?@6+X8V'A/3X_#L&EC38M$%H
MOV468C\OR/+(VF/9\NTC&.*^:OAI_P $T]6_95^)&L^//V(/CY)X+TWQ"ROJ
M_@GQ/X?.M:3(ZD[#&!<6\\6W<V#YC'!()(P!]644 ?*OBW_@F6O[1GQATGXQ
M_MP_&J3XA#P^I&A>#M)T$:1HEKE@S!X3-/+-N95+;I!OVJK;E 6OH#XK>!_%
M_C#X=W?@3X<>-[7PI)>6CVAU(:*+MK:!HRG[B/S(T1QD;2P=1C&T]1U5% 'G
M/[,WP5\7_ 3X1:3\&/%'Q,A\6:9X?TFWTW1;J;0A:7"6L2&-8YBLKI* @1%(
M1#A/F+DY%;]F[]EGP+^R7\([WX3_  0$5E#<ZS?ZG%<7UJ9E6:XE9D#HCH76
M*/RH0 RDI"O(.37I]% 'P]XG_P""--SXK_:J_P"&Q=0_:HOX_%X\36^N1B#P
ME"+6.>%D,:",SDF,"-5P6)('+$\U[K^UM^ROX_\ VN?@7=? /Q1\9[#1=*U>
M.W_M^YTCPHQFNGAN%G41F6[80Q[HXLKAF)4_/AMM>V44 ?.G[!'[!NL?L%>%
M]0^'7A/XV?\ "0^&M4U=]3N['4_#8BN$N6@2$M%-'/A01%%D,CYV<;22:]Z\
M6V'B75/#=YIW@_Q#!I.IS1;+34KC3_M26[$C+^5O0.0,X!;&<$@@%3HT4 >-
M_LB?LQ>//V7- U/PGK/QR;QG8ZKK5YK%W=:IX?6"^>^N9!)+(T\<Q5E+;CM,
M9.6&&  6N6_;^_8 7]OO0=(\&^+/BI'X?TG1-0^VV7V#PX)KPS&-HV#3O.!Y
M9!SL5%Y5<DX%?1M% '@/[)/['OQ0_8_^"LGP.\%?M%QZWIEO,\FA2^(?"?F/
MIGF/OD1/*NDWH6+L%;[K.3DCY:\B_9Q_X(YW7[,/[0(_:3\ _M17EYX@9KLW
M46L>$HI+:Z%P&\T.D=PC $MN&UE((';BOMNB@#YU_;X_X)Q_"[]OOPMH=GXW
MU^;0O$&@3$V7B32[)7D,+C][;LCM\T;,%< ME"O!^9MUGX'_ +'_ ,9O@1^S
MG)^S9H'[4?\ :FF1V4MEI&J:WX0$UYIEM(K*8HF6Z56"[LQ^8K; -N"H55^@
M:* /C']BW_@D5-^PQ\4[GXJ_"?\ :1GOKB_TI]-U"PUSPHDD$UNTD<A_U=PC
M*X:-2&#<<Y!!Q7H'BG]@'5;K]J;Q/^V)\-_VC_$7A3QAKL=I;6]O:6%O<:7]
MCAM883!=VT@S=!GB+Y$D17*[<,NX_1U% 'SI\4/V)_B-^U+=:+HW[87QMTC7
M_"6AZHFHCP;X-\(2Z1;:I<1@B-KR6>]NI9$ 9OW49C!SR3@8]N\??#'X?_%#
MX?W_ ,*_'_A*RU3P[J=E]DO=)N(OW+P\84 8VE< J5P5*@J00#6[10!\L_ W
M_@GU\6/V.WU70OV0OVH(]/\ "6J7K78\'^/O"1UF"SG8 ,\$T%U:R)P%&#N!
M"@MD\F7PC_P3)\+:_P#M$1_M7?M8?%&[^*/C.S\H:+#<:3'I^D:4L9+1"&S5
MY"=C$LN^1AN8N07.ZOJ&B@#S#]K#X"^,OVEOA-JGP9T;XL+X4TG7K-K76;FV
MT,75W+$2"4C=IE2-6 *M\C,0>"M=A\-=!\>^&O"MOHGQ%\=V_B2_MU5/[7AT
M?[$\ZA0-TJ"613(2"2R[%YX48YWZ* /(/VA_V-?AK^T%\3OA]\:=1QIWBKX=
M^);74M,U:" ,US;1RB22REY&Z-L$J<YC?D<,ZMZ_110!B?$?X<>!OB]X&U/X
M:_$OPS:ZSH6L6IM]1TV\3*3(>>W*D$!@P(96 (((!KYT^!O_  3\^+7['9U7
MP_\ LB?M0Q6'A+5+UKM?"'C_ ,)'68;*=@ SP3075K(G 4;3N!V@G)R3]344
M ?+_ (._X)D^%=;_ &B$_:O_ &KOBC=_%'QK:&(:+'<Z3'8:3I2QDM$(;-7D
M/R,2R[Y&&YBY!<[J];_:@^"OBK]H?X1:U\&=&^(T'AO3O$>F3Z?K5V-$^UW+
M02@*RQ$S(D9*[E)97X;C:1FO1:* /E']@S_@F1??L ^(=;U#X;_'^36-.\3?
M9%UW3=9\,+F1;=I2ABDCN%,3XFE&2'7YN5.!7U=110 5\Z_MJ_\ !,S]GS]M
MB\M?&'BDZAX<\8Z=&J:?XO\ #TBQW(5#E$E4@K,JGE<X=?X749!^BJ* /G7P
M;^SI^W[X:T>'PEJO_!0;3M2L;>,1IJUQ\*+<ZJ4  &96NVB+@?\ +1XG)(RP
M))KU3X)? ;P=\#-)OX="O]3U;5M:NQ=^(_$^OWGVC4=7N NT2328 PJ@*D:*
ML<:\(JC-=M10!\G?MH_\$G_AW^U+\6;#]HSX??$[5/AU\1;"6WE'B/2K07$=
MQ)!M\F62(O&?-0(BB177Y5 (; QU-I^R3^TO\1M!'@7]J;]LJ3Q3X8F01ZQH
M?ACP7!HCZQ$ -T-S<I+(_E/R'2$1;E)7=M)%?1%% &+XB\/Z^O@__A&_AGK.
MG^'YXH%@L;B72/M,-I&HV@)"LD8X &W)VC RI'%<%^R7^SUX\_9E^'D/PLUW
MXT?\)AI-G)<2V$]]H"VMY&\T[3.&ECF*.F]Y" 8PPW?>P *]7HH \S^ 7[*_
MPU_9KN/'%]\+;-;:X\=>*[G7K]YH0RPS2J (5"E?W*-O94R,>8P!%?-O[1O_
M  1LF_:=_:"E_:3\>_M17MIX@:2U:WBTCPE%';6WV=5$01))W8@%03N9B23V
MXK[>HH Q-.\,ZKJG@N;PG\4K[3-?-Y:R6VHF#23;074+J49&A>67[RDAOFP<
MG@#BOD#X<_\ !(WQS^RQ\7=5^)?[#O[75[X'T_6D\O4/"^O^%H]8MGC!+(A9
MIXRP0L=A(,BAB/,.6W?;5% 'DGPK_9E\0Z-\0;7XS?'OXQWGQ!\7:;9RVNA7
M4FDQ:=I^C12@"8VEG$6V2R !7FD>20J-@*KD',_;@_9$U_\ ;4^%TWP4U#XN
MIX:\-W=S;W%]'9>'Q<7<\D+[U4RO.%5-P4X$>[*_>P2*]NHH ^4?V4O^"<WQ
M;_8T\"WOPV^"O[8]W%HU]JCZA)::GX%M+C9</''&SJQE##*Q(,9Q\N0 2<[G
M@W]@WX@V_P"U;HG[6?Q@_:NUGQKJWAS3KRTT/2;OP];V=E9+<0M$QCC@8!>'
M))QN? W,<#'TE10!X7\(OV4_BY\,_P!H3Q5^T%K/[2*>(;KQHEE!K6EW_A%8
MX8+6U,GDPVC)<[K<*)9!SY@)8LX=N:Z/]K[]G2^_:M^">J_ B7QI::)I&O0K
M%JUQ)H?VR?"2QRQF$F9%B8-'G+*_48VD9KU&B@#Y7_8)_P"":FJ_L"Z]JC^!
M?VCK_7-!UWRVU?P_JOA^-4>2,,$FB=)LQ2#=@G#!EX*DA2OKO[57P*\4_M)_
M"'6/@KIGQ*A\-:5XAL'L]9NDT/[7=/"Q&5B9ID2/(!4DHYPW!4\UZ710!\K_
M +!7_!-74/V =4UH_#SX^/K6E>))+9M9TW6?#"ACY'F;6AECN%,;8E8$L'7I
M\O%>_?&;P1XQ^)'P_P!2\"^#_&]KX??5K&>SN]1FT<WDD<4L;(3$OG1JKC=D
M,P<?[)KJJ* /C?\ 8F_X)+3_ +"?Q+O?B1\*OVC9]0?5--^P:GI^N>%4>&:'
MS$DR#'<(R."G#9(Y.5/2OLBBB@#QOPI^Q3\+_"7[:'B7]M2P4'7?$?AJVTQK
M,P );S(<37*MG[\D4=LG !'ER'+>:0/9*** /BS]LS_@D#)^W'\68?B]\6OV
MD[BSO;32(M,L;+0_"B1006T<DL@&)+AV9B\SDL6.<\8  'K&H?LT_M=W?@J+
MP59_M]ZA8K%9K;'4K+X>:>MVR!0N=[,0K8'WE .>1@U[W10!Y)^QA^RE8_L>
M_"6Z^&=O\0=1\4W6H^(;O6=4U[5HPMQ=W-QLWN_S-N;"+EB22>37K=%% 'SA
M^WO^P+J_[>^@:;X$\7_&X^'_  [I&J#4+.PTOPVLD[W A:+=+-)/A@ \F J)
M]_G<0#75_L5_LL^(_P!CKX16'P)A^*\?B7PWI'VAM)%UH MKN!IIVG<-*D[*
MZ;Y)" 8PWS_>P *]DHH P/BA\+O 'QH\!:G\,/BCX6M=9T'6+8P:AIUVI*2+
MD$$$$%6! 964AE8 @@@&OGGX%_L"?&7]CRVU+PG^R9^U-#:^$+^\>Z@\)_$'
MP>=8CL)G'S/!/;W=K(H.!\IR#C)RQ)/U+10!\P_#[_@F5X0G_:)/[6?[4/Q-
MO/BCX[@>,Z1)>Z7'8Z7I0C_U7V>S5I,&,DE=\C ,2^#)\]?3U%% 'Q;^V;_P
M2#E_;D^*\'Q;^+7[2=Q9WEGI$>F6-EH?A1(H(+9))9 ,27#LS%I7)8MSG@
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M3=!MM)T^*ST2&73VGMK2*,!57REEC9P%&/O@YY)/.=ZB@#XB\"_\$<+SX?\
M[5O_  V1H_[5%]-XP;Q%>:S,+KPC";66>Z\WST,:SJ1&RS2+A6! /!! ->S_
M +;G[!OP^_;N^#^G?#[XIZQ]AUO2+A+G3?%&DV #VTQ"B<)$[L?*E YC+G!"
M'<2@)]VHH ^<?V6/V)_C)^R/\'+CX(?#O]JQM0TC?*^D2>(/!RW$VD-(<O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% &/XP^(7@?X??V7_P )OXKL-*_MO6(-
M)TC[?<K']LOIMWE6T>?O2/M;:HY.#6Q7X2ZM+JO[?'QI/B?]H#X[:Q;^*M8^
M/6B^%+'P?%>!3H^DW<ERDL]O"^<>2T<48VC"L29-S2J:_3G]DWX*?MS?LH?L
ME>+_ (?^._'>D_$KQ3IEK=2_#6.+49&<MY+"&TGFNQ$ @E"$;FPJLR[MJK@
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M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB
M@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\
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M &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\
M"#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\
M(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?
M\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/
MI'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _
M-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!RVL>&[&PO\
M3[:"YNMMS<%)-UTV<8SQS6C_ ,(/I'_/S>_^!;4>)?\ D+Z/_P!?I_\ 036Q
M0!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\ /S>_^!;4
M?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/
M_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z
M1_S\WO\ X%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#
MZ1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\ /S>_^!;4?\(/I'_/
MS>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U;%% &/_P (/I'_
M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M6Q10!C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M6Q10!C_ /"#Z1_S\WO_
M (%M4,EDGAG4[&/3II6%Y/Y<PGE+_*!GC/2MZL?Q+_R%]'_Z_3_Z": -BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_T$T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7@O\ P3J_Y(?J_P#V/>L?^CZ]ZKP7_@G5_P D/U?_ +'O6/\
MT?0![U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !6;XQ_Y%B]_ZX&M*LWQC_R+%[_UP- %S3O^0?!_UQ7^0J:H=._Y
M!\'_ %Q7^0J:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#-\8_\ (L7O_7 U<T[_ )!\'_7%?Y"J?C'_ )%B]_ZX
M&KFG?\@^#_KBO\A0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?^N!K2K-\8_\BQ>_]<#0!<T[_D'P?]<5_D*FJ'3O^0?!_P!<5_D*FH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S
M?&/_ "+%[_UP-7-._P"0?!_UQ7^0JGXQ_P"18O?^N!JYIW_(/@_ZXK_(4 34
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5C^)?^0OH_P#U^G_T$UL5C^)?^0OH_P#U^G_T$T ;%%%% !1110 4444
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MHH **** "BBB@ HHHH Q_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]'_Z_3_Z":V*
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MA[\:+,)H=]]EU-4W7&D7; 3)ZE>TB^X_$#I7=T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6/XE_Y"^C_]?I_]!-;%8_B7_D+Z/_U^G_T$T ;%%%%
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M(W=W_;OQA^*SZG=2'=/;V,K89O\ :FD!=_P"GWKVGP/X:^"?PWMQ!X*TO3+
M[<-/&FZ5Q_M2-EV_$T >'?\ "$?ME_M!?/XLU:3P[I$W6WF8VJ%>X\E,R/\
M23\Z[CX??L+_  I\+;+OQ=<7/B"Z7!*SGR;<'VC0Y/T9B/:O6O\ A,?#'_0:
M@_[ZH_X3'PQ_T&H/^^J )]%T'0_#>GII7A[1[6QM8_N6]G L:#_@*@"K=9O_
M  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?
M5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_
M\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 0^)?\ D+Z/_P!?I_\
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M_M3?#+XJV*1C4!I>J!?WVEWC?-GN8VQB1?I@^H% 'I5%9O\ PF/AC_H-0?\
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MMK07,J#LQX$<7_ MP]Z?HW['/QB^)EZFN?'#XAM;@G=]DCE^T2KZJ,$11_\
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M D'MPPYXQS7IE $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%9/B"V
MMX-7T@P6Z)F\.=B 9^4UN5C^)?\ D+Z/_P!?I_\ 030!L4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7@O_  3J_P"2'ZO_ -CWK'_H^O>J\%_X)U?\D/U?_L>]8_\ 1] 'O5%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9O
MC'_D6+W_ *X&M*LWQC_R+%[_ -<#0!<T[_D'P?\ 7%?Y"IJAT[_D'P?]<5_D
M*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH S?&/_(L7O_7 U<T[_D'P?]<5_D*I^,?^18O?^N!JYIW_ "#X/^N*
M_P A0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^X'U![@CN#@CN*T*^5_$_P %?C;^RUK,WCGX,:S<:IHF=UW:E-[*@[3Q#AU
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M_:D(/N:]P^%?[//PO^$,22^&M"$U^%P^JWV)+AO7!QA![*![YKN** "BBB@
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M-)^XN6_Z9N>A)_@;GG +5Z]0 4444 %8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\
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M?]<5_D*I^,?^18O?^N!JYIW_ "#X/^N*_P A0!-1110 4444 %%%% !1110
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M*_R%35#IW_(/@_ZXK_(5-0 4444 %%%% !1110 4444 %%%% !1110 4444
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
MZ%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^
M^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: )O&/_ "+%[_UP-7-.
M_P"0?!_UQ7^0KG_$NO:G<Z#=03>&+J%6B(,KLN%]S5FR\1ZJEG$B^$KQ@(E
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M?>5JGB:+_A(-33!\R]B MXV_V8N0?JQ;U&*]'A\0:E;Q+!!X+NT1%"HB% %
MZ  =!3O^$EU?_H4+W_OI: -=$2-!'&H55&%4#  I:Q_^$EU?_H4+W_OI:/\
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M9)/#=S&8[DLB,RYD.WH*T_\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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MJW3A%QYW!Q\Q_P!IC7'7/[)/[0=G-#!<_#_:]P^R$?VK:'<<9QQ+Q^-?:O\
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MZ?\ 8K_X+/>)/@3'^PEXC\7^"$^'RLEK-XJ;40\[V*2^8(-P7SVC! PIB5B
M$+[<BOH+X\?\$G/!7C[_ ()[Z#^QA\/_ !,EGJ7@^1=0\/Z]J$)"7&I?O3.\
MX3++',9Y<@;MF4(#; #]?T4 ?F'_ ,.Y/^"E7[7.N?#_ .%7[<'BOPW8_#KX
M=LB";2[R.2ZU2%%1#CRAEY6CC$?F2;-H9FVLQ(;].;>W@M8$M;:%8XXT"1QH
MN J@8  [ "GT4 %%%% !7@O_  3J_P"2'ZO_ -CWK'_H^O>J\%_X)U?\D/U?
M_L>]8_\ 1] 'O5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %9OC'_D6+W_ *X&M*LWQC_R+%[_ -<#0!<T[_D'P?\
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MD/U?_L>]8_\ 1] 'O5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %9OC'_D6+W_ *X&M*LWQC_R+%[_ -<#0!<T[_D'
MP?\ 7%?Y"IJAT[_D'P?]<5_D*FH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HK%\7?$?P'X"@\_QCXNL-.&,JES<J'8?[
M*?>;\ :\C\;?M[_#'1-]OX,T2_UN4?=E8?9H#^+@O_XY0!D_MI_'C4/"NO:1
MX!\)WVV>TF2_U38W!Z^7"V.Q&YF'H4KTC4/VE_A#X7^'^F>+M8\3Q@7^GQS6
MVGVY$ER^5Y78.A!!4EL+D$9KXB\9>+-7\=>*K_Q?KLH>[U"Y::8CHN3PH]%
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MZG*GW!K3HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K'\2_\A?1_P#K]/\ Z":V*Q_$O_(7T?\ Z_3_ .@F@#8HHHH
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M\V/X1\#6%K,GW;IHO,F_[^/E_P!:ZFBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#-\8_\ (L7O_7 U<T[_ )!\'_7%?Y"J?C'_ )%B]_ZX&KFG?\@^#_KB
MO\A0!-1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !6/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_030!L4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8_B7_D+Z/_U^G_T$UL5C^)?^0OH__7Z?_036Q0 4444 %%%% !1110 4444
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M?V1M.T+RIOAYJ#_%F+PQ!$;"VD65/L<A\H>7'=%R5?;ABKC=U->'?'GXK_\
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M[_X%M0!L45C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;4 ;%%8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;4 ;%%8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U &Q16/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
M@6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L5C^)?\ D+Z/_P!?
MI_\ 031_P@^D?\_-[_X%M69KGA73K74=-ACGN2)[DJY:X8D#;V]* .KHK'_X
M0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_G
MYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJ -BBL?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJ -BBL?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:@#8HK'_X0?2/^?F]_P#
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M#Z1_S\WO_@6U &Q16/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M0!L45C_\
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M>/=5\(Z%IVM:5XOL-2\2:G_8V^;7M-@W"73IF1T)$@*#S6W%0@ &.*]V\#>
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MB1K>A7*G$9?3UN OUECDC8?A&:[SPMX=_:ZT;:/A5^UQ8:L!CR+&Y\431/\
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MQ7X0TZ_)&/,N;1&<?1L;A^!KSCQ3^Q)\&==W2Z+'J&CR'D"SNM\>?=90QQ[
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M0?!_UQ7^0H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K'\2_P#(7T?_ *_3_P"@FMBL?Q+_ ,A?1_\ K]/_ *":
M -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#'\2_\A?1_P#K]/\ Z":V*Q_$O_(7T?\ Z_3_ .@FMB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK'\2_P#(7T?_ *_3_P"@FMBL?Q+_ ,A?1_\ K]/_ *": -BBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *\%_P""=7_)#]7_ .Q[UC_T?7O5>"_\$ZO^2'ZO_P!CWK'_ */H ]ZHHHH
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MBBB@ HHHH **** "BBB@ HHHH **** ,?Q+_ ,A?1_\ K]/_ *":V*Q_$O\
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MZGX4N?M#6NE*UO<"/;<2)(/)E^=<R*[?N^N<]Z[O2?\ @IO\6OA]?)HGQ_\
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MKK3FZ<OFIZ7\D?8E%?$_]C_\%2/@)Q9:E-XOT^'KB:/4Q)CVD"W/Y8J[H/\
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M([G:NQ"Q"[T,BJ2-Q RP^YJ "BBB@ KP7_@G5_R0_5_^Q[UC_P!'U[U7@O\
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MB?&7X8SV\Z_?EM8V@E ]?*EZ_4,!7JG@G]I/X->/-D6E>,[>VN7_ .734O\
M1Y,^@W_*Q_W2:]?*^..&,WG[.EB%&IMR3]R5^UI6N_2YO1S'!UW92L^ST?XG
M=44BLK*&5@01D$'K2U]8=H4444 %%%% !1110 4444 %%%% &;XQ_P"18O?^
MN!JYIW_(/@_ZXK_(53\8_P#(L7O_ %P-7-._Y!\'_7%?Y"@":BBB@ HHHH *
MI:]X:\.>*K!M*\3Z!9:E:M]ZVO[5)HS]5<$5=HJH3E3DI1=FNJ)G"%2+C)73
MZ,\4\>_\$^?V6O'>^9? 3:+</G_2- NFM]OTC.Z(?]\5Y!X@_P""6GBSPK?G
M7?@5\>;BQNE_U":@DEO(OI_I%N<_E&*^RJ*^JP'''%.7QY(8F4H_RSM-6[>]
M?3TL?)YAP+PIF,N>>%C&7\T+P=^_NVU];GQ/]O\ ^"I/P%_X^+2;Q?I\/3,<
M>I^9CW3;<_GBM+PQ_P %5-0T*^&A_&WX'7EA<QD?:)-,F*.O_;O< $?C)7V-
M6;XG\&>$/&UC_9?C+PKIVK6W/[C4K*.=/R<$5Z/^MF1YAIF>64V_YJ3=)^ME
M=-^IYO\ JCGN7:Y5FE2*7V:J56/I=V:7IJ>6^ OV^/V6_'VR&'XDQ:3</UMM
M>A:UV_61OW7Y/7K6CZWHOB&Q35- U>UOK:3[ES9W"RQM]&4D&O%/'O\ P3F_
M9=\;[YK+PE=:!</G,^AWS1C/_7.3?&/P45Y-K'_!,3XH^ [Y]<^ /[0$MI<#
MF-+HS64HQT'G6[-N_P"^0*/[,X#S+_=<94P\G]FK#F5^W-#9>;#^U./\L_WK
M!4\1%?:HSY7_ . SW?DC[.HKXG_X37_@J'\!>->\,R^+=/AZ,UE'J(91U):W
M(G_%ZV/"'_!5W3K*[_LCXP_!K4=-N(FVW$FE7 =@?>&8(5^F\UG5\/L\G!U,
M!*GB8+K2G%_>G9W\E<TI>(F14YJGF$*F%F^E6G*/W-75O-V/L"BO)? 7[<G[
M+WQ"V0Z=\5++3[A^MMK:M9LI]-TH"$_1C7JEAJ.GZK9IJ&EWT-S;RC,<]O*'
M1QZAAP:^4QN69CEL^3%T94W_ 'HM?FCZ[ YGEN90Y\)6C47]V2E^3)J***X3
MN"BBB@ HHHH **** "L?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K]/\ Z":
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M\X]JZ>N8^-6C_$K7_A'XDT?X-^*TT/Q9<:-<+X<U66WCE2WO=A,+,LJ.A7>
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M?Y#[<EE! -#_ (+[^!O#OAS]BKX3G2=/BB.A>([?3--,: >3;MILN47'1?\
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M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
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MWB_3/@U\0+3[#XYT71-8B PJ:E8I-M^F]3CZBNE_L[3_ /GQA_[]"C^SM/\
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M/J?_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJOC7_ (;#_;:^*HV?"7]F^&SMI/\
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M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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M ()U?\D/U?\ ['O6/_1]>]5X+_P3J_Y(?J__ &/>L?\ H^@#WJBBB@ HHHH
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M'UKZ5J.ZM+6^MWM+VVCFBD&)(I4#*P]"#P:^/? 4LN?-D>-JX;^Y?VE/_P
MG^=V</\ 9KI:X>HX>6Z^YGFG@G]KSX*^,=D%SK[Z/<-_RQU>/RUS_P!= 2F/
MJP^E>E65]9:E:I?:=>17$,@S'-!('5AZ@C@UYSXV_9+^"GC3?.OALZ3</_R\
M:._D\_\ 7/!C_P#':\VO?V1_C-\-KI]5^"_Q.=QG=]F,[6LC^@(!,<G_  +
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M "0_5_\ L>]8_P#1]>]5X+_P3J_Y(?J__8]ZQ_Z/H ]ZHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\8_P#(L7O_
M %P-:59OC'_D6+W_ *X&@"YIW_(/@_ZXK_(5-4.G?\@^#_KBO\A4U !1110
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M_P"?WGS;_P +;_;<3YS\,<@<D?V,W/Y/1_PNS]M+_HD?_E F_P#BZ^DJ*/\
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MAN=7M--^T>3J/D3+YWF7$DIX4$<&0KP>U><>!O WB7XB^);?PKX5T]KBZN&
M) .V)<\NY_A4=S_4@5][^ _"-CX"\&Z;X.TYMT6G6B0B0C!=@/F<CU+9/XUZ
M.0^('C'XJ8:='-,VE'#TVI)JA05ZEFK)QIP;M%N^K2NKK8]GA7A++LMQ4\3@
M(^RER\KE>4KIM.UI-KHGW/!/^&R_B_\ ]$3/_?JX_P#B:/\ ALOXO_\ 1$S_
M -^KC_XFOI&BO;_U6XL_Z'4__!5,^Z^IXW_H(?\ X"CYN_X;+^+_ /T1,_\
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M_ALOXO\ _1$S_P!^KC_XFC_ALOXO_P#1$S_WZN/_ (FOI&BC_5;BS_H=3_\
M!5,/J>-_Z"'_ . H^;O^&R_B_P#]$3/_ 'ZN/_B:/^&R_B__ -$3/_?JX_\
MB:^D:*/]5N+/^AU/_P %4P^IXW_H(?\ X"CYN_X;+^+_ /T1,_\ ?JX_^)H_
MX;+^+_\ T1,_]^KC_P")KZ1HH_U6XL_Z'4__  53#ZGC?^@A_P#@*/F[_ALO
MXO\ _1$S_P!^KC_XFC_ALOXO_P#1$S_WZN/_ (FOI&BC_5;BS_H=3_\ !5,/
MJ>-_Z"'_ . H^;O^&R_B_P#]$3/_ 'ZN/_B:/^&R_B__ -$3/_?JX_\ B:^D
M:*/]5N+/^AU/_P %4P^IXW_H(?\ X"CYN_X;+^+_ /T1,_\ ?JX_^)H_X;+^
M+_\ T1,_]^KC_P")KZ1HH_U6XL_Z'4__  53#ZGC?^@A_P#@*/F[_ALOXO\
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MY"IJAT[_ )!\'_7%?Y"IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME\MAC.-F_;CVQ7I6E:3I6A6$>E:+IL%I:PKMBM[:((B#T"C@5G^)?^0OH_\
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M4L*_C-[5C_!=:?.OZA"/UKHM,^.7P<UC L?B;HA)Z)+J,<;'\'(-86J?LF?
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M3Y/2K+!4N1RY>9\TG>U^7XF[6N]K;ZA1117V1]N%%%% !1110 4444 %%%%
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M_1]>]5X+_P $ZO\ DA^K_P#8]ZQ_Z/H ]ZHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\8_\BQ>_]<#6E6;XQ_Y%
MB]_ZX&@"YIW_ "#X/^N*_P A4U0Z=_R#X/\ KBO\A4U !1110 4444 %%%%
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M*Q (7M7V?7D'[%/@7Q=\/OA/J6B>--!GTZ[F\8:I=1P7  9H9)RR/P>A'(H
MQ/\ A7W_  4/_P"C@O G_A+O1_PK[_@H?_T<%X$_\)=Z]ZHH \%_X5]_P4/_
M .C@O G_ (2[T?\ "OO^"A__ $<%X$_\)=Z]ZHH \%_X5]_P4/\ ^C@O G_A
M+O1_PK[_ (*'_P#1P7@3_P )=Z]ZHH \%_X5]_P4/_Z."\"?^$N]'_"OO^"A
M_P#T<%X$_P#"7>O>J* /!?\ A7W_  4/_P"C@O G_A+O1_PK[_@H?_T<%X$_
M\)=Z]ZHH \%_X5]_P4/_ .C@O G_ (2[T?\ "OO^"A__ $<%X$_\)=Z]ZHH
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MX5]_P4/_ .C@O G_ (2[U[U10!X+_P *^_X*'_\ 1P7@3_PEWH_X5]_P4/\
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M_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\
M"7>O>J* /!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWKWJB@#P7_
M (5]_P %#_\ HX+P)_X2[T?\*^_X*'_]'!>!/_"7>O>J* /!?^%??\%#_P#H
MX+P)_P"$N]'_  K[_@H?_P!'!>!/_"7>O>J* /!?^%??\%#_ /HX+P)_X2[T
M?\*^_P""A_\ T<%X$_\ "7>O>J* /!?^%??\%#_^C@O G_A+O1_PK[_@H?\
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MA_\ T<%X$_\ "7>C_A7W_!0__HX+P)_X2[U[U10!X+_PK[_@H?\ ]'!>!/\
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MM'^!?%WBSXL?"36_#F@SW=IH?C"2ZU:>$ K:PF!E#MSTSQ0!Z_1110 4444
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M<2EV($BX&2<UB:</^&@/^"Z5[?'][IOP4^&JPQL.8Q?W:_EN*7T@_P"V'J*
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M@N_A_P"!M-E=O 5OH7B%#9V]OND\MG5V1(O+C2-I"5#2,Y(8!:Z'_@@Q\?\
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M_P '+K-Q;7/AKP>\KQK9Z2S7*Q;XSAB[NDC,TBJS<$*J;%'Z*?\ !3CXM_\
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M%2(_V"]7^,&M>*_A_P"+M.631AKMP7>TE>V>:&55)(C?S(I(&V85PRL5R %
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M2R%#[KNQ^%;-)'&D2"*) JJ %51@ >E+0 4444 %%%% !1110 4444 %%%%
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M!X+^*FH3W/A?P-=MX6UB"4PV3&PEN9?(EMKB)7W23%XCN 8YC*@C ;Z_\(?
M;P!X:_9]TS]FO4M)AU3PU8>%(?#]Q:7<6%O+5+<0-O /5U!)P<Y8G.>:^,M3
M_P"#?OX1R:I<Z%X=_:=\?:9X'O;X75UX.CDC=&8$$8D/R$C "L\3L !DDC)
M/7_^"0W[1GQ%_:F_8MTSQA\7TBN=5TC69](_M#[*D8OH[<1/%,44!0P#A"5
MRT6>N:^<_P!L[_E/=\$_^P%IG_H_4:_0;X*_!CX<_L^?##2/@_\ "CP\FF:#
MHEMY5E:JQ8G)+/(['EW=BS,QY+,37E'Q7_X)\^ ?BS^VAX2_;5U7QWK%KK/A
M"SM[>TT>WCB-K.(GG8%R5W@GSVS@_P (H \@_P""S<LOQ2F^"/['%A*WF?$C
MXFV[:BL1Y%C;;4E+8Z*/M0?_ +8\=#7VW%9VD C$-K&GDQ^7#M0#8O'RCT'
MX]A7C7Q _8XTSXC?MI^"OVP->\>3D>!=!N+#2?"_]GJ83/,LZO=&4OG=MF V
M[>L2G->TT ?FA_P2V_Y2[_M.?]A37?\ T^"N\_;<_9;T[QI^W9X>^,7[(G[7
M7A#P-\>A9"*?POK=XCMJ426SXE:)5E=3]F#*RM$RO&BD;2N6]S_9T_X)\^ ?
MV<?VGOB%^U%X=\=ZQJ&I_$.XO)M0TV]CB$%J;B\^U,(RJACAOE&2>/>L/]N/
M_@E[\+?VT/&>D?%N#Q_K?@GQMHMNMO:^)-!P6DA5F=!(F5.Y&9MKJZL Q!W
M+M /@[0?A%\:;/\ X+?> /#'Q?\ C!;^._',=W::MXOU33;00VUF\5K)/]FC
M4!0L:6T<.#M3)?[N3S^QM?-_[$?_  3,^#7[%NO:I\1K+Q+J_C#QMK<;1ZAX
ML\1.&F$;,&=(E&=F]@I9F9W8C[V.*^D* "BBB@ HHHH **** "BBB@ HHHH
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M*@9:+/7->0:G_P &_?PCDU2YT+P[^T[X^TSP/>WPNKKP=')&Z,P((Q(?D)&
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MM!^$?@JP^,FKW.@_"GQK<^)H].OM,B=M7NI)89461U90BQF$@84Y$C9KW/\
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M/^"?/@']ECX]?$'X^^%_'>L:G?\ Q#O)[C4+&_CB$-J9;I[DB,HH8@,Y')/
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M=(O;O'V2SU/5X;>6;/38CL"W3L*V+S4=/TZR?4]0OH8+:)-\MQ-*%1%]2QX
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MO#79K-8;I;H6EM&\7E3*3MP[-G:>>AKS3XE^!/#G[:O_  5AU'X%_'&U;5?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"TK_ (*F_P#!/?6=0BTRS_:K\,)+,X5&NI)8(P?]J25%11[D@5XW_P %3_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO\(?V"/V.?@-XO'C[X3?L]^'M(UI-WD:FENTTUN2,$Q-*S>42,C*;>"1T)H
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ML=9\:>*?BCI=[I]CI=TD\EG9P"4RWK["?+C4./F.,J'(R$;!\$O%OAK]G_\
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M_#*\%G-#>:G91VEP))YP[LI&?+ **H#>8IR4S7H\G_!+S_@GY+XE_P"$L?\
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MH<FN<O+=?^"P'[4%QIEP9I?V=?A3J+Q2&&5DC\8ZZ%(R&4C,$2MD$'[K _\
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MU#5AJ=]X?BL MK->!543-&."P"(/^ CTKTR""&VA2VMH5CCC4+'&BX55 P
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M8T?398;=%EMWCSN$BLI4(!EOEVA@RY_/[7O#^NVG_!#+XD>/=4T6?3['QO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ssmithsign.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ssmithsign.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A;BY,:6-K
M=&5I9P    60 P "    %   $*:0!  "    %   $+J2D0 "     S0U  "2
MD@ "     S0U  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]MI]QI$[9?396A3/>+K&?^^2!^%3^$D6/16C3A5N)0![;S0!N44E% !2T44
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M/G<3*ZAOGP!P/XJ[VL32B!XFUL+_ 'XB?KLH C'A[4)1_IGB*^<'JD2I&/S
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M [9[D\D_3TH Z2TF2:TBD1@RNH8$'J*YGQ'JH3Q7H%G!=.A^TEKA8V.W9L8
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M ,/Z;J3^9=6RF7'$JG:X_$<U3_X1EU8"'6=3CC'&P3@C\R"?UH N:QKVGZ)
MLFH7*1;SB-,Y:0^BJ.2?855\.PRFTN-0N!LGU!_.*$@[!C"J2.X &??-)!X0
MTN"\-Z\<EU>;2JSW,AD90?3/3\*P]+L?$T6@VOAZ*V6Q%LOE2:@T@;<@/5%'
M.XCUQCWH H^!;"WO+B[EBB:!H5>WN90-KRS,Y9CGJ=ORX/O6?XUM]3'C;P]:
MI<QWA67,:N-K8/)R1QT3KBNRC\%V]DR/H]Y=:=(% D,+*1*1W8,""??K7,ZQ
MI9TSQMIEW=7,][,LL/[Z8C*AF9,    984 =DT>N77R&:WM$(Y*(78?3.!2M
MX;M?[#NM.5WQ=*1+,YW.Y/5B>YK8I: (;:W2UM8H(P L:!1@=@*E90RD, 0>
MH-+10!BMX3TEG^:W/E;MWV?S&\DG.<^7G;UYZ5L(BHH50 !TP*=10 F,]12@
M 444 %':BB@!*4TE+0 "C-%% &%XHL[[4[:WT^T!2WN)=MY,",K%CYE ZY;[
MN1TS6S%"D,2I&H55   '0"I** $P/2EQ24M "4M%% "%0>HS65>>&M-O)_M'
MD?9[@]9[=C%(?^!+@UK4"@#EKCP=.VJVVHVVM77GVJLL0N LB@-C/8$]/6K@
ML?$6,?VO:CW^R'_XJMVB@# _L/5)\?;=>GQW%M$L>?QP:M6'AVPL+@W"(TUR
M1@W%PYDD(]-QY ]AQ6K24  XZ44M% !1244 +124HH 0 #H *6BB@!*444E
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= HHHH !1110 AI:**  TE%% "T444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471461072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 07, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West End Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,300,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,395,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Certain information required in Part III of Form 10-K is incorporated by reference from the registrant&#8217;s Proxy Statement for its 2023 annual meeting of shareholders.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470655632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">FORVIS, LLP(Formerly, BKD, LLP)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Nashville, Tennessee<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471764000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,757,970<span></span>
</td>
<td class="nump">$ 27,040,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances</a></td>
<td class="nump">13,163,681<span></span>
</td>
<td class="nump">6,877,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">9,863,581<span></span>
</td>
<td class="nump">8,429,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">3,084,978<span></span>
</td>
<td class="nump">3,339,969<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">45,870,210<span></span>
</td>
<td class="nump">45,688,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories</a></td>
<td class="nump">7,527,167<span></span>
</td>
<td class="nump">9,048,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">284,039<span></span>
</td>
<td class="nump">442,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">30,590,678<span></span>
</td>
<td class="nump">23,954,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">914,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">5,218,403<span></span>
</td>
<td class="nump">1,024,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,520,661<span></span>
</td>
<td class="nump">3,419,908<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">92,925,158<span></span>
</td>
<td class="nump">84,459,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,819,011<span></span>
</td>
<td class="nump">9,640,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">172,910<span></span>
</td>
<td class="nump">969,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">17,587,911<span></span>
</td>
<td class="nump">8,668,303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">28,579,832<span></span>
</td>
<td class="nump">19,278,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="nump">16,200,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">4,586,301<span></span>
</td>
<td class="nump">90,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">7,585,019<span></span>
</td>
<td class="nump">7,488,844<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">56,951,152<span></span>
</td>
<td class="nump">41,857,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock &#8211; no par value; 100,000,000 shares authorized; 14,366,316 and 14,742,754 shares issued and outstanding as of December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">47,474,973<span></span>
</td>
<td class="nump">48,452,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="num">(11,208,841)<span></span>
</td>
<td class="num">(5,638,600)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">36,266,132<span></span>
</td>
<td class="nump">42,814,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(292,126)<span></span>
</td>
<td class="num">(212,328)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">35,974,006<span></span>
</td>
<td class="nump">42,601,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 92,925,158<span></span>
</td>
<td class="nump">$ 84,459,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520472567184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock, no par value (dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, number of shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, number of shares issued</a></td>
<td class="nump">14,366,316<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, number of shares outstanding</a></td>
<td class="nump">14,366,316<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471818144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 42,010,949<span></span>
</td>
<td class="nump">$ 35,985,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">9,118,521<span></span>
</td>
<td class="nump">8,811,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">16,660,945<span></span>
</td>
<td class="nump">15,015,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">6,688,924<span></span>
</td>
<td class="nump">5,684,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,180,120<span></span>
</td>
<td class="nump">9,780,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">5,067,368<span></span>
</td>
<td class="nump">4,371,300<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">47,715,878<span></span>
</td>
<td class="nump">43,662,463<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(5,704,929)<span></span>
</td>
<td class="num">(7,677,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">98,405<span></span>
</td>
<td class="nump">26,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other Income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,187,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuredEventGainLoss', window );">Other income - gain on insurance proceeds</a></td>
<td class="nump">611,330<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(585,995)<span></span>
</td>
<td class="num">(98,031)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(5,581,189)<span></span>
</td>
<td class="num">(5,562,230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(68,850)<span></span>
</td>
<td class="num">(34,891)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(5,650,039)<span></span>
</td>
<td class="num">(5,597,121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,994,322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(5,650,039)<span></span>
</td>
<td class="num">(3,602,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="nump">79,798<span></span>
</td>
<td class="nump">95,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (5,570,241)<span></span>
</td>
<td class="num">$ (3,507,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (loss) per share attributable to common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">-Continuing operations-basic</a></td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">-Discontinued operations-basic</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">(0.38)<span></span>
</td>
<td class="num">(0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">-Continuing operations-diluted</a></td>
<td class="num">(0.38)<span></span>
</td>
<td class="num">(0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">-Discontinued operations-diluted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">14,563,592<span></span>
</td>
<td class="nump">14,904,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">14,563,592<span></span>
</td>
<td class="nump">14,904,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 40,681,182<span></span>
</td>
<td class="nump">$ 35,045,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,329,767<span></span>
</td>
<td class="nump">$ 939,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuredEventGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuredEventGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470431504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (5,650,039)<span></span>
</td>
<td class="num">$ (3,602,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,994,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(5,650,039)<span></span>
</td>
<td class="num">(5,597,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">5,328,113<span></span>
</td>
<td class="nump">4,606,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">447,503<span></span>
</td>
<td class="nump">741,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1', window );">Decrease in non-cash contingent consideration</a></td>
<td class="num">(2,088,296)<span></span>
</td>
<td class="num">(1,147,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy', window );">Decrease (Increase) in cash surrender value of life insurance policies over premiums paid</a></td>
<td class="nump">613,657<span></span>
</td>
<td class="num">(282,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Noncash interest expense</a></td>
<td class="nump">11,237<span></span>
</td>
<td class="nump">34,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_NoncashOrPartNoncashGainOnTransaction', window );">Noncash gain on RediTrex transaction</a></td>
<td class="num">(37,882)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingGainsLosses', window );">Noncash investment gains</a></td>
<td class="num">(611,330)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Gain on forgiveness of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,187,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities affecting operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(6,115,640)<span></span>
</td>
<td class="nump">5,500,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">911,078<span></span>
</td>
<td class="nump">4,816,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Prepaid, other current assets and other assets</a></td>
<td class="nump">689,260<span></span>
</td>
<td class="num">(35,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">14,536,076<span></span>
</td>
<td class="num">(757,591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">419,659<span></span>
</td>
<td class="num">(1,343,605)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities from continuing operations</a></td>
<td class="nump">8,453,396<span></span>
</td>
<td class="nump">4,348,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,994,322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">8,453,396<span></span>
</td>
<td class="nump">6,342,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(102,148)<span></span>
</td>
<td class="num">(103,532)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(1,971,662)<span></span>
</td>
<td class="num">(250,930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProceedsFromCollaborationArrangement', window );">Return of RediTrex</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy', window );">Proceeds from surrender of life insurance policies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">85,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy', window );">Premiums paid for life insurance policies</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33,375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLifeInsurancePolicies', window );">Life insurance policy proceeds received</a></td>
<td class="nump">877,597<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProceedsFromSettlementOfPatentLitigation', window );">Settlement of patent litigation</a></td>
<td class="nump">21,757<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisition</a></td>
<td class="num">(13,500,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Note receivable investment funding</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(13,674,456)<span></span>
</td>
<td class="num">(501,893)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">52,900,000<span></span>
</td>
<td class="nump">59,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments on line of credit</a></td>
<td class="num">(51,700,000)<span></span>
</td>
<td class="num">(59,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(1,053,042)<span></span>
</td>
<td class="num">(1,386,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash settlement of contingent consideration</a></td>
<td class="num">(2,208,744)<span></span>
</td>
<td class="num">(2,166,681)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(2,061,786)<span></span>
</td>
<td class="num">(3,553,530)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(7,282,846)<span></span>
</td>
<td class="nump">2,287,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">27,040,816<span></span>
</td>
<td class="nump">24,753,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">19,757,970<span></span>
</td>
<td class="nump">27,040,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CashPaidDuringYearForAbstract', window );"><strong>Net cash paid (refunded) during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">523,161<span></span>
</td>
<td class="nump">63,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="num">(327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid', window );">Change in unpaid invoices for purchases of intangibles</a></td>
<td class="num">(1,803,403)<span></span>
</td>
<td class="num">(43,471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Change in unpaid invoices for offering costs</a></td>
<td class="num">(94,689)<span></span>
</td>
<td class="num">(90,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Recognition of operating lease assets and liabilities through adoption of ASC 842</a></td>
<td class="nump">4,590,978<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CreditIssuedForMilestonePayable', window );">RediTrex forgiveness of milestone payable</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Return of common stock - Methotrexate</a></td>
<td class="nump">$ 399,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CashPaidDuringYearForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During Year For [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CashPaidDuringYearForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CreditIssuedForMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Credit Issued for Milestone Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CreditIssuedForMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Proceeds from Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NoncashOrPartNoncashGainOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash, Gain on Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NoncashOrPartNoncashGainOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromCollaborationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Collaboration Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromCollaborationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromSettlementOfPatentLitigation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Settlement of Patent Litigation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromSettlementOfPatentLitigation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProceedsFromSurrenderOfLifeInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Surrender of Life Insurance Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProceedsFromSurrenderOfLifeInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of Intangible Assets Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of right to a contingent consideration asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLifeInsurancePolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21C<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080552-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLifeInsurancePolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520472380048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,988,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2020</a></td>
<td class="nump">$ 46,873,394<span></span>
</td>
<td class="nump">$ 49,121,523<span></span>
</td>
<td class="num">$ (2,131,013)<span></span>
</td>
<td class="num">$ (117,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">(3,507,587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,507,587)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(95,212)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(3,602,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Return of common stock - Methotrexate</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation, amount</a></td>
<td class="nump">741,867<span></span>
</td>
<td class="nump">$ 741,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(438,359)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">$ (1,410,484)<span></span>
</td>
<td class="num">$ (1,410,484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2021</a></td>
<td class="nump">14,742,754<span></span>
</td>
<td class="nump">14,742,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2021</a></td>
<td class="nump">$ 42,601,978<span></span>
</td>
<td class="nump">$ 48,452,906<span></span>
</td>
<td class="num">(5,638,600)<span></span>
</td>
<td class="num">(212,328)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">(5,570,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,570,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary attributable to noncontrolling interests</a></td>
<td class="num">(79,798)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(5,650,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares', window );">Return of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Return of common stock - Methotrexate</a></td>
<td class="num">(399,600)<span></span>
</td>
<td class="num">$ (399,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation, amount</a></td>
<td class="nump">447,503<span></span>
</td>
<td class="nump">$ 447,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares</a></td>
<td class="num">$ (1,025,836)<span></span>
</td>
<td class="num">$ (1,025,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Equity, common shares outstanding at Dec. 31, 2022</a></td>
<td class="nump">14,366,316<span></span>
</td>
<td class="nump">14,366,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, balance at Dec. 31, 2022</a></td>
<td class="nump">$ 35,974,006<span></span>
</td>
<td class="nump">$ 47,474,973<span></span>
</td>
<td class="num">$ (11,208,841)<span></span>
</td>
<td class="num">$ (292,126)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520555837888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-top:8pt;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended December&#160;31, 2022, 2021 and 2020</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.182%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.226%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">beginning&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">period</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">costs and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">expenses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">accounts</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">end&#160;of&#160;period</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963,279&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,606,992)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,964&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,673,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,417,977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,196,121&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,801&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,761,922&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,761,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,795,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,557,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt"><span><br/></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Composed of actual returns and credits for chargebacks and cash discounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475185520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals Inc. (&#8220;Cumberland,&#8221; the &#8220;Company,&#8221; or as used in the context of &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology  and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, field and oncology sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#8217;s products are manufactured by third parties, which are overseen by Cumberland&#8217;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace.  In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET including an investment of approximately $1.0 million from Gloria Pharmaceuticals Co., Ltd. (&#8220;Gloria&#8221;).  As a result, Gloria received shares in CET and joined the CET ownership group. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited ("WinHealth") </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whereby WinHealth made a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment in CET.  Cumberland purchased additional CET shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.8 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that was funded during 2020.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's ownership in CET is now 85% while the remaining interest is owned by WinHealth, Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $79,798 and $95,212 for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC").  CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#8217;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#8217;s ongoing activities including charitable contributions. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Cumberland provided a grant of 50,000 shares of the Company's common stock to the Foundation. The shares will address the ongoing financial needs of the Foundation.  The organization also plans to hold a portion of the shares for long-term appreciation. The Foundation maintains separate financial statements and its ongoing operations will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.  During 2019, Cumberland Pharmaceuticals committed approximately $50,000 in cash contributions that were paid to the Foundation during 2020.  Likewise, during 2020, the Company committed approximately $25,000 in cash contributions paid to the Foundation during 2021. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company made a $25,000 cash contribution to the Foundation.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473179264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2020, the U.S. declared a health care emergency following the outbreak of SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness. The Company has managed through the resulting COVID-19 pandemic, continuing to operate our business &#8211; keeping facilities open and our organization intact. We moved quickly to ensure the health and safety of our team. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded pharmaceutical company.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, Cumberland faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our business and our clinical studies were impacted, as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carefully monitored our supply chain, including the flow of raw materials and the batches of finished products emerging from the facilities that manufacture our products. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio that includes other brands that have delivered a strong performance during the pandemic.  Overall, we have been able to continue the delivery of our products while addressing the interests of our shareholders, employees, partners and community.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liability associated with business combinations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.  Net revenues from customers outside the United States were approximately $1.5 million and $2.2 million for the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2022 and 2021, cash equivalents consist primarily of money market funds.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, as well as amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $0.6 million at December&#160;31, 2022 and $0.3 million at December 31, 2021. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale at third party facilities located in the U.S. and international locations.  Periodic inventory counts are made by the warehouse teams and by the Company on a regular basis.  In addition, the Company re-tests API inventory prior to use to confirm product expiration.  Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.  The Company classifies the Vibativ inventories and ifetroban inventories that it does not expect to sell within one year as non-current inventories. </span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100&#160;million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19&#160;million.  The Company amended the At the Market Sales Agreement on December 27, 2021, in order to allow the Company to continue using its ATM feature to sell shares at market prices.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded deferred offering costs for payments directly related to the current Shelf Registration on Form S-3 that was completed during December 2021. These costs consist of legal and accounting fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2022. </span></div><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#8217;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ and Sancuso acquisitions. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"><tr><td style="width:1.0%"/><td style="width:46.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated economic life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term of license agreement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of patent</span></td></tr></table></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment.  The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit.  The Company's goodwill was acquired in November 2018 with the Vibativ acquisition and in January 2022 with the Sancuso acquisition. As a result, the Vibativ and Sancuso components of the Company are the reporting units evaluated for goodwill impairment.  Cumberland determined the fair value of the reporting units through current and future estimated revenue and profitability of the product.  The Company recorded no impairment charges during 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of $0.2&#160;million convertible note. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Distribution costs were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:65.836%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.110%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Advertising costs were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:65.836%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.110%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,927,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,927,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3 do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the consolidated statements of operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Transactions</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Cumberland named Martin S. Brown Jr. to our Board of Directors. Mr. Brown is an attorney with over 30 years of corporate law experience who brings significant legal, public company, health care and civic experience to our board.  The Company relies on several law firms for legal advice, including the firm Martin is affiliated.  In 2022, the Company paid Martin's law firm $0.04&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 19, for additional information.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475288416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RediTrex&#174;, Vibativ&#174; and Sancuso&#174;<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">RediTrex&#174;, Vibativ&#174; and Sancuso&#174;</a></td>
<td class="text">RediTrex<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> and Sancuso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RediTrex</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#8217;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the license Cumberland paid a deposit of $0.1 million at closing.  The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tied to the products&#8217; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name. The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020.  During December 2020, Cumberland began distributing RediTrex which also resulted in a $1.0&#160;million milestone payment due to Nordic.  The full launch of RediTrex occurred in October 2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after June 30, 2023. Cumberland will continue to distribute and support the product until then.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the terms of the amendment, Nordic has agreed to return the 180,000 restricted Cumberland shares we previously issued to Nordic which will be cancelled, refund to Cumberland the milestone payment of $1.0&#160;million we made associated with the brand's U.S. approval and issue a credit note in favor of the Company in the amount of $1.0&#160;million for the unpaid milestone payment due from us for launch of the product line. The companies will cooperate on any transition and Cumberland will receive a long-term royalty on any Nordic sales of the product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland had approximately $2.6&#160;million in net intangible assets related to RediTrex at December&#160;31, 2021.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vibativ</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland agreed to pay a royalty of up to 20% on future net sales of the product after a $2.5 million threshold is met.  The future royalty payments were required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the Company's Level 3 contingent consideration liability.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,166,682)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,147,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133,113)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,104,690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876,999&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of the contingent consideration liability is $1.3&#160;million and the non-current portion is $2.8&#160;million, as of December&#160;31, 2022. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#8217;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#8220;CINV&#8221;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#8211; including its marketing, promotion, distribution, manufacturing and medical support activities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5&#160;million based on the attainment of various approvals and sales performance. The Company believes that $1.5&#160;million of the milestone payments will be earned and paid.  The remaining milestone of $2.0&#160;million will be paid if and when annual net revenue exceeds $20&#160;million.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a valuation of the contingent consideration liability utilizing significant unobservable inputs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the valuation is classified as Level 3 fair value measurement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was funded by cash and the Company's revolving credit facility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company worked with an outside consultant firm to finalize the Sancuso valuation of the transaction.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value for the assets and liabilities assumed were as follows: prepaid expenses $1.8&#160;million, inventory $2.6&#160;million, goodwill $0.03&#160;million, intangible assets $14.1&#160;million, milestone payable $1.7&#160;million and contingent liability $3.4&#160;million.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:74.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.578%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at January 3, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,384,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash payment of royalty during the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1,075,631)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in fair value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent consideration earned and accrued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">675,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of the contingent consideration liability is $1.7 million and the non-current portion is $1.3 million, as of December&#160;31, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sancuso Intangible Assets, Goodwill, Revenue and Earnings</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An outside consultant prepared the Sancuso valuation and the valuation is complete.  The goodwill of $0.03&#160;million arising from this acquisition consists largely of the synergies and economies of scale expected from combining the operations of the Company and the acquired company. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on discussions with Management, the identified intangible assets were valued as a composite asset referred to as the Sancuso product rights. It is comprised of:</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">   Technology &#8211; patented and unpatented IP and know-how;</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">   Marketing intangible assets including product trademarks/names/dress; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">   Customer base to which the product is sold.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is a common practice in the life sciences industry to value intangible assets under a portfolio approach given the nature of the intangible assets and facts and circumstances that are common to the industry. The Goodwill amount to be deducted for tax purposes is expected to be $0.03&#160;million and will be amortized over 15 years. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sancuso was acquired on January 3, 2022. For the year ended December 31, 2022, the amounts included in the income statement for revenue and operating profit were $13.6&#160;million and $6.6&#160;million, respectively.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a pro-forma basis, the revenue and earnings of the combined entity as though the business combination had occurred in 2021 appears below:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:57.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumberland 2022 Results</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pro-forma 2021 Results</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,010,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,085,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,704,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,447,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 pro-forma results include results for Sancuso as provided by the management of Kyowa Kirin. The Seller is a pharmaceutical company similar to Cumberland. The 2021 results for Sancuso as reported by Kyowa Kirin reflect accounting methodology and reporting which were similar to those employed by the Company.   </span></div>The Company&#8217;s 2022 balance sheet reflects the full year impact of the Sancuso acquisition, as the acquisition occurred on January 3, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473238016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Revenues</a></td>
<td class="text">Revenues<div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-top:7pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-top:7pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:65.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,205,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,993,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,205,603&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,704,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,827,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,657)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,681,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,045,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#8217;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.  The contractual payments associated with the partner&#8217;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The international agreements provide for $1.5 million in non-refundable up-front payments, milestone payments of up to $2.4 million related to regulatory approvals and up to $5.6 million in payments related to product sales.  From 2012 through December&#160;31, 2022, the Company has recognized a cumulative $1.9 million in upfront payments as other revenue and has recognized $0.5&#160;million during the year 2022.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues during 2022 and 2021 also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#8217;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.2 million and $0.4 million for the years ending December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473214304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.339%"><tr><td style="width:1.0%"/><td style="width:60.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,899,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,374,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,390,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,478,449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,527,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,048,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,429,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.5 million and $1.4&#160;million, respectively.  </span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers.  As the API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory total at December&#160;31, 2022 and 2021. Consigned inventory represents Authorized Generic inventory stored with Padagis until shipment.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million  that were classified as non-current inventories.  The Vibativ non-current API inventory was $7.1 million at December&#160;31, 2022 and $8.1 million at December&#160;31, 2021.  The Company had no Vibativ finished goods included in the non-current inventories at December&#160;31, 2022, and $0.5 million at December&#160;31, 2021.  At  December&#160;31, 2022 and 2021, Cumberland had $0.3 million in non-current inventory for API related to its ifetroban clinical initiatives and $0.1 million of finished goods</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473243872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"/><td style="width:34.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,712&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;&#8211;&#160;15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422,439&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,234,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,085,185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,792,153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations.  Depreciation expense was as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:65.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.269%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,066&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475185520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and Goodwill<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31, 2022 and 2021. </span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.217%"><tr><td style="width:1.0%"/><td style="width:59.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,668,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,543,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,891,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,015,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,776,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,528,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,610,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,478,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,051,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,333,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559,210&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,590,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,954,475&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product and license rights include assets associated with the Company's acquired products, including those discussed in Note 3, RediTrex, Vibativ and Sancuso.  RediTrex is only represented in 2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Company recorded an additional $0.2 million in each year in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property.  The Company also recorded an additional $14.1 million in product rights and $0.03 million in goodwill related to the Sancuso acquisition.  These costs will be amortized over the remaining expected useful life of the associated patents.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.756%"><tr><td style="width:1.0%"/><td style="width:65.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.296%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371,300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.769%"><tr><td style="width:1.0%"/><td style="width:72.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,736,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,687,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,652,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,092,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,590,678&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473087520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Current and Other Long-term Liabilities</a></td>
<td class="text">Other Current and Other Long-term Liabilities<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.378%"><tr><td style="width:1.0%"/><td style="width:59.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,347,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,006,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,587,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.897%"><tr><td style="width:1.0%"/><td style="width:59.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,931,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,433,962&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585,019&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,488,844&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473208128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the Company entered into a Fifth Amendment to the Revolving Credit Note and Sixth Amendment (the "Sixth Amendment") to Revolving Credit Loan Agreement with Pinnacle Bank (the "Pinnacle Agreement"). The Sixth Amendment increased the principal amount by $5 million to $20 million. On October 28, 2021, the Company entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement with Pinnacle Bank. Among other terms, the Fourth Amendment extended the maturity date to October 1, 2024.  The Pinnacle Agreement includes specific financial covenants including Debt Ratio and Tangible Capital Ratio.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company and Pinnacle Bank agreed to modify the financial covenants to align with the current use of the line of credit.  On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $8,500,000, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.  For the year ended December&#160;31, 2022, we were in compliance with the Funded Debt Ratio financial covenant. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company had $16.2 million and $15.0 million in borrowings outstanding under the Pinnacle Agreement at December&#160;31, 2022 and  2021, respectively.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90% (representing an interest rate of 6.875% at December&#160;31, 2022).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  In 2022, the LIBOR benchmark rate is expected to be discontinued. When the LIBOR rate is no longer available, the Pinnacle Agreement calls for a new Benchmark rate to be used to determine the interest rate for the Agreement.  It is expected that SOFR will become the replacement benchmark.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Borrowings under the line of credit are collateralized by substantially all of our assets. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Paycheck Protection Program Loan</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PPP is administered by the U.S. Small Business Administration ("SBA").  The loan was scheduled to  mature April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly. The loan could be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.  From the date of funding the Company has used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company has recorded the $2,187,140 as a deferred income liability, which is included as a component of other current liabilities on the consolidated balance sheet as of December&#160;31, 2021. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. </span></div>Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. In October 2020, the Company submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to SBA for the SBA's review and approval. On June 11, 2021, the Company received a notice from the SBA that the full amount of the loan was forgiven. The Company accounted for the forgiveness of the loan under IAS 20 and recorded the $2,187,140 as other income during the year ended December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473214304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)&#160;&#160;&#160;&#160;Initial Public Offering</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;10, 2009, the Company completed its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share, raising gross proceeds of $85.0 million. After deducting underwriting discounts of approximately $6.0 million and offering costs incurred of approximately $4.2 million, the net proceeds to the Company were approximately $74.8 million. </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)&#160;&#160;&#160;&#160;Preferred Stock</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue 20,000,000&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2022 and 2021, there was no preferred stock outstanding.</span></div><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)&#160;&#160;&#160;&#160;Common Stock</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022 and 2021, the Company issued 171,655 shares and 192,684  shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances.  There were no option exercise transactions during 2022 and  2021.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)&#160;&#160;&#160;&#160;Share Repurchases</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act, as amended. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. The Company repurchased 367,793 shares and 438,359 shares of common stock for approximately $1.0 million and $1.4 million during the years ended December&#160;31, 2022 and 2021, respectively. There remains $3.8 million available under the current repurchase program available for share repurchases at December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475288416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (loss) per Share</a></td>
<td class="text">Earnings (Loss) Per Share <div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:67.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,597,121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,602,799)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,570,241)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,507,587)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,563,592&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,904,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,563,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,904,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:66.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.235%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471330432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"/><td style="width:61.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,164,754&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,817,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481,455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303,664&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,708,719&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,824,175&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,150,935)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,253)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,557,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,761,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,557,784)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,761,922)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2022:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"/><td style="width:61.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024-2042</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,656,666&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,790,944&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,062,501&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,475,958&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) benefit includes the following components for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,891&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,678&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax (expense) benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2022 and 2021 reconciles with the federal statutory tax rate as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it is not more likely than not that its net deferred tax assets will be realized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, the net deferred tax assets are fully offset with a valuation allowance as of the periods ended December&#160;31, 2022 and  2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company has general business credit carryforwards of $1.5&#160;million.  These credit carryforwards will expire in years 2023 through 2042.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.596%"><tr><td style="width:1.0%"/><td style="width:78.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024-2042</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319,161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is no longer subject to U.S. federal tax examinations for tax years before 2019, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2019.  Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2019 remain subject to examination and adjustment.  During 2012, the 2009 federal tax return was examined by the Internal Revenue Service with no significant findings or adjustments.  The Company has no unrecognized tax benefits at December 31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475219920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text">Stock-Based Compensation Plans<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has grants outstanding under two equity compensation plans. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#8217; Incentive Plan (the "Directors&#8217; Plan"), which were approved by shareholders, superseded the 1999 Stock Option Plan.  Both plans are available for future grants of equity compensation awards to employees, consultants and directors.  The 2007 Plan and the Directors&#8217; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved 2.4 million shares of common stock for issuance under the 2007 Plan and 250,000 shares for issuance under the Directors&#8217; Plan.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of stock options is generally 100% of the fair market value of the underlying common stock on the grant date. The maximum contractual term of stock options is ten years from the date of grant, except for incentive stock options granted to 10% shareholders, which is five years.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant. Restricted stock issued to directors vests on the one year anniversary of the date of grant.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. Stock compensation expense consisted of the following for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - nonemployees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,964)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,867&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, there was approximately $0.8 million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of 1.81 years. This amount relates primarily to unrecognized compensation cost for employee restricted stock and stock options awards.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 178,950 and 186,900 incentive stock options during 2022 and 2021, respectively, which vest in four years.  There were no options exercised during 2022 and 2021.  As such, there was no intrinsic value of options or weighted-average fair value of options exercised for the periods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incentive Stock Options</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incentive stock options activity was as follows:</span></div><div style="margin-bottom:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.858%"><tr><td style="width:1.0%"/><td style="width:40.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.351%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of option shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average remaining contractual term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,300)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,900)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The weighted-average grant-date fair value of options granted during  the years 2022 and 2021 was $1.29 and $1.10, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is calculated using the Black-Scholes (&#8220;Black-Scholes-Merton&#8221;, or &#8220;BSM&#8221;) option-pricing model on the date of grant. Since 2012, the Company had been issuing RSA&#8217;s (Restricted Share Awards) where the grant date Fair Value (&#8220;FV&#8221;) equaled the closing share price.  The ISO&#8217;s required a BSM valuation to approximate FV.  The following inputs were used in the creation of the valuation.   </span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We estimate volatility in accordance with SAB No. 107, as amended by SAB No. 110. We have been publicly traded since August 2009, so we have sufficient years of trading history and volatility to appropriately evaluate this component of the BSM model.  As such, we are using our own historical volatility to value stock options.  We have noted no conditions that would indicate the historical volatility would not be an indicator of future volatility, as such we are using historical volatility over the same period as the expected term of the awards (7 years) back to 2015 and believe it to be sufficient. Calculated volatility for the grants issued in 2022 ranges from 44% to 45%.  Our average volatility over the life of stock being public is 42% and 45% over the last 6 months.  Based on the similar amounts, we believe our volatility estimate for the ISO&#8217;s are appropriate.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We estimate the expected life of employee share options based on the simplified method allowed by SAB No. 107, as amended by SAB No. 110. Under this approach, the expected term is presumed to be the average between the weighted-average vesting period and the contractual term.  The ISO&#8217;s have a 10-year contractual term and the vesting period is 4 years.  This results in a calculated expected term of 7 years.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Risk Free rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The risk-free interest rate is based on the U.S. Treasury Note, on the date of grant with a term equal to the corresponding option&#8217;s expected term. So, in this case, we are using the 7 year treasury note as of the date of grant, which ranges from 2.22% and 3.92% at the date of the grants.</span></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We have never declared or paid any cash dividends and there is currently no expected cash dividend payments as of the date of this grant. As such, dividend yield is zero. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.192%"><tr><td style="width:1.0%"/><td style="width:50.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.733%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,400)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,751&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:16pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of restricted stock granted was based on the closing market price of the Company&#8217;s common stock on the date of grant.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest.  Once vested they are included in the basic weighted shares outstanding computation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473209712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of 21, having been employed by the Company for at least six months. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2022 and 2021, the Company contributed approximately $60,000 and 50,000, respectively, in each year to the Plan as an employer match of participant contributions.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheets, was $2.5 million and $3.4 million as of December&#160;31, 2022 and 2021, respectively.  The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $2.3 million and $3.2 million as of December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473224496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company leases approximately 16,903 rentable square feet of space at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise serves as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, with the commencement date of October 25, 2022.  This lease currently expires in November 2035.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for paying rent to the Landlord under the Lease beginning three months after the Commencement Date. The Company pays a base rent of $33.06 per square foot of rentable space with a gradual rental rate increase of 2.5% for each year period thereafter of the prior year's base rental. In addition to the monthly base rent, the Company is responsible for its percentage share of the operating expenses of the Building. The Lease also provides for a tenant improvement allowance for the space.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  The research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:64.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#8217;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#8217;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019 and October 25, 2022. Incremental borrowing rates reflect the Company&#8217;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term for the Broadwest lease is 12.7 years and for the CET lease is 0.1 years. The weighted-average incremental borrowing rate used to discount the present value of the remaining CPI lease payments is 9.28% and remaining CET lease payments is 7.42%.</span></div><div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease Position</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company recorded the following on the Consolidated Balance Sheet:</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,586,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,759,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at December&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,482,220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,427,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,668,234)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,759,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473264288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Market Concentrations</a></td>
<td class="text">Market Concentrations<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#8217;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.538%"><tr><td style="width:1.0%"/><td style="width:49.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.819%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was 51.77% and 51.1% at December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475224704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Manufacturing and Supply Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingAndSupplyAgreementsAbstract', window );"><strong>Manufacturing and Supply Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingAndSupplyAgreementsTextBlock', window );">Manufacturing and Supply Agreements</a></td>
<td class="text">Manufacturing and Supply AgreementsThe Company utilizes one or two primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms.  A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAndSupplyAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and Supply Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAndSupplyAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAndSupplyAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing and Supply Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAndSupplyAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475185520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_EmploymentAgreementsAbstract', window );"><strong>Employment Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_EmploymentAgreementsTextBlock', window );">Employment Agreements</a></td>
<td class="text">Employment AgreementsThe Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock and incentive stock option agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EmploymentAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EmploymentAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_EmploymentAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employment Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_EmploymentAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473204896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2016, Cumberland entered into an agreement with Clinigen Group Plc ("Clinigen") for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  Ethyol and Totect are collectively referred to herein as the "Products."</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, Cumberland felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#8220;the Products&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date.  Cumberland recorded the last four quarterly installments totaling $2.0 million during the year ended December 31, 2021.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exit from the Ethyol and Totect products meets the accounting criteria to be reported as discontinued operations.  As a result, January 1, 2020, was the first day of discontinued operations for the Products.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Subsequent to the transaction date, th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475235280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product.  At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Sancuso, the Company is required to pay up to $3.5&#160;million in milestones and tiered royalties ranging from 10% to 5% on U.S. net product sales for ten years.    </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has a number of patents issued through the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) including U.S. Patent number 8,148,356 (the &#8220;356 Acetadote Patent&#8221;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2012, Cumberland has continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Melinta Litigation</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022, the Company filed an action for breach of contract against Melinta Therapeutics, LLC and Targanta Therapeutics Corporation (collectively, the &#8220;Defendants&#8221;) in the United States District Court for the Southern District of New York (Case No. 1:22-cv-00915-VM).  The Company and the Defendants are parties to an agreement (the &#8220;Agreement&#8221;), pursuant to which the Defendants have a license to develop and commercialize products under certain Company patents, in exchange for the Defendants paying the Company certain milestone payments and royalties on net sales of the licensed products.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the Agreement requires the Defendants to, among other things, make a $500,000 payment to the Company within 30 days following the first filing of an sNDA in relation to the Product (as defined the Agreement) and a $500,000 payment to the Company following the approval of the first sNDA in relation to the Product.  </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After Defendants disclosed the domiciles of its limited partners to the Company, as required by the Court, on October 24, 2022, the action for breach of contract was refiled in the Supreme Court of the State of New York, County of New York (Index No. 654234/2022) on November 7, 2022.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaint alleges that, despite the Defendants filing an NDA and sNDA for the Product and receiving FDA approval for both applications, the Defendants failed to make the required total of $1&#160;million in milestone payments to the Company.  The Company is seeking damages in the amount of no less than $1&#160;million, pre- and post-judgment interest under N.Y. C.P.L.R. &#167; 5001, costs, and such further relief as the court deems just and proper.</span></div>The Company is a party to various other legal proceedings in the ordinary course of its business. In the opinion of management, the liability associated with these matters, will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473149728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text">Quarterly Financial Information (Unaudited)<div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,299,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,413,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,123,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,010,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,291,999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,846,538)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,277,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,364,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(423,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,459,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,385,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,335,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(408,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,440,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,570,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,537,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,055,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,072,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,319,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,985,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(324,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,435,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,563,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,353,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,677,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(350,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,583,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,387,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,597,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,994,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,055,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,847,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,507,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI https://asc.fasb.org/topic&amp;trid=2126967<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL124452896-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471412672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment ReportingThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#8217;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 -   Quoted prices for identical instruments in active markets.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></div><div style="margin-top:8pt;padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 -    Significant inputs to the valuation model are unobservable.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.</span></div>The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2022 and 2021, cash equivalents consist primarily of money market funds.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, as well as amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $0.6 million at December&#160;31, 2022 and $0.3 million at December 31, 2021. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale at third party facilities located in the U.S. and international locations.  Periodic inventory counts are made by the warehouse teams and by the Company on a regular basis.  In addition, the Company re-tests API inventory prior to use to confirm product expiration.  Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.</span></div>The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.  The Company classifies the Vibativ inventories and ifetroban inventories that it does not expect to sell within one year as non-current inventories.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock', window );">Prepaid and Other Current Assets</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#8217;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ and Sancuso acquisitions. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.</span></div><div style="margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.</span></div>Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenue</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#8217;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Rebates and Discounts</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#8217;s best estimate at the time of sale based on each product&#8217;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#8217;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#8217;s estimate of the rebate that may be claimed.</span></div><div style="margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#8217;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenues</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Products Sold</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling and Marketing Expense</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Distribution Costs</span></div>Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsAdvertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#8217;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#8217;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#8220;more likely than not&#8221; that the position would be sustained upon examination by the taxing authorities.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings (Loss) per Share</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Agreements</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Agreements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3 do not meet the criteria for accounting under ASC Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The agreements do not specifically designate each party&#8217;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses </span></div>incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Totect</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 19, for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Guidance</a></td>
<td class="text"><div style="margin-top:7pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance </span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, &#8220;Financial Instruments-Credit Losses,&#8221; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#8220;expected loss&#8221; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#8217;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.</span></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#8217;s consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaids and Other Current Assets, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475245360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock', window );">Schedule of intangible assets, useful lives</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense is recognized ratably over the following periods:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"><tr><td style="width:1.0%"/><td style="width:46.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated economic life</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term of license agreement</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of patent</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleOfDistributionCostsTableTextBlock', window );">Schedule of Distribution Costs</a></td>
<td class="text">Distribution costs were as follows for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:65.836%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.110%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">857,842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806,311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleOfAdvertisingCostsTableTextBlock', window );">Schedule of Advertising Costs</a></td>
<td class="text">Advertising costs were as follows for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:65.836%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.110%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advertising costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,927,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,927,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleOfAdvertisingCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Advertising Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleOfAdvertisingCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleOfDistributionCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Distribution Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleOfDistributionCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520476313552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RediTrex&#174;, Vibativ&#174; and Sancuso&#174; (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text">The following table presents the changes in the Company's Level 3 contingent consideration liability.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.265%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contingent consideration liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,200,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,166,682)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,147,750)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,515,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payment of royalty during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133,113)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,104,690)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration earned and accrued</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">876,999&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:74.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.578%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at January 3, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,384,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash payment of royalty during the period</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1,075,631)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Change in fair value</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent consideration earned and accrued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">675,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Balance at December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a pro-forma basis, the revenue and earnings of the combined entity as though the business combination had occurred in 2021 appears below:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:57.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumberland 2022 Results</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pro-forma 2021 Results</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,010,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,085,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,704,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,447,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473264288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of net product revenues by product</a></td>
<td class="text"><div style="margin-top:7pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s net product revenues consisted of the following for the years ended December&#160;31:</span></div><div style="margin-top:7pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:65.243%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.433%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kristalose</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,205,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,993,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,205,603&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vibativ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,704,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Caldolor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,827,200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acetadote</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Omeclamox-Pak</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388,657)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vaprisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,859,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RediTrex</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,681,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,045,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475387184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories, current</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's net inventories consisted of the following as of December 31:</span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.339%"><tr><td style="width:1.0%"/><td style="width:60.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.248%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,899,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,374,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consigned inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods, net of reserve</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,390,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,478,449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">less non-current inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,527,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,048,567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories classified as current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,863,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,429,882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520555597248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"><tr><td style="width:1.0%"/><td style="width:34.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.125%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.892%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">useful lives</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746,602&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,712&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;&#8211;&#160;15 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;&#8211;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,422,439&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, gross</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,234,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and amortization</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,085,185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,792,153)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and </span></div><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equipment, net</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleofDepreciationExpenseTableTextBlock', window );">Schedule of depreciation expense</a></td>
<td class="text">Depreciation expense was as follows for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:65.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.269%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,745&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,066&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofDepreciationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Depreciation Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofDepreciationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520558048624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and Goodwill consisted of the following at December&#160;31, 2022 and 2021. </span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.217%"><tr><td style="width:1.0%"/><td style="width:59.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.915%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,668,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,543,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,891,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,015,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product and license rights</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,776,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,528,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,610,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,478,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,051,018)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,333,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total patents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,559,210&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,145,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397,974&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,096)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,590,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,954,475&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of expected amortization expense of intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.756%"><tr><td style="width:1.0%"/><td style="width:65.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.296%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,371,300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected amortization expense for the Company's current balance of intangible assets are as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.769%"><tr><td style="width:1.0%"/><td style="width:72.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,736,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,687,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,652,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,092,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,421,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,590,678&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520476028464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities consisted of the following at December&#160;31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.378%"><tr><td style="width:1.0%"/><td style="width:59.567%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.452%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.913%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.455%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates, product returns, administrative fees </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and service fees</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,347,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680,677&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee wages and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,440,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sancuso related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,006,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,685,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current deferred charges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued inventory purchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609,621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,587,911&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668,303&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of other long-term liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.897%"><tr><td style="width:1.0%"/><td style="width:59.907%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.732%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.559%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of accrued contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,931,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,830,096&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,522,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,433,962&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,585,019&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,488,844&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520476055680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of numerator and denominator in earnings per share</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"><tr><td style="width:1.0%"/><td style="width:67.148%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.945%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.633%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,597,121)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,602,799)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss at subsidiary attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,570,241)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,507,587)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,563,592&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,904,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,563,592&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,904,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:66.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.235%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares and options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,300&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520472476176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities, net</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company's net deferred tax assets at December&#160;31 are as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"/><td style="width:61.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss and tax credits</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,164,754&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,817,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment and intangibles</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481,455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for expired product</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,148&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,723&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303,664&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative compensation costs incurred on deductible equity awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,708,719&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,824,175&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,150,935)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,253)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets, before valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,557,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,761,922&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: deferred tax asset valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,557,784)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,761,922)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of federal and state net operating loss carryforwards</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2022:</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"><tr><td style="width:1.0%"/><td style="width:61.377%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.599%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">State</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024-2042</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,656,666&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,790,944&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state net operating loss carryforwards</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,062,501&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,475,958&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of the components of income tax benefit (expense)</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) benefit includes the following components for the years ended December 31:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,891&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current income tax (expense) benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,678&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax (expense) benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax (expense) benefit </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective tax rate reconciliation</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for 2022 and 2021 reconciles with the federal statutory tax rate as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal tax expense at statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax expense (net of federal income tax benefit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences associated with general business credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock', window );">Summary of tax credit carryforwards</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the Company has general business credit carryforwards of $1.5&#160;million.  These credit carryforwards will expire in years 2023 through 2042.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.596%"><tr><td style="width:1.0%"/><td style="width:78.046%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.949%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years of expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Federal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024-2042</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,319,161&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total federal and state credit carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520476049904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text">Stock compensation expense consisted of the following for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:64.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.770%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation - nonemployees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,964)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,455&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741,867&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of restricted stock activity</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incentive stock options activity was as follows:</span></div><div style="margin-bottom:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.858%"><tr><td style="width:1.0%"/><td style="width:40.597%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.907%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.351%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of option shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average remaining contractual term</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,900&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,300)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Option shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,900)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock activity was as follows:</span></div><div style="margin-top:8pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.192%"><tr><td style="width:1.0%"/><td style="width:50.498%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.733%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">grant-date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,850&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.21&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,400)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.39&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested, December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,751&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520472561088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock', window );">Schedule of rent expense and sublease income</a></td>
<td class="text">Rent expense and sublease income  as follows for the years ended December 31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"><tr><td style="width:1.0%"/><td style="width:64.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.800%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.567%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,159,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,209,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,411&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of balance sheet classification</a></td>
<td class="text"><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, the Company recorded the following on the Consolidated Balance Sheet:</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-Use Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,218,403&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.133%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease non-current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,586,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,016&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,759,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of operating lease liability maturities</a></td>
<td class="text">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity of Leases Liabilities at December&#160;31, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,061&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,482,220&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,427,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,668,234)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,759,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Rent Expense and Sublease Income [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475378400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of revenues concentration from major customers</a></td>
<td class="text">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.538%"><tr><td style="width:1.0%"/><td style="width:49.941%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.362%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.819%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer 3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520555901504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of quarterly financial information</a></td>
<td class="text"><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the unaudited operating results for each fiscal quarter of 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">First</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Second</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Third</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fourth</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quarter</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,175,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,299,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,413,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,123,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,010,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,291,999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,846,538)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288,588)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,277,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704,929)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,402,433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,364,666)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(423,226)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,459,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,650,039)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,385,253)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,335,620)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(408,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,440,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,570,241)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.17)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,537,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,055,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,072,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,319,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,985,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(324,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,435,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,563,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,353,996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,677,420)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(350,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,583,480)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,387,576)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,597,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) from discontinued operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">498,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">496,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,994,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,055,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,847,697)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,507,587)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings (loss) per share attributable to common shareholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.07)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471863040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary allocated to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,798<span></span>
</td>
<td class="nump">$ 95,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_SharebasedCompensationCharitableContributionofSharesShares', window );">Charitable contribution of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions', window );">Committed cash contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions', window );">Cash contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember', window );">Cumberland Emerging Technologies, Inc (CET)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember', window );">HongKong WinHealth Pharma Group Co. Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPurchaseOfShares', window );">Investment in CET</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ContributionOfCashAdditionalSharesPurchased', window );">Contribution of cash</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_IntercompanyLoansPayableConvertedAmount', window );">Conversion of intercompany loans payable</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember', window );">Gloria Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital', window );">Exchange for consideration, amount</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=cpix_CumberlandEmergingTechnologiesIncMember', window );">Cumberland Emerging Technologies, Inc (CET) | Harbin Gloria Pharmaceuticals Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest', window );">Exercise of options and related tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ContributionOfCashAdditionalSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contribution of Cash, Additional Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ContributionOfCashAdditionalSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_IntercompanyLoansPayableConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intercompany Loans Payable, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_IntercompanyLoansPayableConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Charitable Contribution of Shares, Cash Contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SharebasedCompensationCharitableContributionofSharesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Charitable Contribution of Shares, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SharebasedCompensationCharitableContributionofSharesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Payments For Return Of Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SubsidiaryInvestmentPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidiary Investment, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SubsidiaryInvestmentPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=cpix_CumberlandEmergingTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HongKongWinHealthPharmaGroupCoLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_GloriaPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cpix_CumberlandEmergingTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cpix_CumberlandEmergingTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_HarbinGloriaPharmaceuticalsCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_HarbinGloriaPharmaceuticalsCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520466076928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 27, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from customers outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,123,680<span></span>
</td>
<td class="nump">$ 11,413,072<span></span>
</td>
<td class="nump">$ 10,299,152<span></span>
</td>
<td class="nump">$ 11,175,045<span></span>
</td>
<td class="nump">$ 8,319,861<span></span>
</td>
<td class="nump">$ 8,072,540<span></span>
</td>
<td class="nump">$ 9,055,483<span></span>
</td>
<td class="nump">$ 10,537,159<span></span>
</td>
<td class="nump">$ 42,010,949<span></span>
</td>
<td class="nump">$ 35,985,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities', window );">Shelf Registration, sale of corporate securities (up to)</a></td>
<td class="nump">$ 19,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember', window );">Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowances, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenues from customers outside the United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember', window );">WinHealth Investment (Singapore) Ltd [Domain]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccountsReceivableAllowancesByComponentAxis=cpix_ChargebacksCashDiscountsAndDamagedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_WinHealthInvestmentSingaporeLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520469872016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductRightsMember', window );">Product Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual', window );">Intangible assets, useful life</a></td>
<td class="text">Estimated economic life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Rights</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual', window );">Intangible assets, useful life</a></td>
<td class="text">Term of license agreement<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual', window );">Intangible assets, useful life</a></td>
<td class="text">Life of patent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Useful Lives, (Textual)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520476055680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Schedule of Distribution Costs) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductionAndDistributionCosts', window );">Distribution costs</a></td>
<td class="nump">$ 857,842<span></span>
</td>
<td class="nump">$ 806,311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductionAndDistributionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to the production and distribution of goods or services to customers and clients.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductionAndDistributionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520472298592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Schedule of Advertising Costs) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 2,927,041<span></span>
</td>
<td class="nump">$ 1,927,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520466644016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RediTrex&#174;, Vibativ&#174; and Sancuso&#174; - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 12, 2022</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,931,513<span></span>
</td>
<td class="nump">3,830,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">914,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum', window );">Milestone payments, maximum</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected', window );">Expected sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining', window );">Sales milestone payments, remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold', window );">Sales milestone payments, annual net revenue threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent', window );">Tiered royalty, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember', window );">Nordic Group B.V. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue', window );">Milestone payment credit due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember', window );">Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liabilities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued during period, acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Finite-ived intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability to be paid</a></td>
<td class="nump">$ 3,384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other assets</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">30,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, other than goodwill</a></td>
<td class="nump">14,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPaymentsToAcquireBusinesses', window );">Additional payments to acquire businesses</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill amount to be deducted for tax purposes</a></td>
<td class="nump">$ 30,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Operating profit of acquiree</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Liability to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,154,823<span></span>
</td>
<td class="nump">$ 6,515,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsPercentage', window );">Tiered royalty payments (percentage)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_TieredRoyaltyPaymentsThreshold', window );">Tiered royalty payments, threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion of accrued contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Nordic Group B.V. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable', window );">Restricted shares receivable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Methotrexate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock issued during period, acquisitions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Annual Net Revenue Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TieredRoyaltyPaymentsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tiered Royalty Payments, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TieredRoyaltyPaymentsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPaymentsToAcquireBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPaymentsToAcquireBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_KyowaKirinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_NordicGroupBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_NordicGroupBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_MethotrexateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470222336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RediTrex&#174;, Vibativ&#174; and Sancuso&#174; - Schedule of Contingent Consideration and Preliminary Allocation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,515,627<span></span>
</td>
<td class="nump">$ 8,200,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,133,113)<span></span>
</td>
<td class="num">(2,166,682)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,104,690)<span></span>
</td>
<td class="num">(1,147,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">876,999<span></span>
</td>
<td class="nump">1,629,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 4,154,823<span></span>
</td>
<td class="nump">4,154,823<span></span>
</td>
<td class="nump">$ 6,515,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Cash payment of royalty during the period</a></td>
<td class="num">(1,075,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value</a></td>
<td class="nump">16,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses', window );">Contingent consideration earned and accrued</a></td>
<td class="nump">675,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520472561296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RediTrex&#174;, Vibativ&#174; and Sancuso&#174; - Pro Forma Results (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net Revenue</a></td>
<td class="nump">$ 42,010,949<span></span>
</td>
<td class="nump">$ 50,085,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">$ (5,704,929)<span></span>
</td>
<td class="num">$ (5,447,420)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470367456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Schedule of Net Product Revenues by Product) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 40,681,182<span></span>
</td>
<td class="nump">$ 35,045,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_OmeclamoxPakMember', window );">Omeclamox-Pak</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">29,145<span></span>
</td>
<td class="num">(388,657)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_KristaloseMember', window );">Kristalose</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">15,205,155<span></span>
</td>
<td class="nump">15,993,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">13,205,603<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_CaldolorMember', window );">Vibativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,827,200<span></span>
</td>
<td class="nump">4,970,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_ProductVibativMember', window );">Caldolor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,487,462<span></span>
</td>
<td class="nump">11,704,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember', window );">Acetadote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">501,040<span></span>
</td>
<td class="nump">850,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_VaprisolMember', window );">Vaprisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(447,697)<span></span>
</td>
<td class="nump">1,859,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cpix_RediTrexMember', window );">RediTrex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">$ (126,726)<span></span>
</td>
<td class="nump">$ 55,321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_OmeclamoxPakMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_OmeclamoxPakMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_KristaloseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_KristaloseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_CaldolorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_CaldolorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_ProductVibativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_ProductVibativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_AcetadoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_AcetadoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_VaprisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_VaprisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cpix_RediTrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cpix_RediTrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471851872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductRevenuesAbstract', window );"><strong>Product Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 40,681,182<span></span>
</td>
<td class="nump">$ 35,045,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_OtherRevenuesAbstract', window );"><strong>Other Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_RevenueRecognitionUpfrontPayment', window );">Other revenue, upfront payment</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval', window );">Other revenue, potential upfront payments related to regulatory approval</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales', window );">Other revenue, potential upfront payment related to product sales</a></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_RevenueRecognitionCumulativeUpfrontPayment', window );">Cumulative upfront payment</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_RevenueRecognitionMilestonePayments', window );">Milestone payments associated with international agreements</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember', window );">Collaborative Arrangement, Federal Small Business Grant Programs | Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductRevenuesAbstract', window );"><strong>Product Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_OtherRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Revenues [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_OtherRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Revenues [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionCumulativeUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Cumulative Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionCumulativeUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Potential Upfront Payment Related to Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_RevenueRecognitionUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_RevenueRecognitionUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520469875536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Schedule of Inventories) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials and work in process</a></td>
<td class="nump">$ 12,899,659<span></span>
</td>
<td class="nump">$ 12,374,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment', window );">Consigned inventory</a></td>
<td class="nump">168,923<span></span>
</td>
<td class="nump">164,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">4,322,167<span></span>
</td>
<td class="nump">4,939,088<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total inventories</a></td>
<td class="nump">17,390,748<span></span>
</td>
<td class="nump">17,478,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">less non-current inventories</a></td>
<td class="num">(7,527,167)<span></span>
</td>
<td class="num">(9,048,567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 9,863,581<span></span>
</td>
<td class="nump">$ 8,429,882<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470221616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserves, obsolescence and discontinuance</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories</a></td>
<td class="nump">7,527,167<span></span>
</td>
<td class="nump">9,048,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">4,322,167<span></span>
</td>
<td class="nump">4,939,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember', window );">Ifetroban Clinical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories</a></td>
<td class="nump">7,100,000<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods, net of reserve</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember', window );">VIBATIV | Work in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories</a></td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_IfetrobanClinicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_VIBATIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=cpix_WorkInProcessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=cpix_WorkInProcessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520466967712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Schedule of Property and Equipment) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,369,224<span></span>
</td>
<td class="nump">$ 4,234,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,085,185)<span></span>
</td>
<td class="num">(3,792,153)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">284,039<span></span>
</td>
<td class="nump">442,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 465,508<span></span>
</td>
<td class="nump">1,352,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 746,602<span></span>
</td>
<td class="nump">820,712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 369,365<span></span>
</td>
<td class="nump">638,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 787,749<span></span>
</td>
<td class="nump">$ 1,422,439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520555607808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Depreciation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements', window );">Depreciation, including amortization related to leasehold improvements</a></td>
<td class="nump">$ 260,745<span></span>
</td>
<td class="nump">$ 235,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Including Amortization Related to Leasehold Improvements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520466601840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Schedule of Intangible Assets) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 30,590,678<span></span>
</td>
<td class="nump">$ 23,954,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">914,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember', window );">Product and License Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">49,668,141<span></span>
</td>
<td class="nump">38,543,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(21,891,974)<span></span>
</td>
<td class="num">(18,015,112)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">27,776,167<span></span>
</td>
<td class="nump">20,528,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">10,610,228<span></span>
</td>
<td class="nump">10,478,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(8,051,018)<span></span>
</td>
<td class="num">(7,333,251)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">2,559,210<span></span>
</td>
<td class="nump">3,145,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">397,974<span></span>
</td>
<td class="nump">373,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(142,673)<span></span>
</td>
<td class="num">(93,096)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 255,301<span></span>
</td>
<td class="nump">$ 280,366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cpix_ProductAndLicenseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470335168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="nump">$ 1,971,662<span></span>
</td>
<td class="nump">$ 250,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">914,000<span></span>
</td>
<td class="nump">882,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember', window );">Sancuso</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets, other than goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cpix_SancusoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470636640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Future Amortization Expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 4,736,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">4,687,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">4,652,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">4,092,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter', window );">2027 and thereafter</a></td>
<td class="nump">12,421,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 30,590,678<span></span>
</td>
<td class="nump">$ 23,954,475<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Amortization Expense, Year Five and After</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470178800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrentAbstract', window );"><strong>Other Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ProductSalesRelatedLiabilitiesCurrent', window );">Rebates, product returns, administrative fees and service fees</a></td>
<td class="nump">$ 8,347,214<span></span>
</td>
<td class="nump">$ 3,680,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee wages and benefits</a></td>
<td class="nump">1,440,859<span></span>
</td>
<td class="nump">1,340,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AccruedLiabilitiesStockPayable', window );">Sancuso related liabilities</a></td>
<td class="nump">2,226,725<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent', window );">Current portion of accrued contingent consideration</a></td>
<td class="nump">3,006,310<span></span>
</td>
<td class="nump">2,685,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current deferred charges</a></td>
<td class="nump">614,551<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_AccruedLiabilitiesInventoryPurchases', window );">Accrued inventory purchases</a></td>
<td class="nump">609,621<span></span>
</td>
<td class="nump">18,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,342,631<span></span>
</td>
<td class="nump">943,038<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 17,587,911<span></span>
</td>
<td class="nump">$ 8,668,303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccruedLiabilitiesInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Inventory Purchases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccruedLiabilitiesInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_AccruedLiabilitiesStockPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Stock Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_AccruedLiabilitiesStockPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Accrued, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ProductSalesRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Sales-Related Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ProductSalesRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520469857344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion of accrued contingent consideration</a></td>
<td class="nump">$ 4,931,513<span></span>
</td>
<td class="nump">$ 3,830,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation</a></td>
<td class="nump">2,522,506<span></span>
</td>
<td class="nump">3,433,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">131,000<span></span>
</td>
<td class="nump">224,786<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 7,585,019<span></span>
</td>
<td class="nump">$ 7,488,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520466000656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Line of Credit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 20, 2020</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_InterestRateFloorMember', window );">Interest Rate Floor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember', window );">Pinnacle Bank | Payment Protection Program | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived', window );">Aggregate amount</a></td>
<td class="nump">$ 2,187,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,187,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Ninth Amemdment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold', window );">Unrestricted cash threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Fifth Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity', window );">Maximum increase to line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of credit, current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Revolving line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit, unused capacity, commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Line of Credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Pinnacle Bank | Line of Credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DebtInstrumentCovenantUnrestrictedCashThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Unrestricted Cash Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DebtInstrumentCovenantUnrestrictedCashThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LineOfCreditFacilityAdditionalBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Additional Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LineOfCreditFacilityAdditionalBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_InterestRateFloorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_InterestRateFloorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cpix_PinnacleBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_PaymentProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_PaymentProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_NinthAmemdmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_NinthAmemdmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_FifthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_FifthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cpix_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471763296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2009</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_PreferredStockAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_InitialPublicOfferingAbstract', window );"><strong>Initial Public Offering [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockTransactionDate', window );">Initial public offering, effective date</a></td>
<td class="text">Aug. 10,  2009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering, shares issued</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodPricePerShareNewIssues', window );">Initial public offering, price per share</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering', window );">Initial public offering, gross proceeds</a></td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts', window );">Initial public offering, underwriting discounts</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Initial public offering, issuance costs</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Initial public offering, net proceeds</a></td>
<td class="nump">$ 74.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CommonStockAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,655<span></span>
</td>
<td class="nump">192,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_InitialPublicOfferingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial Public Offering [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_InitialPublicOfferingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_PreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_PreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Gross Proceeds from Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Shares, Underwriting Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_StockIssuedDuringPeriodPricePerShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Price Per Share, New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_StockIssuedDuringPeriodPricePerShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520465977552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares, value</a></td>
<td class="nump">$ 1,025,836<span></span>
</td>
<td class="nump">$ 1,410,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount available under current repurchase program</a></td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_SharesRepurchaseActivityTypeAxis=cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember', window );">Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common shares, shares</a></td>
<td class="nump">367,793<span></span>
</td>
<td class="nump">438,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common shares, value</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=cpix_ShareRepurchaseProgramAuthorizedIn2010Member', window );">Share Repurchase Program Authorized in 2010</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, number of shares authorized to be repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_SharesRepurchaseActivityTypeAxis=cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_SharesRepurchaseActivityTypeAxis=cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=cpix_ShareRepurchaseProgramAuthorizedIn2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=cpix_ShareRepurchaseProgramAuthorizedIn2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520472506432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (2,459,714)<span></span>
</td>
<td class="num">$ (423,226)<span></span>
</td>
<td class="num">$ (1,364,666)<span></span>
</td>
<td class="num">$ (1,402,433)<span></span>
</td>
<td class="num">$ (4,387,576)<span></span>
</td>
<td class="num">$ (1,583,480)<span></span>
</td>
<td class="nump">$ 724,684<span></span>
</td>
<td class="num">$ (350,749)<span></span>
</td>
<td class="num">$ (5,650,039)<span></span>
</td>
<td class="num">$ (5,597,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503,318<span></span>
</td>
<td class="nump">496,787<span></span>
</td>
<td class="nump">498,807<span></span>
</td>
<td class="nump">495,410<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,994,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,650,039)<span></span>
</td>
<td class="num">(3,602,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss at subsidiary allocated to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,798<span></span>
</td>
<td class="nump">95,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (2,440,729)<span></span>
</td>
<td class="num">$ (408,639)<span></span>
</td>
<td class="num">$ (1,335,620)<span></span>
</td>
<td class="num">$ (1,385,253)<span></span>
</td>
<td class="num">$ (3,847,697)<span></span>
</td>
<td class="num">$ (1,055,278)<span></span>
</td>
<td class="nump">$ 1,228,560<span></span>
</td>
<td class="nump">$ 166,828<span></span>
</td>
<td class="num">$ (5,570,241)<span></span>
</td>
<td class="num">$ (3,507,587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,563,592<span></span>
</td>
<td class="nump">14,904,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,563,592<span></span>
</td>
<td class="nump">14,904,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473214304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares (in shares)</a></td>
<td class="nump">227,050<span></span>
</td>
<td class="nump">183,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520465944992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards', window );">Net operating loss and tax credits</a></td>
<td class="nump">$ 16,164,754<span></span>
</td>
<td class="nump">$ 16,817,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles', window );">Property and equipment and intangibles</a></td>
<td class="nump">264,653<span></span>
</td>
<td class="nump">222,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxAssetOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,121,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">866,942<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research cost</a></td>
<td class="nump">1,481,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for accounts receivable</a></td>
<td class="nump">145,803<span></span>
</td>
<td class="nump">83,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct', window );">Reserve for expired product</a></td>
<td class="nump">654,148<span></span>
</td>
<td class="nump">457,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">217,025<span></span>
</td>
<td class="nump">104,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxAssetsDeferredCharges', window );">Deferred charges</a></td>
<td class="nump">1,156,150<span></span>
</td>
<td class="nump">1,303,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Cumulative compensation costs incurred on deductible equity awards</a></td>
<td class="nump">635,989<span></span>
</td>
<td class="nump">834,070<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">22,708,719<span></span>
</td>
<td class="nump">19,824,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="num">(1,150,935)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(62,253)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_NetDeferredTaxAssetsGross', window );">Net deferred tax assets, before valuation allowance</a></td>
<td class="nump">21,557,784<span></span>
</td>
<td class="nump">19,761,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: deferred tax asset valuation allowance</a></td>
<td class="num">(21,557,784)<span></span>
</td>
<td class="num">(19,761,922)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Deferred Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Property and Equipment and Intangibles</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability, Operating Lease Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_NetDeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Deferred Tax Assets, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_NetDeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471486208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 53,062,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,475,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2023 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2023 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2024-2042 | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">46,656,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2024-2042 | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,790,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember', window );">Indefinite Period | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 6,405,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember', window );">Indefinite Period | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 433,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_IndefiniteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520469991248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and other</a></td>
<td class="nump">68,850<span></span>
</td>
<td class="nump">34,891<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax (expense) benefit</a></td>
<td class="nump">68,850<span></span>
</td>
<td class="nump">34,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(61,678)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Deferred income tax (expense) benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax (expense) benefit</a></td>
<td class="num">$ (68,850)<span></span>
</td>
<td class="num">$ (34,891)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520476128224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax expense (net of federal income tax benefit)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Permanent differences associated with general business credits</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(22.00%)<span></span>
</td>
<td class="num">(19.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other permanent differences</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Net income tax expense</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471314016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule of tax credit carryforwards) (Details) - Federal And State<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 1,519,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">200,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember', window );">2024-2042</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 1,319,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cpix_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cpix_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ExpirationTimePeriodAxis=cpix_ExpirationTermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520466438544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants', window );">Number of equity compensation plans available for future grants | plan</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent', window );">Shareholder, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to share-based payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost related to share-based payments, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, shares (in shares)</a></td>
<td class="nump">178,950<span></span>
</td>
<td class="nump">186,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember', window );">NonPrincipal Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue', window );">Stock options, exercise price as percent of weighted-average grant date fair value</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member', window );">Long-Term Incentive Compensation Plan 2007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance under equity compensation plans</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member', window );">Directors&#8217; Incentive Plan 2007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance under equity compensation plans</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Dividend yield | $</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average volatility rate</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted average volatility rate</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">3.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Principal Owner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | NonPrincipal Owner | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shareholder, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_NonprincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cpix_LongTermIncentiveCompensationPlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cpix_DirectorsIncentivePlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_PrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_PrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470356672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 447,503<span></span>
</td>
<td class="nump">$ 741,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">449,467<span></span>
</td>
<td class="nump">730,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_NonemployeeMember', window );">Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(1,964)<span></span>
</td>
<td class="nump">11,455<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cpix_EmployeeNonemployeeandFoundationContributionMember', window );">Employee, Nonemployee and Foundation Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 447,503<span></span>
</td>
<td class="nump">$ 741,867<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_NonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_NonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cpix_EmployeeNonemployeeandFoundationContributionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cpix_EmployeeNonemployeeandFoundationContributionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470571936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Schedule of Restricted Incentive Stock Activity) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, shares (in shares)</a></td>
<td class="nump">178,950<span></span>
</td>
<td class="nump">186,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="nump">$ 1.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cpix_RestrictedIncentiveStockOptionsMember', window );">Restricted Incentive Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">170,600<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, shares (in shares)</a></td>
<td class="nump">178,950<span></span>
</td>
<td class="nump">186,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options shares vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options shares forfeited (in shares)</a></td>
<td class="num">(29,900)<span></span>
</td>
<td class="num">(16,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">319,650<span></span>
</td>
<td class="nump">170,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">2.68<span></span>
</td>
<td class="nump">3.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Options shares vested (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options shares forfeited (in USD per share)</a></td>
<td class="nump">2.98<span></span>
</td>
<td class="nump">3.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period, weighted-average exercise price per share (in USD per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, end of period, weighted-average remaining contractual term</a></td>
<td class="text">6 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cpix_RestrictedIncentiveStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cpix_RestrictedIncentiveStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470574816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details) - Restricted Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="nump">568,181<span></span>
</td>
<td class="nump">779,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted, shares</a></td>
<td class="nump">65,225<span></span>
</td>
<td class="nump">36,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested, shares</a></td>
<td class="num">(171,655)<span></span>
</td>
<td class="num">(192,684)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares forfeited, shares</a></td>
<td class="num">(66,000)<span></span>
</td>
<td class="num">(55,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="nump">395,751<span></span>
</td>
<td class="nump">568,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- average grant-date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning of period, weighted-average grant-date fair value</a></td>
<td class="nump">$ 5.17<span></span>
</td>
<td class="nump">$ 5.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Shares granted, weighted-average grant-date fair value</a></td>
<td class="nump">2.59<span></span>
</td>
<td class="nump">3.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Shares vested, weighted-average grant-date fair value</a></td>
<td class="nump">6.42<span></span>
</td>
<td class="nump">6.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Shares forfeited, weighted-average grant-date fair value</a></td>
<td class="nump">4.67<span></span>
</td>
<td class="nump">5.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, end of period, weighted-average grant-date fair value</a></td>
<td class="nump">$ 4.29<span></span>
</td>
<td class="nump">$ 5.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520466417968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge', window );">Defined contribution plan, eligibiilty, minimum employee age</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility', window );">Defined contribution plan, eligibility, minimum employee service time for participation eligibility</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent', window );">Deferred compensation liability</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation assets</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Eligibility, Minimum Employee Age</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520469908128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 15, 2021 </div>
<div>ft&#178; </div>
<div>renewalTerm </div>
<div>$ / ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseRentIncrease', window );">Rent increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Future minimum sublease income under noncancelable operating subleases | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_A1600WestEndAvenuePartnersLLCMember', window );">1600 West End Avenue Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">12 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">9.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_CETMember', window );">CET</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="nump">7.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Office Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseLeasedArea', window );">Leased area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">157 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseBaseRent', window );">Lessee, Operating Lease, Base Rent | $ / ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property</a></td>
<td class="nump">14,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember', window );">Office Building | Broadwest Lease, Five Year Renewal Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LesseeOperatingLeaseNumberOfRenewalTerms', window );">Number of renewal terms | renewalTerm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Base Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseLeasedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Leased Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseLeasedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LesseeOperatingLeaseRentIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Rent Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LesseeOperatingLeaseRentIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_A1600WestEndAvenuePartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_A1600WestEndAvenuePartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_CETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_CETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=srt_OfficeBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cpix_BroadwestLeaseFiveYearRenewalOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520469856304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Schedule of Rent Expense and Sublease Income) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 1,159,695<span></span>
</td>
<td class="nump">$ 1,209,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 529,411<span></span>
</td>
<td class="nump">$ 699,889<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471465392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Lease Position) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 5,218,403<span></span>
</td>
<td class="nump">$ 1,024,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease current liabilities</a></td>
<td class="nump">172,910<span></span>
</td>
<td class="nump">969,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease non-current liabilities</a></td>
<td class="nump">4,586,301<span></span>
</td>
<td class="nump">90,016<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_LeaseLiability', window );">Total</a></td>
<td class="nump">$ 4,759,211<span></span>
</td>
<td class="nump">$ 1,059,693<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520475843264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities, Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 607,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">575,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">539,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">604,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">619,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2027</a></td>
<td class="nump">5,482,220<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">8,427,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="num">(3,668,234)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 4,759,211<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470633888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Sales Revenue, Goods, Gross | Customer 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | Customer 1, 2, and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">51.77%<span></span>
</td>
<td class="nump">51.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=cpix_SalesRevenueGoodsGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=cpix_SalesRevenueGoodsGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cpix_Customer12And3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cpix_Customer12And3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520469883840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>supplier</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingandSupplyAgreementLineItems', window );"><strong>Manufacturing and Supply Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct', window );">Manufacturing agreements, number of primary suppliers for each product</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingandSupplyAgreementLineItems', window );"><strong>Manufacturing and Supply Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct', window );">Manufacturing agreements, number of primary suppliers for each product</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing agreements, number of primary suppliers for each product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_ManufacturingandSupplyAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Manufacturing and Supply Agreement [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_ManufacturingandSupplyAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520473224064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset', window );">Financial consideration | $</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_FinancialConsiderationPaymentPeriod', window );">Financial consideration, payment period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_FinancialConsiderationNumberOfInstallments', window );">Number of quarterly installments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FinancialConsiderationNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Consideration, Number of Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FinancialConsiderationNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_FinancialConsiderationPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Consideration, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_FinancialConsiderationPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of beneficial interest received as consideration for transferring noncash financial asset. Includes, but is not limited to, trade receivable in securitization transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520471862384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 07, 2022</div></th>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum', window );">Milestone payments, maximum</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsTerm', window );">Collaborative arrangement, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent', window );">Tiered royalty, percent</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember', window );">Kyowa Kirin | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent', window );">Tiered royalty, percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember', window );">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable', window );">Sales milestone payments, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Gain contingency, unrecorded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember', window );">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation | Within 30 Days Of First sNDA Filing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable', window );">Sales milestone payments, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember', window );">Melinta Therapeutics, LLC and Targanta Therapeutics Corporation | Following Approval Of First sNDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable', window );">Sales milestone payments, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cpix_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_KyowaKirinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_KyowaKirinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis=cpix_Within30DaysOfFirstSNDAFilingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementMilestonePaymentThresholdAxis=cpix_Within30DaysOfFirstSNDAFilingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cpix_CollaborativeArrangementMilestonePaymentThresholdAxis=cpix_FollowingApprovalOfFirstSNDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cpix_CollaborativeArrangementMilestonePaymentThresholdAxis=cpix_FollowingApprovalOfFirstSNDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520470112672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 9,123,680<span></span>
</td>
<td class="nump">$ 11,413,072<span></span>
</td>
<td class="nump">$ 10,299,152<span></span>
</td>
<td class="nump">$ 11,175,045<span></span>
</td>
<td class="nump">$ 8,319,861<span></span>
</td>
<td class="nump">$ 8,072,540<span></span>
</td>
<td class="nump">$ 9,055,483<span></span>
</td>
<td class="nump">$ 10,537,159<span></span>
</td>
<td class="nump">$ 42,010,949<span></span>
</td>
<td class="nump">$ 35,985,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="num">(2,277,804)<span></span>
</td>
<td class="num">(288,588)<span></span>
</td>
<td class="num">(1,846,538)<span></span>
</td>
<td class="num">(1,291,999)<span></span>
</td>
<td class="num">(4,353,996)<span></span>
</td>
<td class="num">(1,563,395)<span></span>
</td>
<td class="num">(1,435,729)<span></span>
</td>
<td class="num">(324,300)<span></span>
</td>
<td class="num">(5,704,929)<span></span>
</td>
<td class="num">(7,677,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(2,459,714)<span></span>
</td>
<td class="num">(423,226)<span></span>
</td>
<td class="num">(1,364,666)<span></span>
</td>
<td class="num">(1,402,433)<span></span>
</td>
<td class="num">(4,387,576)<span></span>
</td>
<td class="num">(1,583,480)<span></span>
</td>
<td class="nump">724,684<span></span>
</td>
<td class="num">(350,749)<span></span>
</td>
<td class="num">(5,650,039)<span></span>
</td>
<td class="num">(5,597,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to common shareholders</a></td>
<td class="num">$ (2,440,729)<span></span>
</td>
<td class="num">$ (408,639)<span></span>
</td>
<td class="num">$ (1,335,620)<span></span>
</td>
<td class="num">$ (1,385,253)<span></span>
</td>
<td class="num">$ (3,847,697)<span></span>
</td>
<td class="num">$ (1,055,278)<span></span>
</td>
<td class="nump">$ 1,228,560<span></span>
</td>
<td class="nump">$ 166,828<span></span>
</td>
<td class="num">$ (5,570,241)<span></span>
</td>
<td class="num">$ (3,507,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">-Continuing operations-basic</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">-Discontinued operations-basic</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in USD per share)</a></td>
<td class="num">(0.17)<span></span>
</td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.26)<span></span>
</td>
<td class="num">(0.07)<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="num">(0.38)<span></span>
</td>
<td class="num">(0.24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">-Continuing operations-diluted</a></td>
<td class="num">(0.17)<span></span>
</td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.29)<span></span>
</td>
<td class="num">(0.10)<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="num">(0.02)<span></span>
</td>
<td class="num">(0.38)<span></span>
</td>
<td class="num">(0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">-Discontinued operations-diluted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in USD per share)</a></td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="nump">$ 0.08<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140520466537200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Valuation and Qualifying Accounts (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 340,964<span></span>
</td>
<td class="nump">$ 984,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">6,673,104<span></span>
</td>
<td class="nump">2,963,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(6,417,977)<span></span>
</td>
<td class="num">(3,606,992)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">596,091<span></span>
</td>
<td class="nump">340,964<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Valuation allowance for deferred tax assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">19,761,922<span></span>
</td>
<td class="nump">19,196,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">1,795,862<span></span>
</td>
<td class="nump">565,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 21,557,784<span></span>
</td>
<td class="nump">$ 19,761,922<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>cpix-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cpix="http://www.cumberlandpharma.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cpix-20221231.xsd" xlink:type="simple"/>
    <context id="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0cf98cdc48c644138ca1c6dedc85be6e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i40f46dea598c4f3cba52391f5ebaf18b_I20230307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="ie7de9e3a8f694f75963d43839bcbe61c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic0531c6598004c5d9158b8763683f643_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf6dac19d6f34192bbf220dba001eef3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i82deea75887548fe9dd05c788a9a95d9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i78d55d038f4f4a95b6d5aa9d8870f9f3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i492284a80be94550bc059ef2e65088e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManufacturedProductOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b1f58f544414d679bba8a83be98bb54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i963f0ace48ae4299a000f7fd5b7c18c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia40cff38220f4a42a215676712cd7975_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f553aa99c0e4216aa251a6245b1cab1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia770bc31d52a493aa78146feba302866_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4d8da0743ab4c0488940b1685dbba30_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34f8ac4bf33e4693be58ae3e7731aca1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id569c4eed8f24390a0083034cd6006fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie04970d0133c449fb025dee41a90d071_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffb757a4c3914eb9b95796ad9e20eacc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1705f3f062cc44839738fe486e114ad6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3cb948d137eb4bae9cb3425ba6c840db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibdae3b5e1dd2405b904488b32eb4db3b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d4b30bb244846a8ba4078cdae06919f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9062e0d132343aaa03943a47c77e779_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HarbinGloriaPharmaceuticalsCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifbd696f587e24eb997ec609f8ce82517_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="i7002a7773f304b60a1fb957d9bf22167_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:HongKongWinHealthPharmaGroupCoLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="id417cd67920147a1928abf32d83fb11f_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:GloriaPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i6ed29773e4754bd1a441c809e5231f15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">cpix:CumberlandEmergingTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c780a0c3e87440c8eb1928bb0ce5f86_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i920d5ee9a6184682bc7bf8c05423756f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i478ad941e6444190835fbd70e6a0fda2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia21564bd7ce142dcadc0c24df7ea1958_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie03b356b24224df284680048170d1d18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0ba80f17d75f466d9b1472a3319fada7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i516902d591354e20a3baac1f1747a355_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:AccountsReceivableAllowancesByComponentAxis">cpix:ChargebacksCashDiscountsAndDamagedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cfbfa92c9f74d5d8ecb902cacdb2307_D20180101-20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="if8074777558e4350be02e8d826a67f22_D20211227-20211227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-12-27</startDate>
            <endDate>2021-12-27</endDate>
        </period>
    </context>
    <context id="icc21cd41019b4937823097e3a64ff8a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3025fb68648c4df5b3dc39a998179c33_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c75d11680284d93969ed668e797eebc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3aa1891de07e463882de10e63f32527d_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:WinHealthInvestmentSingaporeLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i021bbc1b476b4fbe8c8498630b3444b9_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i9301d1c169904a1d9355a5854c6f29e3_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i49ea797c011744d19c463a47c6cbbd46_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b29c34edaba455b8ebdd48b45de02d6_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="id9d899e86c97433d9a3fa65fce7361e2_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="if7fa09f75a3b48cea5b2fb00b556fbe9_I20220712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:NordicGroupBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-12</instant>
        </period>
    </context>
    <context id="iec5e58bac724452b876b92a905e3ca14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:MethotrexateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i133c71a4398845698d7d7701abc49b01_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i8e22ba92c2194833a0319101083d1275_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f2090fcc89c46fc8c515cd09cc5ffae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib36b29930b41472aaa5de35a1e59cb95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i924046424f4a4ad5a7dce8e0bfe36d8b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb014f15e52c4aa7b4a00972e8c2037e_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="i44944cd121824f49afdb95c8a1b230c0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4e74c81ece854dfcb8d7c8c3bc0a2f03_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="i155bdf692bf44e60a73258a7452baa96_I20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-03</instant>
        </period>
    </context>
    <context id="if8f59b1cd25d434eb648fc77c3dea5b1_D20220103-20220103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="i81f3f0b045ff491da276024b81457433_D20220103-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if92534bff0f1467fbb22f084f101995f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i469400cc5d084372975262bfe96ab0fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4696b3ec55c74a54b9b5653d2452aca1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if32dce83e48c4a7b91a0d4e335b66480_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:KristaloseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98dc7a56a6ee4bc5ace7b118374a0de5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifaddae84fd5b4b89a3139c9ac38b23c6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:SancusoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f3d9b8292154fa0b504704f80f2e116_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf29047eb0424eef806c96c842debe22_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:ProductVibativMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e3b77ebc51845fd880355bb1563cc5f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i18b3e901750344aba9b2ac8dc3d8398e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:CaldolorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i37ab018ed1464e58a2e6f54a577ad077_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia8fd80adb04d4f22a287d4e54e9550dc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:AcetadoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaa10efc46e9e461386aa80220fb7a4ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibe04d4939aef4eb2ae85d6d4c47c642d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:OmeclamoxPakMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9859c4aed134140b347fcfab3e9f9f9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id6e9d7a75c774347844d3abe0e6a3d75_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:VaprisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i82ef6903bdd04aa7be5bf21326a39725_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iee6aca6f1f4640128e84638b21a73ac8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cpix:RediTrexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if6d9484ddbcb49fda1792dcd0ca0e89c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i16b9bb498b204e8a9f03c0c2fdc55984_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cpix:CollaborativeArrangementFederalSmallBusinessGrantProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if13d0a3b9ba3470186981ffcd4cd386c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cpix:VIBATIVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:WorkInProcessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf903ddd161947ba816eea446f55a857_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i90d887a51969486c9881a5eac45b76a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">cpix:IfetrobanClinicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0b7caf11e1a24164b014dcb9cc1efa95_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib30352d285114277aebd23aebdefc31a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iebc3383fa2574ae1802474eb1d124ef3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic80dac19a3234cf59481be62a47b00c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib15d3092260845f9b57d3c442a6f6c72_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8f1325d766c543488d6cdd933169b69f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i16957755b21643ba9ebe843a90bb7625_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7d4d8a23fe54b748a284173ad96a122_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7da33aa95f3a43abb0a94e5e28dc81d1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i66cf95bb11704c8fa28b1cc8873b54c6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i440984280e14489e94de83929fda92ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f49ad0b1cb54a7283fcda38b5eb92cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie029fb915f8742fabfa273ab1ade8a96_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec1323af37504488a64c07cf8beb4baf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a40ef618bc943579e158b9494ffce7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i57964ce83e4b45c18274c46575c33640_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69aeb359c79e41b78bca28b92da3cc0b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i463edf77a5cf4cd68d974b7c5d2166e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cpix:ProductAndLicenseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d06b1820bd54620a60f0c01d91fbf4d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3983a09554e4ca699dbcaf2db560e0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i574bc1e7d0d2481ea5ad466e8f534855_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic223906cd81348c4bac59dcace59f34e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb47557bdc1b4a7091a589c3dd4e833b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e9d77deb33f4194ba7a35755cec59a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:FifthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac3baa3852034481ab2a2c089e20758c_I20220929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:NinthAmemdmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-29</instant>
        </period>
    </context>
    <context id="i7f310f91304f4cc89cb705d8722a8d08_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28084a381e4f4f1491853ea7f60c1025_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4808a45eee974fbfbe990af48bc945ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i061a02db1e2b4e1792f9dfd792d617e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic015a17daf5344f9a4de26b8e32f3873_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:InterestRateFloorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i755231ed00d14acf800c9c3404c31e20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8724ef42665454e9a5d3f598e52ab38_D20170731-20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-31</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="ic5e93a72679646699ff0eec55311987d_D20200420-20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:PaymentProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-20</startDate>
            <endDate>2020-04-20</endDate>
        </period>
    </context>
    <context id="icf6a2ed9c9c1455893589f101ba5b4cc_I20200420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:PaymentProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-20</instant>
        </period>
    </context>
    <context id="ib78383e8396e49768661e5b1015fc86b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cpix:PaymentProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cpix:PinnacleBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-08-09</startDate>
            <endDate>2009-08-10</endDate>
        </period>
    </context>
    <context id="i1061cd07c59c4fc190c499065ffea5e3_I20100531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">cpix:ShareRepurchaseProgramAuthorizedIn2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-05-31</instant>
        </period>
    </context>
    <context id="i3c8e554b334e4bf692425f706564fc4d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia90dbbcb1d5e494382b065f737613908_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cpix:SharesRepurchaseActivityTypeAxis">cpix:SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0027eb6bc44b4567a5351c10399f22e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifea0d070c6124183897a66bb2df920d4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30e86908009643eebb68ac0e3a1ae95e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i99d9d087686e4acaa131dcf7f56b02b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66d5038d3ea5413287c0c60e6f8d6e13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic8ffa57a973c45d89dc9e53e23854361_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:IndefiniteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if08c5ee420b248ac902a128ef7d90e7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id4ecd0e4253e46d69b1840d128d714e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81a18b4c882d437cb25a611496aa56a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54dfc16f99534c19b2867a069f58d483_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i795293f449e54a6eb5e7aa63c13b396d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cpix:FederalAndStateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:ExpirationTimePeriodAxis">cpix:ExpirationTermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibe55a7e9ab974665911b58f2cf2ab1d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:LongTermIncentiveCompensationPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8296dfa01cf5426fa8af917b505e162d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cpix:DirectorsIncentivePlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13b23c2311f046879e4fd6dafe94a991_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d9c25b92eff4d35973caf424807a5d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonprincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i070ea86904974ad18860cbc73c3202cc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:PrincipalOwnerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i955de8aa181944039f7145e41a74c991_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i09447f6af13b4f27a9f24d32a75cda9b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7684a832b0134542abe7faecbea0573e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66c58bd8eaaf40cd8f6a0c93cdb60c2a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8d9566f966de4bd4968bb2d10e0af05b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:NonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e34c07ebd764d17a96ec1d0f497c811_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i89c60f8924f748d98ade2ba26f585e11_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cpix:EmployeeNonemployeeandFoundationContributionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i214555a81d9942d3a95516724918bd8d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i91bab75ee1804a1097fbe90085dc4f12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:RestrictedIncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:RestrictedIncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3b943054825b4193b3cf6fbcea5877d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:RestrictedIncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:RestrictedIncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idfea5a17cdad49b5b643bd1bf2db9833_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cpix:RestrictedIncentiveStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b65c4b8b6aa447481044537155a6d9a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if838a7aa53664232926aca1c69b23238_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib2a4df839364457ca572567fd0e125dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i430e1a4cd7514fe59de28ed3a49bbab5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i872072012a784d598051e80fd8fb06ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i554be9ce2c1b41b4a99da09551040eaf_I20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="ic57bcfd058014d5d98c77360f419b471_I20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cpix:BroadwestLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="ib2fa7c2f4e86401a88e3022cb2d1309b_I20211115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="i5a4d2edd7a324a55a81eb502f58e0069_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">srt:OfficeBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i48b2fbaeed6a477c8536c9109ab9bde5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:A1600WestEndAvenuePartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffad826a3e6c41bd89cf0a3c062b03ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:CETMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8047e420d87647ca865218062adc1b3c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibb1ed446076641e2b06e8f65764e9641_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie513e297486b4dc29fca145454075e01_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0510690b6b854b9d8843a2b97df3ce27_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40f47c6c3c2345c982dcd1e267fd6145_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaff5c56f78a34c10b47d66d78992346f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">cpix:SalesRevenueGoodsGrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i42772db945f14e0d885bd05151e93291_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:Customer12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3990e4402eb64fb980a6bad3eb7430b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cpix:Customer12And3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic40eb7705a474e4fa7d98cfa3a5cb554_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie088610f3d64485c98806a39268009ee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03b6a63983b64d8bbf3a1a5e92a62c3b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e7165d6a14540d69539b738e13cdf8d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i284259e69f3e4e4e84c466d1e02a1e56_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:KyowaKirinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia952b89d554e4c89bf3b5882567c2d5f_I20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:CollaborativeArrangementMilestonePaymentThresholdAxis">cpix:Within30DaysOfFirstSNDAFilingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="i49eca3268edc4ad8b4e63d2e71cfa018_I20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cpix:CollaborativeArrangementMilestonePaymentThresholdAxis">cpix:FollowingApprovalOfFirstSNDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-02</instant>
        </period>
    </context>
    <context id="i1f878acd95a045fd934d5052dde987c6_I20221107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cpix:MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-07</instant>
        </period>
    </context>
    <context id="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if5de2643b16c42518868295369efe808_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a1250f3410e437492a31418c8974e8c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i34ed7d5354534fbd81b84cc0aa0d8e79_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id183facaeebd467fa69fbb2fec9d0b3e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib9019082259e456fb9c5846dc8fa2c23_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief70e45bdb5146d0818d09d8a9fc3591_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13f27dbe43754f2393a096db946b5293_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70c9db8d427e4e07a83726736dbc62f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idce9bb4f17eb40309dbdc88fdb74adc9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1857a0d9d671486aa8f09353d5b63f37_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>cpix:segment</measure>
    </unit>
    <unit id="plan">
        <measure>cpix:plan</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewalterm">
        <measure>cpix:renewalTerm</measure>
    </unit>
    <unit id="usdPerSqft">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="supplier">
        <measure>cpix:supplier</measure>
    </unit>
    <unit id="installment">
        <measure>cpix:installment</measure>
    </unit>
    <dei:DocumentAnnualReport
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8yLTEtMS0xLTM0Mzg0_693fc9b6-7876-4a40-b6c6-d210990eb130">true</dei:DocumentAnnualReport>
    <dei:DocumentTransitionReport
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8zLTEtMS0xLTM0Mzg0_b9da7085-6105-4076-a145-2460138feb0e">false</dei:DocumentTransitionReport>
    <dei:EntityCentralIndexKey
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl80LTEtMS0xLTM0Mzg0_9d4fabe8-be1d-43ef-917f-fa67f9745f55">0001087294</dei:EntityCentralIndexKey>
    <dei:EntityFilerCategory
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl82LTEtMS0xLTM0Mzg0_94180230-d072-4397-a979-dc511b518443">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentPeriodEndDate
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl84LTEtMS0xLTM0Mzg0_b769ffa9-cd89-49b6-ba78-598080123546">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl85LTEtMS0xLTM0Mzg0_255d4800-37c3-4be8-a701-06d072702afd">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xMC0xLTEtMS0zNDM4NA_6c16f37b-9d81-4b98-83ff-0cddced75087">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xMS0xLTEtMS0zNDM4NA_dcf1ffd5-c952-4522-b7ac-d028817fa5ff">false</dei:AmendmentFlag>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xMi0xLTEtMS0zNDM4NA_f5cabfc5-7df9-4654-9fcf-cb97b32ff100">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xMy0xLTEtMS0zNDM4NA_258c0537-c1d5-431d-94b2-5b33b2f868c3">true</dei:EntitySmallBusiness>
    <dei:EntityShellCompany
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xNC0xLTEtMS0zNDM4NA_72b59c6f-b790-4d32-acb3-3fe12ccd3321">false</dei:EntityShellCompany>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xNS0xLTEtMS00MzY2Mw_5a2332bf-1fdd-4397-a324-65091dafdb8d">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xNi0xLTEtMS00MzY2Ng_5b534e76-0ec0-43a3-945a-86f4a2fd2f64">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xNy0xLTEtMS00MzY2OA_a7cc24e6-aa76-4cc4-8fd1-008db894a3a6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGFibGU6OGJmODg0OTliNTM1NDY3NWFhZjI2MmRmMjRiYTVjOTYvdGFibGVyYW5nZTo4YmY4ODQ5OWI1MzU0Njc1YWFmMjYyZGYyNGJhNWM5Nl8xOC0xLTEtMS00MzY3MA_f554a7d9-d065-4039-b9e7-9e25320efcf0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl80L2ZyYWc6OGMxM2MxYjg2MzhlNGVhMWIyMzYwN2JhOGIxNTUyM2YvdGV4dHJlZ2lvbjo4YzEzYzFiODYzOGU0ZWExYjIzNjA3YmE4YjE1NTIzZl80NA_72237d44-0471-412a-be0c-7af7a5cb15e8">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8xODc_2c55060e-6d1f-4dfb-b0d1-6ff7408dd9e2">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM2_bffd3e7c-47f5-43ca-a114-523ef7399430">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8zMjU_99aa2bfa-d010-4486-ac59-9cd3fe73e5e3">CUMBERLAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzMy_a48c74b7-b8ad-435d-a250-2fa5530ade51">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzMz_449894e6-3107-45bb-ac0d-83a8fde7cf15">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityFileNumber
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM0_ce8ce56e-4bd3-4917-aa0a-106657e96d92">001-33637</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl81NDk3NTU4MTY3OTE_a1a17fe8-42f0-409b-a47c-00a8e0eb4208">1600 West End Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM3_ff92e11a-32ea-4a4d-8f3a-cf0899f01e1f">Suite 1300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM1_fa127974-4a39-4cec-903b-659b42662080">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM4_438a23b5-5f18-49a4-b81c-6f983aee3247">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzM5_02cec2d4-2157-4996-9f5b-2f7b9213e737">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzQw_86079046-6990-4511-a732-03f0bda7cf3b">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzQx_a32a54e4-9c93-45a6-a910-3c9225c79953">255-0068</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGFibGU6Mjk0ODVhOWUwM2UwNDQwMzljNjVjMWEwNmU0NDJiZTgvdGFibGVyYW5nZToyOTQ4NWE5ZTAzZTA0NDAzOWM2NWMxYTA2ZTQ0MmJlOF8xLTAtMS0xLTM0Mzg0_65d7444a-f077-49c6-9be5-bafcb5aae907">Common Stock, $0.00 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGFibGU6Mjk0ODVhOWUwM2UwNDQwMzljNjVjMWEwNmU0NDJiZTgvdGFibGVyYW5nZToyOTQ4NWE5ZTAzZTA0NDAzOWM2NWMxYTA2ZTQ0MmJlOF8xLTItMS0xLTM0Mzg0_ba286f93-0f00-45cb-932d-4d410188ae4b">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGFibGU6Mjk0ODVhOWUwM2UwNDQwMzljNjVjMWEwNmU0NDJiZTgvdGFibGVyYW5nZToyOTQ4NWE5ZTAzZTA0NDAzOWM2NWMxYTA2ZTQ0MmJlOF8xLTQtMS0xLTM0Mzg0_e588fa23-4cb8-4812-bd87-0907b1679a04">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityPublicFloat
      contextRef="i0cf98cdc48c644138ca1c6dedc85be6e_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8xOTI1_0ae9fca7-4104-41ce-b1a2-2b3d3f2f2bce"
      unitRef="usd">17300356</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i40f46dea598c4f3cba52391f5ebaf18b_I20230307"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMDIz_d1b90d8d-3709-43aa-871e-88968e678fb6"
      unitRef="shares">14395401</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xL2ZyYWc6NTZmZWU1Nzk5N2I4NDg0Zjg3NTU0MzRhMzk4ZmYxOGYvdGV4dHJlZ2lvbjo1NmZlZTU3OTk3Yjg0ODRmODc1NTQzNGEzOThmZjE4Zl8yMzQy_ea3043c3-4791-4189-ad15-e8d83a52cc57">Certain information required in Part III of Form 10-K is incorporated by reference from the registrant&#x2019;s Proxy Statement for its 2023 annual meeting of shareholders.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNjAvZnJhZzpkZmJiOWUxNmNiOTI0MDVhYjc0NzUyZmNjZjljYWJlMS90YWJsZTpmMTQyNWI1ZDJmOWE0MjgxOWNlYzA5NzcwZGQ3NWMzMC90YWJsZXJhbmdlOmYxNDI1YjVkMmY5YTQyODE5Y2VjMDk3NzBkZDc1YzMwXzQtMC0xLTEtMzQzODQvdGV4dHJlZ2lvbjpmYWUxZGIxNzQwMDY0MjI3YTk1NTE0YTliNjBjYWUzN18xMzU_2dd22a9e-f662-4a1a-be1d-bd7d44dff3a1">686</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzIvZnJhZzoxMzhmNTAxOTExN2Y0MjExYjkxYWYwNmEyZmM4N2VkYi90ZXh0cmVnaW9uOjEzOGY1MDE5MTE3ZjQyMTFiOTFhZjA2YTJmYzg3ZWRiXzEwODkz_355805b7-b957-468d-8a72-0c263c288022">FORVIS, LLP(Formerly, BKD, LLP)</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzIvZnJhZzoxMzhmNTAxOTExN2Y0MjExYjkxYWYwNmEyZmM4N2VkYi90ZXh0cmVnaW9uOjEzOGY1MDE5MTE3ZjQyMTFiOTFhZjA2YTJmYzg3ZWRiXzEwODk0_fef29421-5135-4db7-b738-1b0dddc7f584">Nashville, Tennessee</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMtMi0xLTEtMzQzODQ_8e357b67-2226-45fe-b3ba-623142dcd2de"
      unitRef="usd">19757970</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMtNC0xLTEtMzQzODQ_ee257a49-08bb-4961-899b-1e0dcf464ade"
      unitRef="usd">27040816</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzUtMi0xLTEtMzQzODQ_b5a26a4f-13c1-4112-af32-7361eb785af9"
      unitRef="usd">13163681</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzUtNC0xLTEtMzQzODQ_80b35395-3279-4f89-935c-28c897949c68"
      unitRef="usd">6877346</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzYtMi0xLTEtMzQzODQ_761d778b-7ac6-4411-9251-f899a72a217b"
      unitRef="usd">9863581</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzYtNC0xLTEtMzQzODQ_a91b6957-c70d-48c0-b9ab-14af4fc7ed69"
      unitRef="usd">8429882</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzctMi0xLTEtMzQzODQ_a57781b9-5195-4a43-909f-2a8e4d552db0"
      unitRef="usd">3084978</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzctNC0xLTEtMzQzODQ_99a2455c-0838-46ef-a15f-7be38189ac83"
      unitRef="usd">3339969</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzgtMi0xLTEtMzQzODQ_e4781204-94d7-4da2-b776-ff04023da4d0"
      unitRef="usd">45870210</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzgtNC0xLTEtMzQzODQ_45ddaa41-6f33-49cf-b411-accf77bf757f"
      unitRef="usd">45688013</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzktMi0xLTEtMzQzODQ_e1fc1e2b-ced5-44d4-8cb9-21fc4e8f5477"
      unitRef="usd">7527167</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzktNC0xLTEtMzQzODQ_5764d81e-0ab7-494d-8352-72d089690ffa"
      unitRef="usd">9048567</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEwLTItMS0xLTM0Mzg0_84db3688-3095-4398-9ac8-cba927846cda"
      unitRef="usd">284039</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEwLTQtMS0xLTM0Mzg0_eec1eeeb-f03f-4ce3-a9ff-5e0e38ab01d2"
      unitRef="usd">442635</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzExLTItMS0xLTM0Mzg0_f0ce02ea-add8-4fe8-b959-eb5c9ff8367c"
      unitRef="usd">30590678</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzExLTQtMS0xLTM0Mzg0_ea4cc267-c650-4b3c-b0c7-88c4b13fd2bb"
      unitRef="usd">23954475</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEyLTItMS0xLTM0Mzg0_78b5da45-50fe-48e7-a004-fb4c05368aa4"
      unitRef="usd">914000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEyLTQtMS0xLTM0Mzg0_0face6d7-076c-4b76-b6ab-3a560ad7a33d"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEzLTItMS0xLTM0Mzg0_3901c6a2-f4db-4ce4-8258-8dfa30c5c735"
      unitRef="usd">5218403</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzEzLTQtMS0xLTM0Mzg0_401c446f-2c3c-431c-95a3-2e3d099fb8c1"
      unitRef="usd">1024200</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE0LTItMS0xLTM0Mzg0_58d8f739-d6cf-476f-bc76-37134f3dda5c"
      unitRef="usd">2520661</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE0LTQtMS0xLTM0Mzg0_b62bc93b-be59-4d89-ae41-86f69c33a1af"
      unitRef="usd">3419908</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE1LTItMS0xLTM0Mzg0_71ad6410-fd91-4ca2-9a80-f32346da4f94"
      unitRef="usd">92925158</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE1LTQtMS0xLTM0Mzg0_4676c965-ba71-4b75-a60a-1497734aefa7"
      unitRef="usd">84459798</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE5LTItMS0xLTM0Mzg0_90537ccc-234d-465d-8e54-59f7a5f3ae9c"
      unitRef="usd">10819011</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzE5LTQtMS0xLTM0Mzg0_5be8ea5e-9f3b-4e0e-9aa4-4b86bde0ff5c"
      unitRef="usd">9640980</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIwLTItMS0xLTM0Mzg0_a2467877-60a1-4855-ab9c-f2eaeeaab8ea"
      unitRef="usd">172910</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIwLTQtMS0xLTM0Mzg0_aa359a79-2780-44d7-a494-e1adb278ff2d"
      unitRef="usd">969677</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIxLTItMS0xLTM0Mzg0_5eb36ea6-a379-43b3-82f2-1989ac49fd77"
      unitRef="usd">17587911</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIxLTQtMS0xLTM0Mzg0_d49f665e-276c-4740-8e6e-bff414fc1a2b"
      unitRef="usd">8668303</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIyLTItMS0xLTM0Mzg0_58bfdf9a-093d-4c4f-82fe-b7ef0389d867"
      unitRef="usd">28579832</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIyLTQtMS0xLTM0Mzg0_ac4bc582-5dbc-4617-845f-4c4580eca05e"
      unitRef="usd">19278960</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermLineOfCredit
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIzLTItMS0xLTM0Mzg0_27cb8e24-2aa5-452c-be26-036b53d2df42"
      unitRef="usd">16200000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzIzLTQtMS0xLTM0Mzg0_640e3f6e-3ad3-47e6-aa91-1edfebfc8b64"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI0LTItMS0xLTM0Mzg0_c303e501-2f8d-4d46-91fe-4b21199aa06d"
      unitRef="usd">4586301</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI0LTQtMS0xLTM0Mzg0_7ebe5c98-c9ee-48e4-be4a-27077ecfe8f6"
      unitRef="usd">90016</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI1LTItMS0xLTM0Mzg0_eaec4cdb-f744-4ead-b122-da3da96da907"
      unitRef="usd">7585019</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI1LTQtMS0xLTM0Mzg0_26c7423e-da97-4a55-a917-c313d2336d19"
      unitRef="usd">7488844</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI2LTItMS0xLTM0Mzg0_7c0184cf-dc5b-46f6-b7e6-d1483483cdd6"
      unitRef="usd">56951152</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI2LTQtMS0xLTM0Mzg0_4e007662-c46f-4148-97ca-4da8352f26d2"
      unitRef="usd">41857820</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI3LTItMS0xLTM0Mzg0_df625dbf-1f40-4c4a-8ba9-bdbef6b8b4e5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzI3LTQtMS0xLTM0Mzg0_0ea1bde9-966b-47d8-9f12-9cb54b42f31d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockNoParValue
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfMTk_2a61f772-8dc5-472c-9127-dd744b3eab65"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockNoParValue
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfMTk_ace6eb65-cf35-4560-a811-cc4d5aa9d618"
      unitRef="usdPerShare">0</us-gaap:CommonStockNoParValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfMzM_894f9261-4c18-4493-8554-12147ff863bb"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfMzM_f67f824a-bc1e-4a45-9230-3264ffc09721"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfNTU_626e21f2-f772-4e4b-8703-9c65973469eb"
      unitRef="shares">14366316</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfNTU_d1b25bd3-11a6-44c8-be11-8cc0afe4e643"
      unitRef="shares">14366316</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfNjI_8399b24e-c5b1-4506-8246-34d253bf75e5"
      unitRef="shares">14742754</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTAtMS0xLTM0Mzg0L3RleHRyZWdpb246YzFkYmQ3NGJlZTg4NGU3MTgwNTRkNmYxNzhjYjczMTlfNjI_c28f7a6a-01b8-4b24-9c1f-5feff49e5988"
      unitRef="shares">14742754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTItMS0xLTM0Mzg0_93930bee-b7e2-42e9-99cd-3bb102ba731e"
      unitRef="usd">47474973</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMwLTQtMS0xLTM0Mzg0_0482ecb4-dd1e-4e5f-9ca1-ac389be90ec6"
      unitRef="usd">48452906</us-gaap:CommonStockValueOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMxLTItMS0xLTM0Mzg0_e15b995a-70de-439d-9cac-839bbae1c21c"
      unitRef="usd">-11208841</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMxLTQtMS0xLTM0Mzg0_ce994bdb-c18b-4890-907d-87a6fb6a56d5"
      unitRef="usd">-5638600</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMyLTItMS0xLTM0Mzg0_a5f0c8ed-f70a-4d8b-9035-c79e59d38f12"
      unitRef="usd">36266132</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMyLTQtMS0xLTM0Mzg0_97194f39-6e2f-43b1-98cd-5dd2eb402ba6"
      unitRef="usd">42814306</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMzLTItMS0xLTM0Mzg0_413cb8ac-24db-4524-95b0-2f3fad2f53ba"
      unitRef="usd">-292126</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzMzLTQtMS0xLTM0Mzg0_0325baf2-fe38-48da-a5cf-507c57d9d99a"
      unitRef="usd">-212328</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzM0LTItMS0xLTM0Mzg0_27fd546a-adad-43df-aa68-c3c3e5521366"
      unitRef="usd">35974006</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzM0LTQtMS0xLTM0Mzg0_750b9710-8c97-4f6a-9408-a7a9e048d261"
      unitRef="usd">42601978</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzM1LTItMS0xLTM0Mzg0_53c3fb80-c3b7-44b2-ac75-4a05a433cb91"
      unitRef="usd">92925158</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzUvZnJhZzpiZjY0MDNmNjIyMTQ0ZDRmODhkYmQxOTEyNWUxNWZjYy90YWJsZToyYmMzZjgwZTUxYTI0NjkzOGNhODdhZDQ2NDdkNGI3My90YWJsZXJhbmdlOjJiYzNmODBlNTFhMjQ2OTM4Y2E4N2FkNDY0N2Q0YjczXzM1LTQtMS0xLTM0Mzg0_31e77d40-3456-446b-9893-ba5b140c9316"
      unitRef="usd">84459798</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="idf6dac19d6f34192bbf220dba001eef3_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzItMi0xLTEtMzQzODQ_8cc4e979-86c8-40d3-a16e-deeb4180bde0"
      unitRef="usd">40681182</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82deea75887548fe9dd05c788a9a95d9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzItNC0xLTEtMzQzODQ_5efeff65-f9a6-409e-baf7-31ba557bd41c"
      unitRef="usd">35045259</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78d55d038f4f4a95b6d5aa9d8870f9f3_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMtMi0xLTEtMzQzODQ_9ced2568-122f-4284-8db6-00da62375981"
      unitRef="usd">1329767</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i492284a80be94550bc059ef2e65088e9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMtNC0xLTEtMzQzODQ_213742f3-de81-4ad7-9e63-5a3d11f7db01"
      unitRef="usd">939784</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzQtMi0xLTEtMzQzODQ_545fdfb8-ad07-4105-974b-5d623cbfcb8a"
      unitRef="usd">42010949</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzQtNC0xLTEtMzQzODQ_cac86d8d-786b-47a2-9785-81a13dcff175"
      unitRef="usd">35985043</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzYtMi0xLTEtMzQzODQ_44cb5588-75b4-47e0-af96-d8ca965abbd4"
      unitRef="usd">9118521</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzYtNC0xLTEtMzQzODQ_d70b80c1-93be-4394-a7b9-b2583650e62f"
      unitRef="usd">8811248</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzctMi0xLTEtMzQzODQ_4502b818-656c-4434-af72-ce671606cb03"
      unitRef="usd">16660945</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzctNC0xLTEtMzQzODQ_82a663af-9f1e-4b6e-9660-2328969c9063"
      unitRef="usd">15015424</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzgtMi0xLTEtMzQzODQ_f555c75b-63d9-4a71-a76b-15e83035efbf"
      unitRef="usd">6688924</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzgtNC0xLTEtMzQzODQ_68376946-5900-407f-9ac2-6cacc5e97e0e"
      unitRef="usd">5684465</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzktMi0xLTEtMzQzODQ_882fe21b-e631-45d7-a3cf-7f223ea24a53"
      unitRef="usd">10180120</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzktNC0xLTEtMzQzODQ_e8683580-c6b5-463d-8446-20117142cc6a"
      unitRef="usd">9780026</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEwLTItMS0xLTM0Mzg0_8a75d7f5-3759-4b9b-8362-dc969071f851"
      unitRef="usd">5067368</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEwLTQtMS0xLTM0Mzg0_7d0e1723-89cd-48fa-84c4-425a24d385a5"
      unitRef="usd">4371300</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostsAndExpenses
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzExLTItMS0xLTM0Mzg0_9e9543af-83ee-4908-a7fc-c8e911480f26"
      unitRef="usd">47715878</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzExLTQtMS0xLTM0Mzg0_6d72a092-f0c5-4076-8c74-445cb5d7e70d"
      unitRef="usd">43662463</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEyLTItMS0xLTM0Mzg0_462e5e9c-f7bc-49db-911d-dd00dbf1da08"
      unitRef="usd">-5704929</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEyLTQtMS0xLTM0Mzg0_9f324b0e-1c16-4ebb-b39b-351a6d11b1c4"
      unitRef="usd">-7677420</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEzLTItMS0xLTM0Mzg0_928c8bd0-0b31-4f63-8b9c-3099f17a6f31"
      unitRef="usd">98405</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzEzLTQtMS0xLTM0Mzg0_77ffff6d-e2ac-4993-a799-eeda6efddb55"
      unitRef="usd">26081</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherIncome
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE0LTItMS0xLTM0Mzg0_2b42df4a-977a-45c4-9a09-855cc40c0df1"
      unitRef="usd">0</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE0LTQtMS0xLTM0Mzg0_6d61a0dc-fb79-412e-86b2-30c4bb7499cc"
      unitRef="usd">2187140</us-gaap:OtherIncome>
    <us-gaap:InsuredEventGainLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE1LTItMS0xLTM4Mzgx_c3295a38-6d16-4e5c-8399-f498655e6d93"
      unitRef="usd">611330</us-gaap:InsuredEventGainLoss>
    <us-gaap:InsuredEventGainLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE1LTQtMS0xLTM4Mzgx_1807ae5c-c948-4ca0-a41c-d20789855bce"
      unitRef="usd">0</us-gaap:InsuredEventGainLoss>
    <us-gaap:InterestExpense
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE1LTItMS0xLTM0Mzg0_94527528-79e9-46c2-882e-eb8ec6f805a1"
      unitRef="usd">585995</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE1LTQtMS0xLTM0Mzg0_bea9a146-b927-4a81-8065-51f41cfb3f94"
      unitRef="usd">98031</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE2LTItMS0xLTM0Mzg0_ce06dcc0-f7b3-4cd2-9916-a523cfef01f2"
      unitRef="usd">-5581189</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE2LTQtMS0xLTM0Mzg0_edce455a-7c41-44ef-9c9d-0a94ccc88883"
      unitRef="usd">-5562230</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE3LTItMS0xLTM0Mzg0_f8001bb8-47c0-4756-ab50-2198621ef6d3"
      unitRef="usd">68850</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE3LTQtMS0xLTM0Mzg0_9a126991-5456-4b6a-abdc-861f795c9d3a"
      unitRef="usd">34891</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE4LTItMS0xLTM0Mzg0_db4d81a0-02eb-4ec4-9f83-43571fc908ec"
      unitRef="usd">-5650039</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE4LTQtMS0xLTM0Mzg0_d4ccc55b-061d-4671-b20f-3aa2e5f7aab6"
      unitRef="usd">-5597121</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE5LTItMS0xLTM0Mzg0_f67cb05b-98cd-4076-b7f8-abd264f3c575"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzE5LTQtMS0xLTM0Mzg0_4207b02a-8aee-429a-a0ab-c761f4d74561"
      unitRef="usd">1994322</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIwLTItMS0xLTM0Mzg0_1b737811-2bb4-4d41-bd6d-cc4c47c638fe"
      unitRef="usd">-5650039</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIwLTQtMS0xLTM0Mzg0_0fd71f32-dedb-474f-b807-cbb1f18941c3"
      unitRef="usd">-3602799</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIxLTItMS0xLTM0Mzg0_b61ce7e9-df0d-44fb-98d4-26d6b618e9fc"
      unitRef="usd">-79798</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIxLTQtMS0xLTM0Mzg0_9d29cd60-538e-4a3c-a017-88646f4ab240"
      unitRef="usd">-95212</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIyLTItMS0xLTM0Mzg0_349e369d-2ed7-4299-94cf-fcc1d4a72964"
      unitRef="usd">-5570241</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzIyLTQtMS0xLTM0Mzg0_c11896fa-9e95-43fe-b104-9b27eb2e768c"
      unitRef="usd">-3507587</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI1LTItMS0xLTM0Mzg0_d11fc394-1d50-46fa-ae71-c2cc576614ca"
      unitRef="usdPerShare">-0.38</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI1LTQtMS0xLTM0Mzg0_ae816b14-8fbf-41d5-aac8-f75c1a1c408c"
      unitRef="usdPerShare">-0.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI2LTItMS0xLTM0Mzg0_8101d92c-7b24-4608-9d91-9c28e4e6bb56"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI2LTQtMS0xLTM0Mzg0_38d883b1-0059-4084-9b96-4da2fb1b08b5"
      unitRef="usdPerShare">0.13</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI3LTItMS0xLTM0Mzg0_0384c07b-5fb9-40c8-9dfd-870db3ad64c7"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI3LTQtMS0xLTM0Mzg0_ecee08eb-ca74-4cb4-8d7a-b970f7fb6e7f"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI5LTItMS0xLTM0Mzg0_4c8e2cd3-6467-4ee5-8e53-2d29154bee16"
      unitRef="usdPerShare">-0.38</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzI5LTQtMS0xLTM0Mzg0_1d85b8d2-213d-414c-afa9-42eee6486514"
      unitRef="usdPerShare">-0.37</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMwLTItMS0xLTM0Mzg0_1117dfb6-8d22-42d0-a280-7492920528c0"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMwLTQtMS0xLTM0Mzg0_edfe25bb-dfba-4062-ae4d-cf1adeff97f1"
      unitRef="usdPerShare">0.13</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMxLTItMS0xLTM0Mzg0_d68ccf0d-6b8f-4e1e-8ea4-765ef06bfc35"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMxLTQtMS0xLTM0Mzg0_06b2af62-7dae-4c33-ad88-77e28c0eb2c1"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMzLTItMS0xLTM0Mzg0_77d73480-200e-48f8-9ba0-2fc417f838ea"
      unitRef="shares">14563592</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzMzLTQtMS0xLTM0Mzg0_3d3efbef-7a12-4391-9370-ef2cdd85ac62"
      unitRef="shares">14904834</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzM0LTItMS0xLTM0Mzg0_158e62d8-1a26-4891-8ed0-1713e4220dce"
      unitRef="shares">14563592</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xNzgvZnJhZzphYWRjMDUyZmE5YjI0MzM4YjI4MTJlZGM1Y2QzN2VjMy90YWJsZTpiNGVjMjAxYzVhNGI0YzFjOTcwYTQwODJiNTFkMjUwZC90YWJsZXJhbmdlOmI0ZWMyMDFjNWE0YjRjMWM5NzBhNDA4MmI1MWQyNTBkXzM0LTQtMS0xLTM0Mzg0_00dc128d-89c3-48fe-bc42-89108b16b078"
      unitRef="shares">14904834</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzItMi0xLTEtMzQzODQ_350ebc79-8574-4ce5-901f-5ce28b6708e3"
      unitRef="usd">-5650039</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzItNC0xLTEtMzQzODQ_a8c24ae2-8503-40b9-a804-1cdd532e1fcb"
      unitRef="usd">-3602799</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMtMi0xLTEtMzQzODQ_5e4a460a-7007-4d3c-bc60-bfb2b5941dfd"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMtNC0xLTEtMzQzODQ_08d8af61-7652-4a8a-b3b4-f2de2d715265"
      unitRef="usd">1994322</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzQtMi0xLTEtMzQzODQ_e0e37b7f-cfc2-48e2-bf03-6e8de9415997"
      unitRef="usd">-5650039</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzQtNC0xLTEtMzQzODQ_95d02f18-6400-4838-b26a-9276f2633e26"
      unitRef="usd">-5597121</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzYtMi0xLTEtMzQzODQ_d0c49473-1ec9-468e-948d-55a21b2ac409"
      unitRef="usd">5328113</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzYtNC0xLTEtMzQzODQ_bb57def1-a423-40b2-b3ad-9d763717a7c1"
      unitRef="usd">4606366</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzctMi0xLTEtMzQzODQ_9e9da306-9d4d-47b2-a70e-6ab46ecb30e7"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzctNC0xLTEtMzQzODQ_ea37bfcc-ccdf-418a-854c-e0e85acbd8dd"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzgtMi0xLTEtMzQzODQ_073467d8-e8c7-494d-a2ce-9d8b7716eacd"
      unitRef="usd">447503</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzgtNC0xLTEtMzQzODQ_ba7ed6af-4314-4776-9fc1-bf70b0b0bdac"
      unitRef="usd">741867</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEwLTItMS0xLTM0Mzg0_1f9ddd31-5923-422d-8cf1-22f2ac266eea"
      unitRef="usd">2088296</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEwLTQtMS0xLTM0Mzg0_7e55cd4e-bfd6-41a1-8b6e-c95617cd5189"
      unitRef="usd">1147750</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEyLTItMS0xLTM0Mzg0_d598b9e3-c274-4a17-8496-adfc32584f2c"
      unitRef="usd">-613657</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEyLTQtMS0xLTM0Mzg0_9bea4e70-bcec-4817-8eeb-a7fed7e83845"
      unitRef="usd">282207</cpix:IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEzLTItMS0xLTM0Mzg0_310a7939-4136-4769-a798-920118f57cec"
      unitRef="usd">11237</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzEzLTQtMS0xLTM0Mzg0_78da5d84-3f77-411a-b959-8cfa2f834b4a"
      unitRef="usd">34053</us-gaap:AmortizationOfFinancingCosts>
    <cpix:NoncashOrPartNoncashGainOnTransaction
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE0LTItMS0xLTM4ODg0_eb20a801-9fdc-4cf0-b6ed-ca51d2e5ab40"
      unitRef="usd">37882</cpix:NoncashOrPartNoncashGainOnTransaction>
    <cpix:NoncashOrPartNoncashGainOnTransaction
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE0LTQtMS0xLTM4ODg0_11df188d-adf6-40b6-af95-5f5215f93d47"
      unitRef="usd">0</cpix:NoncashOrPartNoncashGainOnTransaction>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE0LTItMS0xLTM0Mzg0_05ab363f-47c7-4d76-99c8-03497e391740"
      unitRef="usd">611330</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE0LTQtMS0xLTM0Mzg0_8079d155-723b-4d28-b6c2-81b687b6f2e8"
      unitRef="usd">0</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE1LTItMS0xLTM0Mzg0_0583a41d-3e12-47ab-8df9-e6889a37ef6c"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE1LTQtMS0xLTM0Mzg0_a7437192-834a-4cff-a1de-2537f67e1b0c"
      unitRef="usd">2187140</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE3LTItMS0xLTM0Mzg0_219ffc6a-7d8d-42f7-9467-b4b4e8240d45"
      unitRef="usd">6115640</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE3LTQtMS0xLTM0Mzg0_cbffe78b-28ae-4b8b-b139-8433afd2c0c5"
      unitRef="usd">-5500367</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE4LTItMS0xLTM0Mzg0_9336c5d5-4878-43fb-8882-43c64effd555"
      unitRef="usd">-911078</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE4LTQtMS0xLTM0Mzg0_bb4888b2-29b2-45ce-b984-2fca95febd6b"
      unitRef="usd">-4816450</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE5LTItMS0xLTM0Mzg0_77f11e2e-c511-40dc-8903-3db88f1c3e04"
      unitRef="usd">-689260</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzE5LTQtMS0xLTM0Mzg0_bcadfe6f-1cc8-4a12-94b7-5cba9e40d246"
      unitRef="usd">35568</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIwLTItMS0xLTM0Mzg0_71cccd90-f701-4349-80bf-e8d8a3965bff"
      unitRef="usd">14536076</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIwLTQtMS0xLTM0Mzg0_b9a7704a-8481-4cde-8ddd-379cebc77b78"
      unitRef="usd">-757591</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIxLTItMS0xLTM0Mzg0_910ee84a-14b2-4f4a-ad96-8c65b468cddf"
      unitRef="usd">419659</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIxLTQtMS0xLTM0Mzg0_0951ebb9-b187-4b12-bc42-7c387a45d080"
      unitRef="usd">-1343605</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIyLTItMS0xLTM0Mzg0_eede9e2d-23ea-4605-a740-405219b78737"
      unitRef="usd">8453396</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIyLTQtMS0xLTM0Mzg0_1eb182b5-e817-4052-adf7-5b936c05ad33"
      unitRef="usd">4348121</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIzLTItMS0xLTM0Mzg0_d5134832-c38d-450b-8d4a-21836df1ee08"
      unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzIzLTQtMS0xLTM0Mzg0_7a1b72df-b16a-4b66-bba6-3ce2a03eb578"
      unitRef="usd">1994322</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI0LTItMS0xLTM0Mzg0_50c924cc-5a65-4be6-8361-2770fb48e44b"
      unitRef="usd">8453396</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI0LTQtMS0xLTM0Mzg0_eddcc8d3-63a0-47b1-809b-c11b872ec2c1"
      unitRef="usd">6342443</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI2LTItMS0xLTM0Mzg0_e6ee662e-c291-4b4c-93bf-4ff7f02c0f14"
      unitRef="usd">102148</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI2LTQtMS0xLTM0Mzg0_55ef4d4e-808b-4db6-9589-c9942f4c12b0"
      unitRef="usd">103532</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI3LTItMS0xLTM0Mzg0_d5d2f2bd-7b12-4e78-9a29-8ed6c3b6ca31"
      unitRef="usd">1971662</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI3LTQtMS0xLTM0Mzg0_6782fa9f-d3d5-4d4c-ac74-4f4b547d96e0"
      unitRef="usd">250930</us-gaap:PaymentsToAcquireIntangibleAssets>
    <cpix:ProceedsFromCollaborationArrangement
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI4LTItMS0xLTM4MDU5_57fe2f6b-b29a-486f-9ced-cf80da2f70e5"
      unitRef="usd">1000000</cpix:ProceedsFromCollaborationArrangement>
    <cpix:ProceedsFromCollaborationArrangement
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI4LTQtMS0xLTM4MDU5_1a174d16-d87f-4833-bd56-2811d972e153"
      unitRef="usd">0</cpix:ProceedsFromCollaborationArrangement>
    <cpix:ProceedsFromSurrenderOfLifeInsurancePolicy
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI4LTItMS0xLTM0Mzg0_4b93e108-ab34-4d1b-8d79-ebd7f145447b"
      unitRef="usd">0</cpix:ProceedsFromSurrenderOfLifeInsurancePolicy>
    <cpix:ProceedsFromSurrenderOfLifeInsurancePolicy
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI4LTQtMS0xLTM0Mzg0_77a7af0c-abaf-4efe-a2ed-4a2942e9d462"
      unitRef="usd">85944</cpix:ProceedsFromSurrenderOfLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI5LTItMS0xLTM0Mzg0_91dac0c7-ec2b-4beb-9539-05c5df8815bc"
      unitRef="usd">0</cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy>
    <cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzI5LTQtMS0xLTM0Mzg0_98f79024-8672-4804-a425-96f2c017de89"
      unitRef="usd">33375</cpix:IncreaseDecreaseInProceedsFromLifeInsurancePolicy>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMxLTItMS0xLTM4Mzk4_4388d8ee-18bf-441b-9a3c-904a2b9f8970"
      unitRef="usd">877597</us-gaap:ProceedsFromLifeInsurancePolicies>
    <us-gaap:ProceedsFromLifeInsurancePolicies
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMxLTQtMS0xLTM4Mzk4_9a0c152e-20bf-462c-b29b-19dd4f02d317"
      unitRef="usd">0</us-gaap:ProceedsFromLifeInsurancePolicies>
    <cpix:ProceedsFromSettlementOfPatentLitigation
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMyLTItMS0xLTM4NDA2_7e3714f9-3dd5-4ff1-818f-90ecc82f4255"
      unitRef="usd">21757</cpix:ProceedsFromSettlementOfPatentLitigation>
    <cpix:ProceedsFromSettlementOfPatentLitigation
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMyLTQtMS0xLTM4NDA2_e083a5f5-bcc1-4029-b234-4e2eb5be6e8c"
      unitRef="usd">0</cpix:ProceedsFromSettlementOfPatentLitigation>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMwLTItMS0xLTM0Mzg0_45d682b0-4e6a-48cb-95f2-8f742f8e53f0"
      unitRef="usd">13500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMwLTQtMS0xLTM0Mzg0_ed57d964-7d56-4b9b-8a86-45a62294104c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMxLTItMS0xLTM0Mzg0_209f3969-9782-49f5-ab16-e744fc4ff7ed"
      unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzMxLTQtMS0xLTM0Mzg0_77835488-ac3d-4751-9bb9-b41a197d0e63"
      unitRef="usd">200000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzM0LTItMS0xLTM0Mzg0_bbc50b19-9d3b-4280-8f7e-da3299bcb78a"
      unitRef="usd">-13674456</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo4ZDg2NmEzYjUzZWY0OTg4OGQ4YWMwZTJmM2MzZjM1Yi90YWJsZXJhbmdlOjhkODY2YTNiNTNlZjQ5ODg4ZDhhYzBlMmYzYzNmMzViXzM0LTQtMS0xLTM0Mzg0_c9f02282-ffde-4ff1-9673-08ebad0df766"
      unitRef="usd">-501893</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzItMi0xLTEtMzQzODQ_7a5f50b2-e023-4cdb-9c06-6eb89535f79f"
      unitRef="usd">52900000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzItNC0xLTEtMzQzODQ_6a6f45e2-0791-43f8-a3f5-95e2b9f71014"
      unitRef="usd">59000000</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzMtMi0xLTEtMzQzODQ_c0b2bf7c-90fb-44b7-8283-68669ebf5d22"
      unitRef="usd">51700000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzMtNC0xLTEtMzQzODQ_686690ed-09ea-46ec-b0a9-62a2eaf95eb4"
      unitRef="usd">59000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzQtMi0xLTEtMzQzODQ_78c1e78a-bd9c-4fb9-9e1d-03d1a74b0886"
      unitRef="usd">1053042</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzQtNC0xLTEtMzQzODQ_84855dd2-d555-4714-a985-dbf988a608ef"
      unitRef="usd">1386849</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzUtMi0xLTEtMzQzODQ_18556817-0723-4af5-bd4d-cd911353abb7"
      unitRef="usd">2208744</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzUtNC0xLTEtMzQzODQ_02c2169a-0043-439e-8739-db6336b397e1"
      unitRef="usd">2166681</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEwLTItMS0xLTM0Mzg0_6baa7206-0594-4c98-8502-a8b754ced7aa"
      unitRef="usd">-2061786</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEwLTQtMS0xLTM0Mzg0_825bd200-2e5f-413e-a5e9-da52b6b495f0"
      unitRef="usd">-3553530</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzExLTItMS0xLTM0Mzg0_3e56a357-592b-43db-989c-c71c697b8720"
      unitRef="usd">-7282846</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzExLTQtMS0xLTM0Mzg0_70093414-098f-4cab-ae29-7e56723e1298"
      unitRef="usd">2287020</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEyLTItMS0xLTM0Mzg0_785d6f60-3287-4b69-b706-99ca9d22a1c0"
      unitRef="usd">27040816</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6b1f58f544414d679bba8a83be98bb54_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEyLTQtMS0xLTM0Mzg0_019c0412-25e5-4b92-994d-f2bc085a3367"
      unitRef="usd">24753796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEzLTItMS0xLTM0Mzg0_779c6b7c-72e7-4edc-80c6-6b1f7420016a"
      unitRef="usd">19757970</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTpjOGI5ZjExYTNlZjg0NDU3ODk5ZTY1Y2E0ODM1YTRmMy90YWJsZXJhbmdlOmM4YjlmMTFhM2VmODQ0NTc4OTllNjVjYTQ4MzVhNGYzXzEzLTQtMS0xLTM0Mzg0_c0fa4ae6-224b-4d5d-a96b-d4828cf2ae23"
      unitRef="usd">27040816</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzItMi0xLTEtMzQzODQ_0c179874-2226-4e1e-9554-0e6b244685c8"
      unitRef="usd">523161</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzItNC0xLTEtMzQzODQ_524e8f21-a4ba-4344-8b11-c2fba33289be"
      unitRef="usd">63978</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzMtMi0xLTEtMzQzODQ_8c46aebd-7fc4-423d-97fc-2722604cd560"
      unitRef="usd">3300</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzMtNC0xLTEtMzQzODQ_faabf9eb-3a41-4287-9bf0-3bb4768febee"
      unitRef="usd">-327</us-gaap:IncomeTaxesPaidNet>
    <cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzUtMi0xLTEtMzQzODQ_02197945-af3e-4b45-8fb5-84bf43f02a48"
      unitRef="usd">-1803403</cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid>
    <cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzUtNC0xLTEtMzQzODQ_8adab520-bee7-4875-b0ed-286bc4dcdaa9"
      unitRef="usd">-43471</cpix:PurchasesOfIntangibleAssetsIncurredButNotYetPaid>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzYtMi0xLTEtMzQzODQ_de59117a-c2d3-41f0-8e46-dd640e49edf0"
      unitRef="usd">94689</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzYtNC0xLTEtMzQzODQ_73e1e041-5af7-4c1a-a8cd-997e8caf0208"
      unitRef="usd">90512</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzctMi0xLTEtMzQzODQ_2bf79584-3611-40c4-876d-a5b5a0085934"
      unitRef="usd">4590978</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzctNC0xLTEtMzQzODQ_47196222-a12f-43c4-bc37-d6dacd46e369"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <cpix:CreditIssuedForMilestonePayable
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzgtMi0xLTEtNDIxMjM_63485aa9-b253-4897-8253-6a7e23833dd5"
      unitRef="usd">-1000000</cpix:CreditIssuedForMilestonePayable>
    <cpix:CreditIssuedForMilestonePayable
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzgtNC0xLTEtNDIyMDY_3b797934-cbf4-471f-868a-0cb1403d407e"
      unitRef="usd">0</cpix:CreditIssuedForMilestonePayable>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzktMi0xLTEtNDIxMjM_52f813e1-6c28-4165-937a-c4fb5d3a7153"
      unitRef="usd">399600</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODEvZnJhZzpjZDI0YWE2MTAwNjU0NWNjYmU2YTkxMDMyOWQ0NmIzYS90YWJsZTo2ZTc5NjJmMzI2YzU0NzRiOTMwNzM0YjBmOTJhNzVlOS90YWJsZXJhbmdlOjZlNzk2MmYzMjZjNTQ3NGI5MzA3MzRiMGY5MmE3NWU5XzktNC0xLTEtNDIyMDY_9c681ef7-67f5-4f26-a781-808a1eaf8c4d"
      unitRef="usd">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i963f0ace48ae4299a000f7fd5b7c18c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI2LTItMS0xLTM0Mzg0_e21d682b-cf85-46c2-8536-95f168da3825"
      unitRef="shares">14988429</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i963f0ace48ae4299a000f7fd5b7c18c5_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI2LTQtMS0xLTM0Mzg0_6b4c9d31-6442-4408-b761-42ebd53677b8"
      unitRef="usd">49121523</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia40cff38220f4a42a215676712cd7975_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI2LTYtMS0xLTM0Mzg0_fed9facc-5511-4ec9-b956-92b3bda35325"
      unitRef="usd">-2131013</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f553aa99c0e4216aa251a6245b1cab1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI2LTgtMS0xLTM0Mzg0_4cbc2eb9-882d-46c5-bb20-a36dad4cb7e7"
      unitRef="usd">-117116</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b1f58f544414d679bba8a83be98bb54_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI2LTEwLTEtMS0zNDM4NA_06ed5fe5-18b5-4f9a-9c22-d19d9680b3c1"
      unitRef="usd">46873394</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ia770bc31d52a493aa78146feba302866_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI3LTYtMS0xLTM0Mzg0_9727cfe5-84ba-47b9-84ea-2d7b074a50e7"
      unitRef="usd">-3507587</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic4d8da0743ab4c0488940b1685dbba30_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI3LTgtMS0xLTM0Mzg0_4b9419a0-3c36-452d-ab55-36a4552a2b84"
      unitRef="usd">-95212</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI3LTEwLTEtMS0zNDM4NA_5e1764f6-3a57-4658-ad70-fef8e613a27a"
      unitRef="usd">-3602799</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI4LTItMS0xLTM0Mzg0_056e4d57-6913-493f-9a03-1e95790256af"
      unitRef="shares">192684</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI4LTQtMS0xLTM0Mzg0_bd8086be-0747-4202-9bbe-57df9a853f51"
      unitRef="usd">741867</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI4LTEwLTEtMS0zNDM4NA_a8e0ca43-8267-4908-92fe-6b4d852f3c6a"
      unitRef="usd">741867</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI5LTItMS0xLTM0Mzg0_ece52727-a001-4d35-a5e2-48d66139e4c4"
      unitRef="shares">438359</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI5LTQtMS0xLTM0Mzg0_830d8892-f399-4a5a-8d4b-7584a5caa41e"
      unitRef="usd">1410484</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzI5LTEwLTEtMS0zNDM4NA_28391fd4-eb6d-47fb-b4fd-3d0a80f83032"
      unitRef="usd">1410484</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i34f8ac4bf33e4693be58ae3e7731aca1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMwLTItMS0xLTM0Mzg0_a69af357-e98e-4d35-b54e-3bdf378df58d"
      unitRef="shares">14742754</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34f8ac4bf33e4693be58ae3e7731aca1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMwLTQtMS0xLTM0Mzg0_8684f711-5ed4-475a-88cc-78df33ac7a15"
      unitRef="usd">48452906</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id569c4eed8f24390a0083034cd6006fd_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMwLTYtMS0xLTM0Mzg0_6631f39c-dcdd-4d8c-be44-595676fbb3af"
      unitRef="usd">-5638600</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie04970d0133c449fb025dee41a90d071_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMwLTgtMS0xLTM0Mzg0_3d2a5ec6-4034-4f53-a874-c602a3ce6716"
      unitRef="usd">-212328</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMwLTEwLTEtMS0zNDM4NA_ba1f9625-8e3e-4ceb-9d65-fb62aef3a5b5"
      unitRef="usd">42601978</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="iffb757a4c3914eb9b95796ad9e20eacc_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMxLTYtMS0xLTM2MjY2_82b52deb-3c4b-4ffe-b478-8a808e4156c5"
      unitRef="usd">-5570241</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1705f3f062cc44839738fe486e114ad6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMxLTgtMS0xLTM2MjY2_04972fe0-b9de-4d53-9cc6-b0899e35a446"
      unitRef="usd">-79798</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMxLTEwLTEtMS0zNjI2Ng_309391ea-8dba-4b6e-a571-a1e7c25ef994"
      unitRef="usd">-5650039</us-gaap:ProfitLoss>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMyLTItMS0xLTM2MjY2_8611fe5a-5f2d-43d7-9433-a80951acc8f5"
      unitRef="shares">180000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMyLTQtMS0xLTM2MjY2_39a8dc72-2f43-469c-b76c-4486d9ca4ace"
      unitRef="usd">399600</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMyLTEwLTEtMS0zNjI2Ng_75aa48b9-9510-4cd2-bf8c-1fd513c3e6b7"
      unitRef="usd">399600</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMzLTItMS0xLTM2MjY2_9e77c040-6e8f-4b56-bcba-aa02d4e39417"
      unitRef="shares">171655</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMzLTQtMS0xLTM2MjY2_733af5bc-33ee-4c9d-a0f4-1d344da07c9f"
      unitRef="usd">447503</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzMzLTEwLTEtMS0zNjI2Ng_9f952b50-a526-471b-9a4b-0d33409755f9"
      unitRef="usd">447503</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM0LTItMS0xLTM2MjY2_98476a2c-879c-40e9-97bb-bc5feeaeeef9"
      unitRef="shares">367793</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM0LTQtMS0xLTM2MjY2_446c3e01-b254-4a36-b341-e055c704c9bf"
      unitRef="usd">1025836</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM0LTEwLTEtMS0zNjI2Ng_3be0a2d3-28c4-4058-a21f-c8911366bac5"
      unitRef="usd">1025836</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3cb948d137eb4bae9cb3425ba6c840db_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM1LTItMS0xLTM2MjY2_43a03f0d-9d63-4426-8ad3-6f1662ec731a"
      unitRef="shares">14366616</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cb948d137eb4bae9cb3425ba6c840db_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM1LTQtMS0xLTM2MjY2_9392c0e8-5214-4af1-9f90-0bc9fff6504f"
      unitRef="usd">47474973</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibdae3b5e1dd2405b904488b32eb4db3b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM1LTYtMS0xLTM2MjY2_48bb0f5e-585c-4d2c-b726-f071ada83581"
      unitRef="usd">-11208841</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d4b30bb244846a8ba4078cdae06919f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM1LTgtMS0xLTM2MjY2_daf019e7-6f96-4ffa-8d96-f5d732f74f83"
      unitRef="usd">-292126</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xODQvZnJhZzo0OTU1OTI3OWQ1OGQ0OThiODViODQzYWI5YmYxYjdkYS90YWJsZTpmMzFjZjBhZTgwNWQ0MmNhYjlkZDM3OGM0MjhiNjBhZi90YWJsZXJhbmdlOmYzMWNmMGFlODA1ZDQyY2FiOWRkMzc4YzQyOGI2MGFmXzM1LTEwLTEtMS0zNjI2Ng_01dd64f2-9db3-4d45-b73e-3fc9ab819c5c"
      unitRef="usd">35974006</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzMyNzA_9443dbca-27f7-452f-b5d3-fdc8e4f2252d">Organization&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland Pharmaceuticals Inc. (&#x201c;Cumberland,&#x201d; the &#x201c;Company,&#x201d; or as used in the context of &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products.  The Company's primary target markets are hospital acute care, gastroenterology  and oncology. These medical specialties are characterized by relatively concentrated prescriber bases that the Company believes can be penetrated effectively by small, targeted sales forces. Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet or poorly met medical needs.  The Company promotes its approved products through its hospital, field and oncology sales forces in the United States and is establishing a network of international partners to bring its medicines to patients in their countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland focuses its resources on maximizing the commercial potential of its products, as well as developing new product candidates, and has both internal development and commercial capabilities. The Company&#x2019;s products are manufactured by third parties, which are overseen by Cumberland&#x2019;s quality and manufacturing professionals. The Company works closely with its third-party distribution partners to make its products available in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to build a pipeline of early-stage product candidates, the Company formed a subsidiary, Cumberland Emerging Technologies, Inc. ("CET"), which teams with universities and other research organizations to help advance scientific discoveries from the laboratory to the marketplace.  In 2014, the Company organized equity financing to recapitalize and strengthen the financial position of CET including an investment of approximately $1.0 million from Gloria Pharmaceuticals Co., Ltd. (&#x201c;Gloria&#x201d;).  As a result, Gloria received shares in CET and joined the CET ownership group. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April, 2019, CET entered into an agreement with HongKong WinHealth Pharma Group Co. Limited ("WinHealth") &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;whereby WinHealth made a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.0&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment through the purchase of shares of CET stock. As part of the agreement, WinHealth obtained a Board position at CET and the first opportunity to license CET products for the Chinese market. In connection with WinHealth's investment in CET, Cumberland also made an additional $1.0 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment in CET.  Cumberland purchased additional CET shares through contribution of $0.3&#160;million in cash and a conversion of $0.7&#160;million in intercompany loans payable.  Upon completion of the additional investment by WinHealth and Cumberland, Gloria Pharmaceuticals returned its shares in CET in exchange for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.8 million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that was funded during 2020.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's ownership in CET is now 85% while the remaining interest is owned by WinHealth, Vanderbilt University and the Tennessee Technology Development Corporation. The operating results of CET allocated to noncontrolling interests in the consolidated statements of operations were  $79,798 and $95,212 for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January&#160;1, 2007, the Company formed a wholly-owned subsidiary, Cumberland Pharma Sales Corp. ("CPSC").  CPSC is the subsidiary that employs the Company's hospital and field sales force personnel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company formed the Cumberland Pharma Foundation (the "Foundation") to serve as a vehicle to facilitate the ongoing philanthropic endeavors of Cumberland Pharmaceuticals Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Foundation was formed as a nonprofit corporation designed to qualify as a tax-exempt organization pursuant to Section 501(a) of the Internal Revenue Code. The Foundation&#x2019;s Board of Directors is comprised of Cumberland Pharmaceuticals executives who are responsible for overseeing the Foundation&#x2019;s ongoing activities including charitable contributions. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Cumberland provided a grant of 50,000 shares of the Company's common stock to the Foundation. The shares will address the ongoing financial needs of the Foundation.  The organization also plans to hold a portion of the shares for long-term appreciation. The Foundation maintains separate financial statements and its ongoing operations will not impact the financial statements of Cumberland Pharmaceuticals. Initial annual grants by the Foundation have been and are expected to remain consistent with the historic level of contributions made by Cumberland Pharmaceuticals.  During 2019, Cumberland Pharmaceuticals committed approximately $50,000 in cash contributions that were paid to the Foundation during 2020.  Likewise, during 2020, the Company committed approximately $25,000 in cash contributions paid to the Foundation during 2021. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company made a $25,000 cash contribution to the Foundation.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
      contextRef="ib9062e0d132343aaa03943a47c77e779_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzE4MjU_99ba9d41-77af-4e6b-b939-6a0e0458d64a"
      unitRef="usd">1000000</us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="ifbd696f587e24eb997ec609f8ce82517_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzIwOTE_14c8bd48-b5c0-4d50-88c4-2aab2b0b5f71"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:SubsidiaryInvestmentPurchaseOfShares
      contextRef="ifbd696f587e24eb997ec609f8ce82517_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzIzNzg_0aca40ab-4dd3-4a66-aeff-80a102da0179"
      unitRef="usd">1000000</cpix:SubsidiaryInvestmentPurchaseOfShares>
    <cpix:ContributionOfCashAdditionalSharesPurchased
      contextRef="i7002a7773f304b60a1fb957d9bf22167_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzI0Njg_92fb6f13-c13a-4730-8d42-5a7cc02069e0"
      unitRef="usd">300000</cpix:ContributionOfCashAdditionalSharesPurchased>
    <cpix:IntercompanyLoansPayableConvertedAmount
      contextRef="ifbd696f587e24eb997ec609f8ce82517_I20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzI0OTk_eb7eb769-fd03-40a7-baf2-07bef1de8b19"
      unitRef="usd">700000</cpix:IntercompanyLoansPayableConvertedAmount>
    <cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital
      contextRef="id417cd67920147a1928abf32d83fb11f_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzI2NzU_2fcbf77b-3a7c-4433-a4e2-6ae4a9512970"
      unitRef="usd">800000</cpix:SubsidiaryInvestmentPaymentsForReturnOfCapital>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i6ed29773e4754bd1a441c809e5231f15_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzI3NDc_02dd2402-fa9e-41c2-8daa-a41b31871fbe"
      unitRef="number">0.85</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzI5OTk_e5fa013d-74a1-4eba-9af8-274c51e6d2f6"
      unitRef="usd">-79798</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzMwMDQ_00287421-6934-476d-a4d3-2cb216b37593"
      unitRef="usd">-95212</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <cpix:SharebasedCompensationCharitableContributionofSharesShares
      contextRef="i6c780a0c3e87440c8eb1928bb0ce5f86_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzQ4NDA_e13e060e-6e04-4173-a00f-2871a1b5acc6"
      unitRef="shares">50000</cpix:SharebasedCompensationCharitableContributionofSharesShares>
    <cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions
      contextRef="i920d5ee9a6184682bc7bf8c05423756f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzQ4NDQ_da967638-58ef-4064-bb08-4394b47f6602"
      unitRef="usd">50000</cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions>
    <cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions
      contextRef="i478ad941e6444190835fbd70e6a0fda2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzQ4NDg_26c2346d-7f27-4c93-a0f4-b5d02b7c10e2"
      unitRef="usd">25000</cpix:ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions>
    <cpix:ShareBasedCompensationCharitableContributionOfSharesCashContributions
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTAvZnJhZzo5ZmM3NmI2ZGVlOTQ0NjFjOWI0MWNjOTI3OGExMzc2Yy90ZXh0cmVnaW9uOjlmYzc2YjZkZWU5NDQ2MWM5YjQxY2M5Mjc4YTEzNzZjXzU0OTc1NTgxODc0Nw_1a2964f1-37a3-407c-8962-260e1fcd2112"
      unitRef="usd">25000</cpix:ShareBasedCompensationCharitableContributionOfSharesCashContributions>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE4_3ac6b3bf-994f-4e0b-9ab4-2846e1049086">Significant Accounting Policies&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In early 2020, the U.S. declared a health care emergency following the outbreak of SARS-CoV-2, a novel strain of coronavirus that causes COVID-19, a respiratory illness. The Company has managed through the resulting COVID-19 pandemic, continuing to operate our business &#x2013; keeping facilities open and our organization intact. We moved quickly to ensure the health and safety of our team. We also maintained our ongoing compliance with the many laws and regulations that apply to us as a publicly traded pharmaceutical company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout the pandemic, Cumberland faced the same challenges affecting other companies that rely on hospital admissions and patient visits to drive revenue. Our business and our clinical studies were impacted, as fewer patients sought elective surgeries and our access to medical facilities was substantially limited. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We carefully monitored our supply chain, including the flow of raw materials and the batches of finished products emerging from the facilities that manufacture our products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several of our brands were negatively impacted by the lockdowns and postponement of physician office visits and elective procedures. However, we are fortunate to have a diversified product portfolio that includes other brands that have delivered a strong performance during the pandemic.  Overall, we have been able to continue the delivery of our products while addressing the interests of our shareholders, employees, partners and community.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.  The Company's most significant estimates include: (1) its allowances for chargebacks and accruals for rebates and product returns (2) the allowances for obsolescent or unmarketable inventory and (3) valuation of contingent consideration liability associated with business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.  Net revenues from customers outside the United States were approximately $1.5 million and $2.2 million for the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -    Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2022 and 2021, cash equivalents consist primarily of money market funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, as well as amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $0.6 million at December&#160;31, 2022 and $0.3 million at December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale at third party facilities located in the U.S. and international locations.  Periodic inventory counts are made by the warehouse teams and by the Company on a regular basis.  In addition, the Company re-tests API inventory prior to use to confirm product expiration.  Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.  The Company classifies the Vibativ inventories and ifetroban inventories that it does not expect to sell within one year as non-current inventories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the Company filed its Shelf Registration on Form S-3 with the SEC associated with the sale of up to $100&#160;million in corporate securities. The Shelf Registration was declared effective in January 2018. It also included an At the Market ("ATM") feature that allows the Company to sell common shares at market prices, along with an agreement with B. Riley FBR Inc. to support such a placement of shares. The Company filed an updated Form S-3 with the SEC in December 2020, which was declared effective in January 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 27, 2021, the Company filed a related prospectus supplement in connection with the sale and issuance of shares having an aggregate gross sales price of up to $19&#160;million.  The Company amended the At the Market Sales Agreement on December 27, 2021, in order to allow the Company to continue using its ATM feature to sell shares at market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to continue an ATM feature through B. Riley FBR, Inc. that would allow the Company to issue shares of its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded deferred offering costs for payments directly related to the current Shelf Registration on Form S-3 that was completed during December 2021. These costs consist of legal and accounting fees that the Company has capitalized. Deferred costs associated with the Shelf Registration will be reclassified to additional paid in capital on a pro-rata basis as the Company completes sales of shares under the Shelf Registration.  The Company did not issue any shares under this ATM during the year ended December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#x2019;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ and Sancuso acquisitions. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense is recognized ratably over the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated economic life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term of license agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of patent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and other indefinite lived intangible assets that are not subject to amortization are tested at least annually for impairment.  The impairment analysis for goodwill requires a comparison of fair value to the carrying value of the reporting unit.  The Company's goodwill was acquired in November 2018 with the Vibativ acquisition and in January 2022 with the Sancuso acquisition. As a result, the Vibativ and Sancuso components of the Company are the reporting units evaluated for goodwill impairment.  Cumberland determined the fair value of the reporting units through current and future estimated revenue and profitability of the product.  The Company recorded no impairment charges during 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, Cumberland entered into an agreement with WinHealth Investment (Singapore) Ltd creating WHC Biopharmaceuticals, Pte. Ltd. The joint venture, as a limited liability company, will focus on acquiring, developing, registering, and commercializing development stage and commercial stage biopharmaceuticals for China, Hong Kong and other Asian markets.  The agreement provides for initial investment from WinHealth in the form of a $0.2&#160;million equity contribution and an initial investment from Cumberland in the form of $0.2&#160;million convertible note. The joint venture will seek additional future capital from additional investors and has entered into exclusive option agreements to license intellectual property from both Cumberland Pharmaceuticals Inc. and Cumberland Emerging Technologies.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#x2019;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Rebates and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#x2019;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and Marketing Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distribution Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Distribution costs were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations. Advertising costs were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advertising costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,927,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,927,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#x2019;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#x2019;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#x201c;more likely than not&#x201d; that the position would be sustained upon examination by the taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3 do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2022, Cumberland named Martin S. Brown Jr. to our Board of Directors. Mr. Brown is an attorney with over 30 years of corporate law experience who brings significant legal, public company, health care and civic experience to our board.  The Company relies on several law firms for legal advice, including the firm Martin is affiliated.  In 2022, the Company paid Martin's law firm $0.04&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Totect&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 19, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODI5_fc1f4b1a-4b2a-4248-93ea-cfa2df14975d">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company are stated in U.S. dollars and are prepared using U.S. generally accepted accounting principles. These financial statements include the accounts of the Company and its wholly and majority-owned subsidiaries. All significant intercompany transactions and accounts have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE0_38f6d9c1-8cac-4d40-adf1-3ccb3e725326">Use of EstimatesThe preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period.  Actual results could differ from those estimates under different assumptions and conditions.</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODMy_15ca949c-074c-40d6-a961-8abb866def83">Segment ReportingThe Company has one operating segment which is specialty pharmaceutical products. Management has chosen to organize the Company based on the type of products sold. Operating segments are identified as components of an enterprise about which separate discrete financial information is evaluated by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The Company, which uses consolidated financial information in determining how to allocate resources and assess performance, evaluated that our specialty pharmaceutical products compete in similar economic markets and similar circumstances.  Substantially all of the Company&#x2019;s assets are located in the United States. Total revenues are primarily attributable to U.S.&#160;customers.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzM0Mjg_5bed2b35-0c4f-4ad4-92b2-fa02e9aa295f"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Revenues
      contextRef="ia21564bd7ce142dcadc0c24df7ea1958_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzQzMDA_416fa45e-16e0-499f-9dc2-885397a2841c"
      unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie03b356b24224df284680048170d1d18_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzQzMDU_6ce59c5d-b88b-453a-8e54-bdabee115258"
      unitRef="usd">2200000</us-gaap:Revenues>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODEw_dbba7cf6-62b5-4661-8594-0001366e4964">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of financial assets and liabilities is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date.  The Company's fair value measurements follow the appropriate rules as well as the fair value hierarchy that prioritizes the information used to develop the measurements.  It applies whenever other guidance requires (or permits) assets or liabilities to be measured at fair value and gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels is described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 -   Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 -  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:72pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 -    Significant inputs to the valuation model are unobservable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain policies and procedures to value instruments using the best and most relevant data available. The following section describes the valuation methodologies we use to measure different financial instruments at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, contingent consideration liability and a revolving line of credit. The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to their short-term nature. The revolving line of credit has a variable interest rate, which approximates the current market rate.&lt;/span&gt;&lt;/div&gt;The Company's contingent consideration liability is a Level 3 fair value measurement that is updated on a recurring basis at each reporting period using a valuation model.  Consistent with Level 3 fair value measurements, there are significant inputs to the valuation model that are unobservable.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODIy_f2c6a704-68a6-4304-be23-7c15fdbdd1fc">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include highly liquid investments with original maturities of three months or less.  As of December&#160;31, 2022 and 2021, cash equivalents consist primarily of money market funds.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODIz_262bb82a-fff2-480d-aac9-d2d7e8c12e3a">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at the invoiced amount.  The Company records allowances for amounts that could become uncollectible in the future based on historical experience, as well as amounts related to chargebacks and cash discounts. The Company reviews each customer balance to assess collection status.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s products are distributed through independent pharmaceutical wholesalers.  The allowances against accounts receivable for chargebacks and discounts are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks and discounts. The allowances in accounts receivable for chargebacks and cash discounts were $0.6 million at December&#160;31, 2022 and $0.3 million at December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed. Cash discounts are reductions to invoiced amounts offered to customers for payment within a specified period of time from the date of the invoice.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i0ba80f17d75f466d9b1472a3319fada7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2Xzc5MDk_3e471dee-be7a-419b-8e91-fac3b8ebbfaa"
      unitRef="usd">600000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i516902d591354e20a3baac1f1747a355_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2Xzc5MjI_42e46e5a-33e6-45d6-abc0-ef60e5db300f"
      unitRef="usd">300000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE1_64d51fb0-8002-45f1-8e00-0e96cef18596">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company works closely with third parties to manufacture and package finished goods for sale.  Based on the customer relationship with the manufacturer or packager, the Company will either take title to finished goods at the time of shipment or at the time of arrival from the manufacturer.  The Company then warehouses such goods until distribution and sale at third party facilities located in the U.S. and international locations.  Periodic inventory counts are made by the warehouse teams and by the Company on a regular basis.  In addition, the Company re-tests API inventory prior to use to confirm product expiration.  Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;The Company continually evaluates inventories for potential losses due to expired, short-dated or slow-moving inventory by comparing sales history and sales projections to the inventory on hand. When evidence indicates the carrying value of a product may not be recoverable, a charge is recorded to reduce the inventory to its current net realizable value.  The Company classifies the Vibativ inventories and ifetroban inventories that it does not expect to sell within one year as non-current inventories.</us-gaap:InventoryPolicyTextBlock>
    <cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODA0_3014e112-8251-4dec-90e0-f38eb4ae4ca8">&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets consist of deferred offering costs, prepaid insurance premiums, prepaid consulting services, deposits and annual fees paid to the U.S. Food and Drug Administration ("FDA").  The Company expenses all prepaid and other current asset amounts as used or over the period of benefit primarily on a straight-line basis, as applicable.&lt;/span&gt;&lt;/div&gt;</cpix:PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="i7cfbfa92c9f74d5d8ecb902cacdb2307_D20180101-20180131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzEwMzQw_ca0a6021-6d9f-4e53-98b3-400322efc24b"
      unitRef="usd">100000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities
      contextRef="if8074777558e4350be02e8d826a67f22_D20211227-20211227"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzEwOTE3_a37d79f2-46d2-4319-83e3-d947554f934f"
      unitRef="usd">19000000</cpix:StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE5_2f9d4d9a-2327-4d22-920f-886d5a98c9d2">&lt;div style="margin-top:7pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including leasehold improvements, are stated at cost. Depreciation is recognized using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the shorter of the initial lease term plus renewal options, if reasonably assured, or the remaining useful life of the asset. Upon retirement or disposal of assets, any gain or loss is reflected as a component of operating income (loss) in the consolidated statement of operations.  Improvements that extend an asset&#x2019;s useful life are capitalized.  Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODA1_7cda8ede-fe6e-4353-8763-34c22a7f3a9a">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible assets and goodwill consist of capitalized costs related to product and license rights, patents, trademarks and goodwill obtained in the Vibativ and Sancuso acquisitions. Goodwill is not amortized for financial reporting purposes, but is subject to impairment analysis at least annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of acquiring product and license rights are capitalized at fair value at the date of acquisition for products that are approved by the FDA for commercial use.  These costs are amortized ratably over the estimated economic life of the product. The economic life is estimated based upon several factors.  This includes the term of the license agreement, the patent life or market exclusivity of the product and as well as  management's expectations of continued involvement with the product and the assessment of future sales, the future periods under which the product will be sold and the profitability of the product. This estimate is evaluated on a regular basis during the amortization period and adjusted if appropriate.  If there are any changes made to the useful life of the product and license rights, the costs associated with such a change, if any, will be capitalized and amortized over the revised useful life.&lt;/span&gt;&lt;/div&gt;Capitalized patent costs consist of outside legal costs associated with obtaining and protecting patents on products that have been approved for marketing by the FDA. If it becomes probable that a patent will not be issued or a patent has been declared invalid, related costs associated with the patent application are expensed at the time such determination is made. All costs associated with obtaining patents for products that have not been approved for marketing by the FDA are expensed as incurred.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODI1_40c25816-0952-45a2-883c-58f59a1a4217">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense is recognized ratably over the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:63.141%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated economic life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term of license agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of patent&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock>
    <cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual
      contextRef="icc21cd41019b4937823097e3a64ff8a3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTphOTg3YzBkZWZmZjk0OGY5YjY5NTYzMDU3NjcxYTkzYy90YWJsZXJhbmdlOmE5ODdjMGRlZmZmOTQ4ZjliNjk1NjMwNTc2NzFhOTNjXzAtMi0xLTEtMzQzODQ_725b0238-e56a-4d6e-93b6-36fadbdcdca2">Estimated economic life</cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual>
    <cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual
      contextRef="i3025fb68648c4df5b3dc39a998179c33_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTphOTg3YzBkZWZmZjk0OGY5YjY5NTYzMDU3NjcxYTkzYy90YWJsZXJhbmdlOmE5ODdjMGRlZmZmOTQ4ZjliNjk1NjMwNTc2NzFhOTNjXzEtMi0xLTEtMzQzODQ_841cc257-a6ad-421c-b54f-92770b575e46">Term of license agreement</cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual>
    <cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual
      contextRef="i4c75d11680284d93969ed668e797eebc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTphOTg3YzBkZWZmZjk0OGY5YjY5NTYzMDU3NjcxYTkzYy90YWJsZXJhbmdlOmE5ODdjMGRlZmZmOTQ4ZjliNjk1NjMwNTc2NzFhOTNjXzItMi0xLTEtMzQzODQ_62ffe953-a25f-45a4-9747-9807af43e3d9">Life of patent</cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODMw_f50bb195-0da7-4afc-8921-7db95ab819ce">Impairment of Long-Lived AssetsLong-lived assets, such as property and equipment, operating lease right-of-use assets and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. If events or circumstances arise that require a long-lived asset to be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by the asset to its carrying value. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment charge is recognized to the extent that the carrying value exceeds the fair value. Fair value is determined through various valuation techniques including quoted market prices, third-party independent appraisals and discounted cash flow models.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzE1OTE3_392ce18e-4393-4a7d-b5c5-1ab28046bc66"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzE1OTE3_a1d81838-6bbb-45a0-aa6a-1a1cfb144039"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i3aa1891de07e463882de10e63f32527d_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzE2NDI3_74525836-ebe9-4f2a-b871-0fe183d15de7"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i3aa1891de07e463882de10e63f32527d_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzE2NTA3_855e00c8-8a22-40da-9ec1-ccb532d350dc"
      unitRef="usd">200000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODA2_806f563b-64a8-4a66-9764-473e88c9567c">&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recognized in the amount that reflects the consideration that we expect to receive for these goods.  Depending upon the shipping terms of the transaction, the revenue is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation.  This occurs upon either shipment of the product or arrival at its ship to destination.  Payment terms typically range from 30 to 60 days from date of shipment. The Company&#x2019;s net product revenue reflects the reduction from gross product revenue for estimated allowances for chargebacks, discounts and damaged goods, and reflects sales related accruals for rebates, coupons, product returns, and certain administrative and service fees. Significant judgments must be made in determining the transaction price for our sales of products related to these adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Rebates and Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowances against accounts receivable and accrued liabilities for chargebacks, discounts, service fees and expired product returns are determined on a product-by-product basis, and established by management as the Company&#x2019;s best estimate at the time of sale based on each product&#x2019;s historical experience adjusted to reflect known changes in the factors that impact such allowances. These allowances are established based on the contractual terms with direct and indirect customers and analyses of historical levels of chargebacks, discounts and returns of expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other organizations, such as managed care providers, pharmacy benefit management companies and government agencies, may receive rebates from the Company based on either negotiated contracts to carry the Company&#x2019;s products or reimbursements for filled prescriptions. These entities are considered indirect customers of the Company. In conjunction with recognizing a sale to a wholesaler, sales revenues are reduced and accrued liabilities are increased by the Company&#x2019;s estimate of the rebate that may be claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, the Company maintains a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. The Company&#x2019;s estimate of the provision for returns is based upon historical experience, expiration date by product as well as any other factor expected to impact future returns. Any changes in the assumptions used to estimate the provision for returns are recognized in the period those assumptions are changed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues primarily consist of income from grant funding programs, licensing agreements, leases and contract services.  Revenue related to grants is recognized when all conditions related to such grants have been met.  All other revenue is recognized when earned.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE2_3e2d23f0-f56f-4f1b-8a52-c7da2c840ab0">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold consists principally of the cost to acquire each unit of product sold, including in-bound freight expense as well as any adjustment in the net realizable value of inventory acquired in acquisitions. Cost of products sold also includes expenses associated with the reduction in the net realizable value of slow-moving or expired product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Selling and Marketing Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling and marketing expense consists primarily of expenses relating to the advertising, promotion, distribution and sale of products, including royalty expense, salaries and related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Distribution Costs&lt;/span&gt;&lt;/div&gt;Distribution costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</us-gaap:CostOfSalesPolicyTextBlock>
    <cpix:ScheduleOfDistributionCostsTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODEy_35718620-f413-401c-8573-1f46483fcb55">Distribution costs were as follows for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;857,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleOfDistributionCostsTableTextBlock>
    <us-gaap:ProductionAndDistributionCosts
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTo1ZGMzYWViMDc5OTM0NzBjOTMzNWJmZjA5ODkyNTkxZC90YWJsZXJhbmdlOjVkYzNhZWIwNzk5MzQ3MGM5MzM1YmZmMDk4OTI1OTFkXzItMi0xLTEtMzQzODQ_dc6a10ea-72c6-46e0-a172-1b247e7080b5"
      unitRef="usd">857842</us-gaap:ProductionAndDistributionCosts>
    <us-gaap:ProductionAndDistributionCosts
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTo1ZGMzYWViMDc5OTM0NzBjOTMzNWJmZjA5ODkyNTkxZC90YWJsZXJhbmdlOjVkYzNhZWIwNzk5MzQ3MGM5MzM1YmZmMDk4OTI1OTFkXzItNC0xLTEtMzQzODQ_cb06a171-6462-4484-9fa6-bdc0395a0d03"
      unitRef="usd">806311</us-gaap:ProductionAndDistributionCosts>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODA4_95316f6b-1ec0-42e3-abff-88e40134a1b2">Advertising CostsAdvertising costs are expensed as incurred and are included as a component of selling and marketing expenses in the consolidated statements of operations.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <cpix:ScheduleOfAdvertisingCostsTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODEz_dcb32322-35c3-4a56-bf8f-43dddb848c04">Advertising costs were as follows for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advertising costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,927,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,927,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleOfAdvertisingCostsTableTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTpiZmMzOTVlNzE1ZWQ0YWRmOTVkZTc5ZDA2ZjA2MzUxYy90YWJsZXJhbmdlOmJmYzM5NWU3MTVlZDRhZGY5NWRlNzlkMDZmMDYzNTFjXzItMi0xLTEtMzQzODQ_0f7273a2-b96f-494b-9dd5-b4e34ac58a1e"
      unitRef="usd">2927041</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90YWJsZTpiZmMzOTVlNzE1ZWQ0YWRmOTVkZTc5ZDA2ZjA2MzUxYy90YWJsZXJhbmdlOmJmYzM5NWU3MTVlZDRhZGY5NWRlNzlkMDZmMDYzNTFjXzItNC0xLTEtMzQzODQ_f7f43824-a9ad-41e3-ae91-ed889407c736"
      unitRef="usd">1927864</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODE3_94ac3285-4277-4fed-b164-f5f85e1a43d7">&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed in the period incurred. Research and development costs are comprised mainly of clinical trial expenses, salaries, wages and other related costs such as materials and supplies. Research and development expense includes activities performed by third-party providers participating in the Company&#x2019;s clinical studies. The Company accounts for these costs based on estimates of work performed, patients enrolled or fixed fees for services over the period of time the clinical trials are performed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODI2_9a344509-dd54-42a1-8246-fb2aaa90377b">&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for deferred taxes using the asset and liability approach. Under this method, deferred tax assets and liabilities are recognized for future tax consequences attributable to operating loss and tax credit carryforwards, as well as differences between the carrying amounts of existing assets and liabilities and their respective tax bases. The Company&#x2019;s principal differences are related to the timing of deductibility of certain items, such as inventory, depreciation, amortization and share-based compensation. Deferred tax assets and liabilities are measured using enacted statutory tax rates that are expected to apply to taxable income in the years such temporary differences are anticipated to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period of enactment. The Company only recognizes income tax benefits associated with an income tax position in which it is &#x201c;more likely than not&#x201d; that the position would be sustained upon examination by the taxing authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, management considers whether some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of existing temporary differences, projected future taxable income and tax planning strategies in making this assessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounting policy with respect to interest and penalties arising from income tax settlements is to recognize them as part of the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODI3_89097ba2-f3fd-4870-b41f-87691c8eba2a">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common shareholders by the weighted-average number of shares outstanding. Except where the result would be antidilutive to income from continuing operations, diluted earnings (loss) per share is calculated by assuming the vesting of unvested restricted stock and the exercise of stock options and warrants and unrecognized compensation costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODMx_fd013424-46f8-471a-b947-4d48094e059e">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes compensation cost for all share-based payments issued, modified, repurchased or canceled. Depending on the nature of the vesting provisions, restricted stock awards are measured using either the fair value on the grant date or the fair value of common stock on the date the vesting provisions lapse. Prior to the lapse for those equity grants not valued on the grant date, the fair value is measured on the last day of the reporting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODI4_2c0fe5ca-f70f-48df-8418-730c8b8992bf">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to several collaborative arrangements with research institutions to identify and pursue promising pharmaceutical product candidates. The funding for these programs is primarily provided through Federal Small Business Administration (SBIR/STTR) and other grant awards. The Company has determined that these collaborative agreements, with the exception of the collaborative payment discussed in Note 3 do not meet the criteria for accounting under ASC Topic 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The agreements do not specifically designate each party&#x2019;s rights and obligations to each other under the collaborative arrangements. Except for patent defense costs, expenses incurred by one party are not required to be reimbursed by the other party.  Expenses &lt;/span&gt;&lt;/div&gt;incurred under these collaborative agreements are included in research and development expenses and funding received from grants are recorded as net revenues in the consolidated statements of operations.</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzU0OTc1NTg0NDI0Nw_37c9e544-8a59-42c2-9467-6e057eebec55"
      unitRef="usd">40000.00</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzU0OTc1NTg0NDI0NQ_89bcbe8e-c34a-4aaa-8d39-6ab1a9537fd6">&lt;div style="margin-top:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, Cumberland entered into a Dissolution Agreement  ("Dissolution Agreement") with Clinigen Healthcare Limited ("Clinigen") in which the Company returned the exclusive rights to commercialize Ethyol&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Totect&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States to Clinigen. Under the terms of the Dissolution Agreement, Cumberland is no longer involved directly or indirectly with the distribution, marketing and promotion of either Ethyol or Totect or any competing products following December 31, 2019. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's exit from the products meets the accounting criteria to be reported as discontinued operations and the discontinued operating results have been reclassified in the financial statements and footnotes for all periods presented to reflect the discontinued status of these products. Refer to Note 19, for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTMvZnJhZzo3ZTZlNmUyZmM0MGQ0YzE3OGY4ZGJhN2Q4OTdlYTIxNi90ZXh0cmVnaW9uOjdlNmU2ZTJmYzQwZDRjMTc4ZjhkYmE3ZDg5N2VhMjE2XzI3ODA5_fb9161d0-2fd2-4fa0-97bb-e24aa46fd681">&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &#x201c;Financial Instruments-Credit Losses,&#x201d; which changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, held-to-maturity debt securities, loans and other instruments, companies will be required to use a new forward-looking &#x201c;expected loss&#x201d; model that generally will result in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, companies will measure credit losses in a manner similar to what they do today, except that the losses will be recognized as allowances rather than as reductions in the amortized cost of the securities. Companies will have to disclose additional information, including information they use to track credit quality by year of origination for most financing receivables. Companies will apply the ASU&#x2019;s provisions as a cumulative-effect adjustment, if any, to retained earnings as of the beginning of the first reporting period in which the guidance is adopted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Related to ASU No. 2016-13 discussed above, in May 2019, the FASB issued ASU 2019-05, "Financial Instruments-Credit Losses (Topic 326): Targeted Transition Relief" which provides transition relief for ASU 2016-13 by providing entities with an alternative to irrevocably electing the fair value option for eligible financial assets measured at amortized cost upon adoption of the new credit losses standard. Certain eligibility requirements must be met and the election must be applied on an instrument-by-instrument basis. The election is not available for either available-for-sale or held-to-maturity debt securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted both ASU 2016-13 and ASU 2019-05 on January 1, 2023. The adoption of ASU 2016-13 and ASU 2019-05 are not expected to have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQ1NDU_ac926586-b60c-448f-9713-8542934e94c7">RediTrex&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;, Vibativ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; and Sancuso&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RediTrex&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company announced an agreement with the Nordic Group B.V. ("Nordic") to acquire the exclusive U.S. rights to Nordic&#x2019;s injectable methotrexate product line designed for the treatment of active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis, and severe disabling psoriasis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the license Cumberland paid a deposit of $0.1 million at closing.  The Company provided $0.9 million in consideration through a grant of 180,000 restricted shares of Cumberland common stock to be vested upon the FDA approval of the first Nordic product. Cumberland also agreed to provide Nordic a series of payments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tied to the products&#x2019; FDA approval, launch and achievement of certain sales milestones. Under the terms of the agreement, Cumberland is responsible for the product registration and commercialization in the U.S. Nordic is responsible for product manufacturing and supply.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2019, Cumberland received FDA approval for the first Nordic injectable product and authorization to market them under the RediTrex brand name. The 180,000 shares of restricted Cumberland common stock previously provided to Nordic vested upon approval and were valued at $0.9 million on the vesting date. The FDA approval also resulted in a $1.0&#160;million milestone payment due to Nordic.  This milestone payment was paid in July 2020.  During December 2020, Cumberland began distributing RediTrex which also resulted in a $1.0&#160;million milestone payment due to Nordic.  The full launch of RediTrex occurred in October 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective July 12, 2022, the Company entered into an amendment to our agreement with Nordic whereby they may assume responsibility for RediTrex marketing authorization in the U.S. and the opportunity to commercialize the product in the U.S. after June 30, 2023. Cumberland will continue to distribute and support the product until then.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the terms of the amendment, Nordic has agreed to return the 180,000 restricted Cumberland shares we previously issued to Nordic which will be cancelled, refund to Cumberland the milestone payment of $1.0&#160;million we made associated with the brand's U.S. approval and issue a credit note in favor of the Company in the amount of $1.0&#160;million for the unpaid milestone payment due from us for launch of the product line. The companies will cooperate on any transition and Cumberland will receive a long-term royalty on any Nordic sales of the product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland had approximately $2.6&#160;million in net intangible assets related to RediTrex at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vibativ&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2018, the Company closed on an agreement with Theravance Biopharma ("Theravance") to acquire the global responsibility for Vibativ including the marketing, distribution, manufacturing and regulatory activities associated with the brand.  Vibativ is a patented, FDA approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.  Cumberland acquired Vibativ to further add to its product offerings, increase its net revenue and positively contribute to the Company's operating results.  Cumberland expects to deduct the goodwill acquired in the acquisition for tax purposes.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Cumberland agreed to pay a royalty of up to 20% on future net sales of the product after a $2.5 million threshold is met.  The future royalty payments were required to be recognized at their acquisition-date fair value as part of the contingent consideration transferred in the business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the Company's Level 3 contingent consideration liability.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,166,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,147,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,133,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,104,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of the contingent consideration liability is $1.3&#160;million and the non-current portion is $2.8&#160;million, as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sancuso&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sancuso is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment. The active drug in Sancuso, granisetron, slowly dissolves in the thin layer of adhesive that sticks to the patient&#x2019;s skin and is released into their bloodstream over several days, working continuously to prevent chemotherapy-induced nausea and vomiting (&#x201c;CINV&#x201d;). It is applied 24 to 48 hours before receiving chemotherapy and can prevent CINV for up to five consecutive days. Alternative oral treatments must be taken several times (day and night) to deliver the same therapeutic doses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland acquired U.S. rights to Sancuso and assumed full commercial responsibility for the product in the U.S. &#x2013; including its marketing, promotion, distribution, manufacturing and medical support activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has accounted for the transaction as a business combination in accordance with ASC 805 and the product sales are included in the results of operations subsequent to the acquisition date. The Company made an upfront payment of $13.5&#160;million at the closing of the transaction. The Agreement calls for milestone payments of up to $3.5&#160;million based on the attainment of various approvals and sales performance. The Company believes that $1.5&#160;million of the milestone payments will be earned and paid.  The remaining milestone of $2.0&#160;million will be paid if and when annual net revenue exceeds $20&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Cumberland has agreed to pay a royalty of up to 10% of on-going net sales of the product.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The future royalty payments were required to be recognized at their acquisition-date fair value as a contingent consideration liability, as part of the contingent consideration transferred in the business combination. Cumberland has prepared a valuation of the contingent consideration liability utilizing significant unobservable inputs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result, the valuation is classified as Level 3 fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was funded by cash and the Company's revolving credit facility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company worked with an outside consultant firm to finalize the Sancuso valuation of the transaction.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value for the assets and liabilities assumed were as follows: prepaid expenses $1.8&#160;million, inventory $2.6&#160;million, goodwill $0.03&#160;million, intangible assets $14.1&#160;million, milestone payable $1.7&#160;million and contingent liability $3.4&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Balance at January 3, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(1,075,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;16,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;675,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of the contingent consideration liability is $1.7 million and the non-current portion is $1.3 million, as of December&#160;31, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sancuso Intangible Assets, Goodwill, Revenue and Earnings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An outside consultant prepared the Sancuso valuation and the valuation is complete.  The goodwill of $0.03&#160;million arising from this acquisition consists largely of the synergies and economies of scale expected from combining the operations of the Company and the acquired company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on discussions with Management, the identified intangible assets were valued as a composite asset referred to as the Sancuso product rights. It is comprised of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;   Technology &#x2013; patented and unpatented IP and know-how;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;   Marketing intangible assets including product trademarks/names/dress; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;   Customer base to which the product is sold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is a common practice in the life sciences industry to value intangible assets under a portfolio approach given the nature of the intangible assets and facts and circumstances that are common to the industry. The Goodwill amount to be deducted for tax purposes is expected to be $0.03&#160;million and will be amortized over 15 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sancuso was acquired on January 3, 2022. For the year ended December 31, 2022, the amounts included in the income statement for revenue and operating profit were $13.6&#160;million and $6.6&#160;million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a pro-forma basis, the revenue and earnings of the combined entity as though the business combination had occurred in 2021 appears below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumberland 2022 Results&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pro-forma 2021 Results&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,010,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,085,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,704,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,447,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 pro-forma results include results for Sancuso as provided by the management of Kyowa Kirin. The Seller is a pharmaceutical company similar to Cumberland. The 2021 results for Sancuso as reported by Kyowa Kirin reflect accounting methodology and reporting which were similar to those employed by the Company.   &lt;/span&gt;&lt;/div&gt;The Company&#x2019;s 2022 balance sheet reflects the full year impact of the Sancuso acquisition, as the acquisition occurred on January 3, 2022.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i021bbc1b476b4fbe8c8498630b3444b9_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQzMg_73945a27-438b-4439-9e3a-613a94cf6476"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i021bbc1b476b4fbe8c8498630b3444b9_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQ2OQ_6f523173-544f-4665-86dc-d93970394f33"
      unitRef="usd">900000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i9301d1c169904a1d9355a5854c6f29e3_D20161101-20161130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzUwOA_a1cfee3e-6440-4794-92e9-a57f033d788a"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i9301d1c169904a1d9355a5854c6f29e3_D20161101-20161130"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzExMTg_a1cfee3e-6440-4794-92e9-a57f033d788a"
      unitRef="shares">180000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i49ea797c011744d19c463a47c6cbbd46_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzEyMzY_4f642d35-a2e3-40ee-8d4c-e2b5a27efecf"
      unitRef="usd">900000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9b29c34edaba455b8ebdd48b45de02d6_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzEyOTY_223bb06a-5ebd-4697-818d-1c42ed96978f"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9b29c34edaba455b8ebdd48b45de02d6_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzE1MzQ_223bb06a-5ebd-4697-818d-1c42ed96978f"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <cpix:CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable
      contextRef="id9d899e86c97433d9a3fa65fce7361e2_I20220712"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTE3Mw_9c5d6724-88fa-499c-905b-a4dd41d01fd6"
      unitRef="shares">180000</cpix:CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable>
    <cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable
      contextRef="if7fa09f75a3b48cea5b2fb00b556fbe9_I20220712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTE0NQ_a40283d2-fdee-4a0c-a310-434774ed0689"
      unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable>
    <cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue
      contextRef="if7fa09f75a3b48cea5b2fb00b556fbe9_I20220712"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTE1OQ_2de67d93-cccf-4434-b71c-cd76abb836ac"
      unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iec5e58bac724452b876b92a905e3ca14_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzE3Njc_b2ff4080-86f7-4831-80e1-9449e4b65b0e"
      unitRef="usd">2600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <cpix:TieredRoyaltyPaymentsPercentage
      contextRef="i133c71a4398845698d7d7701abc49b01_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzMwODk_bbe0466a-e0f7-400c-8c31-3f3e906eb1b8"
      unitRef="number">0.20</cpix:TieredRoyaltyPaymentsPercentage>
    <cpix:TieredRoyaltyPaymentsThreshold
      contextRef="i133c71a4398845698d7d7701abc49b01_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzI3NDg3NzkwNzk3MDI_8ed970ae-05a1-48e3-bc8f-c09b250e383e"
      unitRef="usd">2500000</cpix:TieredRoyaltyPaymentsThreshold>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQ1NDg_16029336-6a95-403b-8e41-1bbca0c8c497">The following table presents the changes in the Company's Level 3 contingent consideration liability.  The contingent consideration earned and accrued in operating expenses is paid to the seller quarterly.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contingent consideration liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,200,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,166,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,147,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,515,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,133,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,104,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;876,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,154,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;The following table presents the changes in the fair value of the contingent consideration liability that is remeasured on a recurring basis.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Balance at January 3, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,384,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash payment of royalty during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;(1,075,631)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Change in fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;16,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Contingent consideration earned and accrued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;675,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8e22ba92c2194833a0319101083d1275_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzEzLTEtMS0xLTM0Mzg0_daf23246-d314-4a5e-88ba-54eb38420876"
      unitRef="usd">8200553</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i6f2090fcc89c46fc8c515cd09cc5ffae_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE0LTEtMS0xLTM0Mzg0_6516dfaa-ea89-4cef-95ff-e37433b0733e"
      unitRef="usd">2166682</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6f2090fcc89c46fc8c515cd09cc5ffae_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE1LTEtMS0xLTM0Mzg0_e8eaf588-5ec7-4312-ae2f-483315a5f91a"
      unitRef="usd">-1147750</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i6f2090fcc89c46fc8c515cd09cc5ffae_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE2LTEtMS0xLTM0Mzg0_42f4d485-240b-4fa4-926d-7f4554af0c0e"
      unitRef="usd">1629506</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib36b29930b41472aaa5de35a1e59cb95_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE3LTEtMS0xLTM0Mzg0_70ddd47a-c6d0-495a-a607-acea9b80c84d"
      unitRef="usd">6515627</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i924046424f4a4ad5a7dce8e0bfe36d8b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE4LTEtMS0xLTQxNzAw_54ac0175-6d7b-4244-9f3c-00eb6b2d3d2f"
      unitRef="usd">1133113</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i924046424f4a4ad5a7dce8e0bfe36d8b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzE5LTEtMS0xLTQxNzAw_e995975c-6487-46a2-ad34-4cf9bcc60dfe"
      unitRef="usd">-2104690</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i924046424f4a4ad5a7dce8e0bfe36d8b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzIwLTEtMS0xLTQxNzAw_cab586cf-dc2a-47c6-9062-2dee63fe2471"
      unitRef="usd">876999</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTowMjEzMDY2MWVhNjY0NDIxYmNkNGE0MGM5MWJkMDE3MS90YWJsZXJhbmdlOjAyMTMwNjYxZWE2NjQ0MjFiY2Q0YTQwYzkxYmQwMTcxXzIxLTEtMS0xLTQxNjk4_1dcb699a-67cf-471f-b2b3-338873b5a234"
      unitRef="usd">4154823</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQ0OTg_cc850bdc-7173-412b-96b9-5d4cbac61b08"
      unitRef="usd">1300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzQ1MzI_cc39afcf-616a-46f2-89c6-462ad1e855ad"
      unitRef="usd">2800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="ieb014f15e52c4aa7b4a00972e8c2037e_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTE4NA_058b003f-223c-46e6-becf-67365fd46338"
      unitRef="usd">13500000</cpix:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum
      contextRef="ieb014f15e52c4aa7b4a00972e8c2037e_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTE5OQ_789e9895-73c6-4b56-8165-3cb500790bc5"
      unitRef="usd">3500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected
      contextRef="i44944cd121824f49afdb95c8a1b230c0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTIxMw_559ec805-9121-4a90-bc22-37797b8bddc1"
      unitRef="usd">1500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining
      contextRef="i44944cd121824f49afdb95c8a1b230c0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTIyNw_323ba0b8-1148-40ae-8b27-a4fa49d1bd47"
      unitRef="usd">2000000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold
      contextRef="i44944cd121824f49afdb95c8a1b230c0_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTI0MQ_892a772a-80c6-49e8-9e4c-475b1c7f04e6"
      unitRef="usd">20000000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold>
    <cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
      contextRef="i4e74c81ece854dfcb8d7c8c3bc0a2f03_I20220103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTI1NA_68672903-f067-4f83-8566-ae65202e3063"
      unitRef="number">0.10</cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTI1OQ_608985b0-3640-45ae-9d17-ab6d8fb06f45"
      unitRef="usd">1800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTMwMg_3662f66b-e2bf-4e2a-be88-0b2487cc4680"
      unitRef="usd">2600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:Goodwill
      contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTMxNg_8c75a671-1e23-4bef-8c4c-70d76e5ccc3f"
      unitRef="usd">30000.00</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTI3Mw_e4915840-0ee5-45cf-ac3c-20db31c522df"
      unitRef="usd">14100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:OtherPaymentsToAcquireBusinesses
      contextRef="if8f59b1cd25d434eb648fc77c3dea5b1_D20220103-20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTI4OA_f9cf97cc-e8a7-455a-838d-e80603c1dfc4"
      unitRef="usd">1700000</us-gaap:OtherPaymentsToAcquireBusinesses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgyNTMzMQ_8b69071b-3a6f-4c36-8384-dd813077e136"
      unitRef="usd">3400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTplYjg3OTk3NGU5ZDA0ODAwOTE5ZjRkM2UyZTI1ZDQwZi90YWJsZXJhbmdlOmViODc5OTc0ZTlkMDQ4MDA5MTlmNGQzZTJlMjVkNDBmXzEtMS0xLTEtNDE2OTY_e52b0499-e366-4b8b-8085-982b9daccf28"
      unitRef="usd">3384000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsForRoyalties
      contextRef="i81f3f0b045ff491da276024b81457433_D20220103-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTplYjg3OTk3NGU5ZDA0ODAwOTE5ZjRkM2UyZTI1ZDQwZi90YWJsZXJhbmdlOmViODc5OTc0ZTlkMDQ4MDA5MTlmNGQzZTJlMjVkNDBmXzItMS0xLTEtNDE3MTQ_349a6236-d19c-40b3-ab04-1e5739f9a9ae"
      unitRef="usd">1075631</us-gaap:PaymentsForRoyalties>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i81f3f0b045ff491da276024b81457433_D20220103-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTplYjg3OTk3NGU5ZDA0ODAwOTE5ZjRkM2UyZTI1ZDQwZi90YWJsZXJhbmdlOmViODc5OTc0ZTlkMDQ4MDA5MTlmNGQzZTJlMjVkNDBmXzMtMS0xLTEtNDE2OTY_f137ee35-cdb4-488e-a683-4014d69fab78"
      unitRef="usd">16394</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses
      contextRef="i81f3f0b045ff491da276024b81457433_D20220103-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTplYjg3OTk3NGU5ZDA0ODAwOTE5ZjRkM2UyZTI1ZDQwZi90YWJsZXJhbmdlOmViODc5OTc0ZTlkMDQ4MDA5MTlmNGQzZTJlMjVkNDBmXzQtMS0xLTEtNDE2OTY_b4cfe5db-453d-48a9-a60a-86f1cde4f484"
      unitRef="usd">675237</cpix:BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if92534bff0f1467fbb22f084f101995f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTplYjg3OTk3NGU5ZDA0ODAwOTE5ZjRkM2UyZTI1ZDQwZi90YWJsZXJhbmdlOmViODc5OTc0ZTlkMDQ4MDA5MTlmNGQzZTJlMjVkNDBmXzUtMS0xLTEtNDE2OTY_89d3e5ab-b610-499e-bbb6-931a23852c27"
      unitRef="usd">3000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="if92534bff0f1467fbb22f084f101995f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzI3NDg3NzkwNzk2NDY_c940433c-060c-4e5d-9771-445f285521cb"
      unitRef="usd">1700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="if92534bff0f1467fbb22f084f101995f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzI3NDg3NzkwNzk2Nzg_32d1a419-161d-443a-b64d-2e4338023c46"
      unitRef="usd">1300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:Goodwill
      contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgxNTU3ODE_c6feca57-5cf0-456c-8075-dd9b3765fa09"
      unitRef="usd">30000.00</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgxNTU4MTA_8878acff-35c3-4453-9762-74c851736852"
      unitRef="usd">30000.00</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i469400cc5d084372975262bfe96ab0fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgzMDczMQ_fd6a0e02-8437-4085-896c-bf8a883b0f77"
      unitRef="usd">13600000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i469400cc5d084372975262bfe96ab0fc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgzMDcxNw_ad779922-06c5-4d91-9c29-6902c8a5b3cb"
      unitRef="usd">6600000</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90ZXh0cmVnaW9uOjZlMTM4ZGYyNDhlODRlNzU4YmEzZmJjNDA0OGExMTk1XzU0OTc1NTgzMDcwMQ_46c3f877-e25d-4285-960c-4cbe15ba047e">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a pro-forma basis, the revenue and earnings of the combined entity as though the business combination had occurred in 2021 appears below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.901%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumberland 2022 Results&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pro-forma 2021 Results&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,010,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,085,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,704,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,447,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTpmMWYxNDJhZmFhMTc0MTQzYTcyNmJjMGY1MTBiOTMyZi90YWJsZXJhbmdlOmYxZjE0MmFmYWExNzQxNDNhNzI2YmMwZjUxMGI5MzJmXzEtMS0xLTEtNDM1MDg_c85a7225-4ae3-4383-8ce4-c3827a8a4bd7"
      unitRef="usd">42010949</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTpmMWYxNDJhZmFhMTc0MTQzYTcyNmJjMGY1MTBiOTMyZi90YWJsZXJhbmdlOmYxZjE0MmFmYWExNzQxNDNhNzI2YmMwZjUxMGI5MzJmXzEtMy0xLTEtNDM1MDg_6f570f51-46c7-43e0-a615-bc68401cbcc9"
      unitRef="usd">50085043</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTpmMWYxNDJhZmFhMTc0MTQzYTcyNmJjMGY1MTBiOTMyZi90YWJsZXJhbmdlOmYxZjE0MmFmYWExNzQxNDNhNzI2YmMwZjUxMGI5MzJmXzMtMS0xLTEtNDM1MDg_082099de-1df5-4c11-8381-d340ec8030d7"
      unitRef="usd">-5704929</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTYvZnJhZzo2ZTEzOGRmMjQ4ZTg0ZTc1OGJhM2ZiYzQwNDhhMTE5NS90YWJsZTpmMWYxNDJhZmFhMTc0MTQzYTcyNmJjMGY1MTBiOTMyZi90YWJsZXJhbmdlOmYxZjE0MmFmYWExNzQxNDNhNzI2YmMwZjUxMGI5MzJmXzMtMy0xLTEtNDM1MDg_592ee01c-c25d-4ff4-84a0-0bfc1b6ba02d"
      unitRef="usd">-5447420</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzMyMDE_8a0e588c-6c4b-442a-a08c-92003fe375b7">Revenues&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:center;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product revenues consisted of the following for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,205,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,993,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,205,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,704,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,827,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,970,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,859,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,681,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,045,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has agreements with international partners for commercialization of the Company's products with associated payments included in other revenues. Those agreements provide that each of the partners are responsible for seeking regulatory approvals for the product, and following approval, each partner will be responsible for the ongoing distribution and sales in the respective international territories. The Company provides a dossier for product registration and maintains responsibility for the relevant intellectual property. Cumberland is typically entitled to receive a non-refundable, up-front payment at the time each agreement is executed as consideration for the product dossier and for the rights to the distinct intellectual property rights in the respective international territory. These agreements also typically provide for additional payments upon a partner&#x2019;s achievement of a defined regulatory approval and sales milestones. The Company may also be entitled to receive royalties on future sales of the products and a transfer price on supplies.  The contractual payments associated with the partner&#x2019;s achievement of regulatory approvals, sales milestones and royalties on future sales are recognized as revenue upon occurrence, or at such time that the Company has a high degree of confidence that the revenue would not be reversed in a subsequent period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The international agreements provide for $1.5 million in non-refundable up-front payments, milestone payments of up to $2.4 million related to regulatory approvals and up to $5.6 million in payments related to product sales.  From 2012 through December&#160;31, 2022, the Company has recognized a cumulative $1.9 million in upfront payments as other revenue and has recognized $0.5&#160;million during the year 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenues during 2022 and 2021 also include funding from federal grant programs including those secured by CET through the Small Business Administration as well as lease income generated by CET&#x2019;s Life Sciences Center. The Life Sciences Center is a research center that provides scientists with access to flexible lab space and other resources to develop biomedical products. Grant revenue from these programs totaled approximately $0.2 million and $0.4 million for the years ending December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzMyMDM_6acae24e-e085-4e3f-8160-c1f851a0947a">&lt;div style="margin-top:7pt;text-align:center;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s net product revenues consisted of the following for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kristalose&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,205,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,993,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,205,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vibativ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,487,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,704,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Caldolor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,827,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,970,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acetadote&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Omeclamox-Pak&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vaprisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,859,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RediTrex&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,681,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,045,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4696b3ec55c74a54b9b5653d2452aca1_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzItMi0xLTEtMzQzODQ_eb9a93b1-550c-493c-97f7-1032056bd6d1"
      unitRef="usd">15205155</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if32dce83e48c4a7b91a0d4e335b66480_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzItNC0xLTEtMzQzODQ_74c17705-a313-4874-ae98-9036e7a6d9e9"
      unitRef="usd">15993658</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98dc7a56a6ee4bc5ace7b118374a0de5_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzMtMi0xLTEtMzY2Nzc_80e6f48f-c88b-42cd-b8a3-1f697cbb8f42"
      unitRef="usd">13205603</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaddae84fd5b4b89a3139c9ac38b23c6_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzMtNC0xLTEtMzY2Nzc_9e37825f-6dd2-4c33-b3f5-824f216e78c7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f3d9b8292154fa0b504704f80f2e116_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzMtMi0xLTEtMzQzODQ_1e9c80af-9464-4113-81b7-6f4db0729cb7"
      unitRef="usd">7487462</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf29047eb0424eef806c96c842debe22_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzMtNC0xLTEtMzQzODQ_2972dd2d-0ce2-4477-b58c-eac4128b6615"
      unitRef="usd">11704062</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e3b77ebc51845fd880355bb1563cc5f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzQtMi0xLTEtMzQzODQ_b730d73c-2780-4dd9-9a50-b33132ea491b"
      unitRef="usd">4827200</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18b3e901750344aba9b2ac8dc3d8398e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzQtNC0xLTEtMzQzODQ_e2b58ac3-5cdf-46e7-b371-0d89c227ab5d"
      unitRef="usd">4970301</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37ab018ed1464e58a2e6f54a577ad077_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzUtMi0xLTEtMzQzODQ_5fdb7170-7c10-430d-ac97-381ec20b47c9"
      unitRef="usd">501040</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8fd80adb04d4f22a287d4e54e9550dc_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzUtNC0xLTEtMzQzODQ_4fc50890-1751-4c85-abce-28ed9ed4c5c4"
      unitRef="usd">850993</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa10efc46e9e461386aa80220fb7a4ce_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzYtMi0xLTEtMzQzODQ_f4a0bf31-e0b2-49e1-b900-a137fedc40f1"
      unitRef="usd">29145</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe04d4939aef4eb2ae85d6d4c47c642d_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzYtNC0xLTEtMzQzODQ_673407a2-c2d0-44ae-81e0-563ae8960015"
      unitRef="usd">-388657</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9859c4aed134140b347fcfab3e9f9f9_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzctMi0xLTEtMzQzODQ_a5cec3fe-bad3-4e7e-93c9-8ee56a7b4fb6"
      unitRef="usd">-447697</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6e9d7a75c774347844d3abe0e6a3d75_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzctNC0xLTEtMzQzODQ_52249283-931f-4ae0-a19c-90b3e80939ff"
      unitRef="usd">1859581</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82ef6903bdd04aa7be5bf21326a39725_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzgtMi0xLTEtMzQzODQ_8aede2ee-b194-4258-83ab-10db95bec6d2"
      unitRef="usd">-126726</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee6aca6f1f4640128e84638b21a73ac8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzgtNC0xLTEtMzQzODQ_25b06301-279b-465f-926c-c3f31bfbb85b"
      unitRef="usd">55321</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzktMi0xLTEtMzQzODQ_d9ee1cd2-476f-446d-afe3-bbfd3f72eb1e"
      unitRef="usd">40681182</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90YWJsZTplOWFjNWFhYjZlMzU0YmFhODNkY2M5M2MzMTA0NGY2ZC90YWJsZXJhbmdlOmU5YWM1YWFiNmUzNTRiYWE4M2RjYzkzYzMxMDQ0ZjZkXzktNC0xLTEtMzQzODQ_e9206437-4974-46be-ba21-d4f8bc83adc3"
      unitRef="usd">35045259</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <cpix:RevenueRecognitionUpfrontPayment
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzIzMjg_4b4ff2f3-6a9a-4f86-a0e7-842d31ae6900"
      unitRef="usd">1500000</cpix:RevenueRecognitionUpfrontPayment>
    <cpix:RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzIzOTY_5a56f374-a0f5-4cd1-acaf-a952f747013b"
      unitRef="usd">2400000</cpix:RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval>
    <cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzI0NDE_2f508c2e-f670-40e5-bdc1-d659e0736d5a"
      unitRef="usd">5600000</cpix:RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales>
    <cpix:RevenueRecognitionCumulativeUpfrontPayment
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzI1NDU_33f3b14e-969f-4aa6-bdbd-078e7b642764"
      unitRef="usd">1900000</cpix:RevenueRecognitionCumulativeUpfrontPayment>
    <cpix:RevenueRecognitionMilestonePayments
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzI2MDQ_4dd5b10c-9427-4aa7-9d44-8e06ba73629c"
      unitRef="usd">500000</cpix:RevenueRecognitionMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6d9484ddbcb49fda1792dcd0ca0e89c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzMxMzc_66a1dea7-e5cb-4760-a09c-3ddcf917a212"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16b9bb498b204e8a9f03c0c2fdc55984_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8xOTkvZnJhZzoyYzEyMTA0MGI4Y2M0MDZmYTQ5NTQzN2M2OTU4MzUyOS90ZXh0cmVnaW9uOjJjMTIxMDQwYjhjYzQwNmZhNDk1NDM3YzY5NTgzNTI5XzMxNDI_f4d02420-0c09-4927-b9dc-6d6a47dc33a1"
      unitRef="usd">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzIxODQ_c574e980-dd55-4ecd-8505-a2c520f1907c">Inventories&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net inventories consisted of the following as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.339%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,899,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,374,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,322,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,390,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,478,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,527,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,048,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,863,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,429,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, the Company had recognized and maintained cumulative net realizable value charges for potential obsolescence and discontinuance losses of approximately $0.5 million and $1.4&#160;million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of certain product rights related to the Kristalose brand, the Company is responsible for the purchase of the active pharmaceutical ingredient ("API") for Kristalose and maintains the inventory at the third-party packagers.  As the API is consumed in production, the value of the API is transferred from raw materials to finished goods.  API for the Company's Vaprisol brand is also included in the raw materials inventory total at December&#160;31, 2022 and 2021. Consigned inventory represents Authorized Generic inventory stored with Padagis until shipment.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Vibativ acquisition, Cumberland acquired API and work in process inventories of $15.6 million  that were classified as non-current inventories.  The Vibativ non-current API inventory was $7.1 million at December&#160;31, 2022 and $8.1 million at December&#160;31, 2021.  The Company had no Vibativ finished goods included in the non-current inventories at December&#160;31, 2022, and $0.5 million at December&#160;31, 2021.  At  December&#160;31, 2022 and 2021, Cumberland had $0.3 million in non-current inventory for API related to its ifetroban clinical initiatives and $0.1 million of finished goods&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzIxODU_85541f90-8382-45f5-b387-a086aa8a0772">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's net inventories consisted of the following as of December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.339%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.248%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,899,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,374,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consigned inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods, net of reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,322,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,390,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,478,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;less non-current inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,527,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,048,567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories classified as current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,863,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,429,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzItMi0xLTEtMzQzODQ_aeb7050a-f8e8-4828-81ee-d2e3e9a74fd2"
      unitRef="usd">12899659</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzItNC0xLTEtMzQzODQ_24ad947d-de61-497b-bbe4-b4c863453960"
      unitRef="usd">12374983</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzMtMi0xLTEtMzQzODQ_ef499dad-7f1f-44d0-b53b-f10daf54954f"
      unitRef="usd">168923</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzMtNC0xLTEtMzQzODQ_9c16c44d-ef39-4f56-9923-3f32bac1a0b4"
      unitRef="usd">164378</us-gaap:OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzQtMi0xLTEtMzQzODQ_ef9c1f47-5fac-48e9-8f4d-df00e245ee82"
      unitRef="usd">4322167</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzQtNC0xLTEtMzQzODQ_21d95ed3-a9a7-45a6-a2a7-991128699fc2"
      unitRef="usd">4939088</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzUtMi0xLTEtMzQzODQ_71fb9144-1490-459c-a8ac-2a5ed501b587"
      unitRef="usd">17390748</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzUtNC0xLTEtMzQzODQ_0fe121be-c06b-4691-bd80-c3b3efa55257"
      unitRef="usd">17478449</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzYtMi0xLTEtMzQzODQ_8fca7dea-7aff-4678-b423-a79a76043036"
      unitRef="usd">7527167</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzYtNC0xLTEtMzQzODQ_53f0c8b7-68df-4f37-9d67-7e45992b19bb"
      unitRef="usd">9048567</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzctMi0xLTEtMzQzODQ_0020fa23-0977-493f-ab58-9f78b2573f89"
      unitRef="usd">9863581</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90YWJsZToyNGMyNjEyYTIwMDI0Yzc0YmI5MzRjZmUxMmQ1NThkZi90YWJsZXJhbmdlOjI0YzI2MTJhMjAwMjRjNzRiYjkzNGNmZTEyZDU1OGRmXzctNC0xLTEtMzQzODQ_767737b5-899f-43b4-b761-ac7e954392d7"
      unitRef="usd">8429882</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzExMTY_ad2a5c2e-eea2-4c7f-8ebe-3035b6b5c9dc"
      unitRef="usd">500000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzExMjM_a6270ed4-07a9-4e12-b85c-1849b5b8d66f"
      unitRef="usd">1400000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="if13d0a3b9ba3470186981ffcd4cd386c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzE4MTQ_5bf1d94b-5129-446e-a3e1-4bd93fa5f578"
      unitRef="usd">15600000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzE5MTc_b49bbd5d-eb3f-418b-ae3b-5920d6ea5136"
      unitRef="usd">7100000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ib36b29930b41472aaa5de35a1e59cb95_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzE5MjQ_f85ed280-01b8-4ab6-bc58-0e0feba8537e"
      unitRef="usd">8100000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if5896e7f52a047b09f7db59a5bf0b6a5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzU0OTc1NTgxNzIxNQ_7513d223-b587-4f4f-88ba-408189d047d3"
      unitRef="usd">0</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ib36b29930b41472aaa5de35a1e59cb95_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzEwOTk1MTE2MzA5OTI_6d1bf7b0-4428-4aa2-a98d-0384a99ddee0"
      unitRef="usd">500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNoncurrent
      contextRef="icf903ddd161947ba816eea446f55a857_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzIxMDM_c6eda3fe-ed3b-4274-84fb-a42708f4fef3"
      unitRef="usd">300000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i90d887a51969486c9881a5eac45b76a6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzIxMDM_d2d1b0e9-4e7a-40e5-9586-3c2228c2abd3"
      unitRef="usd">300000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="icf903ddd161947ba816eea446f55a857_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzEwOTk1MTE2MzEwNzk_22ff11d2-0b9a-4eeb-b081-86779e43143b"
      unitRef="usd">100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i90d887a51969486c9881a5eac45b76a6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDIvZnJhZzpjZDZkNjJhYzQ4NDI0Y2M5ODQxODA0NzMxMjNkOWNiMi90ZXh0cmVnaW9uOmNkNmQ2MmFjNDg0MjRjYzk4NDE4MDQ3MzEyM2Q5Y2IyXzEwOTk1MTE2MzEwNzk_ab0da3a9-285c-4371-9ca0-dc218fdee75f"
      unitRef="usd">100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90ZXh0cmVnaW9uOjczOGNkNTBjMWIwMzRiMzM5NzdiYWYzNzI5ZGE0MTkwXzM1Ng_f2abd26c-53d3-46e4-8c6b-d0b3567d3926">Property and Equipment&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;useful lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&#x2013;&#160;15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,234,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,085,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,792,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense, including amortization expense related to leasehold improvements, is included in general and administrative expense in the consolidated statements of operations.  Depreciation expense was as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90ZXh0cmVnaW9uOjczOGNkNTBjMWIwMzRiMzM5NzdiYWYzNzI5ZGE0MTkwXzM1OA_f7e40b8c-7204-44f1-bf02-7731b58aa90e">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.980%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.892%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;useful lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&#x2013;&#160;15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&#x2013;&#160;15&#160;years,&#160;or remaining&#160;lease&#160;term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,422,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, gross&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,234,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,085,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,792,153)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0b7caf11e1a24164b014dcb9cc1efa95_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzItMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjowMjY1ZmRlY2RiMjE0OTRiYjc4YjRjZTkwZThlYzk4Nl80_1f7cd11a-5f17-478b-987f-59796ecf7b09">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib30352d285114277aebd23aebdefc31a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzItMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjowMjY1ZmRlY2RiMjE0OTRiYjc4YjRjZTkwZThlYzk4Nl85_3bce3ebc-73dc-48ae-a500-a664f3f10656">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iebc3383fa2574ae1802474eb1d124ef3_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzItNC0xLTEtMzQzODQ_9ed34f02-1d15-4ec8-bd34-a1f41686f520"
      unitRef="usd">465508</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic80dac19a3234cf59481be62a47b00c2_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzItNi0xLTEtMzQzODQ_42199d93-644a-47c6-b562-897664c87f94"
      unitRef="usd">1352734</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib15d3092260845f9b57d3c442a6f6c72_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzMtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjo1YzhjM2I5YmJkNTk0NmFlYWMzMjViYzMzZDUxMGQ2Yl80_e883d573-36b8-4216-a80a-b695647b538e">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8f1325d766c543488d6cdd933169b69f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzMtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjo1YzhjM2I5YmJkNTk0NmFlYWMzMjViYzMzZDUxMGQ2Yl85_99384b92-58e3-4c74-9d96-916b57622e62">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i16957755b21643ba9ebe843a90bb7625_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzMtNC0xLTEtMzQzODQ_cbc2a271-898d-4f9d-8918-191469f34280"
      unitRef="usd">746602</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id7d4d8a23fe54b748a284173ad96a122_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzMtNi0xLTEtMzQzODQ_45f7f078-660b-4af2-b649-ec1ac11f9793"
      unitRef="usd">820712</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7da33aa95f3a43abb0a94e5e28dc81d1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzQtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjoyZWIwYzJhOGY1MGQ0ZWM2YWFhZGM4NDAzZjI0MzUzMF80_5736e966-5bca-472c-9e84-5eae6dc90c8f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i66cf95bb11704c8fa28b1cc8873b54c6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzQtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjoyZWIwYzJhOGY1MGQ0ZWM2YWFhZGM4NDAzZjI0MzUzMF85_770d5d48-d9eb-4e10-a0d1-8160b7d7d3a5">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i440984280e14489e94de83929fda92ea_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzQtNC0xLTEtMzQzODQ_d427da64-1d9e-4322-b0b6-da38406b5f2f"
      unitRef="usd">369365</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0f49ad0b1cb54a7283fcda38b5eb92cd_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzQtNi0xLTEtMzQzODQ_19597ee6-8c04-4346-8322-66ca5144985d"
      unitRef="usd">638903</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie029fb915f8742fabfa273ab1ade8a96_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzUtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjo1MjFiYjQ1YWNlYzM0MDQ0OGRkZDEzZmJhODBmZjcwYl80_ad36b072-a772-42b0-a70e-37a28dccb673">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iec1323af37504488a64c07cf8beb4baf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzUtMi0xLTEtMzQzODQvdGV4dHJlZ2lvbjo1MjFiYjQ1YWNlYzM0MDQ0OGRkZDEzZmJhODBmZjcwYl85_94221337-7e60-41bb-afb2-5bd2097644fa">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8a40ef618bc943579e158b9494ffce7d_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzUtNC0xLTEtMzQzODQ_fa605282-9abd-4dfd-b332-dd7d145cb486"
      unitRef="usd">787749</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i57964ce83e4b45c18274c46575c33640_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzUtNi0xLTEtMzQzODQ_601a8df4-7a5c-4056-8783-f36112be264f"
      unitRef="usd">1422439</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzYtNC0xLTEtMzQzODQ_57d37ea6-74e3-453b-b208-68725e289410"
      unitRef="usd">2369224</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzYtNi0xLTEtMzQzODQ_0def6d0b-5c39-497d-bedd-043144fb56c6"
      unitRef="usd">4234788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzctNC0xLTEtMzQzODQ_5b9a27bc-2a7c-433c-85d2-d4e3ff216ae7"
      unitRef="usd">2085185</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzctNi0xLTEtMzQzODQ_b269f8a2-f182-4a38-acbc-68da6da8bfd4"
      unitRef="usd">3792153</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzgtNC0xLTEtMzQzODQ_10b0c384-6a92-407c-bdf3-8360b45ff9f5"
      unitRef="usd">284039</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZToxNzkzYWNlMGU3MDU0OTc4OTU2MTQ1ODdmNTI0ZGU1Yy90YWJsZXJhbmdlOjE3OTNhY2UwZTcwNTQ5Nzg5NTYxNDU4N2Y1MjRkZTVjXzgtNi0xLTEtMzQzODQ_36fe9a6a-4a74-45e1-ac28-2bef9d19e028"
      unitRef="usd">442635</us-gaap:PropertyPlantAndEquipmentNet>
    <cpix:ScheduleofDepreciationExpenseTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90ZXh0cmVnaW9uOjczOGNkNTBjMWIwMzRiMzM5NzdiYWYzNzI5ZGE0MTkwXzM2MA_ef8ad0d0-52a8-43ad-b231-78b40b7833a4">Depreciation expense was as follows for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofDepreciationExpenseTableTextBlock>
    <cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZTpkZTAzODJhZGQ5YzI0MTYwYTliNDY2OWEwODJhNjM0Yy90YWJsZXJhbmdlOmRlMDM4MmFkZDljMjQxNjBhOWI0NjY5YTA4MmE2MzRjXzItMi0xLTEtMzQzODQ_e5c2282e-d333-4bcf-af0b-dd8ccb70d1b5"
      unitRef="usd">260745</cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements>
    <cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDUvZnJhZzo3MzhjZDUwYzFiMDM0YjMzOTc3YmFmMzcyOWRhNDE5MC90YWJsZTpkZTAzODJhZGQ5YzI0MTYwYTliNDY2OWEwODJhNjM0Yy90YWJsZXJhbmdlOmRlMDM4MmFkZDljMjQxNjBhOWI0NjY5YTA4MmE2MzRjXzItNC0xLTEtMzQzODQ_fdf594d3-e0e1-407f-8d2e-835b1a54e4d5"
      unitRef="usd">235066</cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzIwMDg_46fe1ebe-4499-468c-9a60-e07effb6cd7b">Intangible Assets and Goodwill&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets and Goodwill consisted of the following at December&#160;31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.217%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,668,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,543,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,891,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,015,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,776,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,528,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,610,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,478,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,051,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,333,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,145,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,590,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,954,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product and license rights include assets associated with the Company's acquired products, including those discussed in Note 3, RediTrex, Vibativ and Sancuso.  RediTrex is only represented in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, the Company recorded an additional $0.2 million in each year in intangible assets for patents, trademarks and capitalized patent costs, including amounts incurred in the protection of the Company's intellectual property.  The Company also recorded an additional $14.1 million in product rights and $0.03 million in goodwill related to the Sancuso acquisition.  These costs will be amortized over the remaining expected useful life of the associated patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.756%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,067,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,371,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected amortization expense for the Company's current balance of intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.769%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,736,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,687,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,652,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,092,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,421,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,590,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzIwMDk_0c07489d-317e-45b4-b8ab-f259ab74e8a8">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets and Goodwill consisted of the following at December&#160;31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.217%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.915%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.489%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,668,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,543,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,891,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,015,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product and license rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,776,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,528,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,610,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,478,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,051,018)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,333,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,559,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,145,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,590,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,954,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i69aeb359c79e41b78bca28b92da3cc0b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzItMi0xLTEtMzQzODQ_ed910ed3-e1ad-487b-8f52-054f61bf0f86"
      unitRef="usd">49668141</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i463edf77a5cf4cd68d974b7c5d2166e3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzItNC0xLTEtMzQzODQ_61848a0b-3739-45ad-a09c-daa2845b197b"
      unitRef="usd">38543542</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i69aeb359c79e41b78bca28b92da3cc0b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzMtMi0xLTEtMzQzODQ_f9abb6ed-b558-4306-b95d-b7c2725988da"
      unitRef="usd">21891974</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i463edf77a5cf4cd68d974b7c5d2166e3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzMtNC0xLTEtMzQzODQ_37fbaf55-3c90-4678-8672-1718935b77a4"
      unitRef="usd">18015112</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i69aeb359c79e41b78bca28b92da3cc0b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzQtMi0xLTEtMzQzODQ_249705f6-6a53-4525-9f58-ee31a3fb1dbf"
      unitRef="usd">27776167</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i463edf77a5cf4cd68d974b7c5d2166e3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzQtNC0xLTEtMzQzODQ_082b81c9-2ad6-4020-a533-c72d3f80eeed"
      unitRef="usd">20528430</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8d06b1820bd54620a60f0c01d91fbf4d_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzUtMi0xLTEtMzQzODQ_4bf1f048-ac98-4362-9dd6-79d2e2c19e6c"
      unitRef="usd">10610228</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id3983a09554e4ca699dbcaf2db560e0f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzUtNC0xLTEtMzQzODQ_323c33dc-f93b-407e-817e-4ee80d8410f3"
      unitRef="usd">10478930</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8d06b1820bd54620a60f0c01d91fbf4d_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzYtMi0xLTEtMzQzODQ_9f234780-0e6d-415d-acd3-e891d8dd32af"
      unitRef="usd">8051018</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id3983a09554e4ca699dbcaf2db560e0f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzYtNC0xLTEtMzQzODQ_da5b2549-a066-4bee-94a0-142272a28d73"
      unitRef="usd">7333251</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8d06b1820bd54620a60f0c01d91fbf4d_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzctMi0xLTEtMzQzODQ_3887e98a-94a1-425c-9cc2-fe8efac3c7e1"
      unitRef="usd">2559210</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id3983a09554e4ca699dbcaf2db560e0f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzctNC0xLTEtMzQzODQ_a8a44f47-600b-4fdc-ae3c-ec2a5024054d"
      unitRef="usd">3145679</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i574bc1e7d0d2481ea5ad466e8f534855_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzgtMi0xLTEtMzQzODQ_3e944ea0-e85c-4daf-9c32-2109763d24e3"
      unitRef="usd">397974</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic223906cd81348c4bac59dcace59f34e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzgtNC0xLTEtMzQzODQ_99b69894-930b-404f-9a1d-5cbe09888ea2"
      unitRef="usd">373462</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i574bc1e7d0d2481ea5ad466e8f534855_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzktMi0xLTEtMzQzODQ_5cd25e3f-f169-4ef4-8533-9e6b3b7302d4"
      unitRef="usd">142673</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic223906cd81348c4bac59dcace59f34e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzktNC0xLTEtMzQzODQ_7fe20f19-6224-4316-9d71-3fb35d8e5d6b"
      unitRef="usd">93096</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i574bc1e7d0d2481ea5ad466e8f534855_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzEwLTItMS0xLTM0Mzg0_ff5d0812-54e1-4d43-867b-a545fac5fec7"
      unitRef="usd">255301</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic223906cd81348c4bac59dcace59f34e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzEwLTQtMS0xLTM0Mzg0_fd74b421-adcf-4e3d-bd3b-1c02618e551f"
      unitRef="usd">280366</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzExLTItMS0xLTM0Mzg0_35220684-d427-462a-8a79-3d663949022c"
      unitRef="usd">30590678</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzExLTQtMS0xLTM0Mzg0_6498e9d5-e707-4bb0-8e7b-eb3a0844f548"
      unitRef="usd">23954475</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzEzLTItMS0xLTM0Mzg0_78b5da45-50fe-48e7-a004-fb4c05368aa4"
      unitRef="usd">914000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTo0MGRmMTc1NDkyYWE0Zjg3YTI3NjRhMzU1YzY3NWUzZi90YWJsZXJhbmdlOjQwZGYxNzU0OTJhYTRmODdhMjc2NGEzNTVjNjc1ZTNmXzEzLTQtMS0xLTM0Mzg0_0face6d7-076c-4b76-b6ab-3a560ad7a33d"
      unitRef="usd">882000</us-gaap:Goodwill>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="idb47557bdc1b4a7091a589c3dd4e833b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzE0ODE_9ad1d029-2c2a-433b-b1a1-fce0dd484db3"
      unitRef="usd">200000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i4c75d11680284d93969ed668e797eebc_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzE0ODE_d72cb995-1bbc-459a-9fdf-8bf9579824a9"
      unitRef="usd">200000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzEwOTk1MTE2MzEzNjA_b8bb3838-82be-40b8-b159-dbfdb87803c5"
      unitRef="usd">14100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i155bdf692bf44e60a73258a7452baa96_I20220103"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzEwOTk1MTE2MzEzODk_1b773546-3e7a-4e2d-b329-be6b984d6432"
      unitRef="usd">30000.00</us-gaap:Goodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90ZXh0cmVnaW9uOmQ3ZGJjOTFlZmE2YjRmOTBiOGNiZDRiNzcxZDcxN2UzXzIwMDU_4afdf478-5d81-41c4-a77f-2680aa0c18cc">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to product and license rights, trademarks and patents were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.756%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.296%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,067,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,371,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected amortization expense for the Company's current balance of intangible assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.769%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.703%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,736,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,687,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,652,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,092,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,421,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,590,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTpmMWRhZDk1ZGY1ODc0OTVmYTg1MWFlMTI0ZjY0YThjYS90YWJsZXJhbmdlOmYxZGFkOTVkZjU4NzQ5NWZhODUxYWUxMjRmNjRhOGNhXzItMi0xLTEtMzQzODQ_39f6c8a0-0fd0-473c-8ce0-106beedc1f67"
      unitRef="usd">5067368</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTpmMWRhZDk1ZGY1ODc0OTVmYTg1MWFlMTI0ZjY0YThjYS90YWJsZXJhbmdlOmYxZGFkOTVkZjU4NzQ5NWZhODUxYWUxMjRmNjRhOGNhXzItNC0xLTEtMzQzODQ_81934119-91dd-439e-8553-87961f187957"
      unitRef="usd">4371300</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzEtMi0xLTEtMzQzODQ_0e53515b-190f-425b-bb72-32e90541994c"
      unitRef="usd">4736657</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzItMi0xLTEtMzQzODQ_04b1bdf3-6ebc-4947-8a3f-3621f15718b2"
      unitRef="usd">4687365</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzMtMi0xLTEtMzQzODQ_70055b73-cdce-4de0-babb-92ee5b45171b"
      unitRef="usd">4652156</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzQtMi0xLTEtMzQzODQ_fa8b3617-bd5a-41b7-bcfa-2fe4709b08ef"
      unitRef="usd">4092961</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzUtMi0xLTEtMzQzODQ_9cfba557-9afa-4672-b7e2-c59d4e5190a4"
      unitRef="usd">12421539</cpix:FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMDgvZnJhZzpkN2RiYzkxZWZhNmI0ZjkwYjhjYmQ0Yjc3MWQ3MTdlMy90YWJsZTowNGU1MTcxNjhhNDE0OWFjYWI2OTJmMDE1Y2MyZWMzMC90YWJsZXJhbmdlOjA0ZTUxNzE2OGE0MTQ5YWNhYjY5MmYwMTVjYzJlYzMwXzYtMi0xLTEtMzQzODQ_912db1ac-2dac-4597-ba27-12999d586816"
      unitRef="usd">30590678</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90ZXh0cmVnaW9uOjc3NjU0NjYwZmRhNDRmYTJhYzMwNGZkMjRkMmI4MWRjXzEyOA_eb041acb-dadc-4dbb-8e98-7bd625a08842">Other Current and Other Long-term Liabilities&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.378%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates, product returns, administrative fees &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and service fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,347,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,680,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,440,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,226,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,006,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued inventory purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,587,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,668,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,931,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,433,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,585,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,488,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90ZXh0cmVnaW9uOjc3NjU0NjYwZmRhNDRmYTJhYzMwNGZkMjRkMmI4MWRjXzEyOQ_b6d2f2b2-325a-42f3-9d80-6effbd58542c">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities consisted of the following at December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.378%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.913%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rebates, product returns, administrative fees &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;and service fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,347,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,680,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee wages and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,440,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sancuso related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,226,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,006,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,685,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued inventory purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,587,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,668,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cpix:ProductSalesRelatedLiabilitiesCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzItMi0xLTEtMzQzODQ_27dd1a06-25ec-4ba8-9c73-afe27a90bd7d"
      unitRef="usd">8347214</cpix:ProductSalesRelatedLiabilitiesCurrent>
    <cpix:ProductSalesRelatedLiabilitiesCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzItNC0xLTEtMzQzODQ_47c7dd26-ee07-4c2a-a340-43668ff97853"
      unitRef="usd">3680677</cpix:ProductSalesRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzMtMi0xLTEtMzQzODQ_463dab6b-fe0a-41a7-b104-deff04e281a3"
      unitRef="usd">1440859</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzMtNC0xLTEtMzQzODQ_6abcd81e-7315-4576-97ed-89ff1092325e"
      unitRef="usd">1340846</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cpix:AccruedLiabilitiesStockPayable
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzQtMi0xLTEtMzQzODQ_c6f08ceb-d882-4179-a607-75091623dc39"
      unitRef="usd">2226725</cpix:AccruedLiabilitiesStockPayable>
    <cpix:AccruedLiabilitiesStockPayable
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzQtNC0xLTEtMzQzODQ_0ada5b9d-4525-4e3b-b26a-5c83632e8767"
      unitRef="usd">0</cpix:AccruedLiabilitiesStockPayable>
    <cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzUtMi0xLTEtMzQzODQ_cccfb567-13ca-4481-a55b-9d2c3fdc15ba"
      unitRef="usd">3006310</cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent>
    <cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzUtNC0xLTEtMzQzODQ_e2768154-589f-409f-940e-0e04f634583b"
      unitRef="usd">2685531</cpix:BusinessCombinationContingentConsiderationLiabilityAccruedCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzctMi0xLTEtMzc5NDk_b727890f-237c-4de8-97df-93e5dffabcf2"
      unitRef="usd">614551</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzctNC0xLTEtMzc5NDk_8adccee8-28f1-414d-a5f0-c433f1d7b437"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <cpix:AccruedLiabilitiesInventoryPurchases
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzctMi0xLTEtMzQzODQ_7e694194-ba93-448d-a28b-455668d78fe1"
      unitRef="usd">609621</cpix:AccruedLiabilitiesInventoryPurchases>
    <cpix:AccruedLiabilitiesInventoryPurchases
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzctNC0xLTEtMzQzODQ_8e1bd4c1-0b04-43db-a761-d537049ad6c7"
      unitRef="usd">18211</cpix:AccruedLiabilitiesInventoryPurchases>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzktMi0xLTEtMzQzODQ_3e9ad4ec-4e60-4daa-a4d8-08140f90cb1e"
      unitRef="usd">1342631</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzktNC0xLTEtMzQzODQ_ba78b7f7-4edd-41ac-9cbc-70a68ba6be87"
      unitRef="usd">943038</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzEwLTItMS0xLTM0Mzg0_d12a9f08-d6bf-48d6-9de6-918214fef2c9"
      unitRef="usd">17587911</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZToyYzdjYmRjYTUyNDc0N2FhOTA0NzQ5M2M0YTBkMDcwYS90YWJsZXJhbmdlOjJjN2NiZGNhNTI0NzQ3YWE5MDQ3NDkzYzRhMGQwNzBhXzEwLTQtMS0xLTM0Mzg0_e299adf3-9f9f-4057-954e-e41d56b1376e"
      unitRef="usd">8668303</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90ZXh0cmVnaW9uOjc3NjU0NjYwZmRhNDRmYTJhYzMwNGZkMjRkMmI4MWRjXzEzMg_988f86e7-c424-48b7-8a6b-af4305bfed6a">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.897%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.732%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of accrued contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,931,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,830,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,522,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,433,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,585,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,488,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzItMi0xLTEtMzQzODQ_aebe7246-f35d-4b89-9ee4-12bed522c15c"
      unitRef="usd">4931513</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzItNC0xLTEtMzQzODQ_8fffdead-baa7-4e19-9363-4a121c978161"
      unitRef="usd">3830096</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzMtMi0xLTEtMzQzODQ_f44a0d8e-1fe4-483a-898f-bed53eab315f"
      unitRef="usd">2522506</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzMtNC0xLTEtMzQzODQ_d2d315d8-d80c-4a4b-bbe7-a7749f4df014"
      unitRef="usd">3433962</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzQtMi0xLTEtMzQzODQ_6bb3bbe1-6850-42af-86d0-6e6f5abd7ed3"
      unitRef="usd">131000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzQtNC0xLTEtMzQzODQ_7f6868a5-8a6c-4e25-801f-a0333442036f"
      unitRef="usd">224786</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzUtMi0xLTEtMzQzODQ_95297be3-c08e-4958-a482-da8846379568"
      unitRef="usd">7585019</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTEvZnJhZzo3NzY1NDY2MGZkYTQ0ZmEyYWMzMDRmZDI0ZDJiODFkYy90YWJsZTo4YjUzMDljNjU1MWI0MGJlYTQ3MWZlZmE3NWM5ODk0NC90YWJsZXJhbmdlOjhiNTMwOWM2NTUxYjQwYmVhNDcxZmVmYTc1Yzk4OTQ0XzUtNC0xLTEtMzQzODQ_38cda877-efbe-46ad-907f-83a76cf05a22"
      unitRef="usd">7488844</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzM5ODE_d5ac46eb-ece6-4bc7-83e4-218ab615915c">Debt&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2021, the Company entered into a Fifth Amendment to the Revolving Credit Note and Sixth Amendment (the "Sixth Amendment") to Revolving Credit Loan Agreement with Pinnacle Bank (the "Pinnacle Agreement"). The Sixth Amendment increased the principal amount by $5 million to $20 million. On October 28, 2021, the Company entered into a Fourth Amendment to the Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement with Pinnacle Bank. Among other terms, the Fourth Amendment extended the maturity date to October 1, 2024.  The Pinnacle Agreement includes specific financial covenants including Debt Ratio and Tangible Capital Ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company and Pinnacle Bank agreed to modify the financial covenants to align with the current use of the line of credit.  On September 29, 2022, the Company entered into the Ninth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank (as amended, the "Pinnacle Agreement") to update the Funded Debt Ratio to mean the ratio of (i) Funded Debt less the amount of Unrestricted Cash in excess of $8,500,000, to (ii) EBITDA, as determined at the end of each fiscal quarter on a rolling four (4) quarter basis.  For the year ended December&#160;31, 2022, we were in compliance with the Funded Debt Ratio financial covenant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company had $16.2 million and $15.0 million in borrowings outstanding under the Pinnacle Agreement at December&#160;31, 2022 and  2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The interest rate on the Pinnacle Agreement is based on LIBOR plus an interest rate spread. The pricing under the Fourth Amendment provides for an interest rate spread of 1.75% to 2.75% above LIBOR with a minimum LIBOR of 0.90% (representing an interest rate of 6.875% at December&#160;31, 2022).  In addition, a fee of 0.25% per year is charged on the unused line of credit.  Interest and the unused line fee are payable quarterly.  In 2022, the LIBOR benchmark rate is expected to be discontinued. When the LIBOR rate is no longer available, the Pinnacle Agreement calls for a new Benchmark rate to be used to determine the interest rate for the Agreement.  It is expected that SOFR will become the replacement benchmark.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Borrowings under the line of credit are collateralized by substantially all of our assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Paycheck Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2020, Cumberland received the funding of a loan from Pinnacle Bank in the aggregate amount of $2,187,140 pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under the Federal Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"), which was enacted March 27, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PPP is administered by the U.S. Small Business Administration ("SBA").  The loan was scheduled to  mature April 14, 2022, and bears interest at a rate of 1.0% per year, payable monthly. The loan could be prepaid at any time prior to maturity with no prepayment penalties. Funds from the loan are to be used to maintain payroll, continue group health care benefits and pay for rent and utilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the PPP, certain amounts of the loan may be forgiven if they are used for qualifying expenses as described in the CARES Act, including qualifying payroll costs, covered rent payments, and covered utilities.  From the date of funding the Company has used the loan amount for such qualifying expenses. Cumberland has elected to account for the proceeds of the loan as a government grant under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;International Accounting Standard 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The permitted analogous use of  IAS 20 outlines a model for the accounting for government assistance, including forgivable loans. As a result, the Company has recorded the $2,187,140 as a deferred income liability, which is included as a component of other current liabilities on the consolidated balance sheet as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland applied for this loan after carefully considering, with its bank, the eligibility criteria to participate in this program, and determining that Cumberland met these criteria. The Company evaluated and provided information on our payroll and other qualifying expenses to determine the amount of PPP funds to apply for. &lt;/span&gt;&lt;/div&gt;Cumberland has not laid off or furloughed any employees as a result of the COVID-19 pandemic and, based on assistance from the PPP loan, the Company currently does not foresee doing so. In October 2020, the Company submitted a request for forgiveness of the PPP loan. The request was approved by the lender, Pinnacle Bank, who then submitted it to SBA for the SBA's review and approval. On June 11, 2021, the Company received a notice from the SBA that the full amount of the loan was forgiven. The Company accounted for the forgiveness of the loan under IAS 20 and recorded the $2,187,140 as other income during the year ended December 31, 2021.</us-gaap:DebtDisclosureTextBlock>
    <cpix:LineOfCreditFacilityAdditionalBorrowingCapacity
      contextRef="i6e9d77deb33f4194ba7a35755cec59a1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzI4OQ_2a46dde0-e70e-44ea-8571-014f44db5ee3"
      unitRef="usd">5000000</cpix:LineOfCreditFacilityAdditionalBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i6e9d77deb33f4194ba7a35755cec59a1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzI5NQ_24424c00-3d64-4d1d-8c48-d74a202fae45"
      unitRef="usd">20000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <cpix:DebtInstrumentCovenantUnrestrictedCashThreshold
      contextRef="iac3baa3852034481ab2a2c089e20758c_I20220929"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzI3NDg3NzkwNzQwMTk_6a6f3bde-b8d1-47bd-8628-bf428ba3c767"
      unitRef="usd">8500000</cpix:DebtInstrumentCovenantUnrestrictedCashThreshold>
    <us-gaap:LongTermLineOfCredit
      contextRef="i7f310f91304f4cc89cb705d8722a8d08_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzY4Mw_d2fab109-498c-4ba8-ac2e-ffd53ca8238c"
      unitRef="usd">16200000</us-gaap:LongTermLineOfCredit>
    <us-gaap:LongTermLineOfCredit
      contextRef="i28084a381e4f4f1491853ea7f60c1025_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzEwOTk1MTE2MzE3NzU_f018d467-a9e7-4c4e-9921-2503a526a3da"
      unitRef="usd">15000000</us-gaap:LongTermLineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4808a45eee974fbfbe990af48bc945ad_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzkxNw_4984ff15-0620-4427-a019-4951dcd1c5be"
      unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i061a02db1e2b4e1792f9dfd792d617e4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzkyMw_e0593284-a0a1-4f7a-b609-20df3fa11cd0"
      unitRef="number">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic015a17daf5344f9a4de26b8e32f3873_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzk2Mg_48f9a57c-95e1-405e-9e7d-b8fd87cacbc4"
      unitRef="number">0.0090</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i755231ed00d14acf800c9c3404c31e20_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzk5OQ_75566fc8-be15-4168-ab40-c974aa942016"
      unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="ib8724ef42665454e9a5d3f598e52ab38_D20170731-20170731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzEwMzM_bb30fdf0-bcb2-4eac-a0d2-1d0c801932ad"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="ic5e93a72679646699ff0eec55311987d_D20200420-20200420"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzE2MDM_a5230a0d-ebc1-4dd7-af4e-5060257d7dc9"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="icf6a2ed9c9c1455893589f101ba5b4cc_I20200420"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzE5Mzk_b4700785-9ae8-4b11-a7f2-98f5893f5733"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="ib78383e8396e49768661e5b1015fc86b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzI4ODU_701f2b74-ce93-45b7-a307-7b0c377eef89"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived
      contextRef="ib78383e8396e49768661e5b1015fc86b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTQvZnJhZzo0MTA4NjE1NDM4YTA0YWFkYmQ4OWFiZWFlYzY3NmE5My90ZXh0cmVnaW9uOjQxMDg2MTU0MzhhMDRhYWRiZDg5YWJlYWVjNjc2YTkzXzM5Mzc_14122d62-fd71-4948-9dfe-d4ba856c3a37"
      unitRef="usd">2187140</cpix:TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzU0MTU_50e8e697-7ec0-400e-b99f-e985cf4a74cf">Shareholders&#x2019; Equity&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(a)&#160;&#160;&#160;&#160;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;10, 2009, the Company completed its initial public offering of 5,000,000 shares of common stock at a price of $17.00 per share, raising gross proceeds of $85.0 million. After deducting underwriting discounts of approximately $6.0 million and offering costs incurred of approximately $4.2 million, the net proceeds to the Company were approximately $74.8 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(b)&#160;&#160;&#160;&#160;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue 20,000,000&#160;shares of preferred stock. The Board of Directors is authorized to divide these shares into classes or series, and to fix and determine the relative rights, preferences, qualifications and limitations of the shares of any class or series so established. At December&#160;31, 2022 and 2021, there was no preferred stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(c)&#160;&#160;&#160;&#160;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022 and 2021, the Company issued 171,655 shares and 192,684  shares of common stock, respectively, as a result of restricted shares vesting as well as other common share issuances.  There were no option exercise transactions during 2022 and  2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;(d)&#160;&#160;&#160;&#160;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company currently has a share repurchase program to repurchase up to $10 million of its common stock pursuant to Rule 10b-18 of the Securities Exchange Act, as amended. In January 2019, the Company's Board of Directors established the current $10 million repurchase program to replace the prior authorizations. The Company repurchased 367,793 shares and 438,359 shares of common stock for approximately $1.0 million and $1.4 million during the years ended December&#160;31, 2022 and 2021, respectively. There remains $3.8 million available under the current repurchase program available for share repurchases at December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockTransactionDate
      contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzYy_531ba6c5-60a6-4e74-bd36-16e4516163af">2009-08-10</us-gaap:SaleOfStockTransactionDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzExOQ_df8e27cc-0fb7-4d1f-aa86-6069846ad242"
      unitRef="shares">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <cpix:StockIssuedDuringPeriodPricePerShareNewIssues
      contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzE2MA_d31a83f8-0d30-412e-8949-3e8a66b045ec"
      unitRef="usdPerShare">17.00</cpix:StockIssuedDuringPeriodPricePerShareNewIssues>
    <cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering
      contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIwMQ_165e8d7f-a912-4017-8dfd-ad817730f8a7"
      unitRef="usd">85000000</cpix:StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering>
    <cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts
      contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzI2Mg_55502961-0223-4808-8b0a-66f07c1bd99d"
      unitRef="usd">6000000</cpix:StockIssuedDuringPeriodNewSharesUnderwritingDiscounts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzMxMQ_d3c5ab0b-3b26-430f-a8ae-795447ad63b1"
      unitRef="usd">4200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="idd6efbaba58c4153b8a8b424c820d032_D20090809-20090810"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzM2Nw_373bdd4c-72b1-40c6-924b-6820d1e46480"
      unitRef="usd">74800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzQyNw_479041e2-92c1-4894-ba5c-6508f3924f1f"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzcwOA_29855f1c-0369-499f-8ba4-a859bf204111"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzcwOA_f6f57106-ae82-4362-8daa-60a229b18d30"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i72718240c04b4ec2ba4b82ad98b68277_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1Xzc5OA_9e77c040-6e8f-4b56-bcba-aa02d4e39417"
      unitRef="shares">171655</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i335f36ffc1e6419c9c6d44aa4dfbab4e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzEwOTk1MTE2MzY5Nzc_056e4d57-6913-493f-9a03-1e95790256af"
      unitRef="shares">192684</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i1061cd07c59c4fc190c499065ffea5e3_I20100531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIwNDE_5d4e89d1-1fe5-4c0d-a906-c72ded2350e8"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i1061cd07c59c4fc190c499065ffea5e3_I20100531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIyMDc_9bdde191-5ac8-40db-be3b-bc1e6831586d"
      unitRef="usd">10000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i3c8e554b334e4bf692425f706564fc4d_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIyOTA_1a7eed0e-a442-491f-aa29-0d7e5c6f81a4"
      unitRef="shares">367793</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ia90dbbcb1d5e494382b065f737613908_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIzMDE_63282362-f6d9-4cbe-ad1a-a826de339f60"
      unitRef="shares">438359</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3c8e554b334e4bf692425f706564fc4d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIzNTk_98ed8ac9-67d2-4601-8c95-730580dd1e93"
      unitRef="usd">1000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ia90dbbcb1d5e494382b065f737613908_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzIzNjM_2cc381fa-05e8-4d64-be69-22154c60519a"
      unitRef="usd">1400000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMTcvZnJhZzozYzY5Y2Y4NGE4Y2U0MjhiYmUxYThlMWNjMDliNDkzNS90ZXh0cmVnaW9uOjNjNjljZjg0YThjZTQyOGJiZTFhOGUxY2MwOWI0OTM1XzI0NDA_55dc105a-f5af-486b-93d0-f9d0ae5b3efe"
      unitRef="usd">3800000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90ZXh0cmVnaW9uOjRkYTI0ODdjYTQwNjRhYmI4ZDhiMzE2NzY5Yjg0ZTZhXzMzMg_b6453cfe-be3e-4000-9fe6-e392bf88547f">Earnings (Loss) Per Share &lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,650,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,597,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,650,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,602,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,570,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,507,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,563,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,904,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,563,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,904,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive shares and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90ZXh0cmVnaW9uOjRkYTI0ODdjYTQwNjRhYmI4ZDhiMzE2NzY5Yjg0ZTZhXzMyOQ_3820e561-4752-4d3e-aa39-3187eb00fbbe">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the computation of the numerator and the denominator used to calculate diluted earnings (loss) per share for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.916%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.148%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,650,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,597,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,994,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,650,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,602,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss at subsidiary attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,570,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,507,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,563,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,904,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,563,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,904,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzMtMi0xLTEtMzQzODQ_8e704678-0623-47f7-976a-9e504b124692"
      unitRef="usd">-5650039</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzMtNC0xLTEtMzQzODQ_ff64fb6b-db67-4784-9fb6-67df26533f59"
      unitRef="usd">-5597121</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzQtMi0xLTEtMzQzODQ_f67cb05b-98cd-4076-b7f8-abd264f3c575"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzQtNC0xLTEtMzQzODQ_4207b02a-8aee-429a-a0ab-c761f4d74561"
      unitRef="usd">1994322</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzUtMi0xLTEtMzQzODQ_20c34513-8d42-4ce0-a686-e966c84de141"
      unitRef="usd">-5650039</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzUtNC0xLTEtMzQzODQ_4d7bfefe-9479-4f1e-9c6c-c287085bca14"
      unitRef="usd">-3602799</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzYtMi0xLTEtMzQzODQ_b61ce7e9-df0d-44fb-98d4-26d6b618e9fc"
      unitRef="usd">-79798</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzYtNC0xLTEtMzQzODQ_9d29cd60-538e-4a3c-a017-88646f4ab240"
      unitRef="usd">-95212</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzctMi0xLTEtMzQzODQ_5049b4b1-e863-4a9a-b9af-fa0fb899c1a2"
      unitRef="usd">-5570241</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzctNC0xLTEtMzQzODQ_0873b96f-570b-496f-97a2-b6620ba0e23c"
      unitRef="usd">-3507587</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzktMi0xLTEtMzQzODQ_6a06b5c8-cbe1-48f9-b206-a2f0aa931ff9"
      unitRef="shares">14563592</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzktNC0xLTEtMzQzODQ_3d3efbef-7a12-4391-9370-ef2cdd85ac62"
      unitRef="shares">14904834</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzExLTItMS0xLTM0Mzg0_158e62d8-1a26-4891-8ed0-1713e4220dce"
      unitRef="shares">14563592</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpkNGUwYzg3ZTc0YTM0YzYwOTFkNjQwODIyNzI2Mzg4Zi90YWJsZXJhbmdlOmQ0ZTBjODdlNzRhMzRjNjA5MWQ2NDA4MjI3MjYzODhmXzExLTQtMS0xLTM0Mzg0_f5df5ed5-bf9a-4c6b-b87e-1d9474280c28"
      unitRef="shares">14904834</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90ZXh0cmVnaW9uOjRkYTI0ODdjYTQwNjRhYmI4ZDhiMzE2NzY5Yjg0ZTZhXzMzMA_7a677ec6-f58f-43cc-96b2-97a05ec8069c">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's anti-dilutive restricted shares and stock options outstanding were as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive shares and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpiYzU0NDhhZDI1MzQ0MWMyODlkNGJjYTg4NjZmYjQ0Ny90YWJsZXJhbmdlOmJjNTQ0OGFkMjUzNDQxYzI4OWQ0YmNhODg2NmZiNDQ3XzItMi0xLTEtMzQzODQ_62c0ee97-00cb-46e5-9282-a6e7b0c010c3"
      unitRef="shares">227050</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjAvZnJhZzo0ZGEyNDg3Y2E0MDY0YWJiOGQ4YjMxNjc2OWI4NGU2YS90YWJsZTpiYzU0NDhhZDI1MzQ0MWMyODlkNGJjYTg4NjZmYjQ0Ny90YWJsZXJhbmdlOmJjNTQ0OGFkMjUzNDQxYzI4OWQ0YmNhODg2NmZiNDQ3XzItNC0xLTEtMzQzODQ_66aa6a58-2025-477e-aaa4-efe34cb399bf"
      unitRef="shares">183300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2Mjc_5bb32a41-24ca-4551-a86c-d9c42bee2f2b">Income Taxes&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's net deferred tax assets at December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss and tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,164,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,817,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for expired product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative compensation costs incurred on deductible equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,708,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,824,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,150,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets, before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,557,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,761,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,557,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,761,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024-2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,656,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,790,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,062,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,475,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (expense) benefit includes the following components for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax (expense) benefit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for 2022 and 2021 reconciles with the federal statutory tax rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (net of federal income tax benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences associated with general business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it is not more likely than not that its net deferred tax assets will be realized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As such, the net deferred tax assets are fully offset with a valuation allowance as of the periods ended December&#160;31, 2022 and  2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company has general business credit carryforwards of $1.5&#160;million.  These credit carryforwards will expire in years 2023 through 2042.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024-2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,319,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,519,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects it will continue to pay minimal taxes in future periods through the continued utilization of net operating loss carryforwards, as it is able to achieve taxable income through its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is no longer subject to U.S. federal tax examinations for tax years before 2019, and with few exceptions, the Company is not subject to examination by state tax authorities for tax years which ended before 2019.  Loss carryforwards and credit carryforwards generated or utilized in years earlier than 2019 remain subject to examination and adjustment.  During 2012, the 2009 federal tax return was examined by the Internal Revenue Service with no significant findings or adjustments.  The Company has no unrecognized tax benefits at December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2MjM_e8dde4a0-23fd-4ccc-871c-ead761f5bdc8">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company's net deferred tax assets at December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss and tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,164,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,817,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;866,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for expired product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative compensation costs incurred on deductible equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,708,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,824,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,150,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets, before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,557,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,761,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: deferred tax asset valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,557,784)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,761,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzMtMi0xLTEtMzQzODQ_915f05e9-5bda-4fbf-9615-2c4bb434156e"
      unitRef="usd">16164754</cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzMtNC0xLTEtMzQzODQ_d90af3d9-7dc1-42e7-99d1-718b0222cb51"
      unitRef="usd">16817070</cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzQtMi0xLTEtMzQzODQ_7166ec7f-73df-45ca-a646-00b4c6d5b1c0"
      unitRef="usd">264653</cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles>
    <cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzQtNC0xLTEtMzQzODQ_84a5f344-7567-470b-b174-826c3ffed0bb"
      unitRef="usd">222893</cpix:DeferredTaxAssetsPropertyAndEquipmentAndIntangibles>
    <cpix:DeferredTaxAssetOperatingLeaseLiabilities
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzUtMi0xLTEtMzg2MDc_dce67d3a-c3b9-4828-aeff-ce983823789f"
      unitRef="usd">1121800</cpix:DeferredTaxAssetOperatingLeaseLiabilities>
    <cpix:DeferredTaxAssetOperatingLeaseLiabilities
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzUtNC0xLTEtMzg2MDc_e5f1fc46-d2b0-4212-bd95-e23707101781"
      unitRef="usd">0</cpix:DeferredTaxAssetOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzYtMi0xLTEtMzg2MDc_2ef2ba7c-0f43-49d9-9d53-6baa2ece9f6a"
      unitRef="usd">866942</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzYtNC0xLTEtMzg2MDc_8be81636-edb3-4e0d-885c-080d59d88949"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzctMi0xLTEtMzg2MDc_43580677-a5da-4712-aaaa-7ae663b09912"
      unitRef="usd">1481455</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzctNC0xLTEtMzg2MDc_1d4bc2a3-02eb-4b3e-8e60-fcc5bd3cc352"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzUtMi0xLTEtMzQzODQ_0182e6ef-f91c-4c82-9010-3202de2f82be"
      unitRef="usd">145803</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzUtNC0xLTEtMzQzODQ_ae863a18-b443-4c7a-b64a-ec7630efee5c"
      unitRef="usd">83931</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzYtMi0xLTEtMzQzODQ_1d450590-dd1a-4002-8440-6b8960106796"
      unitRef="usd">654148</cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct>
    <cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzYtNC0xLTEtMzQzODQ_c83e18e3-99b4-47b2-8e0c-798770e45f0d"
      unitRef="usd">457723</cpix:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzctMi0xLTEtMzQzODQ_28cfa6c9-b28c-48ca-a820-bf3f660dab6a"
      unitRef="usd">217025</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzctNC0xLTEtMzQzODQ_883bcdb8-25e6-43c1-a8d0-bb0219301b27"
      unitRef="usd">104824</us-gaap:DeferredTaxAssetsInventory>
    <cpix:DeferredTaxAssetsDeferredCharges
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzgtMi0xLTEtMzQzODQ_ace9da83-fb03-4ec8-a74d-fc882cee35e9"
      unitRef="usd">1156150</cpix:DeferredTaxAssetsDeferredCharges>
    <cpix:DeferredTaxAssetsDeferredCharges
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzgtNC0xLTEtMzQzODQ_e92f0fd9-fe6d-4f71-a037-5a8f62376fcc"
      unitRef="usd">1303664</cpix:DeferredTaxAssetsDeferredCharges>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzktMi0xLTEtMzQzODQ_7168d7e9-53fb-405f-8719-7335ca4cd3de"
      unitRef="usd">635989</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzktNC0xLTEtMzQzODQ_e9e6343e-61e9-484b-aa58-5835c0336e0f"
      unitRef="usd">834070</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzEwLTItMS0xLTM0Mzg0_9d07038b-4be1-4afa-9d1e-74e65f53994a"
      unitRef="usd">22708719</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzEwLTQtMS0xLTM0Mzg0_a62466ec-a2b0-40f6-a71d-e7cf75cd0f0a"
      unitRef="usd">19824175</us-gaap:DeferredTaxAssetsGross>
    <cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE2LTItMS0xLTM4NjY1_7ebe5cdc-b36c-40e3-9077-df480cb39835"
      unitRef="usd">1150935</cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets>
    <cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE2LTQtMS0xLTM4NjY1_fa212276-7b07-42ad-a8be-ec43beacb26e"
      unitRef="usd">0</cpix:DeferredTaxLiabilityOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzEzLTItMS0xLTM0Mzg0_84a54e01-5faf-4ae5-889e-3fced0979441"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzEzLTQtMS0xLTM0Mzg0_de906b01-c3ab-45b9-834c-8f643c2b51c1"
      unitRef="usd">62253</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <cpix:NetDeferredTaxAssetsGross
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE0LTItMS0xLTM0Mzg0_6cfd394e-fc6e-4e66-b643-a5b26ba917d6"
      unitRef="usd">21557784</cpix:NetDeferredTaxAssetsGross>
    <cpix:NetDeferredTaxAssetsGross
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE0LTQtMS0xLTM0Mzg0_6e456ccb-0948-4f59-8f18-04a579a0970a"
      unitRef="usd">19761922</cpix:NetDeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE1LTItMS0xLTM0Mzg0_2fc804d5-200f-456c-a4b1-b262979402e2"
      unitRef="usd">21557784</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE1LTQtMS0xLTM0Mzg0_9a29dbd7-bb03-47dc-9b66-29cd6d5e18fd"
      unitRef="usd">19761922</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE2LTItMS0xLTM0Mzg0_8d26a4a3-73f9-468b-8738-090cade54c8b"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToyODdkNTNiZDNmM2M0OTU2YWIzMDk2ODQ2ZDMxZTNkNC90YWJsZXJhbmdlOjI4N2Q1M2JkM2YzYzQ5NTZhYjMwOTY4NDZkMzFlM2Q0XzE2LTQtMS0xLTM0Mzg0_be022081-810c-452c-8971-0789bc189344"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2Mjg_5c2c5b37-3857-4eb9-a0c2-135564926a27">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amount and year of expiration of the Company's federal and state net operating loss carryforwards as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.544%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.861%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024-2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,656,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,790,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,062,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,475,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0027eb6bc44b4567a5351c10399f22e7_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzItMi0xLTEtMzQzODQ_fe4585ae-5096-43bf-b41f-f578d7abd673"
      unitRef="usd">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ifea0d070c6124183897a66bb2df920d4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzItNC0xLTEtMzQzODQ_1458ccdd-be91-427e-91ae-e0ecd5710ab9"
      unitRef="usd">251811</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i30e86908009643eebb68ac0e3a1ae95e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzMtMi0xLTEtMzQzODQ_15413f0d-d491-441c-8118-10ca4a6efc6f"
      unitRef="usd">46656666</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i99d9d087686e4acaa131dcf7f56b02b5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzMtNC0xLTEtMzQzODQ_c60a75dd-8fe5-43c5-bef1-1139115770d9"
      unitRef="usd">55790944</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i66d5038d3ea5413287c0c60e6f8d6e13_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzYtMi0xLTEtMzQzODQ_2c97a8d0-c254-4321-84c0-93c927f655f8"
      unitRef="usd">6405835</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic8ffa57a973c45d89dc9e53e23854361_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzYtNC0xLTEtMzQzODQ_a359d6f6-0e6d-4fe3-85dd-bc749d197656"
      unitRef="usd">433203</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="if08c5ee420b248ac902a128ef7d90e7a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzgtMi0xLTEtMzQzODQ_079f3551-b67b-48a2-8b09-cc74bf057fd7"
      unitRef="usd">53062501</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="id4ecd0e4253e46d69b1840d128d714e3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo0ZGY4ZGU2YzUyYzQ0YWJjYTcyYzA2MDc0Yzc4YWJiYy90YWJsZXJhbmdlOjRkZjhkZTZjNTJjNDRhYmNhNzJjMDYwNzRjNzhhYmJjXzgtNC0xLTEtMzQzODQ_68f0e995-0137-45c4-925f-9f50344a7445"
      unitRef="usd">56475958</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2MjU_39ccc5a6-13b8-47ee-b041-1a6c5e54972b">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax (expense) benefit includes the following components for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,678)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax (expense) benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax (expense) benefit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzMtMi0xLTEtMzQzODQ_f9b6f768-53ba-43da-a367-288fdab10c39"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzMtNC0xLTEtMzQzODQ_540f6b6e-b08e-4784-a4fa-c3f7d300af6b"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzQtMi0xLTEtMzQzODQ_2f747be7-cf75-4fd6-bd61-39394ad6d4e1"
      unitRef="usd">-68850</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzQtNC0xLTEtMzQzODQ_fe4cc092-13f1-4fdd-8e37-6136836bdb49"
      unitRef="usd">-34891</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzUtMi0xLTEtMzQzODQ_d35bf5bb-494a-48c6-878e-0384ab61cf90"
      unitRef="usd">-68850</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzUtNC0xLTEtMzQzODQ_8b413d50-1f7d-483f-9bec-2a3688dc7fbf"
      unitRef="usd">-34891</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzgtMi0xLTEtMzQzODQ_578b6a4f-707a-43e1-81c2-8fe7a9a1e51a"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzgtNC0xLTEtMzQzODQ_beb8fe17-86bd-4492-aa18-31992d0ca85c"
      unitRef="usd">-61678</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzktMi0xLTEtMzQzODQ_aaac097c-b498-41ea-875e-cb35764cd309"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzktNC0xLTEtMzQzODQ_2f5b707f-c596-4624-a032-504eaad5f893"
      unitRef="usd">61678</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzEwLTItMS0xLTM0Mzg0_ecab8cb7-4fea-4070-84f3-fc7781314bc8"
      unitRef="usd">0</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:DeferredOtherTaxExpenseBenefit
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzEwLTQtMS0xLTM0Mzg0_15a706d9-2ff8-4cf3-a75c-bea68cd27c47"
      unitRef="usd">0</us-gaap:DeferredOtherTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzExLTItMS0xLTM0Mzg0_625d78de-7e0c-4523-a58a-bee8f2f458fe"
      unitRef="usd">68850</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTo1N2Q3NGZhYjEzNzE0MjcwOWQwOGRjMmJkMGNjOWVlOS90YWJsZXJhbmdlOjU3ZDc0ZmFiMTM3MTQyNzA5ZDA4ZGMyYmQwY2M5ZWU5XzExLTQtMS0xLTM0Mzg0_9d9d1c12-f5c1-4191-ac69-912ff3bfb83a"
      unitRef="usd">34891</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2MzA_5ddd9891-14fa-4280-a559-e551c83c66a5">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for 2022 and 2021 reconciles with the federal statutory tax rate as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax expense (net of federal income tax benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences associated with general business credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzItMi0xLTEtMzQzODQ_e87aaacd-c52c-44e8-95bb-575391bf4822"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzItNC0xLTEtMzQzODQ_7e050f9c-b546-4453-b5e6-07a4d267dbd1"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzMtMi0xLTEtMzQzODQ_fbb62d4a-df31-478e-a666-221b514e52e6"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzMtNC0xLTEtMzQzODQ_779026eb-1ec4-4f52-a720-700cd57f73fe"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzQtMi0xLTEtMzQzODQ_62327273-a20a-4d11-8014-bbbb3e1cb75c"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzQtNC0xLTEtMzQzODQ_0f453276-f510-402e-be2c-eaab95ed9611"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzUtMi0xLTEtMzQzODQ_17a5915e-1002-462a-8b73-e65824029baf"
      unitRef="number">-0.22</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzUtNC0xLTEtMzQzODQ_2d11d1c0-a649-4c34-96c8-4ef99848994f"
      unitRef="number">-0.19</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzYtMi0xLTEtMzQzODQ_55b6223b-dba6-4a39-b91b-f225d9341db4"
      unitRef="number">-0.02</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzYtNC0xLTEtMzQzODQ_548d2dd2-633a-4541-ae54-36ca71e7b80e"
      unitRef="number">-0.04</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzctMi0xLTEtMzQzODQ_98d1c9b3-e887-4ba8-8a30-b16affb7a514"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzctNC0xLTEtMzQzODQ_6a6ce6c3-8ccd-43e9-b4b9-97e07ee82cfa"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzgtMi0xLTEtMzQzODQ_1dd1b20e-5c71-4766-aba7-94ccd29b3388"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZToxOGZjMGJhNmM1ODA0NTZhOTZjMGQ5NDYwYmU3MDNhZS90YWJsZXJhbmdlOjE4ZmMwYmE2YzU4MDQ1NmE5NmMwZDk0NjBiZTcwM2FlXzgtNC0xLTEtMzQzODQ_d6ffa7ba-3605-49da-ae96-e16693b33560"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzE2MjA_d419bf69-a52a-44cf-a38a-7a8df8bd340f">&lt;div style="margin-top:8pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the Company has general business credit carryforwards of $1.5&#160;million.  These credit carryforwards will expire in years 2023 through 2042.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years of expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024-2042&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,319,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total federal and state credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,519,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i81a18b4c882d437cb25a611496aa56a5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90ZXh0cmVnaW9uOjU1MzQwODY1MzlhYTRjNjk4NzFiN2FlNzdiZTdhODJlXzc3NQ_bed46fdd-b2b5-409b-ae32-b47e9897a7c9"
      unitRef="usd">1500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i54dfc16f99534c19b2867a069f58d483_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTpiNmY3NGE3Zjk1NzU0MDRmYmRlOGJhZmIzYTVkYzhhMS90YWJsZXJhbmdlOmI2Zjc0YTdmOTU3NTQwNGZiZGU4YmFmYjNhNWRjOGExXzEtMi0xLTEtMzQzODQ_7c9080ec-a921-4ca1-8300-929e8c747488"
      unitRef="usd">200825</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i795293f449e54a6eb5e7aa63c13b396d_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTpiNmY3NGE3Zjk1NzU0MDRmYmRlOGJhZmIzYTVkYzhhMS90YWJsZXJhbmdlOmI2Zjc0YTdmOTU3NTQwNGZiZGU4YmFmYjNhNWRjOGExXzItMi0xLTEtMzQzODQ_ba520d0e-213e-4813-829c-b1cae7127b92"
      unitRef="usd">1319161</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i81a18b4c882d437cb25a611496aa56a5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjMvZnJhZzo1NTM0MDg2NTM5YWE0YzY5ODcxYjdhZTc3YmU3YTgyZS90YWJsZTpiNmY3NGE3Zjk1NzU0MDRmYmRlOGJhZmIzYTVkYzhhMS90YWJsZXJhbmdlOmI2Zjc0YTdmOTU3NTQwNGZiZGU4YmFmYjNhNWRjOGExXzUtMi0xLTEtMzQzODQ_a36adbba-67d4-4914-91b8-b2f6ff6e178b"
      unitRef="usd">1519986</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzUwMDc_5f3d14dd-908c-4a5a-bfca-18e5267b42c9">Stock-Based Compensation Plans&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has grants outstanding under two equity compensation plans. The 2007 Long-Term Incentive Compensation Plan (the "2007 Plan") and the 2007 Directors&#x2019; Incentive Plan (the "Directors&#x2019; Plan"), which were approved by shareholders, superseded the 1999 Stock Option Plan.  Both plans are available for future grants of equity compensation awards to employees, consultants and directors.  The 2007 Plan and the Directors&#x2019; Plan provide for the issuance of stock options, stock appreciation rights and restricted stock. Vesting is determined on a grant-by-grant basis in accordance with the terms of the plans and the related grant agreements. The Company has reserved 2.4 million shares of common stock for issuance under the 2007 Plan and 250,000 shares for issuance under the Directors&#x2019; Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of stock options is generally 100% of the fair market value of the underlying common stock on the grant date. The maximum contractual term of stock options is ten years from the date of grant, except for incentive stock options granted to 10% shareholders, which is five years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2011, the Company began issuing shares of restricted stock with no exercise price to employees and directors. Restricted stock issued to employees generally cliff-vests on the fourth anniversary of the date of grant. Restricted stock issued to directors vests on the one year anniversary of the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock compensation expense is presented as a component of general and administrative expense in the consolidated statements of operations. Stock compensation expense consisted of the following for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - nonemployees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, there was approximately $0.8 million of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted-average period of 1.81 years. This amount relates primarily to unrecognized compensation cost for employee restricted stock and stock options awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 178,950 and 186,900 incentive stock options during 2022 and 2021, respectively, which vest in four years.  There were no options exercised during 2022 and 2021.  As such, there was no intrinsic value of options or weighted-average fair value of options exercised for the periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incentive Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incentive stock options activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of option shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The weighted-average grant-date fair value of options granted during  the years 2022 and 2021 was $1.29 and $1.10, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is calculated using the Black-Scholes (&#x201c;Black-Scholes-Merton&#x201d;, or &#x201c;BSM&#x201d;) option-pricing model on the date of grant. Since 2012, the Company had been issuing RSA&#x2019;s (Restricted Share Awards) where the grant date Fair Value (&#x201c;FV&#x201d;) equaled the closing share price.  The ISO&#x2019;s required a BSM valuation to approximate FV.  The following inputs were used in the creation of the valuation.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - We estimate volatility in accordance with SAB No. 107, as amended by SAB No. 110. We have been publicly traded since August 2009, so we have sufficient years of trading history and volatility to appropriately evaluate this component of the BSM model.  As such, we are using our own historical volatility to value stock options.  We have noted no conditions that would indicate the historical volatility would not be an indicator of future volatility, as such we are using historical volatility over the same period as the expected term of the awards (7 years) back to 2015 and believe it to be sufficient. Calculated volatility for the grants issued in 2022 ranges from 44% to 45%.  Our average volatility over the life of stock being public is 42% and 45% over the last 6 months.  Based on the similar amounts, we believe our volatility estimate for the ISO&#x2019;s are appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - We estimate the expected life of employee share options based on the simplified method allowed by SAB No. 107, as amended by SAB No. 110. Under this approach, the expected term is presumed to be the average between the weighted-average vesting period and the contractual term.  The ISO&#x2019;s have a 10-year contractual term and the vesting period is 4 years.  This results in a calculated expected term of 7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Risk Free rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - The risk-free interest rate is based on the U.S. Treasury Note, on the date of grant with a term equal to the corresponding option&#x2019;s expected term. So, in this case, we are using the 7 year treasury note as of the date of grant, which ranges from 2.22% and 3.92% at the date of the grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - We have never declared or paid any cash dividends and there is currently no expected cash dividend payments as of the date of this grant. As such, dividend yield is zero. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.192%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;grant-date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:16pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of restricted stock granted was based on the closing market price of the Company&#x2019;s common stock on the date of grant.  The restricted stock grants are included in the diluted weighted shares outstanding computation until they cliff-vest.  Once vested they are included in the basic weighted shares outstanding computation.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzI3NDg3NzkwNzQ1MDU_19b49766-cfd5-42ae-86a2-49fede6aff34"
      unitRef="plan">2</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ibe55a7e9ab974665911b58f2cf2ab1d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzczMg_ccc7ef22-aa9e-4e09-b75e-19970b00c42c"
      unitRef="shares">2400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i8296dfa01cf5426fa8af917b505e162d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3Xzc5NQ_c9ac0f7f-785b-4926-a9d0-9cd49a7d4769"
      unitRef="shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue
      contextRef="i13b23c2311f046879e4fd6dafe94a991_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3Xzg5NA_7e109521-c430-4ea3-80c8-d7bd98c3c94b"
      unitRef="number">1</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i2d9c25b92eff4d35973caf424807a5d5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEwMjE_538b3f65-9919-426a-b322-4e9b22a1987d">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEwOTQ_0285d10c-7f69-431b-a443-ca02f22c0c03"
      unitRef="number">0.10</cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i070ea86904974ad18860cbc73c3202cc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzExMjA_d056c866-e660-4ccf-be83-9fb881783c0e">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i955de8aa181944039f7145e41a74c991_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEzOTQ_22088b4b-19ef-48ed-9d04-ecf0b11b63a8">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzUwMDQ_5402c37a-ecab-4b0a-99bd-2c95d503f18d">Stock compensation expense consisted of the following for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.770%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation - nonemployees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i09447f6af13b4f27a9f24d32a75cda9b_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzItMi0xLTEtMzQzODQ_3807f16d-8f8e-4b4c-a086-2463aae85d2a"
      unitRef="usd">449467</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7684a832b0134542abe7faecbea0573e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzItNC0xLTEtMzQzODQ_6656ee5b-669a-4709-b9d3-2044fc4cddde"
      unitRef="usd">730412</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i66c58bd8eaaf40cd8f6a0c93cdb60c2a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzMtMi0xLTEtMzQzODQ_d5e14e21-c2c8-4a21-bd1e-f12e7ec8afdd"
      unitRef="usd">-1964</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8d9566f966de4bd4968bb2d10e0af05b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzMtNC0xLTEtMzQzODQ_37513f21-2edb-4741-a513-f1e303ad8630"
      unitRef="usd">11455</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6e34c07ebd764d17a96ec1d0f497c811_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzQtMi0xLTEtMzQzODQ_02f5ae8e-4050-4261-ae38-677a0745976a"
      unitRef="usd">447503</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i89c60f8924f748d98ade2ba26f585e11_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTozNzE4OGRmZGJlNmQ0M2IwOWZhNDdmZjJiZDYzMTQ3OC90YWJsZXJhbmdlOjM3MTg4ZGZkYmU2ZDQzYjA5ZmE0N2ZmMmJkNjMxNDc4XzQtNC0xLTEtMzQzODQ_cf849878-73d6-4328-b819-e939a2192528"
      unitRef="usd">741867</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i214555a81d9942d3a95516724918bd8d_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzE2OTc_b61b69a1-4ffd-46fd-a86e-5d56914455bf"
      unitRef="usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6c780a0c3e87440c8eb1928bb0ce5f86_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzE4MzY_d8ebcf59-38e3-41ba-9c36-16e454ac10ab">P1Y9M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzIwMDA_b55a804b-bfdf-4e9b-8cdd-5173abb96bc2"
      unitRef="shares">178950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEwOTk1MTE2MzI3OTM_81fd14ad-0e4a-4d74-9b25-eaae20a9beb1"
      unitRef="shares">186900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzIwNTI_901d1e37-f15f-4e06-9c9e-6a6621c4eb47">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzU0OTc1NTgyMjAwMw_3cd25138-9dc1-451f-a190-b2a5968c8040">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incentive stock options activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.858%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.907%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of option shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-average remaining contractual term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Option shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock activity was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.192%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;of shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;grant-date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested, December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i91bab75ee1804a1097fbe90085dc4f12_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzItMi0xLTEtNDI0Njk_32bde3d9-6bfa-41a1-9f62-972dd4ccd935"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i91bab75ee1804a1097fbe90085dc4f12_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzItNC0xLTEtNDI0Njk_7c62a89f-2742-49f2-a599-01b8f014794d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzMtMi0xLTEtNDI0Njk_7694572e-b761-4cb6-a683-b6fbd6792807"
      unitRef="shares">186900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzMtNC0xLTEtNDI0Njk_fef05afc-9953-4cd3-9f55-b622dc01d10e"
      unitRef="usdPerShare">3.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzQtMi0xLTEtNDI0Njk_b0ea1569-a3ee-4e3d-be92-9054a3764172"
      unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzQtNC0xLTEtNDI0Njk_21b50c7b-343d-4e0a-9e81-172f57d78900"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzUtMi0xLTEtNDI0Njk_9108beed-d466-4c63-8b42-4285bccd1e1b"
      unitRef="shares">16300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i96a4e765721c42ea917004337d0b3ad7_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzUtNC0xLTEtNDI0Njk_20562ba6-9069-4993-87d4-ee025cdb217f"
      unitRef="usdPerShare">3.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3b943054825b4193b3cf6fbcea5877d1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzYtMi0xLTEtNDI0Njk_c262062c-45a5-4fb5-80d0-112cf5d55b8b"
      unitRef="shares">170600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3b943054825b4193b3cf6fbcea5877d1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzYtNC0xLTEtNDI0Njk_56ea6b53-264d-4d1f-b035-f5c453eed2e9"
      unitRef="usdPerShare">3.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzctMi0xLTEtNDI0Njk_72e218a4-ef5c-41ac-8e11-7cbcdae9f6af"
      unitRef="shares">178950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzctNC0xLTEtNDI0Njk_62202713-f0c1-45df-bc78-333df381657a"
      unitRef="usdPerShare">2.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzgtMi0xLTEtNDI0Njk_c7bc2b65-e596-4894-ac34-c578f93a5903"
      unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzgtNC0xLTEtNDI0Njk_019f3616-f5a1-4d8f-b344-a7b879f1e2b2"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzktMi0xLTEtNDI0Njk_185f6aba-7d71-4d09-bddc-96cb397e1de6"
      unitRef="shares">29900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzktNC0xLTEtNDI0Njk_2bfc046f-ff6f-4b7b-a764-9e9222d57c8b"
      unitRef="usdPerShare">2.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idfea5a17cdad49b5b643bd1bf2db9833_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzEwLTItMS0xLTQyNDY5_6a8f4954-69f5-47c5-ab5d-2e5ee3ad0999"
      unitRef="shares">319650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="idfea5a17cdad49b5b643bd1bf2db9833_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzEwLTQtMS0xLTQyNDY5_512d66bf-5ee6-458b-a616-0a9ecaa4007f"
      unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia1c248297d03494eb04a4bad485b30a6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTpmYjZjYmE3NWIyZTI0N2I5YTFiMDkxNDZkYTZmNTJmNi90YWJsZXJhbmdlOmZiNmNiYTc1YjJlMjQ3YjlhMWIwOTE0NmRhNmY1MmY2XzEwLTYtMS0xLTQyNjQ4_519fc1e8-7b3b-46ff-abf2-220468c855c5">P6Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEwOTk1MTE2MzU1OTk_6d57bfe7-46e2-4f05-959d-34b205ce47d3"
      unitRef="usdPerShare">1.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzEwOTk1MTE2MzU2MDc_2dc9ac7c-4da6-4e15-bc16-27f73c95d5a8"
      unitRef="usdPerShare">1.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzMzNzQ_1bded0db-7b6f-4843-83f8-2b60195a2c61">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1b65c4b8b6aa447481044537155a6d9a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzM0ODg_e96dac89-5190-4e79-bfe6-101788bba8c5"
      unitRef="number">0.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if838a7aa53664232926aca1c69b23238_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzM0OTQ_cf0d0e1b-c821-4ace-8213-25fe16722ec9"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i1b65c4b8b6aa447481044537155a6d9a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzM1NjE_43c0059b-fe7b-4496-9012-2c76342bb917"
      unitRef="number">0.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="if838a7aa53664232926aca1c69b23238_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzM1Njg_cdcee96a-8b90-4676-82b4-f492ec5411b8"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i2d9c25b92eff4d35973caf424807a5d5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzUwMTA_bc2e7751-59c6-4327-9acf-c31909ddb11f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzQwNTQ_a0658c65-0c0e-45e4-960e-8a2ce4bc1aa9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzQxMDU_efd4878d-3235-4fa7-8364-d9db23f10916">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1b65c4b8b6aa447481044537155a6d9a_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzQzNzM_2d5a7afd-c79d-4a4b-9910-6252fdde0424"
      unitRef="number">0.0222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if838a7aa53664232926aca1c69b23238_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzQzODA_69981b9c-5226-48f2-9df2-44a461130f29"
      unitRef="number">0.0392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="i9b6757568b9e49e9966bfb7da5c81e59_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90ZXh0cmVnaW9uOmQ0YTMyYjhhMDRhMzRlOWE5ZWU1NjY3ZjA1MDFmZWU3XzQ1OTI_16fa1d38-ddeb-4655-88e8-80559f63709f"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib2a4df839364457ca572567fd0e125dc_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzItMi0xLTEtMzQzODQ_16c79e75-ff71-4c59-958d-1ff54dff452e"
      unitRef="shares">779415</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib2a4df839364457ca572567fd0e125dc_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzItNC0xLTEtMzQzODQ_fa0ea2d4-0117-4abf-a227-d7d1f3ca5992"
      unitRef="usdPerShare">5.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzMtMi0xLTEtMzQzODQ_3a50ed90-36e9-4e73-8d8f-57a0a0c5dd0d"
      unitRef="shares">36850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzMtNC0xLTEtMzQzODQ_2d0f863e-07fe-4171-9640-e8f09788247a"
      unitRef="usdPerShare">3.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzQtMi0xLTEtMzQzODQ_e71fd994-fd7a-4f3d-9028-e20d7a07407c"
      unitRef="shares">192684</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzQtNC0xLTEtMzQzODQ_248c533a-f5df-4356-95e7-8fbf766c56d7"
      unitRef="usdPerShare">6.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzUtMi0xLTEtMzQzODQ_847c841c-12c5-414a-83bc-5c54fd325fb6"
      unitRef="shares">55400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i77bbb8c546584364b444f9dda7535ac1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzUtNC0xLTEtMzQzODQ_9fc52311-ef4f-4aea-8a05-1b9ca904584d"
      unitRef="usdPerShare">5.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i430e1a4cd7514fe59de28ed3a49bbab5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzYtMi0xLTEtMzQzODQ_89d54dbc-3c63-4366-9531-6c35722ea49c"
      unitRef="shares">568181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i430e1a4cd7514fe59de28ed3a49bbab5_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzYtNC0xLTEtMzQzODQ_c3f2125a-f3f4-462a-85ff-8436a1c64459"
      unitRef="usdPerShare">5.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzctMi0xLTEtMzQzODQ_656a3f46-4773-4fea-8a36-12d0d95ecd03"
      unitRef="shares">65225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzctNC0xLTEtMzQzODQ_6a9d4e2f-c72f-4a77-9e8b-b74df99e13c1"
      unitRef="usdPerShare">2.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzgtMi0xLTEtMzQzODQ_0e47d727-1d0f-4d14-af21-f507e6e21d4f"
      unitRef="shares">171655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzgtNC0xLTEtMzQzODQ_24f3c9b7-2b98-4eb9-8355-929dfdc9bcb6"
      unitRef="usdPerShare">6.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzktMi0xLTEtMzQzODQ_0b7d7e9d-3708-4812-b382-f604fd3ac06d"
      unitRef="shares">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i2feebee0d9d3471aa9e1f9a777659632_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzktNC0xLTEtMzQzODQ_eb82cc9f-05fe-468e-bf25-58002fe01cd3"
      unitRef="usdPerShare">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i872072012a784d598051e80fd8fb06ed_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzEwLTItMS0xLTM0Mzg0_dd9bcfdf-65f1-4e61-948b-860b20d0a7e1"
      unitRef="shares">395751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i872072012a784d598051e80fd8fb06ed_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjYvZnJhZzpkNGEzMmI4YTA0YTM0ZTlhOWVlNTY2N2YwNTAxZmVlNy90YWJsZTo2YWVkZjUwN2QzM2U0ZjE0YTVhNzk5NzY1YjBkZTg2Ni90YWJsZXJhbmdlOjZhZWRmNTA3ZDMzZTRmMTRhNWE3OTk3NjViMGRlODY2XzEwLTQtMS0xLTM0Mzg0_6c36ac0c-b96f-4a2a-a5fb-7db619115f81"
      unitRef="usdPerShare">4.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEzMzA_056c4c8e-cbe4-41e9-aa5d-0ec901fead27">Employee Benefit Plans&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors an employee benefit plan that was established on January&#160;1, 2006, the Cumberland Pharmaceuticals 401(k) Plan (the&#160;"Plan"), under Section&#160;401(k) of the Internal Revenue Code of 1986, as amended, for the benefit of all employees over the age of 21, having been employed by the Company for at least six months. The Plan provides that participants may contribute up to the maximum amount of their compensation as set forth by the Internal Revenue Service each year. Employee contributions are invested in various investment funds based upon elections made by the employees. During 2022 and 2021, the Company contributed approximately $60,000 and 50,000, respectively, in each year to the Plan as an employer match of participant contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012 and 2013, the Company established non-qualified unfunded deferred compensation plans that allow participants to defer receipt of a portion of their compensation. The liability under the plans, reflected in other long term liabilities in the consolidated balance sheets, was $2.5 million and $3.4 million as of December&#160;31, 2022 and 2021, respectively.  The Company had assets consisting of company-owned life insurance contracts generally designated to pay benefits of the deferred compensation plans reflected in other assets in the consolidated balance sheet of $2.3 million and $3.2 million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzI5OA_cd0d861c-f0c8-46af-8a95-78a1e9de7b16">P21Y</cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge>
    <cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzM1MQ_00f1fe9e-0744-4d09-aa3e-a7b9d922a3e7">P6M</cpix:DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzY3OA_81bc1796-3e1f-45e5-a084-fc818da45ff8"
      unitRef="usd">60000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEwOTk1MTE2MjkxMzU_f30f0e84-d02f-4287-b5b4-422d2f5df564"
      unitRef="usd">50000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEwMzg_6debcf29-56e7-4612-b6da-f5b6f9941d64"
      unitRef="usd">2500000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEwNDU_aa37b187-38c8-46eb-a351-e4c9641d784e"
      unitRef="usd">3400000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEyOTE_41f0ab71-cf80-4a47-ba5f-327bb44e834c"
      unitRef="usd">2300000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMjkvZnJhZzowYWRjMGYwNTZjNjM0MWY5OWM4NjFjMmRhNGQ4YTFkNi90ZXh0cmVnaW9uOjBhZGMwZjA1NmM2MzQxZjk5Yzg2MWMyZGE0ZDhhMWQ2XzEyOTg_6b676918-072d-4ec3-86a7-ad4d48efbe8a"
      unitRef="usd">3200000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzQxODE_4c545014-df85-4a2d-baea-d585741a500e">Leases&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 15, 2021, Cumberland entered into a lease, pursuant to which the Company leases approximately 16,903 rentable square feet of space at the new development Broadwest located in Nashville, Tennessee with 1600 West End Avenue Partners, LLC. The Leased Premise serves as the Company's new corporate headquarters. The initial term of the Lease is one hundred fifty-seven (157) months, with two consecutive options to renew for a period of five years each, with the commencement date of October 25, 2022.  This lease currently expires in November 2035.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for paying rent to the Landlord under the Lease beginning three months after the Commencement Date. The Company pays a base rent of $33.06 per square foot of rentable space with a gradual rental rate increase of 2.5% for each year period thereafter of the prior year's base rental. In addition to the monthly base rent, the Company is responsible for its percentage share of the operating expenses of the Building. The Lease also provides for a tenant improvement allowance for the space.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the operating leases also include the lease of approximately 14,200 square feet of wet laboratory and office space in Nashville, Tennessee by CET, our majority-owned subsidiary, where it operates the CET Life Sciences Center.  The research lab space at CET, under an agreement amended in July 2012, is leased through April 2023, with an option to extend the lease through April 2028. The Company also subleases a portion of the space under these leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense is recognized over the expected term of the lease, including renewal option periods, if applicable, on a straight-line basis as a component of general and administrative expense. Rent expense and sublease income  as follows for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,209,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the FASB issued ASU 2016-02. ASU 2016-02&#x2019;s core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information. The primary effect of adopting ASU 2016-02 to the Company was to record right-of-use assets and obligations for the leases currently classified as operating leases.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities were recorded as the present value of remaining lease payments not yet paid for the lease term discounted using the incremental borrowing rate associated with each lease. Operating lease right-of-use assets represent operating lease liabilities adjusted for lease incentives and initial direct costs. As the Company&#x2019;s leases do not contain implicit borrowing rates, the incremental borrowing rates were calculated based on information available at January 1, 2019 and October 25, 2022. Incremental borrowing rates reflect the Company&#x2019;s estimated interest rates for collateralized borrowings over similar lease terms. The weighted-average remaining lease term for the Broadwest lease is 12.7 years and for the CET lease is 0.1 years. The weighted-average incremental borrowing rate used to discount the present value of the remaining CPI lease payments is 9.28% and remaining CET lease payments is 7.42%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease Position&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, the Company recorded the following on the Consolidated Balance Sheet:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:right"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,586,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,759,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative future minimum sublease income under non-cancelable operating subleases totals approximately $0.1 million and will be paid through the leases ending in April 2023. Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Leases Liabilities at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,482,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,427,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,668,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,759,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <cpix:LesseeOperatingLeaseLeasedArea
      contextRef="i554be9ce2c1b41b4a99da09551040eaf_I20211115"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzM4OA_a9cf372e-5a79-4330-a7b0-db366286d8a9"
      unitRef="sqft">16903</cpix:LesseeOperatingLeaseLeasedArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i554be9ce2c1b41b4a99da09551040eaf_I20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzY2MA_fab39dee-eb1f-47b8-ad84-647961b51e78">P157M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <cpix:LesseeOperatingLeaseNumberOfRenewalTerms
      contextRef="ic57bcfd058014d5d98c77360f419b471_I20211115"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzY3Nw_46c9e87d-b813-46cf-9a72-7a7a3f087c7d"
      unitRef="renewalterm">2</cpix:LesseeOperatingLeaseNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ic57bcfd058014d5d98c77360f419b471_I20211115"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzcyNQ_fda85d93-3645-4cf7-bf1e-f10ebba06f04">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cpix:LesseeOperatingLeaseBaseRent
      contextRef="i554be9ce2c1b41b4a99da09551040eaf_I20211115"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzExMjY_c96b088c-be17-4feb-a414-6dd34e05f869"
      unitRef="usdPerSqft">33.06</cpix:LesseeOperatingLeaseBaseRent>
    <cpix:LesseeOperatingLeaseRentIncrease
      contextRef="ib2fa7c2f4e86401a88e3022cb2d1309b_I20211115"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzEyMDI_71f24c20-92e2-4e6d-8f2d-b60c70586017"
      unitRef="number">0.025</cpix:LesseeOperatingLeaseRentIncrease>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i5a4d2edd7a324a55a81eb502f58e0069_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzU0OTc1NTgxOTc1OA_67ff1778-c604-4dde-882a-1a9bd72fa5ea"
      unitRef="sqft">14200</us-gaap:AreaOfRealEstateProperty>
    <cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzQxNzg_81d34608-3a7d-4bc3-a73e-f52847dce121">Rent expense and sublease income  as follows for the years ended December 31:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.153%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.567%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,159,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,209,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTpmODAzMTJjNDhkZWM0OTY3YWQzNjliZDkwZmM0MjNiNC90YWJsZXJhbmdlOmY4MDMxMmM0OGRlYzQ5NjdhZDM2OWJkOTBmYzQyM2I0XzItMi0xLTEtMzQzODQ_cccca164-537a-4310-9f49-84ff127fd1c1"
      unitRef="usd">1159695</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTpmODAzMTJjNDhkZWM0OTY3YWQzNjliZDkwZmM0MjNiNC90YWJsZXJhbmdlOmY4MDMxMmM0OGRlYzQ5NjdhZDM2OWJkOTBmYzQyM2I0XzItNC0xLTEtMzQzODQ_58aae358-d391-4e73-bdb5-92b980442c23"
      unitRef="usd">1209102</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTpmODAzMTJjNDhkZWM0OTY3YWQzNjliZDkwZmM0MjNiNC90YWJsZXJhbmdlOmY4MDMxMmM0OGRlYzQ5NjdhZDM2OWJkOTBmYzQyM2I0XzQtMi0xLTEtMzQzODQ_2e1bf8d3-092d-49cf-aa73-b7330fce4cb1"
      unitRef="usd">529411</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTpmODAzMTJjNDhkZWM0OTY3YWQzNjliZDkwZmM0MjNiNC90YWJsZXJhbmdlOmY4MDMxMmM0OGRlYzQ5NjdhZDM2OWJkOTBmYzQyM2I0XzQtNC0xLTEtMzQzODQ_2dbb5645-8658-49f9-a6dd-ab22fdd7e45f"
      unitRef="usd">699889</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i48b2fbaeed6a477c8536c9109ab9bde5_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzM1NzQ_4cc4d1f3-82d3-4832-8c6e-93901092508c">P12Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="iffad826a3e6c41bd89cf0a3c062b03ad_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzEwOTk1MTE2MzI4MDQ_c724cf49-ab6a-4a9c-8391-0606e5eab0fe">P0Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i48b2fbaeed6a477c8536c9109ab9bde5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzEwOTk1MTE2MzI3MzU_2c937a42-7eda-4a67-93da-9f7d990fdbda"
      unitRef="number">0.0928</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="iffad826a3e6c41bd89cf0a3c062b03ad_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzM3MDU_84d96882-eef0-4146-93fb-6a880baa4840"
      unitRef="number">0.0742</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <cpix:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzQxNzk_2a905982-0d8a-4913-bfa9-c03143f26de1">&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, the Company recorded the following on the Consolidated Balance Sheet:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-Use Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,218,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:right"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.271%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.130%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,586,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,759,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cpix:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo1NWI3M2NiZjc1MTQ0YzZiYTQ4OWRjMzM4MmNiNmQxZS90YWJsZXJhbmdlOjU1YjczY2JmNzUxNDRjNmJhNDg5ZGMzMzgyY2I2ZDFlXzEtMi0xLTEtMzQzODQ_b419299c-6b3b-4f73-9ccb-8e7ee43bc2ac"
      unitRef="usd">5218403</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo1NWI3M2NiZjc1MTQ0YzZiYTQ4OWRjMzM4MmNiNmQxZS90YWJsZXJhbmdlOjU1YjczY2JmNzUxNDRjNmJhNDg5ZGMzMzgyY2I2ZDFlXzEtNC0xLTEtMzQzODQ_3f1fa727-82d8-4bd9-aefd-3a0bc71aa765"
      unitRef="usd">1024200</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzEtMi0xLTEtMzQzODQ_f25a2a7a-70df-430e-bb9a-f447d062162e"
      unitRef="usd">172910</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzEtNC0xLTEtMzQzODQ_41d82ab1-f3f3-4cf8-83f1-af6c07b14ace"
      unitRef="usd">969677</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzItMi0xLTEtMzQzODQ_438cf634-b7ab-438e-a5e4-493ee1daa023"
      unitRef="usd">4586301</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzItNC0xLTEtMzQzODQ_98ecc334-2da2-4b8c-8c97-30858d19bc85"
      unitRef="usd">90016</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <cpix:LeaseLiability
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzMtMi0xLTEtMzQzODQ_6980412e-a3e7-4625-a006-e9a1d4c2fa08"
      unitRef="usd">4759211</cpix:LeaseLiability>
    <cpix:LeaseLiability
      contextRef="ic0531c6598004c5d9158b8763683f643_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZTo0YmE2ZmRiODA0YmU0Y2VhOGJiMjk2Y2RlNjg0Y2ZjNC90YWJsZXJhbmdlOjRiYTZmZGI4MDRiZTRjZWE4YmIyOTZjZGU2ODRjZmM0XzMtNC0xLTEtMzQzODQ_125aa044-3921-463d-bfd6-ee02577388f9"
      unitRef="usd">1059693</cpix:LeaseLiability>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzM5NTA_84324d9c-2ea5-4105-9d08-df0ea793e3c8"
      unitRef="usd">100000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90ZXh0cmVnaW9uOjc2MTY3Yzg0MGJmYTQ3M2Y5YTc1ODVjZmZiZDE4YjM5XzQxODM_aa133497-dbe7-4611-9ea9-57cadb40f843">Future minimum lease payments under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity of Leases Liabilities at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,482,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,427,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,668,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,759,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzEtMi0xLTEtMzc3OTg_0d2df6c6-4008-4291-bc10-8d233949ee01"
      unitRef="usd">607061</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzItMi0xLTEtMzc3OTg_1accef55-c7e2-4a0f-aaad-dff71a68ae81"
      unitRef="usd">575209</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzMtMi0xLTEtMzc3OTg_781ddb4a-5213-4f29-abf4-12a92d6c7ebf"
      unitRef="usd">539347</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzEtMi0xLTEtMzQzODQ_93b0b8c8-1e46-4e36-b348-5065fb31b339"
      unitRef="usd">604254</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzItMi0xLTEtMzQzODQ_0370f165-c13c-4943-b9fe-e17cc494d584"
      unitRef="usd">619354</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzMtMi0xLTEtMzQzODQ_12975783-56e6-47c8-a276-c741ba43f95d"
      unitRef="usd">5482220</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzctMi0xLTEtMzc3OTg_224cb619-67dd-4170-9451-d18eabe2ebcf"
      unitRef="usd">8427445</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzQtMi0xLTEtMzQzODQ_b770c709-6d99-44d9-b1bf-6d682b6ad15f"
      unitRef="usd">3668234</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie7de9e3a8f694f75963d43839bcbe61c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzIvZnJhZzo3NjE2N2M4NDBiZmE0NzNmOWE3NTg1Y2ZmYmQxOGIzOS90YWJsZToxMWM5NDhmYzJmMTg0YzAxOThjZmYyMzliYmQ1N2U5Ni90YWJsZXJhbmdlOjExYzk0OGZjMmYxODRjMDE5OGNmZjIzOWJiZDU3ZTk2XzUtMi0xLTEtMzQzODQ_d11c21e4-b2dc-4d0e-a75e-cf94db42b7a8"
      unitRef="usd">4759211</us-gaap:OperatingLeaseLiability>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90ZXh0cmVnaW9uOmNlNGU1YTc5MWFhMDQyMmQ5NDExOTlmZTI5ODM3NWQ4XzkwMw_1b6a8ba4-076a-4b21-8c64-b6c9ce41c2c3">Market Concentrations&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s principal financial instruments subject to potential concentration of credit risk are accounts receivable, which are unsecured, and cash equivalents. The Company&#x2019;s cash equivalents consist primarily of money market funds. Certain bank deposits may be in excess of the insurance limits provided by the Federal Deposit Insurance Corporation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary customers are wholesale pharmaceutical distributors in the U.S. &#160;Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable, net of allowances, due from the customers representing 10% or more of consolidated revenue was 51.77% and 51.1% at December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90ZXh0cmVnaW9uOmNlNGU1YTc5MWFhMDQyMmQ5NDExOTlmZTI5ODM3NWQ4XzkwNQ_1a0d4329-8bf6-4993-80a2-6437feb22a60">Total revenues by customer for each customer representing 10% or more of consolidated revenues are summarized below for the years ended December 31: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.941%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.362%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8047e420d87647ca865218062adc1b3c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzItMi0xLTEtMzQzODQ_56799a9a-f6ea-47e2-8dbb-de5b372f6e36"
      unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibb1ed446076641e2b06e8f65764e9641_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzItNC0xLTEtMzQzODQ_fcdbae52-8d55-42da-94ea-416dd3c6fdc9"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie513e297486b4dc29fca145454075e01_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzMtMi0xLTEtMzQzODQ_f9ab68d6-b706-49fa-a047-e1e0fd745d10"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0510690b6b854b9d8843a2b97df3ce27_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzMtNC0xLTEtMzQzODQ_e5a7bbdc-966a-4449-9e0f-e67fc3216134"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i40f47c6c3c2345c982dcd1e267fd6145_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzQtMi0xLTEtMzQzODQ_fdf9df26-d7e1-44e0-901c-43a674b47326"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaff5c56f78a34c10b47d66d78992346f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90YWJsZTo1Y2RkZTM3YTY1ZmU0Mzk1YjM5MDcyMzJlNjM5ZmU0Zi90YWJsZXJhbmdlOjVjZGRlMzdhNjVmZTQzOTViMzkwNzIzMmU2MzlmZTRmXzQtNC0xLTEtMzQzODQ_dca2fe03-2d42-466a-8a75-1266008c9008"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i42772db945f14e0d885bd05151e93291_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90ZXh0cmVnaW9uOmNlNGU1YTc5MWFhMDQyMmQ5NDExOTlmZTI5ODM3NWQ4Xzg2Nw_e9e71fc8-a87d-4a77-8fb8-e9575dbfc8b4"
      unitRef="number">0.5177</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3990e4402eb64fb980a6bad3eb7430b8_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzUvZnJhZzpjZTRlNWE3OTFhYTA0MjJkOTQxMTk5ZmUyOTgzNzVkOC90ZXh0cmVnaW9uOmNlNGU1YTc5MWFhMDQyMmQ5NDExOTlmZTI5ODM3NWQ4Xzg3NA_fed94039-1c32-4d8e-b57c-c0a45fc2d537"
      unitRef="number">0.511</us-gaap:ConcentrationRiskPercentage1>
    <cpix:ManufacturingAndSupplyAgreementsTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzgvZnJhZzo2ZTc0NWVmNDBmNjg0MGIzYWZjM2Y4MzVkMWViODI3YS90ZXh0cmVnaW9uOjZlNzQ1ZWY0MGY2ODQwYjNhZmMzZjgzNWQxZWI4MjdhXzYzOQ_6a938ac8-27d5-4526-a487-cd260b140731">Manufacturing and Supply AgreementsThe Company utilizes one or two primary suppliers to manufacture each of its products and product candidates. Although there are a limited number of manufacturers of pharmaceutical products, the Company believes it could utilize other suppliers to manufacture its prescription products on comparable terms.  A change in suppliers, problems with its third-party manufacturing operations or related production capacity, or contract disputes with suppliers could cause a delay in manufacturing or shipment of finished goods and possible loss of sales, which could adversely affect operating results.</cpix:ManufacturingAndSupplyAgreementsTextBlock>
    <cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct
      contextRef="ic40eb7705a474e4fa7d98cfa3a5cb554_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzgvZnJhZzo2ZTc0NWVmNDBmNjg0MGIzYWZjM2Y4MzVkMWViODI3YS90ZXh0cmVnaW9uOjZlNzQ1ZWY0MGY2ODQwYjNhZmMzZjgzNWQxZWI4MjdhXzY3_6e9543d6-0c91-4bcb-9c54-75ab58e21d66"
      unitRef="supplier">1</cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct>
    <cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct
      contextRef="ie088610f3d64485c98806a39268009ee_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yMzgvZnJhZzo2ZTc0NWVmNDBmNjg0MGIzYWZjM2Y4MzVkMWViODI3YS90ZXh0cmVnaW9uOjZlNzQ1ZWY0MGY2ODQwYjNhZmMzZjgzNWQxZWI4MjdhXzcz_40fbbfbb-d4ef-49ab-826f-d5fce106328e"
      unitRef="supplier">2</cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct>
    <cpix:EmploymentAgreementsTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDEvZnJhZzpjZjY2ZGYxMTAzMmE0ZjRjOGU3ZTE2MjNmZTEzMDkxZC90ZXh0cmVnaW9uOmNmNjZkZjExMDMyYTRmNGM4ZTdlMTYyM2ZlMTMwOTFkXzMzOA_9ad5acc0-6a12-4d89-8826-eb06ca897783">Employment AgreementsThe Company has entered into employment agreements with all its full-time employees. Each employment agreement provides for a salary for services performed, a potential annual bonus and, if applicable, a grant of restricted common shares pursuant to a restricted stock and incentive stock option agreement.</cpix:EmploymentAgreementsTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDQvZnJhZzo0Y2E1ODA3YWFkMGM0NDFjYTg5ZDNkNzQ1MDk4NTkzNi90ZXh0cmVnaW9uOjRjYTU4MDdhYWQwYzQ0MWNhODlkM2Q3NDUwOTg1OTM2XzMwNjg_9c1fe4f2-ccf9-48aa-ac84-48d617ef892b">Discontinued Operations&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In 2016, Cumberland entered into an agreement with Clinigen Group Plc ("Clinigen") for the rights and responsibilities associated with the commercialization of Ethyol in the United States.  In 2017, the Company entered into another agreement with Clinigen for the rights and responsibilities associated with the commercialization of Totect in the United States.  Ethyol and Totect are collectively referred to herein as the "Products."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Early in 2019, Cumberland announced a strategic review of the Company's brands, capabilities, and international partners. This review followed an accelerated business development initiative, which resulted in a series of transactions. Because of that progress, Cumberland felt that it was prudent to take a fresh look at our product portfolio, partners, and organization to ensure proper focus and capabilities.  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2019, Cumberland entered into the Dissolution Agreement with Clinigen in which the Company returned the exclusive rights to commercialize Ethyol and Totect (&#x201c;the Products&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States to Clinigen. This Dissolution Agreement originally targeted a transition from the Company's arrangements with Clinigen effective September 30, 2019, but was then amended to change the transition date to December 31, 2019. Under the terms of the Dissolution Agreement, Cumberland was no longer responsible for the distribution, marketing and promotion of either the Products or any competing products after December 31, 2019.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the return of these product license rights and the non-compete provisions of the Dissolution Agreement, Cumberland received $5&#160;million in financial consideration paid in quarterly installments over the two-years following the transition date.  Cumberland recorded the last four quarterly installments totaling $2.0 million during the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exit from the Ethyol and Totect products meets the accounting criteria to be reported as discontinued operations.  As a result, January 1, 2020, was the first day of discontinued operations for the Products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Products provided revenue, incurred direct expenses and resulted in discontinued operations income during the periods presented.  The following amounts have been separated from continuing operations, as discontinued operations, for all periods presented. The direct expenses separated for discontinued operations do not reflect the direct selling and marketing costs attributable to the individuals at Cumberland responsible for promotion of the Products.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Subsequent to the transaction date, th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ose sales and marketing individuals who supported the Products shifted their efforts from the Products and continue to support other Cumberland brands.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
      contextRef="i478ad941e6444190835fbd70e6a0fda2_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDQvZnJhZzo0Y2E1ODA3YWFkMGM0NDFjYTg5ZDNkNzQ1MDk4NTkzNi90ZXh0cmVnaW9uOjRjYTU4MDdhYWQwYzQ0MWNhODlkM2Q3NDUwOTg1OTM2XzE2NTU_770a83a3-5840-42f1-b712-afe1514f6b1d"
      unitRef="usd">5000000</us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset>
    <cpix:FinancialConsiderationPaymentPeriod
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDQvZnJhZzo0Y2E1ODA3YWFkMGM0NDFjYTg5ZDNkNzQ1MDk4NTkzNi90ZXh0cmVnaW9uOjRjYTU4MDdhYWQwYzQ0MWNhODlkM2Q3NDUwOTg1OTM2XzMwNjk_2507053a-3619-419f-ab52-567c0ef141d9">P2Y</cpix:FinancialConsiderationPaymentPeriod>
    <cpix:FinancialConsiderationNumberOfInstallments
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDQvZnJhZzo0Y2E1ODA3YWFkMGM0NDFjYTg5ZDNkNzQ1MDk4NTkzNi90ZXh0cmVnaW9uOjRjYTU4MDdhYWQwYzQ0MWNhODlkM2Q3NDUwOTg1OTM2XzE3OTU_21dd2166-c52d-4cb6-83dc-7d652f1fbb78"
      unitRef="installment">4</cpix:FinancialConsiderationNumberOfInstallments>
    <us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDQvZnJhZzo0Y2E1ODA3YWFkMGM0NDFjYTg5ZDNkNzQ1MDk4NTkzNi90ZXh0cmVnaW9uOjRjYTU4MDdhYWQwYzQ0MWNhODlkM2Q3NDUwOTg1OTM2XzE4MzA_6b92f55d-bc78-46de-9746-c2b29eccb538"
      unitRef="usd">2000000</us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzQxNzE_6b7ce4e0-1a7b-4d3d-8370-f7ee59d0bdc9">Commitments and Contingencies&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with its licensing agreements for Caldolor,  the Company is required to pay royalties based on net sales over the life of the product. Royalty expense is recognized as a component of selling and marketing expense in the period that revenue is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Vibativ, the Company is required to pay royalties based on net sales of the product.  At the purchase date, Cumberland recorded the fair value of this liability and will continue to evaluate the liability each period and the royalty expense is recognized as a component of selling and marketing expense in the period that the change in fair value is recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Sancuso, the Company is required to pay up to $3.5&#160;million in milestones and tiered royalties ranging from 10% to 5% on U.S. net product sales for ten years.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumberland has a number of patents issued through the United States Patent and Trademark Office (the &#x201c;USPTO&#x201d;) including U.S. Patent number 8,148,356 (the &#x201c;356 Acetadote Patent&#x201d;) which is assigned to the Company. The claims of the 356 Acetadote Patent encompass the new Acetadote formulation and include composition of matter claims. Following its issuance, the 356 Acetadote Patent was listed in the FDA Orange Book. The 356 Acetadote Patent is scheduled to expire in May 2026, which time period includes a 270-day patent term adjustment granted by the USPTO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2012, Cumberland has continued to vigorously defend and protect its Acetadote product and related intellectual property rights including the use of all its legal options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Melinta Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2022, the Company filed an action for breach of contract against Melinta Therapeutics, LLC and Targanta Therapeutics Corporation (collectively, the &#x201c;Defendants&#x201d;) in the United States District Court for the Southern District of New York (Case No. 1:22-cv-00915-VM).  The Company and the Defendants are parties to an agreement (the &#x201c;Agreement&#x201d;), pursuant to which the Defendants have a license to develop and commercialize products under certain Company patents, in exchange for the Defendants paying the Company certain milestone payments and royalties on net sales of the licensed products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Specifically, the Agreement requires the Defendants to, among other things, make a $500,000 payment to the Company within 30 days following the first filing of an sNDA in relation to the Product (as defined the Agreement) and a $500,000 payment to the Company following the approval of the first sNDA in relation to the Product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After Defendants disclosed the domiciles of its limited partners to the Company, as required by the Court, on October 24, 2022, the action for breach of contract was refiled in the Supreme Court of the State of New York, County of New York (Index No. 654234/2022) on November 7, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The complaint alleges that, despite the Defendants filing an NDA and sNDA for the Product and receiving FDA approval for both applications, the Defendants failed to make the required total of $1&#160;million in milestone payments to the Company.  The Company is seeking damages in the amount of no less than $1&#160;million, pre- and post-judgment interest under N.Y. C.P.L.R. &#xa7; 5001, costs, and such further relief as the court deems just and proper.&lt;/span&gt;&lt;/div&gt;The Company is a party to various other legal proceedings in the ordinary course of its business. In the opinion of management, the liability associated with these matters, will not have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum
      contextRef="i03b6a63983b64d8bbf3a1a5e92a62c3b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzExODY_fdcd9580-3421-48a5-aef2-0f308030a8c9"
      unitRef="usd">3500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum>
    <cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
      contextRef="i1e7165d6a14540d69539b738e13cdf8d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzEyMzc_123d4cfa-23c4-42f5-b9fa-53fbb4f04755"
      unitRef="number">0.10</cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent>
    <cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent
      contextRef="i284259e69f3e4e4e84c466d1e02a1e56_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzEyNDM_71d28cd6-487d-4901-ba8c-f626a551ca4f"
      unitRef="number">0.05</cpix:CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent>
    <cpix:CollaborativeArrangementRightsAndObligationsTerm
      contextRef="i03b6a63983b64d8bbf3a1a5e92a62c3b_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzEyNzY_676ee604-107d-45d4-aa49-9a00fda47c66">P10Y</cpix:CollaborativeArrangementRightsAndObligationsTerm>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable
      contextRef="ia952b89d554e4c89bf3b5882567c2d5f_I20220202"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzU0OTc1NTgyNTQ5Ng_6fa76533-8b7a-4620-aaf8-0f6b10ce1030"
      unitRef="usd">500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable
      contextRef="i49eca3268edc4ad8b4e63d2e71cfa018_I20220202"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzU0OTc1NTgyNTUwNg_3e68ec46-7c71-4be6-a00e-062a1b1a83fe"
      unitRef="usd">500000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable>
    <cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable
      contextRef="i1f878acd95a045fd934d5052dde987c6_I20221107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzU0OTc1NTgyNTUxNg_2e95ce16-03fa-4a46-bacf-50f0d4ff5e57"
      unitRef="usd">1000000</cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable>
    <us-gaap:GainContingencyUnrecordedAmount
      contextRef="i1f878acd95a045fd934d5052dde987c6_I20221107"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNDcvZnJhZzphZjE5MGE0NDcwMDI0YzFkOTIxMDU0MTVmNTM2ZDY2NS90ZXh0cmVnaW9uOmFmMTkwYTQ0NzAwMjRjMWQ5MjEwNTQxNWY1MzZkNjY1XzU0OTc1NTgyNTUyOA_0a15fc9e-ae05-4dfa-a31a-a61db3ced3a3"
      unitRef="usd">1000000</us-gaap:GainContingencyUnrecordedAmount>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90ZXh0cmVnaW9uOjY5N2YxZTM0MTU4MDRhMGI4M2RjOWNlNzE3OWUwZDk1XzM1Mg_ea9eb396-06b9-40ee-9aee-27cac8a1bb14">Quarterly Financial Information (Unaudited)&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the unaudited operating results for each fiscal quarter of 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,175,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,299,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,413,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,123,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,010,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,291,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,846,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(288,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,277,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,402,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,364,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(423,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,459,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,650,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,385,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,335,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(408,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,440,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,570,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,537,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,055,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,072,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,319,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,985,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(324,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,435,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,563,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,353,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,677,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(350,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;724,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,583,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,387,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,597,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;498,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,994,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,228,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,055,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,847,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,507,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90ZXh0cmVnaW9uOjY5N2YxZTM0MTU4MDRhMGI4M2RjOWNlNzE3OWUwZDk1XzM1Mw_0e9c8ad5-a80b-4a83-b1a5-4bbe44840dee">&lt;div style="margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the unaudited operating results for each fiscal quarter of 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quarter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,175,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,299,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,413,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,123,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,010,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,291,999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,846,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(288,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,277,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,402,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,364,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(423,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,459,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,650,039)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,385,253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,335,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(408,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,440,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,570,241)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,537,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,055,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,072,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,319,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,985,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(324,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,435,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,563,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,353,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,677,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(350,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;724,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,583,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,387,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,597,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;498,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;496,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,994,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,228,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,055,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,847,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,507,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings (loss) per share attributable to common shareholders &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-13.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.07)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Due to the nature of interim earnings per share calculations, the sum of the quarterly earnings (loss) per share amounts may not equal the reported earnings (loss) per share for the full year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMtMi0xLTEtMzQzODQ_f10820e2-9fc8-4aa8-b32f-5abacd8566ae"
      unitRef="usd">11175045</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMtNC0xLTEtMzQzODQ_48f5f969-850f-43e7-9964-7233dad4e84a"
      unitRef="usd">10299152</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMtNi0xLTEtMzQzODQ_0e373468-1153-4375-803c-4b075ce60281"
      unitRef="usd">11413072</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMtOC0xLTEtMzQzODQ_5bf55f90-e999-4c38-a93a-a675323b0646"
      unitRef="usd">9123680</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMtMTAtMS0xLTM0Mzg0_083b2ec7-92dd-43d1-9814-402b50f9b147"
      unitRef="usd">42010949</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzQtMi0xLTEtMzQzODQ_b5a5797b-9c6e-429a-a226-01d7152cc966"
      unitRef="usd">-1291999</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzQtNC0xLTEtMzQzODQ_5bc820b6-7504-4c05-9a08-3450d16dde40"
      unitRef="usd">-1846538</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzQtNi0xLTEtMzQzODQ_ee62f3ae-dfea-47fe-8bf5-eb079cb53a5f"
      unitRef="usd">-288588</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzQtOC0xLTEtMzQzODQ_70e616cb-3cf6-4964-a3b9-d50a13d13fbe"
      unitRef="usd">-2277804</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzQtMTAtMS0xLTM0Mzg0_e41cea7a-a760-42e4-9bd5-8004ec49635c"
      unitRef="usd">-5704929</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzUtMi0xLTEtMzQzODQ_b116281f-b493-4a19-a62a-126ee72c5279"
      unitRef="usd">-1402433</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzUtNC0xLTEtMzQzODQ_7fa9b083-1d78-442a-b3c0-a8a3e8eb056c"
      unitRef="usd">-1364666</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzUtNi0xLTEtMzQzODQ_f71458f3-188a-45c4-a7aa-2c9f166576a8"
      unitRef="usd">-423226</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzUtOC0xLTEtMzQzODQ_1ad765cc-1a5f-453c-bd79-4424086e4d9c"
      unitRef="usd">-2459714</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzUtMTAtMS0xLTM0Mzg0_20dc1b98-e13b-4956-910a-8cac75847869"
      unitRef="usd">-5650039</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzctMi0xLTEtMzQzODQ_f6233868-e602-4a91-86c0-eeac0970470a"
      unitRef="usd">-1385253</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzctNC0xLTEtMzQzODQ_33f787f4-4757-4c14-b191-74d0f146bf26"
      unitRef="usd">-1335620</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzctNi0xLTEtMzQzODQ_be462f91-af07-425a-a78b-e9cf46b2df20"
      unitRef="usd">-408639</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzctOC0xLTEtMzQzODQ_a9aa53d2-aa9d-4940-845e-c06f8827f84d"
      unitRef="usd">-2440729</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzctMTAtMS0xLTM0Mzg0_b71b95d0-fc57-46cc-96ed-9dc5a90f1e94"
      unitRef="usd">-5570241</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzktMi0xLTEtMzQzODQ_e4067b22-c74a-4da6-9bbd-b225015fa549"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzktNC0xLTEtMzQzODQ_a9cc1609-5d14-4c3a-ba0c-e8cd9bcb573d"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzktNi0xLTEtMzQzODQ_432de364-39de-4efe-8aba-814b10c034e2"
      unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzktOC0xLTEtMzQzODQ_5dcd3ad6-728f-4a01-b454-2b5084a862bd"
      unitRef="usdPerShare">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzktMTAtMS0xLTM0Mzg0_5dfd8dc3-bb54-42cd-9751-95a51828e7ec"
      unitRef="usdPerShare">-0.38</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEwLTItMS0xLTM0Mzg0_b0d6fba1-2ff6-4722-ba82-7313c1f1f7b0"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEwLTQtMS0xLTM0Mzg0_03819879-7c72-461d-abc7-0ca781b95161"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEwLTYtMS0xLTM0Mzg0_fa56d630-94cb-4998-bb53-611517f22617"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEwLTgtMS0xLTM0Mzg0_22cda5b4-7bfd-4ce4-9537-316b9ece3aef"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEwLTEwLTEtMS0zNDM4NA_c9675e1c-13c0-4255-9e49-8d9372c2fb47"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzExLTItMS0xLTM0Mzg0_506cdbbb-f774-49e0-acff-61c7f22044d8"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzExLTQtMS0xLTM0Mzg0_e4dda22e-6419-4d85-9f0a-5d3a56f45db0"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzExLTYtMS0xLTM0Mzg0_f526160c-32a4-4c3e-9e80-1b876bf33c96"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzExLTgtMS0xLTM0Mzg0_a7035de0-c160-408d-bce6-a5b9e3b7fb35"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzExLTEwLTEtMS0zNDM4NA_b21f773c-e5c4-4d5c-a6b1-4cfbf0571d3e"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEzLTItMS0xLTM0Mzg0_48f65c86-5ab6-4b69-a643-7f9a7d07f998"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEzLTQtMS0xLTM0Mzg0_e7096625-c098-4637-92f6-2e8d093e3eef"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEzLTYtMS0xLTM0Mzg0_5889da6c-753d-4027-8950-983d36fd74d7"
      unitRef="usdPerShare">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEzLTgtMS0xLTM0Mzg0_0a92ab88-cbeb-4db6-a505-5b0ce9fcda1d"
      unitRef="usdPerShare">-0.17</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzEzLTEwLTEtMS0zNDM4NA_f98f24ef-68a9-41db-8734-b16427bb6272"
      unitRef="usdPerShare">-0.38</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE0LTItMS0xLTM0Mzg0_7316830b-4f5e-459d-920a-a423d7c7e4f3"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE0LTQtMS0xLTM0Mzg0_6043ff49-5817-461b-8b8b-1212189476ea"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE0LTYtMS0xLTM0Mzg0_c8741812-7226-4919-8ad8-acd4a547bba4"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE0LTgtMS0xLTM0Mzg0_94361242-036c-420a-a9e7-f94f03db8b94"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE0LTEwLTEtMS0zNDM4NA_29770a5b-b254-4fe9-898b-b44b8398c306"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i64c3421e0d2e4d6594a1310b2092eef6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE1LTItMS0xLTM0Mzg0_7efd16fa-f737-4879-99e3-56ed363c7b9a"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7f2fe16a8bbd495ea60a640bf9253bff_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE1LTQtMS0xLTM0Mzg0_c05afa12-ba25-41b7-a9e1-e5697cd2d685"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i51cefa1dd6e647bc8991a306ad56646f_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE1LTYtMS0xLTM0Mzg0_2dbe362d-aaa9-4127-af58-7216c86f6fac"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE1LTgtMS0xLTM0Mzg0_933b3a07-1134-4a6f-9886-8e869dfc7a12"
      unitRef="usdPerShare">-0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE1LTEwLTEtMS0zNDM4NA_f116d8e6-315f-4667-b0d4-a0a6308b5710"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:Revenues
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE4LTItMS0xLTM0Mzg0_ef041951-ca12-4002-ba50-931cd6a8bff1"
      unitRef="usd">10537159</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE4LTQtMS0xLTM0Mzg0_96000932-0374-4546-9549-dc9cc593b299"
      unitRef="usd">9055483</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE4LTYtMS0xLTM0Mzg0_2a78de12-a49f-4b14-8662-259feb4a9ad1"
      unitRef="usd">8072540</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE4LTgtMS0xLTM0Mzg0_cb276c4b-c0b3-4d04-af90-e587bd63ea67"
      unitRef="usd">8319861</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE4LTEwLTEtMS0zNDM4NA_df5f82c3-b080-439b-946e-1bb7024fe9a1"
      unitRef="usd">35985043</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE5LTItMS0xLTM0Mzg0_fee854b5-9c2f-4b1c-b681-1c3a202f9d70"
      unitRef="usd">-324300</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE5LTQtMS0xLTM0Mzg0_c08a8225-232a-4fcd-87c3-3084770edf04"
      unitRef="usd">-1435729</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE5LTYtMS0xLTM0Mzg0_acdb2854-fc06-45d6-82ab-85c2012cea12"
      unitRef="usd">-1563395</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE5LTgtMS0xLTM0Mzg0_737ff08b-cba5-4819-8648-386479e3df1e"
      unitRef="usd">-4353996</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzE5LTEwLTEtMS0zNDM4NA_19cb8c05-8e85-4338-a787-7dd54be09730"
      unitRef="usd">-7677420</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIwLTItMS0xLTM0Mzg0_66127bc2-b539-4d74-9390-056a563a7eb2"
      unitRef="usd">-350749</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIwLTQtMS0xLTM0Mzg0_72752da9-76c4-44a9-b299-ea014a4de724"
      unitRef="usd">724684</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIwLTYtMS0xLTM0Mzg0_83d16a29-7627-4ce6-b0e2-d17ca38809bf"
      unitRef="usd">-1583480</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIwLTgtMS0xLTM0Mzg0_a6267f36-45fb-404a-9313-15fd40361916"
      unitRef="usd">-4387576</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIwLTEwLTEtMS0zNDM4NA_d1ad7396-3385-4387-8896-2a9c50aef556"
      unitRef="usd">-5597121</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIxLTItMS0xLTM0Mzg0_269a04e1-772e-4528-96a1-4260a4c641ff"
      unitRef="usd">495410</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIxLTQtMS0xLTM0Mzg0_4174497e-1732-4f40-97c6-b3be909443e3"
      unitRef="usd">498807</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIxLTYtMS0xLTM0Mzg0_2f3e8c88-dcc5-4211-8f07-0b3447ec4a27"
      unitRef="usd">496787</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIxLTgtMS0xLTM0Mzg0_a9fb0ef2-ac01-47fc-843f-3b2d27086ab9"
      unitRef="usd">503318</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIxLTEwLTEtMS0zNDM4NA_4ee2f49a-4763-48b8-9c02-6ee1a7a0f0be"
      unitRef="usd">1994322</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIyLTItMS0xLTM0Mzg0_f4cccda9-08e5-4603-be57-606cba65057d"
      unitRef="usd">166828</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIyLTQtMS0xLTM0Mzg0_fd8e2473-5863-4a9d-b688-0dbe10eea184"
      unitRef="usd">1228560</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIyLTYtMS0xLTM0Mzg0_8fde1823-1547-4d74-b93f-30e767f1c684"
      unitRef="usd">-1055278</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIyLTgtMS0xLTM0Mzg0_63b7601a-06eb-4631-996c-edf111a4cb65"
      unitRef="usd">-3847697</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzIyLTEwLTEtMS0zNDM4NA_6677bf5c-5aff-4625-9f21-8628b660d8b7"
      unitRef="usd">-3507587</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI0LTItMS0xLTM0Mzg0_fa48d15d-ef36-4614-91a8-ec96ff8da22f"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI0LTQtMS0xLTM0Mzg0_2eaae03a-9377-40f1-ad02-8f0f4d952476"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI0LTYtMS0xLTM0Mzg0_deabef38-79c1-4d29-89ea-bc71e8ae0471"
      unitRef="usdPerShare">-0.10</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI0LTgtMS0xLTM0Mzg0_aca43702-48bd-43b6-a171-42a4645280b5"
      unitRef="usdPerShare">-0.29</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI0LTEwLTEtMS0zNDM4NA_56d79589-7900-4f34-9991-3f1567c7745e"
      unitRef="usdPerShare">-0.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI1LTItMS0xLTM0Mzg0_df1c704d-a720-4774-81ae-2fee3bc2a370"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI1LTQtMS0xLTM0Mzg0_592988dc-7fe0-405b-8729-532b1809f3d7"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI1LTYtMS0xLTM0Mzg0_997c5c6a-5701-4ca1-a2ff-20294d41270a"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI1LTgtMS0xLTM0Mzg0_5fc6248a-d392-40c3-a214-e26bb3a866b5"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI1LTEwLTEtMS0zNDM4NA_ef38ecf9-8129-4bbd-bdfc-7aa2a6defb96"
      unitRef="usdPerShare">0.13</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI2LTItMS0xLTM0Mzg0_61db8188-7054-4c70-8dde-5a1f43f4900a"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI2LTQtMS0xLTM0Mzg0_970eee0e-406c-4eb6-805b-a2dfe48db11f"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI2LTYtMS0xLTM0Mzg0_80ca3f37-bfc6-48cc-bf35-a141eda8b8b0"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI2LTgtMS0xLTM0Mzg0_f2f0ee4c-686d-4b24-b729-d3a27bc3f9fb"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI2LTEwLTEtMS0zNDM4NA_ca138677-f4d6-4a85-b1cb-e9fb7c5b699d"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI4LTItMS0xLTM0Mzg0_1cce7548-20d7-42e7-9e3b-60ab7c734bdf"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI4LTQtMS0xLTM0Mzg0_f86c691b-c248-4b39-8499-852cb99f7d8d"
      unitRef="usdPerShare">0.05</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI4LTYtMS0xLTM0Mzg0_4df581f8-589e-4aff-84da-ed1c659247d1"
      unitRef="usdPerShare">-0.10</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI4LTgtMS0xLTM0Mzg0_3fa2c47d-08b8-4c72-b3f3-c7cda026f16b"
      unitRef="usdPerShare">-0.29</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI4LTEwLTEtMS0zNDM4NA_207d2429-21f5-47f9-88bf-6a3cb4e87548"
      unitRef="usdPerShare">-0.37</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI5LTItMS0xLTM0Mzg0_54bcc6e4-9463-4230-a4d3-daa1618fe67c"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI5LTQtMS0xLTM0Mzg0_01f6d502-e5b3-46ac-8e19-b771bf305f7e"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI5LTYtMS0xLTM0Mzg0_5c9c3ba5-361e-4894-83d1-bffaadd7d4ad"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI5LTgtMS0xLTM0Mzg0_d832061e-3dde-4f52-9a23-a49c5b7fcb8d"
      unitRef="usdPerShare">0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzI5LTEwLTEtMS0zNDM4NA_8418700f-6016-4980-8361-0b702c0d1d56"
      unitRef="usdPerShare">0.13</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8bb6789dd2f843cb82a83fd5fc2577ba_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMwLTItMS0xLTM0Mzg0_dcf435e4-88e9-4c52-a486-f1f131b1cf09"
      unitRef="usdPerShare">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib02166c7239b48fa890b13833088a8d6_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMwLTQtMS0xLTM0Mzg0_543bdb15-7469-4071-8d67-a2790733e3a0"
      unitRef="usdPerShare">0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMwLTYtMS0xLTM0Mzg0_4dc8019e-1ce7-44a6-a80f-394c9e93f379"
      unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4fc808860d28405daa2fbb90f800fb9c_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMwLTgtMS0xLTM0Mzg0_6ea292bf-08be-4457-8326-f43489ab5699"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic1cd77b3e81042d4af50499387a9dae9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTAvZnJhZzo2OTdmMWUzNDE1ODA0YTBiODNkYzljZTcxNzllMGQ5NS90YWJsZTpiMDk3NTE3ZGY5Njg0YWUyOGUwMWZiNjZiYTVjNzYwZi90YWJsZXJhbmdlOmIwOTc1MTdkZjk2ODRhZTI4ZTAxZmI2NmJhNWM3NjBmXzMwLTEwLTEtMS0zNDM4NA_5dba6695-53eb-4f40-a575-7f4c6e9120ee"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90ZXh0cmVnaW9uOjM0MGEyNzRlZDE4MTQyYmM4NjVhYzI3M2Y5MGI5MGMyXzIxMg_eebc72d0-73e2-4c0f-867a-2c721aedba84">&lt;div style="margin-top:8pt;text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Schedule II&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation and Qualifying Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Years ended December&#160;31, 2022, 2021 and 2020&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.278%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.387%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;beginning&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Charged to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;costs and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Charged&#160;to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;end&#160;of&#160;period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;984,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,963,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,606,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,673,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,417,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ended &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,196,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,761,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,761,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,795,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,557,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;   &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Composed of actual returns and credits for chargebacks and cash discounts.&lt;/span&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if5de2643b16c42518868295369efe808_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzUtMi0xLTEtMzQzODQ_c4bb0b63-4f03-4462-893c-31cd20b21b50"
      unitRef="usd">984677</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i3a1250f3410e437492a31418c8974e8c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzUtNC0xLTEtMzQzODQ_c5e9e937-0870-4796-9eda-237ab787d18f"
      unitRef="usd">2963279</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i3a1250f3410e437492a31418c8974e8c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzUtNi0xLTEtMzQzODQ_be24a9ce-af22-451a-9f95-fdef1b26ea1a"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i3a1250f3410e437492a31418c8974e8c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzUtOC0xLTEtMzQzODQ_25479654-2fa1-4d77-8158-5e2d3888d851"
      unitRef="usd">3606992</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i34ed7d5354534fbd81b84cc0aa0d8e79_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzUtMTAtMS0xLTM0Mzg0_62b3968d-2b51-4ce0-b452-a94223e0140d"
      unitRef="usd">340964</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i34ed7d5354534fbd81b84cc0aa0d8e79_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzYtMi0xLTEtMzQzODQ_8e5f7ff0-4c2b-4c76-b006-1d0009e06a9f"
      unitRef="usd">340964</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="id183facaeebd467fa69fbb2fec9d0b3e_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzYtNC0xLTEtMzQzODQ_806db7f6-7c50-45fb-b5ae-638e5455eef0"
      unitRef="usd">6673104</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="id183facaeebd467fa69fbb2fec9d0b3e_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzYtNi0xLTEtMzQzODQ_c25011be-45b9-47de-a406-daaf9617a76d"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="id183facaeebd467fa69fbb2fec9d0b3e_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzYtOC0xLTEtMzQzODQ_43d642a4-8c71-4805-ba9b-bd2d02a27f70"
      unitRef="usd">6417977</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib9019082259e456fb9c5846dc8fa2c23_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzYtMTAtMS0xLTM0Mzg0_3dec28da-86ab-403d-830b-71dba4612df6"
      unitRef="usd">596091</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ief70e45bdb5146d0818d09d8a9fc3591_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzExLTItMS0xLTM0Mzg0_350e1d22-161f-410b-b01c-bd358e67a109"
      unitRef="usd">19196121</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="i13f27dbe43754f2393a096db946b5293_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzExLTQtMS0xLTM0Mzg0_3d139dc2-ee73-4768-9284-5cfdd6447245"
      unitRef="usd">565801</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i13f27dbe43754f2393a096db946b5293_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzExLTYtMS0xLTM0Mzg0_dd71b828-d578-402d-964e-a09ebeda0468"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i13f27dbe43754f2393a096db946b5293_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzExLTgtMS0xLTM0Mzg0_4563f5b0-6a8a-4177-9cb5-d59ff949b3b2"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i70c9db8d427e4e07a83726736dbc62f8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzExLTEwLTEtMS0zNDM4NA_5f35502a-68a7-4c78-87a2-31db9c3c128b"
      unitRef="usd">19761922</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i70c9db8d427e4e07a83726736dbc62f8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzEyLTItMS0xLTM0Mzg0_1c776c7b-4a4c-4a57-a228-d2d6d96b271f"
      unitRef="usd">19761922</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="idce9bb4f17eb40309dbdc88fdb74adc9_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzEyLTQtMS0xLTM0Mzg0_3659327f-d347-412b-b9a9-67067ac0b83c"
      unitRef="usd">1795862</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="idce9bb4f17eb40309dbdc88fdb74adc9_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzEyLTYtMS0xLTM0Mzg0_33d23c93-056e-4b54-b676-6e6ab08a357f"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="idce9bb4f17eb40309dbdc88fdb74adc9_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzEyLTgtMS0xLTM0Mzg0_0dd3cae7-881f-46fd-ac6d-0d9f6524baa0"
      unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i1857a0d9d671486aa8f09353d5b63f37_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNlMzZjZmM1NmUxYTQyNzVhNTJiN2Q1NjAwMTRkMTc2L3NlYzozZTM2Y2ZjNTZlMWE0Mjc1YTUyYjdkNTYwMDE0ZDE3Nl8yNTMvZnJhZzozNDBhMjc0ZWQxODE0MmJjODY1YWMyNzNmOTBiOTBjMi90YWJsZTpmYjM0NjQ5NDQ1YWY0ZTM1YjgyNTRkOTcxZTVkNzQzZS90YWJsZXJhbmdlOmZiMzQ2NDk0NDVhZjRlMzViODI1NGQ5NzFlNWQ3NDNlXzEyLTEwLTEtMS0zNDM4NA_f1e3fb31-af04-45d3-b1c7-041d204ae47b"
      unitRef="usd">21557784</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M-8(AR?**ZWQ'T%U6@[RB0M XV]P2#-CD!7!^3:DX[,@;E'7OXW\!4$L#!!0
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M@E7MSRW-Y!Y%"<C_UXR)YP<UP'#%/O\?4$L#!!0    ( $2(;5:"55,%JPD
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M6"@BIBZMAK;L7,VKQ%'-<5S[+K=M";!"19_?OT9,YO34JU/)!JOL_!:V)T'
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MMD"T5TIK*%Z;,;[GBBX%L\SH%D:A'6C_P+FZ&#I =Z\O_@502P,$%     @
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M51U.E$\?C--#=+5\I,7X'%TE/PN"&9XWX/W:85!O'_B"_JO]Z?\!4$L#!!0
M   ( $2(;5:GVN"0&B4  *QQ   9    >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;.U=69/;1I+^*XA>QXP405)]R+(L'Q&MEC265QKWJF7/P\8^%($B"3<(
MT"B@6YQ?O_EE9AT P99FYV'G82)FK&X2J,K*RN/+HZJ_OV_:6[>QMLL^;:O:
M_7"RZ;K=BR=/7+ZQ6^,6S<[6],VJ:;>FHU_;]1.W:ZTI^*5M]>3\]/39DZTI
MZY,?O^?/KML?OV_ZKBIK>]UFKM]N3;M_::OF_H>3LQ/_P8=RO>GPP9,?O]^9
MM;VQW:^[ZY9^>Q)&*<JMK5W9U%EK5S^<7)Z]>/D4S_,#OY7VWB4_9UC)LFEN
M\<O;XH>34Q!D*YMW&,'0/W?VRE85!B(R_M Q3\*4>#']V8_^AM=.:UD:9Z^:
MZF]ET6U^.'E^DA5V9?JJ^]#<_V1U/5]CO+RI'/\WNY=G+\Y/LKQW7;/5EXF"
M;5G+O^:3\B%YX?GID1?.]85SIELF8BI?F<[\^'W;W&<MGJ;1\ ,OE=\FXLH:
MFW+3M?1M2>]U/]Z4Z[I<E;FIN^PRSYN^[LIZG5TW59F7UGW_I*-)\.B37 =\
M*0.>'QGP[#Q[W]3=QF6OZ\(6PP&>$'6!Q'-/XLOS!T=\9?-%=G$VR\Y/S\\?
M&.\B+/F"Q[LX,M[$,K/_OERZKB41^9^I%<MX3Z?'@]J\<#N3VQ].2"^<;>_L
MR8]_^H^S9Z??/4#MTT#MTX=&_[]LT#\U8';=EG5>[BKZL5EE5TWMZ)O"L Y]
MW-@L#Y_8(EN5M:&G396YCCX@;>WXM8X>O&JV.U/O,]-:^;;(RCK[=7&SR(JF
MJDSK,E,7_#7Q;4?_%EGO0 L_L[:U;4U5T0!Y;G=XW41R=X'*!:AR=IH4>JCJ
M"\OTZ-N']!$1)7U\OVEX-OIU:WYOVK+;SYO[FN9U_=*516G:$M-=5C1%PL2R
M[FR;ZV D1+4S;'%T>7[6C;FSV=+:.K-529KL&9*G'%YD5[_\]O;5_.S;[)K>
MMMLRS][2&Z8ERDC^3V=,NC#1YA4SS60;:ZIND^7@):V\)=[E^VQ%ZVGNP2V\
M0Q9Y26;[%LN_N?QP,[]J?IN?S^CMNKFSX%I+-AS?YDW;U.:N;'M';YJ.QNT=
MB8,G#>^0H._*UG1-N\_*JJJMDXT(7-T81VRLR; 7-$C;].L-DT$ODL$$46&E
M.UWI#+R@KWHFN<G(\] ,H)PL+R2#)LG^]!_/S\_.OLMNK=WAN97)RZKL(+GP
M5,QSO$!^RM3EWT5N:8MH3Q;9WVRVI<46V1]]F=\22VD6<C!]*Q*B;,00SJQL
MMP<W,%AGS9;?-I5K,OBZCOYO=:9ZW8 2B$!5D@Q:LN&=K'8+5E3F7F2AM>N^
M,B(;S%BSVPD1Q&GBE\EV_9+4L&(Y(NN9[3:&7$]N^XYDK<I4RL!IYBCM*4\3
M.7C5;Y>VK3 ;<89Y3]IGMJ2W&U(F6Z^)46:U@E,DFAOZNM5AP4*FJK5$ '%M
MT] >=S2M*;:E<T&D=[0$TJ[LKG30&R*_:,FUTGMWMN[M(OLEW3"_(3D9(EZ$
MZ_H"<]U;8GM),^>D"3.L?V7I,S^\RQR6V&7BP6E\VJ>UA0Z&,6$9'%.PM04/
MGHC#/8T(S>U(24LV)- [FHMW$KJRZO'IMJE+DF/=3=?SGA"WRGJF]L.KT(K4
M"2+1FGO:6=)Z&E:(P;=+TQ%D8O-"MJ@DGTRL:INBSVDMK)4LKVVSE<$BI<QU
M$I6>/NL@C"#$O[K(;HBO9 F],"[)Q!3*OMJN#7A#%'M.9LL]CU\U^6U!]DOW
MK''=KJG9+&*@W6;OR-X;*#S9,>LW$\\&AA,))$)$$!'Q4W,/,F8T+YMLPH-=
M#R,&[K-M,UE!+[6.[&)<.4W<=F2(RD96J0;9J>3I6O@K'J0@XTB#L%4CB]3
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M)^ P.:]%WQ4<K+E.M(:700YF33I5(5G5MYHD7:FOV$J5!OZ1D[>7_-U#..Z
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MT9)B(.F-O(K6!<NVD*2! /RT\B/UM?R6Y"]6D=9-4VAX90 97@[L@W<<[(7
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MY]!^+,D/(EWPDY$.F:@DW'3+!R2+K<8915\HE&V1 863%:3#8-B+ :A,Q,]
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M3B?BZ_5:>63E[4QG/M&/4P964WXVX3]4P_HEZX!GT]F':22<[WZ+6:L#B3K
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M?-(:ZS'RP*TLO=4^:3 =A1,]G4V6*2^H%?ET*^L-YQB<@6HI[51\#CC./IR
MGCTH!1*/H(]<,L!62A:OQY%/? 4B>0</HQQ6L_*>W?P-6!=<<2?!%8?7C_GB
MIC(K61T#@*B2KL$H2]**_3"B099@IZFS(ZD4V;K#_HT]>*J(HX*9GW3/P0C
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M"^-5^Y[TN+Q]V_Q-V!U/:"VWV!I/5]FD'4_]C3=U>&O:&(]WL'"YQTNOM+P
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M^[WRJE^G#M?[I?0#-VO96J3$"D3C69Y&?99'PNEM6*Z6VL&J%HX;V(V%\1>
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MA?<@T6?9YV^R7.H%)-[*2@?P\*N!N"\9WOL1)H;]"I!D1T;V%C;3^8;)CQE
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MZ:.8.4S5N,WC<NED$3LN6OH$I6Z0(BX;_+VMJ8X,9=FAJ("WF.Z\CAB&"HG
M@SEWMGC1I'5,E%PB/$N*U[:!GB3]\>6'_OA\)*K:^5INI\%;9O)2\\M/ETDR
M^C2;S?AJ_.EL%Y@JHZ"@13E;RB?M@.V)QI!X4$:KO,\%^QGU9 N,X[E*XV2?
MI-B_>K>3A\]SNNZ=H5NN-+KQ&OT:G8^3^8=T>))\B,%IIOYL1@F7&<'6QWFW
MB*/V^V ^$/.",C&M/5*(X3!IZ'C8E% YGT[:C8S#2/KHR)C5IIG=M'RH)C'C
M\[:7DQL+0-9O2Q*5)KMF,!Z,MKCN=U LZ+C1MDQ6F-K:D"AT,%5)S2.)>GO
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MK5P6GC<&L]-*+/$._9_5C:6W08>2RQ*UDT:#Q<59=)Z<7(Q8/@C\)7'EMM;
MGLR-N>>7Z_PLBMD@5)AY1A#T>,2OJ!0#D1D/:\RH^R0K;J];]&_!=_)E+AQ^
M->IOF?OB+)I&D.-"U,K?FM6ON/9GS'B942[\PZJ1'4XBR&KG3;E6)@M*J9NG
M>%K'84MA&K^AD*X5TF!W\Z%@Y:7P8G9JS0HL2Q,:+X*K09N,DYJ3<N<MG4K2
M\[.[0E@LC,K1ND]P]5!+_WPZ\(3,YX-LC7+1H*1OH"0I?#?:%PZN=([Y+L"
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M- O+@F9AM"Q YPM#,\7ZA3_03=>S_P%02P,$%     @ 1(AM5DE1%UJ% P
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M(0R0$9"^XD0JMI)(&!7.!75BHW()\RN7SR/4R-*R;;#T$\^[1;5'_<WHZJ[
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MU9_.DXG;;_<W1FWL%X*E,D95]K(0'%B2 -ZOE3+]#3D8/AG=_ ]02P,$%
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M@MDDIK,]^7+*6T\.L=X\BE&O3#US:V[QVAO #J=L:^[<5=X1+;4=XJQR-Q[
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MVR0LD_<#:E XEAZZ=NWLS#H"?M:>K1:*[GG+N@G$"PXOQS]>XDS0$L@J"F]
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M2V0.5W].>0'YCI$M([99O)5-N\NH:5A.$+,\KP\!FD6A5XTQ;42;O-^WL:S
M#KW4<#&4'K-47WP^7#FP>DLD$4"$[8'B437(B4=9U"IT%;K$[#6@)Q$#8&!
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MSF=O7Q>0QDX]3BAV0W?<1>)>.PPM/VZ8Q(#WZQCI-!&"Z;G<_ =02P,$%
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M\6O<WURZX:6'8)MXJUK8@#M:_%GA4DR.!7!>6LQW]\ .AFOVZ3]02P,$%
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M*Y8I2^_W.\+[X2,Y4G&R3U?G]-7C<_AJ>]VZX+6%P:?S\"TSMTPG$&^TB1&
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M:U)JTK_[@F[NG?M2LW-O*7("C*[JR3R#7>C%@M;D+6^[FA%%.M&P&Q 0E%J
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MN*5ICS8XT/K:T $>E+#!\?^Q^ =02P,$%     @ 1(AM5C)6G:3O @  308
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MVG'Y+-ED%*9%'(ZRW(O9* ^SK !J![H7K3YL[_V9R^DH'+"11WX/IX2;Y>'
MRR_!2\FM%0M!'.GF=E@G4(3Y, T'>4(R!62DYPP.O9]HK\5K-,MVD/D2K97K
MNKW?[6?E>3<B_IEW@_8+-TNA+.6V(-?X;#0(P'3#JU.<;MJ!,=>.QD\KKFC>
MH_$&=+[0VNT4'Z#_@\S^ E!+ P04    " !$B&U6,J3(0F\#   %"   &0
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M,""_"KVI&D.Y59)J<#6AJ]'#T!DV5K5]HU\K2V.C7VYI3J-V O2_5,H>-L[
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M*P0PNZ,V9%X807_ DL"9(IQ?JO38Y>)^FU'\MDHNRM2P. H=+TQ8&$V<B1_
MU#OX+]4#\RE"?L0\-W02/]R'/EUSM:K\C!#5R,55X 9.'(?LLMR4.2>ZM'4
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M7BRLN,&;'$BC@-]70NCCPC@8[H;S?P!02P,$%     @ 1(AM5G*)C9H+!
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MWZ!^Q&#V\T])'O]RAF!Z))B>0Y\]4*4MFPI!K4CGT@(^4<T9!"Z75"V4&'(
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M*3X,%;>0Z+Y&@Q_#!C@?R+0AY,)4%CYMN^_6C=OU7M@!N>>/-@ RPAV37^!
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M&IP,\9)2]9N@[AA9NCJ\E :KNFNN\!T%RD[ [YF49M.Q"[0OL_@O4$L#!!0
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M(*<[;NYE\QDZ/]>6+Y5<NR=INMS (^E.&UEU8%10,=&^Z5-7AR- .#X#B#I
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MLZ!L I[G4II#8#_0#^[D-U!+ P04    " !$B&U6#&$6#PH,   %D@  &0
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M^B9^:&4)=:Z@-!]*HU!: *4Q*(U#:0)%4[7;V%NNC;_MQ84:65":#Z51*"V
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MFT 1X&73I1Q(MM-MB"<F)4OUY1:(VG^%@;J_9DR^#HH'U*VOV7]02P,$%
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MXS<2+N..%]T&^UH/)491!YWM:75W[G0!<F%;G2*IJ+BN[T ;;;MIWS:1O?@
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MU;MI9GC! J$GX/,5Q^.][>@%NBM;]!U02P,$%     @ 1(AM5B3RW%+J @
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M_15"+8HLL(DXU#VU#603;!L@!8)-MWTH^L!(M"VL)+HD'6_[]:5D1=:%$F)
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MJH$ONXS5$ ]<!ZC[,\;D>J$3E/\6\/\#4$L#!!0    ( $2(;5:6ID<VQ0(
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MG7JFF:OO$N!Z@AI?,B:?.OKH:[]TTK]02P,$%     @ 1(AM5M3H@_IP P
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MIE&TI]GME3SSW'S&8D681!26&NE=7&H*T93PIJ-X9:O@@BM=4VUSK5\]$"9
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MIX1$Z(_-!AC)ME=H+5<%&(,8/0@:/2.<Q6A%TU2NH.ZX0K]CQK!:RTMT$8+
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MK"R!EA>"YKHH^$2%H*EN[@#+\U4](.]O*!6'"S5 78A>_@=02P,$%     @
M1(AM5HO )KP(!   /1$  !D   !X;"]W;W)K<VAE971S+W-H965T-C4N>&UL
MM5A=<Z,V%/TK&MIIDYEL^/17:GO&"=GISFS:3++;/G3Z(,.UT40@5A)VTE]?
M21",'<QN,B0/,8A[#E='W(,NTRWC#R(!D.@QI9F868F4^85MBRB!%(MSED.F
MKJP83[%4IWQMBYP#C@THI;;G.$,[Q22SYE,S=LOG4U9(2C*XY4@4:8KYTR50
MMIU9KO4\<$?6B=0#]GR:XS7<@_R:WW)U9M<L,4DA$X1EB,-J9BW<B]#U-,!$
M_$5@*QK'2$]ER=B#/OD4SRQ'9P04(JDIL/K9P!50JIE4'M\J4JN^IP8VCY_9
M/YK)J\DLL8 K1O\FL4QFUMA",:QP0>4=V_X.U80&FB]B5)C_:%O%.A:*"B%9
M6H%5!BG)RE_\6 G1 +C#(P"O GB'@. (P*\ _B' /P((*D!@E"FG8G0(L<3S
M*6=;Q'6T8M,'1DR#5M,GF5[W>\G55:)P<GZ?8 X)HS%P\2NZ_E80^81.S"BZ
M@[S@4:)4%6?HJDB7P"G.8G2= E^3;(V^0)1DC+(U 8'TE4;01U9D,39K^P?F
M'.OE/44G(4A,J#A%']#7^Q"=_'PZM:6:A\[&CJJ<+\N<O2,YNQZZ89E,!+K.
M8HCW"6PE0*V"]ZS"I=?)&$)TCGSW#'F.Y[4D=/7C<+<%'G;#;_!3A7:=CLGX
M]9+ZALX_0E<NHEHQBH5 ;(6^*$,0!7]"]Y)%#^B?SPJ /DE(Q;]MXI?L03N[
M]J$+D>,(9I8R&@%\ ];\EY_<H?-;FW!]DH4]D>VI&M2J!EWL\UTQ:$DCEJ;J
MR1:Z3E1Q;# MH$W+DG-@.+4%;^:NXPW&_G!J;YHRM<0%KA.,@_VXL#/'-RHP
MJ!48="JP2%5)2X0WJH#QD@)2!0Y<F13GH,;Y3J"<LS7':9L@@Q<3]<>._CL0
MI#.5USXW/9'MJ3:L51MVJF:L5#2\] PM*#U#UX\1Y!*I%ZNDD&H!=:7B1_29
MX"6A1!*#HEA"C"13\< C4CY]91W_F6MW%6TJ=Z;TVA+NDRSLB6QO*4;U4HS>
MU1A'?:K:)UG8$]F>JN-:U?';C;'\;1.S)!TVC6 X&DW\ Q]X&1;X8W\P.?#%
MSA3?*,"D%F#R#F^&2<N;H<T(6^*"EKBP,\<W*N ZNUVD\WV7:Y@<NBU? 6A1
MR(1Q\I\R,9*U['"J_5XG^VM+JU>VL"^V?64;^W/W74VKHN]+VC[9PK[8]J7U
M=M)Z/_#0OMRWG*',]#%:[;*.$=X]QNI=O&RBXE;5.^_\:M7[9 LKMA;KV7E*
MJ:C=Z"MUSV?Z<Z$L3NT#R^:J'JV_ 2Q,YWLP?NE>7)6=_(ZF_+!P@W4K*1"%
ME:)TSD<J+5[VZN6)9+GI7I=,JE[8'": U<93!ZCK*\;D\XF^0?W%9/X_4$L#
M!!0    ( $2(;5;H$$3UC04  "HB   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8V+GAM;*V::W/;*!2&_PKC[G32F6TM(:%+ZGBFB7S?=C+-=/N96-C65 (O
MH"3]]PNRHMHR5NU=OB2ZO.\#B', "PV>&?\A-H1(\%+D5-ST-E)NK_M]L=R0
M HL/;$NHNK-BO,!2G?)U7VPYP6EE*O(^=)R@7^",]H:#ZMH]'PY8*?.,DGL.
M1%D4F/^\)3E[ONFYO=<+7[/U1NH+_>%@B]?D@<AOVWNNSOH-)<T*0D7&*.!D
M==/[Y%XOW,I0*?[.R+/8.P:Z*8^,_= GL_2FY^@:D9PLI49@]>^)W)$\UR15
MCW]J:*\I4QOWCU_IXZKQJC&/6) [EG_/4KFYZ44]D)(5+G/YE3U/2=T@I'E+
MEHOJ+WBNM4X/+$LA65&;50V*C.[^XY?Z0>P9%,=L@+4!M@W^"8-7&[QS#7YM
M\,\UH-J SC4$M2$XUQ#6AO!<0U0;HG,-<6V(VX;@5,<YKSWGG%N&VW3V+NAV
M45*%6((E'@XX>P9<ZQ5/'U1Q6OE59&54I]2#Y.INIGQR.,*<9G0MP-5?3(AW
MX)YP\+#!G("K!Y6^:9D3P%;@CA7;4N(J"]3IE[(@'$O& :8I2 AEJG+5>49!
M@VQ8[\!50B3.<E7 >_#M(0%7?[P;]*6JOZY%?UG7]7975WBBKA[XS*C<"#"B
M*4D-_GFWWX4=@+YZ<,W3@Z]/[Q9V$A.R_  \]T\ '0@-%;KKMC^0K;([)^U)
MMWU>TD[[J-O^&?/.RH_/;[MKL$_.;[O)/CV_[2;[[/RVF^SS_]?OB__\Z ["
MT&N2V*MXW@E>DX[7IJ3:>7VS5T_9UV*+E^2FI^9D0?@3Z0W?OG$#YZ,IH&W"
M$INPD4W8V"9L8A,VM0F;V83-;<(6EF 'Z>0WZ>1WT8=?U$HVHTM6J$DPKV;%
M%6<%6*JY(Z.EFMJ 6M'R:C(4IH3;T5%%UTO:I^%[Z*,X=/U!_VD_F0Q"'WH0
M!H>ZQ*!SO< /@I9P9!+Z#O0][U X-I7L12$*6\2)B8@BSX^<0^'T6!A"/XA:
M39X9>!YR0C\^U,T-.A0@Q_%:PH5)J)^U'EB?#$& FB! G4&09*+N<)+N]3>@
M*CC4"DCB%U/7=S(O'6MMPA*;L)%-V'@'"_9Z$#F>YT:M2#R6^7$01F$K#DVR
M*'):LIE)AGRW%=7S8UE+L3A6N''L>WI98 J_H F_X+(QR!1MG8A+H\TF++$)
M&]F$C6W")C9A4YNPF4W8/#B*\1.#L4'H!0X,X]B<#6&3#>%OLT%G < 2B/)1
M9&F&^4^ \YPML50#M&2 ,JH';,[R7$_1&95$-4T:9^C.TBY-')NPQ"9L9!,V
MM@F;V(1-;<)F-F'S\"@?PCB,6S/;XE@5(^B>F$"B)F6B"Q>Q6$J>/982/^9$
M)XRZ5S *A'Y#LV%Y2K@Q5R+3:M9W0MA*_CN#T'>BH#U() :=ZWDH@*VI=604
M1@BB]FK6(/0B/PSBUJP_,1$=A&#8ZI+IL="%,$)!JXHS@RX((MC"S0WE(A2J
MA;G;"@532]3R&.TM<PZB(6ZB(>Y\0[#WBL[XCB"V.2#:A"4V82.;L+%-V,0F
M;&H3-K,)F]N$+2S!#A+*=7Z].'<Z!]COU6X-2=_C)_7C<$UV ZD K)1"8IKJ
M1<C;-Q%TW8]ZTR=;@JNL'FW-J_GN\BY-0JNTQ"IM9)4VMDJ;6*5-K=)F5FGS
MFG;PT]5'@8=BV)J5C,K8\2//-T]+[M[VDVLMB](L+_5B_W=YU%GBQ7EDDY98
MI8VLTL96:1.KM*E5VLPJ;5[3SLDCD]*81_V]'=V"\'7UT8%02_:2RMV^4'.U
M^;#A4[6=W[I^ZU[/7,/UN?X0HMI!_H7??47Q&?-U1@7(R4H5Y7P(U6J4[SY,
MV)U(MJWVDQ^9E*RH#C<$JY\/6J#NKQB3KR>Z@.;SD.&_4$L#!!0    ( $2(
M;59[RT5I?0(    &   9    >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;*U4
M74_;,!3]*U>>-!5ID*]2$$LCM04TI"%55-L>ICVXR6UCX=B9[;3=OY_MI*&P
MPO:PE\2^ON?XGFO[I%NI'G6):&!7<:''I#2FO@H"G9=847TF:Q1V925518V=
MJG6@:X6T\*"*!W$8CH**,D&RU,?F*DME8S@3.%>@FZJBZM<4N=R.243V@0>V
M+HT+!%E:TS4NT'RIY\K.@IZE8!4*S:0 A:LQF417LZ'+]PE?&6[UP1B<DJ64
MCVYR5XQ)Z I"CKEQ#-3^-CA#SAV1+>-GQTGZ+1WP<+QGO_7:K98EU3B3_!LK
M3#DFEP0*7-&&FP>Y_82=GG/'ETNN_1>V76Y((&^TD54'MA543+1_NNOZ< "(
M1J\ X@X0OP0,7P$D'2#Q0MO*O*QK:FB6*KD%Y;(MFQOXWGBT5<.$.\6%47:5
M69S);J@23*PU##Y+K4]@C@H6)54(@X6],47#$>0*)L*PTX+QQC4=%I@WBAF&
M&FYV.6\*+.!6R0IFLJH;0_T!651/WK.>P. :#67<;G4*VH5T&A@KQ)43Y%W1
MT[;H^)6BHQCNI3"EW5[8O9\3!+8#?1OB?1NF\9N,UYB?01)]@#B,XR,%S?X=
M'KU13M*?2N+YDK^=RM-Q?)\LM5'VUO\XUJ^6;GB<SCG!E:YICF-BG[I&M4&2
MO7\7C<*/Q[3^)[)GRH>]\N%;[-GSB]9>$!@PT0U/CHEO&4>>T;G6)HOCB_ \
M3(/-H:P_TZ++) F?TMJ"@X/'5*%:>X_1D,M&F/9"]='>QB;^];Z(3ZV]M6[T
M1--ZXSU5:R8T<%Q9RO#LXIR :OVFG1A9^R>[E,8:@!^6UJ)1N02[OI+2["=N
M@][TL]]02P,$%     @ 1(AM5DGK/'A]!   ?1   !D   !X;"]W;W)K<VAE
M971S+W-H965T-C@N>&ULK9AM;Z,X$,>_BL6=3JW4%,PSO212-]5I*_7NJG;W
M[K4#D\1:P%G;).U]^K,AA208MBOU3</#S/";P3-_T^F>\6]B R#12Y&78F9M
MI-S>V+9(-U 0<<VV4*H[*\8+(M4I7]MBRX%DM5.1VZ[CA'9!:&G-I_6U1SZ?
MLDKFM(1'CD15%(2_?H*<[6<6MMXN/-'U1NH+]GRZ)6MX!OEU^\C5F=U&R6@!
MI:"L1!Q6,^L6WRQPHAUJBW\H[,71,=*I+!G[ID_NLYGE:"+((94Z!%$_.UA
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MD7+FS;=N<R+9MOY<7#*I/C[KPPV0#+@V4/=7C,FW$_T%VO['8?X_4$L#!!0
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M[1F%<=#K"\[5SC MHVOXR6]02P,$%     @ 1(AM5L7%-8 L!P  &#<  !D
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M1A"!+Q0$D7];&$,4*23)XU\&:N1[JL3B^(!^K\5+,7/"84RCWV$@5GVC8Z
M%F03B2>Z^P:9H);"\VG$]2_:9;&6@?P-%S3.DB6#.$S2?_*2&5%(P-Z)!#M+
ML%\GN"<2G"Q!.V>FS+2L"1%DT&-TAYB*EFAJH+W1V5)-F*ACG DFGX8R3PQF
M@OK/UR-I1(#&-);5P8GV=QJ1A*.+F:R;8!,!H@LT6Q$&5;%W+VH,E^AB H*$
M$;]$U^CG;((N/E_V3"%IJLU,/Z,T2BG9)RAA&SW21*PXNDL"",H IM27B[0/
M(D=V+>($_!ODX"MD6[9=06C\_G1<0\?)/7<TGG/*<^WC_*V/0\9(L@3YE@@T
MWZ-BW)3L]?)P1UB _GR7D.A!0,S_5AF<[N]6[Z^^#+=\37SH&_+5Y\"V8 R^
M?,*>];7*G(; 2E:YN55N'7K)*K]@597H%*FED=37:SMPW7;+<GKFMBCG;5C;
MQ1VOG8>5B+9RHJU:HG?Q.J)[@"IBM9GGGD9#8"617B[2^^#"]9JTJB&PDE7M
MW*IV8X6;(GFEPNVZA8I,Y;P-:SN6B^WJPNWD1#NU1'_0!&IJMS;YW -I"*RD
MLYOK['YP[7:;M*HAL))5V#I>"JS&JC>#*M;E->YZ[JOJK0C#V&VUJJL7%^XO
M^%T?WBM4J&1$D@#=TTT2I&<\EO<)%LXW)S74[G'NV36%5G;$/CIB?W"E9P2:
MLJLAM+)=Q\L8KKW G%?KSOON&!5QE9<,LW!QCX$M=3_#)8U-(M+K;;Z:]TQ#
MW2F\6A^I7DHW!$>8M!%[)&P9RIM\! L):=VT)2F6]C;I1-"U;@_F5,AF0P]7
MLA\$I@+D\P6EXC!1&^0=YN _4$L#!!0    ( $2(;59DV<C#0P0  (,3   9
M    >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;,5876_J.!#]*U;V:M5*+8D=
M"*0+2(7N:N_#W5L5W;W/)AD@:F*SMH'VWZ^=I F!)("6:E\@'S/'Y\S8XXF'
M.RY>Y0I H;<D9G)DK91:/]BV#%:04-GA:V#ZS8*+A"I]*Y:V7 N@8>J4Q#9Q
M',].:,2L\3!]]BS&0[Y1<<3@62"Y21(JWB<0\]W(PM;'@Y=HN5+F@3T>KND2
M9J!^K)^%OK,+E#!*@,F(,R1@,;(>\<.4.,8AM?@[@IW<NT9&RISS5W/S-1Q9
MCF$$,03*0%#]MX4IQ+%!TCS^R4&M8DSCN'_]@?Y'*EZ+F5,)4Q[_C$*U&ED#
M"X6PH)M8O?#=GY +ZAF\@,<R_46[W-:Q4+"1BB>YLV:01"S[IV]Y(/8<2+?!
M@>0.Y, !-SFXN8.;"LV8I;*>J*+CH> [)(RU1C,7:6Q2;ZTF8B:-,R7TVTC[
MJ?%,\>#U?J(#$:(I3_3LD#2-[W-,F40W,SUOPDT,B"_0"T@EHD!ITZ\L &82
M@%( ]&BR$:GW6W3S!(I&L;Q%]^@+LI%<40%R:"M-U@QI!SFQ24:,-!##!'WC
M3*TD^IV%$%8!;*VRD$H^I$Y(*^(3!!WDXCM$'$)J"$W/=\<M=-PB\FZ*YS;@
M_;5)YB!,7)M#E"%TZQ',"G^0:QK R-)+6(+8@C7^]1?L.;_5R;L26$5LMQ#;
M;4,??U^;22714E"FY\]=KAG=1"R_O*W3GX%Z*:@I2-LQ[@_\GC.TM_O*:LP&
MGN^49A7.O8)SKS5!/],2 .$]W8+0)0W!&X@@DH#6>A7H7YV]E'L=\]XU,W<E
ML$H4O"(*WF69VYT;EC2Y/V9/Y9/:'&?#]_>3UR'^08;KC'!]>ON%L'ZKL)9J
MEFNN8]N*>6E>KP16D3\HY _^<_D97%/LE< J8OU"K-\^B3=**LK"B"WOT!R6
M$6/ZTHC7<S/BX:DZY-?4(<=S#NO0L5E#"<).N3T[GU$X<]23E;/.KJ5TXKVV
M I_%.Z>[U8L-3H8YQZP/8$ZXS:3*E91<R25<=6^\@.@<NN2(RSWQ_:-I46>'
M/;<QR&4'@5OW[.JT!A:>/Z%SX'U*+O:]X_EQ;'<P\ZO4RWX =S]O<\6MS<:E
MA>E::-5(E%T&;MV^3]:FZ^^X.:']W=3MN.YAZC.KWADKK>PE\/_<3.3C#_9(
MDXXW.)1V;*4#0!K4E0T%;N\HFFO>&<3[ITM?FTF5<MD$X-9MM[WTG<%Z4!-N
M_RC<QU9NAS2%N]S3\06;>J7Z?<*\\H\6P]%Z\=M75?6;M6P R(D&X!*5 LS)
MC2D?@?YV%C10&QHC!2*I$W5B9 ^] Q428928#W%$NBBD[W6-XK0=Z=(2:N\=
M9R0@ENDIC]22-DQEG_O%T^(DZ3$]/SEX/L$/T^P\J(3)CJ>^4:$+K40Q+#2D
MT^GKS(KLQ">[47R='IK,N5(\22]70$,0QD"_7W"N/F[, ,6YV_A?4$L#!!0
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M F4-<'XJI=ET;(#Z497\!E!+ P04    " !$B&U6[AC%?;,$  !#%P  &0
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MD!D7"*>UP)(W]KBAL2V=^X/S[;^]DK>.Z(U\SVN^YU:^T_>?33RL0:_-YY;
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MFN;,W=KAU-O+'YE8Q)E$ASM'**^C]V-%N6-;GBB^*C8]9UPIGA:'2V 1"/T
MWI]SKEY.]#YJO6\^^0]02P,$%     @ 1(AM5LLSS1Q^ @  2 8  !D   !X
M;"]W;W)K<VAE971S+W-H965T-SDN>&ULK571;MHP%/T5*YNF5MJ:Q!!*NA"I
M0*M56J6JJ-O#M >37(A5Q\YL![J_G^V$#&B*]K 78COWG'O.Y?HFV0KYK H
MC5Y*QM7$*[2NKGQ?90641%V("KAYLQ*R)-ILY=I7E022.U#)?!P$([\DE'MI
MXLX>9)J(6C/*X4$B59<ED;^GP,1VXH7>[N"1K@MM#_PTJ<@:%J"?J@=I=G['
MDM,2N**"(PFKB7<=7LTB&^\"OE'8JKTULDZ60CS;S5T^\0(K"!ADVC(0\]C
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MTM@FZ*=K>TV!<@EV?RFE>0A<)^PNOOP?4$L#!!0    ( $2(;5;:_'J7XP(
M  X(   9    >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;(6676_:,!2&_XJ5
M35,K=4WB? &#2&U1M4JMALJZ74R[,'  JTZ<V0ZT_WZVDZ:H&+@!V_$YS_LZ
MG&.&6RZ>Y1I H9>"E7+DK96J!KXOYVLHB+SD%93ZR9*+@B@]%2M?5@+(P@85
MS,=!D/H%H:67#^W:1.1#7BM&2Y@().NB(.+U&AC?CKS0>UMXI*NU,@M^/JS(
M"J:@GJJ)T#._R[*@!922\A()6(Z\JW!P'=H N^,7A:W<&2-C9<;YLYG<+49>
M8!0!@[DR*8C^VL -,&8R:1W_VJ1>QS2!N^.W[+?6O#8S(Q)N./M-%VH]\GH>
M6L"2U$P]\NUW: TE)M^<,VD_T;;=&WAH7DO%BS98*RAHV7R3E_8@=@(P/A"
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M=BN&6* R0#Q?$\)/"_D#Q5CL_0902P,$%     @ 1(AM5HN7-W57 @  )0<
M !D   !X;"]W;W)K<VAE971S+W-H965T.#,N>&ULQ95M:]LP$,>_BO!@M%!B
MQWD:F6-H&L8*ZP@-VUZ,O5#L<RRJ!T^2D_3;[Z0X)MV2;!3"WMAZ^M_][GP^
M)1NEGTP)8,E6<&DF06EM-0Y#DY4@J.FH"B3N%$H+:G&J5Z&I--#<BP0/XR@:
MAH(R&:2)7YOK-%&UY4S"7!-3"T'U\Q2XVDR";K!?>&2KTKJ%,$TJNH(%V"_5
M7.,L;*WD3( T3$FBH9@$M]WQ=.3.^P-?&6S,P9BX2)9*/;G)?3X)(@<$'#+K
M+%!\K>$..'>&$.-G8S-H73KAX7AO_8./'6-94@-WBG]CN2TGP;N Y%#0FMM'
MM?D(33P#9R]3W/@GV31GHX!DM;%*-&(D$$SNWG3;Y.% $/=.".)&$'ONG2-/
M.:.6IHE6&Z+=:;3F!CY4KT8X)MU'65B-NPQU-GV@LBXP-;5F<D6HS,FBKBK^
M3&Y7&@"S;PWYES-7GZG6U&7XFES-P%+&S7426D1TCL*LP9GN<.(3.#/(.J37
MO2%Q%,=8*>B&@7YI)\00VSCC-L[8&^Z?BI-))FIQC.BLT/T48U/1#"8!5KT!
MO88@??NF.XS>G\'JM5@];[WWZO23[Y]00^XM"//C&'[O OC]%K]_/JLO\=MR
MN"&R%DO01!6DTLS][NW'- 1;"0&:E;BE\CJSQZ+:^1UZOZZQK--N$JZ/H Y:
MU,%?4+>G"N"L\)49'+98PTL7P/ "^*,6?_2?"F#T1P'$OQ5 >-#UW 7R0/6*
M24,X%*B).B/\KGK7E'<3JRK?")?*8EOUPQ+O,=#N .X72MG]Q/76]F9,?P%0
M2P,$%     @ 1(AM5C?68(S& @  NP<  !D   !X;"]W;W)K<VAE971S+W-H
M965T.#0N>&ULK55M3]LP$/XKIPQ-(#'2)FV96!JI+V/C QL"L7V8]L%-KJV%
M8P?;::FT'[]SDF:%E6B@?4G\=L\]SYU]%ZV5OC-+1 L/F9!FZ"VMS<]\WR1+
MS)@Y43E*VIDKG3%+4[WP3:Z1I:51)OR@TQGX&>/2BZ-R[4K'D2JLX!*O-)@B
MRYC>C%&H]=#K>MN%:[Y86K?@QU'.%GB#]C:_TC3S&Y249R@-5Q(TSH?>J'LV
M&;CSY8%O'-=F9PQ.R4RI.S>Y2(=>QQ%"@8EU"(Q^*YR@$ Z(:-S7F%[CTAGN
MCK?HYZ5VTC)C!B=*?.>I70Z]]QZD.&>%L-=J_1EK/7V'ERAARB^LJ[.GH0=)
M8:S*:F-BD'%9_=E#'8<=@[#WC$%0&P1/#(+@&8.P-@A+H16S4M:4619'6JU!
MN].$Y@9E;$IK4L.ER^*-U;3+R<[&4VX2)2V7!:;P-4?-7'0-O(-1FG(W9@(N
M9'5=7-P/IV@9%^8(#H!+N.1".(/(M\3&8?I)[7E<>0Z>\=P-X)(\+PU\E"FF
MCP%\DM%H";9:QD$KXA23$PB[QQ!T@@!N;Z9P>'!$)(UE0M#-LWM(3OX=LK.%
M;*$:-F$/2]SPA6%G,@7:RY6AL'_2JL@-_!C-C-5TWW_N"W+EI[??CZL!9R9G
M"0X]>N0&]0J]^.V;[J#S85\P_A/8HY#TFI#TVM#C<RZ93#CIIL@8GM8Q@5]P
ML$]W!=8OP5RI6L5!Y*]VQ?Q]HM^<>,2PWS#LOX;A,>1LXZX74!ZY2O>Q;0<.
M8(-,[WM#DU;#5V9DT.@=M-+Z4F0SU*#F<%\P;5&+S>YK,I2:]L<UKO '.RGH
M/4E2*X.7ZO-WZF"&>E&V!T/9*J2MRDBSVG2@45EXGZR/J3-5C>0/3-76+IE>
MD&@0."?(SLDI)4A7K:*:6)67U7:F+-7N<KBD[HK:':#]N5)V.W$.FGX=_P90
M2P,$%     @ 1(AM5DHJ-4'?!   FB,  !D   !X;"]W;W)K<VAE971S+W-H
M965T.#4N>&ULK9I=<]HX%(;_BL;;V6EG4OP!A"0+S*38V>TV:3--NKW8V0MA
M!&AJ6ZXDH,SLC^^Q<6R4&B6TYR;XZSR2SFL?^74TW CY12T9T^1;FF1JY"RU
MSB]<5\5+EE+5$3G+X,Q<R)1JV)4+5^62T5D9E"9NX'FG;DIYYHR'Y;%;.1Z*
ME4YXQFXE4:LTI7+[AB5B,W)\Y^' 1[Y8ZN* .Q[F=,'NF/Z4WTK8<VO*C*<L
M4UQD1++YR+GT+Z*@#"BO^(>SC=K;)L50ID)\*7;>SD:.5_2()2S6!8+"SYI-
M6)(4).C'UPKJU&T6@?O;#_2K<O PF"E5;"*2SWRFER/GS"$S-J>K1'\4F[]8
M-:!^P8M%HLJ_9%-=ZSDD7BDMTBH8>I#R;/=+OU6)V OP>P<"@BH@>&Y MPKH
M/C>@5P7TGAO0KP+*H;N[L9>)"ZFFXZ$4&R*+JX%6;)39+Z,A7SPK;I0[+>$L
MAS@]GH@TY1J4UXK0;$8F(M,\6[ LYDR1ER'3E"?J%7D-9Y*$3H6DA;+D4DH*
MEQ6!)^0>MA7=*;_A>DENJ=1;HL7A( !^N@O)RQ>OR O",W*_%"L%'5!#5\.P
MBLZY<36$-[LA! >&$+*X0[K^"0F\(&@)G]C#WXMUAWB#@^&A/?R*32$\.!@>
MV</_IAF$=]O"79"RUC.H]0Q*7N\ []U6;"AYQR7/VC)I#2Z*TH7*:<Q&#E0=
MQ>2:.>/??_-/O3_:\HH)"S%A$1+,4*!;*] MZ=T#"GS02R;)_G/U[S5<0MYJ
MEJK_VD3I8HJ""0LQ81$2S!"E5XO2LSX6-SQA4$M!AIQN2U5.BBK*TU7:IL@.
MUB]AQ52['G?[GC=TU_N9MK9X;*8Q8=$3W3<RV*\SV+=FT*SD=+_\:R9;LV@'
M^A[9,BK;"O[$&GEL:C%A$1+,D."TEN#TN;6=_$]N>';H]K5BCBTHF+ 0$Q8A
MP0PM!K46 ^0J/\ 4!1,68L(B))@AREDMRIGU ;GG3+(9D6)+$[T](3F3,6C3
MIL8.=+Y7(KV.UW]4X:VM'9ME3%B$!#.R?%YG^?R8,G1X%K5BCKWC,6$A)BQ"
M@AE:^%[CWSSD0E0!D71!I86HM B+9DJS9ZU]K')4D<QZY#\J1_;FCDXU)BUZ
M8@!F!ALSZ]O=[ V#(YJ2>[C':<Y6FL?PXGY]/2F_5=Q3N:"/3\.C(//R-56T
M.F![BT??_:@>&)468=%,[1H;[&/[8!_5"*/20E1:A$4SI6G,L&]WPW<4W#!)
M6SRQ9#'C:SI-6*M F"YUXO]H4WWOL<L.4=N,L&AFXAL/[=L][Y\4WIGB^A,K
MS FK#%(NY SF"9J*U8'9 =/"3BK:4WE'M<U8-#/OC7'V[<[Y%^<1>,W]S/42
MM.MZ)*1;13[,R1672A/U/KR$3< O6I5#M>*HM!"5%F'13(4;.^YC^W$?U9"C
MTD)46H1%,Z5I3+EO=^4_/=M@.N8)*BVL:/LU](</Q!%6DV;>&YONVWWZKQ>]
M*Y$D8@.EC5SFN11KFIB%KU4U5->/2@M1:1$6S?P_7V/\ VSC'Z :?U1:B$J+
ML&BF-(WQ#^S&_V<KGAU[M$"HGPLJFKWB836YR[N[MZRA6+5R R6+9XHD; YX
MKS. SLC=0I#=CA9YN=)A*K06:;FY9'3&9'$!G)\+H1]VBL43]7*<\7=02P,$
M%     @ 1(AM5JD#S/!0!@  .R(  !D   !X;"]W;W)K<VAE971S+W-H965T
M.#8N>&ULK9K9;MM&%(9?A5"+P@9J:U8NKBP@-K4C;1HC[471"TH:6T2XJ.3(
M3MZ^P\6T-#RD6)>YB"7J^_^9X5FXCE[BY&NZ$T(:W\(@2F\'.RGW-\-ANMF)
MT$NOX[V(U"^/<1)Z4GU-GH;I/A'>-A>%P9 @9 Y#SX\&XU&^[5,R'L4'&?B1
M^)08Z2$,O>3[G0CBE]L!'KQN^.P_[62V83@>[;TG\2#DE_VG1'T;5BY;/Q11
MZL>1D8C'V\$'?+/"+!/DQ!^^>$F//AO94M9Q_#7[LMC>#E V(Q&(C<PL//7G
M6=R+(,B<U#S^*4T'U9B9\/CSJ_LT7[Q:S-I+Q7T<_.EOY>YV8 ^,K7CT#H'\
M'+_,1;D@GOEMXB#-_S=>2A8-C,TAE7%8BM4,0C\J_GK?RAUQ)% ^L("4 J(+
M6(. E@+:5<!* >LJX*6 =Q68I<#L*K!*@=558)<"NZO *06.+C"; H=>(X>Z
MCH&K8!=)5V1)GF*N)[WQ*(E?C"3CE5_V(<_37*\RRX^RDGJ0B?K55SHY_OW@
M)5(DP7=CZD=>M/&]P%A$1:EF*7_QH(IX>PB$$3\:9^$OD7?8^E)L+R^-"U=(
MSP_22^/*^/+@&A<_7HZ&4DTY&WBX*:=W5TR/-$R/&A_C2.Y28Q)MQ1;0+]OU
MF+08#-6^JG88>=UA=Z35T16;:X/BGPV"" $F=-\N?Q![)4>-<K==OCQ$K?))
MN_RCE[1.?MI][1B0S[JO'9+/NZ\=DB^ZKQV2+_]?W%?OWG4G:4BKNJ6Y'WUG
MW;I^N@GB]) (XZ\/ZU0FZMCU-U1_Q3 ,'B8[H-^D>V\C;@?JB)V*Y%D,QC_]
M@$WT"Y3[?9JY?9I-^C2;]FDVZ]-LWJ?9HD^S99]FJY[,3BJ/597'VMS'G\6S
MB XBA8JI4/)<F9W,/H\=3*AIH]'P^;A.ZAS&#%-DD5/0!4!$' =S#9Q CMCB
MB/%3<%H';8H=V\2GW S@U/0XTY8R!Y:,.&<V/>46T$HXM3!W3L%E'60$8>0P
M#5S50<H=6RWY;>B3 /,JP+PUP+_M1:*::/1D^-$F#H5QH1II"IZ\%$;FT12N
M"+$L&S$MX!!HV]RVM7@#'+:9R:D&3B"0.-AQM+TT!4!&.74<4PLXY,A-2ATM
M@^80J"PMH@V] $!*&$5:"BT!CEN(.;KA"@ MT[)4?L 1-ZN(FZT1_U5=NI[$
MVGA,XM#8J#-'/SIDF1 7.1%'8-F;0'09=RRLIP$ ,D()T6+A ARF)C--#9Q
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M+W!MH+YO&)/'@9Z@Z:5G_P%02P,$%     @ 1(AM5KF- WU) P  K!0   T
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M*^JM!'HKZJT$>BOJK01ZZV2SA$!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95
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M+_?6V^.ORZ^3$W:N.(?[BN'Y+U!+ P04    " !$B&U6(=OYL3$"  #-,0
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M2P$"% ,4    " !$B&U6!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $2(;594XPA[[@   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M $2(;5:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ 1(AM5A(H2J*)!P   R\  !@
M     ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M $2(;59&,SL910(  ,D%   8              " @<P/  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " !$B&U6<UVPL54&  !L&0  &
M            @(%'$@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ 1(AM5G1@XMF9 @  6@<  !@              ("!TA@  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $2(;5;11O:RM08  &X?
M   8              " @:$;  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " !$B&U6@E53!:L)   1+   &               @(&,(@
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 1(AM5E#*RW07
M!@  \28  !@              ("!;2P  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( $2(;5;X"C_EA ,  .,'   8              "
M@;HR  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !$B&U6
M.UZJ2:8)  #!%P  &               @(%T-@  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ 1(AM5J?:X) :)0  K'$  !D
M     ("!4$   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M" !$B&U6*XY$W;@/  "J*@  &0              @(&A90  >&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $2(;58F2QM\C@8  %(/   9
M              " @9!U  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!
M A0#%     @ 1(AM5A-DV;7T!   HPL  !D              ("!57P  'AL
M+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !$B&U6)R=$V94#
M   5"   &0              @(& @0  >&PO=V]R:W-H965T<R]S:&5E=#$T
M+GAM;%!+ 0(4 Q0    ( $2(;58W1D$LX 0  'D+   9              "
M@4R%  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 1(AM
M5B *V#1[ P  # @  !D              ("!8XH  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " !$B&U6<XSE1J0(  #H%   &0
M        @($5C@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( $2(;5888K 6VP0  &D+   9              " @?"6  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ 1(AM5DE1%UJ% P  &@@
M !D              ("! IP  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " !$B&U6HE\*(5P'   ^$@  &0              @(&^GP
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $2(;5:J3(;L
ML@H  "$=   9              " @5&G  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ 1(AM5GU&D>%D!   -0H  !D
M ("!.K(  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !$
MB&U6!/]88N4(   P%0  &0              @('5M@  >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( $2(;58;UVB-G0,  !@(   9
M          " @?&_  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#
M%     @ 1(AM5NJDAS<F P  .@<  !D              ("!Q<,  'AL+W=O
M<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !$B&U6P+E#7I("  #@
M!0  &0              @($BQP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;%!+ 0(4 Q0    ( $2(;59+RDN-) 8  '(/   9              " @>O)
M  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 1(AM5BML
M)B!H!P  ]Q$  !D              ("!1M   'AL+W=O<FMS:&5E=',O<VAE
M970R."YX;6Q02P$"% ,4    " !$B&U6@SFS"\@$   X#0  &0
M    @('EUP  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M $2(;5:%P=,:51T  "Y?   9              " @>3<  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ 1(AM5O*94X@+ P  J <  !D
M             ("!</H  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " !$B&U699$S3AX$   0"@  &0              @(&R_0  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $2(;59_WT;B# ,
M $L&   9              " @0<" 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ 1(AM5C)6G:3O @  308  !D              ("!
M2@4! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !$B&U6
M,J3(0F\#   %"   &0              @(%P" $ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( $2(;5;2<F)>\P,  (<)   9
M      " @18, 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ 1(AM5IF3>X.C P  B@@  !D              ("!0! ! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " !$B&U6R5PJV[\#   8"0
M&0              @($:% $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( $2(;58EXG)U6P8  %01   9              " @1 8 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 1(AM5FYX![W\
M P  )PH  !D              ("!HAX! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " !$B&U6<HF-F@L$  #\"0  &0
M@('5(@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $2(
M;5;7JD__D@(  )T%   9              " @1<G 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ 1(AM5GY!3T3>!   %0T  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( $2(;59/%]#980(  ,0%   9
M  " @2-" 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M1(AM5@QA%@\*#   !9(  !D              ("!NT0! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " !$B&U6NRI?U20$   &$P  &0
M            @('\4 $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( $2(;5;QXCX?JP(  (<&   9              " @5=5 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ 1(AM5A@E>Z>$!
M3!H  !D              ("!.5@! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " !$B&U6W5PQ0HH#  "^#0  &0              @('T
M7 $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( $2(;58D
M\MQ2Z@(  &@(   9              " @;5@ 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ 1(AM5MX8C/QG P  H0\  !D
M     ("!UF,! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $2(;5:6ID<VQ0(  /4(   9              "
M@;UW 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ 1(AM
M5M3H@_IP P  (PH  !D              ("!N7H! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    " !$B&U6MFV40\8"  !3!P  &0
M        @(%@?@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( $2(;59FFL 15@8   L[   9              " @5V! 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ 1(AM5C069X)E!   E!8
M !D              ("!ZH<! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    " !$B&U6B\ FO @$   ]$0  &0              @(&&C $
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( $2(;5;H$$3U
MC04  "HB   9              " @<60 0!X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ 1(AM5GO+16E] @    8  !D
M ("!B98! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " !$
MB&U62>L\>'T$  !]$   &0              @($]F0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( $2(;5;-N,Y/] ,  .\9   9
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M970W,RYX;6Q02P$"% ,4    " !$B&U6*4W%9TT#  !M#@  &0
M    @('TL@$ >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    (
M $2(;59DV<C#0P0  (,3   9              " @7BV 0!X;"]W;W)K<VAE
M971S+W-H965T-S4N>&UL4$L! A0#%     @ 1(AM5B0S:DRB P  D T  !D
M             ("!\KH! 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"
M% ,4    " !$B&U6402-M0X#  !@"0  &0              @('+O@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( $2(;5;N&,5]LP0
M $,7   9              " @1#" 0!X;"]W;W)K<VAE971S+W-H965T-S@N
M>&UL4$L! A0#%     @ 1(AM5LLSS1Q^ @  2 8  !D              ("!
M^L8! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    " !$B&U6
MRV831)$"   $!P  &0              @(&OR0$ >&PO=V]R:W-H965T<R]S
M:&5E=#@P+GAM;%!+ 0(4 Q0    ( $2(;5;:_'J7XP(   X(   9
M      " @7?, 0!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%
M  @ 1(AM5I::RF!9 P  (@\  !D              ("!D<\! 'AL+W=O<FMS
M:&5E=',O<VAE970X,BYX;6Q02P$"% ,4    " !$B&U6BY<W=5<"   E!P
M&0              @($ATP$ >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+
M 0(4 Q0    ( $2(;58WUF",Q@(  +L'   9              " @:_5 0!X
M;"]W;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ 1(AM5DHJ-4'?
M!   FB,  !D              ("!K-@! 'AL+W=O<FMS:&5E=',O<VAE970X
M-2YX;6Q02P$"% ,4    " !$B&U6J0/,\% &   [(@  &0
M@('"W0$ >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( $2(
M;58P%&$X$ 0  %</   9              " @4GD 0!X;"]W;W)K<VAE971S
M+W-H965T.#<N>&UL4$L! A0#%     @ 1(AM5KF- WU) P  K!0   T
M         ( !D.@! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !$B&U6EXJ[
M',     3 @  "P              @ $$[ $ 7W)E;',O+G)E;'-02P$"% ,4
M    " !$B&U671[!1V@&   ?.0  #P              @ 'M[ $ >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ 1(AM5D#*==&. @  3#,  !H
M     ( !@O,! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ 1(AM5B';^;$Q @  S3$  !,              ( !2/8! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     %\ 7P 0&@  JO@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>202</ContextCount>
  <ElementCount>408</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts</Role>
      <ShortName>Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - RediTrex??, Vibativ?? and Sancuso??</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RediTrexVibativandSancuso</Role>
      <ShortName>RediTrex??, Vibativ?? and Sancuso??</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Other Current and Other Long-term Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities</Role>
      <ShortName>Other Current and Other Long-term Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Earnings (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Market Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrations</Role>
      <ShortName>Market Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Manufacturing and Supply Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements</Role>
      <ShortName>Manufacturing and Supply Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Employment Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmploymentAgreements</Role>
      <ShortName>Employment Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - RediTrex??, Vibativ?? and Sancuso?? (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoTables</Role>
      <ShortName>RediTrex??, Vibativ?? and Sancuso?? (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RediTrexVibativandSancuso</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Revenues</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Inventories</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipment</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Other Current and Other Long-term Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables</Role>
      <ShortName>Other Current and Other Long-term Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Earnings (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlans</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Market Concentrations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrationsTables</Role>
      <ShortName>Market Concentrations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketConcentrations</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Organization (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails</Role>
      <ShortName>Organization (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Organization</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails</Role>
      <ShortName>Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Significant Accounting Policies (Schedule of Distribution Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails</Role>
      <ShortName>Significant Accounting Policies (Schedule of Distribution Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Significant Accounting Policies (Schedule of Advertising Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails</Role>
      <ShortName>Significant Accounting Policies (Schedule of Advertising Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - RediTrex??, Vibativ?? and Sancuso?? - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails</Role>
      <ShortName>RediTrex??, Vibativ?? and Sancuso?? - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - RediTrex??, Vibativ?? and Sancuso?? - Schedule of Contingent Consideration and Preliminary Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails</Role>
      <ShortName>RediTrex??, Vibativ?? and Sancuso?? - Schedule of Contingent Consideration and Preliminary Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - RediTrex??, Vibativ?? and Sancuso?? - Pro Forma Results (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoProFormaResultsDetails</Role>
      <ShortName>RediTrex??, Vibativ?? and Sancuso?? - Pro Forma Results (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails</Role>
      <ShortName>Revenues (Schedule of Net Product Revenues by Product) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Revenues (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/RevenuesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Inventories (Schedule of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories (Schedule of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Inventories (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/InventoriesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Schedule of Property and Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Property and Equipment (Depreciation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails</Role>
      <ShortName>Property and Equipment (Depreciation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Intangible Assets and Goodwill (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Intangible Assets and Goodwill (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Intangible Assets and Goodwill - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails</Role>
      <ShortName>Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Debt (Line of Credit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DebtLineofCreditDetails</Role>
      <ShortName>Debt (Line of Credit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/Debt</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EarningsLossPerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails</Role>
      <ShortName>Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails</Role>
      <ShortName>Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails</Role>
      <ShortName>Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Income Taxes (Schedule of tax credit carryforwards) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails</Role>
      <ShortName>Income Taxes (Schedule of tax credit carryforwards) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Incentive Stock Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Schedule of Restricted Incentive Stock Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Leases (Schedule of Rent Expense and Sublease Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails</Role>
      <ShortName>Leases (Schedule of Rent Expense and Sublease Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Leases (Lease Position) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails</Role>
      <ShortName>Leases (Lease Position) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails</Role>
      <ShortName>Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/LeasesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails</Role>
      <ShortName>Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/MarketConcentrationsTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails</Role>
      <ShortName>Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Discontinued Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails</Role>
      <ShortName>Discontinued Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails</Role>
      <ShortName>Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="cpix-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails</Role>
      <ShortName>Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:DocumentAnnualReport, dei:DocumentPeriodEndDate, dei:DocumentTransitionReport, dei:EntityEmergingGrowthCompany, dei:EntityFilerCategory, dei:EntityShellCompany, dei:EntitySmallBusiness -  cpix-20221231.htm 4</Log>
    <Log type="Warning">[EFM.6.05.45.cover-page-fact-not-visible] Submission type 10-K has 4 cover page fact(s) in ix:hidden that should be visible or referenced by an -sec-ix-hidden style property: EntityCurrentReportingStatus, EntityInteractiveDataCurrent, EntityVoluntaryFilers, EntityWellKnownSeasonedIssuer - cpix-20221231.htm 4 - cpix-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="cpix-20221231.htm">cpix-20221231.htm</File>
    <File>a2022-10kxex1011ajkazimi.htm</File>
    <File>a2022-10kxex1014johnhamm.htm</File>
    <File>a2022-10kxex1015jimherman.htm</File>
    <File>a2022-10kxexhibit311.htm</File>
    <File>a2022-10kxexhibit312.htm</File>
    <File>a2022-10kxexhibit321.htm</File>
    <File>a2022-xex232consentofforvi.htm</File>
    <File>a2022q4exhibit411.htm</File>
    <File>cpix-20221231.xsd</File>
    <File>cpix-20221231_cal.xml</File>
    <File>cpix-20221231_def.xml</File>
    <File>cpix-20221231_lab.xml</File>
    <File>cpix-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cpix-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="793">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cpix-20221231.htm": {
   "axisCustom": 4,
   "axisStandard": 28,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 793,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 202,
   "dts": {
    "calculationLink": {
     "local": [
      "cpix-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cpix-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cpix-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cpix-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 662,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 16,
    "total": 16
   },
   "keyCustom": 77,
   "keyStandard": 331,
   "memberCustom": 52,
   "memberStandard": 32,
   "nsprefix": "cpix",
   "nsuri": "http://www.cumberlandpharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cumberlandpharma.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cumberlandpharma.com/role/RediTrexVibativandSancuso",
     "shortName": "RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Revenues",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cumberlandpharma.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cumberlandpharma.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Intangible Assets and Goodwill",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Other Current and Other Long-term Liabilities",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities",
     "shortName": "Other Current and Other Long-term Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cumberlandpharma.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Shareholders' Equity",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Earnings (Loss) Per Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.cumberlandpharma.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Stock-Based Compensation Plans",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlans",
     "shortName": "Stock-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.cumberlandpharma.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.cumberlandpharma.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Market Concentrations",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrations",
     "shortName": "Market Concentrations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAndSupplyAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Manufacturing and Supply Agreements",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements",
     "shortName": "Manufacturing and Supply Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAndSupplyAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:EmploymentAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Employment Agreements",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.cumberlandpharma.com/role/EmploymentAgreements",
     "shortName": "Employment Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:EmploymentAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Discontinued Operations",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.cumberlandpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Quarterly Financial Information (Unaudited)",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited",
     "shortName": "Quarterly Financial Information (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "30",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoTables",
     "shortName": "RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Revenues (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.cumberlandpharma.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.cumberlandpharma.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Other Current and Other Long-term Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables",
     "shortName": "Other Current and Other Long-term Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Earnings (Loss) Per Share (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockNoParValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.cumberlandpharma.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Market Concentrations (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrationsTables",
     "shortName": "Market Concentrations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables",
     "shortName": "Quarterly Financial Information (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Organization (Narrative) (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
     "shortName": "Organization (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i6c780a0c3e87440c8eb1928bb0ce5f86_D20180101-20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "cpix:SharebasedCompensationCharitableContributionofSharesShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Significant Accounting Policies (Narrative) (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "icc21cd41019b4937823097e3a64ff8a3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails",
     "shortName": "Significant Accounting Policies (Schedule of Intangible Assets, Useful Lives) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "icc21cd41019b4937823097e3a64ff8a3_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:FiniteLivedIntangibleAssetsUsefulLivesTextual",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductionAndDistributionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Significant Accounting Policies (Schedule of Distribution Costs) (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails",
     "shortName": "Significant Accounting Policies (Schedule of Distribution Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductionAndDistributionCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Significant Accounting Policies (Schedule of Advertising Costs) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails",
     "shortName": "Significant Accounting Policies (Schedule of Advertising Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
     "shortName": "RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b29c34edaba455b8ebdd48b45de02d6_I20211031",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ib36b29930b41472aaa5de35a1e59cb95_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae - Schedule of Contingent Consideration and Preliminary Allocation (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails",
     "shortName": "RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae - Schedule of Contingent Consideration and Preliminary Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i924046424f4a4ad5a7dce8e0bfe36d8b_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae - Pro Forma Results (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoProFormaResultsDetails",
     "shortName": "RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae - Pro Forma Results (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Revenues (Schedule of Net Product Revenues by Product) (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails",
     "shortName": "Revenues (Schedule of Net Product Revenues by Product) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "iaa10efc46e9e461386aa80220fb7a4ce_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Revenues (Narrative) (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "cpix:RevenueRecognitionUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Inventories (Schedule of Inventories) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories (Schedule of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Inventories (Narrative) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryValuationReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Property and Equipment (Schedule of Property and Equipment) (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Schedule of Property and Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Property and Equipment (Depreciation Expense) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails",
     "shortName": "Property and Equipment (Depreciation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Intangible Assets and Goodwill (Schedule of Intangible Assets) (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets and Goodwill (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i69aeb359c79e41b78bca28b92da3cc0b_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Intangible Assets and Goodwill (Narrative) (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PaymentsToAcquireIntangibleAssets",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i4c75d11680284d93969ed668e797eebc_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Intangible Assets and Goodwill - Future Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails",
     "shortName": "Intangible Assets and Goodwill - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProductSalesRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails",
     "shortName": "Other Current and Other Long-term Liabilities (Schedule of Other Current Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ProductSalesRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails",
     "shortName": "Other Current and Other Long-term Liabilities (Schedule of Noncurrent Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ic0531c6598004c5d9158b8763683f643_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermLineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Debt (Line of Credit) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
     "shortName": "Debt (Line of Credit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ic015a17daf5344f9a4de26b8e32f3873_I20221231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails",
     "shortName": "Shareholders' Equity (Initial Public Offering, Preferred Stock and Common Stock, Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails",
     "shortName": "Shareholders' Equity (Share Repurchases, Cumberland Emerging Technologies and Cumberland Foundation Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Schedule of Computation of Numerator and Denominator in Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ica6fdfd9286c4d57995a6511ca191736_D20210701-20210930",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails",
     "shortName": "Earnings (Loss) Per Share (Schedule of Anti-dilutive Securities Excluded From Computation of Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails",
     "shortName": "Income Taxes (Schedule of Deferred Tax Assets and Liabilities, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "cpix:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "if08c5ee420b248ac902a128ef7d90e7a_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
     "shortName": "Income Taxes (Schedule of Net Operating Loss Carryforwards) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "if08c5ee420b248ac902a128ef7d90e7a_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i963f0ace48ae4299a000f7fd5b7c18c5_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i963f0ace48ae4299a000f7fd5b7c18c5_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails",
     "shortName": "Income Taxes (Schedule of the Components of Income Tax Benefit (Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes (Schedule of Effective Income Tax Rate Reconciliation) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i81a18b4c882d437cb25a611496aa56a5_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Income Taxes (Schedule of tax credit carryforwards) (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails",
     "shortName": "Income Taxes (Schedule of tax credit carryforwards) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i81a18b4c882d437cb25a611496aa56a5_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Stock-Based Compensation Plans (Narrative) (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
     "shortName": "Stock-Based Compensation Plans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "plan",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation Plans (Schedule of Share-Based Compensation Expense) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i09447f6af13b4f27a9f24d32a75cda9b_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Incentive Stock Activity) (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails",
     "shortName": "Stock-Based Compensation Plans (Schedule of Restricted Incentive Stock Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i430e1a4cd7514fe59de28ed3a49bbab5_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation Plans (Schedule of Restricted Stock Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ib2a4df839364457ca572567fd0e125dc_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Employee Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cpix:DefinedContributionPlanEligibilityMinimumEmployeeAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ib2fa7c2f4e86401a88e3022cb2d1309b_I20211115",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "cpix:LesseeOperatingLeaseRentIncrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Leases (Narrative) (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ib2fa7c2f4e86401a88e3022cb2d1309b_I20211115",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "cpix:LesseeOperatingLeaseRentIncrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Leases (Schedule of Rent Expense and Sublease Income) (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails",
     "shortName": "Leases (Schedule of Rent Expense and Sublease Income) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Valuation and Qualifying Accounts",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts",
     "shortName": "Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Leases (Lease Position) (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails",
     "shortName": "Leases (Lease Position) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cpix:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "cpix:LeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails",
     "shortName": "Leases (Schedule of Lease Liability Maturities and Future Minimum Payments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ie7de9e3a8f694f75963d43839bcbe61c_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i8047e420d87647ca865218062adc1b3c_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails",
     "shortName": "Market Concentrations (Schedule of Revenues Concentration from Major Customers and Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i8047e420d87647ca865218062adc1b3c_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ic40eb7705a474e4fa7d98cfa3a5cb554_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "supplier",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
     "shortName": "Manufacturing and Supply Agreements Manufacturing and Supply Agreements (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "ic40eb7705a474e4fa7d98cfa3a5cb554_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cpix:ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
      "reportCount": 1,
      "unique": true,
      "unitRef": "supplier",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Discontinued Operations - Additional Information (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails",
     "shortName": "Discontinued Operations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i03b6a63983b64d8bbf3a1a5e92a62c3b_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "cpix:CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i03b6a63983b64d8bbf3a1a5e92a62c3b_I20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "cpix:CollaborativeArrangementRightsAndObligationsTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails",
     "shortName": "Quarterly Financial Information (Schedule of Quarterly Financial Information (Unaudited)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9732767fb209402a8b3130d4446cf0dd_D20221001-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i34ed7d5354534fbd81b84cc0aa0d8e79_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Valuation and Qualifying Accounts (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails",
     "shortName": "Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "if5de2643b16c42518868295369efe808_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cumberlandpharma.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cpix-20221231.htm",
      "contextRef": "i9b63832dfc274b8f80f0e64dc5212d3f_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 87,
   "tag": {
    "cpix_A1600WestEndAvenuePartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1600 West End Avenue Partners, LLC",
        "label": "1600 West End Avenue Partners, LLC [Member]",
        "terseLabel": "1600 West End Avenue Partners, LLC"
       }
      }
     },
     "localname": "A1600WestEndAvenuePartnersLLCMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AccountsReceivableAllowancesByComponentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowances by Component [Axis]",
        "label": "Accounts Receivable, Allowances by Component [Axis]",
        "terseLabel": "Accounts Receivable, Allowances by Component [Axis]"
       }
      }
     },
     "localname": "AccountsReceivableAllowancesByComponentAxis",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_AccountsReceivableAllowancesByComponentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Accounts Receivable, Allowances by Component [Axis]",
        "label": "Accounts Receivable, Allowances by Component [Domain]",
        "terseLabel": "Accounts Receivable, Allowances by Component [Domain]"
       }
      }
     },
     "localname": "AccountsReceivableAllowancesByComponentDomain",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AccruedLiabilitiesInventoryPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Inventory Purchases",
        "label": "Accrued Liabilities, Inventory Purchases",
        "terseLabel": "Accrued inventory purchases"
       }
      }
     },
     "localname": "AccruedLiabilitiesInventoryPurchases",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_AccruedLiabilitiesStockPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities, Stock Payable",
        "label": "Accrued Liabilities, Stock Payable",
        "terseLabel": "Sancuso related liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesStockPayable",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_AcetadoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acetadote.",
        "label": "Acetadote [Member]",
        "terseLabel": "Acetadote"
       }
      }
     },
     "localname": "AcetadoteMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets and Liabilities, Lessee",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of balance sheet classification"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cpix_BroadwestLeaseFiveYearRenewalOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broadwest Lease, Five Year Renewal Option",
        "label": "Broadwest Lease, Five Year Renewal Option [Member]",
        "terseLabel": "Broadwest Lease, Five Year Renewal Option"
       }
      }
     },
     "localname": "BroadwestLeaseFiveYearRenewalOptionMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "label": "Business Combination, Contingent Consideration, Earned and Accrued in Operating Expenses",
        "terseLabel": "Contingent consideration earned and accrued"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationEarnedAndAccruedInOperatingExpenses",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_BusinessCombinationContingentConsiderationLiabilityAccruedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Accrued, Current",
        "label": "Business Combination, Contingent Consideration, Liability, Accrued, Current",
        "terseLabel": "Current portion of accrued contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityAccruedCurrent",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CET",
        "label": "CET [Member]",
        "terseLabel": "CET"
       }
      }
     },
     "localname": "CETMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CaldolorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Caldolor.",
        "label": "Caldolor [Member]",
        "terseLabel": "Vibativ"
       }
      }
     },
     "localname": "CaldolorMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CashPaidDuringYearForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid During Year For [Abstract]",
        "label": "Cash Paid During Year For [Abstract]",
        "terseLabel": "Net cash paid (refunded) during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringYearForAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ChargebacksCashDiscountsAndDamagedGoodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks, Cash Discounts and Damaged Goods [Member]",
        "label": "Chargebacks, Cash Discounts and Damaged Goods [Member]",
        "terseLabel": "Product Sales Related Allowances - Chargebacks, Cash Discounts and Damaged Goods"
       }
      }
     },
     "localname": "ChargebacksCashDiscountsAndDamagedGoodsMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CollaborativeArrangementFederalSmallBusinessGrantProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]",
        "label": "Collaborative Arrangement, Federal Small Business Grant Programs [Member]",
        "terseLabel": "Collaborative Arrangement, Federal Small Business Grant Programs"
       }
      }
     },
     "localname": "CollaborativeArrangementFederalSmallBusinessGrantProgramsMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CollaborativeArrangementMilestonePaymentThresholdAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment, Threshold",
        "label": "Collaborative Arrangement, Milestone Payment, Threshold [Axis]",
        "terseLabel": "Collaborative Arrangement, Milestone Payment, Threshold [Axis]"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentThresholdAxis",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_CollaborativeArrangementMilestonePaymentThresholdDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment, Threshold [Domain]",
        "label": "Collaborative Arrangement, Milestone Payment, Threshold [Domain]",
        "terseLabel": "Collaborative Arrangement, Milestone Payment, Threshold [Domain]"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentThresholdDomain",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Credit Due",
        "terseLabel": "Milestone payment credit due"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentCreditDue",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone Payment Receivable",
        "terseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePaymentReceivable",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable",
        "label": "Collaborative Arrangement, Rights and Obligations, Restricted Shares Receivable",
        "terseLabel": "Restricted shares receivable (in shares)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRestrictedSharesReceivable",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Annual Net Revenue Threshold",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Annual Net Revenue Threshold",
        "terseLabel": "Sales milestone payments, annual net revenue threshold"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsAnnualNetRevenueThreshold",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Expected",
        "terseLabel": "Expected sales milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsExpected",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Maximum",
        "terseLabel": "Milestone payments, maximum"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsMaximum",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Receivable",
        "terseLabel": "Sales milestone payments, receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsReceivable",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Remaining",
        "label": "Collaborative Arrangement, Rights and Obligations, Sales Milestone Payments, Remaining",
        "terseLabel": "Sales milestone payments, remaining"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSalesMilestonePaymentsRemaining",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Term",
        "label": "Collaborative Arrangement, Rights and Obligations, Term",
        "terseLabel": "Collaborative arrangement, term"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsTerm",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "label": "Collaborative Arrangement, Rights and Obligations, Tiered Royalty, Percent",
        "terseLabel": "Tiered royalty, percent"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsTieredRoyaltyPercent",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights and Obligations, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CommonStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock [Abstract]",
        "label": "Common Stock [Abstract]",
        "terseLabel": "Common Stock [Abstract]"
       }
      }
     },
     "localname": "CommonStockAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ContributionOfCashAdditionalSharesPurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution of Cash, Additional Shares Purchased",
        "label": "Contribution of Cash, Additional Shares Purchased",
        "terseLabel": "Contribution of cash"
       }
      }
     },
     "localname": "ContributionOfCashAdditionalSharesPurchased",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CreditIssuedForMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Issued for Milestone Payable",
        "label": "Credit Issued for Milestone Payable",
        "terseLabel": "RediTrex forgiveness of milestone payable"
       }
      }
     },
     "localname": "CreditIssuedForMilestonePayable",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_CumberlandEmergingTechnologiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumberland Emerging Technologies, Inc [Member]",
        "label": "Cumberland Emerging Technologies, Inc [Member]",
        "terseLabel": "Cumberland Emerging Technologies, Inc (CET)"
       }
      }
     },
     "localname": "CumberlandEmergingTechnologiesIncMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_Customer12And3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 1, 2, and 3",
        "label": "Customer 1, 2, and 3 [Member]",
        "terseLabel": "Customer 1, 2, and 3"
       }
      }
     },
     "localname": "Customer12And3Member",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CustomerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer One [Member]",
        "label": "Customer One [Member]",
        "terseLabel": "Customer 1"
       }
      }
     },
     "localname": "CustomerOneMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CustomerThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Three [Member]",
        "label": "Customer Three [Member]",
        "terseLabel": "Customer 3"
       }
      }
     },
     "localname": "CustomerThreeMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_CustomerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer Two [Member]",
        "label": "Customer Two [Member]",
        "terseLabel": "Customer 2"
       }
      }
     },
     "localname": "CustomerTwoMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_DebtInstrumentCovenantUnrestrictedCashThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Unrestricted Cash Threshold",
        "label": "Debt Instrument, Covenant, Unrestricted Cash Threshold",
        "terseLabel": "Unrestricted cash threshold"
       }
      }
     },
     "localname": "DebtInstrumentCovenantUnrestrictedCashThreshold",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Operating Lease Liabilities",
        "label": "Deferred Tax Asset, Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetOperatingLeaseLiabilities",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsDeferredCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Deferred Charges",
        "label": "Deferred Tax Assets, Deferred Charges",
        "terseLabel": "Deferred charges"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredCharges",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards and Tax Credit Carryforwards",
        "terseLabel": "Net operating loss and tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsPropertyAndEquipmentAndIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Property and Equipment and Intangibles",
        "label": "Deferred Tax Assets, Property and Equipment and Intangibles",
        "terseLabel": "Property and equipment and intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyAndEquipmentAndIntangibles",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves for Expired Product",
        "terseLabel": "Reserve for expired product"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReservesForExpiredProduct",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DeferredTaxLiabilityOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 1.0,
       "parentTag": "cpix_NetDeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liability, Operating Lease Right-of-Use Assets",
        "label": "Deferred Tax Liability, Operating Lease Right-of-Use Assets",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilityOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DefinedContributionPlanEligibilityMinimumEmployeeAge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Eligibility, Minimum Employee Age",
        "label": "Defined Contribution Plan, Eligibility, Minimum Employee Age",
        "terseLabel": "Defined contribution plan, eligibiilty, minimum employee age"
       }
      }
     },
     "localname": "DefinedContributionPlanEligibilityMinimumEmployeeAge",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cpix_DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility",
        "label": "Defined Contribution Plan, Eligibility, Minimum Employee Service Time for Participation Eligibility",
        "terseLabel": "Defined contribution plan, eligibility, minimum employee service time for participation eligibility"
       }
      }
     },
     "localname": "DefinedContributionPlanEligibilityMinimumEmployeeServiceTimeForParticipationEligibility",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cpix_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denominator.",
        "label": "Denominator [Abstract]",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_DepreciationIncludingAmortizationRelatedToLeaseholdImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation, Including Amortization Related to Leasehold Improvements",
        "label": "Depreciation, Including Amortization Related to Leasehold Improvements",
        "terseLabel": "Depreciation, including amortization related to leasehold improvements"
       }
      }
     },
     "localname": "DepreciationIncludingAmortizationRelatedToLeaseholdImprovements",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentDepreciationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_DirectorsIncentivePlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors\u2019 Incentive Plan 2007 [Member]",
        "label": "Directors\u2019 Incentive Plan 2007 [Member]",
        "terseLabel": "Directors\u2019 Incentive Plan 2007"
       }
      }
     },
     "localname": "DirectorsIncentivePlan2007Member",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employee"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_EmployeeNonemployeeandFoundationContributionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee, Nonemployee and Foundation Contribution [Member]",
        "label": "Employee, Nonemployee and Foundation Contribution [Member]",
        "terseLabel": "Employee, Nonemployee and Foundation Contribution"
       }
      }
     },
     "localname": "EmployeeNonemployeeandFoundationContributionMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_EmploymentAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Agreements [Abstract]",
        "label": "Employment Agreements [Abstract]"
       }
      }
     },
     "localname": "EmploymentAgreementsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cpix_EmploymentAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employment Agreements",
        "label": "Employment Agreements [Text Block]",
        "terseLabel": "Employment Agreements"
       }
      }
     },
     "localname": "EmploymentAgreementsTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmploymentAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ExpirationTermOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration, Term One [Member]",
        "label": "Expiration, Term One [Member]",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "ExpirationTermOneMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ExpirationTermTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration, Term Two [Member]",
        "label": "Expiration, Term Two [Member]",
        "terseLabel": "2024-2042"
       }
      }
     },
     "localname": "ExpirationTermTwoMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ExpirationTimePeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration Time Period [Axis]",
        "label": "Expiration Time Period [Axis]",
        "terseLabel": "Expiration Time Period [Axis]"
       }
      }
     },
     "localname": "ExpirationTimePeriodAxis",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ExpirationTimePeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Expiration Time Period [Axis]",
        "label": "Expiration Time Period [Domain]",
        "terseLabel": "Expiration Time Period [Domain]"
       }
      }
     },
     "localname": "ExpirationTimePeriodDomain",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_FederalAndStateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal And State",
        "label": "Federal And State [Member]",
        "terseLabel": "Federal And State"
       }
      }
     },
     "localname": "FederalAndStateMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_FifthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifth Amendment",
        "label": "Fifth Amendment [Member]",
        "terseLabel": "Fifth Amendment"
       }
      }
     },
     "localname": "FifthAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_FinancialConsiderationNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Consideration, Number of Installments",
        "label": "Financial Consideration, Number of Installments",
        "terseLabel": "Number of quarterly installments"
       }
      }
     },
     "localname": "FinancialConsiderationNumberOfInstallments",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_FinancialConsiderationPaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Consideration, Payment Period",
        "label": "Financial Consideration, Payment Period",
        "terseLabel": "Financial consideration, payment period"
       }
      }
     },
     "localname": "FinancialConsiderationPaymentPeriod",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cpix_FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Amortization Expense, Year Five and After",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five and After",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveandAfter",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_FiniteLivedIntangibleAssetsUsefulLivesTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Assets, Useful Lives, (Textual)",
        "label": "Finite-Lived Intangible Assets, Useful Lives, (Textual)",
        "terseLabel": "Intangible assets, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsUsefulLivesTextual",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_FollowingApprovalOfFirstSNDAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Following Approval Of First sNDA",
        "label": "Following Approval Of First sNDA [Member]",
        "terseLabel": "Following Approval Of First sNDA"
       }
      }
     },
     "localname": "FollowingApprovalOfFirstSNDAMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_GloriaPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gloria Pharmaceuticals",
        "label": "Gloria Pharmaceuticals [Member]",
        "terseLabel": "Gloria Pharmaceuticals"
       }
      }
     },
     "localname": "GloriaPharmaceuticalsMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HarbinGloriaPharmaceuticalsCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harbin Gloria Pharmaceuticals Co [Member]",
        "label": "Harbin Gloria Pharmaceuticals Co [Member]",
        "terseLabel": "Harbin Gloria Pharmaceuticals Co"
       }
      }
     },
     "localname": "HarbinGloriaPharmaceuticalsCoMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_HongKongWinHealthPharmaGroupCoLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HongKong WinHealth Pharma Group Co. Limited",
        "label": "HongKong WinHealth Pharma Group Co. Limited [Member]",
        "terseLabel": "HongKong WinHealth Pharma Group Co. Limited"
       }
      }
     },
     "localname": "HongKongWinHealthPharmaGroupCoLimitedMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IfetrobanClinicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ifetroban Clinical",
        "label": "Ifetroban Clinical [Member]",
        "terseLabel": "Ifetroban Clinical"
       }
      }
     },
     "localname": "IfetrobanClinicalMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "label": "Increase (Decrease) In Cash Surrender Value Of Life Insurance Policy",
        "negatedTerseLabel": "Decrease (Increase) in cash surrender value of life insurance policies over premiums paid"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashSurrenderValueOfLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_IncreaseDecreaseInProceedsFromLifeInsurancePolicy": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Proceeds from Life Insurance Policy",
        "label": "Increase (Decrease) In Proceeds from Life Insurance Policy",
        "negatedTerseLabel": "Premiums paid for life insurance policies"
       }
      }
     },
     "localname": "IncreaseDecreaseInProceedsFromLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_IndefiniteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite",
        "label": "Indefinite [Member]",
        "terseLabel": "Indefinite Period"
       }
      }
     },
     "localname": "IndefiniteMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_InitialPublicOfferingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Public Offering [Abstract]",
        "label": "Initial Public Offering [Abstract]",
        "terseLabel": "Initial Public Offering [Abstract]"
       }
      }
     },
     "localname": "InitialPublicOfferingAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_IntercompanyLoansPayableConvertedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intercompany Loans Payable, Converted Amount",
        "label": "Intercompany Loans Payable, Converted Amount",
        "terseLabel": "Conversion of intercompany loans payable"
       }
      }
     },
     "localname": "IntercompanyLoansPayableConvertedAmount",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_KristaloseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kristalose.",
        "label": "Kristalose [Member]",
        "terseLabel": "Kristalose"
       }
      }
     },
     "localname": "KristaloseMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_KyowaKirinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kyowa Kirin",
        "label": "Kyowa Kirin [Member]",
        "terseLabel": "Kyowa Kirin"
       }
      }
     },
     "localname": "KyowaKirinMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_LeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Liability",
        "label": "Lease, Liability",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseLiability",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LesseeOperatingLeaseBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Base Rent",
        "label": "Lessee, Operating Lease, Base Rent",
        "terseLabel": "Lessee, Operating Lease, Base Rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBaseRent",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "perUnitItemType"
    },
    "cpix_LesseeOperatingLeaseLeasedArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Leased Area",
        "label": "Lessee, Operating Lease, Leased Area",
        "terseLabel": "Leased area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeasedArea",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "cpix_LesseeOperatingLeaseNumberOfRenewalTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Terms",
        "label": "Lessee, Operating Lease, Number Of Renewal Terms",
        "terseLabel": "Number of renewal terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalTerms",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_LesseeOperatingLeaseRentIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Rent Increase",
        "label": "Lessee, Operating Lease, Rent Increase",
        "terseLabel": "Rent increase"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRentIncrease",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_LineOfCreditFacilityAdditionalBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Additional Borrowing Capacity",
        "label": "Line Of Credit Facility, Additional Borrowing Capacity",
        "terseLabel": "Maximum increase to line of credit"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_LongTermIncentiveCompensationPlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Incentive Compensation Plan 2007 [Member]",
        "label": "Long-Term Incentive Compensation Plan 2007 [Member]",
        "terseLabel": "Long-Term Incentive Compensation Plan 2007"
       }
      }
     },
     "localname": "LongTermIncentiveCompensationPlan2007Member",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing agreements, number of primary suppliers for each product",
        "label": "Manufacturing agreements, number of primary suppliers for each product",
        "terseLabel": "Manufacturing agreements, number of primary suppliers for each product"
       }
      }
     },
     "localname": "ManufacturingAgreementsNumberOfPrimarySuppliersForEachProduct",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_ManufacturingAndSupplyAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and Supply Agreements [Abstract]",
        "label": "Manufacturing and Supply Agreements [Abstract]"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "xbrltype": "stringItemType"
    },
    "cpix_ManufacturingAndSupplyAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and Supply Agreements",
        "label": "Manufacturing and Supply Agreements [Text Block]",
        "terseLabel": "Manufacturing and Supply Agreements"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ManufacturingandSupplyAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Manufacturing and Supply Agreement [Table]",
        "label": "Manufacturing and Supply Agreement [Line Items]",
        "terseLabel": "Manufacturing and Supply Agreement [Line Items]"
       }
      }
     },
     "localname": "ManufacturingandSupplyAgreementLineItems",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ManufacturingandSupplyAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and Supply Agreement [Table]",
        "label": "Manufacturing and Supply Agreement [Table]",
        "terseLabel": "Manufacturing and Supply Agreement [Table]"
       }
      }
     },
     "localname": "ManufacturingandSupplyAgreementTable",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Melinta Therapeutics, LLC and Targanta Therapeutics Corporation",
        "label": "Melinta Therapeutics, LLC and Targanta Therapeutics Corporation [Member]",
        "terseLabel": "Melinta Therapeutics, LLC and Targanta Therapeutics Corporation"
       }
      }
     },
     "localname": "MelintaTherapeuticsLLCAndTargantaTherapeuticsCorporationMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_MethotrexateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Methotrexate [Member]",
        "label": "Methotrexate [Member]",
        "terseLabel": "Methotrexate"
       }
      }
     },
     "localname": "MethotrexateMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NetDeferredTaxAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Deferred Tax Assets, Gross",
        "label": "Net Deferred Tax Assets, Gross",
        "totalLabel": "Net deferred tax assets, before valuation allowance"
       }
      }
     },
     "localname": "NetDeferredTaxAssetsGross",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_NinthAmemdmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ninth Amemdment",
        "label": "Ninth Amemdment [Member]",
        "terseLabel": "Ninth Amemdment"
       }
      }
     },
     "localname": "NinthAmemdmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NoncashOrPartNoncashGainOnTransaction": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or Part Noncash, Gain on Transaction",
        "label": "Noncash or Part Noncash, Gain on Transaction",
        "negatedTerseLabel": "Noncash gain on RediTrex transaction"
       }
      }
     },
     "localname": "NoncashOrPartNoncashGainOnTransaction",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_NonemployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonemployee [Member]",
        "label": "Nonemployee [Member]",
        "terseLabel": "Nonemployee"
       }
      }
     },
     "localname": "NonemployeeMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NonprincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NonPrincipal Owner [Member]",
        "label": "NonPrincipal Owner [Member]",
        "terseLabel": "NonPrincipal Owner"
       }
      }
     },
     "localname": "NonprincipalOwnerMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NordicGroupBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nordic Group B.V.",
        "label": "Nordic Group B.V. [Member]",
        "terseLabel": "Nordic Group B.V."
       }
      }
     },
     "localname": "NordicGroupBVMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Numerator.",
        "label": "Numerator [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_OmeclamoxPakMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omeclamox-Pak [Member]",
        "label": "Omeclamox-Pak [Member]",
        "terseLabel": "Omeclamox-Pak",
        "verboseLabel": "Omeclamox-Pak"
       }
      }
     },
     "localname": "OmeclamoxPakMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_OtherRevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Abstract]",
        "label": "Other Revenues [Abstract]",
        "terseLabel": "Other Revenues"
       }
      }
     },
     "localname": "OtherRevenuesAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_PaymentProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Protection Program",
        "label": "Payment Protection Program [Member]",
        "terseLabel": "Payment Protection Program"
       }
      }
     },
     "localname": "PaymentProtectionProgramMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PinnacleBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Bank [Member]",
        "label": "Pinnacle Bank [Member]",
        "terseLabel": "Pinnacle Bank"
       }
      }
     },
     "localname": "PinnacleBankMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock [Abstract]",
        "label": "Preferred Stock [Abstract]",
        "terseLabel": "Preferred Stock [Abstract]"
       }
      }
     },
     "localname": "PreferredStockAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaids and Other Current Assets, Policy [Policy Text Block]",
        "label": "Prepaids and Other Current Assets, Policy [Policy Text Block]",
        "terseLabel": "Prepaid and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidsAndOtherCurrentAssetsPolicyPolicyTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ProceedsFromCollaborationArrangement": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Collaboration Arrangement",
        "label": "Proceeds from Collaboration Arrangement",
        "terseLabel": "Return of RediTrex"
       }
      }
     },
     "localname": "ProceedsFromCollaborationArrangement",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProceedsFromSettlementOfPatentLitigation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Settlement of Patent Litigation",
        "label": "Proceeds from Settlement of Patent Litigation",
        "terseLabel": "Settlement of patent litigation"
       }
      }
     },
     "localname": "ProceedsFromSettlementOfPatentLitigation",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProceedsFromSurrenderOfLifeInsurancePolicy": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Surrender of Life Insurance Policy",
        "label": "Proceeds from Surrender of Life Insurance Policy",
        "terseLabel": "Proceeds from surrender of life insurance policies"
       }
      }
     },
     "localname": "ProceedsFromSurrenderOfLifeInsurancePolicy",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProductAndLicenseRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product and License Rights [Member]",
        "label": "Product and License Rights [Member]",
        "terseLabel": "Product and License Rights"
       }
      }
     },
     "localname": "ProductAndLicenseRightsMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductRevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Revenues [Abstract]",
        "label": "Product Revenues [Abstract]",
        "terseLabel": "Product Revenues"
       }
      }
     },
     "localname": "ProductRevenuesAbstract",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_ProductRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Rights [Member]",
        "label": "Product Rights [Member]",
        "verboseLabel": "Product Rights"
       }
      }
     },
     "localname": "ProductRightsMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ProductSalesRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Sales-Related Liabilities, Current",
        "label": "Product Sales-Related Liabilities, Current",
        "terseLabel": "Rebates, product returns, administrative fees and service fees"
       }
      }
     },
     "localname": "ProductSalesRelatedLiabilitiesCurrent",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ProductVibativMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Vibativ",
        "label": "Product, Vibativ [Member]",
        "terseLabel": "Caldolor"
       }
      }
     },
     "localname": "ProductVibativMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_PurchasesOfIntangibleAssetsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of Intangible Assets Incurred But Not Yet Paid",
        "label": "Purchases of Intangible Assets Incurred But Not Yet Paid",
        "terseLabel": "Change in unpaid invoices for purchases of intangibles"
       }
      }
     },
     "localname": "PurchasesOfIntangibleAssetsIncurredButNotYetPaid",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RediTrexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RediTrex",
        "label": "RediTrex [Member]",
        "terseLabel": "RediTrex"
       }
      }
     },
     "localname": "RediTrexMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_RestrictedIncentiveStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Incentive Stock Options",
        "label": "Restricted Incentive Stock Options [Member]",
        "terseLabel": "Restricted Incentive Stock Options"
       }
      }
     },
     "localname": "RestrictedIncentiveStockOptionsMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_RevenueRecognitionCumulativeUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Cumulative Upfront Payment",
        "label": "Revenue Recognition, Cumulative Upfront Payment",
        "terseLabel": "Cumulative upfront payment"
       }
      }
     },
     "localname": "RevenueRecognitionCumulativeUpfrontPayment",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Payments",
        "label": "Revenue Recognition, Milestone Payments",
        "terseLabel": "Milestone payments associated with international agreements"
       }
      }
     },
     "localname": "RevenueRecognitionMilestonePayments",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Potential Upfront Payment Related to Product Sales",
        "label": "Revenue Recognition, Potential Upfront Payment Related to Product Sales",
        "terseLabel": "Other revenue, potential upfront payment related to product sales"
       }
      }
     },
     "localname": "RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval",
        "label": "Revenue Recognition, Potential Upfront Payments Related to Regulatory Approval",
        "terseLabel": "Other revenue, potential upfront payments related to regulatory approval"
       }
      }
     },
     "localname": "RevenueRecognitionPotentialUpfrontPaymentsRelatedtoRegulatoryApproval",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_RevenueRecognitionUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Upfront Payment",
        "label": "Revenue Recognition, Upfront Payment",
        "terseLabel": "Other revenue, upfront payment"
       }
      }
     },
     "localname": "RevenueRecognitionUpfrontPayment",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SalesRevenueGoodsGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Revenue, Goods, Gross [Member] [Member]",
        "label": "Sales Revenue, Goods, Gross [Member]",
        "terseLabel": "Sales Revenue, Goods, Gross"
       }
      }
     },
     "localname": "SalesRevenueGoodsGrossMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_SancusoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sancuso",
        "label": "Sancuso [Member]",
        "terseLabel": "Sancuso"
       }
      }
     },
     "localname": "SancusoMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ScheduleOfAdvertisingCostsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Advertising Costs",
        "label": "Schedule of Advertising Costs [Table Text Block]",
        "terseLabel": "Schedule of Advertising Costs"
       }
      }
     },
     "localname": "ScheduleOfAdvertisingCostsTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ScheduleOfDistributionCostsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Distribution Costs",
        "label": "Schedule of Distribution Costs [Table Text Block]",
        "terseLabel": "Schedule of Distribution Costs"
       }
      }
     },
     "localname": "ScheduleOfDistributionCostsTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]",
        "label": "Schedule of Finite-Lived Intangible Assets UseFul Lives [Table Text Block]",
        "terseLabel": "Schedule of intangible assets, useful lives"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsUsefulLivesTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ScheduleofDepreciationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Depreciation Expense [Table Text Block]",
        "label": "Schedule of Depreciation Expense [Table Text Block]",
        "terseLabel": "Schedule of depreciation expense"
       }
      }
     },
     "localname": "ScheduleofDepreciationExpenseTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_ScheduleofRentExpenseandSubleaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "label": "Schedule of Rent Expense and Sublease Income [Table Text Block]",
        "terseLabel": "Schedule of rent expense and sublease income"
       }
      }
     },
     "localname": "ScheduleofRentExpenseandSubleaseIncomeTableTextBlock",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cpix_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Amendment",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Plans Available for Future Grants",
        "terseLabel": "Number of equity compensation plans available for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlansAvailableForFutureGrants",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Price as Percent of Weighted Average Grant Date Fair Value",
        "terseLabel": "Stock options, exercise price as percent of weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePriceAsPercentOfWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shareholder, Percent",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shareholder, Percent",
        "terseLabel": "Shareholder, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardShareholderPercent",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_ShareBasedCompensationCharitableContributionOfSharesCashContributions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Charitable Contribution of Shares, Cash Contributions",
        "label": "Share-based Compensation, Charitable Contribution of Shares, Cash Contributions",
        "terseLabel": "Cash contributions"
       }
      }
     },
     "localname": "ShareBasedCompensationCharitableContributionOfSharesCashContributions",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions",
        "label": "Share-based Compensation, Charitable Contribution of Shares, Committed Cash Contributions",
        "terseLabel": "Committed cash contributions"
       }
      }
     },
     "localname": "ShareBasedCompensationCharitableContributionOfSharesCommittedCashContributions",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_ShareRepurchaseProgramAuthorizedIn2010Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Repurchase Program Authorized in 2010 [Member]",
        "label": "Share Repurchase Program Authorized in 2010 [Member]",
        "terseLabel": "Share Repurchase Program Authorized in 2010"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAuthorizedIn2010Member",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_SharebasedCompensationCharitableContributionofSharesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Charitable Contribution of Shares, Shares",
        "label": "Share-based Compensation, Charitable Contribution of Shares, Shares",
        "terseLabel": "Charitable contribution of shares (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationCharitableContributionofSharesShares",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cpix_SharesRepurchaseActivityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Repurchase Activity, Type [Axis]",
        "label": "Shares Repurchase Activity, Type [Axis]",
        "terseLabel": "Shares Repurchase Activity, Type [Axis]"
       }
      }
     },
     "localname": "SharesRepurchaseActivityTypeAxis",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cpix_SharesRepurchaseActivityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Shares Repurchase Activity, Type [Axis]",
        "label": "Shares Repurchase Activity, Type [Domain]",
        "terseLabel": "Shares Repurchase Activity, Type [Domain]"
       }
      }
     },
     "localname": "SharesRepurchaseActivityTypeDomain",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]",
        "label": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options [Member]",
        "terseLabel": "Shares Repurchase, All, Except Settlement of Tax Liabilities Related to Exercise of Stock Options"
       }
      }
     },
     "localname": "SharesRepurchaseAllExceptSettlementOfTaxLiabilitiesRelatedToExerciseOfStockOptionsMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Gross Proceeds from Initial Public Offering",
        "label": "Stock Issued During Period, Gross Proceeds from Initial Public Offering",
        "terseLabel": "Initial public offering, gross proceeds"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodGrossProceedsFromInitialPublicOffering",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_StockIssuedDuringPeriodNewSharesUnderwritingDiscounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, New Shares, Underwriting Discounts",
        "label": "Stock Issued During Period, New Shares, Underwriting Discounts",
        "terseLabel": "Initial public offering, underwriting discounts"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodNewSharesUnderwritingDiscounts",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_StockIssuedDuringPeriodPricePerShareNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Price Per Share, New Issues",
        "label": "Stock Issued During Period, Price Per Share, New Issues",
        "terseLabel": "Initial public offering, price per share"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodPricePerShareNewIssues",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cpix_StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities",
        "label": "Stock Issued During Period, Shelf Registration, Proceeds From Sale of Corporate Securities",
        "terseLabel": "Shelf Registration, sale of corporate securities (up to)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShelfRegistrationProceedsFromSaleofCorporateSecurities",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPaymentsForReturnOfCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Investment, Payments For Return Of Capital",
        "label": "Subsidiary Investment, Payments For Return Of Capital",
        "terseLabel": "Exchange for consideration, amount"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPaymentsForReturnOfCapital",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_SubsidiaryInvestmentPurchaseOfShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Investment, Purchase Of Shares",
        "label": "Subsidiary Investment, Purchase Of Shares",
        "terseLabel": "Investment in CET"
       }
      }
     },
     "localname": "SubsidiaryInvestmentPurchaseOfShares",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "label": "The Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "TheCoronavirusAidReliefAndEconomicSecurityActLoanProceedsReceived",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_TieredRoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Percentage",
        "label": "Tiered Royalty Payments, Percentage",
        "terseLabel": "Tiered royalty payments (percentage)"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsPercentage",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cpix_TieredRoyaltyPaymentsThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tiered Royalty Payments, Threshold",
        "label": "Tiered Royalty Payments, Threshold",
        "terseLabel": "Tiered royalty payments, threshold"
       }
      }
     },
     "localname": "TieredRoyaltyPaymentsThreshold",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cpix_VIBATIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIBATIV",
        "label": "VIBATIV [Member]",
        "terseLabel": "VIBATIV"
       }
      }
     },
     "localname": "VIBATIVMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_VaprisolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaprisol [Member]",
        "label": "Vaprisol [Member]",
        "verboseLabel": "Vaprisol"
       }
      }
     },
     "localname": "VaprisolMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WinHealthInvestmentSingaporeLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WinHealth Investment (Singapore) Ltd",
        "label": "WinHealth Investment (Singapore) Ltd [Member]",
        "terseLabel": "WinHealth Investment (Singapore) Ltd [Domain]"
       }
      }
     },
     "localname": "WinHealthInvestmentSingaporeLtdMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_Within30DaysOfFirstSNDAFilingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Within 30 Days Of First sNDA Filing",
        "label": "Within 30 Days Of First sNDA Filing [Member]",
        "terseLabel": "Within 30 Days Of First sNDA Filing"
       }
      }
     },
     "localname": "Within30DaysOfFirstSNDAFilingMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cpix_WorkInProcessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Work in Process",
        "label": "Work in Process [Member]",
        "terseLabel": "Work in Process"
       }
      }
     },
     "localname": "WorkInProcessMember",
     "nsuri": "http://www.cumberlandpharma.com/20221231",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r623",
      "r624",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r238",
      "r239",
      "r349",
      "r374",
      "r579",
      "r584",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of directors.",
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r309",
      "r603",
      "r665",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r415",
      "r529",
      "r543",
      "r565",
      "r566",
      "r600",
      "r607",
      "r618",
      "r664",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r415",
      "r529",
      "r543",
      "r565",
      "r566",
      "r600",
      "r607",
      "r618",
      "r664",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r309",
      "r603",
      "r665",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficeBuildingMember": {
     "auth_ref": [
      "r725",
      "r726",
      "r727",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Building designed primarily for the conduct of business, for example, but not limited to, administration, clerical services, and consultation.",
        "label": "Office Building [Member]",
        "terseLabel": "Office Building"
       }
      }
     },
     "localname": "OfficeBuildingMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r306",
      "r534",
      "r601",
      "r616",
      "r658",
      "r659",
      "r665",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r306",
      "r534",
      "r601",
      "r616",
      "r658",
      "r659",
      "r665",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r403",
      "r415",
      "r445",
      "r446",
      "r447",
      "r528",
      "r529",
      "r543",
      "r565",
      "r566",
      "r600",
      "r607",
      "r618",
      "r657",
      "r664",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r403",
      "r415",
      "r445",
      "r446",
      "r447",
      "r528",
      "r529",
      "r543",
      "r565",
      "r566",
      "r600",
      "r607",
      "r618",
      "r657",
      "r664",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails",
      "http://www.cumberlandpharma.com/role/ManufacturingandSupplyAgreementsManufacturingandSupplyAgreementsNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r238",
      "r239",
      "r349",
      "r374",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r248",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "terseLabel": "Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r307",
      "r308",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r602",
      "r617",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r307",
      "r308",
      "r550",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r568",
      "r569",
      "r602",
      "r617",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r653",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r246",
      "r247",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.",
        "label": "Accounts Payable and Accrued Liabilities, Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24",
      "r615"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net of allowances"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r94",
      "r206"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising costs"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofAdvertisingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r642",
      "r643",
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "terseLabel": "Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r214",
      "r314",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowances, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r40",
      "r368",
      "r515",
      "r637"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Noncash interest expense"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r60",
      "r86",
      "r90"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Anti-dilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofAntidilutiveSecuritiesExcludedFromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of real estate property"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r170",
      "r182",
      "r210",
      "r235",
      "r291",
      "r300",
      "r304",
      "r316",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r497",
      "r501",
      "r507",
      "r615",
      "r662",
      "r663",
      "r711"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r201",
      "r217",
      "r235",
      "r316",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r497",
      "r501",
      "r507",
      "r615",
      "r662",
      "r663",
      "r711"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r489",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r135",
      "r136",
      "r489",
      "r605",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Business Acquisition, Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill amount to be deducted for tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r487",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoProFormaResultsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r487",
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Net Revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoProFormaResultsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r142",
      "r144",
      "r145",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Liabilities incurred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": {
     "auth_ref": [
      "r494",
      "r636"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset",
        "negatedLabel": "Decrease in non-cash contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r494",
      "r636"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r143",
      "r146",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Liability to be paid"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r143",
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current portion of accrued contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r143",
      "r147"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current portion of accrued contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "RediTrex\u00ae, Vibativ\u00ae and Sancuso\u00ae"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancuso"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Operating profit of acquiree"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue contributed"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expense and other assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets, other than goodwill"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Finite-ived intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r137",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r62",
      "r204",
      "r580"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r56",
      "r62",
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r56",
      "r166"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r6",
      "r56"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r235",
      "r264",
      "r265",
      "r267",
      "r269",
      "r279",
      "r280",
      "r316",
      "r337",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r372",
      "r373",
      "r376",
      "r380",
      "r387",
      "r507",
      "r567",
      "r629",
      "r638",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r33",
      "r175",
      "r187"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r331",
      "r332",
      "r552",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r647",
      "r648",
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "verboseLabel": "Common stock, no par value (dollars per share)"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, number of shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, number of shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Equity, common shares outstanding",
        "periodStartLabel": "Equity, common shares outstanding",
        "verboseLabel": "Common stock, number of shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "verboseLabel": "Common stock \u2013 no par value; 100,000,000 shares authorized; 14,366,316 and 14,742,754 shares issued and outstanding as of December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r75",
      "r76",
      "r163",
      "r164",
      "r309",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r75",
      "r76",
      "r163",
      "r164",
      "r309",
      "r549",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r75",
      "r76",
      "r163",
      "r164",
      "r309",
      "r551",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "Concentration Risk Disclosure [Text Block]",
        "terseLabel": "Market Concentrations"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r75",
      "r76",
      "r163",
      "r164",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r73",
      "r75",
      "r76",
      "r77",
      "r163",
      "r165",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r75",
      "r76",
      "r163",
      "r164",
      "r309",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of beneficial interest received as consideration for transferring noncash financial asset. Includes, but is not limited to, trade receivable in securitization transaction.",
        "label": "Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset",
        "terseLabel": "Financial consideration"
       }
      }
     },
     "localname": "ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r389",
      "r390",
      "r401"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current deferred charges"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r42",
      "r534"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Products Sold"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r641",
      "r697",
      "r699"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "negatedTerseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r471",
      "r479",
      "r641"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total current income tax (expense) benefit"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r641",
      "r697",
      "r699"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "negatedTerseLabel": "State and other"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r74",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsScheduleofRevenuesConcentrationfromMajorCustomersandNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r102",
      "r233",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r362",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r171",
      "r172",
      "r181",
      "r240",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r516",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r30",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r31",
      "r240",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r352",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r516",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "negatedTerseLabel": "Change in unpaid invoices for offering costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "terseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation liability"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationPlanAssets": {
     "auth_ref": [
      "r630"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.",
        "label": "Deferred Compensation Plan Assets",
        "terseLabel": "Deferred compensation assets"
       }
      }
     },
     "localname": "DeferredCompensationPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r641",
      "r698",
      "r699"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r60",
      "r133",
      "r472",
      "r478",
      "r479",
      "r641"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredOtherTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r132",
      "r641"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.",
        "label": "Deferred Other Tax Expense (Benefit)",
        "negatedTotalLabel": "Deferred income tax (expense) benefit"
       }
      }
     },
     "localname": "DeferredOtherTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r641",
      "r698",
      "r699"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredOtherTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedTerseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r129",
      "r696"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research cost"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r129",
      "r696"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r695"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r129",
      "r696"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Cumulative compensation costs incurred on deductible equity awards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r129",
      "r696"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for accounts receivable"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r468"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Less: deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r129",
      "r696"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails": {
       "order": 2.0,
       "parentTag": "cpix_NetDeferredTaxAssetsGross",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r60",
      "r289"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r419",
      "r449",
      "r450",
      "r452",
      "r457",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "auth_ref": [
      "r5",
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r9",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per share attributable to common shareholders",
        "verboseLabel": "Earnings (loss) per share attributable to common shareholders:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r226",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r262",
      "r264",
      "r267",
      "r268",
      "r269",
      "r273",
      "r505",
      "r506",
      "r538",
      "r541",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r226",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r264",
      "r267",
      "r268",
      "r269",
      "r273",
      "r505",
      "r506",
      "r538",
      "r541",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r270",
      "r271",
      "r272",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (loss) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r463"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Net income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r236",
      "r463",
      "r480"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax expense at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r694",
      "r700"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r694",
      "r700"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r694",
      "r700"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r694",
      "r700"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income tax expense (net of federal income tax benefit)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r694",
      "r700"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedTerseLabel": "Permanent differences associated with general business credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee wages and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to share-based payments"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation cost related to share-based payments, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r106",
      "r198",
      "r221",
      "r222",
      "r223",
      "r249",
      "r250",
      "r251",
      "r253",
      "r259",
      "r261",
      "r278",
      "r317",
      "r388",
      "r453",
      "r454",
      "r455",
      "r474",
      "r475",
      "r504",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r527",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r208",
      "r328"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedTerseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r89",
      "r536"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r89",
      "r535"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillFutureAmortizationExpenseDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyUnrecordedAmount": {
     "auth_ref": [
      "r660"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.",
        "label": "Gain Contingency, Unrecorded Amount",
        "terseLabel": "Gain contingency, unrecorded amount"
       }
      }
     },
     "localname": "GainContingencyUnrecordedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r207",
      "r322",
      "r537",
      "r594",
      "r615",
      "r655",
      "r656"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r60",
      "r323",
      "r324",
      "r325",
      "r594"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r37",
      "r169",
      "r177",
      "r192",
      "r291",
      "r299",
      "r303",
      "r305",
      "r539",
      "r593"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net income (loss) from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r152",
      "r235",
      "r252",
      "r291",
      "r299",
      "r303",
      "r305",
      "r316",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r506",
      "r507",
      "r593",
      "r662"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss) from continuing operations",
        "totalLabel": "Net income (loss) from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r36",
      "r176",
      "r178",
      "r188",
      "r226",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r264",
      "r267",
      "r268",
      "r506",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "-Continuing operations-basic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r36",
      "r188",
      "r191",
      "r226",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r264",
      "r267",
      "r268",
      "r269",
      "r506",
      "r538",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "-Continuing operations-diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r7",
      "r189",
      "r200",
      "r483"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r38",
      "r189",
      "r191",
      "r226",
      "r265",
      "r267",
      "r268",
      "r720",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "-Discontinued operations-basic"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r159",
      "r265",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "-Discontinued operations-diluted"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r236",
      "r464",
      "r465",
      "r470",
      "r476",
      "r481",
      "r484",
      "r485",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r237",
      "r260",
      "r261",
      "r290",
      "r462",
      "r477",
      "r482",
      "r542"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit",
        "negatedTotalLabel": "Total income tax (expense) benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftheComponentsofIncomeTaxBenefitExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r220",
      "r460",
      "r461",
      "r465",
      "r466",
      "r469",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Net changes in assets and liabilities affecting operating activities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Prepaid, other current assets and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuredEventGainLoss": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess (deficiency) of insurance recovery over the loss incurred from an insured event.",
        "label": "Insured Event, Gain (Loss)",
        "terseLabel": "Other income - gain on insurance proceeds"
       }
      }
     },
     "localname": "InsuredEventGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r88",
      "r531",
      "r532",
      "r533",
      "r535",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r167",
      "r180",
      "r224",
      "r288",
      "r514"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r227",
      "r230",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateFloorMember": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts in which the floor writer, in return for a premium, agrees to limit the risk associated with a decline in interest rates based on a notional amount. If rates fall below an agreed rate, the floor holder will receive cash payments from the floor writer equal to the difference between the market rate and an agreed rate multiplied by the notional principal amount.",
        "label": "Interest Rate Floor [Member]",
        "terseLabel": "Interest Rate Floor"
       }
      }
     },
     "localname": "InterestRateFloorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r85",
      "r582"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods, net of reserve"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r633"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r216",
      "r581",
      "r615"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Total inventories",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r630"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "negatedLabel": "less non-current inventories",
        "terseLabel": "Noncurrent inventories"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r203",
      "r215",
      "r275",
      "r319",
      "r320",
      "r321",
      "r530",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r85",
      "r583"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r84",
      "r633"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Inventory reserves, obsolescence and discontinuance"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r44",
      "r287"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Initial investment amount"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of operating lease liability maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "After 2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r524"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Future minimum sublease income under noncancelable operating subleases"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r235",
      "r316",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r498",
      "r501",
      "r502",
      "r507",
      "r592",
      "r662",
      "r711",
      "r712"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r174",
      "r185",
      "r615",
      "r640",
      "r654",
      "r705"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r202",
      "r235",
      "r316",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r498",
      "r501",
      "r502",
      "r507",
      "r615",
      "r662",
      "r711",
      "r712"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Rights"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r25",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Line of credit, current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r25",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r25",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Line of credit, unused capacity, commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans Payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r31",
      "r99",
      "r100"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit, Noncurrent",
        "verboseLabel": "Revolving line of credit"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r31",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManufacturedProductOtherMember": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by labor or machinery, classified as other.",
        "label": "Manufactured Product, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ManufacturedProductOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r35",
      "r173",
      "r184",
      "r235",
      "r316",
      "r337",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r507"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r56",
      "r58",
      "r61"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r56",
      "r58",
      "r61"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities from continuing operations"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r39",
      "r61",
      "r179",
      "r190",
      "r200",
      "r218",
      "r219",
      "r223",
      "r235",
      "r252",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r261",
      "r266",
      "r291",
      "r299",
      "r303",
      "r305",
      "r316",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r506",
      "r507",
      "r593",
      "r662"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income (loss) attributable to common shareholders",
        "verboseLabel": "Net income (loss) attributable to common shareholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r155",
      "r158",
      "r218",
      "r219",
      "r260",
      "r261",
      "r635"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss at subsidiary attributable to noncontrolling interests",
        "negatedTerseLabel": "Net loss at subsidiary allocated to noncontrolling interests",
        "terseLabel": "Net loss at subsidiary attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails",
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Guidance"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest": {
     "auth_ref": [
      "r114",
      "r153",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from sale of a portion of the parent's controlling interest.",
        "label": "Noncontrolling Interest, Increase from Sale of Parent Equity Interest",
        "terseLabel": "Exercise of options and related tax benefit"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OrganizationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r150",
      "r388",
      "r647",
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r291",
      "r299",
      "r303",
      "r305",
      "r593"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r706"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Lease Liabilities, Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofLeaseLiabilityMaturitiesandFutureMinimumPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails": {
       "order": 1.0,
       "parentTag": "cpix_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease current liabilities",
        "verboseLabel": "Operating lease current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails": {
       "order": 2.0,
       "parentTag": "cpix_LeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease non-current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r517"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/LeasesLeasePositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r523",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r522",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r10",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r209"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r193"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of inventory owned by the entity but in the hands of a customer, typically a reseller.",
        "label": "Other Inventory, Materials, Supplies and Merchandise under Consignment, Gross",
        "terseLabel": "Consigned inventory"
       }
      }
     },
     "localname": "OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r615"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Current [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Current and Other Long-term Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "totalLabel": "Total other long-term liabilities",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesScheduleofNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of other long-term liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingGainsLosses": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Gains (Losses)",
        "negatedTerseLabel": "Noncash investment gains"
       }
      }
     },
     "localname": "OtherNonoperatingGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments to Acquire Businesses",
        "verboseLabel": "Additional payments to acquire businesses"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Cash settlement of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "negatedTerseLabel": "Cash payment of royalty during the period"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Initial public offering, issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r48",
      "r491"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedLabel": "Cash paid for acquisition",
        "verboseLabel": "Payments to acquire businesses"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Additions to intangible assets",
        "terseLabel": "Additions to intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Payments to Acquire Notes Receivable",
        "negatedTerseLabel": "Note receivable investment funding"
       }
      }
     },
     "localname": "PaymentsToAcquireNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r416",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrincipalOwnerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity.",
        "label": "Principal Owner [Member]",
        "terseLabel": "Principal Owner"
       }
      }
     },
     "localname": "PrincipalOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Initial public offering, net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLifeInsurancePolicies": {
     "auth_ref": [
      "r46",
      "r55"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy.",
        "label": "Proceeds from Life Insurance Policy",
        "terseLabel": "Life insurance policy proceeds received"
       }
      }
     },
     "localname": "ProceedsFromLifeInsurancePolicies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).",
        "label": "Proceeds from (Repayments of) Lines of Credit",
        "verboseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductionAndDistributionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to the production and distribution of goods or services to customers and clients.",
        "label": "Production and Distribution Costs",
        "terseLabel": "Distribution costs"
       }
      }
     },
     "localname": "ProductionAndDistributionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofDistributionCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r200",
      "r218",
      "r219",
      "r228",
      "r235",
      "r252",
      "r260",
      "r261",
      "r291",
      "r299",
      "r303",
      "r305",
      "r316",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r496",
      "r499",
      "r500",
      "r506",
      "r507",
      "r539",
      "r593",
      "r611",
      "r612",
      "r635",
      "r662"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r553",
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r93",
      "r205"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r95",
      "r186",
      "r540",
      "r615"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r72",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Information (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related party expense"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedTerseLabel": "Repayments on line of credit"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r123",
      "r194",
      "r719"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r113",
      "r183",
      "r547",
      "r548",
      "r615"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r198",
      "r249",
      "r250",
      "r251",
      "r253",
      "r259",
      "r261",
      "r317",
      "r453",
      "r454",
      "r455",
      "r474",
      "r475",
      "r504",
      "r544",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r285",
      "r286",
      "r298",
      "r301",
      "r302",
      "r306",
      "r307",
      "r309",
      "r399",
      "r400",
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r402",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r225",
      "r235",
      "r285",
      "r286",
      "r298",
      "r301",
      "r302",
      "r306",
      "r307",
      "r309",
      "r316",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r507",
      "r539",
      "r662"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net revenues from customers outside the United States",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationScheduleofQuarterlyFinancialInformationUnauditedDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r521",
      "r614"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Recognition of operating lease assets and liabilities through adoption of ASC 842"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockTransactionDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.",
        "label": "Sale of Stock, Transaction Date",
        "terseLabel": "Initial public offering, effective date"
       }
      }
     },
     "localname": "SaleOfStockTransactionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/OtherCurrentandOtherLongtermLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r135",
      "r136",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoScheduleofContingentConsiderationandPreliminaryAllocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of the components of income tax benefit (expense)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities, net"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of numerator and denominator in earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]",
        "verboseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesScheduleofNetProductRevenuesbyProductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of net product revenues by product"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails",
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesScheduleofIntangibleAssetsUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r21",
      "r22",
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories, current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of quarterly financial information"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/QuarterlyFinancialInformationUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r417",
      "r418",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted stock activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r113",
      "r211",
      "r212",
      "r213",
      "r279",
      "r372",
      "r373",
      "r374",
      "r376",
      "r380",
      "r385",
      "r387",
      "r600",
      "r629",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of expected amortization expense of intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r73",
      "r75",
      "r76",
      "r77",
      "r163",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of revenues concentration from major customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/MarketConcentrationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "verboseLabel": "Selling and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Shares forfeited, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares forfeited, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares granted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares granted, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested, end of period, shares",
        "periodStartLabel": "Nonvested, beginning of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, end of period, weighted-average grant-date fair value",
        "periodStartLabel": "Nonvested, beginning of period, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Shares vested, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Shares vested, weighted-average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Weighted average volatility rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares reserved for issuance under equity compensation plans"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options shares forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted, shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period, weighted-average exercise price per share (in USD per share)",
        "periodStartLabel": "Outstanding, beginning of period, weighted-average exercise price per share (in USD per share)",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options shares forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted, weighted-average exercise price per share (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r423",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock options, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, end of period, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Options shares vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options shares vested (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofRestrictedIncentiveStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r69",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleofNetOperatingLossCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r235",
      "r264",
      "r265",
      "r267",
      "r269",
      "r279",
      "r280",
      "r316",
      "r337",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r372",
      "r373",
      "r376",
      "r380",
      "r387",
      "r507",
      "r567",
      "r629",
      "r638",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r106",
      "r198",
      "r221",
      "r222",
      "r223",
      "r249",
      "r250",
      "r251",
      "r253",
      "r259",
      "r261",
      "r278",
      "r317",
      "r388",
      "r453",
      "r454",
      "r455",
      "r474",
      "r475",
      "r504",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r527",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r278",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r15",
      "r16",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Stock issued during period, acquisitions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r106",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Initial public offering, shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r106",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityInitialPublicOfferingPreferredStockandCommonStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r34",
      "r106",
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Stock issued during period, acquisitions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r113",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation, amount",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/StockBasedCompensationPlansScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodShares": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Stock Redeemed or Called During Period, Shares",
        "negatedTerseLabel": "Return of common stock (in shares)"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Stock Redeemed or Called During Period, Value",
        "negatedTerseLabel": "Return of common stock - Methotrexate",
        "terseLabel": "Return of common stock - Methotrexate"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program, number of shares authorized to be repurchased"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount available under current repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r15",
      "r16",
      "r106",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchase of common shares, shares",
        "terseLabel": "Repurchase of common shares, shares"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r15",
      "r16",
      "r106",
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Repurchase of common shares",
        "terseLabel": "Repurchase of common shares, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity",
      "http://www.cumberlandpharma.com/role/ShareholdersEquityShareRepurchasesCumberlandEmergingTechnologiesandCumberlandFoundationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r83",
      "r615",
      "r640",
      "r654",
      "r705"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r150",
      "r151",
      "r157",
      "r198",
      "r199",
      "r222",
      "r249",
      "r250",
      "r251",
      "r253",
      "r259",
      "r317",
      "r388",
      "r453",
      "r454",
      "r455",
      "r474",
      "r475",
      "r504",
      "r508",
      "r509",
      "r513",
      "r527",
      "r545",
      "r546",
      "r640",
      "r654",
      "r705"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, balance",
        "periodStartLabel": "Equity, balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets",
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r119",
      "r234",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r386",
      "r388",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r520",
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/LeasesScheduleofRentExpenseandSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of federal and state net operating loss carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfTaxCreditCarryforwardsTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Summary of Tax Credit Carryforwards [Table Text Block]",
        "terseLabel": "Summary of tax credit carryforwards"
       }
      }
     },
     "localname": "SummaryOfTaxCreditCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IncomeTaxesScheduleoftaxcreditcarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Text Block [Abstract]"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r312",
      "r313",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "verboseLabel": "Collaborative Arrangements and Non-collaborative Arrangements [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/CommitmentsandContingenciesDetails",
      "http://www.cumberlandpharma.com/role/RediTrexVibativandSancusoNarrativeDetails",
      "http://www.cumberlandpharma.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Gain on forgiveness of debt"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r281",
      "r282",
      "r283",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r642",
      "r643",
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "Valuation allowance for deferred tax assets:"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r241",
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "terseLabel": "Charged to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "terseLabel": "Charged to other accounts"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ValuationandQualifyingAccountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/DebtLineofCreditDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r263",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r262",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cumberlandpharma.com/role/ConsolidatedStatementsofOperations",
      "http://www.cumberlandpharma.com/role/EarningsLossPerShareScheduleofComputationofNumeratorandDenominatorinEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7,9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080552-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r621": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r622": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r623": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r624": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r625": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r626": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r627": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r628": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "https://asc.fasb.org/topic&trid=2126967",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001628280-23-007727-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-007727-xbrl.zip
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M AKI"3P+W?@>]MB60\O!61G>X.H_>/4WV:C^?H[]+!BJ1HU#"A!%55?(C*B
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M/RQFH*R+^'SP%@<*0$9XET6-W!QGS= ]GU(6#L,FHV987>-Z2O L>#K+-G<
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M=F#8R8@6 KV!P>$)K#]P!EC!N$7H";0+*X!:E>+S-_-H9[F!94]A'L1!/)G
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M3">8O\80\2@XKDEFG I]!O16&[%F%#-8L9J:#]+#H SJ[KH%>G>N#_1&.3F
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MMK>J :@X1^P*Z.) !0KQVE1S74V 14L$Y#0/N$F-P4*/>Z($^XE?ZW)%W[*
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MS4Z5A:_&P63V"H..-4;6+&1! ,(#,!Y#NZXQB34O\>T71P WFQBY_<F/;VW
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MUO_--9XW5^Y\RW])[<8/!3+I?BG1=6\S3/C:3P<6U&J/1[R%"@V 7W.SKO+
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MJ:2Z.P/U;ZND["D-JS9)?4E+R)*K0%TR%$+M"Y*+C;1T81J%U-1(I1?QW+X
ME4DBC.'\GAC@2\@8L)T)L,\J>0%P!LK52.GP+R;(U1[D?^0"S+?[+4\#=$*_
M?"J8OEL<[\>0<D$** !96)-B=1L(#E H8_&B<)EQ>H7!M4C!;'BUR:,],()5
M^W* E35&<2)P"Y-1!ATU7Q#9G6 L4T[H HB"S+!>1'@-X5WG"> !9LDZ4P:0
MI2TKU=ACCMX[6-'T(4B'"FBA#LO,+9,!4.QY7HFH>A'C1#J5\91CH$OII#R6
M5"7Y\22+Y9Q#ZRR2!>/1-;P"OKY+%K"80&,KG'(&?0 35PV8R)AFFO>J'X=
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MXHI\K[CI,.4;=\:7?&L/39QE%^H#Z>9FL\MGKIF7?XM+[_;Z_?%?4$L#!!0
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MEC=9OO'.OSJ67R"*;R&#?P%02P,$%     @ 1(AM5F/KX5$0 P  Z0@  !X
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MN<2WW.T&8V^L ="S?V_1X'G#HF,+)5;6*U*:2H)($%-TX1,8-[0/\#FH?%&
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M6O,G,08[Q[XQ,HX(7@-<Q1H83G[:DC<Y46F-A9?HI&(% -? AT).?#C'J]I
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M'MR @?#!G0?[[RR>]A)[5[F5>I!",!"&&!1-#M08APXUB>'I733!NQV19Q:
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MD[H*VH6X U;O;E_3W!=('H@29[N:P.76H6C \K4I)6P]'G\ A&>:11"WAT&
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M71TQ+%_LB+\]D+['\,7_ U!+ P04    " !$B&U6Y?1VXURB P  QB$ $0
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M]?''+=\O>WG_JMO>E*5G;O%D=O3?XGP7,J<M5BX+E&%%C F@B)W10"/O WT
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M9U@Q8;3$F?>:L2QPKB6?XPJVWT&8G>"'56ET?[/(^[$\\8(01R$GI= <JPP
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M; $LUWSUJ;R;%62J)-5(<<X\LSI3RH$J#,09GB&/PI*)U7T2Z?8DB8.FLQC
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MYI=8 *53/,N"RC+GF7%,93*&-&'DD0Z(+T(BQ?Q0\('JQ]%8FM\;)S+F,%C
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MVR/[PHV*).[2M2NZ?$7%U$!2@*."W=.$7@,;_G7'3T]W7(^:,+<W& \8;;C
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MAM,^J7]<IOV0M+80C7ZC/ULE?]$I]%G=1LD<C\U2,VEZ,&@& ;.H8\+E8&3
M*L;?*IW2(J],NUP"4''4<$+L4I;VH"8L, 5H@;2)9\!/TKV41%@4/K47T4W>
M7UR 2'6\FWG)Q_F"5;1A97\JD='-F/1V1:(3\_>&R9RY*FWBQXVPD6_,[.=0
M 8QDU3) #D\#M\ZEI:7@S_S4(D<=7VO8 6O>! 8 <QU'Q%E/.%-;&QD9GCK&
M$U,\? 9W! 12QP8I8*GA/8J\%],*$_M%X0VC^&M<V@(PVK)@1,XQE?)$QT"[
MRZ6S.'<!Y#OR<:7/@!V;U;%F,/$H>''VI-F^"S$][F0Z(3*IB21D@,N:FUV.
M-,WT)8CQ-S3U"\.A;Z(#4P!G)>U9>7C'M(2F8>ZCOK@8)-HU2BI.DN^#.BS[
MC3M51TU,FL4SH';DE5E5ZT'7E>/MD+@&YB.C-@FMD_6!L5@DXB?^ Z4-\]PH
M4_"8?/RE@ANGIT;5/,VYPX;64=/V_.,)VP\F33*F7BN]E 42E"DMN-W320G1
M#;^.860#. $UP_6Q+UCD\GJ28JTC8_B+SG&C']-=HQP#P;OQ7^#YA%U;=VPL
M 3,P>0F8!^QQI/_CZ?S?1#'P/\=Z8.S23+);'T=?HQJ..>0"+/JE)=']?CD"
MVS+M%[0A*]->U:6H)OL/BA+D-1G1T/E3P[.[<0?%=?ZZ*,]TYZ^XG@/,%1]2
MPS2"'P<>^S ->0S[Z^:6[;/2&UTZT=$] IX_3H/M1O>FFX;=:M*Q\[[X!/W,
M7C6TF:9M\@\;(_-X[ &-5\@O,\S+B:",A;')KF^2Q9-Q:>L/C+D@K0SZ=HTC
MR1]  G]2%@X\,7"Y 7.4%SYYLF/W;+R6,P(3<6.L\$!8/-[F#Z\=>- 5O&B]
M^)RR$_--0.#V[;",=0PF>B#"TY91^O"HD\NW!M*"X$6(T'#7[U6IW1D0';BC
M-QA-%MM>1W-0@:<]?/(F'MU.A*ZJW$7='#I[NCXYS0$DM0L%D<^ ?]*V3WIF
M'4L3=,O0A1^Z\.@9Y $7@C&)M:O2^6/L'DV>C>Q4NC$8;Z3Z\<R"783(S6*"
M\</X3JE$0[-!-%/A(.J?Y$$D6S/FUS'SWKADP0/QZR&,&DQ;N]SQH+O/#Q=)
M$&/,(^&70E@W1L<PIDLQ;1?B6F =85K<<.Z/8D7>&>)WFDGH_&NJ*A'<!5]]
MVN5F!.AZ>P(F LXIX#&7#L^DF_SE\EQGT.R5CSUB&-(4S(P[?6G[M$@R=!SM
M;UIUCD!_F*0)<",8I;&!@D'!VU;7ODH>80M6K;,:_=QD2/)A6VNGGKTJ.1&7
M_G :9%QJCPNJ<7&AM5B@H@9EX\E/&MVO=3824@1="?X1S+_)RVMK#(U2B:"T
MQW&I-"\+/>WFKGL(EOFDV<8&TQ@?6_OBM*F0DEQ[('I\3'2LG*Y<,J<^AF8G
M]!EGW+8^6MKG3N<U!K@7IR;-:O2B@"$ )WT:+[].6>LTP<DSC+YGNXD!W#X<
M1<?P<5N3JC7+$P=LBIQ+ 9-\YWH9Z/3+Q$C1<W3-^GCZ/$93;8V;N'/0+&:M
M<<!41=$L/C=XR96UKS]?67Z<UFO@"I?7@S();TB+[9WL,;PP0.Q1OR7Y^6 2
M0N)T+SE2$WC6[*+!X\L). =Z@Q=>7R[^M,?'UK&M1E/$0CV3,EAM39DDR[O>
MO8D^-@#HM**T48!$-][4'R.8[WA"8L*7DW>9NOUX&$F&Z\O-%C<N=#/]J V7
MMA<ZVZG]4#/E<8Z;S?5F2Z;\PCL$4>H!H9KLK;0/%T QM5MR8\D W5*ZZ261
M5HJ6GV4;HL/Y1;QFHD=!M0RG?>X)#I^I(C6UG@D.MVT6(\<!-9?@?697"Z8X
M;IHEKSJ2;')2JWJ:[;&S-/N1*ZLTSK%8G0&DZE]ZY_ S8_\G,OX59B9N^:3B
M6.DYF/^?L5A=ODQ:<X@U4JIDCI:"W)?D^<R<3<U\LB0)$4]7[VK%[V*F3IR-
M4S.SX]P(Z^/Q&EU"%*?1K3X>Y2Y%+[:&9IC'2%D S/7PT@;=P1Q_HY[LHMWW
M'[=;2*[?+5QM_'W/QM^%B0;2 O2X]-T6695=>NDQ^&>H/\8-L$$3"A'Q-MC]
M0;/3T*HB'<-!_7]BD$:SQ)L\\>EI6>O,[-SE<?$A;I"!PHMKNG%-(I[> 0=#
MVX]CS%3//!9\FZG<\)A$=-R8OK2N6#:Y H-"_U1XS /QT$8;30L*?Z9[[*(S
MTWB#(>]/W+7D8&&E5$ODTVBJ@,.^<,(FZTZ/.T<Q5K:.^Q+@$Z4@*^M3$9:U
MSE:#^ E"JET7!YB1ZG3J?FM[BW8#-"Z(M<NG8Q>R!RS<K'TV/%>T860MY(8A
M./T?F+32?@20;T]T_[A=!COS!A2^GQCL;\>6_FP1^N^,JSP[.UNS$WC6>,%K
M\,9W/,JOCFGM0:,X(]DVFC67!H;7G7\!H2=M57YYW/F[8<#BXLHS_OXE[B17
MU:4C-'5<P@T:" ?X;KPEFBH&U>/5GZ9L;1O95/BQ0S]AI;C/&]5;O$#795PU
MO1A#N'1!,L%M/=:X!0.<.MG*23LSAXV^'6\,;[<L&Q5ONXTP*5%ZN+TY7CT:
M%]IM;MF.,NT:3(;:+GBT@@0NP?PQ.]B:M>/R=/&4_\N#_:U7FT>'MZON4[^(
M2Y@:0\>[\$:%'M1^??SAU[BT4>B+];R?QI4N&O>/:+'M%?E2Z7'-X1;KJ6Q-
M*!;A7MLXIGUPBP37$A(<]R:9.4;1&E;XVL-P] >/943\T)5?&RS':U)>?WB^
M!HO)FA+\1K?]\98_#8Z_MG?,/<M3\CC&:UX3>?K._D?+, <[_53,?AI$_@-G
M(19-'\WRP=7MM-17VFFUNC-UTQD,8SW W'7&8__97EL+_,C;;1/6RYTK_#<Z
MA=T5/$S,<M\EPZ_L)G4;6<LW;@3V<_+^52H^& $GI;=?CDMO/[ "?- IV4U9
M'=Y=I0*71G#ON=KW2FYOF7XOQZ6SG\6<OI6X+KFXWGNY[I7 WK;"/:G LC9!
MYANIF]/F5+'KE0 ON0!/"FPONOP^Q.1-%R7_I^J/2;'IN-DUM:=WT-9[WAK7
M>WZ5ZCVW%2!6>F7)]<H]EYA>P8+;]K_'A8>3,+\<EQE>R>V2R^W=UCA>B>T=
MDV_OLC;OZW%MWHW/"JAM3A7A7<GSDLOS/9?[70GT+=-O>Z8H[A_317'_F"J*
MNY+C99?C>RW"NQ+CVX95;2';WR?59R?>\@I37RF[3U+XTGQ%?ET;R'9-(/!#
M;T+?5NGLQ8U9GI"@DSS9F&A>Z5/?C[(X50,PI<9W9UM3QRHYKBT$?661ZE3
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M1VS*,MCQ%0,JXR[(1GWW&QZ"6VL%SNF?@ RSG?=0= %7AIRI8U/2C>@QI'R
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M+B05??#/SIAF,E+J0F,'U'/PUVEV>WJ>K5J:_8[6D73)ACO?;:$/1;Q])=&
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MH75 W:O(.QPR&RL:U VKW(V+O+B2.-85R%J=GSB$P6)L1U3UKXBTPJR,_R[
M>D<3))N15/IT3E:1]"9ARG3+P;5=@?NMO8OMFL)61J:F_<R,JYZ2)1:?WB^?
MY.<Y0QFLH\9SL3TU!**9SFC7)ND0U)6V:QZDQ5HO*'I;W)0I,!<D%)&*4$!O
MQ])FCZ9"-$RW=JF[27P*./Z&FH1A6G#?X[F4)\*MG*0N7GE>%E?UQ)XJ#Y*K
M8A]OTG5+_XB3(+".VTJ>%J,RL6H-,I/((TT+B6?8X)+1R.:2L@XDC\<IQA=?
M*F1 P7Z39I=+DPM+>@PO7KOL$G!%#^AVO%"CC-S8F3#%C;E*4H[:%1J[R"F+
MW1>U'GYJK@T\/KI,[O-5R^3>%R5SR^!#6R=]*O[ C[E5/,$:=M>X4RN@V<\F
M3IU(^7-[6='1TVC#&5J3<B1VZ&I%'RC2L3204>-8)R6;RPD?S>,*G_"<M187
MW&E:Q%7ULAIFXEF[(PD7%(ZY7;@HS^-<\TB;Z)]!%RAOIX, <8/'4XJ<"_H>
MG!7]O1"UUP;T%[5:>C5$ZV=RC7AP<&\>)$WIPY(6->5"2A1W[)3N[()LVX]Q
MT(F629>EE%:'G=B;D94.,9_Y@Q*<W!BC:G6$(#1)/4W=]N!SK-TE2G"LV5:B
M;TUH0)F%G]*+/DZ2AJP5G]VIFF'2U'%N4 F_6"?0&C\2):Y5G\,]+73QF447
M7P%=Z?:!_9*J,V]I2!@(DA!=5!/3H*85;0AV10::9<CF,0Y/@V3"7PVL-F2<
M1FE!3YS [G1+B'@;4V\[E8NJNXSK)E&,46HB>Z3VHZ;I?-5%N%<V"28)_[#&
MMII/9[!%:\G=@:4=&VVG5!J2J"3%?0KTAK2*ARQ#;G.#[@\;6$<XTI+-<V.B
MY-LEU2-!1\Z:J'T,=V$%1.1/2,)4VDCI[<^?19S!IW.S-T6+(5(/M#6.$)IQ
M)"QR22 GVJC-IQ8[-BTT2,2Y"D6A8Z==,G3D%LF^2 2^#>>6)$5I!82+K/;?
MB%\!:7%O;Y_J$';/^WI6][0;>_I$G1$_PEEP#@"I0#L[!/"F:)T=FB *A]!<
M33Z(\X&0=ZR-3%8*M$7^D:1="&A4**J0KZZ"PCGT=?.MW1%(/B,%RR97,$ 6
M.[=N(H"\PZH-Y@.1N;&YHL.WL';(*2E8RT_&P0FR6>=CI%!"L69+=1]8X@9A
MC7]KK EP[\A^F&M1C-&.+U$$"8DS21CYV\B>)20;Y)!*EIDS0@!XT#BKESE\
MB49YQ&FMCG@)0!![$558]!^\08/S-NS:"C(MFT4,]"!O=-JG^9VH)@@<27F=
M!";L^.V:K8 \'K':7K9&Q4P]+5=$,:5=QSV OTQ9E4R-J9T@5"VE%URG>H5P
MP0&D+I6F*E_NI@:/W%TF&V^X"O5!U.YI8:MM9N3FB1M24OQ)E+Z=A05T]HD\
MHQ%+[3"X=?E-L9?%0@PI8[V?+)VRR38"2E#I57!:\@>A#ET6#&6POMQ,X 9B
MJ5J3=0%B W<!!- 'U47*,RE0CF(5.4XIKNR% T=#IR. '[3SWQ:",E1IJU>L
MM2BNJP!A6E.S =LNTJA[%FT0#1O>55SS?+)]PX"U)EPDV:6,<[?*J.H<-UF[
M@V+3.XZN9Y,O/[^=K6E;);<"Q^PPC_9-8DM_MU]K,GY9!Y<S2SET8<AC1GI)
M<F(BMF&A=MOC0*@R0OC<%WN[%TG5=^8^;RLI/4*QQS"=I#,!DJ5W>#,97;K<
MA043I&&)V_?1 EOB+>6MN"(T+",!8R#U]HU[$'3Z\"@XG*FU%4$Z;0R0C0F=
M ](PAB%44$:] N+133:WO-3ZB@X1+<;(02$C<M4IZ/T >S#1+/% G8R1W\[&
MNG+.S[6>(3?]:@RN#\W+[;T(5W3<E%43NTY0>,QN< S"1BXU*4A5Y3["Q)59
M(VT/&]@!XSZAMS;3H'Y7#%[IU+# 1M96[O&S6U#'$<=FHU\;LFIW2?II27<?
M7.SH.[$ZK4-'M\!:$!O'Y".K=A8/ZF*9_6_SXBJ.?DO+E U)C84'PNKCX3X*
M?L><7E]KK^]BEZ(?@#Q%_@,9*+DD"T8 H"(W$JAGTZ<(U[33FT6.P9W/;6X
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MURB$DKI1[!<IS7/T39&P?+5([LZ+S1=W=F.U.5;[F<>8C!R.4C,3  "'+[#
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M0G-^L?MCZ][M$[&''WX]8L07;]@>:XO@P]<CK>(?G[F[!F"AXY0N-!Z\)>%
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MN7NO98N,Z=0(09KJ)[9&R!Y< 5*7?9FT8Q("NI>PE(1 8^9C*N0I;6?$AJ?
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MFC&K (>NJPWC/C,+(GN_3*U?BX8K\.A$')4U4'F1S3LKXV8:WZVM%231&5C
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M-SRVH45\?7 +EL*?.P;Y\?2 2%4P_#>$K>&.1:4P64@HTR"9T-O1"\1(P:U
M@:0C2I6$H8VXXPZ>I5E1>XWBEP+)7BS9=G"*JF8\-J6#F']K9E -'.4YG><C
M^AVKAXRT#?B^41*;2U]#KBVK_KD9D-=YOS5D8VG6\:N=[M$]9LL^(IO&E HH
MLG!^DTE9T(;JDU4"V=XOS:--#%P]YLGGQ:.=.L.#HB M?[Q),4EJ/=KI,Z/A
M-ZH;>@C3%X*5U(P>[1+@6GRTDR<3[M'.G7RE1SOW8OQHI^Z\_,>[ H]WZNRR
M/MK9N\#SP_?6?<V\>N?6*4<5AHOC(5QLHWUA\R?'YAA QL9-BG+#UP$*%,4J
MM!:T:PQ;3 =VP9#OY,A@V<P86S](R'.886MG*T@5A@G'G,GMN*V$/K7#=$CS
M+CN3!J*J%)UT'&$I33$SN0+S(/@U1=EY4AH)A(0-Q=S=BX;2&I4W)IR-1=4*
MPK],#7<5IPJ4&13QU)K/Q(1=^'=HQJB>&9E$V,>TS'-((M$F6HG11./8-<]]
MO7@H;((DIHTTM'O)!(O#HT8;SX,K.<&#W]J.GF,-B+]Q ?$5J0#KT+MVN;2X
MOKHHIZX6M,5DEW>*O$D<AFAS=:Q8_!'?=X-TWWNM:]H;72*2/X]^*M#8A+P:
M^ D-FA@<[V4((EQP_KW)A3Q,8*):%(A\5(HRFT<]A(A[C$O%1Z*%*H'W5@T3
M2XX;I.:%- 7=;7;>>E!]2'16F@4M,I8FE4F1H3T8N)/<,L+)BW,L5E!\CD7U
MO6*&P9170=FV^P#\>L4V=&Q+NIE[>63&J>5;5HKZXB*5/ $POD'.K?A1BBZ(
M)XWCRZ+D*D*M1E8H8I76M.JGTNRKZ&!0$7Y5@;K ?HZI#,U]R&.!S+.I*AM'
MUJS!O;8D'H!%MM?.*LP]:6G0E9"[DH'P!G3RY3.?0=8BV&VH#3K-#-24UJWM
MTX,MT O2]B!]321%'V%3F5GE)<M*54M )*FZ"DGWP*0\@U7(*,P\N_LLY+>^
MYCIDPWF1;[BC;WP!8T"!SFS 9-5H54J;)U(A%#RV8<4(IG0IU6DF+=6LX<([
M0X"R*RL\S+?KDY'[*?@KQ;IZ+Q 0M$KG O[0![%GZQWWWQ_NVWK'@4,6P2,_
MV,3HH=(O\T3VLLR4-WCNA\.]X,&/UGOD<K]@^?H7ECTP+9'U"_C6[XO<?MQJ
MXS=H'R0GKFQ)OXY]>=O0N*-3*S&NM/7MJ7]BS#U7%G/&TH>?HU0SY_*EST;-
M??$EJ+E+<&A7^C&/KS3S]:J59MX5YO/1R?'1R=[900CZ_-!\9G_-KKO'KAG.
MSRB*7Y'^%6M[PUM6P_M^+79@^AVSFQGYY;_;-A6LE=[G?DBN886L3O5[M6A9
M&=8G*<T%"%LS<I0-[3\\8K8Z%F::,"H(4(4/\^1>NZHW1WP+-@\!*Q4[V[,R
M,C/#PQS L.?8 #S%<F9+"FUX!\O+U#1C+IZ.HSK^N&$^ OE"RD/3O^4+LZ:L
M@$2$+YPJ3-'SK>T?XJ=A>3:7E9X #8W\R#?%2 ,.[6UEU"4)=]%7]YE! EN7
M2H=[F3*2Q[7[2"-,&M@2@BG=0WS-'3J5,=;QZ!F"%25%E9-2/@<O3&],I4^3
M.RB5A6D5<B9_&HTJ(,X7Q)3(!Q.[^_D6-S95M 1BQW,<7YH;JKI(+FP.P"^J
M!I;D&U?HZ[%!R?#0CM,<('TV'&DEQS]&F^RYF\)6O<HS@05C@4R'!C%2W^O@
M0Z)SP3F5K@/ 545 FN'(K$'YHS*!A$U,/8(Q;A@FZ^'O=$=16#ZA*M00P:94
M=5P+P9S4B==56_9E8_.B!HP0(+$%=J3GZ]>>7B2*6/P 4D&Z1P2O<D7(?L"^
M4%E21--8&IK!<H"ANQC6A'Y1 #J%FTLLD*@?^#2FZX.>?\V@'JZ-&?K)?YHL
MRW'LCHM,VNRB/5'6;YC[LS;FX8MUJT3[(1A<M]N@>V.-'>^]L6:8Z/=B^)<R
MM*ARID]P!YQ7J9[Q4 +6 #3PB2K+9Q(<7[],3O^&/*<C@75U0-L*),C#T?$)
MBJ._Q%E+T1VAH 59D:!G@K63$.6:$6?]15=HZ%MALKF[:)@RE5]*ZXA4=@ZT
MI8=_:K!B>N\K$3!D;<I=RM4DG=W*_IK.LF)N+&H$Q,#A7=EW()KKVA\:!9"3
MJ]7]C;=*B<6BRR)KZ'XJY]S.2%9)PR,-]3@_ZYIQC9PQR2%N-\K/COR]_G3D
M[XX")>_W/OS^\]Z;L]]/#C_\PJQ8^X>G9R>'/_U^=GCTX4'E899,,"3"?$C'
MKW\Z=XUQ!HU&FLS:3"F8 &+)+3/=N[)K<1ZH0,]:$@OQ3NK:;NDW I:;F@Z&
MONF0%3,J8TA>V\D7<:Y2D6NE?2QD4)5 ,9UWTDJ:G^YQ\!0<ER$,%+=4K,2,
MN^GHC=R@AJ*P[ML?U.E8DJ6TM27?1*Q>@(#T,TYM3[ ?:[FQR\^[1"U# BXG
M7M(A;1,> /[5[9?/;DQC?!_.^"<,TR!O:FD=PR,"X #$+9SSC?O8E.)%@4U<
M*QA] 9& ^.VL%-CG6G+OH>1:L=5>4D?+%0JOQZ]E8>V@N.=A[>@.P)R*H=(Z
M](FYUF6B5]_U$B^^C/OR6U \_!XPSZ!0RKU=D=&G9@FU\8,[++^!FR?.BF]4
MKAX<E_7AN)5:MT=@UI3)1 T.OUG1WO&AG*!%#"F1?/(IN5;9HC1U#*B2R4.#
MDPAN@^0B!@!_Z^H8 [!EPH#=_N*04AN/@A<</*9.B<&=!Z>Z*5'U5X4G=C-:
MA7-S-#5)%D^+CQO'\<7ZZ-QET,')+22QM2^1R14I7@19 \F.YU:!)KJM!R C
M*@"<HF%H7#_:C>#0C5*Z,P1*'7$##CPU92DH0553<?![U*F'OD(3@%9.RH4#
MNF 49W>.%-Z1%](PZVHH'4IF .#DW]GD\66<9D@H]?<H3&<>ZP,*Q(^>:Z4R
M517FXXQVCML4F*0LSE2W(!?&R0_20&5K("Y&)AN!*NMUX8X5T)VM=>'.-P.8
M'J5GI?FXUKYWR&BUL[7]@C5;N]XWM&3PLY KBW;]F&0-QWNX?K+$\UBUL"7C
MT(NGAO143=N+L+I5>8Q#C\:MTFR,4^$^FD-;"3J1Y_*^GATA?)RTRY#$F;P2
MLH-N($A,(0M9Y"\<*9DGE6NR'M^CJ]17(-WK,71W%K<< $8Q[?=(;$IMF^N$
M*3X4)<BT)*R^&1T'11]8*O]]YB<B29DPQ3UVP5_?MGE ,_KZS&G,*&+--(CD
M"?$6ONV#A3:>V"->E>T:8L$4LJM? 8:VNS7 K'<?7!+WE):LJ;X-\LY-(B%]
MHWKD.G.O79'.FE'6 [_2#1NTPAIQ[I)>7K4XO^R\*$:5MR65Z;9][MH1=!)K
M_RH!(JY\N59361N7%+9P??B.%7F9NH+VXRWG[LRK/.4=UD-%OT3['W<O<MG4
ME-EBH"ARE_ -!^D+J=@2I5]K;H!5/3H&516Q98Q^-/V(L)DX/IH ?$[X[.P;
MQ%>5%=75N"<\KP_8*K,0KFNK['YJ&+L_'143!2!E=/&FTICFU4T97]'1T=ZK
M0-G\B>LV3B:BIKS:\3IAR\:7<$);2B@HO6TT"H6:N@VNJ5L2;N(W5LVP,O]N
MQ/-M=R/6):W<6#1<GX_:#H.IW='2'1(0V.87"45YUPE?%@ECQLBB#KQRYY.[
M+*/SR3M&:4>#B57:7C&I4I$L*PC?B_)":AR"1DN8T5H8:<$G?@8R[+-7NY$T
MGY<,?I I)2;#DDE5"C@ZT=2M!2GO39QS7$"H(7$7=%XX#>MR8N9+3E$)P^'(
M=!H(#[:H:!1?.H@:]B.UNWB$72K9(L/12+M+;ODX)J$HHE:V5R$!J\ST:S5Z
M=Z%%8==F-Z:C0V5ONBI4:-5 T[U$<0[X##$9GQI#7+.TU)(+HH=.F_M^63V6
M>7'5CR<AI5!M_=%5IE!R7Z) @[(X:?,%(K F(+1<8KDC3CK/Z;O[ZUGUE]OL
M!]4G#U_6WZ471E!U9JV*-^&=RKD>AQW^<R:);%73R.V.G27E"Z/<&^H2("F
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MM"Z4I<,#\[O:JP^LDK7_3OANE:QK5^H:E:5@3NPG<:##H]VU*U%_H!N)1I>
MO(8>])3LOK_T8,4^L.6PSO[07A.+/>E8HM@=P6D!I% [!*SP0T:!%FVH&A7=
M]806ANEO:!WHO[4AQ8 1I0D9=^DH^N')P?[9WI.G'N]Q7>O@:AVVU[4.7P=
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MP8ZMFI(CP0D02\CY^I&/UGJGON-.574\S-)J8CO0XM%E3$KNW"#E0B/+A//
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M:%&_G%H+>R?-@EDE%5"@$7+.'+BD=2?)B#[KWB"G@8%WECGG,1L2;V#$ /T
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M0X]?)K=_/-9_WL'T/FU"9J=A:.C5254-U9R^3SX$0#YHH>;FL1D(N>@><".
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M[' ]I2S&A<R>KH/6[7VP;:?.,FWMC$18)BL%E\A[-2_D3-!ZD^ZG[XMN#OT
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M](>C+\&(R<'DBS@7X>;O])F._-F]VKE.F=+\!5=RYY$&#99-:KJP%BX#D6L
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M=<-N!M2WASWZS'NTQ87.%&ICPK0XTEHP4^D$%O:P>Y]Y]X)A<B.ZNRPO_CV
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ME,5 NTR[[6:=[:+'<N(7D$[K92[!->-'53E&*!DVTFKFXXBBLL+E4OV< ,
MZTOEB J>**+X<(/L+6,*">.N]X-D?5[)"LB)M)>277]0@@V"XM.!ZW['6XJJ
M6RYJ8EO7% O,A38@Z&BV$O>RN:3+=[WPR"&O*;K(\=*( 3.-$S=W0O,A;U(<
M)T_+SL\@'S&0MZ0VJWX*5\RC! X"]7F]%D;]ZG;YH;M:<[?TUV!^=FDR)H+
M;D]HHSBX\RQ_Q\F)N_B'R<(^A'F_V;@(JQJ]06!L@,94VZ Z-N272_+L+W?G
MKK=9$6R&A'**^)2#N@C" >@H;:PBYL/N:!: E2&":A'2$7M1'=+1'1,S)"3-
MNI'$Y:7;+A[\QEUZKG6_]O8\6?'8*9?]D(2H-,]T7$9DOD3R_1>+5 =/ [SG
M:&!T[*F Z_#;UFTJSZYF'DX;%*%.WDAT%"LE\[O3 [K"HRL>'- 5?TVA_OB_
MCY.?LC_*52FJXLFR+!;)L[?%?.#DQPLD#Y'-<!1$P;D@,2^;\&B FE*4_RXN
MNABJX1230T@>)[^T_HG6PN/%YZ)M>,ZBXY (VV)E)A.3C="9S(NYHL,Z003"
MBZ7395J8ITS8R5,*IIS4P%*+*)8Q'ROJH%R19QO:S"/ZGTAG^T$V5;DH! K(
M2 5UR.8(#PSJQU^AQ_$O["]0Z-AG[D)VAE6M<I&AP6,QJDLKF[3@BS%IN=56
M/=RTYB!"5(*$ . 4C,IU=<Z?(8T\5T8V#V^W!+&P_,B<3.6S(C^"AWIFPNS+
MC47NU_)X HUXCHVC%Z_8+H4OT8B0R>6QU_ZMX+C8-0O>.;@311M<.='M92P;
M%J@1H'>IS5/VD2:\6QD=)ZDTU=P P#%W+E>=F?.O[QVO5+#^FA(X'S*$987A
M)JW:HU+E.T_=B^B\E!@-.\&O-&'GT=Y)TL?3Y7A(KS<_J>0>\<AI!!YG>\/]
M[*ZS0G/M$GC"K-1LD9Z\?\D6V^V?PN^1GQ'C3.P$1EW?QI.VACT?$Z\=O"]L
M[!C-)98T)/T+ZQR\;&Z&AUPQOBE]@ZUM$Q)Q1/-7.0V;NY[,208@4RFC$^)V
M(B^5/MK75%?BL"DI0$R'O^T4;HU;NOF.VB1CGY2UF+*/YUQQ4U;#FI[\7_RZ
MJ&T[1_4Q#_?@\$1Q8B,J*C=>;1L9A>S9>-:NRF DH\-:"]Y:Z*9-O62.J6R[
M?6_G4^U!P,.32;@52+5W@ YP,^L\HT;0TU^!@A[&=G14^6!P4/E7% "_%#D_
M8<U@\VO_\W_=>W3W\8-[P13;):W&-P]#&V%D/D';E 'Z@PXPK][3T M*Q[PA
M[*YY^A'4&=M<!L='#4.^U\B(G=G-D)22M8CZOEOY>D#2EOH'C9RZ,9_S5)-Y
M,(A[7 6)NYE"F@?G)3GMGZ>NBVFT:/J%U.0P4"!A#Y1:EVY."^H$VR='N66+
M%($T)!BM0V#Y=W/RC*KGHI?\3NEP2)TX2LI.?(.X46;D)(@ L-/#'F[P:GZ4
MGRHB3>E&AS1H!MP'A?1;(;0Y6RP^Y&+;JM&Z-!WW[K( +$)6\WF5E2N!A,V8
MT[!W)/Z#;[DCH1G:J.'>7UT*M2YA.B&U,4FW$45K[6=4^=L#W6=;PG95&$Q<
M+71[<]QH!0Y01/=) 4Q<Q?@(150;RM8=$%PPU<[6H>/A?+2293ZP>[]1HN0L
M> R6@V#K(2::)MUQ^V!:BH07TAV3K=> YS#* -O-?V(510_Q^\!@Q1 G'O4M
MY\6B$$5/7@IGD/2! K+<\4._AY R-N'G^&=&7&PP%.MN@ );976^!;!_K,]O
M1J$MUH.$BH]'PX%CYC--8Y5KA*&/XS$1?OP$ RP?1T]/ 8E0_6?PO82/M+5)
M.5W1]S+ 732R$53X.<8RO)@^,#]=FRX>.\&)O+[WLCY[<3BUICT6)I^PT&S"
M!6=ZABTFNS0F67-1SQ96;%A+GO4_[MU-5BA LH]8XQ#RC$W@*$07IB$X7N?1
ML"1R&R %D6HZO44SV@K_U/S ,(V0:V9BX3^&C1_\%4D'C0_#MO+?@\W^S@:$
M+%3>+792/#,W!H[7;U>?N>M?GUARIO>2K I_7;I)6VN"F?B%=$ZYT62><::C
M@]PQZW.X2\K>#0:>LKLAM$(?Z,F\VL&3SI1](VYDI%V,RB @,6/3B?I",-()
MK:W!' ]'.<77UOR#HW*:& WF6VV"L6/[4#,"'><4-WVPM-OKJ3![HT[VB^M7
M,PLW*4?RD"\TD\EKMKB*+_2;%_4PF!,4(<6B0A]XU16Z[Y#Y&_[4/Y6*S[;T
M, 98+]=%-PF)+'@6<CR5/'H>$TX *_FQ3"/'J[)-CQ .O0BH2:YB C&J!$$H
MYR[5X.)-_?O>]KX9B!  'IZE)2-2!DLVG@]E7N"G<:;?$YFXSD!2K_BCQ,LV
MS,K41S=T4LYNG4\W*4&.!DXV+74\J)GZ7>P>9QN+@A=XLE3\MWCXTJ&PZ0J;
M7QT*FW_-U-JR.V]:S;8C]TZ!Q":-\^E2(5,\]>]#K<-<(*!MB8H3)Q(Z+H5*
MJ6@C( Z?L$>I)%)"^Y!/B1+G$0.Q-1QKA<28*B]TD;M-UQ<KTU- G('D"VH>
MPCI?%A'[!I9SOD$MV;X%Z 44;9?Z>O$%U]U<]5E!1?(LI)U<MUG0T^M; 4:<
MS9EUB$I3 %.VY.1UMNCF><R4SJ,W0EVKJLB(#"(,(!N3R](;%'\2PO0EV98@
M:>M*D\XPI\;6-J:C#I==-E\;.QWGCGVJ7=/LJ@)MT\I4>^F6;-IPBH,541W+
M#IA1?5]V"1[4E0!LE)?&Y">@*-%&X %57'L&\=?>0U!"*17GSV?1KY2AE)VF
MBZ%"RZ.Z37FV0K C(WXA[D=9WV?S-UWJG_"B;"5Y--390'>4&??2+I(F=48/
MQ9U<'5.[(/HNVI:^U2'S@]H[=Z%4@(RNAMI</W8S(;PM>_9V+$>5L9+?B9-S
M0KB@B<J9#0Z438NV>N+ ^A6C**]K5O183#U6R3_6R[);"AU[PVDZYCPJ& V1
M1INOEY:#KZ1.[C[<(TLWL 4-<GHZS$\&?<!1G5A+*7U,2H )":)<$*UV#1X9
M)?">"_OZ6/T2@#$W$DO5$YY*'6KV:?39G)AC/N6JY!UV(-P!<VAY&X6V K +
MY@.83UZ^ :6!U0+L81E_(84+^T3S+UK?5\#&+#AIQ[O=K1NCL72.8 /$L[1=
M(UOJIG4Z\"/FJ?:\FZ#4YF@KS_HLE-9)#9]:X.%&C?KC$HB/)!&S?@LGPR4J
M%@B7,9%2<A9,M9*NK_!Z6Y@>M6YXYJCIU.:":O^PM)RJCE9R\&@,&_ _!DLI
MXW< L)<D6W)[V[.Y7K8-/>5*C&UJ0TLM$FD6LE+!.6*!\^+)-2IQ"X;U>9OE
M+FN.1@>9;K[$>=[F31?PUO25+T.069@PEE=6T)FUFH]09^'[19,_@H?5-\28
M,U$]S'H5NS/6M3]( 1$ZV5R3<GRGB8&S[C&]3V,2D(_YX7UCR,T_O+\Q<=UE
M$55J=8@\BA 0]G4P/WBGU4ZO<OWT9Z'[IU8M-L]JC&'BEO0/SG>WYJ_F!@^T
M(RD*F^W:@IP-.543OJE,>F$)5EF1_?>F(#K 03DBL++07,K]'>!7V)"AFK0>
M9F0S*@;VSP$ISAF/))+:-U51AYF<<#1KZ(5,R+4,I"^W9390@J&P2\4;.*G'
M#NU.2T3>BF-6XO@)?#DFY^VD>08_ FW_X[ JQ,@!5]GUZ> !_<%"OCC?!*&&
MICB[8253?$R.4&3T>Y4!PSAG(< ?'@>E+)Q(\=FX!%;D##<5B"D<OHA&LJR1
M\^#BFMOQM>G,QN5LPDIE)QPL*&/D BQ@&B$+B79>(OTX:"V_Q$=/>D[.HN%V
M#DL;ZJQMQ6B79CTGM;?6%E6-#!_SQFV$#5W$>0X)N52VQ=C@Z1=B/86S-;30
M$>]25 [U,F.;8)255^ T)JOX+L?(XE[DZ'P)LG+(*?#XWI%:<@'(0D&EXLVU
MA1IE32STD<]W#7M]\VW+BUTK+[,9*E\("=+?H8^4JIMB[E-1+_'Q2JN'JZ(8
M=>IDE8U#^,UHDUL,)Q!GQS YEJN>>#;M"HUXGM\%;W4 I![!5AG821GRI*[$
MU$K@R$4,U2Z>3@.&?&%6=Y3C/HBGYZDVTUC9>#0V4C-@6PT7*C"0T7ACI^U"
M<)9HCY@<S=!-^R"JF 8*0VPA90Q<XZY/I\=FP=1RA;75T:072 _R>Y/ /ZD!
MP Y&6!*Y;Y1 ,?N?"$G!2JRP2#%XBB]8)[OM$EP+7*>I_-Z.^'N'SA8[_QY!
MDKI%$XD_%=,T\*9ZT>!Z'L;YEJ"IQ87?7;/H+Y7D69BAU6#IU17(/TXYN91)
M'1:RUZUD$K<7>*MXM14JC$@=)V'+V\X)%UET+<$D7"JQ:>9@;F+7YJ2SY(#.
MH=^J*O.+9!1F3#>X!7 OI^3%:H7ZPGM1<OL-->^J+"X4J= (LFJ<M*3WS7G@
M;/:&:2+H4+"Z:P/A"$3!'1Y%V##LWW> 3LG#"%_N@N\PXM!J<3EY(@)2&HDF
MR+>OFZ"+A7U.#_XUKDJ'D.3V!WY^P<SY^RJ>D@O=:Y(5'@5OE+@3:<1#J<^5
M^AX>2GU_R4)N"WR0ZCZ;=+:O^,E6T!O%NJD&NJF+:L*@5J)7<:LQ/\75$[>2
M0U.3#\3]=T?VI*JV@@+<KVSGPZIC N0N<KE& >(N>FR?'9T,"L(N CM4HT#!
M&=C-KBIH$$WOER&P=B7N2EH6P: <Y>7I@DD5X8@;QEB,<IGF:9BZU.9"S#2C
MN-)?0I<Y!7&':''X8N?^AS)5@FN2G-(&DIIYBJR[S U]&V-O%-/C'IY1N $U
M68#G$S8B!_H('B^%3R!,,0+O<(B2\!T,7XMC&*9W/-@R&7>&\4#<4NQ+-))(
MR>*B"P5>+J>D.?SJ@&C&.O!,;!F%)&[C5%U7R9TR(0<(I^199P@;?!+2W*:5
M"#.3<VCU"CA1?"2#K)!_U*TTNM\( 7!MR93S4VU;Y=R]@_1[[X )OQ6V)'&J
MYKQJ9EB%QWY0HI,?:Q22'!)#IUJZ9AW&GQI;28LOYU JI(Q][X_]1NT(2MA2
MM>#A&OL $_:,M?:NLM*"YG,S:#6+W*$[@G'=?J;)CM'4?YZK\!O0V!QX?SZ8
M]T>IP@R!-]_,?5=RW'\IFI%=>]_J+GET5I*"E\)X"U@"A"Z,E$]L'K$3&8XS
MU8/Y2-*PPVY_W&Z#84*JN)QRI"BU63'XNW.CQG@.N:'<W"A#^H<.*"G4#2P.
M6_>9MTZK6S[/P[.@4,7B(4OLZ9-_0<<6MI]3,1WJYNTY_C(C)9T-<SCP\VU;
MINE8=H=F6=N"N>.PP9]U@\,Y0D&+HVVDC0%K^_^"H]+V2C_2);=]-M6=W#N'
MS?NLFX>3*(,O/7@+GU79I8>N<%B@A6X)\.4;AY/V>3?+QBD6VK+OW)=L/A<R
M>^_'*"33)[8E+?/[0)YL7GHS>;".U[NEF#^[P1YRU1.'*@V:7K9TJW:]2&.*
M#4]DE*EK5TWC\0QA\^KNH3GO$(Z\D8:9JCK(R;7(B6_M$&10*!BT4?'.!598
M,B_,?D++70:,#@&9<].Z,:\\@>H=(X 3&9#AAXO\EXX)86;E@V!\=@5B#&>L
M\JN&^=)(0#Q[H(*U%:A@/VD.KO)GWJPH-2$I".U29Q8XCVI6QBA+/80%#.\T
MXT*#%<@K\M4&(-!PCX+K00H,TIPSNA(\JV"@/]"7P;P_3?M&<L@V(MC!J#Q"
MT;%T'_R)&R!A(\QY,.R>_SN:OL((TK'/(4;".@F\"N& .VXD*I+O55J?2-$P
M>>G&')[,^X,<7)\<&$X8M53!Q[#/>&6=Z$\0V1_V[./V[.]7ESD)H<$+A1VM
M,M1<7>M;Q:E=1@F=M\VP3C\&-CP]ADW[T%S]L2OI';-6BSU73&'=/=TZ.>G&
MS1\*PXXU:*7]'6'M+EX&#K8,+KHG]4VIU*/EB+$ VZ14GH^,FX1",C)8K=*F
M3G?3Q"8+(<#WE6T&H8T(Z$3B,C^RX5(Q,0J7!L8]!)PR\S+]H#8P0C!J1AI[
M=N_.WP_W]6C?<%]?BJY\AK&XI6NGF#HCDOTK)@]'ZMGKXTG=EHVW[.\:\P&#
M"Y!VNBA(XJ5_((@F1J1I#/L02D-$GP%U3YJX5#+0.!G@1OC29<:N96<)+6GY
M2I5?)4VV0EO3SRCU#>@=:$+B'8F"YLS"&+"B364T9B$9G*< I^_]4H#;!Q3<
M)QZ7&A&&C316&^GZ^(^>*(GU#8:@BOHJ\JDM^C.X_R]&RY^$9%XLH-$:7!9*
M3>F2F$R)9(O+K>U&DS2?%VM& F*_ULM-A['QB%>-"C$-1X7K['17%'0AZHJW
ME-,>H _H_PPK[)>F#%S[8PAFMEFK4R:RN5*!^*E[P2C R=WLHC,A4[#[(FK:
M\#25["QUV^SY<QU**&.;"[R0^$#1G0PYF,V7C%)D[*=V(7#&D5_*"<MQ\M*)
M2C",5M!YN7]M3^)(Q[?2T7-'<!V\9K,V/G$/S3,+:.($/#=!*A<NL,^;R@SY
M3!M=M%>S4K<02'STK*R$&L*VF-LJK^*OF[Q5V24%L!%5V2VYG39>$R;.,!\,
MG._SMIP5DZO_'F-:^1EC#<LC04IA:@XRS4')'N#)(P%/!D>7NS&-F:76KEGC
M.]&D9>)TA-Z[W*M!W[]LJ;^I'198JAW-!=NAB"4X#0FW$12%<#85Y<.HW6NJ
MNB]=%.%"U  K;_;-G8C S#DK9KCK+<DXS+/\S#L9<]=K379B8Z"W L>4+%C=
M!^,(]<##$/)T&.OH;C!!2,'MVZJ92[L2YKJ9'.L66=>#''QF.:"(!#NH*8;W
M.L2Q$1U;Q#08?.H=C=2;?EQZ1F9R4?;=M!\0^AM"]J6=HF(\0SX F.5L71X$
MY[,+#H?$EDP4-E/?T9J!"S5B03[,F+V.PTTZU4_<"EW=R7-G.3YI:->A8(%[
MOP>1ON9S+6"T?+N&D3QN.64&Y^3WIJ1U0I,?]R R(=R;0I.G@N5%PSO'!?\_
M>V_>W#9VI8U_%92G,V-700Q7B6S_9JK4LMU1TEY>2YV>_#4%$J"$& 08+)*9
M3_\[V]U 4*)D+23%J3=O')$$[G+NN6=]'A.-T8CHQ/1M7%R?><?*&G&IYA_'
M>%:J2Y]T]]X2V9@Z<$+-N/V.PW%!S6AUH#A/N",7VF5GBFL[ED>;*%QQC (K
ML1K5(D[PWI0_9G1*"S3.WG"&RXF^<4=:22BJ\$]7 &S\.#T80W )"H]RU%S%
MGTKG-K'*1(*MSYD3.55U&%3&+8>MR1<VQ(C+,J79;-"THB D-YSKNCE_33$5
M=+I*0SQ1#Z*UG'YM]G[C5'G4YD4UWZW6V"CP$;"CJE0C\F5W&,_"5\&O2<!7
MOCLBA:02B4U 0"O!1!=\D'.I._5\U;_'S 7D.F(>9TR58Y@V*1>JKY8C>].*
M;)[ZHPT%&(5D.$A*%G3*_"G41F_9,\0,8$9>6\JFE>1^9+6.S@LMI@<S?T?P
M':8:$EQ'T$QOL<8]Q,$CT:+5&BRE$Y?QG*9@G9+K2"E+$BYAX7-8D7G2ZFNA
M]4H)GDE2LD  ,-"*W]+L.C5!Z(LH+6U.'%X-1(FJ4GN-#=+,J8NIHU_L!,6M
M.>AC:]"%EFD?!5$"#\HU@L%=:W@W;@K'ZF0"][S(<%T;<*J6UIQ;35TUE3LG
M9D8M( OLW:-!UCO=[=#D=1Z7T0&<?67X*L@RB;:0; O46L.RW@R6O<QJZ;;^
M<MAV<IG1\<BX_-XKX/>15B!%F4V^<;PP+1 FV*8[J)V),$XJU2-,O\4G768)
M@@L[J[!#1D<-,FB6A3#(.NFR5!]AOF!A0<?8@F (Y7+[KF =CR (D>90K@'C
MH>!)Q[/5P2Q=V#7ROQVP+?2Z4\S>2A]:/>I.4?'R(HFZ_#TEYI&S4E.<J3H7
MMY;0)<0QK?F(^\8WM]L![OT6?R-UM+"4E\918GO ,++RXRBSG_%_2_(T-*"'
M=K1Z,8^*.N@82F"$]9OT,#O*S<A0-V_]RRL-.-J7!CPFYBP>#BSXP[HHD/H2
M3ZK(K',.*4].O<P64A:E$771H&2%\"P:L@*\WOFF$3-?\=,)'2=>9ZJ8H';Y
M-H'G[1,.3QC!L.\\!?]*G(.^(J[1@&KF,I/>>C$^:V"%V(0;QG;;8/1]DE2%
M^-U_1G<J&H--1!TD-06IT.=\"_NC2K@6A"NS(B98J$2Y&IO*N>,)@57UZ</"
MI5&^#UX^;4.B[A"U*X.HJT',T2;,-ZPJN,KB4,%J-&&CNX:%J\/VF_R4#?PU
MNM']VC]E;WTS;O<:7+;[',&3[A2CUL:E8'G;%RZY%U*%;@=(."QBPB3+ 9+&
M6Z_!I8C#_WX5]Z+>X60Z&1Q&G:#?/1H$@^[X*!P<MMN=?M@Y.OR_8??59OG^
M-[.%GI[][<S[^OZWX_/33[]ZYY^]7S___?W73Q_??SJ'/__Z.W[P^=/VN]9_
MC_.2^QP0=R_@=,12$-]$$\A4E]H^S@O:KN=%E$YT6+K6(F[(4WS/J<^=!Y-O
MU''H6^6Y;C3<Y5DL NPD(W(CBW&Q!C+O"QQ3 ;XJEQY>(\.350^7\^^XN)?,
M2'>65IS!B2R8%C75PW'3\E!70<Z%_4(4_.'=,9,\?Q",X7-"D#G)9K.X*&C"
MKU]].#]Y]8:_=J(H%[[(97C&A7CV#RBXT3I#/B],PZAPYO%%'G.G9J1+ >AK
M[].K.,_4E+X8+H=CW,,%CN#]EV,<08"Q8Y(-G ZG]$E)J-UVNH40"2)7(K"\
M-((-;ZT/UO81-Y-ZFBQ284(TU%0<*T0M#GNZ+>%$*I6$+>P"Y*5V* N**/)(
M<[??>H^LNE=&%%=02,L)H_QA]^VOYBQ]U5+VZOENFU?_@RO^!?-ZI[YWBF"N
M'4UU] &SJYWVP=]V(,)(X3O4@#60"JND*N>JXYIF,,K 9HIFF 3[B'_(LM#W
MWF&:'D7Z)"MF$6)*'<-CX+"_.X&SQL"T2#*,Z?S"F\$:>6,I\Y57<HH&WG&@
MRR_5#VP6!CR_G][1^1T3:"-CRDKTFNM7&>E]*2K*RAMG@2T#E""3B")E_S1O
MK<Z2?+)8BS7"9QY=Q3 NKLTU[1SPAHJ.N,4\+&,Q:V;'L:F4=V'&9&=_;.9<
M'(1F3+8+_]=Z/F<<KVL!UJL()T1A5HY=C;.*P2?P#3KE[Y9%F^)AWDYW*RUY
M$H(:>B.N+3F?OW[\(A>74]!A"5Q]TDU/UI<M_9.N5_S7992$TJ@"URP/ ,%[
M\M!T9=LK@/DG[A<1.?F$/-IG,7T9]Q6[(]-E0-YZ':*YDF%Z+HI:&",_C]O?
M:"/;.N=/9==KOZF:[ TL,M9YR*EY[D'C<W/=-$FFD+7<<4HFD9QO,A,<8T!=
M6[["3K"&T,0[H.&J(V*!OL0"?-X(!69K#1SY )BC40V"V3ZI),5*AS-QPLWS
ML^9$S4LA(QA:D[-XJC'%FPMVO>G;WP$]3WT-S!74V*:FPGE65KA0C:/D\ZYR
M>>L-"<PBODFE[<?8*+=J]3I;ZOUV=(E<'AW(G6/?+DRJ188G;%^XT-?!Q@22
M=GA;\$8MJ-P<@Q%+C#1(Q%.IV@_K>[";6;Y)E< [O$5\<C"TBK>18J0Q_4UV
MZ][^4&W"CE'6 [?&BKL@946("35"6*%&9BHHF90:O4]5\B]5\>.V2]1%-4IO
M5/AVA[?R BNR$?ECDH,>).X4)Z+EU.3O@/%U(L:597FI'!XE;"=Q81G+7/Y:
M<CC'% >@X<4(^05&I=PX$!7-W9W<<0V^%DWXN,3L^-$QM>$!^Z(;770SW+6B
MFV=:R%HG-P=RX]SV%>M$Q,J=59$8X0"L.WZ%[?G9#(?&.3+U9*K3U\%Q0Y_>
M_- B_[6@W!3I)G5SV\^F8#,QT>)M5A 5&H:#D>93ZHOG-DVZ0;4PI1_Z;%^I
M<B"WWKC PGT!Z9_FC/J^\ 6,S'FT+.?"NR8J-^Z\X3!27-0B+$WS(%[<V3SC
M>J4R5]6$%"2Q,'^D[-=VTFW_4878 L52I7^HZQ %I8*P2 JL(A4SV@E R*HS
MUA/&!5*AX%X"\+4%:0EP%:ET!%YDGDB<:GF;E\A>,N2"S##.;S<?,L;PJL4C
MHC_'??:D>M^EX]H[U8]OG7!EN,#D>$G$M77$+E[&)88/Y6][J_\)-H.URB2^
MBLE3F^0Q7(A81:DJY_:;\.B;P*HV9#!RR8(T1!'WY^'IMH):8:23IP8)MM^&
MQ]^&/)I6W$<D.2F/ZI#2"Y<1GB'3YJI@F[]N/@:S=1:74@]0[3?NZ>Z3NI6Z
M NH[*S#=AN%<UVJT[;VWL,O[C7M\Q1<)\%_(#9PVAH;*BW-X1!-Y&B! CO3N
M0"0)VS$%C5A2T^"^ZH1\0W[_?E&A5>&?%8"^?V#'<XK=O@8%EGK9Y?D6#J4-
M<X[:$>LB! ./NV,H3SS'+EVA;+V,^-TQ!>)G57(12 X9+$"D /<-)V<=A%C6
M:%JAJ]GRSBBMRX,A/QA/-KPV+E1)WE,LUP[T@W[),U2CH;UX#"N NX_G[8#)
MQW2+,U>#<%>)M/)+P1RW?*OZ/%O]+M766>$)?IZJ?T,H)L1KR06$B8&#59$/
M/=9N&EZ'X[89N((^03B$)&G:]1W0,*>ICD5YBRC XB][D[$T:AQ%1&%.RI6+
M.$[ %LWQQ&&XAYJM]>'D>FL1#(II7\=A5,PQ@W:SH"SO?TU4#!$U"TU4?]Z*
MQ]Q;C%B#.!HCLP#,E\+[[DJP\.F""H5O(S5%U =K>LU5J9.^YVBRC#!1Y>E=
MZ)J?6I0W1DUA^S16B=D!/*HK_OK^^/S]&=8@[L")/2=IICN+3J9#H!Q-+-X9
M<M932VM?1<I:(@!K.)8P/V[NCU(0,()](9C9>.("0V,0N9G6S-;@F(L-J<12
M@O%4GA<2'A&Q8<FCFZK=<.!+HRKF5=XX(,3\R.&' IC+Z ]4FC>!F>>^#O-_
M.#^QUFJ:32J\Q[ 0+.<LFC2QBU$%;T]CCD=3+H+<.:H'->P\]?$@6.K4X'+3
M4-[!1M"F=-N=D52W8Q94I3N_PG<S\BW>(PPAB"8AV\![X'_'5T&"VWB&]?],
M[*+YWBU91FSOPE*\I!U1C:"^!;&PMCW!PJXIE3@J#C*"'F8T$EI1+AOEAS"+
M66+B\5(F1DW'02K@TD458RL$$@64%AK ]256Q2I_F9*7S7B,'/./<[V3QL9/
M+9S59"%@N!B%5PQ\!V/JRT+KDW.DL$^(7T2YDAN&K[;9J?S0'KIMVC)2"?J#
MTJ/-Y<GS:$+%.]+Z35V3,/,&1HQ,BAK7.XP[ 4N^2@'?R%FT RKYCTCZ80Q8
M2GT)7$".&Q?$.LJ7\1A!FL@6,2>,S)PHO6#ZLIC.(^B:A=54+C_%0R7]Y808
MI9C.Z#ABT?=4U KHV;G@5AHR0PV?Y&($?= &E@S(O@(*.A1+:-(^+1">*RMW
MRT#8:JPZ?UH'HJ:9*@>8?J Q9W2QO[*GX*P2+QLI:HT$*(Z(GC4:7593#XU9
MFXN^=Q%?J79 >QP$B7X%ZDM&4T3"\*2/?+T#W[P1E>*,-.X%X15>1C/4Q-QM
M@/@I>M')1X79(6".D@2QJ:N2<)= Z6(F68^%M!;=<188.;6>X36M(<+S?<&&
M*=@8[0LV'F0A:P:>/LNL/699&HN90YU4@BJ$=/,$?"A7K53A+[)*,,T0FXQ8
M%",;*0./K +MPY\9O2#U^PQ9A./0_(A\YL81]X3 ,.<(]06V@=8TJU^$&FN:
M5=SGP^>+WACJ5UJ:2*/&H:V#M6Y8C!&9M.4N^U>:"L+[PI<-^,V(S9=&+_5^
MOWE%E%J7YQ4U?TA%17Q-J@+V:ZSP*\<Q3/H"_ZQ@7,CKH1H@%$RR%:;2C6<S
MMP@:##>MD;&LFD"TB4">6(F%0C &<$*JB*XK KVSN"VH+BM"IA XV)=902Q>
M2Q6"]163EY(B<$ODI1L)OH/M32>D'%F?**(@[S_!%7HK_S.&98YR7I'7KTX^
MGF%'H8O^1S>Z=-:J; &_7[!,[=ZOB9!OVI82+YRG5@Y=JMS2$(2W.97-XH4:
M2S^>NY?C:)%).[);-#1UNB:=\^)Y)^30)XRL6Z"#P2E%6,C 0QEF[TG?[5)
M:VMB5#\+K=P0V25+KDR'&W&N*&[[+%5]=+ZGWEDL"A($%(\D8&3723"G7C?U
M "7'L*%8>3:-.;,9H"-4(J"B-XWS&4LI.4Z$12IY ;499'W*RK?J,Z<V:MNJ
M"61@'+)@3C]\/,T'W6%^L&!K(E!KLC PK6!M1WQ#S#!L&3#L*R)'8#\YRK%B
M9U%+Z]OK2CWYO"[^#=?7-=-.J.65U  )/P;?:*C!!&S' $>G2@95]9GY9-6)
M>1F7#:R*O2RVOF5R2"5 )/RB93.0$X7 9OI@M=J@MN2OT3@HM3XT9]II=U1
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MR&1EI"1,3P?:O"+?23#'E'_KE&B)1448.MH#0'O)>!]6TH3A*21;H5^"(DH
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M6W!6XUDU\\9Q6'.'I4S*LCEQHZ=81,F>WD^=5KO-QTN=*MCUZ#M1T L;)N,
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MDKQ]LK#EFY_TYDYM1@\@_6L83B'<+[HWFTYJ55*I/O=/V?,LKH,YQS2#21,
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M8]&+AP/X(6K0YU9Q-[I[NZ'OU)F6[!+1$*-NXT8XB]9<.':YCU'_M9KC'T"
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M[%F*9MA]6X KA15L%S%2VM(VQ?FDFL& 4RHW_H(/5#V5EU$RYU)R_":,P#0
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M7D@Y/*-R)4F-S,ZT0R+EJ":VD8Y"Z9E?MF+ Z;@$7:!Z@)@&AMP)@A*^OLS
M$8+_F?O:)U*=K+DTM41,PD9.4E3KL27@>Z29*)A7QVYK53TYO%H*.A77WYLD
M <A#N LM7FNXGDWNY4IODDX^-K(ZE"2Z4[@J#+NIU;:J.L9RNQO,Z2EK,4=Y
M=%N;A:*+:?:0?=5&2^705E^$D_=2<\PCE&!AW$6%]L\L%R(,;D.FH'7+.UM^
M5TW0',=\J:?);EKRA7S1Z6S"#T#@RP!/U4]#NVD$NTAZK2/S!S(M;VDD\=Q.
M$K6VV+[$/>&^<Q+,7+ARO!99L!8*A]=I#=SA=5H:H*3>P7)]&2?1K7NB9]ZU
M)\J/'C4_NN6=*G$AKXGGQ6R7Q:6QR7W75M=[U"3>W.M=F*9'U4!OU@E4B%'+
MOJ8)EI]&)*&LB;&)O/ZD^BFP.A^;#L2Q>.H$]%$I 7/T%S6&<:\6$C!)XR1U
MKA,Y%+OS2&$=J=Y-F(+;\-74M=37?U"=!(1.PPVX=^IB:GE+\W#7_0'FLW+
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M6ZXY#[^%]UUW_?MNQ[O0_4%OX \'>S2I1T(_[_3A,GTN!(4MLMR?8WN^2MT
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M#C;?QFY/V4P!;'24F1C($$_PIB:,$TG@B%-*[Q@8:"H+]M>T/Z0]H.I!/\W
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M;+G:L6[:+U(PCZH32N_09.(^*^::CVB6<2<^C!R_S.J8PHK..71@'VE_O&_
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MOV28<S]L95@)4..$_7$^1!0N&@X"W$*MXD.=][B%B%PY=I J)S+C%2B\,-,
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M810Y68(6>A0:O*')<.3K#>,;<7NIUJ%R%2!@?BF! VO#@>GR)X9GJ#YE^:"
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MOJ?;6BS@M$OQ?BVC)B_>^U4T^1$T>?;HFB54@EV%! <EYDY:T.3@D98D*2.
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MC9CBQ"VGEA(AE52$^J",NA['9IHT%$!;9D#[<!G04@PF6>^1$+F)5?0&.2.
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M&!8P7#HPO$U5?16BB<SJ) U/2AC) F>:&>==E,07.WF%(7 N\H'!!) \462
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MIT:*!C?&L%)3[['Q"K!Q&^U2&%.KE&*)8>XD"#/E#N/!N 0$4-9UO;)VU:;
M#]5L>VHD!VG;#HZW)B-OE&RL=*%HVS7:!O<]^FAH<C(1ACQA%G'%8&<,G")A
ME?>88FDBWMC$+ZX[H#K>&6%9>9!"XSS,DJ_MYMLODX6 <&WQC3S4?_1 ;U[;
M\^Q(V:Z'!=QWZR1[]LK*N&YE'!Q^_AB=@O\O#4H! PYCJY"SB2*L7$PD1.V(
MR2M#_7AE5%/R:'6R0(!YU!(!''I_VNO6X81.'.-*34<ND&@*O2[9 GFM385*
MKC,]^W7_T&PS ?NX;$?"?^(W@(GN4>,#7QF[ @QUY8-4)CN(E"6&:NL2HT&S
MY A)MT/3*TF+/:_CK+_U^DT#U@RSM6NIJ,TU:D/WO[__2)-W22F'&" HXG4G
M31XIDC9R:P2A1M6 .M_2O+745D8=/_IJ@;^?U?&ZT'C#*>P1H,2K[VRY'&>\
M\":-D6+0ZO:^MJY5T6Z-0S-:*F, <2L6N1+<!6(Y)UYC$P5E)!%Q]4$F.NOT
MW*NZ &P7CLR#\>!> ZKF)(FC^/*\\7A.U _1YZ=_;'_'?P03(5<4H+!*3$0P
MWQ0(C;6@A,0QHA70SKBQJ>=[XOP_V?W?B?7FTX\G8/8VH=1FSO,"R(LB7-J"
MVJT_<_2Z[ZK.,(=GFF#!^<0J/HQ@T X&,5Z$'<Y;.U/!KNU>_S3' &  32BI
M=QKSK_#DQA,Z,=IMI].;A'J[E]S@DT$.IA( +I*A+M(2\[U&#\CQBJ_PI=:M
MMIT':WF_'[,3OW<2<]?[-3J6]_A*(&KN)A+8R2P@Q2U!P*,M,C9I!%+S@D09
M:)(;F\JTE;EB'\JK]S:KPA,?8,=C41/,:> V"<R-85I9$VQLHCQDO"I(616/
MGR@&SW_S$2QPK3@E2!K&P=:3 5 QEYST#BQPQY0P;&/3B#8H[ORJ&/OMSJ/M
M#UJQ)@'C8HD-XQ]73*P74)9T.X/8Z3BY90TBUJ_&J3JM_]CN&?#EYL7K]\;J
MFHCTUV-8I.>HV3VN"4^/@C3OZK27O"G44>G7[[8W<F0L_Y WH'S[BQLT*3T1
M#*?>^6#ZT?]W,)4,E?,]ZOR:J92:%NP!@^QK[:R!3':[%S4[8>NY6@KUG^:F
M^[?,IYM,M)_R%1L7?]CX.>^S,"20M<V!R2_QN/*9'O1:R?J<D *[:GW?7O>H
M5R>& 'VPW>PK.ZU\K2#V2Z_?;. _2/Q;?2ED[C(UG;6A,%* /'N )#EOIAK"
MSC%A/+ '9.!O*$V=<)/.F\N']AN*WV!I#R^E6&1'Y>#,YD!'K_5N%"D0F/QD
M?QZ[#7;'*45O@65US_)""+&A5A?#FV3Y-#$-^.I.U8?;96F!FF5G1+^JLQK_
M470P0G^6T6"0=;S.*LIX!]2JRED[&3!'64;CC*HKAC!>/1EFOS2))A>I&#D!
ML:IWO$N^U\'LBOG73-;M<S]S0O#UATZ6XOC(PWUM90^8K,P\W/<@2JOUT_8X
MV_WGFY\J(N+&&\"5.?@WR*E_HNT;=FU]B0TUF<PU>3KJVR8)[7;5I*57&EL,
M+PR,EV.OH\L^4N>P!]M(R]H_JD<F"='_4%:Z<9#F9[C99G?;$W2>#D?UTE1;
MY%5I&?7H%LD;OK^S]3$2%K'$$<F(P2(ABB&+<4)@IQ!+G+#>@YTJ<!M?T79]
M*JOA,OD==V++:0[CS,J+G;<A Z/O?JURYO(HV7V:S%TD2M9I[N.'3-^F\==,
MTY,Z"^&T8T>YH+TFH[6I-32^P^C!F1QTX&$($.NDSK#,1P\NQC?%I;(K*F=A
M#(".GMI\9N#*,Z=-1OSP@E%,>WKR:W9[]0$ F+V95-#+#J+K"4_.T:CJ)'#;
M!6CI-,HY:-*L+PWYV )M=CF[NHX' C&*W[(=V%"]QKM6.ZFJP7"2NY;O<0Q_
MZ.6S9IWL)&O:ZDWQGB;%XU+&]OP@6SMCUW2=-'<]?\OKI!KF0=T]P]50'$2,
MQDJBN=34>>62]EAP"O:T' =B1D!CYC)<V3S.S#75O!IGQMDDV^.WR%'PZ0L*
M]OP#]KSY"'N>5))I)'1,B&/)$6P/&G%FN.,J28GI]=@SCG=?7IY-D"2[54]M
M%>:Q9R9J\D?U.7X%0Z,]_??+]NLBUBA7V@;#292<<UB,FHGD@L)16IR"I;5_
M#H_]<[BLT259HT<?J022QF5 *E&5VXBSIHVX$P%3ISS!$=8H%;=9HS]<F>3%
M \7!Z=TSJ!Z5C5)Z60>;O,+'#)0L0N6*IMU,T][C@T-/]@^/OAWL>+S_]2.Q
MU$B>"&+*YL07Y9$VDB(*1)4D'W($XWJEF].X*QCHQ.B;<]O<OJP 6ZFR O01
MR@J\@_?,AZZ FV[Y^@AG7?&S4_DJ#I:G6,#>>)VSO^%Z>,8Y/ OO_?X&?_C^
M"M;V!_[W[_\YAF?Q@\/0^7"X^VV_FEWG(7^/_GWX'UCO;[[^O?/V$XR'__WI
M^/.'DU?L[YTCL4__/-[[](KF\/C!SBO^D5DO'7,)&</S.1^<&X@[#B87AU6&
M.= #.7L</YH4$X\J6&^XT,;($)E6SKM:7&&V6L"4!%H7(FB-97"' @(_'L%,
M 0%I2=*<>V$3]]0;V#5MA%6D&$] ]2;U:!]J$5ZJ9U&_^/GS7GJ[XF/R)'%'
M+.*.PC^4:V18M,@G"W--N%%B;BDM:S"DON,O]4E+?P/@>PWDRE>GG=$AC.G%
ML1ZQGQ^6Q)IQT]1.@?K3NFK%^Q?O7K1"K]/)L>6QS^"TG_T=<,'9(,-'?<U1
M[,:^[8 %9+V/I[5A=($PIY-I'I=VN'(H38 ECBI6U-^>']_(F])$;T?GP#_5
M>5BSH=SZ9/I6IU.G,8QQ[U+.Z[ /T]LPA-'KC9]ZX2F)G>H$!CN:$#^]1%[,
M1WNFX7-)U\PM563[X,_='41,ZW5.J3JI_./8 5</9@TBLF#*U ?HIYP*C99%
MWZFURK:.FSSJN@1(S ?D8]?GD'FGT_LZ#EGVSH9UB"SKQ[NMM^_0=N]/! 92
MCNEF%]T UG;5;3QU_5[7?JGZ9R-'B+=UF8FQ8-O-\=[3:G3FO>IT<G+<Y1(*
MN38$O+H]JH/V%Z?9FFRX/*C).CD=K9/V>.\?G8%O_)YYY/V6R]"1?;MUO)7\
MVOH<8UV?8A3#S^%6N+[Q4^8O7/+G9K^K'[YH_15;)W4AD_\]J_SG3GVV#:RP
MLWX#(<<7Z>@#FV)35R7?+%<2J+\].I[6^''CZ$DC-VV=^E[5!0,F;M"3.E'>
M?FW HA^/SCIVRL-D3T^;0<!,U_'RTS,'2M:I@:8NIG-EL9XU2/8X;)8$+,KF
MC.-D"4R7-X$7;S(^!D#)<@R]TXG=HUS!H4G?R;[QNHY#,R_5N%Y//SO6LO=Z
MDCP33JJZTD<CAU&!F-:77.&H=O&'?LX%ZC>I!B]:!],K;KRB/+Q%4UUH>!;R
MLVK_8..(CZ&NGY(B_.VB_LP@O^(0-H11KA$LM*.F=,3XGGGO&S1E0T;%>*;6
M<\Z]R'O3T-856^"=.LV)[ZO].D^>6?Y74ZPIG>6AGO2Z%:##2$<&9_5*!Q%6
MW?947D0=OP"0RHK6MU];V2G:K[)/?YQYZ^S0'S=L"RA -3B>+D,4Q\5 )J4X
MIJ:O7@I3963J@5P4I%I]'7H'R[7?5/*I(3(7X!JMRFX\&M>W&B_0<70G&RX!
MB,](%7J#X6FO&\<E0DZ/SP=@V]F\$0 !BF,=R==.UC%,(F@F3"E,X[][7_,P
MVO#<UJ@"U?"L6Z=4]1I29%NAR:=.U87LZF@:;%!5;U30JF%R@Y%"C]ZE_JB^
M20!6]24VNUVN!)8Y8NS7CK ,N".GYS24O&BU#NKYZ=1CFXIDN2;[:VQHUM\:
MW7^"^),EUN22CR*+XV=<Y&F/+J^#@:,6)>U1*E_,=6DFE8'&U9#J,]6K >"W
MY'T/;(B_S^>N7\$<9(P8/$O3^Q7^R'22P7B"M+>Y\Q['R(;LXO3>L:BH8'3.
MZ^.9<(I0SV22W!"0!??6)<R)MXQ@-VNJOV]J#4SF^I_=/$NZ>/\1.:])K/G1
M/-4&<F/,3LH>SIW2N,90S1=EN,JG2FIZ>"LK&*@)4-:<;]!PZC%<3QNZX]IC
M<2RWQD =#,Y.3J<Y9\V=1EP\HW!^YLG$=(;KXPCO@<R."[;5OX=)I=9Q/!\&
MF0=RZ<+FUJ$F[C>=GO%F?]6 1J1LM 5]RU$3^&4:\&$-]$*N.P3;/-QW?-X&
MIK&3!PWOVQ\3A-Y@>G[R ;C^Z(JZ8MW47#5XW6W.KN8B;;,N_MF*EB>PDUYR
M'%P\9[2Y_=+*U7CKW30;9GGC:O)'<G;H4<S\;>)4Z)]E$I0_S/E*8V&.-\_F
M).R@E=WPM>_C\OUZ.<$3=+I>)/U<^[$NS3$J00?369MM^88_L9];7VSG;+*<
MIZ1:IW6$4>K)1,8YL7?0RRDN(*9Z(4^(,FQOKFH*-<Y6M2MYK3-YK63U\UI+
M@NK*)ZA>O0W^*.0R0R^ T5'OL64^1YVD,<+ZQ"PF5FC81^W:^/X?.MP9C[+4
MWM9[X#C2>5Y"3@<[>^<?B?#6<.,15AQX+PX262.!!EOGM)0AY@ZK,PN38ZH9
MT#>9*.66*AML4,F(3.F,3W@NVMD(H#61P',AOC^<J,U9S^[U2=S-'"XVBV8J
MBWMRHK1V$QZD@_$QZY'P+F?'P#3YG"'SM=</@]A=HN28QU:CW/GSZ*-P,5#'
M!,(^YPS8P)&A+A^QQS0::ZD1:6.SUXWSZ3 7Y]E'(AX5V:T&U]>6OW"V[5U8
M+7GY^$S$ZX2:<17<RS76[50E^N'Y:6U)3#PRL.<!VS^8'4]3-KH*3:7>YKQ:
M]@O#VXQ-FVY3=;,^$]:R+CN?FY>8Y&-G$P?(]72XL>HV"ZK6ED$K-G3YPI_F
MCZN8IJ8G+]M!D^[].?O%@("/_X3@3_F2NK!I=H.V1G\87Y#MO"/;#Z.R 75!
M[W'!@#HOO3'H1IZH*0?8I=C+N/YQ';2YQOBZ]%;Y %].7V\J)1SWOF;)C.L4
M3%46OWC\]+/;4W-26YBU0^Q':Z*639YI>/J@ JBS_5:$P?9.8&N=M /(D9C1
MA[[J^[.3[ ROZ^>WWEWRC,,_,_;PY&#>V*+MU[[/<5QVO@YWZ[ WK,W'L;U9
M1ZYSFX(J/V#JU'J>GFR^-X>&/4!\#S:(JXW$_3B\N&5MA4ZNSR&Y;&%=412_
M=N+>/5'84B(D=T'Y2#@-W@://>4AJ6B)$?K6Y9I'AS!7IN+A8\/KF^][.UL?
M.9'Y2%9$1$:,N#$)F9#KEFC!C+)4<^)SQ</YFB63DD&W+=D0,0,\EXYRFN6;
MD[\TQEP3A0,)1/^@9$.1]%TD_?ZC]%$8+P)R6CO$!;-(1\&1"];%2(B@0F]L
MTA=7E%^8%-E><!F&AS5.?K-5_T] ^3C5PVFW.P#B7.^]C97R[!9#[93_^C$X
M9Y5/$DGJ!.(RVR7"< 1<GC I(UC%<U9SR&<V.<-@9X,DF-!4&,NT"=A%@K59
MT_RYO(Y:]4+*V_6%TV)J+:V^E56_Y)?Q2UZ0KFM\ZZ."(, U_&4>_+7V8(]*
MYS=E+/(IQVYSH[J;CVU:3N2TM.SFME-^VBKO)DUCCLZES+7&;6M'+*OIJ>*K
MT^RS'GGO3Z+-;OZ:KV?F.->^*5V\X=2U@U'*4>.3SNP%WJFFD&<YAC'58*8)
MU4_N 12ZG_MPC$JAP+=R?A[,^& 4;KT@JW63JIRQT13?FAUN9H:[36)-G4)Q
M'+LY/#T**Q^= 1'.\>))..6G/(F9^@X'/X_EDT]T3HDG-S69/"/D*9H:>9;E
M45TYHCGU>'2<:XR-7J!)[>G:D-=GG774:YI,5:-N2+:)IX_I;MX2&@/&7ZR6
MF='\]$=]H))<>NF?)Q$4F/WY ?1<KG\R<O^? ND<WX5=OLLZ)$5LM09G)W5K
ML9$Y<+-E-C5%>2JOFK/QRAM-V?2-ZR8.P^-^C"W7[]G0G'H=-)V]FH9B(7<.
MZWW]Y:8S?)KKIG:/4">F46CD"0Y_7#W%XQ6(6JW6FTM+^O("KBXP?7ZQWS@%
M8NDG@N:)F)^'L=WZC[/PZPPF7)[ Z^\R1HPFHIL3?GK#T:U_;5*<>R%V@*[W
MZZ8KDQ!?G08]F"SING_6Q4*'YS4?3X<QFQ5>)\CU9[^Q/D)D]6INO;N4^%W/
MT>C4UT64M)[:>B*F46(U4GI^E+\W3FUMG8Z.^(S#SJ-\KSP;8\B[6)!GD\0H
MES>?9OT-ZCS,^,4V',)>M$%KG%47V<F#40&H,50.9B<\#H][8=3J*^=R 1)/
M _%% '_:OW4QO,L[=C:R,Z<ZZ]<9!,X.JG7HP7950[VKIV-\:&)2YKW^(1,B
MF*!\1?OB5$/#/;/0IOXX*OG=;O(4XB4RV[Y1!D%=6[X?O_0Z7[(,QGWB//"K
M:M@L#V_[_;I9>RVU49[$/4=\D5P19[);+CQMHXZ1%PLFYYK$$0I4.=.OUQ\V
MQ3ZZ-J>5-L.][F5J=[>%.P$1;KC$J QM=C=/VAA>/+Y9^WEQY@D<,?1\[6H>
M';E#,.J'AO%,A><;K+>Z ^X8YZ\V7499J(!EIXVK_"J8R$@2+0BL/XX0CI*/
M1@AH9W>)7/)QICC*/P^C:8;8;U)I!S?>C"8T8&9'FG-'/Z;+J&[FT:TK1;RZ
M4-42SS[8V3W_F*B75F&.I+82Y>6.7*0,*4]$"BX$DOR:NH"VQRA>_S"U-%9_
M$]Z^;H.:;+K90U ?Y(#/PE1#C%&?4K!'X4UAPS[)>\OH6%,:F98G\/SCQB%0
M'[?*C;]RR<L?.8WG!C,JV#05W8+;P-WC^7C'R;T!KLKANY0,47+Z+N?TT9+3
M5W+ZEC.G[X<Y>K.%(EB4@G"AN&0<:^:H,HP#%Z#:26 ##YX,=YC//P)[^/_9
M>]/F-G(L7?BO,!3SQE1%$&HD@,Q$5MUQA&S9-:HN2E[D<MM?%-A2HDV1&B9I
M6?KU[SD ,IE<)%$N6XO-N;>[;9/,Q')P<-;G.4!S*$)/5*\;V_XGSC?M71ZQ
MC&DMF2)E63(B)+5$*5,0RVSNI$F8X^H6QL-<<(9G-]^PY$'9$[5T=&;B\?@M
M"2__J[S:B$YM,*]CZWP-V!&COFGZ)N;3-?';2UT'=8]%:/'VJ2;MD*0!O B8
MIF_V:Y'6EU/?1-G49M4(CZ"=L"MCW'>^%JB5Y*E?X*_]$#M?['3PIHGG5)_Z
MW,W\L#_WW7D5/*ZZ: ;>/_ 9'*Q0"J5(]5@]4BB833]*-*=&J;BJKJFII%(^
M!E:%^J16NSU.X\SYN2Q682$8AD,B@7$5A:4E'.H804HG*Z5O5;M*LW]A)+&4
MK/:AXS")OB!U^XIWIKNAH:?"BJK0UJLOVMU-JEHY:Q]AK%MK:OF'OP5Z7)C1
M3$*]X,1W-K]?*;:=)D7G44U+E*?.I^'H?-@)I'(-(0_V$B.Z? @7!!#6:HHQ
MG&;]:L22]HJ.W?Q,VP6.'F-,A=XE7+KH"EB/9!_@2X;Q+[/2,1_) D?AH@H>
M0FM:,?>$(:BK-FI[<<M]8F*]W9X_LJ%2[3852U0KL >2W.9I*;+,%CH1.5.<
M)T6IK,I7<VDM%RKMU*-_,1KOCJ9Z4DX'RX;"LQ!)VU0SK38H3-K;_72$O&:)
M=>"7N%P1D12:2%<DH-H,U])I72J%5'?9-75KD^O\T-O(1YID!64V+1*>"L?
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M0"-+9ET"BIB7G*4LMQYLGE)YD_:=[72U-]PI2]@/Q$U\,]55W_85@@3NU$6
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MMX5B&#\QF./9:(QL@8L+IH;Q4FS(02-Q9[B=8.R3@8OT1PY^BI#IP[7DTK,
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MJ9'";CW)NG!%@U[.-Z&X32CN(?K&!9@4(A-,E$()95.56P,.$=6EXYF5^@:
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ML0&#405[:A75+/DL!$Y$9Z@/I?.Y?+H\Y7P2(XR*42+M\[$OQN%55FC@3E8
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MJR;<:__XD#4;6ZQ^O'M4&^R1YJ#)ZM_V!ONMZ43CG<O]S\WO]4%.3O[SJ-D
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M8G1^;B/:<H&?;8&#HMX9(Q!Q#HRA,!:9%!+2+AFAC*;<FI4UO#I[9F#F#Q4
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M&$D7I3-@UL#EHQDT\>SY@LGU/QPWRN[&X>&??J? K!&U'!+67H$_0YP"AEI
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MVVVXL.^<#B\%$-VV?CBBZSEX7#Q]"=R:RH<;%_#&];@M,(4T%#4S8?+ .QO
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M6ZO71/,45O,HT\QK2?*=BW86D0IXP^>V5>P0YAVJ/NA CIAF_M:YR:DH8B7
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MG[;6WFU\V=E\M_;7Y\9F\]U*(W_Q^<L?GS?7-]<^;6Y\OO,#+=Q[F"T]S>X
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MS_6]%5F68IKLU.%#"XL/KYHRU>%#CXL2T^%#B7GC%*+.:,2C,T@S(9"A)J0
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M1V\P2=$&JDJ^7\CH6O9DP/?:&N8LY8I3RK4!VA]9" P;3HQ<:D2@T<=9(7O
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MP>R/BNO_ZQ>C\=W><;>7 SL/H@UYZ"#X_?(R+9#5O(06+L;*[BXNW6@!<>[
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M9!%*W4P6^A=,H3!\&R6L#+?^&XS\=OUNRD,U>>9NS(W/N_J_%<<?A@8411,
M"=KVN!]_&_[R>VCUC]OV[+=6I]#GXJ3?JW%6\03B>+K.5QYF^76U2V[D"A$L
M;Y175<:J&U=[Z"O%'OI$_8?R.\E7#+[Z:[Q"[OF=ON=5KQLLX2N4L9<R6+$B
MI+KM96=4(1H*!\AVO/N1MRR)>V51M0<=.J-441EL\$R5>:9VX(OYOF5ANM?\
M_+?IZSD7.9R(K3+%FWQ*T;Q5^\+%O.6C L'++SXYRB8>H\[D@SL&O/PJ;:^D
MW-I\\S&GG"CCSM+*RGC='I2R.MKQT?;ZVOG6SI^'S?6#[WM?M_!VMCJ^?CQO
M'K;!POA^"N.&^S=;S7<3U=&.=OG6^M;/+?A^^\,G&/='T3P,!WOK6W3[ZY_?
MMW?^.(+/SK;H)O[/^>94,6\/_U@B.1),6<09P<@D;E".CR(4&#G)#9[(,A%F
M69H[MG![":U-:G!ZI>#TP)S@&IR>'IPF2Y(+;6UD0J/ 3*ZEJQARP>56*LYH
MS#GUE&5PHM@L$[Q(_52>SA @XCDM 0;O)W2S\^GI3(&'W;.V!:[OFS/N2'P.
M<V"\?.HUL_V*E^2[O8-7LV;/VZ 8WYZH%^OY+=8?IRP)&HE+.C"$34Y+-#XA
M:_.*K1C#R4?N'5@2@IIE3AZG\/T-:K+@AD8->V\6]N9MJM2P]WBP-]7N,3@G
M<M"QEF"H<),,LC($9!VE*005N4A+J]*89:T?I\#\D\+>'.CS17GZJ13REQL[
MLMEI;!7!/4!.JA*G[]<^_]%H]?LG,336/G\IOD&8KHS^,5)UOE<$*W9\Z[A=
M1)\,NI?QJX,>#.W8]F+'E\%,15V1WK!DDCW*]9"ZO6^VTSJW9<*".[N(7[D(
MH!L6 \E7&"V<U!T6CA^M!Y(/"F5-XGR![_$,QE,"R475)A@PS-!9 V0R^K+8
M4\@Q+W#\R$,.PRN',4:Y!E.13^%S6'@AB:B;T,GX +L.YKEZF&$$0Q65=!EI
M[]MP1EFW*I<TF(@7?!51D=OC#S4V<:<Y#*U\C^4;*$->8S]OZ(ST23BRK<[E
M%8[+1B7]1J<[:)SE?@BV%<;?<1G>E*<_E[/+5<'Z9:!^%51]5$99 P[UNJ=%
MQ%..MX:YZ/I6D<U7A*(5\;G%]58:DX\Q:]I[<3CV[C4/;4.>H5B.^,)6A;-:
M1:Y?)URD[X56+XNE[_8'( MK8UF %YI7R53H%J\CXQ&\K!QSVV[YUF#B$?O+
M-[R#:DX 4_U)NZJR4S6B&-&>AOUA6^TBP,4.AE62&T7]#6**1YA.-=F\YIY5
MW9^9SQ=!FH^J#,N<VML?5"?EUU?$T0QR9%D1YG9QW:KR<;\% FU[(S)1)4@.
MNTL@6[:MF9*Q0GZ&(C62[#E,HKPN5HUK1Y.S,09IN5)>"R:](=A89UR(8C0B
M]SH7[41KG4_#(5ZD4)*%+9_\]'G I'G^<9][SP-)#&DPMA$'2QQI+R,RS #Y
M-%1@[9=6"5V92IVL@LNRZ YG/8?#WFJ^4[)!4VE9E)X3%S28CM@RCR5UF-E0
MS_<C)&!<5N(\WP3^^W'?*\I]WOFS3EK$K?%(9Z\[EEA&$:W#"6@<7IDJGEU.
M_16X<,UJ<=(OBYP-5YG9B]?@8!1<WOV].;F(70K7+7-[[@(OUW9LO%;ZUJNG
M^I1S <H,D3>=\#,J;RQ7?J7>,&4Y12J&+&]2 <S ;R:I8 Q.P06[M&I6J)Z1
M_9-Q9D0J+I#F_E)Q%Q"JI6)>JP[;6O^RKWDP4FN*P+;%B!,N01*20])JC9VU
M7'.\M*I6^/0&W[\>T+^JLI%1]IKE<+KY-;2J;U3W KM#Y3AY=>6XN@9<70/N
MB6K S<S3>% 5K >@Q".\Q^**O[6 B+;\+=YLF97[=X4G4P7&'BO/JJQ_NM8)
M?UUZ/,I$\CJWZOS[/K4&"P-4 0<-I-$0AERR!GD,TL@2E2&2R5RIF[Q^S^_B
M6QO<7(IUU(%ZX?'+'Y997D6]Z4YUU @4_%'Y=#]GG^YO]_"&/BN\7;AOGS89
M#);+%5PNF7?-!A-RA:K[)E%=ER:E]?W2MJY-L-(KA,T_=>T1!WN[R]XR<^ME
MY!A]&CK*O\!Z5"X/;SGE:B1QM<3(^F5<OHSQ9+3[QBK>ND/YXD8QWF*WZ?DC
M&^_5&/Y-!/[<[\V\FG"@^_76N"%AH5A'MA.L(L4B\A:"@KJD^743;(IF:P_N
ML;7S$>^>[[5@C'P[MVLXW^);1\U6$\[;^SP1%'3XA>P>^O-=^N=1\_S+S^;Z
MI\/FT9\'S?5O8N\#G'G^[6R7;M*]]??M_YQO3,5".DX,-<8CZ9A#,(<,&>\=
MTE'%R)GSU/JE5;%,B5[F,XKJSB,LZ%Y*]*)B)&L K0%TCEUJ:@!]/@"=C*ID
MB22KJ,J1"!IQ%PRR,07$+'9>$6N5%#GS"]/9!<%>'(".1T;>WC]37/K)R^74
M'I)%'>P;])"4KOH1AWGM$JC](XO@'RD6 O62_"159/5HO.TS^DG>-)-_,V3]
M4;P=DQUUWP1;Q[M'&_#-I];V^AK\_@7OTG\.MC_\V=HZ_ YC^-1N'G[#Q5@F
M<Z ./P&KWSO:^Y!C03^U]G8^'>Y]W>"[1YMGVSOPO!^^T&U@\#F':I:[(U%A
MJ546*1P2X@Q'Y)RQ*'&N I:42!J!K2NZ;,B<N?JK\&?40/<6@.Y1O!(UT#TF
MT$VZ)3@)FEI'4&*)Y38S&L'<$623]%@YPJT'H#/2+$NE7@30W<T2?'F,%MX_
MNA^KO=$JHC/?TDRP?M&X];@$K=GM^!JZY@U=TX7^8,9\DHPCIZP#CJ8CLB)R
MQ V+D01K<:ZEQ9>%ELL,W[% Q^-1KEH+GX0]U%KX.%HX22",CMXST$(:+$7<
M:8^T-PHQK(4.!"!5"R 0>!F3Z6Y8CZZ"K[ZZV4YW8-O/'_DS4;&C-@,?_&I>
M#<P_D&Q5G>=&H;T&]/D!^M84K9*Y$"FA0*98_/_;^]*F-I*MS;^B8.;.=$<H
MN;DO[AE'T,;NH:,%;1NW+_[BR-7(%HBKQ3;\^CE9)0$J@<TF)"#?^S:VD:HJ
M*S.?)\]^%.*2"F0QEB@:2P+W-%FLLU@%*]FF]U/W[%&9Q@IC%L9<J&!<&'/!
MC-D4@0D5H&QRCIBA!!B3!>12 ,:,F JEF-;)5*$]5<7YQ<1&WB]C7A#;TVRY
M5?WR^HG8JUNVZL7X8%QG;;?2>#0>Q%9N6G<P/IAK558W$ZSL=#E5K2Z+=%8
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M*1SW1L/UBU3YYCE[17F4DP<OC^JER*,O#XYZ_:I<U>K)H* XG2EEG^&J/_9
M"=LXZ1S =SZ_^;SS1\Z5?TD[G[=!N7IYTMG\\OW#O%(&G/GARX?/+[]W-CO'
M>[MO#K;_Z/ /NZ'7V=T[[E 8QV[G&RA[7_YSTCG9V?AH;!#6>XRD)9529I &
M&D318>FM-DKIN51"I:+AVGO&B.<A&$,Y_#^AE@7/B1)-&?1LVI^@U/G3R9J1
M.O=MSJW)U:,"<!50<CR;.WLZ=S73V5ZO(M0T[O70"-YD\N68#Y4L EQX\30%
M;UAE]-C,9ODHR_^ ]_[:]? )D%>6&JJ<PG.IBO80WJS7<OW#<46-[58WY3;
M/3A_*L.=;7T:V)I(<_DK6-9,X'!8',!L#.&XRO<>#X;C_"5X.7O^:\,1@+!B
MW&YE1,DMB^O?]>L#Z/05KL2E\\E&/]DN/TD_?XJU%?2=U%;@O-16*+45EE!;
M85G"C5E6Q81-D(3[0.A_#/KCH^'6H>^-LWLZUTV8SM7.J8R]>M44MC=?3]5
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M1\>STM$6"!3?*_%("DX9_W<>QZ]Y<-O]KW6PNZH'=U7%:HEQ[%GU!3TW&P!
MU/Q4'>46IAJ4R:/N))CBW-I.J!7&FG=M)LAJ^S;BR5MGR8[YVUG[/=W[U1KU
M<ZFNNDC6)'JY^1S;G2C E<A0YVJ>Q@J,:@Q=AYE)TDK;['^VF(L4#.-!8$%#
MB$8K/_7Q$:PN3IY<$C,_O5"!&6;^#LQ,HQ$@+$B$60(QP@)'.^L3$CCAP%,2
M4:BUY_/UT2^/&3B3UYLVIAGE)IMB8OR2=W"P!S9C8\(>=?A^WH(YZ3M6MB:
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MY/=F(9^LD &H&AGN<\:WT5D)8D@2(@A0/I5$%<@_'<C?WNA:(+]JD/_4*/)
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M_'(/EA[<J8ZLF_,\]]GU;XA-B/_%I8R@R$_ QE" #=R-%-?(6V4U81:/3V)
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M*)"*)*.?6U.%)L!K;L?K=D1CLH ,A&"<?C9*_&NQJ%^FL]E$E%9+5H5H:,F
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M0K:]Z;4CM9)2#T0EIM*[7I?(G2C?"_#3+-+:BY2'$_#0)N.\"O+"S$@*[8S
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MF<[.KCOBS>+<YYF#YW >/ %,&9R;GW]R,/9X.O]PNJNWF*\F*$23I32H7E*
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M6369&NDL=&+)D)A*@^^0%+%26A(B8R%3)H'7OBZS&ON$2+*7.#?H=8@H184
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MS!=^FLK"0[/UD$/9H;PBDDJ),Y= F& !K&!"Z/K[P(.03I,1^\J\]LG%K3C
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M$&E-*7_C/<G..<NRBT!K7QE_'-7)$Z:O)H:Z2[$%X3_]Y!)&SG*J'+6$98,
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M!\Q["(]M>D\RTEA+>YV"C+M(\8"AIRZP3C#(N),V.L:@]A'E 35MLK=)2$]
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M;0+&L0Y))1O0&2XA$RU<DP0$D[O\X[-[].\E_R<>_?L(KW6NZ._S&=ZE1NG
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M:8CW@?\&AS*"D&<U+ND%+M.1?(+RJF1:'MPBF)OC1[9YSFYYW@Z%>JOY'9S
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M(P;2<? B.B4$\/1'"1U@QOMA\2@?HYE@&L#?]S&"N6Z<:Z#]ZB=NC&8-]^7
M>X>"_\P-H!#DCR*!SC :P-1&)\I[8"36).[PIY1*7BA^+.6C8XO#BGQDB@,A
M7"3H1#2L3?9#Q*(5W5N@B\.K@&?G<Q5R8J&\KH.@G:EK$MPJ]GE\_%)33"_K
M48NE.MN;3*2KW:6%,W2#G&E 0GO^(,^/*E/P/4;8XO9<K[YLVJW/.0/][_SD
M4TV=W97>]#SP,I.)+G]U47 *U<.BZUD>GD]E.RH'D8-8L?6^+KF9G5HWR/.P
M5SBE[-U\#JH1$'%$EH#B*RV;0$T,>B&N=_'OGE X?.#I%F%;ZYS+)T?OTKP[
ME#671HF)TE/C(P\>J3TK"J*[&$S]_F03ET)B&B+P#^[+4D]-^]<VP?ENOCNQ
MM-1S\K0K!/C"F:T# $NX:!:EKS ,-E!DRT%AQZ84O!D93PIH77]EZ,^"=),X
M?\],)N8W3U[EBN&V(PQO;!DG)0<:TN.X^.H6P2(]KQ$<.;I-X/K<.6(SNV >
M7IR0K%>HXYX=96ND]YOQH')]J&^<G]H#$])G1'ZG 9P?OVDYR^"%DW0M[@LK
MB:^:N/NIXEX<\0EQ4^<>V.V$#: 7C!<"YZ\LKL-Z(I]_GD'X5_Q81,!,AO::
MN<P?V$8FZ<J,R#Y%L0_(!S7-?4,U5^[0T\E%YQTF)S RHL1[)2P9P8OO,YS[
MZY22GWUZ"DNZ(2/Q9D+XE,E*^'H-!Y75NAIA#E(PR]"^KLLM%\)U,!6544'8
M^3)7Y/1[^%"+K#0>^95_-7N+^)N0$2<-U43U5DWH<Z!Z?'7E\/E]WZ;F0=0:
M+!''%]$6F63Z\6ALLZ-C-SLKU-7W+YK*<2%%@<QOO78_!'+2^\&#,+'F0J6#
M]74%\D<V3QK@'DB/VF1H[C]>NL;*IP'/?<@6-* V2IT^W+4$,QS8D7F_FH$1
MU?2R4]!7W:+K=96/&_CM\"I'?T?<2(5&2G"47AIY632HS?'=?=8-]C449HG+
M>BT%?$7@-VK)PW4*M'/R.\OPW<^ZHWZVUTX7XF4T&/2%M8U4Y00E\VH3]4%&
MD@5U@"KS:AV5J.GDP]HEYW1%HV<-=WMVX+MR\-%M8MZ16H],XN.#!B%I107V
M8F0VX@RHAV_%!,:?PO/TT !@"RDQB7FTY5+NH&PZ%I3O]VCWX84=<PG. N G
MRI<.V#.@%?[JK3;0W^,<V;-V7"@!$\G7'?&O>5ZMVRQ :^C@Y@:&%?/(4O!X
ME0:P4*C3[4,)78KA?<3+8%:DKO6? XN/7A.K:@?\5O%^G^,3-R,'JTY)=HV?
MTBT@0896M,!2@CAQV"D,6]OCW>F-78W/L_;&ELSA_$HM>5>NBM\X?D$E%#=D
MGQ9';CO?X#F-UJ*KEF(J%/Q"$J''U% C:X$ZA%7NXM27GA/NOVQ;\*]3.&@T
MA-^$^#O]*9_6R)C]S$%:SN5;D%TNI!JJY[2,*1I3@SR=*LM>10/8I&T8HYF&
M4BE(T)X@TTL#1+K$O6""",$(8H9"O\,-L<0B!=']GP:8\Y(BGDRATIG?P59Z
M4?X![4H1].D]]DUX7[?#RN>:K:!EU11$M7G?D\.Q-V'^J@5863/_99%<A=#!
M$37@0MU:M-Y5*K=B UXKB;"-;4WN%)IP $>BQ/Y8>/CKQK?MEQ9 ZZ\/G%]L
MC2I6"CD^SS.B]L\*3]P>>M*Z$U'B3+:/-2)HCO?Y>A*4P]B2A$<KWW_BUM%^
M 9>9TSR&X&NMT713 E ]-QTM*"UD=4BZ?P[!]=F E'2S=J-<9[K^UVI'W8Y7
MC_S%Z^R?L]U"_%8C6:];7.FS UVJ?-IM=NRT6ATX]Q?O]4B'_\PH=JWY>-%=
M.I85$V< S5[%!]P^1?FHZWO&ZA-"]RG+D+0XZ08-.'5L1^<B9C;*.X0;"4K/
M@FNG-F%US2[NG.8JA[>^<*P*RU=IP<9"MM-M>3]:A^7M"]W&M &!7$Z1("@^
MP([\)C #O5/XA0:4S^;^4R!D89-V^DA(G\*+E)=4C?"SXHLT(.E?;HE*OYV.
MJK_0_J#XBQI,MH%7G%#.A<I']:W'<9P PU!X[4!1@S!9L /#V:[="Y7P6LA/
M;DIQ^1Y\L5E.ZU]F4A1_U?N<"YS9_3\1E<'<Z1]#\Z3M7J%ZPM%^1>+(\57F
M)M58%,=AV]]1^-#>(TV]FU-7GCENU3'Q&:=?,L[]:;-TZ4<.S]HHXC&)/CSU
M7-37H%]5R!:ER"D:P$!567'V.KEM)O2RNE\WP\2L[=1+F3=V&[F2-OGA#(ZY
MP;>ZM=^C>A[J*JV/IZ,;[;I1BV('!N&W2;WXH36OT^FXND]=+:WMR;S?[<+?
M7'AR,JZ*'2!!J*SS> 5Z#;+ 7'A8?2][Y++[K%QHOORK#2$CY?[UQK?[MY_@
M3'6;&8MUDG]F(!KI"=C&#Y:3],FAH!/)E2PT4TX7T6GG1K^7$ZLJD;B-O+DO
M7K*(H%-J7Y7]Q$]E"W+?<>V:^I\N.6Y&F"/SD[#.567W9%-\L7>#MV*+VE2J
M-!O?_]4I@;VHS41A-FJ%MSQ-06L\4?3[WLKVG1FYA)L.%V,7^^.SC%TQJ#GU
M+0.H&<(,G*M SL'Q)GLG$3XSP:]"]&5 ]S!-2K'%9%\D:_BO^0Y=N?Z;MP[%
M[QP*'H^OTP ((HINPBGDDFWA67S9G%AE0NW\XHU"U]L\)[V9AUYYJS%RZ*+.
MW=2WXQUFF04H.,Q>'/U(1CKH##I!^#K')95F1WBBV)M?;[TO/"7N+W<>^?/'
M33X;_V'B6O&91!RFY"#%D0M0QD/5.!2O2K^%XL%?)^>+<1;E*^].Z\0?#EYO
MV @T=A\>,X 4(NS!+_@J8CG(@4];A_6]^MVL)VX-MF%]JZZ>Y;DP&X(V"B]S
M#C47#S"63+XH>])RZA ,(LEJXV1(DM3%!<B.'$'%@4O]%ECYU@GNO1\0+N5U
M;CT\$'=W_6?>>8:+Q_E>]\7."Q])1>NSTCW>1\X[:X$,>$]#\!0>[5AD\;T3
M,0=;*,@M2Y!OG79AE=)P&1%UMG'J>Y,B356>>T>O-@DD$PC'H'=.87".YE-O
MLVP)&47$W3;$R8A\%76U>+7M9NG]&>[H7;V[<]]6\4&;/;5\?QP4^M!9#C;I
MS[P+'%>\_O6_*TOS?#ZDTB$1;'OFP@;A*;W22,)4MJAU/84A>!VDM]K1Y),9
MWUSO0^]I/UBHXVW_,NO?8=>\&-=J057+Q&;8_/;Z9N_>(C^FIEPUB6SWY!PN
ML-E"A[?SF4.$"E-6IJS\I;*,N <73K\=(<!ODZ^"!Q"<&3U7403XT&,W"3XP
M"<M2I7G8=*_,+FC10N#/RTV?48F8QV- [<O_*DS$.Z,2H0A&,/TYP@5]\.$W
MJ%21N-N:>L&D5/L%A/)8<Q<I FJNP:*A^*MZ;MBPM)V5Q3M-H%[U\A^AG!JI
M%<=/NS4+\I(O.4FL.W<F(#'TF+4<$2_;9A!:[WQ7=6EI:1%C:A46YF/*E+69
M^:JNAKT#F"E$,T=5X8]Z8>PP'[0P^3*EO9.C](?#ZI;VPO?/+=4"!E\_;"FK
M*I<N84XLOCSUYJKG?6^!J#7+31CYY#;Q!BA(<@A775>(1UX$C2UNKC"4R#VO
M\^%W_.KW0"QQ\RK_.P7%)$[11Z72Z7'_'I-.DD6^HSQ1\UE]14R:2=D;^&__
M,M*M1XHU^SG>W3M6OQ]\<%J1!I@4\]C5#KX)6\NLI4,ZD%XKU5XHMDZGJJ4O
M^"'CN8"Y&Y.GW^0)3W\LS3&3NU])<?^2K 1;L<F](R&M25(V-E;"KU/9ADI7
MJ$-PO%V4*E9A /"K:)H]5.4VUQSZ^OE7[)WFD'&;E]_$+8,49:H!Y+*7OCC^
M**%)',X.>EYMFO[[52DD=MRRH>5N<:R<"&MR\=EW$O<Y[;*HXT7UXW%HC[T%
MV%K@ #310;,POQAQ9?JO=Y%9XZT4_W>+G_%M9T1$3)<]8KHE KW/ ]VU_N].
M?]>8/Q1M2@YAE=I=4/SYJ=G>,$?V48]H_J5; Q(GGNSX!6LPT.<!(BMJ35H\
MF5Q.IWJ.,&L_-[!E;)Y\7+L0X9H:7B!::F=RNR;]@HA4<>8:6A@A0V=XL@37
M61\O%U6"Z_%SF"C?P)ET&M =5Z-?@O;4C++MNS(5T#QJ^].EN;$U8M?C<8R$
M5_G+E+\ OX&4*KT>9YM;&BEQ2,'%!8/Z8GQ&A[]AS+,<RQGZS]P&"C>$%W:B
M%&%!-Y([^3S/?5W#]W^X-'\VK.\4C"96/71]-B&<XBH==MXT<FZ;3IOHFYUT
M%G5!)0@=330],L,XZ4>EG[_RE7T8#6ZG$J!\R&]JU%GZU&#VJC;!UM9<JUF@
MO:L2&Y?U,D0\ZC9AS>;O 0MHMM.H"43:):#\QMG":XF2392&IHY305QS"7E$
M/?GEABD?DR,Z]O[\.J!(/*F7:CYF(P6093^#VO0*8<9GQ9#-0O/;E] _A*EG
MT1*45IN.%_><1PNQE7DW/$MPDLR1^>230[9@$:$"2P,\)9&C1=TH'K*=<(:J
MW//7E$\R)KZNAA(*"W><&>9WQH\R@HKP=O!C\\)G-,!)E_Z(MR8&T/)5O/6&
M&0Q3M"KX?88N;5G3-YG"F$TIOAN!H-;D2<1%\+VBU:?M)_=5,DU/CF?]0EW^
M1P.H[$YN8>^0W6@A_QV,MR1"..R,C>@IWK!ZLJ 968G._J#6V)H0&$%P^/Z
MY=IL4ZO[N+1(   #M\CO&'=X%I&](\==)Z-:IBXABC(=F.HCDKF'3JQSJD]D
M.1S P7.N,JB>2[IWOQ7G?F_**<M,PDWR_/&=1OO-R[3-4CE_\U[4MD.+!;?&
M\AZ]O-_2^2F[_O=[?K[(H&UG=WK8OM*E>1#80>UMMZ3F7S60""2+CR6CZ\9J
M1HJ%P"SDW9@92DX_ZCJII4N !L0]@6T,' :2%.=HP#\S=SB<3FT=Q0A=@F<<
M@C<26O0^?-'YV8VIZMNWQ(]LGRV/JHG(EI@$S!\%BXH*,+PG< P5BH).&#W/
M-<OTO8&:9\5;SU;_:$/ 4RD<;8QMO:^Y-T^@3\'<LQ;6UV'=JJ#2K_H:Y'0>
M_^_'"(L9F3J"5G[8.3O+3,+I?(L-0O)5QX%/E!_?7A_63A0M.O;KGR=L9B D
M21J(RWBFPK/>>Z<)EID:R2&*_HQ>1.NWL9 <5P&V/41V:PYA\=XYM0+P*I7C
M+=YS'9+N\=]W;/ZUR'%MJ9/F(L^NS=7:]=OF=X7:%TY=D;YTI6PD8;'F=[X,
M< NR'8JNT&I^Z_Q[^WSZ\H(9Z].:T-W;;4,(CRY?2@45 JH3'])IZC:XC4%'
M__VALJ,!3;0+_8F)/]7^PI"TF,18-4QZD_)%+B,8C;>P7,B ^6;-,]*%#;\F
M!T&KPQ-"M$QE\*N;4>FMZG@B>FM(2X<M&F='5_5ET'T7E! -V+DV _MK5<R3
M#L,LRMGAX0/](<PWRTOIFC3KW&[7S#3,,XL%.0YGZE+VTF=J;&V9))L]KMIN
M^>?T^5.FDGR1989<BL&Z=]X9"0"PDKZE?Z\HC7X0SS$_DCY0_K TH8]K82'_
MSA!*J:9[:; =>[IZG@HKYAE1!;6Y3E(G5V!/WRWI\D5K70)6C(HV8&</H>!%
M%/&N16"/OCBE!J%>P1A2<KU=(55*XV>UG.MLHW;##6?=0WDLQ- 93E=O6-27
M ;(!#:@_"Z,HI:)M]'414O@A'"/>MW^5N=--*GB/[_?!W5'YY4&AD&/Y6Z@4
MJ&\MR521<1B%R44W_4-^A]4G)9"=WL-3FG'LT!U5/O>&P3_S-M<R]F2-SUCZ
M#9OXS%%>-$DJK+4.K(I3Y^VT>"_->4B)XBWF#>YZ74;45-@$= 0$<GWKI@$"
MY@&^^XM4MOKU\05A(I)23#V%['XBF;$DMI>Y8LEMID>?LI]*'G:.2OS+V01=
M&[5S3D#&OO#X4#[@[>+(.OBCGG]VT9TR%>6%N25;$S^V6K(I/^ZG, 45_SL;
M8P#-@N*#'KVC-.K*]QA;]HG?>!U" U(RW\+?Z4N#;_%'3F N-G!>O=\AX%FU
M=JHN?]1[7P>]O[X7S2_JCXI%9+<8SXMY,#[<'/$+UCQ&T86A, WX\A,TIW[)
MJ*6^#F$GK6.A.XQX- :."\*B%G0PJ'A'L\89,ANJ JR85:K,X7\X.(G[927#
MEQ![_2-D)/1M]R59QA\H]]48!]3.--[\!BA7LJ1<@$R)HHLI=YR'CHH\^E,A
MZX]6N;PS5G>/W/4^!-)/-4E$>\,2IA"RA!<F4^<.J\\=6+?DZ6V%,)=3/B\N
MU@T?/SCYXLN.1,$"'M5?RQ6^W:\OA]]+DO?>P%?4%'A47<:II;6T)/XLN<WV
MY>[NZ>5IYOH9L=^*C ?K5&ZYAL9IE!N,V?M?2-DMQQZ"T.Q%Z<3S[\6X+H/,
M-O3:[&8L?^))YD/1.3JNZRQ=O,AW\N"WUUAB C]X+8P553O\T=*V2C1S\W?^
M*_69]0_KQDG6GA.=](/5:, S&!Y%>5Z%HFBOVM6A>H31/\6@G#1@NY"N(2K3
M%H#C.2H',^E*^!SQ'"4;*8KLAW&0X;IA_[(2[D^'C(;.G?_VSS^C4VO1#J)&
M>7O0 =D=_#HY&J5 ;Y6I("\6%0NMRXK9G/S[SFT&X5@VM,85<.AVPOS]N:17
M0NM+LBIBBK]/;+Z7);^DITV*+$90^8;FT=??FKU@4>YH^/CMGV>G<U3*/?@=
M=_]RZQ**[C!^JJ5/S9A7A>I3B# 2,UENMLDW/D<)Q7C7>TK@4G]+-H>]W1\I
M(6@"@*!;P#P_J9DUGT4LHO=C%P3WS :=ME(U?2,_!89PZ;"Z%WXIGI>-*WNU
M]FG_A=956<.[O -1S7CX33P4]P6[%UO4TIH2'&DF-]FI'A7F5F8.>2E94Q5"
MO+N1RP$]=IV=8VT3_98ZSVR$<*+;+@NVWNS\KL]'OM3PW/S=@%0U2J_]T;9$
MAJ^ B232(_,^;*FVG6YX(1JB:XCG("J!(?BJ@;SJP ];*U#[$"5[%K&5R!2I
M7Z:O*&7>J= 0#8;C-_131>B%C*73[I?R5NIKU>U#F;6CG0/,^ (4BTX('N>;
M7ZP^2@JIACI-'&JW\JB\&2CO5W^3%*O;GU$2@-Q)FK#[B29+N-$ A20L#TD^
M;_7?0W3MCRP.&C#<6(F:BX?] XHYM%M;GOB_;L]\&R(AA+\V9:E1(RAC).KA
M&@X 9II@S_K>8N1:;2\,5-)*(3F3C:?W@L?9P8*%F2VMQE@F*G<;BX@'VYS<
MG64_&E XXONWDGA,4$W3+&+8@C=Z]EF<B(+W0_EJG4>V;S:A,V>MWAH(6=PV
M5(Y7CBP^_4/M]U%*>J'2.AQ4@?>HIL-$D"Q>:-%=M+NWKCR:^V1/1!0DQ2]@
MCG3.P[0?>0<2*I/_58:1M?K418D)R!_!YM'//SO#0I^5U5^/6<O3XJPI>W#2
MA(EW!2V"QJR5V5!:R!=L#%3P+?WUC.^IDS-)?VL_T1.0BFJ&D34\=WPK0#OG
MF<X]7H1^R,2A]%Y^SG<[K<=0-];]_0@5Q@(PC,JM1,?& AY-R?D*I5SRN<-
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MHV0-H0>M!)97'CEF*E4G'!:NN6K+DR]O_.3>B2*.)?6I_J !Z]I]//.IJ/F
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MPPH;G9SVQ*2+XS<NXC+.LQ&,X?O)>^B2$"0+@P\),&W"5A,FNE:6\ V--1V
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MC)8FFU>H(<&EWH -+#")2UTSQI>B/=U6O.VE2J.'T(B/:;O?1,C!FI%R^/F
MZI.>TY-[E_!#]J4\+UP4#YZX^/3-3,Q8%VOP7P;8=.<:,D^)HP$+-7:P+3K,
M I.G85.O)([AJ\B<_=*WG!D+O4:OQQ]'5^<=LH&%[:,J,VRX"Z30 /;8$-B"
M"AME\P)91I,>5*?U0;?Z 7M#4PS^.6A-#;J*FKR&:K#&QNYPGZ$!?E=9$_Y%
M]3/5/?#?MB+H&ONXM1&Z(1)$W7E/ _B],AJW4J%5)27]=[PE#O#RK^L#SC]M
M)-V]"58U&@YKBRX?#;GYC,= .R*)R@?E0G4Y0$A+_LHY[R?!RP@Z/#B3 UM[
M!\,JX5LIK&ET5<UANA3Q]:>N,OY%]5>H(+\M$?VV0B0':98XA*?,AZ[BG-QO
MIEX(>ZRC_O3&"N(6-F<E/7KSN?:12[L.IC<#CMW_&.KU3TWU.]RO_].-ICY;
MX6ZBKPPN)W,;R=QTCKQ41^DN>YNV._EO58*0K6FVP.+V>S5]"'U;%PZNZJ(O
MO"9+!HS^JH<*1'\4JL?@40V7B!.B\?--@GIUYE+K6+8)$W&-/A7O5VNM+B.Q
M,X]#!NOW\H*^^DFQQ5KG8(IO4PV>TPWHY3K-/H:-@JA:29 /B\L>1=A/5\F?
MY)C;.VU5TTHZ=*P39+*4GXD='3T3,T."8@V"\DM\LYV>C%D>CE%U'K6VJ*+L
M;KQ)Y:;$(B0]/2E5A-#IHB5/(_'>T:'/0_=^O(G&X$EF1/L0T4R@XQ2ZT?<A
M_3%JCM7A&@U$G!-:24:JMS!\6A+B])#P BZ)= 9!/=*?B5^-4S/W?CZ2;CG3
M=ID.V'1AIU8UH<@&.B!$R!>N-0\*:NZKM-A3A)89@]IUS5*$PX@%9G]%C@>[
MW<0AC3X^]I82W;C[3M:D1.*#(W:P*5D@U_T?0VW^DZF8-7^W[FK143-]BW7>
MN%<FZ%IXHNCKG@\P-Z<E1^/_6CN5HJQD<6Y@BU>N9>EZ]^#^@*E B*$I#?AC
MGMDBR'<I44?<.7MG7 +5,$.5Q0;?\@(O60>/N3Y_[LKI ZGJ7=U\CPZ!E6Q%
MJ'/2W4U#!25CPSS%\?FN6-*UT;@#NUNN0?W\I*YD%-FJ;+#])"A7*%^U)!WC
MK$93XF:TG92TD%^]^9Q2QU(7P)F%1]GER@Q#]B(M"06+'Y9%9#)8QK,:7 *_
M35Q=6%[:-=6?O+U[7A^L(4DM/W*$01#Z$E78MU+CZD(RZJC>FT7/1ZG)^UN9
M#H*.8[6\U+Y)KEK9H4SKJR*6.8);([=F$,.KUO?OZ.S<W@G0DDC0H<^%WQ[8
M\*=AU1*Y=L/E)XZAOXF((>N_E^SW2_9J/]UHNU0YD)#K*&*T.-BFI/>E7+M7
MUH[I]7^TRY"S.IWH:WH[<#'-,SI!1H<E0^I!W=%]<8-/='1U .0):A>T!(X;
MQL.G!4.HNZECM;L&U<T5']>>LDNE(\+P]QO/\V;ZG5;(<ZJEM9=U^6L?N+DQ
M?3L_\?[8@]HY>IRRC8>WH(>?8I-P3'10RD28KW.DL,ZT/&U[ZP7#YM4\"YQA
M= R_$]7P3ESRV%BK"#FBGG?2SJB"U#Z=5(\*A0ECL.)07F6U6KI^&S??0$IV
ME8ZW"PYOBMZBGFMMMYD0]$5$)YR<%5G*8<)G3%UH@<=H\E%RW U&YHEH2BCB
M(<&Q.4F-TY4>%^EX6CN]&6-\N"]L^#*T_6KD'G(NCX7_S<,&M=6N>0AC>I!3
MAJI7T]RWR$?MK QM[.0_D[\+H9'F:+(F.:%O5UIFAYTK"[)+^A+/D#"R2ZKL
MJN;X:W^8$$*?I(OL00N@K.0A5';K+&J;A+*!V,C$R&)E0M/(_;"0CHFUSM!#
MG[CN"Q^X87O@Z,>BU?H&RGZ2#PVH5]4\L(3&7X:$HMB0@HOR>6 !UN+JK5N+
M1,Z:M:8GY;7F[DNX;^5Q)FO'6K18PM@V3D4 9!]*&E(9V0W%W_ 3Q,)78J<*
MAC%-E2PT('3MSM-6D8E<N^F!$:S539&I^(S/X=??^.5[?G3789[Q7&X-V> ^
MW9 J_@%?&R>LIZ_Z6<[\VL&$&.5=&>N,^=U:+#I^5M;OS'2SESP,+<P_5]D$
M>C5FQ)[-#I0U.\3$217P;(3M'/01I'+LIP'3CBTT8.K5*8]43=:EST?V,R!<
M<_W5T^OX #:#2SNL?[3\M8H>'D&1P48:@ R&_G:JKP-H4U[1%;DS"K:U8/C;
MZ;6^J\RP?Y'\VWVV7I4MGV'<ENH>#^5V7>%H81 H^'FO.\6@=T6D@?%^NE1#
MA8S2@JS+"@Y&_5$_ W,V^K?EPK1=J*)B&K!-"*52.&"_G29' *&DTP8T "V$
M6NO*^.WT;<[_=A*N6,&;PQ>PN:TQ'=)6[/4WZP[D+>[X!=W4TG\F]=Q$JD6#
M1?L/-V*A_P0Z]0]+XGT0IT3(U@$UWGO=&9 3LDGV.V> XFAA-U?9;S'3-XNC
M 6Z#N<L^WZ*Q-0I.+O"^J:+BLK.]%A87>7E\G\(!Q'TPR9/@.'TE:^9PY"[I
MI/8/X9BYA,H'D3&M4/J4L8\&_"AWDV4R;/9F67,7?S#8T\:5$W&].T2;:>',
MUP=H'I3=9 !LM]KH4B4E:V[DKBBWK'2JQ8XX1A9ZSPJN@A#O0AY#=A&#L%E)
MS7RVF0L#82(=TW-]WBQA0M' ]P=>V[% 0%Q=@2?H1^(A[\?'M&/V2+>&*0S&
M#V;?!4CGLN-6FH.!!Z>R<58$\^GH[PLP1DV^L.U18FFQX+&TE=8 ,3A>OG$"
MG8%LA0G5REB^J2 T3HN:!WKZQ9]$=LONY-3S7J !#&,:N8M^BA=[BD_S]RK?
M.C;1,;(_#(>SNME]H3 'N!X!?%\+I0&%6_4NH58RO0A)@<T1:\KI&\U-+S89
M0IHUEUY7859PZFX?_S%FV?]MD@:">$*R0^6EK$PM%2P7LW5<\0"&Z(&F 9I'
M:<!DNFGM[Y/2>&B K3T-^#X#H>SPH_YT*J#"SP#YB?#"3^?&AO_Y5$SVR8YO
M+_1.[8OBN2,DN5[ "PZ2!!<D#KXBF^,3O38T;HE^(1W8D]A[8EZN[+GY.!)N
MU5;@_MI?\P[H2KKJ58"U+-44I?9(""28[1%POU'"ZF89\)(A_"FE9#YV6F7#
M,@B%->!?/+I<*Y;ZF=B!]=1V=2I)".WSW!37N0I&X\OJ:(" FW:ZU^"YF*6C
MD+@3VS8!L03)F&O44+% N7E]7ZQGJ\NPY(V49AK N6GO'KL[<=*3(:J< S9?
MK=V%:K_6HM0Q-NVO^8;:T4L#YEN@I(U#OYW*=2!W4?N0 -C*[V/ZW-YG8A*M
M5_D$B=]2@C&>P37N]FI567SVWRKMGZE,-?>5E@69]'#M77A1?7+(WW9.I>+O
M39WYR\.2\\=W$&A /#27!@QMO4<M[&R]^WWZ7!=;S:]N5=[X+9&M./>G5'/!
MGQ*+DM-_REP"#KV.^*7C3_N4_;]M4[X%_S QFN]OYMP0#C>U3XQW$$F8O8$_
M&YR5ZLUXX-"2G@2P,QA*OD8IKQ;'#L//@O!L-(^#=*ETA[#3]1TNZV_/Y@NG
M)+YJ28R_74IVCK12>/O>@<=L]&S5F_**9P?V;1[Q8JQ6G([%M6%K9+'5I_&1
M%_Q\KWJLSU3%J^[%=@*RL:G&J8UV&N'YQI=!/M)Y9(\:P2MT!A9^L'LC;Q1;
M^.)H':KW]$/_EP\K\!-?+1?Q55.*C8J/;RS3@%WHT*YQ7%/RJPFI<A3\9>PS
MJ [@>Y6ME0:(9X/C"*+(8$N>D=>J"M S9,_W22 M["&FS?( ,SGCA'7Q_!O'
M3L<U&B!&[82R4:66OTZC1+WT"PJ2I:.^C+SZ#$1VG\T,T%KN<I?:5/F\C"XT
M6-FVS5G\8(Z C20)2LM 1\IL'XR^=%7\4>\S%V\P?6NR 1Y^RB4J_<CM"+C"
M#PU-+%UKS#_]$M%(R1+88;?QM7]KJITS9''D@\6Y0FU9L=P,KA"VKD!N;PQ9
M:7!EA@:<HS^1[!::[%-% [A Q_-X9) C-A9B5KQ7U=#;XT/UVOYSXH*N\4V[
MA]5WG^( :GXUN?+?WY>__]>)SP!1O#K\#'0!8:SAG%[?3-6-\=,W-^3OJ[V8
M:^$8M8!9/*EN&J9*S_3M<;7P],<X0,/1S)O-X$/2>3N3^&:)O?+Z26X+KYB<
MQ2P.DK16E]LEY!9'F@AKC06LY,M=HXT3*EW3-64GE9*$O,Q)GQJ?:<XL/#K$
M.!FB;HR=%%[H D,;*K\($HVC6A\ZDP(VV<HERT](EN=Q;,.;?A2/4Z6VFWV9
M. DJO1]S2);QO#7R;.)S4#%AM[@6?0C" T_"%,TV80&3):$!F@I'S!0R%S.6
MHP 22Q-:BHYO+K^<\21E<V^VV#'UV_TTO>2@39AUP6X:L+Q! Q9D2G]W[:_Z
MJ_/U3PW_+A72<O,/;!"P]>Y7<W[_9 \&?MJ48/S9#AA?._4;;M;_Y;Q.X=H_
M2%>X#ONC9?9#C [_$;N'B_2YJ_4?/I3-M,MZ-?Z!?W?FTRZ3*+(II80J!HJU
M98*'4=C]?4ER*?9*CJ*^;1TTX#4C9"L8\)7O[R])J)JPM+C 97C87CJAX=VA
M)5UU!LN#!#AQ B_XV%)?%(LK(TN=BO%@M[Y3FC.N20-,-2/KJ?C\O:/8;)P&
MR=A"YBU!T,2/2<L#(E#\4=F^+$=I-*BB,^.BCX301H$C:$A2)<N#Y^/&[9(/
M5?4]0XSDIS$_M:7$*$')S$PQF5UL$4-D"4H6QK[]TR8F4F2C4B("CE!]>LZ8
MJ2SI_JYYRMM=FM]J&K'PE>]X#)9+5S&D>+\*:*&9ZQ>N(#K()G1F)<WW6]6_
MK0C]14[1[W\ AOZ.#X,S_?O:6_H?-U(@!LZ0)$"U:6.]:1B;LH]$N:ZKE&ZD
M;](RJ1GJ'DY5F:_@MFS5 1!54Y@1M>G)E:W\"_COQ("N_+4C27-E?>R3Q])F
M'NGVN.V\:AR,+MGP?*QNCW616(CSBJS?&1,D/J(,WW:I1%76K;\__1:(<(E6
MY\3"PGS$4L4(B:$LFYDO5Q*\SU/7/\R)CO$XSD,%J9T8(<P]BC,\#,I0TEY%
M448,WMCO^?ECC$>;T/1=&F#'W9C/JG:5K>^9R1,R-Z5 G8]PL1E+ _B\?60J
MAPQ=E-'E%2X[]^;3#X*BJ0\X30K^D[-R_P4M?G><V7_FW@FFMRJSF+V8^_#@
M26[R^'&="NID/Y_DRL">6!G5#6]OIH6JL%46P*>]\GR(KIAL3OMQ,4##L94J
MCQRF>\!:Z'8E/$2*!CP.-;8H2+(]M)=01C):AW0S^>R1^\IWCO(6XWB0;UF-
MK9$J_&S.,"$]H+??>*UST[I,8U>!%:A'DD7(@=?G')06,2,C[V[3XU&'BT(9
M/BUH#YAU.ZI$2P(&"8(YP$9*K]<00M(FH/C9*.']\:H1,I9IF2<GE5:%.S1$
M:M!8M95Z? 'V4 S)H =5['ZN_M2;UTR?\I8BMZQW M!&CMW_Q2\9_&UYB']C
M4Q!I<(XD!8I.EZ=8=C78C2S;1(_Q4I>PF,5WNS-I  (Q455I\@(TGFEMB1U.
M,H^L@XL5Z[W2TV5SROM&69>%3(<8-[UCPRMQG1"V3-A4N0<6-$@($SHB%4,1
MYJ_K4;9'MZ=>'6-8J=N\(?[\=DR+_WX\+):\GP#5-N#U.FX1LM,/6@LWGI\<
M=U?/\.61NU,+)[2N=!.,IU3+:0 OQC;:8_W;L*;]QMQV]K7EXC=*#U*'QDY,
MQ556_:CJ6*KV&+F_VE*$,**3[OAX1<+ZS@AVQ\JT=L86%%U@5[_*5C3P.T!C
MHC%]RUI/4Z%'F0$E.'HN9&ID=9N<;X+44'N8#"S8_=49\($J U:Z  A5 B0&
MMZ+9+Q.>/CZ9E0-;CCI:'7!B<S2VQ5\E?U,<9J D3R$?%<[D;9!YIOA\_G6^
M#]K**%>.*Y>IXX3*MO$[:J>JV58C9'B>2 &S"(*F!)>F@C"X*%E.A9CEF?.Q
MJ!>GH)#YS-3</#91*K8]^N(\5Q1K=[.?(M: TP%5V$H6$)FL2V4BK.:BL*CH
M2HF2:7%4PTXT-EE#[GJ(X7%++=A<O%[-4Q?7)[H< 8!FW5\UY2PT(- =U0;I
MIP$KO@.P#3_?_C]X)7DBYU>1S&_&Q^SZGS(HTSA_6IW3O[KXT\NSOY+5^..X
M]X<VYQKYCY(IT]C_DOWJSNE!G#E]\IJD9*MF4 K>O;E ='Z)+57+C-TR'GLT
MN=+%]L8D$6%&R:\5("M]=QL]/8FK,3RFV9A]D4/21U=1MG;*V6K1\O(.!J=/
M,CT9JNL/HAJ/O12\87?;;0N%>;@!3]((]DEJ@ ^M83T;7>2,!^0Q927GZDDW
MTGG6,URN129 ;XQ=N'.(J=V#VD<#2C)L8LF25*'G]%.6ZG"ZT!5.T #_NRAN
MG\$&^# 4"V^$R!E5?J2.]O.QX4:B;K]3>__P4>[*E6\2)4M:P%%68('EOR_C
MEN'?2RLU_\7$W23$ TH"@H40(#T@;WWKH(6D7,[H>=4O?M)7F&A 3:/O$R7+
M##J6R,5V1M(#,I2-^!TH"^)6][?^8O%1>85S*9_.3+#'3@"H=K5Z,4ABN3?&
M#G=^F?@D=D:Y ?Y1>JFI-/3=$%/9O5/.HTD;$ZZ6_21/LEY1ESJ#"_[;^)WX
M+;-GNH?<N:S*H@/&CG<5^3-L0.#[N]@6_1)P;[)L=F=8/2BL?_AC;?+1CX\U
M0<_N4I'WLEU1(5A3]W0RZ.&_7Z\8]TN;61F-/6:FM(VL$I5;X3"IZ/KC.AIP
M2NC*<93]-OS>>@I. JEZO_5KE;I3BVNJDE&?2/X+J[S%I%.J;YUE2JH"L!7A
MX0PS[K+MK>J!.@#R <*8\EA=R>:A%1VV#+M2.>BSGLM+3I<0)7$(OQ6HKHVR
MR3%?,'MV3#FNS5'RLD%B_NJYRU57D(]FGUJ22+S4CDGN:C:"[0VPE\!$;/P(
MMA-LS7MJFQ4*5>1N'U'>O(UCR7MO!'N6@C<-86/B2$GQ:"6?@E+9Z;'R^9HL
MU-0 B0;$#L:1I2BI&%N#H4XJ1T4Z60UDFB()Y9'M\:L[JS1 WS&THAR_T54N
M=^31Q:\'M!_XOXUN$WTF4%>7!JGZ84_)H> \"8&<0)6J-7%">9%?J9*]U="I
M:+D9RS@LFJU5;.)6,S57J5RUP&/4_,OC]_=[FBX\8XY[JWLI$?ICFTX390<;
M,9@1K+^E;4CYJ,DUZ05MHDK4VBFL;G(KZ(DZ71J3P;I%*HZW"&FR7V%B9'*"
M!V*<T>#!T&;,L.C,[B#"4Z(6F,LRD3#=&55YE2ZU;Z^T;WK%)7N_#S#Y6OVQ
M9<(A]_/UN'L<VHP=R)H?1<NH8ZFG*25DM9G.0&AQJ/]4M[KK5#BF"*''$J]^
MV%7LC1U\R^9YLZRZD:1_T]VW%G=S@.UY*L>/[U=]KL+/A[VOE4 V2"B65E [
M*^X1V**D>B7+2\J=,N5+RE]<=&<[TC/#_.ZQU%UT-R8*Q7,;-,9[-L/XUU2]
MD6+X\=6W,M3'9YS7Z:9R4F [E-YD'^45E8/ZA0843384A&*8-,47J>(]@TVG
M(ML%DOFDFU+/27Y)-I'118LY>UC[LSZ0VS @MH+'9^ CHD0+0FB]8FCM_H\]
M)2Y\]@=:."D787$BRN'?0H8X$=ULE@QSP0""#2]*I".&P 5J+PJR'\S#:T\-
M!KGG,4Y_,_=R9]7CO+I^?M2"N;PF&@\1'HTI5S?IA15GX[X2(HF'*?YNL*A)
M:#7?&W1$94ZDO@CCYY!NE9/JK4>^L8L)Q1\:_G3A=-CUL:I"S>L@W? PUU-R
M,59KPXSS,YZ!*&<,[^AR*E/)J<>I0EW.J[=[7C_NK+SK_^+\3)+][H7 3X^R
MSKM:TF-(ED.4-^HV)#.Z)IRL92#?(SS;E?RJHRIW>!GG(G3Q3749YZ[GA["(
M9B/2>4"A[L$AIB$4=@:.-\(,\]T$_0CFQ$D\)E0%$HKB%8:V]:S,Q*SI!?>+
MS7RNU[UQDCG5(F4KV&;L/3N\-]<W3 '7LSI@$W_XJOHC21O3BY_V;3&;S!N0
MQ?B5ZTD""+6]*;!9UQ*2ZN3V'"7%]:6O7V=/[2(E%3E) SC8ZB9'JFKISG07
M\@7Q%0716=A:I;G]%?#@-S35/$78_19KL&L2C#V'SYNH\+1GB.>6:7ZF[S8,
M/;!W!@:_! S\I3_6IP'<5H0B:A2J%04*.-& 9A,878;S!-4/DXSN)T7K!],P
MT2H7[AZI.-O#*NO7%Y\]=I6MY]D-&%FJ$D/A$,1L]=!C.W8%NC<_&[Q&V2BF
M1RT_7A#7HT<>7>ETP?K)0_'Q]%ADXQ#=74_J:8GR_XOV;Z;][>V0'!16FCYH
M"U?IMJ,V,0=,LNQ;=1/-D<$W]\EV\]AX6"A6I.T.^ND=U%R.]B:?=Z9-D5BY
M%D9IAB %B+@#'-1U1^WP*Z+6LM*X(^2@U#VWX-1@SDG2XH\<TB03&I!^=HNZ
M8T8/_.G [.<.8_]%^0N4[-5_A!/S44V5Q&S7M/$S:B$*Z3?"@N0*L7Y?30L)
M$N\2'QX +Q'\P[5NMP>UF@'C_WELE:/"826V_K5"IX<<2XOT<@[1V7$O_K0>
M1)W8S4=E"5K@!GR"O0>;T2.A6'B#E70T,8^2\4Y&JV?CV^ZEB7BU\=B%*VM:
MCLTE!A'P8AJ .]%SDZS>Y:Q\B^5Y1KO=EXC&=,@#+06_Z\ 6:^7:8QI0Z!F$
MX.I>FCB&CUX+*Q$XC>E)N#%R'+>7+H;<>$A:VFXCN!"R#UWBEF>+%67%TX!0
MJ3L%RH^4KQ9N0535OO@*G(F]7G")'D$+D95 OSF'5)E(ZAYN_:.(]B'_LFC,
M<.03Y'OSOCLU$E >AQN$(SQ>"K@?;]#Q,V@M .(LIW\2#-,M7LDS8@X"UZRN
M<0&''?^)U.??I_Q]" [[N9DBE:^NAFC#WKM/&SV5GJ_J'3BN</>T#P>PM/ >
M]5L/&3^+Z4Y$ZY_U\&?M^:L>^A?AWT$(_%1-(R]B[H]'I?<?0)O^EU!NN\S8
MUAF,V$X/-KW2:S%&G+9B+MSVX%4ML"7ENF$%)3S9_D_6R,-!6*$!CLU6^:@%
M&3:R!2GDI>3:>8K9BNFUSL =_MQ7&V'Z%57$;?7,\T1\]9/0AY\'5<UI*&E!
ME1%\(#OI,ED:?/H&_ P-O?]_-N7Z5VB KS/YU$S'[,PW*.Y00<%?K:&"&I&D
M<G"3>,F\A/-O\:=G,"W@AH95,;YLQZO'9=8MQ*LP4Y=K=\6A8:&3 FL"7\#!
M.O0NA3LUA+(F"),7<M9LI'AP)#$[LU%.2BE=^L4P>T,.3.L0TW<8E9<&@/L,
M*.(FT3"\?3YJ7=[OQW?!9\KIJ% /-)C.3\=.#N6V?,T#)V_V2CFVCU\1OV1>
M5A2=\&JO7HXAK]I]*05.GHKQ8NNO)0;@88V8;)=TL !K2]YS4@7-X575!!N:
MX""PYGG;O*$!3A;QT\HQQVWV<5&O/1?]])DW_KQ</^H.:@33"A=&V8\;8%FK
MZ'VO]]3RCH&>VFK)<[B!M\XN_=*G;_.>DW>:N/@J(2!.+6V$85_A+--*<LSJ
MP,C.@+G<I[TW[T7'WQRSN76QGMF3^=JSJVPS93A>$C-R"/K!MDF1<P'%0';)
M6*(R$@1;N?=LU=TPBVKT*PMC>'XS[_,)(0:]C$]1-W3.'>$/OD[*I;*7D#C
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M+L ^AC;2 #[IU*RI;<&K>&I-SMFS%@[PFN/5V&/M8BW>CUAQ+\XRW0<H*!T
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MWM1"-F=3"B_7H>Y$LD!PXJ^ \.:,:^4&VY[=&=_;:$# +-ULQ5YER^J&'W=
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MYB0QD4?\-7-?UQIIBE%JG:BZRMMCJ:[$%"9Z&%RR/Y2X%#3_M%%M-YL0#;@
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M/*DC7*K.P'G6S'3DQ+5[M5S3,.]7!(FWVSI$EJ0D64'JU8\67*"B.+D.K[-
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MT)(;\>FJ'%.&2#'#!L-6#E!:_9Z-P;[HU#L\+@>&"_9A"$FB;#XSQ@4_[N?
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M3AKYG!")/&/*@4B>!E'TRCTKO44"0][%CR':%*6NVK/XTM =!#Z[6W"3-"9
M%\$N'E)N<N>_5>0=K80:*6.MXJ57L"K@T<:3\(71&9@"/Q/CGM6>!?^1-C1C
MR[;"%<'F/4<Y.>WEB#M+-4B3>N:T.&5$?WP<L-+)(O4!0<*V&#I)#)@]LMZQ
M3Q[I=^N<(>6&$1@V'5EJBXAK?>35M90;8[,PO+M*.;-6_2Y.K1<8C]E[07.H
M2IFZY"?Y^(+GNQ]@Y#MI$2;-.! 2$5&R',S#O F4\"24+3W-0PP!,Y_7@)RW
MTM9TL89 N6N>3/?;'(BE7QV:NN+D7U<L0[=473RC2.Z@&R,HINA=()N(DTF]
M-)"API_*=K"Y#[-^5HWH :\,24K=G3?%P(3]5FUV0XCQZ#!F6F\+?0/+P#D$
M)\1FM["G@E@!V?JLZ1.-E]J,IQ#^KV@I/Y6/!GJ10;HE%P'<1YQ19_1 ^>;V
M3K-W%NYG*8 !4&NN[?I.*Z0)C)OW86&UBI]:'P *A]VG]9B74F4QC*H[<*8(
MB $:0>RC<'Z0XOSBKB$F,M0W90/3$*=0G:"R,5JFW\0?]$&#,43)Y$!*@$)<
M!QO,3E[15U.;I=2V#9UVAN>4*X.@U2'6>&\62C'O>-%CQP@@F>-=6<L%(Q=T
M8,MIDL@TAAG2G#(-#@3MO]PHQ&LU=B%K[MG  M5Y[_'K.)O<4QKCD37(KM+?
M# ]B,\?QNZDF;=,"&[M8"=(E/[JGIZ)*GE=Z.05 E9O8Q^X<B37)?FDG6D(+
M.ZNKV=RJ.*NU,=D_H!/<#QO/PPP-W=IR9ZIR( G3LJ/@F..FH2&#SBX 71$_
MN#@1Q!9;/KOG)$ Z,?\4O;F&C93']L+(8A0]UG9@\AJ>F;B)8/[./@UR/9Z9
M!9KQE[!;, <T* ,I.)P0>*4.P$A2[!9V'T-OBV>(^7.A<WD,%%^@Z= ZNG%9
M-=HS:5&Q$3^>BEAQP.WA0,I#V&]/N@RY;,;"ZF_6.I3GGA-QO)@^(9)3:.RD
M6%EV[\L<8$1A'\>=/5)WUZ6RW3N[Q5#75UYV-"ZF,E#D6;@\]MAZW;]N>/R/
MWO#X7PK,;S\?1SV'$P_H2&SZ"QPU@.N_&1G4Z_QV*B04:OR;7O;-LP.-</,R
M#;B*Y9AUE>KODS+AIL>_UHP_$SH<-(2_XA)&+Z)$D+!1:CEY#@VXW47E5=$2
M>=]-)+(D568NP"ZZK+B=H_2PG!IS'^W^\,)%1D9QI67X;$YQ=X^#CVL>-B+1
M'G8+4YRY>+)L$,-G;34R-D)P<'!;-5!\'B[_LNBL\!.(1(RA\Y9H/>QS9D8V
M7:K5O+?*YF0<]FNFI:O5WF-&]R;WO+RDN"WRY0TAB&?L$E0()\A4I@AX.ML*
M4VQ2\EI_AW6')\J(29!&XL5HZOWPE'HIH=N_G7J[FGB\.Z8P\M9KN^FVI6;<
MT+&2L2V[H*_9)@8#R+8U>"'+,!%?"+@:/KLUN_'0+_9&!%V$/92^.\CEKOW!
MA7*1 A)LN.QZ] 1#D>S[U&UM_KEKD<%=WQ?NM#2D"ON!R\PA M6A?GF'WQQQ
M :=,R8M^5^F1Y^7&#]I<>]P*>P>\!_@D1C/)UT\TT 5:O[0.7>J"A2MV+RQL
M1<N&,*KA;MU]0)*\G^*$<AT'$GH'7F>K5EB1N&55G'J+N+%((69XKY-2U5DO
M=*!SC?E5>[%C,ST^5T :O/)<JL;M"&' <PL.HL,NW\44BN$49:I(+M1[YLLE
M";R+375(@NPQQ >4-Y#+-'OME#R9[VG=6X_SF?_*^E$U+)1O)P](Q0WXS=/=
M E5UD:LD]'!&,0._ (1S($(G'[A):R590RZ8+ N4@T?#A=&PEA1#@B&(FWM*
M=4D8<<OFLVM%*<S$HIF]%&O*5ZROPL1)L?:,YN & F;3?JF%56%_GPT_(V]'
M>1-U1!W5H;>AFO<A7'&V_2\K':?':$U=VE^0HRB@\OFK6O%-'E@N4HYN298
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MUT&;O/@II-@#J&1TOD<ST@< GFAM:2^^$6N_9T-71NPEH4=^+L_W<T #XV_
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M2+.M+-J]@N8PC%9U'SO=Y->NV+$N1#_>E[+>EU>':J=>5LH<^ZI]0^C-J4B
MD$4?Z+N#/#<AX';@8+B62YW3->74I"_.LX-MZMY;<\A,Y08WP1KRISLYY#RM
MJTWZ,6E%$47PFTZ#^=&$H5\#'9P H]#:8.RH?"CS..@HC\)[B$6$!A9L8J!V
M$4HF,(]09A%#>$<.Y/SJ<S8\SO,8#+CKUI%0N13I(#&A7ON6$K+7@RUR]]3:
MZ</$X\A._^+1/#'-0I0>2K_IEF:#5O:=PBWFJM%#EWC/+C7L8UVEH7FOC_]0
M@(@DD@WW,<]17/%#3 1V9LC4HB,YVT9W^\3<#[[-(>\YLZ1(8=<UJZ+9XZ99
MUW:;.,GTS83]E0S"*E"!Q3;&4;^SWEY,W<)>6=N7LP?VW5K:.B/;T9;36F4#
M9K8%_>I=*^7M3&B?NJ:$HK/*)<?<P,L=:A.4G;A8[EJDV1OK[^/3;BNW<I;C
M7JUJ+6F0M+^PA\7X\U\AEY="5'6R?CTAG#H'$ES/*L4=C\+P O?I#Q;3.1"X
M7RHT-;!BEC%[K7$S3YX.)A#W*7JIKQ^!+(&2#+YA*0X/[W5=&[X=4F9''\AA
MOQ^HFW]CYWAS*457 1@_5<W^63X30:'GJ2R(^+.2,B>$F'SF92.!@3E( WK
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M,K'%$W&WRI0#6?%Q4HXYSCS'RL!M9YHH0)_BCCMNQ#9OG/A1L>(FQ"I,<.%
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M!$\,9HV^CY#EX:6I0D++U/U7UO7(O(V1G]NP$TR@>3_M?.^^54ZDBT#Z%BI
MNXH1N0*)%1YGR@ )1XMB')+"8P.,OBJBW\ZSAZL8AD!4?._)!]G4HEW$9+^.
MZ?[6157AA45UZF>X=4<[T>OUH#0-&]<8% A%O;G>G<X$[L;[]J2!GOSC8<VU
MP87X]U:AW_R]OD *;\^DW9K(1JXP=K!H@)^Q\)PH!DYZ1GAP4L+=:2(_UP>W
M.[LH-"\/_6XB/$:S:795/$ ?M9J5[+Q>3#].(8.6 8\&:^$E]J6+$3CA1+B
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MN?XL=S2M+E5M@><_K]37P01\_KB=1E$&OY%;/O8CCXV,GRM\V$X]<>O)XCV
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MCULY:4)V[05\%R.G/0Z?*^&P*/0TW<DPU?_U&>6,!15T&E='9V8K<\ESC4Q
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M"<?@TB5YG2?7IQ%A*7!9I".9TXBTQ+]LR;OXP]A#4)7M'!,XGI44]=3R\ E
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M26V]\M$,HCM2:RLCOSM?-2PUY600 I(C\]ND"SX'8_BU_;MJG!VU)=U_<<Y
MM%,?"#MU1/M^?M<CFKO%^E911J>B2NE+6=4<IDU1;G&YOWQYE5LO,FRWHZP\
MT">E::/HXJ(*@4!XWLE1_^)8,G$,Z8F.*(SF=>BKJ9O7)MRCC^7$K%EMRA1\
M"I<HZ*DXY[R\,OY98"7C#65#\CL"L#Y:#^*L"[K(O7B%JY--Y4)CP7E](4_M
M.1='/ 8"O'NO2'7*,018"D<YYS]0AYDBP;"_7G))1^@JE.VNC6RB!"*3+,T2
M>O;3?:^3;/53L@=_BK?FO??>:4CDF4(JM@N?"55&JT4"3"HI[: 16_J'_<+2
MV?%'TM::F@*G+FV+\JA3DRU#N3,]_***)</;;_\0PG\+HD:BA@1Z*M!BZ:[O
M8'P[$"1YQJ2?+!/KD02SR^[^^ZGV;RZ7X4ZLAU:V9MGY=3TON,27MROURAV^
MI$JZYB*R>SB;(]@&AM%AG0RS;VF)7Y,(9\;W;.TI&<B_YC1 #GG\<OL\XBAF
M"MK81Z##.<(\3$NR)TNST!O0R:\$"X9[)8Q+&+F6L_N;&'G[JKX(0U:$'[7=
M=Q8XSD6=4#KA)L;P.UZ8Y$_(L-1JF$0'4_%99E[K>+^G\UJ;;C/OM T7B%WH
MU^.F?_(,'[U_;]L)./82E=EX;IZOQZMTZ-.QKJVC.F#YX^]E^-18_0O^&?JG
M]% 6U3ZY9,CKJ(\RQV&!IM_UOI-3H0VXM0:F28B)MR:X!S _!7 J4>FZXV%A
M U]"=76,"DX-WK)7LMES3D!5> :<89JRA-F5O_99'*</+P;@J"$>;B*S8N?&
MCQ4/1K[NU>CN.\=_(_^^Z.=_O6N:JW)81^A;'.% IAEK'VA=._O3O37YM]A%
M!#UIJ-1PL,REW(Y_O&ALC]*@]ID"<>]#EK'UP9:[,1_(S:[]<"X62^U  C9F
M]?K)/!S=[Y@#KU_2'SP@$N3N$=MR6%.$ )W!E^^_<GSWZKV,^E \D(0#S!E7
MV7A20-VA)7M0#BBQ!09=_9V6RV()&_4WV"-:=:5:O+H\]U(*\YZ]M#R&Z<*^
M4J")42.7D#E82(Q8R)4#-3K56F)B/9U6PEJH4G=/"&3A'*3_#.0/;Q>BR:!?
M(AO_,I#F G0O*?2$P?KOL(Z/$9H>*% /E0;<Z:WK"WMZ4*)D\ZA=@Y#_T.GN
M@ZRCUDQW[YE5!. H,6/N,;Y>V=K40'=-7C<X%!!1+>KX=-!M!B=<^<9H.R,?
M$*#@,SFR<.#H2=#CL1O*\L>D8PA>?#9X5:YVY/T1C1AG7GG.WOCPY1$J(AG*
MA_8'RB12O ^ ?I4_U"6:&U,GI[JG+E]G?.X6W"5G XOV<9FU%>SG3[94Y7K\
MW55+>;H$K1/07+K<2E_Q #*[V8'VXS&*1"V4BE<>[S,$U)3P]XIX_A.B3^X]
M>H/_!QX5)7+S\-H(\RCH"@>JNLDYV-9M&A]=>JF7H]74#&RD_2(I3?\8&XYP
MV%Q'W_83UKRL$5]*>=T7%;GMA%OK9\*"N1Y,93]X#-H]=J2@I":AHO,SMVD7
M8^KV[[DVOQ6?-Z1R7#1*T"@%\&/(L>_L0 (),JVY1'$TS^=C7CXU!Z[GOQL=
M%O2Q%ERX''!+TMY<\+WIJI5ZXW]UY$*8<,:P#:V]&[EXV:_TJ31+HQV([Y4/
M_J)ZOM^^B!KN$L'0DE>,?J7+_?!7ZC/7[&4'"HX6E4WLUS./":[/++I_[;7H
MMM#O4/=P!;B#:7O-;R?+JN5,F@0PUX,0Q!S^"15GN5&QM ?6<"9LUDA_"+UA
MN'#<M43[M:O(\'9(%J$>%DJ8GF(4@'5,!Q2N?X$'C&2P=78@:]AK[9SIQNS!
MF<#=89L?#%]V5XI;K>;WB<5GLLP'&%RA_?CD#J2$GQNA'^38YPOHX3:NNMUP
MF=S'+\PBHLX]T0PVK?</J7$C.^J%8G4#T7OPYX<BCP&O#PP55!O)5P\Y]#IL
M$D/,YST\VM=1S4DGF!:8'JP2QP"M/L+9BX(O53&,\<^3*M?^(LNC+/"'J/;E
M-WTZ7LDO,2=ZL=T=I%"#OUK0/Q'<I6'E(VY@^D@27#Y4Q0@#5I+1297LM,LO
MF8&S-,L15:(W\\,RHLS8_[C=Q<X3$?'O"65+Z\>Z?5XE1'^,O%1U?MSAR>+%
M^:]%\\TMU2'(0U5C8%*GXOWPZ M*1/G:_0?"GHVOUH<'N44')ZF,<I)$R(VZ
M77 YE@SH)I&"#ER2X'++C8!2PK9]5/U)$2;WHRT$2Y8Z? 7D9=JRN$(V-7WV
M>XGKK$1RL_D#:#_,[^8'[6</$C*D(IMB7:2'CG-,;D6V$2>>&^F;G)N,6?V5
MZP=/71_](9_U;?+;'JUHVV[1G%I!?XT[)REIB"'30:]0S"%4&5EV+OR#=MQR
MD]VO>A$!:X,N:S&;Q#L.>BWS)>43%7%06@E3UQ'XQ7*!SYIT5EG)+\2/PQ8U
MTG@B'[2;(,ES WTL5GMT+PK>29IMI4[1;C,/LA+ !JH$GULP0J*OM,Z-9=@A
M'VT=7SUC%QRA51&Q_M$6_5+X0/+"U?MW/R58X ''85!WF:B] [G9L /Q-Q!.
MJADD?Q5QE9\9PBY],2G$A=UC$(++N]3E\%U1*+&.$P%M!]L2KQ"+U-J>DF:R
M% ?WR$)D?.>:(O/T[OVPY$JYU*M<QF"^ [E*SH6];$W&Z*+/L_&_D@*])\(,
M5)S'Z_WO6WPU6->\<.J]@&"6J5K-V@XD#=NXTBDQ\_-T>3=I-T8^J$*QZ4UL
M8M/H06F=U[YWZO12VD[Q:,AKY4R2NDF9EGR@(V7.(!,OAM8/?/P]X7K;=/ -
MJ= ,R-#H81=:<0"RVJC9"BJ/[;18MB=1'B&:6:]>NR"DOVN7YD'4O1]]J(_:
MG,=27D*;^?I*(P)*&+'@Q><=%Q3]K^'ZS+Y?,%2R'Y32NR:)^<F[ ]'GP!O"
ML('#J2TFQ$/CM1B5X A/%.,(-&<E0PU7N\_52E?C:]_,-:B=YMOK:"/0%]BB
MK*358:#H@T X_F%0L<VG^M*G<P>=^[RR&X3-BZ\Z_'!X*)$+NXJ HAH9(NS*
M>A*E#*$6^V&]P^2%@\XC;I8T^=3[J;$A8.S!W_CD]2YZIJB ]"F]]:QESCZ6
M$&A.?^&D@\TBBS>]O>'%OTU+.+C-Z'S2@$_[QM48\2H'JC3R7."^7O[_L\@&
MU=IO,--(->C9@:A_H!+$T.<X'YL3KU#ER[\I^@OH+FM$>[O2$8P;( [([C2Q
M-*8+]/W1RN*_E+&POTK"(B?B^9OPMPZ_(!43OVEH)A/!,@9I]#COEY\[9"A]
MKS__FN[H/#)>5RGS!79Y=I,WW7/?>]7BM2#>Y3_^Q?'N\<N!<5>'UF<.PB_
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MQ3W=:F;[9:\I3CBSYY_L>A+U9)?@WA=!V$;H&GN1G(8%AA,"NT[(<"0?O)(
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M(B^(M?$MH(]3%'!E@L>!44[]<!'FM@B^7ROY]/%DW3I1K8'*FE'R+L!F3WK
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M^ZYNV?.\JW_MO.[/GS;)9WY&A>Z+/??GZX)O[LGWQ@&_E]CQ451+%J2QQT@
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MX_O1Z.\7?^;>"5O%]TM_V"7^PK7N(DK+75?)),8"QYS!2"0>1"%/89H*]5/
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MD)S(]AL*HJ/RH6,=:E\:;09E1"\>79O>-HQD;M7K\%&](/7YJY^R1-EX&+)
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MLDI9+LJP;/P3SYHSO/TN"I;I8F=JE[Q,)4DB(5,8(1TRQQ&&1.<8^0(1CXO
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M^0SC2"#(0DH@HCZ&*0IC2 2+0A9CS*5Y*8WK9)G;BMAI<UAY&I!:BP78U'J
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M49C_&E!-B_=?-<:P->*VR)^4Z?I#)S57NA;FWS?94RW+MOL1P2A./(9@3.-
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M/_W6H/PSV H/;B[#;$UO]H@Y(C:+@2>E-'M GI/9@"<,WAYK;Z1.<]%>2/5
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MM*&KC(%<2J%E7W2NCJQ6:$!7G<L38&8MN(=U9))HZK0W$H-&Y#:8<]&>7"^
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M-F)O=X0PAP^0!';_*K\Z?(Z[[6M[>F.C_U#@6>8=E50KJ6S7?/H#\"%1+PJ
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MG$LS"1'C&<0TDMHLB2A-2<Y4@6_*$.U2FYY>6E;WE!5S-^8Z'J!J<;X,B=7
M.N9B?F.%W_L!\+LQ6]07QY?.%[7#\_:,T7/X..>,'@SRLEFCY^2YFC=Z]J5
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M9!#Q5$&]/AE4A*J<"QHEBKFLTW-$IK9F=SR"BDFWU7@61;N5>2LV Z_2(UC
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M#(KF6&JQP_3,E)T%%=O '$J;5*1?/O1"[*T"K>$*K.VNTWT1Q68-QR4=9C^
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M8):3 B+!%62,1[!@19XIA!*DG"[(+Y.:FO;8<5IE_;:\.O9RN@RLG0H) ]?
MVN,\4@-45KV.1JB>2I<)C=LVZ:K )YV1KK\1LBR>IJ+_\+C:T,5OZ]73X\:Q
MMZ+CJ!/ZZ"^4;JN60,L\J+D?I,>B)W*#UG&[3'T"%=VN0F-7V^WZ,'[KJ^Y>
M]OIIO38NZ78529&*C.(,QJR((:(HAX3E$A8%B6.9B#S%V*UJV%DZ+NMJI(KE
M-8--QUC'%K#GL;332#?C,[#>J?F;@1:@(71++P:!-,AY&J/JB5XQC[5!_\.W
M1L4;>WZ7?/.'9K^F,Y<,)P6C)DW6= ^CF8!$$ Q%K)=_+B2*E%-E\JL4IV:%
MGYQ(=SS/P)YKWW#X2[!G(F<QC@HH$4,0:2T,L:("IH@D3/$X3M+43>T&!7X<
M%;R'?E%UDEZNEK!AMMN].S3V=FHZ*)X#J^P;O^$;<A"N8!,\ ^$2O1?*/[@B
M_N7L@VLONJG[S7H[_VP"$*KJ'A%F.$L8AY(H;=+)2$*F%;LVZ9#*"XYBS)"-
M2C\8=6IJNV+,J2S*(4C]2L!;]($7N@E\+S?;DNNCW^_Z&]*'[SK!(%#=D[-R
M]RUB_4)G >M_[1?OX5BC+-"S[+>+\/P?/7T5DFW-;;>I&5#U!GA?K^#F\MLL
M:+KY]G']B:Y-)[WFWU_7=+G11IVY^$N2C.5***C2W.0%F60"GC(H9<H+;1D(
MJ7A;1.VK0Y7_6QFS^M@/"ZU]':,<TK=JO9=+\+0T54ST3]]7)9=U_;"VLRO@
M1F3'[@ W3Z6E(VJ4F1G)-:5E :TPH)(&M.*T,3R- 'I9@4:DW:\Z0@5T5X7"
M-Y0#ZV9^QG5IA8+OQ,D5;&!/MY<0U;TX7;PKEYH)3>/]4BN-A\K;9EQPBY79
M1_=91BP75!(90:72""*184A212'&IGA13I5E0VUO#B9G:]5!!HZ*U1UX2__9
MD' .[5O;\0YVS(,.]V#//OAKD$PO;_1">>6<Z8_KL?.%Y\2;YSW0375[WZW6
MURKO-/PL[^^T>OU>>5CFF$G&8DJAH+G0UBA)(2L*"A/&&,\%H2BC7B5]_?CQ
M,$*'MC^-W;*1V^VB/G!5)7]W]:QX5S"OZK^>\V:G,8>?BU%K!E<F_Z5J8EW7
MUTX:L!<G>$'AVU -6VO8DY>7*$-\&VP7*A3?.*AGC&2Y-,60JT3?=Y175#[(
MI1[@S>J!EDNM7!$2G FH>)%!E)D@R:PH((JR3!2YXBJW\L?9$IR:^6CXK>IZ
MUUGM+<LS4#,-_JK9=JP5<A5V.]T8$LR!U=_-.+J'45J"$RJ.\AJY<0,I+84_
MB:2T?<\W))MNY+?50KQ_>%ROOLNZ]T,=\L?,Q6&1"LAP=9E+,XB3HBHV)"+"
M,Y9)IT3\'EJ34S(MJZ#+JVM0]F5H+;5)&,"&5B1GL1H@G-("CF AV)<IC1Q^
M?57DT]#KZZ_XZ8K/<JL5CA1OZ=H4G-[<<?[T\+0PYZ4W4I6\W,XQ3J.8%!%4
M.240,44@YBR%,8]%P1#)(YF[!2)<)SJ]2(269R ;IMT4AP7.=OHC+'8#JY$=
M:"VWX)<.OZ!A^-=PZL0>G4!:Q8+@J,K%'H!C'>/PIJ>;G7/3Y7;S67)9?C>5
MJOZ0VR:8;9[$2I*<1Y!D(C8= 7)(68PA3I%,><RX$LPQR+2'W/342\LM6._8
MG8&EK-Q(=+%8_3"7(Z[N]3[ +3WI@4 <VFG>HO>Y@U[=1/:N!:_V"=4'(U/:
M<Q>^&M!S;H%6*"=Y'ZEQ_>$60I^XOFW>\<C_UXI*FHO#K_1G%2M[/IK*N$6+
ME*,",PX3*4RE1IYHS9/GD"1%E B1*YQ:56IT(SNU(]%Q>*5S2*4CZOU*9S@L
M!P]VJ'FN*C-67)^DL8(/ T/K4#1@$(A'JAX0"FJW0@+.B/56%+ ?;;S2 LX2
M'M08<'_;LR05_R;%TT)^5._*9;G5(W\W];"V^@LI]292YT?4E:%CKI("D1BF
M29)J!<^T;C>5_''.5$QXH:3*G(I269.>FI)O.3>F9,T[K)@'>^[KE;3Q+,EM
M/REV1N<P4 ^\!P1$V;U.E3-@H2I5V1,>MU:5,R GU:K<1[BQ&4!=_<^4#%PM
MC7NOBD''L6)"$%,S)3.E#RB%5+$4*IX)Q0E.J7 K*-Y';6J*JZDPNF?RMAZG
M9P&VU$BA8!M8"3DCYM]6H ^)T%T&SM)ZF:8#?6)?[$'0^Y)O>L&AQ:5UT<_V
M=V]_FJJC\K/<R/5W:;+%]7E[_407FYTSY-UJ_6;UQ+;J:=&>Q><*2YRF$841
M14KKFIQ#;2<E,,%IGL51K!61DZX)S^+4%-2A;XF>NO!<\PR"SZF=>GO9F7J!
MP[GY<??[1D)3:*J2L2J?T0AI*HN><2U>="J&3%88:DZ"92\$9W#D=(:A #[-
M;QB,DM_F\75-A7R@ZW_LHT(PCI(<09EFV+3$)/JPC O]3YRJ.!%9D3NUQ#PF
M,#7%O>?/34.? &>G7V^!8V#MN&=M@.".2W('TD GPX^J/RX)=[SZ+S[G>5Z4
M]\:D_"P?5VOC8:M[9!XW9I49RS->1)"K@D/$LQABPI%>VG%12%$4"7;S?ME0
MG=HJ;Y@&.ZX=#XY62%L>($/C-[0WZQBZ<=KB.L$4ZI1I17/<TZ8+#">G3J>7
M/2Y9O?M;-%TLWOZ4:UYNY*=UR>7=YI/^EW[BH[K>[X?C+)<(9U"RS(3)*PHI
M53',$<:8L 1S:G]I^V)B3$Y-5NT55FW#'MG(!1Z-8(!N3 \+WF0TG>\G!;SZ
M2;WPQV1Q%_TO\8D,O1-4':"89:<H=JY3U*X75(L'^-1^6I_VG]:-;:&F]&DY
MW,7_2WQB(]WM_ZM\:FZQ R\^P[VQ""_'W7BQ#2\^ P>Q$B_/C=_!\]73IES*
MS:;3J^?3>O7.Y*MWTM;W!R,JTC2.(PG-W0%$22X@QGD.L1)$Q#%%1>9TG>!(
M?VI65LM^MU65/E2M5Z 2H5OBP>V8ZCHO=@?6 =$>V&!Q 'K0ALF>" 8ZU;I2
M'_5\ZPG-\4G7=QB/,^_=DRCU='>&M2SI?.7M":V;ALG#]7&]L+,35@Z&<1C,
M1K)<SV 7R'J\#D.O>=?S^GCVUW49#@PDB\<]5O!OB]6ZI)^T9?6@Y_"I*I#9
MWN+$:4+C/$YA'/$,HEP($V7%84(1HE+0E,56Y1>N$9J:35*S"HYX=5CJ?:!:
MZ,5 4 VL&,^C=/VZS TN!]48"+:1=*/C1^:F'BV@Z-6/?>^/IR MI#C0D#;/
MNZE((<OYF^9[>%=N]'C_+>GZG?[-9BY0QJ1(&%1U)#W-($4D@YP+S&@<%1&V
MJO_?0V-JBK%E$]1\ L,HJ#BU6^U]</;KQ4 @#:P2/?"Q7M<6")PY(VTD_]O]
MZOO_TF_7QR/]P_Y4U#?F*,O<0JAVA=L\&J0U\J?55I,HZ>*P'^AG6>5\;U?Z
M+"6>^/8+7<C-G.LE'XN40%EHZPC%A8*49"9=&[.,"R80MNKQ'H"7J2F+H[;*
MCZTHQPV6]2-UV8/M"CS6\H"-$>BFWL%.LVAADXTW-P/KJ+-]AG>R''<<!I_W
MD],(!+Z,.SDWM7T>:I)>LBETP,FZM6^T#[R.7:6=2+QDSVD?+*YTI/8:TN\:
MPQ0:H)MO>L3OI9#BU?/?-R:Q:Y>QNB_ZN&^ QS!3,260HUCO?3@O((ZS N:<
MQ#PC)"ZP8VT2=R9<UNQ(W?%,O5NU6/W8 //)@-4N"YONN'?LF><Q-W:W&</B
M/?!&IID'%=@M^^8._!<C 2B7OW:RW_=2#-*1SQ_$0'<:'@R,>JWA#]#QS<8-
M(]V8A?JA7,KW^L?-/,U$0G'&85RP#**TX)!B22!3>21X1$DBG'H<G)*8FB&_
MXQ#\97@$%9.^V:9[(.U4U&WP#*R"')'QSRH]$3YT*NF>P,ODCYX(>#%I]/1)
MSZ7M&V]29ZV^7VH%4QT!-M5!]^LWNFPB4?Y8+;_+C3;0_GBJ7=A%AE*L*(Q(
M)B'*"PFI-'U#HQ0+%,6X2,E<J[!R);24ZZVEWAB+?Y?U=BS%@+M_R^0,,'E?
M+DUM/A/#5G,P QLCNV,:TWB?1(PRG"5%!BE+N3&=3>'A.()I&M,$(2JPRII/
MXNW2LF_$A#^(5H91/@>Y%/\Z'X+E)CC%J1UZ;ZVB65]91KV^.A?UVI1]Z(@/
M:J?D5@.PCXGM?#LU"@$W\+$G+I1=,!K?XYH;8T_'B14S.@.!RFB\-R%D7&XV
M)B-;#_?M;BG>R.]RL7HT[,R53)6*: :C!.E3$8LXQ AAJ/0RY[E,9$;$344R
MKC PM3/3:_I8;NFB_*?62NN&XZK'YHVE+Z[-@]U^,B2Z0U^QGI2MT!J\7(*&
M?] *4%6KZ(@P8 4*2_"&JB]QC?S+5H^P!.=J;0C;<6X+XM=:F97+2BE?:X?4
M%HRFA20R%QD4TICR*I&0T"2&*9$9QEG$XY3[Q/.[LS(Y'5BS!:J$6VVXF9+=
MIHB'7KQA.L#=,&MV>G*<N1A88^X"_SM2S"YV@9MUV\ %KP1^.Z"!\P \&'F1
ME !_P"YE!]PPHI^._9.N2Y-6\IEN9=-H+&,T4ZDDD*89@R@6"%**,Q@K$3$F
M8L81=M&=IR2FIA-;#H%AT;-_VQD@[=39;? ,K*8<D7%6/9>%#Z12SA 8555<
M%O!8!?0\Z;>T>VK!_K9>;3;S(LJ13%D.$Y0KB#B-(!5Y G$BL. 9CG!B%29G
M2W!JR[Y3[)@V9Y;[=5]=/#^8[=1 2/ &5@K]%:-GX+=>$)UUA"TR@33&57*C
MZ@];X8^UB?5[0Q_-.FZTS>MOYL?WR[L'4QCPH[IFXL1SS%66)#B&11QK6R2)
M"22($JBR*"*)-E20R(<YQ]W$]]0T72V \<BXUKT9>\)#'P%'F\9)G1>[US&F
M=]1N^FO1JZZ[UX^:+W'"##)?HQ]';^-ZHF?7(%/A?] -0]YO>VO.UN^7?/4@
MO]*?3>';5W(I5;F=LU0H6N 41HQ(B)0^(6,32L+T89ER0E5$X_E2WIMXX*^K
M+5W8;4[]5*V4$:F5T0GMX11310/PQJM85KR#+?T)?I$U^[\"5@O@MN%<F0*[
M?2( HN.H]]8K6W-:7:,TO()?&FX#-AZU@R60%KU";%3E9R?XL<ZR?,LCS^UW
MNGQ2E&^?UB9.=BF^/#T^+I[O[M>RUGO[0C@XQSC*32MT14PK])A#PG("D3:/
M*<4BRZ755:X;V:G9L0>,5Y>)->M@S[M#"I0]^OW:9CA,!]8Z%G""OVSJ#=V"
MK4,FV2 8CY0T=LNGZY80YHQ2;^Z7_6CCI7DY2WB0T>7^MI\1V>2!-24S4*$X
MYRK2:EL:FS%6D,HLAADB/!;ZKU'L=*MR,/K4]'3#G)O%=XB7G8'GC<+ FK5-
M] S?IN"LQ(%,M<.Q1[7,SHIU;(B=?\AO=1YV_?QLRE%^5'_?U#[2>9KH0QQG
M0F,D,428$\C21/]'YE'$$,&Q2MVR*'OIN7RYXR1,'C=;7AN&X4K!ITU[6^*V
MNOOQC@B-XBA%D!)*-=X(0\94#"DK(I:F6%+A%*\3#.V7:&P],-9VFC48@@-K
MVJ-^RC/PN45/,UM?2853OE:@!%+&_;1&5<Y68A\K:[N7?#- M7GV63[JC^B;
M"<I^4]ERGZKDDKJJN4HHTKI::VR>"7U>9@KB-,IAGF69,D$L0JK616>G4J[2
M]'#0#:Q8]MP:CS]?/3RLEGZI-U?QIEDAXY0H&)MX<Y2E!<0":56>"OV;F"M9
M.%W4A4%[1"7>@_7,Y\+M.N1V>CPHD /K\KJY1X=94',+/C5I8X%*W3MC$RRQ
M]QJ]D?-\+<4_3?NU?=&G8\^NF?6;<K-=E^RIOB3:-"VL.SY1EA%<B +&C"00
M2<*@MAESR'.9\4@8MRBS[[!C2W9JBJ?;R[W+.JAX=VE!8@V\A3MT$#B'5C^]
M2+K47[\%7)=^+$. /%;_%+_/UK&=B2M _>U'K$<;L5V(JX2'[3V<W_:SU]\_
M/-)R;;ZJCVM-Z7&UH8N/ZL-*'PY,A%H=EW;<K+ 0.:)Q&D..LPBBF!.(BX+#
M6.0RQS@GA2 N)J4/$U-3]GL9S+HQO#=AF'<>;@*O6;&S.H?&>N"=H OS&K0"
MG(5\G%Z3M^ 9R'CU8F%4>_86D(Y-W)O&<B]GW;01>*=)OA?S*%>,,8PA92B'
M2*04LE@2*%@B19%F A.KP_3)R%-39VTK"L,=>/_&OE[U(5[].NDF% 96-+8
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MN>1(Q4*F4$9)#E%*.&0Q3J!*<9XI)I'*K&[#^HA,;:'O6COM&04UI^ZMKTX
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M(Q@)]\'##'9RF/ "<PZX$]_-C2G8KL!>,*W8.J+-P%ZX6?52)1]H!0P9FA
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MI3VX</ =P\_H-*DS=:K-+CGC;BD^RXU<?Y>;.D!:?%U5T8%MP,@\BEB1);R
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ME'6B@ZWLH!$>U-(K _5?0*N !77:K(3!ERP0OH$_6A;0NB1GV6!L\24*A/5
M'QT?C[/=5\4!K]X/B,UXPWTK'+0\^"RXW._F6OHJ7LAKW=_E7GY9K$77/W,J
M12R+/*.PQ 53C)^KGR2*H2!YPK(T10G-'+KL79K/Z.48OIG>3ERPF(/9@=/(
MSA%T$6@S/\]-N U#X/M825 +>;41L+5[YAH.GKPO%Z<9U+ER3=ECW\G5Z]TX
MXJ.40F=-B:;=W2/Y^56]?U^%UJ*:-9[ONW5;>Z6.9U9K^'IP\;1D/$\3E,.R
MH 5$:8HAC9(<9EE.*4)17,C$QA'M0::QV9:ML&!-?G;'9G4/STYXH'8)EMYG
M'RMGQD\#KT=@*MMJT_7R5"("+2,XU&BB%ZA;MZU6QS=YW)D'@-L38_J0:%!R
M]0CA,0_['-IA8]^FF.GYGN9U]MF#^AC,UQ69_?ZB@)BO']K/Q%<QTY;4>O%5
M/&UF^IE[O7O1N>]D-F41YQ%B$<1$IA 1G452JC\*ED8L3PEGS'S+[T6DL1%V
M$PBZ;%2;@)=.([!I5 );>VC9**7;_RZW:@'2ZF6QB_6SM 8^A,$7++AQVM0Z
MVU-(T?)VQ5J=0*<4^+I;L9U>X.ZM5LS"(S'XR@WDJQAH!>W<&5[![G5T^)EI
M.!>(5V0.G"-^1W;XOGY9S,7SRVSQ*K;5PD24YDG.8*%SK1'/,_6M% 3&#"<Q
MQQ&+*3?^5IX,/[;OWIZ %D1XBIK!9^@F+ )_4O9D<W%(G^)A0?(WX3(085OA
M8T>[%]7OI=#3NX:CPXL2'U#;Y:L<:.I#VR]([2B:.&GU0_>[CXU_X:M8B>4/
MH0\:[QA;;LALU?WJTV*I+JK4M0_+!=^P]91E!6<9*V"<:(]PDL>0HBC2'F%2
M,"I2'IMWQ/,LW-@HLA44R,52^W*TI+JFF!;5@B)\KZ !X;[AN@2FZTZ+VBW3
MY7?HG[?_H=5O CIUFK#K5L>]7^M5;?4$#V^^JA:?C3=<W8$^.F^TRG:?KT#+
MT/OQ\SWG<)_.0&@=?'A#S>$8[R^4#&);LNXW05;B42R?[V77%FU:)CCA"=)A
M.!&""*48$EQB*'*61X*7.(^, D[-IQS;)U9+5Q_&MO)9QN5?A]CLX,,O<(&_
M@8VPD[U"F;6\BB%;,-]? ],^GMX8'U^!\]<G'#9"WAB DU!X\SM=.F!OZ*KB
M%=$'#[I-B?XX/[2M7N]ET_QU6G"4)Y3K?D@B4C8_SF IX@B63+)2E!F/(F'>
M!=M@QK&QS$Y24,W!^X^/-BV;31 VL,E]XQ:89';B@IV\$]!)#.XE:&3V#:5-
M!VS/D [5!?MF:"W[8%O U-\+VV2@ ?MA6^AUV!/;YD8WXV_7[6(V6_Q)E#+:
MY.Q,S?=U[V?^N'B_6*W5[UOC=)I*D:12,7,ADE+9@[&$A.@_"IJIE4CSN#3R
M0-\DQ=C(NQ53'P$Q)6BSTVM#:RP+&KFMBID)&1SKT(3?WUEGIU6-?Z?7!-QQ
M7K6I+(V2>J&TEO5U'Z]4#K"V1&^"V9-QZB;#H/;J33 =F["W#6;?WNJ];@DD
MEB]DN7[]HA[9NY_5:AKGG$<TXS"*BQ0BP03$688@B7#!$IJ@/(Y-N/'2!*.C
MO3T9@182_*'%-#R<N@AC/YGY "<P3UGC8M78JT_Y&]IXG1UVL*9=?4KMM^CJ
MO<[-#JJ-J7=$)WXOGC4O-#RRRY%[][J[I#WQO_N3+/G]2_U1N=^L5VOU(5$[
MYR^;^GRU()31C!0P1@F#*!,Y)'E6P$0*FB.):"RRJ=IM5PO^;:TT,;.4O,MI
M\\8<2QLPV&TGY@10\53-YW7?&PD:&< O:G^\J@U@P\IDX1:ZI#G-1$G4RJ8Z
MV%QGXPM4P"(K8DX+GI<Y;Q?ZXYS_99:YDW6@11;*"!OE\II9U6^Z8*$M;BTX
MK"4'^]KMYXWKUDC[U[4J@EI'[0)N3>^#-6\T]6=S!UL$3_:X?_D&M=6#P7ML
MQX>;R,5SK0/I^9V:@^MYVN@I+'A6BDS 0GW.(<)8&?@TP9"I16=)C*,,&5GY
MEZ<8FYW?" FV4MKX4\]":.*+OA68T,QXA(E+9-YY<&R\R[>"-)0[V?0!LO0:
M]ZG?[R8^>^> ?N$^R0\=P;U7.NYX6A_:O?RV7K!_OGM]/R.KU6.=)2S41@47
M)(%1CC.(>)% 4D8)1%&NV"U3)JW=>7_/7*.CN594;8S6PFK+IA87_%$+;/AN
MF\!L:%KZ 2\T%;KC9F_G74?$E\76,].PMM=UE4^L*(-;;FL\J:PS6LWKST:;
M'_$_@G_F.CM"5F1;,;EN3+<4_$[M*'==:=1_4U^=O?+*JRFGB3:G$DAE$4.4
M8P(I320L42Q+SIC$W.I8*9"<8Z.LMJQX756\VHGIUNS2]YJ:<=P(5BHP/VZ;
M:NZI. $[)<&^EETCH4[/^HAJ3U/0JCH!%TK*>^PX''AI/#?T]"WEFS0!#03U
MI<:AH:9S;3:J4].7+XNF2;).6!>UPW_Y^G[!=9'IE!2<$!A'A"G;5 I(N?:^
MQCG.:42E(+E=S]'>^<9&]HW(X$#F25T-0IE>2]!*#K3HMFU(^W'O)_( : 8F
M9!] .C0H-8+GACZE_>,/W*[42-G3KJ5FMX4K+U1/J6E.K>=L>YTR9J(LS7..
ME45:ID@?]6!(9,HAH410ABDKA/>Z0I>$&1LQ-6].U12CV:\J],M<K/6N4+:5
M:_8NH6(N9+6V/..Y:0G-[-&A%B8TQQE7%FI6KS8SM3I[U^O8J3>I*'0-WP%+
M"5T4970UA*Z!YE(\Z.J8;DS\L%R\B.7Z]4$]LG4\EC(O7[1[\XM83R,6I3AC
M$I*4"8A('$-<)@(*6I09317=4FG7[ZAO.IM7=I@^1YVT31!I)^H$*"ZU(\M>
ME&/,,B9B]153UC-$<1I!6F01+!,:Y07+\Z14MO1B36;#8KR;,AS"CWH.G28]
M ,YF'QU?Z 7^J'1BJL^"%K0)G]TA]Z4'.>OOA DDGKX#O5,-RO,F2A_SN-$]
MCAMRM<MOSBL*5LI<X0:SB"CS-\JD(F7$H% \(0J4)IP:Y6>=C#PV6[83SN[(
MYQ0PPSVS"PQ#[(Y-$+#? A]KZ[[9W8XT[+;V6(&3#>S)!;>=T"YD3SO*3YNU
M[DB^U_ZMC6NO)= =*M\IX?\YC7"6Y+)(U <^QQ").(64Y0)&(B68RTSPQ*BE
M< CAQO;Z[Y]EZETLTY7=SC6:U!?L3ER<>I=[762[ ^6AEV[ $^AKG78;[0Z:
M7'8I0"WC :TBJ'4,<'+M$WK/1]U>1'N3LW&?H%XZ3/<ZA]MGX3\V9*E8</:J
M)"%JEZ[WY'*Q?*XGW'$!+S-ED&4YS%A$($HB#'&J=M L3V59JKT>*I$-X9M-
M.S8JWTH-MF*#/;G!+[_/R8;K!A>63DC#53!C9/_8!N;::[#^$80][6#RQ(N&
MDP[*>'9 ''.9Y=UN+'4O9<7$=AO:AK46.$T+$DFH=HPZ*4H[G'0/2XS*6"*>
M"FQV>-L[R]@XJ!%RYR.Q(YKS0)KQRLWP!*:18V0\5NXT@L 319R?8U!&Z%7S
MF #Z+W8\5VTKB=:QADT>1ONH2D%XR7&F=IXXABBF$212Q% DB%.6XAP7I=6A
MZ:69QO;>-V&P;4Z*Y1'G130-SR]]8!1ZOW8N76R_$VDC=P!.N(J.KZ/%B_,,
M>VYX3=V30\&K-SB>^"U6ZZ;B<)W$U1S^K^[HRJ8$7O\@(WJ^#P4%G:3@CTY6
MCT^T&2B^3DKZ)QOVK,1(\9/3$K.[7+(%75,7FT3%>ZD/<%9W/T@UTSZ#3XME
MXU3X50VP7DWC,DIED1<048G5MS2AD$8RA66!)2=Q@C*+-CEA91W;U[@1NG;I
M*L-G_0K8?BKSBU8%D$Z7NARO;)R$3[4Z-AE]89^!?IH<V<H.8D-0P]1T>BXU
M??=<U$J#NX-GH'44_SJR9\ F/70TS\)0>:;C>"8LLU@'6:7^=-BP(@R85SL(
MEH<)NL-,:5^B[+%:ZPS SW->_:CXALS^4:V_UYV*]*;T>_7RN&ABKC\LGDDU
MGU(I,8Z+'$:Y9!"Q-(,DSQ-=\SLI,6:HI(5I]3++N<=F,-3B:P[8*0#^5!J
M?15T$<$VD^"/1@V+PF>VB]/_Y0\,>> O^3FTKR)J53+-$9L;JJG9SCA8H35'
M*/9KL+D.,7!YMD^D6NJRD*+.4VM<<1_;D([_7&AI9TK&NO5PE*49B7FDN$ZH
M#5:.8HB18D)<(*3V5UG"D%V$3'B9QT:9G93@QU9,AS[20RRVF:]I9$LXH$/6
ML<Z7UKLNQBO GN83L'TP=LK7>2@CJ/UEOU1O70W,0N*_1GTP^R7P5C',86JW
M+]BV)+&R[3\L-G0M-[,[QG1>X^JK8*+ZH0W_]YOE4HDVC4M<XBA1WR+"=? .
M$5"]LSE,"IZQ!.<EDU8%>*QF']M7I1,4++>23@#9EGB> -;(;?>5L5L0L^]%
M,)@#,_\6X:]["&^5J9T>[Y>"5VOPVV*E"ZA? =R:O9V \\3#=G,/RJA.L!QS
MH]L@ ]OI'VN?_.?Y:KVL?82KNMW]XW<R;\_/E?!2Z#B]S_.'ND;LM"AQ*HM"
M0IKGF<Y&*2%F$8.2DUSD*(\(BJ9S\:2;,C\.8+;;JV#$ &7# ">*!+8#ZXZ$
MC;B3MA3O0%:\PZ,0V)H/M+)_&:N^T1_L 0!J!,!:0;"K[;M%03>O:G 8@7WO
MOGAO;><[2/[7L/?=E\2;W7^#"-YJYNF^>I62<[Y6/ZTJ+IJ")UUQI=<O:AE:
M\Y/AA"/UB8,\HCE$M*"0EIGZJXRS(A,\R@JK_<!-THQM?Z D@ZUHX$7G7BAR
M6TA =-]4149LJYC^<:?9S?7Q+-;/[ ,UV*H$_N2<KW6W4P4<Z#+95K9[G8"=
M/D$KV-G#&JY.G84L;UV-SAXV@YIS#H.Z4;":\UE7,UFP?S8F[MUF_7VQU-7N
MICB+"IE$$I9I5$(4XQ*6 A<P%HB75#!"HLBNWDC/;#:OZC#E1AIAP4I+.P'S
M;?A#8_@#LA7=CC3[$#>C1$\H!B:\%KYO#7SM_NGN.FC65&8 AR>BZIMI4!HR
M4/F89$QN<:.0DXS/73+HPV)6L=<I$I%,)4\AUVE.""49)(10R$16DBQE:2FM
MTBZOSC@V:^PDV[HN$//K8L'_K&8S._ZX#K<9BW@%,3"7G,M6W\MFGX!&8O!'
M^^\@F9;&@'EBF^OS#<HYQNH?,X_YC?:A7'\G/ZOGS7.;!Q31F*<QBR"-*88H
M21)89JF$<99D/&%YDIAE4IZ,/#8^:84SCZHZQ.EZS)2S]H&)H)7+8_[316UO
MB'$Z'&^P"*:S:NS')YV_X-96*4U(TS_4)F4O9?JK^"'F&_%)"?CQIWHEYF3V
M?J-,Z6?U=KQ[?5@N^(:M=2?:;V+YHV)BM5>5AY<E)TD*I3(.("HDAX2Q%$81
M3?3_.,=6'0^"23HV5M@O]J+KR[XTLH-EH^%*>[3;W[GV:_&]UH:'%&-8P<#,
MUBH!]"L-.C7 5@^]=ITFM?'8Z3)(:9Y@P'MO2>-;SC=J:!,([LOM<$)-Z/9Q
MJ4/\6V.E9%&91R6&)(Z442>Y@+@L4[5YQ#(K!8\0(S:?@[VQQT;@M6AVU+R/
ME!F9.NH?F/YJJ0*DM9_1UA/G[(\\*$N<4>GXO3YWB6-Z^H:J+=KOZ[:SR>>Y
M8@2%^.NC&J[-P,AYE,HHTZFW3$)4IA26219#FI<%B^(H9L@H_]9\RK&]MUL1
M+?-=+$ V>[?]0A?<J6.,FGWNOS$0OO+_KT\X; T 8P!.Z@"8WWGKSK$[^*J[
M**VJ.L;@W>O>WYJ*P:14]!*I3WZ,]$%_*1*U(4PYE++(.$,QSIA5L1Q; <9&
M-_O[O.VQ\KX*$[U;V/O%K5TZ#=?)=C/G'_W C.4?^!MV9';H>=]H&4[_1OLG
M.W N;XLLQ_%6'.6]^FVUKF.0%_/ULJ(;_=M[V1S=Z;.\:KU6MY#5]_T+5M,B
M0RFFD80LI=H84W883ED!"T%BD8@,D\BH&U, V<9&HUM) 5.BUB%16UEOKFKA
MO(#])/K&RQ*:7R]4J9B G7)@7_BZL7*MGPZEZI93JWAPV1LNY\U%2898UC<N
M0A)N>7W4&[EU 1SJBSA/^=;U1&[%RJ!^R,U3.,;)J?'NYO6P.DSZ!YGI .F[
M]7NR7+Y6\Z<Z7W(:1RAG*<DAQ5Q]?1DN(,Y3#!E+&2<1B=3>Q3)BSF3>$<;.
MZ7=4'U/4GU:QD]PR5LX(=;-]AW<D W\,MQ#6/^R)/ %D#3JIF\1RC\%T-BCY
M"JLSFG/8 #L;&$Y"[:QN=M@S?!!2[4KX/K_I6DD?9]53U<0'_[V:ZY/^KFCI
MW9.8TH@*&94$D@ASB")%4#0I,BBP4%N%+)4X,?*B.$LP-ON_U>' \*]K'DZ
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M@@E=&&J:1 3E6!)(TJ2$2$@!2\PY+ 3/)*-8_VGLE;I9G+&1P=W3TU(\D;4
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M!85YDA00X;2 N$@2Q?&9I!&6N8B-CIML)QX;;>^+KJF *>&MW'/FD!NY48,
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M1AJ.VZTT.R!TNSO=/#M'3J,OFV<JEO>R*9-WOUFOU%:#5_.G;50)$F64\%A
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M%FRD?.2O393C>IFQU3#POT$%YH.#Q6$:2=T&H/_JS8[RO%6AY]O@ZZD)?>/
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M)6N&IWMJMOGI+G:_/7Q0A2?JOUREF=WYAT!/K4U0M .KRR%:WK7\@P8 4"$
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ME<=J(@<XQ"Q+*,PP"2!"3$!",A\&.,ABC\<LI(&.NKV0CJGIXFW%=64;;ED
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M=2Z/_MUN>_\??,D+LI O]PU[D;:A2C=0!]0VO<>0)V(4IM!/B70W*4DA1EX
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M\J>M8] _]BB*18N]5D?H77SJ=>_*XK/\]O>_M;^1'^J0RM__]O]02P,$%
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M)UM(_,5T>A$F'_#+;+X<&>.Y=3*!#ZD0_3*"*QII$X859IBP*321_/:J!R%
M#!\!1W-R($AXC_/Q++^>YI_H1!YYXT3R1D')S((2=&AZI27XB%K*;(- V00*
MMY8]" MR^%@XGI<# <.G>9@NQI7Q&T"C\"X9Z4!('4"9R" RX8 Y60)/F7L3
MVQP*=U8^"!)J^) XB:,]H^+U=#E>7G[ LW%EQG3Y6SC'D8ZZ('<!(A(;5':D
M[!C2)D1B.NAHH\*3$+%KU8/0H(>+AI,Y.0@DO"'?;DX@7C'^(_$?7\TNILOY
MY:M9QA%*I;FT 5"E:@4Y \YK 6BU3 ZC$L4T ,9>(@["B1DZ3MKQ>1"P^12^
MO<G$OG$9K]W6WU8NVD@:(:,CUYMK0TPJ@H[&H!Q$XA(I1R:+/,W6V+O\05"Q
M0X=*"]X. B0_CR>XH3T;HPKF4$_(&M4A;$>?"VB&T2HABU:Z 2YN5CP("F[H
M4#B2@X.0_BOBTSQ,WDPS?OLWO!SQ*+UD3$$*6=8-:#H50P2.T7.E+<^F!03N
M+'L0#OS0<7 *+WL&PZN+>>74S^-%"I/_Q#"_<J4TBXE[<J2M#(;460K@3; @
M/+,V!O3"GV9;/+3R87$J-EQ,-&'I0+S3FTW\3#]9C&QR(2NMP+)"KA1W&;Q4
M!3(Z84JRVFAW$BH>6/@P4'P'T<M3&#HH3*P#+^M-8!1<9$6'7["D[T(,E2D*
MM%),2V^8=J4A*K:6/@P7WT%,\S2F]HR,%[2#O-K%))R-K'+!60S ,RI0-A4(
M1I"WE-$G9VA?>%IL^]9RAR%@P)',XYDW"#OR1<[$\\7F/V_'4^3D+Z>LI<I@
M+!<$76G .Q/ N92%L8G)V,+-W+'T86@8<!"S#5,'B@PQ$MHQ%+R C#62(ATG
M!CD/FAO:D2_D,IUV4CRX]&'(&'Q \U2F#@D9K^C+=_-/LS^GHQ"2BRPGL+D&
M3]"6:AHG$%QG-$I%THGM<'&S\&&H&'SX\C2&#@D3J]CKN_G[^>SK>)IPI K9
M.4I'\IGJC1XS'EPA(QD92YXS'R-KJ##NK'X8.@8?L6S VB%!Y/ULL0R3_W?\
M916;9^0FN9@D.*T3*&$RA, Y./36RF@DL:T=0&ZM?1@\!A_%/)FM?8>PZA[F
M&%9T2V2:*Z)6RNQJ8E"&:*P!9:Q+*J*7A9T$A^W5#@/ @,.71[.N9Y'7;,S)
M^\^SZ57X/9HL2TX!H@ID'!<B.SIGH!#I!A/7I.E.$OO=%0_+I1IPE/(D%O8L
M_H^8+N8$72[BI_%R@B.C&4.M-.1"YYGRA8/7(@-WTA!_DG/LM+?^[HJ'B7_
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M+(BMU[NT.A@>M03A7";=5PW<FA:6<\J66VERV'>2'+/+VQ3T8U]TAH0K%=.
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MFP>!EO4.1LQ:HW.A S/P0)P0Q F-&JR32IOBF+2MS=WUROWTM^_L]NE)C!R
MI_QV'.)X,EZ.<4'&^"H5^/-L0DQ?5,-\>7G-FB"814P(!EV=[%$*Q$ GJ[/T
MM7%.2K:O><@Q #F4MGY]ZLYOOSL1T2!TS];.[H6ND@\NUW1S[^N,$"; )T20
M1H:8'6V)[<O*.A%N@[HA[T;^#X/L%%$, E97]VOOPV6]7+N*86I1# _%0W)(
MFCGYVL%'!,#B#.-*IXRM/:O=E P&3B=)^H%+S1.8/@CPW'8&KIAU>7T]*WB4
M6ACP.HO:05A )"\34LS<"END8*U!M)^B?@^_CL#44 @#<.OIU9A?T*KW>#4*
M=22:E0RDY054G9D6K.*@??&6"]+:S8VJ!XGI-\+<G59JP/H!8&C7#JP1(I.S
M$G/M0AI(OSHN+%@=0RPZ9(G[:MG:F$C]!I0[0LV)S!Z"6S>;GGW"^?G;\13?
ME5=$P'@Y$NB"-%BCX('V8$R F%2]\)<AB60CP]8!Q%UT#.;$ZM":/I7]0S:%
MMJ)=,B?GN%;@1"8>B=H4,S$#F"(J7U5L;GU^/4K48,ZQ[N#55C #.-U6L=0M
MUFWM)!5=@@V27A//07EC(>I< +4V4>80!6]^Z_$@-8,Y[3K$5AM1#$*!;6UC
MQ"1Y#*'$>HVC0>5@P+$B('"ER.Z3]+JTKK;86K[?J]7GCB ]B=D#L)9J'XSQ
M<M7,H*;ZSZ95M^(TU:U$G7C1+H'UG$YM9Q&B#0%L;>;G$XMN;V.BH^HL'B:G
MWSO79\%1*V$,0@/=Y]&;:9I<U 8K[VL?+Y+;<CD?QXME#9I]FE5M2SLF.NB)
M9ZN&3KBX<6JRU<Q(.L?)"ZFMYZV&VG@<LA1&RV(RW]NJ][ARRI8[Z/?V]UGP
MVZ/(!PKYZ[V0F\QMB!Q,IAVH3&>#XYSVPKTKA6G/L74ZW(FWAAW6S/:'DD<!
M>Y3 !@&^K8Y6J\*\6PVM=#'(Z/ 03E6?R->AT@Q!<L,2LY9EO:^5W+$G^0/D
M# U^Q\E\Q]G=@OV#P-('7(;Q%//K,)_2!A8O4KHXOYC4[@H_81FG\7+$E2@R
M<PDB1[)S2U3@K5<0DV1*:F^5;NV</DY5W^D0G2"KL3 & ;#[K!IYP62R,@%C
MM8L.5QPBJR6@C NEH\A*M=91]ZGH-X+6$8!.9/8 O-1?Q]/9_*K-*QW^H\ M
MDUY;\,42.US6$%*TP*30)KIH,+>^B[Y+P]!T36]&U$G"&4 $M@TK1]H75WPV
M$(PB!YV1EQY9LI"53L$*98-K#<DVE ]-YPW(&^@<" /0K8]%!D8992G696 B
M2+)>R82-?C4JF@X>[KEGJ748\#&:^LV<?NZ8\NEB:0:SYVXY]WXED,^X'*<P
MN;V;$_O/W7[R\S2CV[.;Y^Q,IP4+19-&DL759H4F@C/D,O 2G!,\9";:6]K=
M=Z;;\L!_FQ&KU^V)>,Z*DP,$<E6Y%+D"YY.N)&J&J4B.K;.I=Q+2=]"C,2[V
MA#^.9/X@_-)[;>%?7"P_DW7[#\PC;7RVA7NP/M:9A[5"QOA(WZ)(:%:#,;M#
MTEUR^G8_G@]/)PEBF*A:C;S*H^0]:IT5)%Z3>6VPX) L5GI1"B/W/BO785AV
MFY2^?8#G1M,1 A@FDK;#S+PX%[U$X*M.-4X+\"1_^LHK]"84MW=@3!,X/37,
MWUG&T/-CZEA1- 36,YCGUWQ=S,HF&8]^>ZII_L!3.S/+#]E%(Y.\S@@YQ^L%
M;[*T/2)#7ALT.$/.H9;DNLD,(@:'6MB40NL+E =(.3V MGG@IQH7&7G)5& H
M(+ D:@C&0K2.7BHDSS0PG4(,7;D7*PKZ-;5;R/M^9.IH#O<88%W,E[7G4;Y(
MRW?SCSC_.D[XXMMX,1(J>2>* L0Z/9QQ#C&D )*Y9&K;+&X/:LA "VRA@[Z[
M0<9#:P_$#3M"CK.&3!T&*%:!K?4.%C_-SL-X.M+,^VQT JN5I$W0T>P-*HA%
M%CHTM17A(!_K,&3<)Z ?>+21Z7V G,C@ =S-;#;R*]9#?61UC!C)Y^,Y1+*E
MH@>7D8,(UBCKDA"Y=2.76P3TCHY3!7J_(=V1W!T -'X-TXM"!^L%+7WU\M0$
M_LUN#+TLNK (WLO:TU4$>G4D!R4+*XG98%SK$L']%/43L.D./ WY/P T79_,
MY%O@&_IR,8J>2\4T@K&,3N>L$+S4"H+1=7 @O2ZE=877?2H&$N8[WEYIQ. !
M0.0#?L7I!=ZT3 K:L,"\!*'CJBNY(X5)B$=A L^TNR):SPJX2\- S-DC97HO
MT>T$!@\(("//-4<T$5A>!1-I_Y[5L))4RB/7KMC6G=VOUNX7$*=)\ $X/(F=
M XG2+E:G[:;I_ T[G.)",L: QUH'K3RQ(QD/V9MB5, 47.O0R$.T#.1@::,Y
MFC!\,-!Y5VH7UVUS[>-LDD=2FZQB\1 XHW>)U:^TT\"UY\JF4@IO;8\\3$V_
M>J:-O'> J 'K!W 0?<151AKMXM<P_P-K%>&&4Z-L."^KD=>F=H>NTRJ#Y75/
MV6=O)<K8NMGEP]3TJX,Z 5$CU@]"%WT@>1 )=0;83W063V:K9O57VZ&36VI)
M1SLRI%-9TZGN/ :0PD1O19%1MJXJWTM0OU?8G8"IG0 &@:=?<(KS,*'=O,CG
MX^FX<F@Y_HI7&V).259T +V*1J!4X#19?$Q8'Y64T6+K\-XC)/5[A=T)IEH*
M81"H>G%><[/_L9+*NW)W(L(H9";IJ$[ N*S9V"Z UTC?HHN9T=9":AT'W$]1
MO_TP.L%40Q$,P'JZRZ)12<B*L0EB89Q>"<<AHN=@34F^1$F[:QWGN4M#O\TO
M.C.WCV;S .HFKCM1K2_\W\X6BQ$&*5PN%EQ0A8[DG,#7\B=7HHO2(B^IM7^_
M@XR!)/.U<>U/9?, D%+GA2U6;5W6>[BN%$+KI8@$]L(Q@I))$N(%AX EJCK;
M4O'6<'F(EH$DZ[7!3!.&#\*X6=VHK3<Q"CYPKI4&;2I'7"C@HJ[7:D)IE[*4
MO),Q)NOE^S5;6BN5(]DZ .ODS711;UQ?UQ&$OX3Q=*408^2"*T*SMG7ZH JZ
M#GMBP!QBX2X(KEO7GNZBHU\KI;D2.9'1@P#+6O%=.7<QHN;,"++2<JV<H#T$
MM1K1PW@(9+$EV]J2O4-"OUVPFD/D>/8^'1U^C8XIGM4,YD;XN+*I?B9>K1O.
M79"M=9,2_1++;([KSWT*WW#Q^AN9_B2G\33,+U<L?* ,.C-E2B1F6"FP%K_6
M\0=*@G5HZ/3E*$TW^<V=;*??BN/FN!V&V =AFV^VN'F'7^(4RW@Y2BDGIA*2
MBU$;I/@0P$=R;S.7@07#56'M->5.4@Y"GO^ND'<:N[\3S7E4[XAB!?>Z]@=S
M,9%G6XBMB@70C@MF&:+D[2=U=[&3P^Z'V7<%VUZE/1A=><6%G\:+M&8$YAL^
M_(;+=X7>[Y$7CF7O,[@<ZO2CZ,C+=AQ,E,):GI)H?IGS%/H.P^?WDCG7F60&
MX,.\G\_HA%AY7U*;$+(NH#FOY;HR0K1,0>'%9I>M#+EU7MW-ZH<AYGO)F#J2
MJP/00H3C&[@?I&9-#*@Q%.!2DIIEC #O6"2WC-#NA;(QM\Y4>#*1AZ'K>PG:
M=RNC01B M[8XLD)GE4F3TJ%=9R0Y66_-)7T;L_$\*OIQEQ [##[?2_S^>-X.
M0#]=M6E]C_-57X"ML5Q<8S0(6@E3;ZUB;391ZR@<UCQFPV-KV_XA6@Z#R_<2
MS6_"\4%<]SSN9] >7X;%.*TV.D(NBL5(#H07MF;&(P2>%%C/2C:Y6,:>/\9V
MB\1^\X3;(./)SN#Q0AJ O?T47^+V1H/S)=GDP*9ZALM BKIX5B=O,2&S]*9Y
M1NC1Q/:;>OP,N.Q*< - Z%WNK78RDM'G;+'V>W6U?-E9VH1F(&S2(LM ID+K
M 3$[">DW^Z839)W.\ &@YB"U_=-X<E'; ZU>"Z.,E4S7^8&UW+5@ I^"AQ*=
MMU+&Z)K/;'DRD?WF[?1WOAXMJ,$A\5%%?6NK3*B27(I #G&=I*IJ1TU50*HL
M';V-.:6>S]@GH[,S-V,(I^S1PAL 3N_R;[.7$8^,E1BJI2 E*,XT1,$2E"Q2
M$8[V55J']A\@I=^$HV<Y:X]A^@"P\W<<GWTFNE^0>QS.\+=55[YWY5ZGQ&N>
M&4TL\UP#SUG3_G2U*TP$7YQBN1AMFS>O?"J-A_FRWTM^6Z<2&D0TY= =KLW9
MDE44Q9,VYB*0FXZ%=E8BD/L>BA+)E=PZX^-)!/8;2>D6+4="\^F"&S(NMTV%
M6\UDM?*R<.7!"EO3"G6"0!X6E"0D"S8&]*U+V)Y(8K_1E"%@LXGPOM].P*_"
MXO//D]F?31L!WSST6?H /["']I,YKA>Z!F0T):=L/"17YR1P4F9.*PNZ%,-=
M_55J??;LHZ?!W6A]YOOY[.N8./?R\O<%YC?3ZU*N%VDY_KH>;7-M,DO/"IH
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MSW-_5U7]3^F/QG761.WBS%& M\F3^@\9(NT$E/<H"CU-V/:=]_<0U.\M4V]
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MX_+-8G%1BQE6PP^N=K4^<V[UKA^'R>;[[<;UC@69DRC500Z@++WX$9V#H'A
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MY A-=NOOF^JMAREK5,VYO<!-,>D:".^WR']7-M7'87)39WH#P.A-L"*#,$J
MBI%!\-) 2L)&9(KIV/J2J@GAIYJ%)Q&QZZVR10AEK8>21:RSZ!0$(PM8%9TH
MEE[TYJ'"UGOH-_WP^?%\UW[L%1-#U[0?QV?3<1FG,%UN#I>56;T9 GZ$ZMW_
MP*:Z^ FT-U+.]Y>Y1BB/=: &><X\*?*AO4_@4DK F6 Q*<&E:IW9]# U)WO7
M^SA[\R*0^Q0]0PM(NZME+34 [SCHJ#SZ4JM;FL>L#Z*L7Y77""7W_.#V0AFZ
M=OJ >?QICM_^8QSIF5_I$Q])05\L9L=HIH<?UE0K'4AS(XUT-=[[U>P\TNE5
MR;Y!F[5!N6 8&"U=S=8K=<*M AL+8TXF9WGKGA_[Z#E5*^UX]J[CF=XJSG56
MX&S4M&L6P9E072(5C5%*8O-"M<,HZU<K-4/*7;W4@5B&KY>^XO3B. /I^F\;
M:YU=%#52,E</OS''C42"AX5:Z0A*F@PQ&00?O53%&Q)EZU9A=VDX59F\R'F\
MBC].KJW^K6['NP",D@662@&4UH 2-8N+:P,Q&L&L9 )%:VOGR43VJV).PLE=
MM=*M@(:N86J;N2DA^$@O;/O/F^J9!^EJI&JNGG^YHY&>-5[KXAEH&VHW!LLA
M9B' FA24-XRGTGZPQ(/DG%X_?>_1-U".@0L>BH:@:X?)I#B$8.N-K)7>YU5*
M0/=;'8A::86)^R72C20P=&7R?C[[@O/E)?VJ7J!^J9&M8[3*SN<T52^/4]I(
MSUPM]'Y2W>FMU;;&IRJ3LM/@1&+D1W,)T6,&%W@R7%AI7&MM\RA1#>JA=B^P
MZPTHM0U@P02\> G*<(3(Z-LB/*L'=V1WAQ%TQX#!Z:2V^-E11=6-G(:NJ>X.
M8:"/_#*;Y3_'D\EQ9M##CVML%AU(=R/U=?5PPL;=I7<<DJXD5HI/D&549!A;
M#T&0&1Z<1IL=*SZVMB:>1&"#"60/K+!UGDNOR0$A5T2*1&^)D?5*WH%5F0<M
MR5&0K:-"!Y#5KQ+K#D4[AI<UE=#0]=B[Y6><OZJ#-^K&\^K;M[/I&2U_?C63
MX$C7[M!'MTU[.&8_K3(B5HO=++(AXZ:_>N%*9^^!()CK1%>"9$$Z=Z5W62H"
MJFW=\OD1DD[.8KCS^%UO2\JL6"\56)G)/^$JU8GAFKYE)7C&(O/-$Q,>)ZOG
M7(.&2+F71=!8)D/78'60T#'J:?5W377/?4H:*9;ZX!WG'',V1%>/(,<,_2,S
MG4-% H901REDE7AK2V$W)2V&?^V":49O;"!? 347M:T<.0R&-BB%QL*9D%:W
M3GI_@)1^U44#^>\:OW4JRX>N&5;U([?R\8_*$[K_E+;)08]0V6SXQMWBA-]F
MRRV;F><H3/# N7$U/.G!9ZO!<"4,<]Z&;F;J/$A1^[J;^O2=67(Q)4XO## 5
M B@Z&<&3>0]2.U?#$EQC:Z?S8.+Z[O39##./U\JT$$_#9F,=Z:2KOMVU\=![
MG*]>_F.TTL[G--5+CU/:2#-=+72UR#6^M%=12BNA1!2U=I[PI6O#.2]$$F@-
M-ZUUTD.TG#R*X\YSM[)-@F2"H0,>(P<5D0[<.A%+<D(]*\QRV5K[/$A,S_,5
M6N#@WC2.)HP?NJ6S-4;]N.CSS9\WCC8_0%>S2_C-\W=% 2W+P48/UGFLW6$8
M1#I"P*:<"W?")M%Z1M(><AHT,;_[Z!LH2Y9MPN) :TX'L:"WA,Q_#DDH[ICG
MQ976BG(?/7U?PK?!Q(X^Y6TD,'PC966<W>ME4^_XCJNTV/.XMJ[4H72WBLM<
M(^%=V5[Q TYJFXK56.O5J1,K3>_#Y>U:H826J5049./H7"O.@8]6@$$I"I(E
M[5GKR.AI%)\<YSET]9?;J]^\95S%8HRVH#$K4*;FZ*ILZ6V.FI5@BFW>2/!$
MDGN.&ST?/N_%EYY1U$.WSEZ3DIQ=(K[$*9;Q\F@]NO,Y;7V^1REME=5$\L?5
M8E7NF^5ND(<\RH#D[F=GZ)PN)8 7-H,UQ UK AK5VJ#93]')^4R$_W4AY^IZ
MIBXVQ^5XCMN+[2R63X)>PSJ+B=L:_0@> GI%[(@F:*>J/=.:$T?2VG.>4SM$
MW4MR>@[A#5V)O:W=<XY26YN_;*JH=E'32#6M'WU3&5"T8#XQ"(;5#N%&0\S6
M@':L<(D2LVRMBFY3<*KJ>8N+!>*[+S@/M0YS_? ;C#IEZ) 7&C07I09Q(WBI
M$+*R63G. QD'S?>WCZ)^U<@)TK^K-AHR?NC*X=<P_P.7KV;31$^=KTOVCE$5
M.Y_35'$\3FFK4K3QXH\%'1F_TTKS.K-SN5U>K;6+J'T$S4Q-A<VU303!P&.@
M4\(&)U-K3V8O0:<W4]QB:%UI9]9)P61X=I"<L[7@6T#0J6:=2-0Q&X^J=:C[
M$+IZ+D5KAI/[G10;RV3X6FAZ48AKJ]ZDM9S]XLN7R>6+LSFN6Z0<IY$>>69C
M[?24'9RHJ>IF1[=6?'%_Q9O0J=*)H!?II.*$Q"S)C)5< !K'LT7G<RR/,?-)
M*QZKD@Y:9.MZ609KK'8@:OA6J42.@4)!+T 4Z+A'-+')OGK6-]U)^TKO=,CX
MH6N>U]>.YVG:9N=S.HCP[*.TA5;9M<HUM@0SV4@C0)HZP9H+4\\T!4'E&+(*
MK* ]Z(W;M\I)VF/7@[?N>K33U@H)(:.G=R-F\@X2A^)3,"A#LEP?3?\0M$0S
MZ=W2#.V8.G1M4.VL66UZ=(%YX_X=Z0\]\*2V6<L'4-OPONS^4G1*T"^^S!9A
M\LM\=O'E!FN,%::\K2,F6:8C(@>@XT=#4KHP^C\72VN'X8DD-K@1VWKJ=;OH
MW53LK*DT/'+!$TCIZ+UAKD!DA8,.*0OR$0A,'5R)G41S_W=B76%PQR78\TEW
MZ%JQ-O8?+U=JGW[[:L6 ,YP>V[YQW^.:ZL>#Z6ZD)+?6>W%GO1T9+5JC95P6
M*(8.3^7H\ S!(]ADO:0SV1;7Q:"*@PEL,:7CT<5N7ABFG=69'!7'%;&C=L2(
M(4601:F:T.<9:UT2\S0*^U5^W6%KUQB/CN0V=$7W[Q=A3DM-+G>U@_I]&N@,
M6&(^1N<=^.2FZN^8W332A'N7WE4/Y;UC46G0S->9SX%#0.YK:#,999VULG5]
M[1-)/%4;[EUN*[6Y]A&+7H'1.I'9@!:"2,2(D)DS/+G(6M]9'D99O]JO2SS=
MU7\=2&KH>F]OV]_..G7WT+&[K\[=R1K'<K9@3"9OP"D$Y[V HI7(/ABK1>L^
M1]UU[K[5X'[U\,NM!HDB&6-8!%OJM;M3'IR6&C)7*IF@DDVM<_?WT3/8+MU/
M0<2.Z\$V AC V-+?%_BNO%XLQZ1?<3'RT@C-C ?)I !E2X 8I0-?A$VFD..,
MK0V!VQ0<!)C.QO5U!)@3F-RPY.&$BF \J_[(!_Q2A[%MF'-Y#_FHHA4N0M2^
MEIBE1(>^*\"$E)$E)5E0C;%S$&$'0:JS,7H=0:J]2 :@C'X.X_EJ)NK6G)8W
M4^+6Q<H=7N]NY&S(J8@,2>A(EI\-X!EWH+-CPB)CSK8>:'L080?A3'UG.&LO
MD@'@[%58?*ZQ%?I/K:#_&B8W>]EZ>:)4BDYLD%'49FA>DX>!#%+MN:BTUJAU
M:U/J$,(.PIG^SG#67B0#P-FG><AXE?Q^-=CO R:D_<4);EX>Q93GNI 3J^ME
MB>&2+$9CZLV%]9)%K7)KF^L@P@["F?G.<-9>) / V767Z[OO"Y.)^^@$(*(A
M2S-IB#X%X*$PVHH**%J;9 _1<A":['>&IB:,[Q% J_22]W/\$L9Y<?567+74
M6W7QW&U79IZ\EK% \>2\**\8Q)P\,,F<CEZS9.],0GL@D>?I:Q^$(_>=X.@Y
M^#\ _?1@K^M[YWL*PF9N(1A-Y[NED]X[*2%B$=(A>NU;7T(>2MM!N//?">XZ
M%<P  '>W%S&Y+N,EOAU_Q;PYX34F[PMQS1E59S^$"*[&8&R0V@4GG4JMC?M'
MB3HL6,J^,XRUE<40P'5.ZGI>WY)W\ZL\I7>EMDI>;6I;;]^\0$$)%W*.D%(B
M@X#3/\[9VD))HZ,=A]1\3M\Q=!X&P>\M8-^YQ : RLU@KI^)IS5GI/+L[^/E
MYU<7B^7LO)9>W]Z=4MEY+C)(S9'8F6H"B2%/VFH>5&$EF]:S;)]&X6%(_-YN
M CJ4T@ P6'N3O"L?PP3OO4TB$O&9S(9@0ZEN-4+@N8 P,:!B/*G<.FC[,#6'
M8>M[NQ)HQ/T!X.A%_DI6Z7A!'%JUN[EGC3*EL[0%DN21K%%Z04*)9#58G964
MS@5L;;P]0M)AB/K>@O\MY3  6'T@J1 !-<[\$^GAR6SEZKS^5ELL747^ZD3M
MR N]'\S1J:\8^3B6,W#DYN3(M1/-)X >0-9A\/K>8OZMY3$ B%VW.KS[JI24
MN1'10+'9@0H"P?LL0!/["CDZD;/6&4@/T7(8F+ZWP'X3S@\ 07?;[MX[RFD_
MIH0$DBGB$>H(GE6/V9.WPH3DMOC&0'J$I,/P]+V%]EO*80"PNND8N-U3\-V7
MY;H]UYM5PPMRAE>-ZS:Z-[ALE H,2E!N7<45N0N0)0H9 DK'7&.H'4'F8?#[
M7FX$GDM> X#DJ]F$?CJK17Q?\<5\'J9GJ]KF.QR]'&6OM>2%^&B=K%/I&'CT
M"$)[E:3A5L7VE5J'T788^+ZW:X%.)#, Q.TN'[T7^"O)"XN!'!I#7HU&\FJ$
M2X \:>F1A<!:A\8.(NRPU-CO[7J@O4P& +3?\,\M=LUG4_HRX5;&W-W]<>LT
M:N$AQ1RJFV/ N^0@$N>RYERKYM<#3Z7Q,/A];U<#G4KJNZX[^E3SH=I7'6T>
M^WPU1[OVT7W%D:I&5ZT CH;1R2B3ARA$ ">#=-(4)4)KV[E]Q=$J/>5C^HSY
M8K). +ZZN;U[J?O[ LO%I/YJS>^M]C2%E+4H@EZ5H.@?0T:I17HYC:37R 8N
M67@,4 WH&&PATE. <BMMZ!GETG>&VLU6R5I8SL?QH@IN%9*^LRN76$R%(6B,
MJ8XI<> X<OHJI9B<"L6S)Z+MD24'6[#4 %@MN3T<#-V]U;BS*?391\TXT%M
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M5[(#62/5;L="H2O4CI3+"*#V:O[UVQ4][F8IF^A<UJEP)01(5N^ZV!J80^_
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MZMV<%;C$(FCME",WVQ;5VO'\.0MB#L'4"04QA\AKW$["@[1Y\9SS2,9ES2V
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MVT7R[K]PYPLGA*1:D] T3-4K?QJ%KJZ)NGW7YNVWK1 ]^I!UO:LD R@E,[A
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MT2/047N8-=$^,>&B ,?6\1[)(5I:E51(BK84E6SK*R![2.D$)ON2P-22]R.
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M)#Q/DMAH4?E8I'G"=&T$E36X+!(HIRW0B@((J05JZZ30YPD4/$;=L(,_SHO
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M3#];@<%XL?."9Q'<SNI]G*V;&?7]3"HX\.7GFF-P"D_&,>6 &1>*9X'<?9U
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MJ/^(88W_YW_]?U!+ 0(4 Q0    ( $2(;59H&RJ6)!L  '&1   <
M      "  0    !A,C R,BTQ,&MX97@Q,#$Q86IK87II;6DN:'1M4$L! A0#
M%     @ 1(AM5JGY5/41&P  EI   !P              ( !7AL  &$R,#(R
M+3$P:WAE>#$P,31J;VAN:&%M;2YH=&U02P$"% ,4    " !$B&U6Q>:&?3$;
M  !XD@  '0              @ &I-@  83(P,C(M,3!K>&5X,3 Q-6II;6AE
M<FUA;BYH=&U02P$"% ,4    " !$B&U6]WNS='8(  #@,0  &
M    @ $54@  83(P,C(M,3!K>&5X:&EB:70S,3$N:'1M4$L! A0#%     @
M1(AM5NXQO;LG"   V2\  !@              ( !P5H  &$R,#(R+3$P:WAE
M>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( $2(;5;^O*>O)P4  &89   8
M          "  1YC  !A,C R,BTQ,&MX97AH:6)I=#,R,2YH=&U02P$"% ,4
M    " !$B&U68^OA41 #  #I"   '@              @ %[:   83(P,C(M
M>&5X,C,R8V]N<V5N=&]F9F]R=FDN:'1M4$L! A0#%     @ 1(AM5OLP?:D.
M%   (G$  !4              ( !QVL  &$R,#(R<31E>&AI8FET-#$Q+FAT
M;5!+ 0(4 Q0    ( $2(;5;E]';C7*(#  #&(0 1              "  0B
M  !C<&EX+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    ( $6(;58RT;#X^!H  ((\
M 0 1              "  9,B! !C<&EX+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0
M   ( $6(;5:8GFWI_R,  %IL 0 5              "  ;H]! !C<&EX+3(P
M,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !%B&U6PGH!S@!O  !CT 0 %0
M            @ 'L800 8W!I>"TR,#(R,3(S,5]D968N>&UL4$L! A0#%
M  @ 18AM5F[,FDY)0@$ 2JT! !0              ( !']$$ &-P:7@M,C R
M,C$R,S%?9S$N:G!G4$L! A0#%     @ 18AM5OS;=$T)-0$ (? , !4
M         ( !FA,& &-P:7@M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M $6(;59.'B IE[X   YI"  5              "  =9(!P!C<&EX+3(P,C(Q
A,C,Q7W!R92YX;6Q02P4&      \ #P ,!   H <(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
